
<html lang="en"     class="pb-page"  data-request-id="ab3ef4cc-e372-4560-9552-f220971137e8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01093;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives" /></meta><meta name="dc.Creator" content="Wei  Zheng" /></meta><meta name="dc.Creator" content="Zhen  Wang" /></meta><meta name="dc.Creator" content="Xiangrui  Jiang" /></meta><meta name="dc.Creator" content="Qingjie  Zhao" /></meta><meta name="dc.Creator" content="Jingshan  Shen" /></meta><meta name="dc.Description" content="Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH ..." /></meta><meta name="Description" content="Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 14, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01093" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01093" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01093" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01093" /></link>
        
    
    

<title>Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01093" /></meta><meta property="og:title" content="Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0036.jpeg" /></meta><meta property="og:description" content="Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH remains a severe clinical condition, and the long-term survival of patients with PAH is still suboptimal. Thus, potential therapeutic targets and new agents to treat PAH are urgently needed. In recent years, a variety of related pathways and potential therapeutic targets have been found, which brings new hope for PAH therapy. In this perspective, not only are the marketed drugs used to treat PAH summarized but also the recently developed novel pharmaceutical therapies currently in clinical trials are discussed. Furthermore, the advances in natural products as potential treatment for PAH are also updated." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01093"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01093">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01093&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01093&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01093&amp;href=/doi/10.1021/acs.jmedchem.0c01093" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15153-15186</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01082" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01192" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wei Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">School of Pharmacy, University of the Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Zheng">Wei Zheng</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhen Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhen Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhen++Wang">Zhen Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9450-2260" title="Orcid link">http://orcid.org/0000-0001-9450-2260</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiangrui Jiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiangrui Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiangrui++Jiang">Xiangrui Jiang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5941-6105" title="Orcid link">http://orcid.org/0000-0001-5941-6105</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingjie Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingjie Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingjie++Zhao">Qingjie Zhao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jingshan Shen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingshan Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">School of Pharmacy, University of the Chinese Academy of Sciences, Beijing 100049, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#e4978c818a8e8d8a83978c858aa4978d8989ca8587ca878a"><span class="__cf_email__" data-cfemail="64170c010a0e0d0a03170c050a24170d09094a05074a070a">[email protected]</span></a>. Phone: +86-21-20231962.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingshan++Shen">Jingshan Shen</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9679-9934" title="Orcid link">http://orcid.org/0000-0001-9679-9934</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01093&amp;href=/doi/10.1021%2Facs.jmedchem.0c01093" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15153–15186</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 14, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>26 June 2020</li><li><span class="item_label"><b>Published</b> online</span>14 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01093</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15153%26pageCount%3D34%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWei%2BZheng%252C%2BZhen%2BWang%252C%2BXiangrui%2BJiang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01093%26title%3DTargeted%2BDrugs%2Bfor%2BTreatment%2Bof%2BPulmonary%2BArterial%2BHypertension%253A%2BPast%252C%2BPresent%252C%2Band%2BFuture%2BPerspectives%26numPages%3D34%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15186%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01093"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1104</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01093" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Zhen&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xiangrui&quot;,&quot;last_name&quot;:&quot;Jiang&quot;},{&quot;first_name&quot;:&quot;Qingjie&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Jingshan&quot;,&quot;last_name&quot;:&quot;Shen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15153-15186&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01093&quot;},&quot;abstract&quot;:&quot;Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH remains a severe clinical condition, and the long-term survival of patients with PAH is still suboptimal. Thus, potential therapeutic targets and new agents to treat PAH are urgently needed. In recent years, a variety of related pathways and potential therapeutic targets have been found, which brings new hope for PAH therapy. In this perspective, not only are the marketed drugs used to treat PAH summarized but also the recently developed novel pharmaceutical therapies currently in clinical trials are discussed. Furthermore, the advances in natural products as potential treatment for PAH are also updated.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01093&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01093" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01093&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01093" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01093&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01093" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01093&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01093&amp;href=/doi/10.1021/acs.jmedchem.0c01093" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01093" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01093" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01093%26sid%3Dliteratum%253Aachs%26pmid%3D33314936%26genre%3Darticle%26aulast%3DZheng%26date%3D2020%26atitle%3DTargeted%2BDrugs%2Bfor%2BTreatment%2Bof%2BPulmonary%2BArterial%2BHypertension%253A%2BPast%252C%2BPresent%252C%2Band%2BFuture%2BPerspectives%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15153%26epage%3D15186%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292016" title="Therapeutics">Therapeutics</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0036.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Pulmonary arterial hypertension (PAH) is a devastating disease that can lead to right ventricular failure and premature death. Although approved drugs have been shown to be safe and effective, PAH remains a severe clinical condition, and the long-term survival of patients with PAH is still suboptimal. Thus, potential therapeutic targets and new agents to treat PAH are urgently needed. In recent years, a variety of related pathways and potential therapeutic targets have been found, which brings new hope for PAH therapy. In this perspective, not only are the marketed drugs used to treat PAH summarized but also the recently developed novel pharmaceutical therapies currently in clinical trials are discussed. Furthermore, the advances in natural products as potential treatment for PAH are also updated.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">1.1.  What is PAH?</h3><div class="NLM_p">Pulmonary arterial hypertension (PAH) is a global disease and a subtype of pulmonary hypertension (PH). PH is characterized by persistent high pulmonary arterial pressure (PAP), defined as an increase in mean PAP (mPAP) ≥ 25 mmHg at rest as assessed by right heart catheterization. PAH is characterized hemodynamically by the presence of precapillary PH, including an end-expiratory pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) > 3 Wood units (WU).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Some researchers have suggested that a standard of 20 mmHg should be defined as the upper limit of the normal value of mPAP and have recommended that the definition of PAH be changed to an mPAP > 20 mmHg, a PAWP ≤ 15 mmHg, and a PVR > 3 WU.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> PAH has multiple subtypes because of its many pathogenic factors and its complicated pathophysiology (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Updated Clinical Classifications of PAH</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">idiopathic PAH (IPAH)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">heritable PAH (HPAH)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">drug- and toxin- induced PAH</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">PAH associated with:</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">connective tissue disease (CTD)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">HIV infection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">portal hypertension</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">congenital heart disease (CHD)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">schistosomiasis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">PAH in response to long-term calcium channel blocker use</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">PAH with overt features of venous/capillary involvement (pulmonary veno-occlusive disease (PVOD)/pulmonary capillary hemangiomatosis (PCH))</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">persistent PH of the newborn syndrome</td></tr></tbody></table></div></div><div class="NLM_p last">The initial symptoms of PAH include shortness of breath, fatigue, weakness, angina, and syncope. A small number of patients also suffer from nausea and vomiting caused by dry cough and exercise.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Thereafter, the consequent increase in PVR causes right ventricular (RV) overload, hypertrophy, and expansion, eventually leading to RV failure and death.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Currently, the 1-, 3-, and 5-year survival rates for PAH patients are 85%, 68%, and 57%, respectively, with medical treatment.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The approved drugs can extend the lives of patients but cannot prevent or reverse the development of the disease. Therefore, PAH remains a progressive and fatal disease that seriously threatens the lives of patients.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">1.2.  Epidemiology and Risk Factors for PAH</h3><div class="NLM_p">The global incidence and prevalence of PAH (for only idiopathic PAH (IPAH), PAH associated with connective tissue disease (CTD) (CTD-PAH), and portal hypertension (PH)) are crudely estimated at 5 million adults per year and 15 per million adults, respectively.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Many risk factors are associated with the progression of PAH. First, many diseases, such as CTD and congenital heart disease (CHD), play important roles in PAH development.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Among them, CTD-PAH is one of the most common subtypes of PAH, and systemic lupus erythematosus and systemic sclerosis (SSc) are the most common subtypes of CTD-PAH.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a> Moreover, schistosomiasis and human immunodeficiency virus (HIV) infection can also cause PAH and may be important factors in some areas.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Second, sex and specific genes are also related to PAH development. The number of female patients with PAH is always higher than that of male patients, which indicates that female sex is a risk factor for PAH.<a onclick="showRef(event, 'ref8 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref10">(8,10)</a> Interestingly, the survival rate of female patients is markedly higher than that of male patients.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> With regard to genes, bone morphogenetic protein receptor 2 (BMPR2), bone morphogenetic protein 9 (BMP9), activin a receptor like type 1 (ACVRL1), endoglin (ENG), sterile alpha motif domain-containing protein 9 (SMAD9), caveolin 1 (CAV1), potassium channel subfamily k member 3 (KCNK3), and prostaglandin I2 synthase (PTGIS) are known to be related to PAH.<a onclick="showRef(event, 'ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14">(12−14)</a> Third, age seems to have some impact on the progression of PAH. Although early statistics suggested that PAH affected mostly young people, more recent data indicate that the average age of patients is relatively old.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Finally, drugs and toxins have been identified as risk factors for PAH development, and their associations have been divided into two subgroups: “definite associations” and “possible associations” (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Because of the complex and numerous factors associated with PAH, it is difficult to envision a unifying pathogenic mechanism. Therefore, a multiple-hit theory has been suggested to describe the pathogenesis of PAH.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Knowledge of epidemiology and risk factors for PAH not only helps with prevention and screening of patients but also inspires scientists to develop more effective drugs based on the pathogenesis.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Classification of Drugs and Toxins Associated with PAH</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">definite association</th><th class="colsep0 rowsep0" align="center">possible association</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aminorex</td><td class="colsep0 rowsep0" align="left">cocaine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">fenfluramine</td><td class="colsep0 rowsep0" align="left">phenylpropanolamine</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dexfenfluramine</td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">L</span>-tryptophan</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">benfluorex</td><td class="colsep0 rowsep0" align="left">St. John’s wort</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">methamphetamines</td><td class="colsep0 rowsep0" align="left">amphetamines</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dasatinib</td><td class="colsep0 rowsep0" align="left">interferon-α and interferon-β</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">toxic rapeseed oil</td><td class="colsep0 rowsep0" align="left">alkylating agents</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">bosutinib</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">direct-acting antiviral agents against hepatitis C virus</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">leflunomide</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">indirubin (the Chinese herb Qing-Dai)</td></tr></tbody></table></div></div></div><div id="sec1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">1.3.  Pathogenesis of PAH</h3><div class="NLM_p">PAH is a progressive disease characterized by persistent high PAP and elevated PVR that causes RV overload and eventually leads to right heart failure and death.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> It has been reported that the reasons for persistent high PAP and elevated PVR are mainly sustained vasoconstriction, vascular remodeling, and thrombosis (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Drugs on the market for the treatment of PAH are able to alleviate the symptoms of PAH and prolong the lives of patients by reducing PAP. However, these drugs cannot prevent or reverse the pathological process or prevent eventual death from the disease. Therefore, increasing numbers of studies on the pathogenesis of PAH are being conducted to identify more effective therapeutic pathways than those currently used.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> PAH is now considered to be a vasculopathy in which pulmonary vascular remodeling driven by excessive vascular cell growth and inflammation play major roles.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Pulmonary vascular remodeling is considered to be the result of a combination of genetic, epigenetic, and environmental factors, and a variety of vasoactive molecules, ion channels, and signaling pathways exert important regulatory effects. Because of the critical role of vascular remodeling in the pathogenesis of PAH, development of drugs targeting pulmonary artery remodeling may be promising for PAH treatment. In addition, thrombosis may also be an essential participant in PAH development. Thrombosis is caused mainly by abnormalities in platelets and by biochemical features of a procoagulant environment within the pulmonary vasculature. Many phenotypes of PAH can cause thrombosis, but it is unclear whether it is the cause or consequence of the disease in most cases.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p last">Although no fully effective treatment for PAH currently exists, novel strategies are continuously emerging to cope with other pathological signs, such as inflammation, metabolic switching, and epigenetic changes. In this perspective, we summarize the targeted drugs approved to treat PAH and the compounds under development, and we also provide an outlook on potential new targets and emerging therapies under clinical investigation for use in the fight against PAH.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">2.  Molecular Targets for the Treatment of PAH</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33331" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33331" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">PAH is characterized by continuous high PAP; hence, reducing PAP is the most direct treatment. The current targeted drugs for PAH mainly regulate the constriction and relaxation of pulmonary arteries, thus decreasing pulmonary arterial pressure. The prostacyclin (prostaglandin I2, PGI<sub>2</sub>), endothelin (ET), and nitric oxide (NO) signaling pathways are three main pathways regulating pulmonary vasomotor tone.</div><div class="NLM_p">The PGI<sub>2</sub> signaling pathway was the first pathway targeted for PAH treatment. PGI<sub>2</sub> is an endogenous substance with potent vasodilatory and antithrombotic activities, so drugs targeting this pathway can effectively relax blood vessels to treat PAH.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Two types of drugs are available that target this pathway: PGI<sub>2</sub> analogues and PGI<sub>2</sub> receptor agonists. The ET signaling pathway is also associated with the regulation of pulmonary arteries, and there are three ET isoforms: ET-1, ET-2, and ET-3.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Among them, ET-1 can effectively constrict blood vessels by binding to ET receptors. Because inhibition of ET receptors can reduce PAP, a variety of ET receptor antagonists (ERAs) have been approved. Finally, NO is an endothelium-derived relaxing factor that has a strong vasodilatory effect, which allows it to effectively reduce PAP by activating the NO pathway.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Two types of drugs affect this pathway: phosphodiesterase 5 (PDE5) inhibitors and soluble guanylate cyclase (sGC) activators, which play important roles in the treatment of PAH. Drug candidates currently in clinical trials that regulate vascular tone via other pathways will be discussed later in this perspective. Moreover, pulmonary vascular remodeling is the most prominent histopathological feature of PAH, and many associated pathways and targets have been identified, including growth factors, cytokines, metabolic signaling, and the BMPR2 pathway (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The related drugs in clinical trials will also be discussed later in this perspective.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Endogenous substances and related pathways that are associated with the development of PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">3.  Drugs for the Treatment of PAH</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.1.  PGI<sub>2</sub> Pathway</h3><div class="NLM_p">PGI<sub>2</sub> (<b>4</b>), which belongs to the prostaglandin family of lipid mediators, is synthesized mainly by endothelial cells through metabolic arachidonic acid (<b>1</b>, AA). The biosynthetic pathway of <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) begins with the oxidation of <b>1</b> to prostaglandin G2 (<b>2</b>, PGG2) by cyclooxygenase (COX), which is followed by the conversion of <b>2</b> to hydroxy endoperoxide (<b>3</b>, PGH2) by COX. Finally, PGI<sub>2</sub> synthase converts <b>3</b> to <b>4</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The main target of <b>4</b> is the PGI<sub>2</sub> receptor (IP), a G protein-coupled receptor located on vascular smooth muscle cells (SMCs), endothelial cells, and platelets. Activated IP stimulates adenylyl cyclase, which can catalyze the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP); cAMP then activates cAMP-dependent protein kinase (PKA), which triggers downstream pathways that lead to vasodilatory and antithrombic effects. <b>4</b> can also inhibit the differentiation, proliferation, and migration of vascular SMCs and mediate injury protection and immune regulation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Moreover, the levels of PGI<sub>2</sub> synthase (PTGIS) and PGI<sub>2</sub> metabolites have been found to be reduced in the pulmonary vasculature and serum of PH patients.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The drugs currently targeting the PGI<sub>2</sub> pathway are divided mainly into PGI<sub>2</sub> analogues and IP agonists, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PGI<sub>2</sub> pathway and potential targets of PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. PGI<sub>2</sub> Drugs for PAH</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug type</th><th class="colsep0 rowsep0" align="center">drug name</th><th class="colsep0 rowsep0" align="center">year launched</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PGI<sub>2</sub> and PGI<sub>2</sub> analogues</td><td class="colsep0 rowsep0" align="left">epoprostenol (<b>4</b>)</td><td class="colsep0 rowsep0" align="left">1982</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">iloprost (<b>5</b>)</td><td class="colsep0 rowsep0" align="left">1992</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">beraprost (<b>6</b>)</td><td class="colsep0 rowsep0" align="left">1992</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">treprostinil (<b>7</b>)</td><td class="colsep0 rowsep0" align="left">2002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PGI<sub>2</sub> receptor agonists</td><td class="colsep0 rowsep0" align="left">selexipag (<b>14</b>)</td><td class="colsep0 rowsep0" align="left">2015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ralinepag (<b>16</b>)</td><td class="colsep0 rowsep0" align="left">pending (Phase III)</td></tr></tbody></table></div></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">3.1.1.  PGI<sub>2</sub> and PGI<sub>2</sub> Analogues</h4><div class="NLM_p">Epoprostenol, a sodium salt of <b>4</b>, prolongs the lives of patients with PAH and has ushered in an era of targeted drug therapy. Its therapeutic effect on PAH has been verified by several clinical trials. A 12-week prospective randomized multicenter open trial of continuous intravenous <b>4</b> in 81 patients with severe PAH (New York Heart Association Functional Classification [NYHA-FC] III or IV) demonstrated that the drug increased patients’ 6 min walking distance (6MWD) (median distance walked in 6 min: 362 m vs 315 m) and decreased mPAP and PVR.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In another 3-year clinical trial, 162 patients who were treated with <b>4</b> were followed, and a markedly improved survival rate was observed.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> On the basis of these positive results, <b>4</b> was approved in 1998 for the treatment of PAH with common side effects consisting mainly of flushing, headache, diarrhea, and leg pain.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Although <b>4</b> has achieved great success, it still exhibits a very short half-life (3–5 min) due to its rapid nonenzymatic hydrolysis in blood (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) and shows poor chemical stability; it requires cooling and continuous administration via an infusion pump and a permanent tunnel catheter.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In addition, the delivery of <b>4</b> is associated with serious adverse events, including pump malfunction, local infection, catheter obstruction, and sepsis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0028.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Metabolism of PGI<sub>2</sub></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Iloprost (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), a PGI<sub>2</sub> analogue, exhibits better chemical stability than <b>4</b> and is available for intravenous or aerosol administration.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In a clinical study on the treatment of severe PH, both <b>5</b> and <b>4</b> significantly improved the patients’ exercise tolerance and demonstrated similar therapeutic effects.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Moreover, a 12-week randomized, double-blind, placebo-controlled multicenter clinical study on aerosolized <b>5</b> (median inhaled dose: 30 μg per day) in 203 patients with selected forms of severe PAH and chronic thromboembolic PH (NYHA-FC III or IV) demonstrated that <b>5</b> can markedly improve hemodynamic and exercise tolerance. The common side effects include flushing and jaw pain, both of which are usually transient and mild. Furthermore, inhalation of <b>5</b> has been proven to be more convenient and safer than continuous intravenous injection of <b>4</b>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of some PGI<sub>2</sub> analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Beraprost (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), the first orally active PGI<sub>2</sub> analogue,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> can be absorbed rapidly under fasting conditions, and it exhibits an elimination half-life of 35–40 min after a single oral administration.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The results of a 12-week randomized, double-blind, placebo-controlled trial of oral <b>6</b> (median dose: 80 μg four times daily) in 130 PAH patients (NYHA-FC II and III) showed that <b>6</b> significantly improved exercise capacity and symptoms without significantly affecting cardiopulmonary hemodynamics or functional class.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Another long clinical trial confirmed the efficacy and safety of <b>6</b>, but the effects weakened with time.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The adverse effects of oral <b>6</b> are similar to those of other PGI<sub>2</sub> analogues, including flushing, headache, jaw pain, diarrhea, and nausea. The PAH indication of <b>6</b> was approved in Japan in 2007 but has not yet been approved in the United States, Europe, and China. Although <b>6</b> can be administered orally, its short half-life and poor long-term effects limit its application.</div><div class="NLM_p">Treprostinil (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) is a more potent and longer-lasting PGI<sub>2</sub> analogue than the others. The effects of subcutaneous <b>7</b> on patients’ exercise capacity, hemodynamics, and symptoms were identified in a 12-week randomized, double-blind, placebo-controlled multicenter study in 470 patients with PAH. The most common adverse effect was infusion site pain.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><b>7</b> was first approved by the Food and Drug Administration (FDA) for intravenous and subcutaneous injection in 2002. Then, a new inhalation formulation of <b>7</b> was approved in 2009, and oral administration was approved in 2013.<named-content content-type="anchor" rid="fig4" type="simple"></named-content></div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Development of PGI<sub>2</sub> drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15">3.1.2.  PGI<sub>2</sub> Receptor Agonists</h4><div class="NLM_p">Selexipag (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), a first-in-class orally available selective IP agonist, exhibits a high degree of metabolic stability with a half-life of 7.9 h, which is longer than that of <b>6</b>. <b>14</b> is a prodrug that can be slowly hydrolyzed into metabolite <b>13</b><i>in vivo</i>, and its use reduces the adverse effects associated with high concentrations of PGI<sub>2</sub> agonists because of the slow, sustained formation of the active compound. Moreover, active metabolite <b>13</b> can specifically activate IP with high affinity (<i>K</i><sub>i</sub> = 20 nM) and has more than 130-fold selectivity for IP over other prostanoid receptors.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a> Octimibate (<b>8</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) and BMY42393 (<b>9</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>), which have different skeletal structures than PGI<sub>2</sub> and its analogues, were the compounds that led to the discovery of <b>14</b>, indicating that the PGI<sub>2</sub>-specific skeleton is not essential for IP activation. 2-Amino-5,6-diphenylpyrazine derivative <b>10</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was obtained through extensive modification and showed moderate inhibitory activity (IC<sub>50</sub> = 1.5 μM) against ADP-induced human platelet aggregation. Next, compound <b>10</b> was continuously modified as a lead compound and extensively studied, and diphenylpyrazine derivatives were obtained as a novel class of IP receptor agonists. A structure–activity relationship (SAR) study demonstrated that both side-chain length and the diphenylated heterocycle played essential roles in potency.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Therefore, the side chain containing the carboxylic acid moiety was optimized to obtain compound <b>11</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). To improve metabolic stability against oxidative degradation <i>in vivo</i>, compound <b>12</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was obtained. Then, research showed that the nitrogen atom that joined the pyrazine ring and the alkyl side chain was indispensable and that the substituent on this nitrogen atom accommodated only a small hydrophobic group. Finally, to extend the <i>in vivo</i> exposure time of <b>10</b>, an acidic surrogate, <i>N</i>-methylsulfonamide, was used to replace the carboxyl group in order to obtain <b>14</b>, as <i>N</i>-methylsulfonamide improves the pharmacokinetic properties of carboxylic acid drugs. <b>14</b> has weaker activity than compound <b>10</b><i>in vitro</i>. However, <b>14</b> can be slowly hydrolyzed into the active form <b>10</b>, which can prolong its pharmacological activity while potentially reducing side effects. Therefore, <b>14</b> has been further developed as a candidate drug.<a onclick="showRef(event, 'ref36 ref40'); return false;" href="javascript:void(0);" class="ref ref36 ref40">(36,40)</a> A phase II clinical trial of oral <b>14</b> (maximum dose: 800 μg twice daily) has demonstrated that compared with a placebo, <b>14</b> significantly attenuates PVR and improves 6MWD performance in patients; in addition, the adverse events are consistent with the known side-effect profiles of PGI<sub>2</sub> analogues.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In another randomized, double-blind, placebo-controlled phase III trial of oral <b>14</b> (maximum dose: 1600 μg twice daily) in 1156 patients with PAH, the results showed that <b>14</b> can reduce the risk of the primary composite end point of death or a complication related to PAH.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Supported by these positive results, <b>14</b> was approved in 2015 in the USA by the FDA for the treatment of PAH.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0029.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Design of Selexipag</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ralinepag (<b>16</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), a new PGI<sub>2</sub> receptor agonist, exhibits potency and efficacy comparable to or better than those of compound <b>13</b><i>in vitro</i>. <b>16</b> was derived from <b>15</b> by deleting the fused aromatic ring and optimizing the linker group that serves to orientate the two required aromatic groups. <b>16</b> is rapidly absorbed after oral administration with good selectivity to most members of the prostanoid receptor family. Its elimination half-life ranges from 5 to 8 h in rodents, and 10 and 18 h in dog and monkey, respectively. Thus, it has been selected for further development for the treatment of PAH, and more details about the discovery can be found in the article by Tran et al.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The efficacy, safety, and tolerability of oral <b>16</b> were identified in a randomized, double-blind, placebo-controlled phase II study in 61 patients with PAH.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Moreover, the phase II study demonstrate <b>16</b> allowed for twice-daily dosing with a long half-life of ∼24 h. <b>16</b> was granted orphan drug designation for the treatment of PAH in the USA and the EU in 2014 and 2019, respectively. Currently, <b>16</b> is being tested in several large-scale phase III clinical trials to assess long-term efficacy and safety in patients with PAH (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT03683186, NCT04084678, and NCT03626688). As a next-generation non-prostaglandin-selective prostacyclin receptor agonist, <b>16</b> is a promising drug candidate.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of PGI<sub>2</sub> receptor agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">QCC-374 (<b>17</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) was another selective IP agonist under phase II clinical development, but unfortunately, the study was terminated early for strategic reasons (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02927366). Moreover, FR-181157 (<b>18</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), FK-788 (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), and FR-193262 (<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) have been developed as selective IP receptor antagonists with different backbone structures.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> However, these compounds were not developed in a clinical trial for PAH, and <b>18</b> was due to the unpredictable potent activity derived from its complicated metabolism, while <b>19</b> and <b>20</b> may be due to the short half-life.<a onclick="showRef(event, 'ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49">(47−49)</a></div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.1.3.  Thromboxane A2 (TXA<sub>2</sub>) Pathway</h4><div class="NLM_p">TXA<sub>2</sub> (<b>21</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) is a type of thromboxane that acts as a vasoconstrictor and promotes platelet aggregation. Its main binding receptor is thromboxane receptor (TP), also known as the prostanoid TP receptor. TP belongs to the prostaglandin receptor family, similar to IP. <b>21</b> and <b>4</b> are synthesized from <b>3</b> by different synthetases (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> They exhibit opposite biological effects and exist in balance within the circulatory system; their balance is important for maintenance of the homeostasis of blood vessels. <b>21</b> is upregulated, while <b>4</b> is downregulated (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), in PAH patients compared with healthy people. Since PGI<sub>2</sub> analogues and PGI<sub>2</sub> receptor agonists have been successfully developed, it can be inferred that a strategy inhibiting TXA<sub>2</sub> may produce similar therapeutic effects. Inhibition of <b>21</b> can reduce excessive vasoconstriction, thrombosis, fibrosis, and inflammation in patients with PAH. In addition, TP inhibitors have been shown to improve RV function by reducing fibrosis and transforming growth factor (TGF)-β signaling.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> On the basis of these speculations and research results, some TP antagonists have been used in research on the treatment of PAH.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Biosynthetic pathway of TXA<sub>2</sub> and PGI<sub>2</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Imbalance between TXA<sub>2</sub> and PGI<sub>2</sub> in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ifetroban (<b>22</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) is a TP antagonist and has been evaluated in phase II clinical studies for the treatment of PAH. It is currently being evaluated in a randomized, double-blind, placebo-controlled phase II study in patients with SSc-PAH, but no results have been published (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02682511). NTP-42 (<b>23</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) is a TP antagonist with orphan drug designation and shows efficacy in animal models of Sugen/hypoxia and monocrotaline (MCT)-induced PH. Ono-1301 (<b>24</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), a long-acting PGI<sub>2</sub> agonist with thromboxane synthetase inhibitory activity, has been found to improve symptoms and has demonstrated potential efficacy against PAH in rat models of MCT-induced PH.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of ifetroban, NTP-42, Onoono-1301, and TRA-418.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">From the first PAH-targeting drug, <b>4</b>, to the current orally available IP agonist <b>14</b>, drugs targeting the PGI<sub>2</sub> signaling pathway have gradually overcome the shortcomings of poor chemical stability, short half-lives, and unsuitability for oral administration. At present, <b>16</b> is the drug candidate targeting this pathway with the greatest potential for marketing approval. <b>16</b> is expected to be used as a once-daily oral treatment for PAH patients in the future, and its pivotal phase III clinical trial (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT03626688) is expected to be completed by the end of 2021.</div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">3.2.  ET Pathway</h3><div class="NLM_p">ET is a peptide that exists in three isoforms: ET-1, ET-2, and ET-3. Among them, ET-1 can induce many biological effects, including vasoconstriction, proinflammatory actions, mitogenic and proliferative effects, stimulation of free radical formation, and platelet activation.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Upregulation of ET-1 has been identified in PAH patients, suggesting that the occurrence and development of PAH are related to increased ET-1 expression in vascular endothelial cells.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> ET-1 mainly activates two receptor subtypes, ET receptor type A (ET<sub>A</sub>) and ET receptor type B (ET<sub>B</sub>), which are G protein-coupled receptors and generally exhibit opposite cardiovascular effects under normal physiological conditions. ET<sub>A</sub> activation mainly mediates pulmonary artery vasoconstriction, while ET<sub>B</sub> activation causes pulmonary artery vasodilation. Although both ET<sub>A</sub> and ET<sub>B</sub> are abundantly distributed in the pulmonary arteries, their main distribution sites are different. ET<sub>A</sub> is distributed predominantly in the SMCs of pulmonary arteries and resistance vessels. When ET<sub>A</sub> is activated, G proteins induce activation of phospholipase C, which is followed by 1,4,5-inositol triphosphate formation and the consequent release of Ca<sup>2+</sup> from intracellular stores to mediate the contraction of blood vessels.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> ET<sub>B</sub> is expressed mainly in pulmonary vascular endothelial cells. When ET<sub>B</sub> is activated, it induces endothelial cells to release NO and PGI<sub>2</sub>, thereby mediating vasodilation.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In addition, small amounts of ET<sub>B</sub> are expressed in pulmonary vascular SMCs, where ET<sub>B</sub> can mediate vasoconstriction, and this effect may be further enhanced in patients with PAH (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In summary, antagonizing ET receptors reduces PAP, and high levels of ET<sub>A</sub> expression in lung tissue enable ERAs to target the reduction in PAP without affecting systemic pressure. Therefore, inhibition of ET receptors is an effective strategy for treating PAH. ERAs that have been successfully approved include bosentan (<b>25</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), sitaxentan (<b>26</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), ambrisentan, (<b>27</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>) and macitentan (<b>28</b>, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). However, <b>28</b> has been withdrawn due to severe liver side effects.</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Roles of the ET receptor in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Approved ERAs for PAH</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug name</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">year launched</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bosentan (<b>25</b>)</td><td class="colsep0 rowsep0" align="left">ET<sub>A</sub> and ET<sub>B</sub></td><td class="colsep0 rowsep0" align="left">2001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sitaxentan (<b>26</b>)</td><td class="colsep0 rowsep0" align="left">ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">2006 (withdrawn)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ambrisentan (<b>27</b>)</td><td class="colsep0 rowsep0" align="left">ET<sub>A</sub></td><td class="colsep0 rowsep0" align="left">2007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">macitentan (<b>28</b>)</td><td class="colsep0 rowsep0" align="left">ET<sub>A</sub> and ET<sub>B</sub></td><td class="colsep0 rowsep0" align="left">2013</td></tr></tbody></table></div></div><figure id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of ERAs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>25</b> was the first oral dual ERA to be developed with a nanomolar affinity for ET<sub>A</sub> and ET<sub>B</sub>. Research on this compound began with a high-throughput screening of 100 000 compounds that identified compound <b>29</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), which has IC<sub>50</sub> values of 2 μM and 18 μM for ET<sub>A</sub> and ET<sub>B</sub>, respectively. A total of 1200 related compounds were synthesized and tested for activity, and <b>25</b> was ultimately obtained. An important optimization process involved replacement of position 5 of the central pyrimidine ring with an electron-rich 2-methoxyphenoxy group, which increased the activity by more than 10-fold and yielded compound <b>30</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Then, it was found that introduction of a phenyl group into the 2-position of the pyrimidine ring could further increase the activity, and compound <b>31</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) was obtained. Finally, various aromatic and heteroaromatic rings were substituted for the benzene ring at the 2-position of the pyrimidine ring. It was found that substitution with pyrimidine gave <b>25</b> with the best activity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> In a randomized, double-blind, placebo-controlled, multicenter trial of oral <b>25</b> in 185 PAH patients (World Health Organization Functional Classes [WHO-FCs] III and IV), <b>25</b> markedly improved the 6MWD and hemodynamic parameters, with side effects of increased liver aminotransferase concentrations.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><named-content content-type="anchor" rid="fig11" type="simple"></named-content></div><figure id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Development of an ERA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0030.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Design of Bosentan</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since ET<sub>A</sub> mediates predominantly vasoconstrictive effects in the lung better than ET<sub>B</sub>, it was once believed that selective antagonism of ET<sub>A</sub> could more effectively relax blood vessels and achieve better therapeutic effects than general antagonism of ET receptors. Therefore, a variety of selective ET<sub>A</sub> receptor antagonists were subsequently developed. <b>26</b> was the first approved drug to selectively inhibit ET<sub>A</sub>. Unlike <b>25</b>, it is taken orally only once a day at a dose of 100 mg.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><b>26</b> was successfully marketed in the UK in 2006 but was withdrawn due to the risk of life-threatening idiopathic liver injury in 2010.</div><div class="NLM_p"><b>27</b>, representing the next generation of ERAs, was developed as a selective ET<sub>A</sub> receptor antagonist to avoid the adverse hepatic effects of <b>26</b>. It was optimized from diphenyl propionic acid derivates screened from the BASF Chemical Library.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a><b>27</b> is taken once daily at a recommended dose of 5 mg. In a phase III study, after 12 weeks of oral <b>27</b> treatment, patients with PAH showed significant improvements in both exercise tolerance and related hemodynamics parameters.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In another clinical trial, <b>27</b> was tolerated by PAH patients who discontinued <b>25</b> or <b>26</b> due to liver function test abnormalities, demonstrating the high safety level of <b>27</b>. However, it has been reported that <b>27</b> may cause peripheral edema as a side effect.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">With the widespread application of nonselective ERAs and selective ET<sub>A</sub> receptor antagonists in PAH patients, it has been found that there is no significant difference between these drug types in clinical settings. Moreover, selective ET<sub>A</sub> antagonists induce more fluid retention (mediated by ET<sub>A</sub>) than nonselective ERAs. Related research has also indicated that the contribution of ET<sub>B</sub> in pulmonary vascular SMCs to pulmonary vasoconstriction increases under the pathological state of PAH.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Therefore, dual ERAs may be slightly better than selective ERAs for PAH treatment. The research has thus shifted to focus on nonselective ERAs.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p"><b>28</b>, an approved dual ERA, was developed through optimization of bosentan. The specific optimization strategy was to replace the <i>tert</i>-butyl benzene sulfonamide moiety of bosentan with a series of simple alkyl sulfonamides and introduce a pyrimidine to the ethylene glycol moiety.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> After modification, the affinity of <b>28</b> for the ET receptor was greatly improved, making it a potent inhibitor of ET<sub>A</sub> with a significant affinity for ET<sub>B</sub>. <b>28</b> can be taken once a day and is highly effective and safe.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> In a randomized, double-blind, placebo-controlled, multicenter event-driven phase III study on oral <b>28</b> in 742 PAH patients, the efficacy and safety of two doses of <b>28</b> (3 and 10 mg once a day) were evaluated, and the results showed that <b>28</b> significantly reduced mortality with adverse reactions mainly in the form of headache, nasopharyngitis, and anemia. Furthermore, few patients had liver side effects, and the incidence of peripheral edema was similar between the placebo and <b>28</b> groups.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p">Getagozumab is a humanized monoclonal antibody against ET<sub>A</sub> that is currently in the early clinical stage of research. In an MCT-induced PH model in cynomolgus monkeys, getagozumab markedly attenuated PAP and RV hypertrophy while exhibiting fewer liver side effects than other therapies and a long half-life of 7.7–9.9 days. Getagozumab has received orphan drug designation in the USA based on its safety, efficacy, and pharmacokinetic properties in animal models.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_p last">The liver toxicity induced by drugs targeting the ET pathway has limited the application of these drugs. Moreover, <b>25</b> and <b>26</b> tend to induce worse liver toxicity than <b>27</b> and <b>28</b>. <b>26</b> was withdrawn from the market due to three cases of irreversible and fatal liver failure. Despite their side effects, all three clinically available ERAs are the first-line oral therapies for PAH functional classes II and III. Because ERAs are not curative for PAH and because their efficacy is similar, the introduction of generic drugs caused the development of most small-molecule ERAs for PAH to be suspended or terminated; however, getagozumab, a humanized monoclonal antibody against ETA with a long half-life, is now under development and will be a promising new treatment option for PAH patients in the future. The current research and development of ERAs is not as active as it once was, but for readers who are interested, more information about ERAs in human clinical trials can be found in a review published by Aubert in 2016.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">3.3.  NO Pathway</h3><div class="NLM_p">NO is an endothelium-derived relaxing factor that is derived from <span class="smallcaps smallerCapital">l</span>-arginine in the airway epithelium or vascular endothelium and whose formation is catalyzed by NO synthase (NOS). NO is highly lipophilic and can diffuse freely into pulmonary vascular SMCs to activate sGC, which can catalyze the conversion of guanosine triphosphate (GTP) into the second messenger cyclic guanosine monophosphate (cGMP). The resulting increase in cGMP stimulates protein kinase G (PKG), which regulates many physiological functions; for example, it promotes vasodilation and antiproliferation (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> The expression of NOS is significantly reduced in PH patients with severe histologic abnormalities, and the decrease in NOS has a negative correlation with vascular resistance.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> As an endothelium-derived relaxing factor, NO has been proven to be beneficial for the treatment of many diseases; for example, inhaled NO was approved by the FDA in 1999 as a treatment for persistent PH of the newborn and has also been used in other PAH patients.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Two main molecules in the NO pathway are targeted to treat PAH: PDE5 and sGC. The phosphodiesterases (PDEs) belong to an enzyme superfamily whose members degrade the second-messenger molecules cAMP and cGMP. Among them, PDE5 predominantly mediates the degradation of cGMP in the pulmonary vasculature. Therefore, inhibiting PDE5 can effectively prevent the degradation of cGMP to effectively treat PAH. The PDE5 inhibitors launched thus far include sildenafil (<b>32</b>) and tadalafil (<b>33</b>), while vardenafil (<b>34</b>), udenafil (<b>35</b>), and simmerafil (<b>36</b>) are in the clinical research stage (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). However, the therapeutic effects of PDE5 inhibitors dependent on the production of cGMP are lost when the NO level is insufficient to produce enough cGMP. For this reason, sGC activators that do not depend on endogenous cGMP have been studied. These drugs can directly activate sGC, thereby causing the production and accumulation of cGMP and ultimately achieving the purpose of reducing PAP. Riociguat (<b>50</b>) is the only currently approved sGC agonist on the market (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>)<named-content content-type="anchor" rid="fig13" type="simple"></named-content><named-content content-type="anchor" rid="fig14" type="simple"></named-content>.</div><figure id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0012.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. NO pathway and potential molecular targets for PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PDE5 Inhibitors and sGC Activator for PAH</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug type</th><th class="colsep0 rowsep0" align="center">drug name</th><th class="colsep0 rowsep0" align="center">clinical stage</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDE5 inhibitor</td><td class="colsep0 rowsep0" align="left">sildenafil (<b>32</b>)</td><td class="colsep0 rowsep0" align="left">launched (2005)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">tadalafil (<b>33</b>)</td><td class="colsep0 rowsep0" align="left">launched (2009)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">vardenafil (<b>34</b>)</td><td class="colsep0 rowsep0" align="left">Phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">udenafil (<b>35</b>)</td><td class="colsep0 rowsep0" align="left">Phase III</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">simmerafil (<b>36</b>)</td><td class="colsep0 rowsep0" align="left">Phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sGC activator</td><td class="colsep0 rowsep0" align="left">riociguat (<b>50</b>)</td><td class="colsep0 rowsep0" align="left">launched (2013)</td></tr></tbody></table></div></div><figure id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0013.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Development of drugs in the NO pathway for PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0014.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of PDE5 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23">3.3.1.  PDE5 Inhibitors</h4><div class="NLM_p"><b>32</b>, the first approved selective PDE5 inhibitor, was originally developed as a cardiovascular drug. <b>32</b> was approved in 1998 in the United States by the FDA as a drug for erectile dysfunction (ED) and was one of the best-selling drugs. <b>32</b> was later approved for the treatment of PAH in 2005. The development of <b>32</b> began with zaprinast (<b>40</b>, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), the first PDE5 inhibitor, which was reported to have weak activity and selectivity.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Extensive research on a novel 2-alkoxyphenyl-substituted heterocyclic system found that derivatives of pyrazolo[4,3-<i>d</i>]pyrimidin-7-one generally showed effective PDE5 inhibition, and compound <b>41</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) was obtained. A comparison of compound <b>41</b> and cGMP (<b>43</b>, <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) revealed that these compounds have similar sizes, shapes, and dipole moments. Therefore, given the structure of cGMP, it was hypothesized that extending the 3-position may better fill the active site of PDE5 and that the 5′-position of the phenyl ring could be optimized to obtain a binding effect similar to that of the phosphate group. Structural modifications of the 3-position and 5′-position of the phenyl ring were then studied. Substituting n-propyl for the methyl group at the 3-position produced compound <b>42</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), which showed better activity and selectivity than <b>41</b>, thus confirming the above hypothesis. It was also found that removing the methyl group at the 1-position decreased the inhibition. To fill the space occupied by the phosphate group of cGMP in the PDE active site and solve the problem of the poor solubility of <b>42</b>, a series of polar or charged groups were introduced at the 5′-position. The resulting compounds showed not only better water solubility but also higher activity. In addition, a series of modifications were made to the 2′-position of the phenyl ring. It was found that substitution with H reduced PDE5 affinity by approximately 200-fold, and substitution with hydroxyl, nitro, and sulfonamide derivatives also weakened the activity. These findings demonstrated that the ethoxy group had the best activity. Afterward, researchers performed SAR analysis and investigated the X-ray crystal structure of sildenafil, consequently proposing that the 2′-alkoxy series not only increased lipophilicity but also made the phenyl and heterocyclic systems coplanar through the hydrogen bonds formed with pyrimidinone. Thus, <b>32</b> was selected as a candidate compound for clinical research due to its high activity, selectivity, and solubility (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> In 2003, three-dimensional structures of the catalytic domain of human PDE5 complexed with <b>32</b>, <b>33</b>, and <b>34</b> were presented, and developments in structure-based search, design, and optimization of PDE inhibitors were reported (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a></div><figure id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0031.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Design of Sildenafil</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig15" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0015.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Crystal structure of the catalytic domain of PDE5 in complex with sildenafil. Sildenafil is shown in green, zinc ions are shown as gray spheres, H-bond interactions are shown as yellow dashed lines, and Π–Π stacking interactions are shown as purple dashed lines (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2h42">2h42</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>32</b> was identified to be effective in treating patients with PAH in multiple clinical trials.<a onclick="showRef(event, 'ref78 ref79 ref77'); return false;" href="javascript:void(0);" class="ref ref78 ref79 ref77">(78,79)</a> In a 12-week randomized, double-blind, placebo-controlled clinical investigation of 20, 40, and 80 mg of oral <b>32</b> in 278 patients with PAH, the final 6MWD test scores for the patients in the <b>32</b> groups were 45, 46, and 50 m higher, respectively, than those for the patients in the placebo group, and all doses decreased the mPAP. These results demonstrate that <b>32</b> can markedly improve exercise capacity and hemodynamics in patients with PAH.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> However, <b>32</b> also has obvious shortcomings, as it has a short half-life of approximately 3.7 h, and it needs to be taken three times a day.</div><div class="NLM_p"><b>33</b> is a PDE5 inhibitor that was optimized from ethyl β-carboline-3-carboxylate and exhibits modest PDE5 inhibitory activity.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Compared with <b>32</b>, <b>33</b> exhibits a longer half-life (approximately 17.5 h) and only has to be taken once a day. <b>33</b> showed good therapeutic efficacy in a 16-week randomized, double-blind, placebo-controlled study and increased the 6MWD in a dose-dependent manner.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Currently, <b>33</b> is approved in several countries for the treatment of PAH.</div><div class="NLM_p"><b>34</b> is a highly potent PDE5 inhibitor that contains an imidazo[5,1-<i>f</i>][1,2,4]triazin-4(3H)-one heterocyclic system and shows 10-fold higher activity than <b>32</b>.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a><b>34</b> is rapidly absorbed, reaching its peak plasma concentration in less than an hour, and has a half-life similar to that of <b>32</b>.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> The results of a clinical evaluation of <b>34</b> (5 mg) in PAH patients showed that it is effective and safe for these patients. Its adverse events are similar to those of other PDE5 inhibitors.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a><b>34</b> was granted PAH orphan drug designation in the United States by the FDA in 2019.</div><div class="NLM_p"><b>35</b> is a PDE5 inhibitor that can be used once daily and has been approved for ED in some countries. <b>35</b> has the characteristics of fast absorption and a long action time; the average time for <b>35</b> to reach its peak plasma concentration (<i>T</i><sub>max</sub>) is 0.8–1.9 h, and its half-life is 12.3–15.1 h.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> The therapeutic effects of <b>35</b> in patients with PAH have been identified in some clinical trials.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Among them, the phase IIb clinical trial of <b>35</b> showed that it is safe and effective in patients with PAH. Based on these positive results, <b>35</b> may become a new option for patients in the future.</div><div class="NLM_p"><b>36</b>, also known as TPN171, is a PDE5 inhibitor developed by our group. It was obtained by incorporating the structure of sophoflavescenol and through continuous pharmacokinetic optimization via adjustment of the substituents on the benzene ring.<a onclick="showRef(event, 'ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90">(88−90)</a><b>36</b> exhibits improved hydrophobic interactions with the residues of PDE5 and shows better activity and selectivity than <b>32</b>. More importantly, <b>36</b> demonstrated a sufficiently long half-life (10.9 h) for once-daily administration in phase I clinical trials and is currently in phase II clinical development for the treatment of PAH in China.</div><div class="NLM_p last">In addition, many PDE5 inhibitors have not yet been developed for PAH treatment. For example, mirodenafil (<b>37</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) is a highly selective PDE5 inhibitor that has been launched in Korea. Avanafil (<b>38</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) is also a strongly selective PDE5 inhibitor with favorable pharmacokinetics, safety, and efficacy.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Finally, TPN729 (<b>39</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) is a PDE5 inhibitor that has been evaluated in a phase I trial and is under active development.</div></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25">3.3.2.  sGC Activators</h4><div class="NLM_p">sGC activators are different from PDE5 inhibitors in that they can directly enhance cGMP production. <b>50</b> was the first and only successfully launched sGC activator. It has a dual mode of action: enhancement of the sensitivity of sGC to NO and direct activation of sGC when NO is scarce or absent. The development of sGC originated from YC-1 (<b>44</b>, <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>), which can stimulate sGC directly. The first step in optimization of <b>44</b> was variation of the benzylic moiety. It was found that introducing either a carbonyl group or an alkyl group into the methylene bridge decreased the activity, and removing the methylene group directly eliminated the activity. Next, the substituents of the aromatic moiety were studied, and compound <b>45</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) was found to have better activity after introduction of a fluorine atom at the 2-position of the benzene ring. Then, the benzopyrazole center was further optimized to give compound <b>46</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) with a pyrazolo[3,4-<i>b</i>]pyridine ring, which showed the best activity <i>in vitro</i>. Later, various substitutions were made on the furan ring, which revealed that ensuring rotational symmetry of the heteroatoms in the heterocyclic ring could significantly increase the activity. Compound <b>47</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>), which was formed through introduction of a pyrimidine ring, was found to have better activity than compound <b>46</b>. The compounds BAY 41-2272 (<b>48</b>, <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) and BAY 41-8543 (<b>49</b>, <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>) were obtained by further modification of the pyrimidine ring and found to produce long-lasting blood pressure-lowering effects in animal models; however, unfortunately, both of them exhibit relatively unfavorable pharmacokinetics.<a onclick="showRef(event, 'ref92 ref93 ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref92 ref93 ref94 ref95">(92−95)</a> Therefore, pharmacokinetics-driven optimization of <b>48</b> and <b>49</b> was conducted, and <b>50</b> was ultimately developed.</div><figure id="sch5" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0039.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Design of Riociguat</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The result of a randomized, double-blind, placebo-controlled phase III clinical trial demonstrated that <b>50</b> improved the primary end point 6MWD as well as secondary end points including PVR, WHO-FC, and time to clinical worsening in PAH patients.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Because of these favorable clinical results, <b>50</b> was approved in 2013 in the United States by the FDA for the treatment of PAH. <b>50</b> is rapidly absorbed after oral administration and reaches its peak concentration within 0.5–1.5 h after administration. <b>50</b> has a short half-life of 5–10 h, and due to this limitation, oral administration is required three times a day.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> To obtain a drug with a longer half-life, optimization of <b>50</b> was continued, and vericiguat (<b>51</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) was obtained. <b>51</b> demonstrates better pharmacokinetic properties than <b>50</b> and has been proven to be suitable for administration once daily in humans.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Currently, <b>51</b> is in phase III clinical study in patients with chronic heart failure and may be developed for patients with PAH in the future.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><figure id="fig16" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0016.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of other sGC activators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Nelociguat (<b>54</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) and cinaciguat (<b>55</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), like <b>51</b>, are currently under clinical phase II development, but no relevant reports have been published in recent years. MGV-354 (<b>57</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) is in a phase I/II clinical study for patients with ocular hypertension or glaucoma. Ataciguat (<b>58</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) has undergone phase II clinical evaluation for patients with peripheral arterial occlusive disease.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Furthermore, praliciguat (<b>52</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), olinciguat (<b>53</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) and runcaciguat (<b>56</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>) are actively being developed in clinical trials for diseases other than PAH. These drugs may all be developed in the future, and their structures are presented in <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>. Among them, <b>52</b> has been confirmed to be tolerated by healthy adults without serious adverse events and has a half-life of 24–37 h, which supports once-daily dosing.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a><b>53</b> has also successfully completed a phase I study, and the results showed good pharmacokinetic properties, with a half-life of 30 h, a <i>T</i><sub>max</sub> of 2 h, and low renal clearance.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a><b>56</b> is mainly under development for patients with chronic kidney disease and renal failure and is currently in phase I clinical trials. Finally, another sGC activator, BAY-1237592 (<b>49</b>, <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), is also being studied in phase I clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.</div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">3.4.  Kinase Inhibitors</h3><div id="sec3_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28">3.4.1.  Receptor Tyrosine Kinase (RTK) Inhibitors</h4><div class="NLM_p">In PAH, pulmonary vascular remodeling is an important pathological feature that manifests mainly as significant proliferation, migration, and antiapoptotic tendencies of pulmonary endothelial cells, SMCs, and fibroblasts. Some researchers currently suggest that pulmonary vascular remodeling may more accurately reflect the clinical reality of patients with PAH than the imbalance of vasoconstrictors and vasodilators. Moreover, the proliferation of pulmonary blood vessels shows certain similarities between PAH and cancer, so PAH can be regarded as the “cancer” of cardiovascular diseases. Therefore, the field of PAH treatment has absorbed some theories from the field of cancer treatment. In the area of targeted cancer therapy, RTK inhibitors that can effectively inhibit cancer cell proliferation and antiapoptotic activity occupy important positions. Because of the efficacy of RTK inhibitors in cancer, a wave of research into RTK inhibitors has gradually begun in the PAH field. The proteins in the RTK family mediate numerous functions in cells; for example, they regulate cell cycle progression, migration, metabolism, survival, proliferation and differentiation.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> At present, no related drugs have been successfully approved for PAH. Several RTK inhibitors that are used to treat cancer, such as imatinib, (<b>59</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), nilotinib (<b>60</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), and sorafenib (<b>62</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), have been clinically investigated for PAH treatment, but the research for most has been terminated due to safety issues, although GB002 (<b>61</b>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) is still in development.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Clinical Studies of RTK Inhibitors for PAH</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0032.gif" alt="" id="gr34" /></img><div></div></div><div class="NLM_p"><b>59</b>, a drug that inhibits Bar-Abl tyrosine kinase, platelet-derived growth factor receptor (PDGFR), and c-Kit receptors, has achieved great success. PDGFR is an RTK whose endogenous ligand is platelet-derived growth factor (PDGF). Activation of PDGFR can improve tissue remodeling and cell proliferation, so SMC and fibroblast proliferation and migration can be induced by PDGF. More importantly, overexpression of PDGF and PDGFR in the lungs has been confirmed in some PAH patients, indicating that PDGF and PDGFR play important roles in the progression of PAH.<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104,105)</a> In a rat model of MCT-induced PH, PDGFR inhibitors not only reversed hemodynamic deterioration but also impressively improved the survival rate of the model rats.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> These favorable research results suggest that PDGFR inhibitors may be effective treatments for PAH. C-Kit is commonly used as a marker for bone marrow-derived hematopoietic stem and mast cells and is able to regulate cell proliferation, differentiation, and survival. Increases in c-Kit levels and the numbers of associated c-Kit cells have been observed in the lungs of IPAH patients, suggesting that c-Kit may be involved in PAH development.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> In a 24-week randomized double-blind placebo-controlled study on the efficacy, safety, and tolerability of oral <b>59</b> in patients with advanced PAH, <b>59</b> improved exercise capacity and hemodynamics in the patients, but it caused a high incidence of serious adverse reactions.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a><b>60</b>, which has effects similar to those of <b>59</b>, can inhibit PDGFR, c-Kit, and Bar-Abl kinase receptors and has been found to prevent pulmonary proliferative lesions in animal models.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> However, development of nilotinib was terminated in phase II clinical evaluations due to severe heart, pulmonary, and liver dysfunction. An inhaled form of the PDGFR inhibitor <b>61</b> is currently being studied in a phase Ib trial to evaluate its safety, pharmacokinetics, and efficacy in patients with PAH. Moreover, <b>61</b> received orphan drug designation for the treatment of PAH in the United States and the EU in 2014 and 2019, respectively.</div><div class="NLM_p"><b>62</b> is a drug that can target multiple RTKs, such as PDGFR and c-Kit, and has been approved for the treatment of hepatocellular carcinoma and advanced clear cell renal cell carcinoma. In a 16-week clinical trial of oral <b>62</b>, all patients experienced at least one adverse event, the most common of which were diarrhea, hand-foot syndrome, rash, and alopecia.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> On the basis of the side effects commonly elicited by these RTK inhibitors, the risk is significantly greater than the benefit for normal PAH patients. Another <b>62</b> clinical trial targeted patients with refractory PAH who had taken targeted drugs but showed poor treatment outcomes and poor prognoses. These PAH patients started taking <b>62</b> as an add-on therapy at 50 mg or 100 mg, and the dose was gradually increased to 100–400 mg daily. The results demonstrated that the mPAP improved in 6 of the 9 patients, and only one patient dropped out, indicating that <b>62</b> can improve symptoms and objective variables in severe PAH patients.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a></div><div class="NLM_p last">In initial clinical explorations of the use of RTK inhibitors for PAH treatment, these drugs have generally elicited obvious and severe adverse reactions, which has greatly restricted their development. In addition, the RTK inhibitor dasatinib, a drug used to treat patients with imatinib-resistant chronic myelogenous leukemia, has been confirmed to induce PAH.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Therefore, more research should be conducted that focuses on the safety issues of RTK inhibitors in PAH patients. These drugs may be suitable for patients with refractory advanced PAH. Because PAH is a pulmonary disease, inhalation permits effective delivery of drugs at high concentrations to target sites within the lung while minimizing systemic exposure and reducing the occurrence of side effects; thus, inhalation may be a bridge enabling RTK inhibitors to be used for PAH treatment.</div></div><div id="sec3_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30">3.4.2.  Rho Kinase (ROCK) Inhibitors</h4><div class="NLM_p">ROCK belongs to the serine-threonine kinase family, has multiple physiological functions, and is associated with many diseases. ROCK is regulated mainly by Rho GTPase, which is a switch-like protein that changes state when it combines with GTP and GDP. Rho is turned on to activate downstream ROCK when it is bound to GTP, while it is turned off when it is bound to GDP. In the activated state, ROCK can induce migration, contraction, and proliferation in vascular SMCs (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> It has been demonstrated that the ROCK activity of circulating neutrophils in the lung tissue of patients with PH is significantly increased, and there are marked correlations between ROCK activity and the severity and duration of PAH.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Together, these findings suggest that ROCK is a potential effective therapeutic target for PAH.</div><figure id="fig17" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0017.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Roles of ROCK in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Fasudil (<b>63</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>), the first-generation selective inhibitor of ROCK, is primarily used to treat cerebral vasospasm. In a rat model of MCT-induced PH, <b>63</b> reduced pulmonary vascular remodeling and had stronger therapeutic effects than <b>25</b> and <b>32</b>.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> A randomized, double-blind, placebo-controlled phase IIa clinical trial of oral <b>63</b> in 23 patients with PAH showed that <b>63</b> improved pulmonary hemodynamics but had no effect on 6MWD.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Another study on inhaled <b>63</b> in PAH patients showed that <b>63</b> markedly reduced mPAP and tended to decrease PVR.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><figure id="fig18" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0018.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of fasudil.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Unlike RTK inhibitors, ROCK inhibitors did not exert severe side effects at the early stage of development. However, the effectiveness of ROCK inhibitors for PAH is uncertain; more evidence is needed for proof of concept. In addition to the above kinases, many other kinases, such as LIM, PKB, and p70s6, have also been reported to participate in the development of PAH; however, related research is still in the early stages, and no potential targets or inhibitors have been confirmed thus far. More PAH-related kinases are discussed in a review by Rita et al.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">3.5.  5-Hydroxytryptamine (5-HT) Pathway</h3><div class="NLM_p">On the basis of some findings, the substrates of 5-HT receptors or 5-HT transporter (5-HTT) can induce PH. Numerous studies have been performed to show the role of 5-HT in the progression of PAH. 5-HT receptors are divided primarily into seven subtypes, which are distributed in various systems to mediate multiple physiological functions.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Thus far, research has revealed that the main 5-HT receptor subtypes associated with PAH are 5-HT<sub>2A</sub>, 5-HT<sub>1B/D</sub>, and 5-HT<sub>2B</sub>.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> These receptor subtypes can cause pulmonary artery contraction and pulmonary SMC and fibroblast proliferation (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).</div><figure id="fig19" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0019.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Roles of the 5-HT pathway in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32">3.5.1.  5-HT Receptor Antagonists</h4><div class="NLM_p">5-HT, also known as serotonin, has been studied in the context of PAH progression. In the 5-HT receptor family, 5-HT<sub>2A</sub> mediates signaling in systemic arterial blood vessels, while 5-HT<sub>1B/D</sub> is generally distributed in the pulmonary system and participates in the contraction of pulmonary blood vessels. Studies have shown that 5-HT<sub>2A</sub> is capable of mediating bovine pulmonary vasoconstriction in the absence of vascular tone and that the 5-HT<sub>1B/D</sub> agonist Sumatriptan becomes an effective vasoconstrictor when tone is present.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Furthermore, pulmonary artery vascular tone is frequently observed in PAH patients. However, treatment with the 5-HT<sub>2A</sub> antagonist ketanserin is unsuccessful in patients with PH.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Therefore, some researchers believe that selective inhibition of 5-HT<sub>1B/D</sub> in PAH patients may more effectively inhibit pulmonary artery vasoconstriction than selection inhibition of 5-HT<sub>2D</sub>, and because 5-HT<sub>1D/B</sub> is mainly distributed in lung tissue, its inhibition does not cause systemic hypotension. In addition, 5-HT<sub>2B</sub> receptors are related to proliferation: in a mouse model of chronic hypoxia, 5-HT and the 5-HT agonist dexfenfluramine have been confirmed to promote SMC proliferation and pulmonary vascular remodeling by inducing 5-HT<sub>2B</sub>.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Thus, the 5-HT<sub>2B</sub> receptor may also play a key role in the pathogenesis of PAH.</div><div class="NLM_p">PRX-08066 (<b>68</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) is a selective 5-HT<sub>2B</sub> antagonist that has been shown to be effective in PAH treatment. In a rat model of MCT-induced PH, treatment with <b>68</b> was found to markedly reduce PAP, RV hypertrophy, and pulmonary vascular remodeling.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a><b>68</b> entered phase II clinical evaluation, but the trial was terminated for unknown reasons (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT00677872). Terguride (<b>69</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) is a drug used to treat hyperprolactinemia that antagonizes 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> and activates dopamine receptors. It has also been extensively studied for the treatment of PAH. First, <b>69</b> was confirmed to prevent the progression of PH by inhibiting the proliferation of pulmonary artery SMCs and attenuating 5-HT-induced pulmonary vasoconstriction in a rat model of MCT-induced PH.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Then, <b>69</b> was observed in some animal models to reduce RV fibrosis and improve heart function.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Unfortunately, the development of <b>69</b> was also discontinued because the drug failed to significantly improve exercise capacity and hemodynamics in a prospective phase IIa study in PAH patients.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Lisuride (<b>70</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) is a dopamine agonist, a partial agonist for several 5-HT receptors and a 5-HT<sub>2B</sub> antagonist.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Notably, updated reports have revealed that <b>70</b> has received orphan drug designation from the European Medicine Agency (EMA) and the FDA for the treatment of PAH.</div><figure id="fig20" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0020.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of 5-HT receptor antagonists, selective 5-HT reuptake inhibitors, and a tryptophan hydroxylase (TPH) inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33">3.5.2.  5-HTT Inhibitors</h4><div class="NLM_p">5-HTT is a type of monoamine transporter that transports extracellular 5-HT into cells. 5-HTT is distributed mainly on platelets, endothelial cells, vascular SMCs, mast cells, and presynaptic membranes of the nervous system.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Administration of 5-HT to rat pulmonary artery SMCs increases DNA synthesis and mitosis. Therefore, 5-HT transport into cells by 5-HTT may cause activation of some downstream signaling pathways and lead to cell proliferation.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> One study found that the RV pressure of 5-HTT-overexpressing mice was 3-fold higher than that of wild-type controls under normoxic conditions. RV hypertrophy and pulmonary vascular remodeling were also potentiated in the 5-HTT-overexpressing mice under hypoxic conditions.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Moreover, overexpression of 5-HTT has been found in the pulmonary tissues of patients with PH, which indicates that 5-HTT is closely related to the progression of PH.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p last">Fluoxetine (<b>71</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) is a selective 5-HT reuptake inhibitor that is used mainly in the clinical treatment of depression and has been used for clinical research on the treatment of PAH. However, <b>71</b> was not shown to improve PVR in a small-scale clinical phase II trial, and the improvement in exercise capacity was not significant (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT00942708 and NCT03638908). Another selective 5-HT reuptake inhibitor, escitalopram (<b>72</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), was evaluated for its efficacy in patients with PAH in phase III clinical trials, but no results have been published so far (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT00190333).</div></div><div id="sec3_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34">3.5.3.  TPH Inhibitors</h4><div class="NLM_p">The reaction catalyzed by TPH is a rate-limiting step in the synthesis of 5-HT, so TPH has an important effect on the formation of 5-HT (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). TPH has two isoforms: TPH1 and TPH2. TPH1 is expressed primarily in the gut, pineal gland, spleen, and thymus, while TPH2 is expressed primarily in the brain stem.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The expression of TPH1 in pulmonary artery endothelial cells has been identified to be increased in PAH patients.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Model mice with TPH1 gene deletion demonstrate clear attenuation of RV pressure and pulmonary vascular remodeling caused by hypoxia, suggesting that TPH1 and peripheral 5-HT play important roles in the improvement of PAH and pulmonary vascular remodeling.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> In both the MCT-induced and Sugen/hypoxia-induced mouse models of PH, the oral TPH1 inhibitor rodatristat ethyl (<b>73</b>, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) (also known as KAR5585) can significantly reduce 5-HT concentration in the lungs and decrease pulmonary vascular remodeling in a dose-dependent manner. In addition, TPH1 has been shown to reduce the perivascular mast cell accumulation associated with PH, indicating that it also has an inhibitory effect on inflammation.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a><b>73</b> is a prodrug designed to cross the blood–brain barrier, so it can selectively inhibit peripheral TPH production. On the basis of its efficacy in animal models and new mechanism of action, <b>73</b> has received orphan drug designation in the United States and the EU. A phase I study assessing the safety, tolerability, and pharmacokinetics of <b>73</b> has been completed, and the compound is being evaluated in a phase II clinical trial that started in 2019 (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02746237 and NCT03924154).</div><div class="NLM_p last">Thus far, clinical studies evaluating the effects of pharmacological manipulation of 5-HT activity on PAH have been disappointing. Drugs targeting the 5-HT pathway have not shown sufficient efficacy except for <b>73</b>, which is still under development. Moreover, 5-HT receptors and 5-HT transporters are widely distributed in the central nervous system (CNS), and manipulation of 5-HT activity may cause many adverse effects in the CNS, so selective regulation of peripheral 5-HT activity is a promising strategy.</div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">3.6.  Inflammation and Immunity</h3><div class="NLM_p">It is generally recognized that the occurrence and development of PAH are associated with dysregulation of inflammation and the immune system. First, many autoimmune diseases induce PAH. Second, different degrees of perivascular inflammatory infiltration have been found in PAH patients with pulmonary vascular lesions, including infiltration of T- and B-lymphocytes, macrophages, dendritic cells, neutrophils, and mast cells. In addition, circulating levels of cytokines and chemokines, including interleukin (IL)-1β, IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), fractalkine, CCL5/RANTES, and tumor necrosis factor (TNF)-α, have also been found to be abnormally elevated in PAH patients.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> The interaction of inflammatory cells, cytokines, and chemokines in the pulmonary system may cause excessive activation of the inflammatory and immune pathways, which then triggers proliferation and antiapoptotic activity of the pulmonary vasculature and fibrosis of the lungs. Therefore, intervention strategies targeting inflammation and the immune system may be useful for patients with PAH.</div><div class="NLM_p">Some studies on cytokines have found that overexpression of IL-6 can promote pulmonary vascular remodeling through proliferative antiapoptotic mechanisms.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> One study has revealed that inflammatory cell recruitment and pulmonary vascular remodeling are reduced in IL-6-deficient mice compared with wild-type mice under hypoxia exposure.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> These findings indicate that IL-6 has a strong interaction with pulmonary vascular remodeling and may be a potential therapeutic target for PAH treatment. Tocilizumab (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), a humanized antihuman IL-6 receptor monoclonal antibody, has already been approved for rheumatoid arthritis. This compound is now in the clinical evaluation for PAH treatment. The phase II trial of tocilizumab has been completed, but no results have been published.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Anakinra (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), a recombinant nonglycosylated human IL-1 receptor antagonist used to treat rheumatoid arthritis, has also been tested in a phase I study in patients with PAH; however, unfortunately, research was terminated early in the phase II trial due to nonexperimental factors. Rituximab (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) is a chimeric monoclonal antibody that targets the protein CD20, which is located mainly on the surfaces of B cells. Binding of rituximab to CD20 causes B cell death, thereby reducing the B cell inflammatory response. Rituximab is commonly used in the treatment of certain autoimmune diseases and cancer and is currently in phase II clinical development for the treatment of SSc-PAH.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Inflammation and Immune System Drugs in Clinical Trials for PAH</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0033.gif" alt="" id="gr35" /></img><div></div></div><div class="NLM_p">Dimethyl fumarate (DMF) (<b>74</b>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) is a drug generally used to treat psoriasis and multiple sclerosis. Although the mechanism of <b>74</b> has not yet been clearly elucidated, the compound has been shown to activate the nuclear factor erythroid-2-related factor 2 (Nrf2) pathway and inhibit the nuclear factor κB (Nf-κB) pathway. Nrf2 is a key regulator of antioxidant genes and is involved in regulating the inflammatory/immune response, while Nf-κB is mainly associated with cytokine production and cell survival. <b>74</b> has been proven in mouse models to effectively reverse hemodynamic deterioration by reducing cellular inflammation, oxidative damage, and fibrosis.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> It is currently being assessed for safety and efficacy for patients with SSc-PAH in a phase I development trial. Bardoxolone methyl (<b>75</b>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), like <b>74</b>, exhibits an anti-inflammatory effect by activating the Nrf2 pathway, inhibiting the Nf-κB pathway, and increasing the bioavailability of endogenous NO. Phase II clinical trials on <b>75</b> have been completed in patients with PAH, and the drug has been designated an orphan drug for the treatment of PAH in the USA. However, the phase III trial of <b>75</b> in CTD-PAH was terminated since preliminary analysis of the clinical data showed that the trial results were disappointing and because of the potential high risk of SARS-CoV-2 infection determined by clinical experts. Additionally, an open-label extension study of <b>75</b> in patients with PAH (RANGER) may be halted.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><div class="NLM_p">CXA-10 (<b>76</b>, <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) is a novel nitro-fatty acid with multiple anti-inflammatory effects, including activation of the Nrf2 pathway (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). In preclinical studies, <b>76</b> successfully reduced the levels of biomarkers related to altered inflammation and metabolic stress, indicative of its positive effects on inflammation and metabolism. <b>76</b> has received orphan drug designation for the treatment of PAH in the United States, and phase I clinical studies in healthy and obese subjects have been completed. The results have demonstrated that plasma concentrations of <b>76</b> increase proportionally with the dose and that CXA-10 decreases the levels of biomarkers of inflammation and metabolic abnormalities, including leptin, triglycerides, cholesterol, MCP-1, and IL-6, from baseline. Moreover, <b>76</b> has exhibited good safety and tolerability, and the most common adverse reactions are diarrhea, abdominal pain, and nausea.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a><b>76</b> is currently being evaluated in multiple clinical phase II trials for its safety and efficacy in patients with PAH (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT04053543 and NCT03449524).</div><div class="NLM_p last">In summary, research on inflammation and immune pathways is currently very popular, but the relevant clinical data are sparse. Most drugs are still under phase I or phase II clinical trials, so further exploration is necessary. Furthermore, inflammation and immune pathways have strong correlations with PAH induced by autoimmune diseases. For patients with this type of PAH, inflammation and immune pathways may be key factors in the treatment of the disease. At present, a variety of drugs that target inflammation and the immune system have begun to be developed in clinical research, specifically for patients with PAH induced by autoimmune diseases.</div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37">3.7.  Vasoactive Intestinal Peptide (VIP) Pathway</h3><div class="NLM_p last">VIP is a peptide containing 28 amino acid residues that is secreted mainly by VIP-containing nerve fibers that are distributed in large quantities around blood vessels and are thereby able to regulate the vessels. There are two subtypes of VIP receptors, VPAC-1 and VPAC-2, both of which are widely expressed in the cardiopulmonary system. Binding of VIP to its receptor can activate adenylate cyclase, which can catalyze the conversion of ATP to cAMP, causing vascular SMC relaxation and preventing the proliferation of these cells. VIP also induces an anti-inflammatory response and improves heart and pulmonary blood circulation.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Significant reductions in both VIP content in the lungs and VIP-immunoreactive nerve fibers in pulmonary arteries have been observed in PAH patients. In a prospective clinical evaluation of VIP, eight patients with PAH who had not been treated with epoprostenol and PGI<sub>2</sub> were treated with inhaled VIP. After three months of treatment, the mPAP and PVR of the patients had decreased, and the 6MWD had increased by 113 m.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> These results preliminarily confirmed that VIP had beneficial effects on PAH patients. Additionally, Vasomera (PB1046), a VIP-containing fusion protein, is currently being evaluated in phase II trials for safety, tolerance and efficacy in patients with PAH (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT03315507, NCT03556020, and NCT03795428).</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">3.8.  Mitochondrial Dysfunction</h3><div class="NLM_p">Mitochondria are organelles that provide energy to cells by mediating the production of ATP. Mitochondria are well-known to be involved in various cellular metabolic pathways and are closely related to signal transduction, differentiation, death, the cell cycle and growth.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> A mechanistic study has shown that abnormal signaling, such as hypoxia-related signaling, inflammation-related signaling, and tyrosine kinase activation, cause pyruvate dehydrogenase kinase (PDK) to phosphorylate a serine residue on pyruvate dehydrogenase (PDH), thereby inactivating it. Then, cell proliferation, inflammation, and antiapoptotic effects occur. In a rat model of MCT-induced PH, the use of the PDK inhibitor sodium dichloroacetate (<b>77</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>) effectively reduced pulmonary vascular remodeling, PVR and RV hypertrophy, suggesting that the regulation of mitochondria cannot be ignored for PAH treatment.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The results of a 4-month open-label clinical study confirmed that oral <b>77</b> reduces mPAP and PVR, indicating the effectiveness of <b>77</b> and the potential of PDK as a PAH target.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> In addition, compound <b>78</b> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>) is also a PDK inhibitor that has been designated as an orphan drug by the FDA for PAH treatment, but there is currently little information available.</div><figure id="fig21" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0021.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of PDK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39">3.9.  Bone Morphogenic Protein (BMP) Pathway</h3><div class="NLM_p">BMPs are a group of growth factors, also known as cytokines, that belong to the TGF-β superfamily. They can mediate a variety of cellular functions, including cartilage and bone formation, cell growth and differentiation, and they play important roles in embryonic development and in maintaining tissue homeostasis. BMPs have a variety of receptor types; one that is associated with PAH is BMPR2. BMPR2 is a serine/threonine receptor kinase that is essential for maintaining the barrier function of the pulmonary arterial endothelial cell lining in the lungs. BMPR2 deficiency increases inflammation of the endothelium, leading to cell proliferation and antiapoptotic activity, thus contributing to vascular remodeling.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Mice with BMPR2 gene knockout in pulmonary endothelial cells have been found to be more likely to develop PAH than wild-type mice, suggesting that the BMPR2 gene is highly correlated with PAH development.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> More importantly, mutations in the BMPR2 gene are common in patients with PAH: some surveys show that approximately 25% of cases of sporadic IPAH and at least 70% of cases of HPAH are associated with mutations in the BMPR2 gene.<a onclick="showRef(event, 'ref12 ref150'); return false;" href="javascript:void(0);" class="ref ref12 ref150">(12,150)</a> In addition, PAH patients with mutations in the BMPR2 gene have a worse prognosis and higher mortality rate than patients without such mutations, indicating that mutations in BMPR2 significantly contribute to the development of PAH.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a></div><div class="NLM_p">To find drugs that activate the BMPR2 signaling pathway, Spiekerkoetter et al. used high-throughput screening to screen 3756 FDA-approved drugs and biologically active compounds. They discovered that tacrolimus (<b>79</b>, <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) showed the best response with regard to activation of BMPR2 signaling, which was accomplished via inhibition of calcineurin and FK-binding protein-12, a repressor of BMP signaling. <b>79</b> is an immunosuppressant that can inhibit the development and proliferation of T cells by inhibiting the production of IL-2. Low-dose <b>79</b> has been shown to exert certain therapeutic effects on pulmonary artery endothelial cells in PAH patients and animal models of PH.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> A 16-week randomized, double-blind, placebo-controlled, single-center phase IIa clinical trial <b>79</b> in 23 PAH patients demonstrated that oral <b>79</b> increased the expression of BMPR2 in patients with PAH. All doses of <b>79</b> were well tolerated, and the most common adverse reactions were nausea and diarrhea (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT01647945).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a><b>79</b> has received orphan drug designation for the treatment of PAH.</div><figure id="fig22" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0022.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structure of tacrolimus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Activin, like BMP, belongs to the TGF-β superfamily and mediates various physiological functions, such as cell proliferation, differentiation, apoptosis, metabolism, and immune responses.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> Activin is now a new drug target, and inhibiting it can prevent apoptosis, fibrosis, and inflammation.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> In PAH patients, the activin and BMP signaling pathways are imbalanced. Sotatercept is a human activin type II receptor fused to a human IgG-Fc fragment and is highly selective for certain members of the TGF-β superfamily. Sotatercept has been shown to inhibit activin-induced proliferation of pulmonary artery SMCs and pulmonary endothelial cells <i>in vitro</i> and has also been confirmed to inhibit cell proliferation and RV hypertrophy in preclinical animal models.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Sotatercept has just received orphan drug designation for the treatment of PAH in the United States and is currently being developed in a phase II study to treat patients with PAH (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT03496207 and NCT03738150).</div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">3.10.  Estrogen Pathway</h3><div class="NLM_p">Women are more susceptible to PAH than men but have a higher survival rate. This paradox has attracted the attention of some researchers.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The effects of estrogen on patients with PAH are complex, and the specific relationship between estrogen and PAH is not fully understood at present; moreover, conflicting results have sometimes been obtained in animal models and clinical studies. Specifically, estrogen has been shown to improve pulmonary vascular remodeling and RV function in some animal models, while it has been shown to promote PAH development in others. These differences may have been due to various environmental factors, including oxygen tension, estrogen receptor distribution, estrogen metabolism, duration of exposure, and the biochemical environment, that caused estrogen to exhibit different effects.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Among these factors, imbalance of estrogen metabolism may ultimately play an important role in the development of PAH. Increased expression of the estrogen-metabolizing enzyme cytochrome P450 1B1 (CYP1B1) in IPAH patients and murine models of PH has been confirmed. Hypoxia-induced PH symptoms are reduced in mice with reduced CYP1B1 gene expression, and the use of the CYP1B1 inhibitor 2,3′,4,5′-tetramethoxystilbene has been found to alleviate symptoms in a mouse model of PAH <i>in vivo</i>.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> In addition, mechanistic studies have suggested that the levels of estrogen or estrogen metabolites may be related to BMPR2. In humans and mice, expression of the BMPR2 gene in females is lower than that in males, and the reduced BMPR2 gene expression may be the reason for the higher prevalence of PAH in women.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Treatment of BMPR2 mutant mice with the estrogen inhibitors fulvestrant, anastrozole, and tamoxifen helps prevent and ameliorate PAH.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Furthermore, in animal models, testosterone has been shown to increase RV hypertrophy and fibrosis, suggesting that this steroid may be responsible for the lower survival rate and poorer prognosis in male patients than in female patients.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Thus far, the specific roles played by sex hormones in PAH have not yet been elucidated; more detailed research is needed to clarify the interrelationships. On the basis of positive results in animal models, anastrozole (<b>80</b>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), fulvestrant (<b>81</b>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), and tamoxifen (<b>82</b>, <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>) have been studied in clinical trials in PAH patients.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Antiestrogen Drugs in Clinical Trials for PAH</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0034.gif" alt="" id="gr36" /></img><div></div></div><div class="NLM_p last"><b>80</b> is a nonsteroidal aromatase inhibitor that inhibits estrogen synthesis. The final results of a small proof-of-principle clinical phase II trial demonstrated that anastrozole was able to significantly reduce 17β-estradiol levels and improve 6MWD values in patients with PAH and showed that it was safe and well tolerated.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a><b>80</b> is currently being evaluated in another clinical phase II investigation for long-term efficacy and safety in patients with PAH. <b>81</b> is an estrogen receptor antagonist that has just undergone phase II clinical development for efficacy and safety in postmenopausal women with PAH. The results have shown that <b>81</b> exhibits some therapeutic effects, and it may continue to be developed in a large-scale phase II study.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a><b>82</b> is a selective estrogen receptor modulator commonly used in the treatment and prevention of breast cancer and is has also been used in clinical studies of PAH patients. Its feasibility of use and effects on patients with PAH are currently being evaluated in phase II clinical studies, but no results have been published.</div></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">3.11.  Adrenaline Pathway</h3><div class="NLM_p">Adrenaline is a hormone released by the adrenal glands, and its main receptor types are α and β receptors. In the cardiopulmonary system, α receptors are associated with vasoconstriction, and β receptors are associated with vasodilation. Among the latter, β<sub>1</sub> and β<sub>2</sub> receptors are associated with cardiac contractility, heart rate, and diastolic rate.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Downregulation of β<sub>1</sub>, α<sub>1</sub>, and dopamine-1 receptors has been found to occur in the context of PAH-associated RV failure, demonstrating that the epinephrine pathway contributes to PAP and RV hypertrophy failure in PAH.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Thus, these symptoms can be treated through the adrenergic pathway. In rat models of PH, treatment with the nonselective α<sub>1</sub>/β<sub>1</sub>/β<sub>2</sub> adrenergic blocker carvedilol was shown to increase exercise endurance, improve RV function, and increase cardiac output.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> In another animal experiment, the selective β1 blocker bisoprolol was shown to reduce RV fibrosis and myocardial inflammation, delaying progression toward right heart failure.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></div><div class="NLM_p">A 24-week randomized, double-blind, placebo-controlled clinical trial in which 30 PAH patients with heart failure were treated with carvedilol (<b>83</b>, <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) demonstrated that <b>83</b> is well tolerated, can effectively reduce heart rate and blood pressure, and can improve clinical and mechanistic outcomes.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a><b>83</b> is currently being investigated in a phase II trial for the treatment of PAH. Bisoprolol (<b>84</b>, <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) was also evaluated for efficacy and safety in patients with IPAH in a clinical study, but unfortunately, it was not effective in these patients.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> In addition, zamicastat (<b>85</b>, <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) is an oral dopamine beta-monooxygenase inhibitor that can inhibit the conversion of dopamine to norepinephrine, thereby reducing activation of the adrenergic pathway. <b>85</b> is currently being assessed for its safety and efficacy in patients with PAH (as an adjuvant therapy) in a phase II clinical trial in Australia. Moreover, the orphan drug designation was assigned to <b>85</b> in 2019 by the FDA.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Antiadrenergic Drugs in Clinical Trials for PAH</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0035.gif" alt="" id="gr37" /></img><div></div></div></div><div id="sec3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44">3.12.  Renin–Angiotensin–Aldosterone System (RAAS)</h3><div class="NLM_p">The RAAS is a hormone system that regulates blood pressure, the balance of fluid and electrolytes, and systemic vascular resistance. When renal blood flow decreases, the secretion of renin increases. Then, renin catalyzes the conversion of angiotensinogen into angiotensin I. Next, angiotensin I is converted into angiotensin II by the angiotensin-converting enzyme (ACE). Angiotensin II is an effective vasoconstrictor and can reduce blood pressure. When the RAAS is overactivated, the binding of angiotensin II to angiotensin II type 1 (AT1) receptors increases, producing many effects that promote the development of PAH, such as increased blood pressure and inflammation, endothelial dysfunction, proliferation, and fibrosis in vascular cells (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> In patients with IPAH, the levels of renin, angiotensin I, and angiotensin II in the RAAS have been shown to be abnormally elevated and related to disease progression and mortality; the activity of ACE and the expression of AT1 receptors in the pulmonary endothelial cells of these patients are also increased abnormally. In addition, it has been demonstrated that the use of the AT1 receptor antagonist losartan (<b>86</b>, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>) can delay pulmonary vascular remodeling and decrease RV afterload in an MCT-induced rat model.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Furthermore, a phase III clinical trial of <b>86</b> in PAH has been completed, but clinical development may have been discontinued due to poor efficacy (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT00519870).</div><figure id="fig23" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0023.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Roles of the RAAS in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig24" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0024.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structures of losartan and spironolactone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, aldosterone in the RAAS has a clear impact on the development of PAH. It is regulated by angiotensin II, and its content increases with angiotensin II stimulation. Aldosterone binds to mineralocorticoid receptor (MR) and then inhibits the production of NO mediated by ET<sub>B</sub> receptors, which reduces the levels of NO in endothelial cells. Aldosterone levels have also been confirmed to be increased significantly in the plasma of patients with PAH.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> The aldosterone competitive inhibitors spironolactone (<b>87</b>, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>) and eplerenone have been shown to successfully prevent and ameliorate pulmonary vascular remodeling in animal models.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a><b>87</b> has been investigated in several clinical trials for its efficacy in PAH, but no clear treatment results have been obtained (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT02253394, NCT01712620, NCT01468571, and NCT00240656).</div><div class="NLM_p last">Recent studies have also shown that ACE2 levels decrease significantly with increasing mPAP levels, suggesting that ACE2 may play an important regulatory role in PAH.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> ACE2 is an enzyme that can convert angiotensin II to angiotensin-(1-7). Then, angiotensin-(1-7) can activate the Mas receptor to antagonize angiotensin II and produce vasodilation and anti-inflammatory, antiapoptotic and antifibrotic effects.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> In MCT-induced rat models, oral administration of ACE2 or angiotensin-(1-7) has been found to significantly prevent disease development, improve right heart function, and reduce pulmonary vessel wall thickness.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Furthermore, GSK2586881, a recombinant highly glycosylated soluble form of ACE2, has been developed in clinical studies. GSK2586881 has not been found to improve 6MWD or mPAP, but an increase in cardiac output and a significant decrease in PVR have been observed 4 h after drug infusion.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> A phase II clinical study was recently completed for GSK2586881. The results indicated that the product was not able to provide sufficient benefits to patients with PAH, and its development has been suspended (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT03177603). Angiotensin-(1-7) has been granted orphan drug designation for the treatment of PAH in the United States, but relevant clinical research results have not yet been published.</div></div><div id="sec3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45">3.13.  Elastase</h3><div class="NLM_p last">Elastase is a serine protease that mainly hydrolyzes elastin and is primarily inhibited by alpha-1 antitrypsin (AAT) in the human body. A lack of AAT causes uncontrolled hydrolysis of elastin to induce emphysema and endothelial abnormalities that promote the development of PH.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Increased elastase activity has been confirmed in patients with some types of PAH, revealing that excessive activation of elastase is likely one reason for the development of PAH.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> A study on oral serine elastase in a rat model of MCT-induced PH demonstrated that it effectively reversed pulmonary vascular remodeling.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> At present, elafin is the only agent in clinical development that targets the elastase pathway. Elafin is a low-molecular weight peptide and one of the most effective inhibitors of serine elastase. A transgenic mouse model overexpressing the elafin protein was found to be resistant to pulmonary vascular disease caused by hypoxia.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Then, in the rat Sugen/hypoxia model, elafin not only reversed PH by reducing elastase activity but also activated the BMPR2 signaling pathway to promote angiogenesis, indicating that elafin has great potential for PAH treatment.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Elafin is now in a multidose, randomized, double-blind, placebo-controlled phase I trial to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT03522935).</div></div><div id="sec3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">3.14.  DNA Damage/Poly-[ADP-ribose] Polymerase 1 (PARP-1) Pathway</h3><div class="NLM_p">In PAH patients, DNA damage has been confirmed to be significantly elevated in pulmonary arterial endothelial cells and peripheral blood mononuclear cells. Peripheral blood mononuclear cells from unaffected relatives also show similar damage, indicating that DNA damage may predate the onset of PAH, which may be one of the reasons for pulmonary vascular remodeling following endothelial cell injury.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Persistent inflammation, oxidative stress, and BMPR2 variations in PAH patients are the main causes of DNA damage.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> DNA damage activates PARP-1, which is responsible mainly for DNA repair and can cause proliferation. In addition to increased DNA damage, overexpression of PARP-1 has been observed in distal pulmonary arteries and pulmonary vascular SMCs. Furthermore, PARP-1 inhibitors can effectively reverse PH in rat models, indicating that PARP-1 has the potential to become a new target for PAH treatment.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Furthermore, the role of PARP-1 in promoting PAH development may be related to downregulation of miRNA204 and subsequent activation of the transcription factors NFAT and hypoxia-inducible factor (HIF)-1α. Olaparib (<b>88</b>, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>) is an oral PARP-1 inhibitor with good safety. It has been approved by the FDA for the treatment of ovarian cancer and is being further developed in a phase Ib clinical evaluation for PAH (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT03782818).</div><figure id="fig25" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0025.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure of olaparib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47">3.15.  Other</h3><div id="sec3_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48">3.15.1.  Apelin</h4><div class="NLM_p last">Apelin is an endogenous ligand of the apelin receptor, which is expressed in a variety of tissues, including the heart, lungs, and vasculature, and binding of apelin to its receptor can regulate heart contraction force and vascular tone.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> There is evidence that apelin is able to reduce blood pressure by activating NOS in the arterial endothelium to stimulate NO production.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Apelin has also been shown to inhibit the proliferation and induce apoptosis of pulmonary vascular SMCs by rescuing the BMPR2 pathway and alleviating endothelial dysfunction. Apelin significantly reduced in the pulmonary endothelium of PAH patients, and it also reduces the symptoms of PAH in animal models.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> The results of a clinical trial in 19 patients with PAH demonstrated that intravenous (Pyr1)apelin-13 was able to reduce PVR and increase cardiac output compared to the placebo.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> (Pyr1)apelin-13 is still undergoing further clinical research; however, current progress reports are not available at present (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers: NCT01590108, NCT01457170 and NCT02129309).</div></div><div id="sec3_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49">3.15.2.  Metformin</h4><div class="NLM_p">Metformin (<b>89</b>, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>) is a first-line treatment for type 2 diabetes that works by reducing glucose production by the liver and increasing insulin sensitivity. <b>89</b> is a widely studied drug that has been confirmed to influence many diseases. Interestingly, recent studies have indicated that <b>89</b> also has a certain therapeutic effect on PAH by inhibiting aromatase, reducing inflammatory reactions, and increasing NOS activity.<a onclick="showRef(event, 'ref190 ref191 ref192'); return false;" href="javascript:void(0);" class="ref ref190 ref191 ref192">(190−192)</a> In rat models, <b>89</b> has been shown to prevent PAH, and this protective effect may be due to improvements in endothelial function, vasodilation, and antiapoptotic activity.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a><b>89</b> is currently being evaluated in phase II clinical studies in patients with PAH (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT03617458).</div><figure id="fig26" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0026.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structures of metformin, rapamycin, MN-08, CDDO-NO, and compound <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_15_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50">3.15.3.  Rapamycin</h4><div class="NLM_p last">Mechanistic target of rapamycin (mTOR) is an atypical serine/threonine protein kinase that interacts with other proteins to form two different complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The main function of mTOR is to coordinate the growth and metabolism of eukaryotic cells, and its dysregulation is related to various diseases, such as cancer and diabetes, and the aging process.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> In addition, mTOR can promote the proliferation of vascular SMCs, and studies have found that mTORC1 and mTORC2 are significantly upregulated in small remodeled pulmonary arteries and distal pulmonary artery SMCs isolated from patients with IPAH.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> An mTOR inhibitor, rapamycin (<b>90</b>, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>), has been demonstrated to reduce pulmonary vascular remodeling in animal models of PH.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> ABI-009 (Nab-rapamycin), an albumin-bound mTOR inhibitor, is currently being developed in a phase I clinical trial in patients with severe PAH (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02587325).</div></div><div id="sec3_15_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51">3.15.4.  Agents with Dual Activities of Vascular Remodeling Inhibition and Vasodilation</h4><div class="NLM_p">MN-08 (<b>91</b>, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>) derived from memantine is currently being investigated in a phase I clinical trial in China (<a href="http://chinadrugtrials.org.cn" class="extLink">chinadrugtrials.org.cn</a> registration no. CTR20200520). This agent can inhibit the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor and induce NO release for vasodilation at the same time. The NMDA receptor is a major neuronal glutamate receptor that has been confirmed to contribute to the development of PAH. Accumulation of glutamate and upregulation of the NMDA receptor have been demonstrated in PAH patients, and the NMDA receptor has also been shown to potentially participate in pulmonary vasoconstriction, hyperplasia and fibrosis. In addition, NMDA receptor blockers have been observed to prevent pulmonary remodeling in a mouse model of MCT-induced PH by reducing endothelial dysfunction, cell proliferation, and antiapoptotic activity.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> These findings suggest that the NMDA receptor is a potential target for inhibition of pulmonary vascular remodeling.</div><div class="NLM_p">Similar to <b>91</b>, CDDO-NO (<b>92</b>, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>) can be metabolized in the body to produce bardoxolone methyl and NO, which can inhibit remodeling and relax the vasculature, respectively. After inhalation administration, <b>92</b> successfully reduces pulmonary arterial pressure, ameliorates RV hypertrophy and reduces medial pulmonary artery thickness in rat models of MCT-induced PH. Moreover, inhibitory effects of <b>92</b> on excessive perivascular cell proliferation, macrophage infiltration, and oxidative stress have been confirmed.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Although clinical trials on <b>75</b> have been terminated, compounds that inhibit remodeling and induce vascular relaxation deserve further exploration. Thus, the dual effects of <b>92</b> warrant further research.</div><div class="NLM_p last">Compound <b>93</b> (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>), a promising lead compound that also has dual activities (inhibiting remodeling and relaxing the vasculature), exerts moderate vasodilatory effects via sGC stimulation and exerts stronger anti-remodeling effects than riociguat via AMP-activated protein kinase inhibition. It significantly improves RV hypertrophy and reduces the thickness of the medial pulmonary artery in hypoxia-induced PAH rat models.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a></div></div></div><div id="sec3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52">3.16.  Natural Products</h3><div class="NLM_p">In the field of PAH research, some natural products have been identified to improve the symptoms and prognosis of PAH, showing great potential and attracting increasing attention from researchers.</div><div class="NLM_p">Sodium tanshinone IIa sulfonate (<b>94</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), a water-soluble derivative of tanshinone IIa extracted from <i>Salvia miltiorrhiza</i>, exhibits a variety of beneficial cardiovascular effects and shows therapeutic efficacy for PAH. In a rat model of chronic hypoxia-induced PH, injection of <b>94</b> has been found to significantly reduce related pulmonary vascular changes, and most importantly, to dose-dependently inhibit the proliferation and migration of pulmonary artery SMCs. In addition, <b>94</b> has been confirmed to significantly improve hemodynamics in a rat model of MCT-induced PH.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> In a clinical trial, five patients with severe PH who had not sufficiently benefitted from sildenafil treatment for at least three months exhibited improved hemodynamics and exercise capacities after treatment with <b>94</b> via infusion for 8 weeks.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a></div><figure id="fig27" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0027.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structures of natural products for PAH treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ligustrazine (<b>95</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), also known as tetramethylpyrazine, is a natural product isolated from the traditional Chinese medicine <i>Ligusticum wallichii</i> and has been extensively studied for its prominent beneficial cardiovascular and cerebrovascular activity. <b>95</b> has various physiological effects, including anti-inflammatory, antioxidant, antiplatelet, and antiapoptotic effects.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> In a dog model of acute hypoxia-induced PH, <b>95</b> significantly reduced mPAP, PVR, and plasma ET-1 levels.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> The mechanism of action of <b>95</b> may include regulation of ion channels, stimulation of the production and release of NO, inhibition of the proliferation and migration of vascular SMCs, regulation of inflammation and apoptosis, and prevention of platelet aggregation.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Furthermore, <b>95</b> has been shown to reduce plasma ET-1 and mPAP levels in patients with chronic obstructive pulmonary disease.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a><b>95</b> is currently being investigated in a randomized controlled trial in China for its efficacy and safety in patients with PH (ChiCTR1800018664).</div><div class="NLM_p">The juice extracted from beetroot (<i>Beta vulgaris rubra</i>) is rich in nitrate, which can enhance the synthesis of NO. Moreover, betalain pigments from beetroot juice have been proven to exhibit strong antioxidative and anti-inflammatory effects both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> A randomized, double-blind,2 placebo-controlled exploratory clinical trial of beetroot juice treatment in 15 patients with PAH demonstrated that beetroot juice increased NO production and relative arginine bioavailability and improved RV function (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT02000856).<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a></div><div class="NLM_p">Rhodiola is a traditional Chinese medicine that has been widely used. Rhodiola extract has been confirmed to reduce mPAP, RV hypertrophy, and pulmonary small artery wall thickness in a rat model of chronic hypoxia-induced PH.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> In a mechanistic study, Rhodiola extract showed a variety of biological effects; for example, it reduced VEGF and TNF-β expression, inhibited cytokine production, decreased kinase and ACE activity, and repaired mitochondrial function. In addition, Rhodiola may be a potential NO stimulant and ET-1 inhibitor, and NO and ET-1 are related to the development of PAH.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Salidroside (<b>96</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) isolated from Rhodiola has been confirmed to inhibit proliferation of pulmonary artery SMCs and resistance to apoptosis by activating the monophosphate-activated protein kinase pathway in experimental models.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a></div><div class="NLM_p">Tetrandrine (<b>97</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) is a bisbenzylisoquinoline alkaloid, a natural compound isolated from <i>Stephania tetrandra</i> S Moore. Compound <b>97</b> can significantly inhibit cell proliferation and DNA synthesis in growth factor-induced rat pulmonary artery SMCs.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> Moreover, in a rat model of MCT-induced PH, <b>97</b> was able to reduce mPAP and RV hypertrophy. A mechanistic study suggested that <b>97</b> can upregulate the expression of type 1 protein kinase, downregulate the expression of NOS, and reduce the content of malondialdehyde.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a></div><div class="NLM_p">Triptolide (<b>98</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) is a natural compound extracted from <i>Tripterygium wilfordii</i>. In a rat model of MCT-induced PH, <b>98</b> has been shown to significantly reduce mPAP, RV hypertrophy, and pulmonary remodeling, but the specific mode of action is unclear.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Breviscapine is extracted from <i>Erigeron breviscapus</i>, and scutellarin is its main compound. Breviscapine has a variety of cardiovascular benefits and has been shown to have an inhibitory effect on PAH development. In a rat model of hypoxia-induced PH, breviscapine was observed to significantly reduce mPAP, inhibit RV failure, and decrease the mRNA and protein expression of ROCK.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> Breviscapine has also been confirmed to effectively reduce serum ET-1 and NO levels in another rat model of chronic hypoxia-induced PH.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> Flavonoids from hawthorn have also been shown to have beneficial effects on PAH. In broiler chickens with ascites at high altitudes, hawthorn flavonoid extract is able to enhance the expression of NOS in the heart and significantly increase the circulating concentration of NO while also reducing the concentration of serum malondialdehyde and the number of lymphocytes. This extract ultimately successfully reduces RV hypertrophy and mortality caused by PH.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a></div><div class="NLM_p last">Moreover, the polyphenolic compound resveratrol (<b>99</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) has also been indicated to prevent PAH via its antiproliferative, anti-inflammatory, and antioxidant activities in hypoxia-induced PH rat models.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Polydatin (<b>100</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), an active ingredient isolated from <i>Polygonum cuspidatum</i>, is able to dose-dependently reduce mPAP and reverse remodeling in hypoxia-induced rat PH models while regulating the levels of NO, angiotensin II, and ET in serum.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> Icariin (<b>102</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) is the main active compound of the herb Epimedium. It has been reported to increase the concentrations of NO and cGMP by increasing the expression of NOS and inhibiting PDE5, and these effects have been proven in a rat model of MCT-induced PH.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> Qianhu is a traditional Chinese medicine that is mainly used to treat diseases related to the respiratory system. Pyrancoumarin compounds extracted from qianhu demonstrate relaxing effects in the tracheas and pulmonary arteries of rabbits.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> Osthole (<b>101</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) is a coumarin isolated mainly from <i>Cnidium monnieri</i> that has been found to be beneficial for PAH treatment. In a rat model of MCT-induced PH, <b>101</b> has been found to significantly reduce mPAP and decrease pulmonary artery thickening, and mechanistic studies have suggested that these effects may be due to regulation of the TGF-β/Smad/p38 signaling pathway.<a onclick="showRef(event, 'ref220 ref221'); return false;" href="javascript:void(0);" class="ref ref220 ref221">(220,221)</a> Astragalus polysaccharides extracted from <i>Astragalus propinquus</i> also attenuate the development of PH in MCT-induced PH rat models. The specific mechanism of action has been suggested to involve relaxation of blood vessels that is accomplished via promotion of NOS synthesis and NO secretion. Astragalus polysaccharides have also been shown to reduce the inflammatory response by reducing the levels of various cytokines and chemokines.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> Silibinin (<b>103</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) is extracted from silybum and has been identified to reduce the symptoms of early PAH in a rat model induced by MCT and chronic hypoxia. This effect may be associated with the inhibition of C-X-C chemokine receptor type 4, which may play a role in PAH development.<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> 18β-Glycyrrhetinic acid (<b>104</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) has also been shown to have protective effects in animal models of PH by regulating the activity of ROCK.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> Baicalin (<b>105</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) has been found to improve pulmonary vascular remodeling in a rat model of MCT-induced PH, and it has been suggested that baicalin may attenuate PAH development by inhibiting Nf-κB signaling and activating BMP signaling.<a onclick="showRef(event, 'ref225 ref226'); return false;" href="javascript:void(0);" class="ref ref225 ref226">(225,226)</a> Moreover, oxymatrine (<b>106</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), caffeic acid phenethyl ester (<b>107</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), betaine (<b>108</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), aloperine (<b>109</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), and dihydromyricetin (<b>110</b>, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>) have also been identified to attenuate the development of PAH in experimental models, and most of these compounds exhibit outstanding anti-inflammatory effects.<a onclick="showRef(event, 'ref227 ref228 ref229 ref230 ref231 ref232'); return false;" href="javascript:void(0);" class="ref ref227 ref228 ref229 ref230 ref231 ref232">(227232)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">4.  Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53311" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53311" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The existing drugs for the treatment of PAH are mainly PGI<sub>2</sub> analogues and PGI<sub>2</sub> receptor agonists that target the PGI<sub>2</sub> pathway, ERAs that target the ET pathway, and PDE5 inhibitors and sGC activators that target the NO pathway. After years of development, drugs targeting these pathways have gradually become widely used, and various earlier defects, such as short half-lives, low bioavailability, and excessive liver toxicity, have been overcome. The emergence of these drugs has greatly improved the hemodynamics, exercise capacity, and quality of life of patients with PAH. However, these targeted drugs were developed primarily to reduce PAP; they have little effect on pulmonary artery remodeling. Therefore, PAH remains an incurable disease with a very poor prognosis and a high mortality rate, and the clinical needs are still not met with the existing targeted drugs.</div><div class="NLM_p">Although early reports indicated that vasoconstriction plays a key role in PAH pathogenesis, PAH is now generally regarded as a vasculopathy involving remodeling of the pulmonary vasculature that is characterized by pulmonary vascular cell proliferation and inflammation.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Various types of drugs targeting vasoconstriction have been approved to treat PAH, but there is a lack of agents that can reverse remodeling. In this regard, more attention should be paid to remodeling of the pulmonary vasculature. Pulmonary vascular remodeling is considered to be the result of a combination of genetic, epigenetic, and environmental factors, and a variety of vasoactive molecules, ion channels, and signaling pathways play important roles. Modern researchers are eager to find agents that can inhibit or even reverse pulmonary vascular remodeling in order to eventually achieve a healing effect. Therefore, many drugs targeting the pathway driving pulmonary artery remodeling have been developed.</div><div class="NLM_p">Proliferation plays a key role in pulmonary artery remodeling, which is similar to the pathological mechanism of cancer. Therefore, research on PAH is no longer confined to the cardiovascular field but has incorporated some concepts and theories from cancer research. A variety of cancer-related growth factors have been shown to promote the development of PAH, so a variety of cancer-related drugs have been investigated for their therapeutic effects on PAH. Although these drugs inhibit pulmonary vascular remodeling to some extent, their utilization is very limited, as these drugs cannot differentiate healthy cells from diseased cells, which often leads to severe toxicity and side effects.<a onclick="showRef(event, 'ref232'); return false;" href="javascript:void(0);" class="ref ref232">(232)</a> The safety problems associated with kinase inhibitors with intolerable side effects have yet to be solved. At present, inhaled GB002 is still under clinical trial, and inhalation may be an effective administration method for RTK inhibitors.</div><div class="NLM_p">Inflammation and the immune system play important roles in pulmonary artery remodeling. Different degrees of inflammatory cell infiltration are observed in the pulmonary vascular lesions of PAH patients; this infiltration causes the circulating levels of cytokines and chemokines to increase significantly in these patients, thereby affecting the remodeling of pulmonary blood vessels. Thus, research on inflammation and immune pathways related to PAH has also gradually become popular. Inflammation-related drugs with novel mechanisms that have been developed in recent years are still being evaluated in early clinical trials but have not yet exhibited enough efficacy in patients with PAH. Moreover, some drugs targeting inflammation/the immune system have received orphan drug designation, which indicates the considerable potential of inflammation-/immune system-targeting drugs for PAH treatment. In addition, clinical drugs targeting other pathways related to pulmonary vascular remodeling, such as pathways involving 5-HT, vasoactive peptides, elastase, mitochondrial modulators and BMPR2, are still in the early stages of investigation and have often been shown to have insufficient efficacy. Therefore, further studies are necessary.</div><div class="NLM_p">Clinical trials of inhaled NO, GB002, PGI<sub>2</sub> and PGI<sub>2</sub> analogues have identified inhalation administration as an effective method. Inhalation administration can deliver drugs directly to the pulmonary system to selectively target the lungs and avoid systemic side effects. However, inhalation administration is rarely used for the treatment of PAH due to the need for a special inhaler to deliver drugs to the lungs at specific doses, which increases the difficulty and cost of research and development. In addition, unlike asthma, PAH does not require fast delivery of medication. Nevertheless, with breakthroughs in technology and reductions in cost, inhalation administration will likely account for a large proportion of PAH treatment.</div><div class="NLM_p">At present, combination therapy is being accepted by an increasing number of doctors and patients, and it is one of the main directions for disease therapies. Combination therapies that exploit different pathways and targets to intervene in multiple pathological processes have been clinically proven to be feasible. For example, combination therapy with ambrisentan and tadalafil has been confirmed to show better treatment efficacy than monotherapy in large-scale clinical trials.<a onclick="showRef(event, 'ref233'); return false;" href="javascript:void(0);" class="ref ref233">(233)</a> Currently, dual therapy with a PDE5 inhibitor and an ERA is the most widely utilized combination regimen, while triple therapy targeting all three pathways offers additional benefit to patients who respond inadequately to dual therapy.<a onclick="showRef(event, 'ref234'); return false;" href="javascript:void(0);" class="ref ref234">(234)</a> In the future, combination therapy targeting different pathways related to both pulmonary vascular tone and vascular remodeling may further improve patient prognosis.</div><div class="NLM_p">In view of the individual differences among PAH patients, precision medicine may become a trend for PAH treatment in the future. Precision medicine uses in-depth clinical information as well as omics (genomics, transcriptomics, metabolomics, and proteomics) data to identify the molecular basis of PAH and redefine patient subgroups; it is helpful for identifying patients who respond better than others to a specific treatment and thus for improving the success rate of drug development.</div><div class="NLM_p">Furthermore, the efficacy of natural products as a therapy has increasingly received worldwide attention. Many experiments have indicated that some natural products act simultaneously on multiple targets and pathways and are uniquely advantageous for PAH therapy. More importantly, the novel skeletons, targets, and mechanisms of natural products may provide new inspiration to researchers, which may lead to theoretical innovations in the field of PAH research.<a onclick="showRef(event, 'ref235 ref236 ref237'); return false;" href="javascript:void(0);" class="ref ref235 ref236 ref237">(235−237)</a></div><div class="NLM_p last">In summary, the development of drugs for PAH is still an enormous challenge. Though increasing numbers of researchers are focusing on the discovery of potential drugs, they are far from curing PAH. With increased understanding of PAH pathology, discovery and application of new and effective therapeutic strategies will enable the discovery of new drugs for clinical treatment that will be approved by the FDA. Such drugs will improve PAH-related mortality and PAH prognosis until PAH is finally cured.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01093" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingshan Shen</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, University of the Chinese Academy
of Sciences, Beijing 100049, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9679-9934" title="Orcid link">http://orcid.org/0000-0001-9679-9934</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a5d6cdc0cbcfcccbc2d6cdc4cbe5d6ccc8c88bc4c68bc6cb"><span class="__cf_email__" data-cfemail="394a515c575350575e4a515857794a50545417585a175a57">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Zheng</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, University of the Chinese Academy
of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhen Wang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9450-2260" title="Orcid link">http://orcid.org/0000-0001-9450-2260</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiangrui Jiang</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5941-6105" title="Orcid link">http://orcid.org/0000-0001-5941-6105</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingjie Zhao</span> - <span class="hlFld-Affiliation affiliation">CAS
Key Laboratory of Receptor Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>W.Z. and Z.W. contributed equally to this study. The manuscript was written through contributions of all authors. All authors have approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The Shanghai Institute of Materia Medica has applied for PCT and Chinese patents that cover TPN729, simmerafil, and related compounds.<br /></br>The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Wei Zheng</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=BIO-d7e3813-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wei Zheng</b> received his Bachelor of Science degree in Pharmaceutical Science from East China University of Science and Technology in 2014 and is currently a Ph.D. student under the supervision of Professor Jingshan Shen at Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS). His research focuses on the rational design and synthesis of biologically active small molecules and their chemical biology in the context of cardiovascular and cerebrovascular diseases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Zhen Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=BIO-d7e3818-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zhen Wang</b> received his Ph.D. in Pharmacology from the College of Pharmaceutical Sciences, Zhejiang University, in 2014. He is currently a Drug Development Fellow at SIMM, CAS. His research focuses on the pharmacology and clinical evaluation of new anti-PAH drugs and CNS drugs.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Xiangrui Jiang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=BIO-d7e3823-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiangrui Jiang</b> received his Ph.D. in Pharmacology from the College of Pharmaceutical Sciences, Zhejiang University, in 2005. He completed postdoctoral training at SIMM, CAS, where he is currently a Drug Discovery Fellow. His research efforts are directed towards the discovery of small molecules for interventions for PAH, viral diseases, and CNS diseases.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Qingjie Zhao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=BIO-d7e3828-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Qingjie Zhao</b> received his Ph.D. in Medicinal Chemistry from SIMM in 2008. He completed postdoctoral training at the University of Nebraska Medical Center, Cornell University, and the University of Michigan. He is currently a Drug Development Fellow at SIMM, CAS. His research focuses on the medicinal chemistry of natural products.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Jingshan Shen</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=BIO-d7e3833-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jingshan Shen</b> received his Ph.D. in Medicinal Chemistry from SIMM in 1998. He works on drug discovery programs for respiratory system-targeting, CNS-targeting, and antiviral drugs. He also works on industrial-oriented green and sustainable chemistry with a “control from root” design strategy.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83756" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83756" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Strategic Priority Research Program of the CAS (No. XDA12040103); the National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China (No. 2018ZX09711002); and the Central Asian Center of Drug Discovery and Development Program of the CAS (No. CAM201901). The authors thank Dongye Shen for his contribution to the English editing and polishing of this manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AA</td><td class="NLM_def"><p class="first last">arachidonic acid</p></td></tr><tr><td class="NLM_term">AAT</td><td class="NLM_def"><p class="first last">alpha-1 antitrypsin</p></td></tr><tr><td class="NLM_term">ACE</td><td class="NLM_def"><p class="first last">angiotensin-converting enzyme</p></td></tr><tr><td class="NLM_term">ACVRL1</td><td class="NLM_def"><p class="first last">activin a receptor like type 1</p></td></tr><tr><td class="NLM_term">AT1</td><td class="NLM_def"><p class="first last">angiotensin II type 1</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">BMP</td><td class="NLM_def"><p class="first last">bone morphogenetic protein</p></td></tr><tr><td class="NLM_term">BMP9</td><td class="NLM_def"><p class="first last">bone morphogenetic protein 9</p></td></tr><tr><td class="NLM_term">BMPR2</td><td class="NLM_def"><p class="first last">bone morphogenetic protein receptor type 2</p></td></tr><tr><td class="NLM_term">CAV1</td><td class="NLM_def"><p class="first last">caveolin 1</p></td></tr><tr><td class="NLM_term">cGMP</td><td class="NLM_def"><p class="first last">cyclic guanosine monophosphate</p></td></tr><tr><td class="NLM_term">CHD</td><td class="NLM_def"><p class="first last">congenital heart disease</p></td></tr><tr><td class="NLM_term">CHD-PAH</td><td class="NLM_def"><p class="first last">pulmonary arterial hypertension associated with congenital heart disease</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">CTD</td><td class="NLM_def"><p class="first last">connective tissue disease</p></td></tr><tr><td class="NLM_term">CTD-PAH</td><td class="NLM_def"><p class="first last">pulmonary arterial hypertension associated with connective tissue disease</p></td></tr><tr><td class="NLM_term">CYP1B1</td><td class="NLM_def"><p class="first last">cytochrome P450 1B1</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethyl fumarate</p></td></tr><tr><td class="NLM_term">ED</td><td class="NLM_def"><p class="first last">erectile dysfunction</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicine Agency</p></td></tr><tr><td class="NLM_term">ERA</td><td class="NLM_def"><p class="first last">endothelin receptor antagonist</p></td></tr><tr><td class="NLM_term">ET-1</td><td class="NLM_def"><p class="first last">endothelin-1</p></td></tr><tr><td class="NLM_term">ET<sub>A</sub></td><td class="NLM_def"><p class="first last">endothelin receptor type A</p></td></tr><tr><td class="NLM_term">ET<sub>B</sub></td><td class="NLM_def"><p class="first last">endothelin receptor type B</p></td></tr><tr><td class="NLM_term">ENG</td><td class="NLM_def"><p class="first last">endoglin</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GEF</td><td class="NLM_def"><p class="first last">guanine nucleotide exchange factor</p></td></tr><tr><td class="NLM_term">GTP</td><td class="NLM_def"><p class="first last">guanosine triphosphate</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">HIF-α</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor 1-alpha</p></td></tr><tr><td class="NLM_term">HPAH</td><td class="NLM_def"><p class="first last">heritable PAH</p></td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine</p></td></tr><tr><td class="NLM_term">5-HTT</td><td class="NLM_def"><p class="first last">5-HT transporter</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">prostacyclin receptor</p></td></tr><tr><td class="NLM_term">IPAH</td><td class="NLM_def"><p class="first last">idiopathic pulmonary arterial hypertension</p></td></tr><tr><td class="NLM_term">KCNK3</td><td class="NLM_def"><p class="first last">potassium channel subfamily K member 3</p></td></tr><tr><td class="NLM_term">MCP-1</td><td class="NLM_def"><p class="first last">monocyte chemoattractant protein-1</p></td></tr><tr><td class="NLM_term">MCT</td><td class="NLM_def"><p class="first last">monocrotaline</p></td></tr><tr><td class="NLM_term">mPAP</td><td class="NLM_def"><p class="first last">mean pulmonary arterial pressure</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mechanistic target of rapamycin</p></td></tr><tr><td class="NLM_term">mTORC1</td><td class="NLM_def"><p class="first last">mechanistic target of rapamycin complex 1</p></td></tr><tr><td class="NLM_term">mTORC2</td><td class="NLM_def"><p class="first last">mechanistic target of rapamycin complex 2</p></td></tr><tr><td class="NLM_term">6MWD</td><td class="NLM_def"><p class="first last">6 min walking distance</p></td></tr><tr><td class="NLM_term">Nf-κB</td><td class="NLM_def"><p class="first last">nuclear factor κB</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term">NOS</td><td class="NLM_def"><p class="first last">nitric oxide synthase</p></td></tr><tr><td class="NLM_term">Nrf2</td><td class="NLM_def"><p class="first last">nuclear factor erythroid-2-related factor 2</p></td></tr><tr><td class="NLM_term">NYHA-FC</td><td class="NLM_def"><p class="first last">New York Heart Association Functional Classification</p></td></tr><tr><td class="NLM_term">PAH</td><td class="NLM_def"><p class="first last">pulmonary arterial hypertension</p></td></tr><tr><td class="NLM_term">PAP</td><td class="NLM_def"><p class="first last">pulmonary arterial pressure</p></td></tr><tr><td class="NLM_term">PARP-1</td><td class="NLM_def"><p class="first last">poly [ADP-ribose] polymerase</p></td></tr><tr><td class="NLM_term">PAWP</td><td class="NLM_def"><p class="first last">pulmonary artery wedge pressure</p></td></tr><tr><td class="NLM_term">PDE5</td><td class="NLM_def"><p class="first last">phosphodiesterase 5</p></td></tr><tr><td class="NLM_term">PDGF</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PDH</td><td class="NLM_def"><p class="first last">phosphorylate pyruvate dehydrogenase</p></td></tr><tr><td class="NLM_term">PDK</td><td class="NLM_def"><p class="first last">pyruvate dehydrogenase kinase</p></td></tr><tr><td class="NLM_term">PGG2</td><td class="NLM_def"><p class="first last">prostaglandin G2</p></td></tr><tr><td class="NLM_term">PGH2</td><td class="NLM_def"><p class="first last">hydroxy endoperoxide</p></td></tr><tr><td class="NLM_term">PGI<sub>2</sub></td><td class="NLM_def"><p class="first last">prostacyclin</p></td></tr><tr><td class="NLM_term">PH</td><td class="NLM_def"><p class="first last">pulmonary hypertension</p></td></tr><tr><td class="NLM_term">PKA</td><td class="NLM_def"><p class="first last">cAMP-dependent protein kinase</p></td></tr><tr><td class="NLM_term">PKG</td><td class="NLM_def"><p class="first last">protein kinase G</p></td></tr><tr><td class="NLM_term">PTGIS</td><td class="NLM_def"><p class="first last">prostaglandin I2 synthase</p></td></tr><tr><td class="NLM_term">PVOD/PCH</td><td class="NLM_def"><p class="first last">pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis</p></td></tr><tr><td class="NLM_term">PVR</td><td class="NLM_def"><p class="first last">pulmonary vascular resistance</p></td></tr><tr><td class="NLM_term">RAAS</td><td class="NLM_def"><p class="first last">renin-angiotensin-aldosterone system</p></td></tr><tr><td class="NLM_term">ROCK</td><td class="NLM_def"><p class="first last">Rho kinase</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">RV</td><td class="NLM_def"><p class="first last">right ventricular</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">sGC</td><td class="NLM_def"><p class="first last">soluble guanylate cyclase</p></td></tr><tr><td class="NLM_term">SMAD9</td><td class="NLM_def"><p class="first last">sterile alpha motif domain-containing protein 9</p></td></tr><tr><td class="NLM_term">SMC</td><td class="NLM_def"><p class="first last">smooth muscle cell</p></td></tr><tr><td class="NLM_term">SSc</td><td class="NLM_def"><p class="first last">systemic sclerosis</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">TGF-β</td><td class="NLM_def"><p class="first last">transforming growth factor beta</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor-alpha</p></td></tr><tr><td class="NLM_term">TP</td><td class="NLM_def"><p class="first last">thromboxane receptor</p></td></tr><tr><td class="NLM_term">TPH</td><td class="NLM_def"><p class="first last">tryptophan hydroxylase</p></td></tr><tr><td class="NLM_term">TXA<sub>2</sub></td><td class="NLM_def"><p class="first last">thromboxane A2</p></td></tr><tr><td class="NLM_term">VIP</td><td class="NLM_def"><p class="first last">vasoactive intestinal peptide</p></td></tr><tr><td class="NLM_term">WHO-FC</td><td class="NLM_def"><p class="first last">World Health Organization Functional Classe</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 237 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noordegraaf, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, M. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancellotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonagh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierard, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zompatori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M.</span></span> <span> </span><span class="NLM_article-title">2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1183/13993003.01032-2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01032-2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26318161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=903-975&author=N.+Galieauthor=M.+Humbertauthor=J.-L.+Vachieryauthor=S.+Gibbsauthor=I.+Langauthor=A.+Torbickiauthor=G.+Simonneauauthor=A.+Peacockauthor=A.+V.+Noordegraafauthor=M.+Beghettiauthor=A.+Ghofraniauthor=M.+A.+G.+Sanchezauthor=G.+Hansmannauthor=W.+Klepetkoauthor=P.+Lancellottiauthor=M.+Matucciauthor=T.+McDonaghauthor=L.+A.+Pierardauthor=P.+T.+Trindadeauthor=M.+Zompatoriauthor=M.+Hoeper&title=2015+ESC%2FERS+guidelines+for+the+diagnosis+and+treatment+of+pulmonary+hypertension&doi=10.1183%2F13993003.01032-2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Humbert, Marc; Vachiery, Jean-Luc; Gibbs, Simon; Lang, Irene; Torbicki, Adam; Simonneau, Gerald; Peacock, Andrew; Noordegraaf, Anton Vonk; Beghetti, Maurice; Ghofrani, Ardeschir; Sanchez, Miguel Angel Gomez; Hansmann, Georg; Klepetko, Walter; Lancellotti, Patrizio; Matucci, Marco; McDonagh, Theresa; Pierard, Luc A.; Trindade, Pedro T.; Zompatori, Maurizio; Hoeper, Marius</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">903-975</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">This article describes on 2015 ESC/ERS guidelines for diagnosis and treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorK3std3OPyrVg90H21EOLACvtfcHk0liJgb6ao7jV3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslSiu74%253D&md5=b8fbd51d60af38c30146a8e3c60de880</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1183%2F13993003.01032-2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01032-2015%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.-L.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DNoordegraaf%26aufirst%3DA.%2BV.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DM.%2BA.%2BG.%26aulast%3DHansmann%26aufirst%3DG.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMatucci%26aufirst%3DM.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DPierard%26aufirst%3DL.%2BA.%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DZompatori%26aufirst%3DM.%26aulast%3DHoeper%26aufirst%3DM.%26atitle%3D2015%2520ESC%252FERS%2520guidelines%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520pulmonary%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D903%26epage%3D975%26doi%3D10.1183%2F13993003.01032-2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celermajer, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatzoulis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krowka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span> <span> </span><span class="NLM_article-title">Haemodynamic definitions and updated clinical classification of pulmonary hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1801913</span>, <span class="refDoi"> DOI: 10.1183/13993003.01913-2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01913-2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30545968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=1801913&author=G.+Simonneauauthor=D.+Montaniauthor=D.+S.+Celermajerauthor=C.+P.+Dentonauthor=M.+A.+Gatzoulisauthor=M.+Krowkaauthor=P.+G.+Williamsauthor=R.+Souza&title=Haemodynamic+definitions+and+updated+clinical+classification+of+pulmonary+hypertension&doi=10.1183%2F13993003.01913-2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Haemodynamic definitions and updated clinical classification of pulmonary hypertension</span></div><div class="casAuthors">Simonneau, Gerald; Montani, David; Celermajer, David S.; Denton, Christopher P.; Gatzoulis, Michael A.; Krowka, Michael; Williams, Paul G.; Souza, Rogerio</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1801913</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation.  Recent data from normal subjects has shown that normal mPAP was 14.0 ± 3.3 mmHg.  Two std. deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile).  This definition is no longer arbitrary, but based on a scientific approach.  However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure.  Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH assocd. with mPAP >20 mmHg.  Prospective trials are required to det. whether this PH population might benefit from specific management.  Regarding clin. classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_4e3AX60qrVg90H21EOLACvtfcHk0liJgb6ao7jV3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7rL&md5=3864bf280a8c2d38ebf6710debf9287e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1183%2F13993003.01913-2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01913-2018%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DCelermajer%26aufirst%3DD.%2BS.%26aulast%3DDenton%26aufirst%3DC.%2BP.%26aulast%3DGatzoulis%26aufirst%3DM.%2BA.%26aulast%3DKrowka%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DP.%2BG.%26aulast%3DSouza%26aufirst%3DR.%26atitle%3DHaemodynamic%2520definitions%2520and%2520updated%2520clinical%2520classification%2520of%2520pulmonary%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2019%26volume%3D53%26spage%3D1801913%26doi%3D10.1183%2F13993003.01913-2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galiè, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez Sanchez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancellotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonagh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierard, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zompatori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M.</span></span> <span> </span><span class="NLM_article-title">2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS): endorsed by: association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehv317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1093%2Feurheartj%2Fehv317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26320113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC287nt1Gitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=67-119&author=N.+Gali%C3%A8author=M.+Humbertauthor=J.-L.+Vachieryauthor=S.+Gibbsauthor=I.+Langauthor=A.+Torbickiauthor=G.+Simonneauauthor=A.+Peacockauthor=A.+Vonk+Noordegraafauthor=M.+Beghettiauthor=A.+Ghofraniauthor=M.+A.+Gomez+Sanchezauthor=G.+Hansmannauthor=W.+Klepetkoauthor=P.+Lancellottiauthor=M.+Matucciauthor=T.+McDonaghauthor=L.+A.+Pierardauthor=P.+T.+Trindadeauthor=M.+Zompatoriauthor=M.+Hoeper&title=2015+ESC%2FERS+guidelines+for+the+diagnosis+and+treatment+of+pulmonary+hypertension%3A+the+joint+task+force+for+the+diagnosis+and+treatment+of+pulmonary+hypertension+of+the+european+society+of+cardiology+%28ESC%29+and+the+european+respiratory+society+%28ERS%29%3A+endorsed+by%3A+association+for+european+paediatric+and+congenital+cardiology+%28AEPC%29%2C+international+society+for+heart+and+lung+transplantation+%28ISHLT%29&doi=10.1093%2Feurheartj%2Fehv317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</span></div><div class="casAuthors">Galie Nazzareno; Humbert Marc; Vachiery Jean-Luc; Gibbs Simon; Lang Irene; Torbicki Adam; Simonneau Gerald; Peacock Andrew; Vonk Noordegraaf Anton; Beghetti Maurice; Ghofrani Ardeschir; Gomez Sanchez Miguel Angel; Hansmann Georg; Klepetko Walter; Lancellotti Patrizio; Matucci Marco; McDonagh Theresa; Pierard Luc A; Trindade Pedro T; Zompatori Maurizio; Hoeper Marius</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-119</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcJiEtRxzflCnGiHuhFGv8fW6udTcc2eZCbxV9XQm9Y7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nt1Gitg%253D%253D&md5=8ef6fec63bd8bb337bec7485660ea933</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehv317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehv317%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.-L.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DA.%26aulast%3DGomez%2BSanchez%26aufirst%3DM.%2BA.%26aulast%3DHansmann%26aufirst%3DG.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMatucci%26aufirst%3DM.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DPierard%26aufirst%3DL.%2BA.%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DZompatori%26aufirst%3DM.%26aulast%3DHoeper%26aufirst%3DM.%26atitle%3D2015%2520ESC%252FERS%2520guidelines%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520pulmonary%2520hypertension%253A%2520the%2520joint%2520task%2520force%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520pulmonary%2520hypertension%2520of%2520the%2520european%2520society%2520of%2520cardiology%2520%2528ESC%2529%2520and%2520the%2520european%2520respiratory%2520society%2520%2528ERS%2529%253A%2520endorsed%2520by%253A%2520association%2520for%2520european%2520paediatric%2520and%2520congenital%2520cardiology%2520%2528AEPC%2529%252C%2520international%2520society%2520for%2520heart%2520and%2520lung%2520transplantation%2520%2528ISHLT%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D67%26epage%3D119%26doi%3D10.1093%2Feurheartj%2Fehv317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benza, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span> <span> </span><span class="NLM_article-title">An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1378/chest.11-1460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.11-1460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22281797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC38vht12iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2012&pages=448-456&author=R.+L.+Benzaauthor=D.+P.+Millerauthor=R.+J.+Barstauthor=D.+B.+Badeschauthor=A.+E.+Frostauthor=M.+D.+McGoon&title=An+evaluation+of+long-term+survival+from+time+of+diagnosis+in+pulmonary+arterial+hypertension+from+the+REVEAL+registry&doi=10.1378%2Fchest.11-1460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry</span></div><div class="casAuthors">Benza Raymond L; Miller Dave P; Barst Robyn J; Badesch David B; Frost Adaani E; McGoon Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">448-456</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) was established to characterize the clinical course, treatment, and predictors of outcomes in patients with pulmonary arterial hypertension (PAH) in the United States.  To date, estimated survival based on time of patient enrollment has been established and reported.  To determine whether the survival of patients with PAH has improved over recent decades, we assessed survival from time of diagnosis for the REVEAL Registry cohort and compared these results to the estimated survival using the National Institutes of Health (NIH) prognostic equation.  METHODS:  Newly or previously diagnosed patients (aged ≥ 3 months at diagnosis) with PAH enrolled from March 2006 to December 2009 at 55 US centers were included in the current analysis.  RESULTS:  A total of 2,635 patients qualified for this analysis.  One-, 3-, 5-, and 7-year survival rates from time of diagnostic right-sided heart catheterization were 85%, 68%, 57%, and 49%, respectively.  For patients with idiopathic/familial PAH, survival rates were 91% ± 2%, 74% ± 2%, 65% ± 3%, and 59% ± 3% compared with estimated survival rates of 68%, 47%, 36%, and 32%, respectively, using the NIH equation.  CONCLUSIONS:  Comprehensive analysis of survival from time of diagnosis in a large cohort of patients with PAH suggests considerable improvements in survival in the past 2 decades since the establishment of the NIH registry, the effects of which most likely reflect a combination of changes in treatments, improved patient support strategies, and possibly a PAH population at variance with other cohorts</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKENQHdcnpUBe4jJGKT5N0fW6udTcc2eZCbxV9XQm9Y7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vht12iuw%253D%253D&md5=1c56fc60b035ab670af101300c0ee76f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-1460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-1460%26sid%3Dliteratum%253Aachs%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DD.%2BP.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26atitle%3DAn%2520evaluation%2520of%2520long-term%2520survival%2520from%2520time%2520of%2520diagnosis%2520in%2520pulmonary%2520arterial%2520hypertension%2520from%2520the%2520REVEAL%2520registry%26jtitle%3DChest%26date%3D2012%26volume%3D142%26spage%3D448%26epage%3D456%26doi%3D10.1378%2Fchest.11-1460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwa-Hahnle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S. R.</span></span> <span> </span><span class="NLM_article-title">A global view of pulmonary hypertension</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(15)00543-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS2213-2600%2815%2900543-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26975810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28fgtFKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=306-322&author=M.+M.+Hoeperauthor=M.+Humbertauthor=R.+Souzaauthor=M.+Idreesauthor=S.+M.+Kawutauthor=K.+Sliwa-Hahnleauthor=Z.+C.+Jingauthor=J.+S.+R.+Gibbs&title=A+global+view+of+pulmonary+hypertension&doi=10.1016%2FS2213-2600%2815%2900543-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A global view of pulmonary hypertension</span></div><div class="casAuthors">Hoeper Marius M; Humbert Marc; Souza Rogerio; Idrees Majdy; Kawut Steven M; Sliwa-Hahnle Karen; Jing Zhi-Cheng; Gibbs J Simon R</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Respiratory medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">306-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pulmonary hypertension is a substantial global health issue.  All age groups are affected with rapidly growing importance in elderly people, particularly in countries with ageing populations.  Present estimates suggest a pulmonary hypertension prevalence of about 1% of the global population, which increases up to 10% in individuals aged more than 65 years.  In almost all parts of the world, left-sided heart and lung diseases have become the most frequent causes of pulmonary hypertension.  About 80% of affected patients live in developing countries, where pulmonary hypertension is frequently associated with congenital heart disease and various infectious disorders, including schistosomiasis, HIV, and rheumatic heart disease.  These forms of pulmonary hypertension occur predominantly in those younger than 65 years.  Independently of the underlying disease, the development of pulmonary hypertension is associated with clinical deterioration and a substantially increased mortality risk.  Global research efforts are needed to establish preventive strategies and treatments for the various types of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL7LiBqZ0M-DToTC3aBaesfW6udTcc2eYpM8ZJxHgXhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgtFKntg%253D%253D&md5=597061e505456222734077cee4fc9112</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2815%2900543-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252815%252900543-3%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DIdrees%26aufirst%3DM.%26aulast%3DKawut%26aufirst%3DS.%2BM.%26aulast%3DSliwa-Hahnle%26aufirst%3DK.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%2BR.%26atitle%3DA%2520global%2520view%2520of%2520pulmonary%2520hypertension%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D306%26epage%3D322%26doi%3D10.1016%2FS2213-2600%2815%2900543-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffels, M.G.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelfriet, P.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.M.F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loon, R.L.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoendermis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vriend, J.W.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velde, E.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, B.J.M.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2006.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ijcard.2006.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17182132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2svgvF2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=198-204&author=M.G.J.+Duffelsauthor=P.M.+Engelfrietauthor=R.M.F.+Bergerauthor=R.L.E.+van+Loonauthor=E.+Hoendermisauthor=J.W.J.+Vriendauthor=E.T.+van+der+Veldeauthor=P.+Bresserauthor=B.J.M.+Mulder&title=Pulmonary+arterial+hypertension+in+congenital+heart+disease%3A+an+epidemiologic+perspective+from+a+Dutch+registry&doi=10.1016%2Fj.ijcard.2006.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry</span></div><div class="casAuthors">Duffels M G J; Engelfriet P M; Berger R M F; van Loon R L E; Hoendermis E; Vriend J W J; van der Velde E T; Bresser P; Mulder B J M</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-204</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary arterial hypertension (PAH) associated with congenital heart disease is usually the result of a large systemic-to-pulmonary shunt, and often leads to right ventricular failure and early death.  The purpose of this study was to determine the prevalence of PAH among adult patients included in a national registry of congenital heart disease and to assess the relation between patient characteristics and PAH.  METHODS:  Patients with PAH associated with a septal defect were identified from the registry.  Gender, age, underlying diagnosis, previous closure, age at repair and NYHA classification were recorded.  PAH was defined as a systolic pulmonary arterial pressure (sPAP) greater than 40 mm Hg, estimated by means of echocardiographical evaluation.  RESULTS:  The prevalence of PAH among all 5970 registered adult patients with congenital heart disease was 4.2%.  Of 1824 patients with a septal defect in the registry, 112 patients (6.1%) had PAH.  Median age of these patients was 38 years (range 18-81 years) and 40% were male.  Of these patients, 58% had the Eisenmenger syndrome.  Among the patients with a previously closed septal defect, 30 had PAH (3%).  Ventricular septal defect (VSD) was the most frequent underlying defect (42%) among patients with PAH and a septal defect.  Female sex (Odds ratio=1.5, p=0.001) and sPAP (Odds ratio=0.04, p<0.001) were independently associated with a decreased functional class.  CONCLUSION:  PAH is common in adult patients with congenital heart disease.  In our registry the prevalence of PAH in septal defects is around 6%.  More than half of these patients have the Eisenmenger syndrome, which accounts for 1% of the total population in the CONCOR registry.  Whether the prevalence of PAH will decrease in the future as a result of early detection and intervention remains to be awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX_lSrZ52mf_IW7hznt0zpfW6udTcc2eaznOxTxie83Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svgvF2htQ%253D%253D&md5=21ff12220d90b72ab10a01c12f14927d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2006.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2006.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DDuffels%26aufirst%3DM.G.J.%26aulast%3DEngelfriet%26aufirst%3DP.M.%26aulast%3DBerger%26aufirst%3DR.M.F.%26aulast%3Dvan%2BLoon%26aufirst%3DR.L.E.%26aulast%3DHoendermis%26aufirst%3DE.%26aulast%3DVriend%26aufirst%3DJ.W.J.%26aulast%3Dvan%2Bder%2BVelde%26aufirst%3DE.T.%26aulast%3DBresser%26aufirst%3DP.%26aulast%3DMulder%26aufirst%3DB.J.M.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520in%2520congenital%2520heart%2520disease%253A%2520an%2520epidemiologic%2520perspective%2520from%2520a%2520Dutch%2520registry%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2007%26volume%3D120%26spage%3D198%26epage%3D204%26doi%3D10.1016%2Fj.ijcard.2006.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.-C.</span></span> <span> </span><span class="NLM_article-title">Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1378/chest.10-2327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.10-2327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21330386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3MjjsVejtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2011&pages=301-309&author=R.+Zhangauthor=L.-Z.+Daiauthor=P.+Yuanauthor=X.+Jiangauthor=J.+Heauthor=W.-P.+Xieauthor=Z.-X.+Yuauthor=B.-X.+Wuauthor=L.+Panauthor=M.+Humbertauthor=Z.-C.+Jing&title=Survival+of+Chinese+patients+with+pulmonary+arterial+hypertension+in+the+modern+treatment+era&doi=10.1378%2Fchest.10-2327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era</span></div><div class="casAuthors">Zhang Rui; Dai Li-Zhi; Yuan Ping; Jiang Xin; He Jing; Xie Wei-Ping; Yu Zai-Xin; Wu Bing-Xiang; Pan Lei; Humbert Marc; Jing Zhi-Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-309</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In a previous study of Chinese patients with idiopathic pulmonary arterial hypertension (IPAH) in the nontargeted therapy era (defined as the time before 2006 when new pulmonary arterial hypertension-specific drugs were not available in China), we reported 1- and 3-year survival estimates of only 68% and 39%, respectively.  However, it is not yet known whether the survival of patients with pulmonary arterial hypertension is improved in the modern treatment era (defined in China as after 2006).  METHODS:  A retrospective cohort study was undertaken in 276 consecutive patients with newly diagnosed incident IPAH and connective tissue disease-related pulmonary arterial hypertension (CTDPAH) who were referred between 2007 and 2009.  Baseline characteristics and survival rates in the two groups were compared.  RESULTS:  The 1- and 3-year survival estimates were 92.1% and 75.1%, respectively, in patients with IPAH, and 85.4% and 53.6%, respectively, in patients with CTDPAH.  Patients with CTDPAH had a significantly lower mean pulmonary artery pressure, more pericardial effusion, and more severe impairment of the diffusion capacity of the lung for carbon monoxide than patients with IPAH.  A diagnosis of CTDPAH, World Health Organization functional class III or IV, single-breath diffusion capacity of the lung for carbon monoxide < 80% predicted, and the presence of pericardial effusion were independent predictors of mortality.  The 1- and 3-year survival rates of male patients were 93.5% and 77.5%, respectively, in those with IPAH, and 71.1% and 47.4%, respectively, in those with CTDPAH.  CONCLUSIONS:  The survival rates of patients with pulmonary arterial hypertension have improved in China in the modern treatment era, despite the high costs of treatment and financial constraints.  However, the survival rates of patients with CTDPAH are inferior to those of patients with IPAH.  Our study also indicates poorer survival rates in male patients with CTDPAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlooHjtlZHBczK395ZObgVfW6udTcc2eaznOxTxie83Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjjsVejtA%253D%253D&md5=e76725c02d6e5e4b04ae7e7f38a4093e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1378%2Fchest.10-2327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.10-2327%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DL.-Z.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.-P.%26aulast%3DYu%26aufirst%3DZ.-X.%26aulast%3DWu%26aufirst%3DB.-X.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DJing%26aufirst%3DZ.-C.%26atitle%3DSurvival%2520of%2520Chinese%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520in%2520the%2520modern%2520treatment%2520era%26jtitle%3DChest%26date%3D2011%26volume%3D140%26spage%3D301%26epage%3D309%26doi%3D10.1378%2Fchest.10-2327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thenappan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomberg-Maitland, M.</span></span> <span> </span><span class="NLM_article-title">A USA-based registry for pulmonary arterial hypertension: 1982–2006</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1183/09031936.00042107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00042107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17804449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2sjhs1aisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=1103-1110&author=T.+Thenappanauthor=S.+J.+Shahauthor=S.+Richauthor=M.+Gomberg-Maitland&title=A+USA-based+registry+for+pulmonary+arterial+hypertension%3A+1982%E2%80%932006&doi=10.1183%2F09031936.00042107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A USA-based registry for pulmonary arterial hypertension: 1982-2006</span></div><div class="casAuthors">Thenappan T; Shah S J; Rich S; Gomberg-Maitland M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1103-10</span>
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    </div><div class="casAbstract">The aim of this study was to define the epidemiology of World Health Organization (WHO) Group I pulmonary arterial hypertension (PAH) in a large referral centre in the USA.  The Pulmonary Hypertension Connection registry, initiated in 2004, evaluated all patients in a single USA practice from 1982-2006.  For comparison, the authors divided the group by incident versus prevalent cohorts, aetiology and by treatment era.  In total, 578 patients (77% female) aged 48+/-14 yrs were entered.  Of these, 80% had class III or IV symptoms.  Over time, connective tissue disease-associated PAH increased, while referrals for HIV remained low.  One-third of patients were referred on calcium channel blocker therapy even though only 4.6% had an acute response to vasodilator challenge.  When compared by treatment era, there were no differences in the severity of PAH.  However, survival had improved over time, with a 1-yr survival of 85% in the incident cohort.  In the USA, pulmonary arterial hypertension patients are still referred to tertiary centres too late.  Referral of connective tissue disease is increasing, while referral of HIV remains low.  Inappropriate calcium channel blocker treatment is common.  Survival rates have increased but remain low suggesting that prognosis is improving but PAH is still a progressive, fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI4aZiQhHccedfST00W0BcfW6udTcc2eZAIJJh0XV2oLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjhs1aisg%253D%253D&md5=4339a0d226727687947e35be0a8eb78e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1183%2F09031936.00042107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00042107%26sid%3Dliteratum%253Aachs%26aulast%3DThenappan%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26atitle%3DA%2520USA-based%2520registry%2520for%2520pulmonary%2520arterial%2520hypertension%253A%25201982%25E2%2580%25932006%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2007%26volume%3D30%26spage%3D1103%26epage%3D1110%26doi%3D10.1183%2F09031936.00042107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alves, J. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavilanes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jardim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, C. J. C. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morinaga, L. T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1378/chest.14-1036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.14-1036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25317567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2M3gsFKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=495-501&author=J.+L.+Alvesauthor=F.+Gavilanesauthor=C.+Jardimauthor=C.+J.+C.+D.+S.+Fernandesauthor=B.+Diasauthor=S.+Hoetteauthor=L.+T.+K.+Morinagaauthor=M.+Humbertauthor=R.+Souza&title=Pulmonary+arterial+hypertension+in+the+southern+hemisphere%3A+results+from+a+registry+of+incident+Brazilian+cases&doi=10.1378%2Fchest.14-1036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases</span></div><div class="casAuthors">Alves Jose Leonidas Jr; Gavilanes Francisca; Jardim Carlos; Fernandes Caio Julio Cesar Dos Santos; Dias Bruno; Hoette Susana; Morinaga Luciana Tamie Kato; Humbert Marc; Souza Rogerio</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary arterial hypertension (PAH) is a rare and ultimately fatal disorder of the pulmonary vasculature.  There is increasing interest in the worldwide characteristics of patients with PAH, although data coming from the Southern Hemisphere remain scarce.  The objective of this study was to describe a cohort of incident patients with PAH from a large reference center in Brazil.  METHODS:  All consecutive patients who received a diagnosis of PAH by right-sided heart catheterization between 2008 and 2013 were included in the study.  RESULTS:  A total of 178 patients with newly diagnosed PAH were enrolled in the study (mean age, 46 years; female/male ratio, 3.3:1; 45.5% in New York Heart Association functional class III or IV).  Idiopathic PAH (IPAH), connective tissue disease (CTD), and schistosomiasis-associated PAH (Sch-PAH) accounted for 28.7%, 25.8%, and 19.7% of all cases, respectively.  The patients were treated with phosphodiesterase type 5 inhibitors (66%), endothelin receptor antagonists (27%), or a combination of both (5%).  For the PAH group as a whole, the estimated survival rate 3 years after diagnosis was 73.9%.  The prognosis for the patients with CTD was worse than that for the patients with IPAH and Sch-PAH (P = .03).  CONCLUSIONS:  The distribution of PAH causes and the baseline characteristics in our registry clearly differ from the previously published European and US-based registries.  These differences highlight the importance of regional registries and also raise questions regarding the need to better account for such differences in future clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ_TzsVWqSnEGy1nwu7K2mfW6udTcc2eZAIJJh0XV2oLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3gsFKgtQ%253D%253D&md5=aa653375cc31c01b00c7609b5d77ebc6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1378%2Fchest.14-1036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.14-1036%26sid%3Dliteratum%253Aachs%26aulast%3DAlves%26aufirst%3DJ.%2BL.%26aulast%3DGavilanes%26aufirst%3DF.%26aulast%3DJardim%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DC.%2BJ.%2BC.%2BD.%2BS.%26aulast%3DDias%26aufirst%3DB.%26aulast%3DHoette%26aufirst%3DS.%26aulast%3DMorinaga%26aufirst%3DL.%2BT.%2BK.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSouza%26aufirst%3DR.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520in%2520the%2520southern%2520hemisphere%253A%2520results%2520from%2520a%2520registry%2520of%2520incident%2520Brazilian%2520cases%26jtitle%3DChest%26date%3D2015%26volume%3D147%26spage%3D495%26epage%3D501%26doi%3D10.1378%2Fchest.14-1036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sztrymf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span> <span> </span><span class="NLM_article-title">Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">73</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-11-73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-11-73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20534176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3cnltlCjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=73&author=B.+Girerdauthor=D.+Montaniauthor=M.+Eyriesauthor=A.+Yaiciauthor=B.+Sztrymfauthor=F.+Couletauthor=O.+Sitbonauthor=G.+Simonneauauthor=F.+Soubrierauthor=M.+Humbert&title=Absence+of+influence+of+gender+and+BMPR2+mutation+type+on+clinical+phenotypes+of+pulmonary+arterial+hypertension&doi=10.1186%2F1465-9921-11-73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension</span></div><div class="casAuthors">Girerd Barbara; Montani David; Eyries Melanie; Yaici Azzedine; Sztrymf Benjamin; Coulet Florence; Sitbon Olivier; Simonneau Gerald; Soubrier Florent; Humbert Marc</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Previous studies indicate that patients with pulmonary arterial hypertension (PAH) carrying a mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene, develop the disease 10 years earlier than non-carriers, and have a more severe hemodynamic compromise at diagnosis.  A recent report has suggested that this may only be the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients with truncating mutations.  METHODS:  We reviewed data from all patients with PAH considered as idiopathic and patients with a family history of PAH, who underwent genetic counselling in the French PAH network between January, 1st 2004 and April, 1st 2010.  We compared clinical, functional, and hemodynamic characteristics between carriers and non-carriers of a BMPR2 mutation, according to gender or BMPR2 mutation type.  RESULTS:  PAH patients carrying a BMPR2 mutation (n = 115) were significantly younger at diagnosis than non-carriers (n = 267) (35.8 +/- 15.4 and 47.5 +/- 16.2 respectively, p < 0.0001).  The presence of a BMPR2 mutation was associated with a younger age at diagnosis in females (36.4 +/- 14.9 in BMPR2 mutation carriers and 47.4 +/- 15.8 in non-carriers, p < 0.0001), and males (34.6 +/- 16.8 in BMPR2 mutation carriers and 47.8 +/- 17.1 in non-carriers, p < 0.0001).  BMPR2 mutation carriers had a more severe hemodynamic compromise at diagnosis, but this was not influenced by gender.  No differences in survival and time to death or lung transplantation were found in male and female PAH patients carrying a BMPR2 mutation.  No differences were observed in clinical outcomes according to the type of BMPR2 mutations (missense, truncating, large rearrangement or splice defect).  CONCLUSION:  When compared to non-carriers, BMPR2 mutation carriers from the French PAH network are younger at diagnosis and present with a more severe hemodynamic compromise, irrespective of gender.  Moreover, BMPR2 mutation type had no influence on clinical phenotypes in our patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRS3xCW_uwW7FU0A1HOshhfW6udTcc2eZAIJJh0XV2oLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnltlCjtg%253D%253D&md5=fb95b84821fb87adddc23018d4e56f7f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-73%26sid%3Dliteratum%253Aachs%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DEyries%26aufirst%3DM.%26aulast%3DYaici%26aufirst%3DA.%26aulast%3DSztrymf%26aufirst%3DB.%26aulast%3DCoulet%26aufirst%3DF.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DAbsence%2520of%2520influence%2520of%2520gender%2520and%2520BMPR2%2520mutation%2520type%2520on%2520clinical%2520phenotypes%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D73%26doi%3D10.1186%2F1465-9921-11-73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventetuolo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praestgaard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palevsky, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halpern, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span> <span> </span><span class="NLM_article-title">Sex and haemodynamics in pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1183/09031936.00027613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00027613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23949961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3sbgsFCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=523-530&author=C.+E.+Ventetuoloauthor=A.+Praestgaardauthor=H.+I.+Palevskyauthor=J.+R.+Klingerauthor=S.+D.+Halpernauthor=S.+M.+Kawut&title=Sex+and+haemodynamics+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.00027613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sex and haemodynamics in pulmonary arterial hypertension</span></div><div class="casAuthors">Ventetuolo Corey E; Praestgaard Amy; Palevsky Harold I; Klinger James R; Halpern Scott D; Kawut Steven M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Female sex is a risk factor for pulmonary arterial hypertension (PAH), yet females have better survival than males.  We sought to determine if sex was associated with baseline haemodynamics in subjects with PAH, and whether age modified these relationships.  We conducted a pooled analysis from 11 randomised trials submitted to the US Food and Drug Administration.  The study sample included 1211 subjects with idiopathic PAH, 25% of whom were males, and 489 subjects with connective tissue disease-associated PAH, 13% of whom were males.  After multivariable adjustment, right atrial pressure was 1.36 mmHg higher (95% CI 0.44-2.27, p=0.004), cardiac index was -0.14 L · min(-1) · m(-2) lower (95% CI -0.23-0.04, p=0.01) and pulmonary vascular resistance was 1.23 Wood units higher (95% CI 0.18-2.27, p=0.02) in males compared with females.  Younger males had 5.43 mmHg (95% CI 2.20-8.66, p=0.001) higher mean pulmonary arterial pressures than younger females, but these relationships were attenuated after age 45 years.  In the subgroup of connective tissue disease-associated PAH, males may have had higher right atrial pressure.  These findings implicate age as a modifier and provide further evidence of sexual dimorphism in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIxZz-_QwTccvLc4ARHEmzfW6udTcc2eb0XZmHJMyWNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbgsFCrtA%253D%253D&md5=e3f78e675238be6fdadf7b750785e257</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1183%2F09031936.00027613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00027613%26sid%3Dliteratum%253Aachs%26aulast%3DVentetuolo%26aufirst%3DC.%2BE.%26aulast%3DPraestgaard%26aufirst%3DA.%26aulast%3DPalevsky%26aufirst%3DH.%2BI.%26aulast%3DKlinger%26aufirst%3DJ.%2BR.%26aulast%3DHalpern%26aufirst%3DS.%2BD.%26aulast%3DKawut%26aufirst%3DS.%2BM.%26atitle%3DSex%2520and%2520haemodynamics%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D523%26epage%3D530%26doi%3D10.1183%2F09031936.00027613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickelberg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraci, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembath, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span> <span> </span><span class="NLM_article-title">Genetics and genomics of pulmonary arterial hypertension</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">S32</span>– <span class="NLM_lpage">S42</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2009.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jacc.2009.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19555857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVOks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=S32-S42&author=R.+D.+Machadoauthor=O.+Eickelbergauthor=C.+G.+Elliottauthor=M.+W.+Geraciauthor=M.+Hanaokaauthor=J.+E.+Loydauthor=J.+H.+Newmanauthor=J.+A.+Phillipsauthor=F.+Soubrierauthor=R.+C.+Trembathauthor=W.+K.+Chung&title=Genetics+and+genomics+of+pulmonary+arterial+hypertension&doi=10.1016%2Fj.jacc.2009.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics and genomics of pulmonary arterial hypertension</span></div><div class="casAuthors">Machado, Rajiv D.; Eickelberg, Oliver; Elliott, C. Gregory; Geraci, Mark W.; Hanaoka, Masayuki; Loyd, James E.; Newman, John H.; Phillips, John A., III; Soubrier, Florent; Trembath, Richard C.; Chung, Wendy K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1, Suppl. S</span>),
    <span class="NLM_cas:pages">S32-S42</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Pulmonary arterial hypertension (PAH) is a rare disorder that may be hereditable (HPAH), idiopathic (IPAH), or assocd. with either drug-toxin exposures or other medical conditions.  Familial cases have long been recognized and are usually due to mutations in the bone morphogenetic protein receptor type 2 gene (BMPR2), or, much less commonly, 2 other members of the transforming growth factor-β superfamily, activin-like kinase-type 1 (ALK1) and endoglin (ENG), which are assocd. with hereditary hemorrhagic telangiectasia.  In addn., approx. 20% of patients with IPAH carry mutations in BMPR2.  We provide a summary of BMPR2 mutations assocd. with HPAH, most of which are unique to each family and are presumed to result in loss of function.  We review the finding of missense variants and variants of unknown significance in BMPR2 in IPAH/HPAH, fenfluramine exposure, and PAH assocd. with congenital heart disease.  Clin. testing for BMPR2 mutations is available and may be offered to HPAH and IPAH patients but should be preceded by genetic counseling, since lifetime penetrance is only 10% to 20%, and there are currently no known effective preventative measures.  Identification of a familial mutation can be valuable in reproductive planning and identifying family members who are not mutation carriers and thus will not require lifelong surveillance.  With advances in genomic technol. and with international collaborative efforts, genome-wide assocn. studies will be conducted to identify addnl. genes for HPAH, genetic modifiers for BMPR2 penetrance and genetic susceptibility to IPAH.  In addn., collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clin. drug development, thereby providing an invaluable resource for trials of PAH prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowGr7nzbP5HbVg90H21EOLACvtfcHk0ljUK-2-WMBq5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVOks7k%253D&md5=e1f7082de0347dec4a97b2767a53fb5b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2009.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2009.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DMachado%26aufirst%3DR.%2BD.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DElliott%26aufirst%3DC.%2BG.%26aulast%3DGeraci%26aufirst%3DM.%2BW.%26aulast%3DHanaoka%26aufirst%3DM.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26aulast%3DPhillips%26aufirst%3DJ.%2BA.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26aulast%3DChung%26aufirst%3DW.%2BK.%26atitle%3DGenetics%2520and%2520genomics%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2009%26volume%3D54%26spage%3DS32%26epage%3DS42%26doi%3D10.1016%2Fj.jacc.2009.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman-Campos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tregouet, D.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borczuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span> <span> </span><span class="NLM_article-title">A novel channelopathy in pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1211097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1211097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23883380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=351-361&author=L.+Maauthor=D.+Roman-Camposauthor=E.+D.+Austinauthor=M.+Eyriesauthor=K.+S.+Sampsonauthor=F.+Soubrierauthor=M.+Germainauthor=D.-A.+Tregouetauthor=A.+Borczukauthor=E.+B.+Rosenzweigauthor=B.+Girerdauthor=D.+Montaniauthor=M.+Humbertauthor=J.+E.+Loydauthor=R.+S.+Kassauthor=W.+K.+Chung&title=A+novel+channelopathy+in+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1211097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A novel channelopathy in pulmonary arterial hypertension</span></div><div class="casAuthors">Ma, Lijiang; Roman-Campos, Danilo; Austin, Eric D.; Eyries, Melanie; Sampson, Kevin S.; Soubrier, Florent; Germain, Marine; Tregouet, David-Alexandre; Borczuk, Alain; Rosenzweig, Erika Berman; Girerd, Barbara; Montani, David; Humbert, Marc; Loyd, James E.; Kass, Robert S.; Chung, Wendy K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-361</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Pulmonary arterial hypertension is a devastating disease with high mortality.  Familial cases of pulmonary arterial hypertension are usually characterized by autosomal dominant transmission with reduced penetrance, and some familial cases have unknown genetic causes.  METHODS We studied a family in which multiple members had pulmonary arterial hypertension without identifiable mutations in any of the genes known to be assocd. with the disease, including BMPR2, ALK1, ENG, SMAD9, and CAV1.  Three family members were studied with whole-exome sequencing.  Addnl. patients with familial or idiopathic pulmonary arterial hypertension were screened for the mutations in the gene that was identified on whole-exome sequencing.  All variants were expressed in COS-7 cells, and channel function was studied by means of patch-clamp anal.  RESULTS We identified a novel heterozygous missense variant c.608 G→A (G203D) in KCNK3 (the gene encoding potassium channel subfamily K, member 3) as a disease-causing candidate gene in the family.  Five addnl. heterozygous missense variants in KCNK3 were independently identified in 92 unrelated patients with familial pulmonary arterial hypertension and 230 patients with idiopathic pulmonary arterial hypertension.  We used in silico bioinformatic tools to predict that all six novel variants would be damaging.  Electrophysiol. studies of the channel indicated that all these missense mutations resulted in loss of function, and the redn. in the potassium-channel current was remedied by the application of the phospholipase inhibitor ONO-RS-082.  CONCLUSIONS Our study identified the assocn. of a novel gene, KCNK3, with familial and idiopathic pulmonary arterial hypertension.  Mutations in this gene produced reduced potassium-channel current, which was successfully remedied by pharmacol. manipulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUvoY6Pc_sj7Vg90H21EOLACvtfcHk0lha-C2dNoQPyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7E&md5=497004fe0de551415ca15fbeb9ebdaf6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1211097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1211097%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DRoman-Campos%26aufirst%3DD.%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DEyries%26aufirst%3DM.%26aulast%3DSampson%26aufirst%3DK.%2BS.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DGermain%26aufirst%3DM.%26aulast%3DTregouet%26aufirst%3DD.-A.%26aulast%3DBorczuk%26aufirst%3DA.%26aulast%3DRosenzweig%26aufirst%3DE.%2BB.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DKass%26aufirst%3DR.%2BS.%26aulast%3DChung%26aufirst%3DW.%2BK.%26atitle%3DA%2520novel%2520channelopathy%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D351%26epage%3D361%26doi%3D10.1056%2FNEJMoa1211097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.-C.</span></span> <span> </span><span class="NLM_article-title">Association of rare ptgis variants with susceptibility and pulmonary vascular response in patients with idiopathic pulmonary arterial hypertension</span>. <i>JAMA Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1001/jamacardio.2020.0479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1001%2Fjamacardio.2020.0479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=32236489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB383pvVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=677-684&author=X.-J.+Wangauthor=X.-Q.+Xuauthor=K.+Sunauthor=K.-Q.+Liuauthor=S.-Q.+Liauthor=X.+Jiangauthor=Q.-H.+Zhaoauthor=L.+Wangauthor=F.-H.+Pengauthor=J.+Yeauthor=Y.+Wuauthor=R.+Jiangauthor=J.+Zhangauthor=W.+Huangauthor=W.-B.+Weiauthor=Y.+Yanauthor=J.-H.+Liauthor=Q.-Q.+Liuauthor=S.+Liauthor=Y.+Wangauthor=S.-Y.+Zhangauthor=X.+Zhangauthor=Z.-C.+Jing&title=Association+of+rare+ptgis+variants+with+susceptibility+and+pulmonary+vascular+response+in+patients+with+idiopathic+pulmonary+arterial+hypertension&doi=10.1001%2Fjamacardio.2020.0479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Wang Xiao-Jian; Xu Xi-Qi; Sun Kai; Li Su-Qi; Jiang Xin; Peng Fu-Hua; Ye Jue; Wu Yan; Yan Yi; Li Jing-Hui; Liu Qian-Qian; Xu Xi-Qi; Sun Kai; Jiang Xin; Zhang Shu-Yang; Jing Zhi-Cheng; Liu Ke-Qiang; Zhang Xue; Zhao Qin-Hua; Wang Lan; Jiang Rui; Zhang Jin; Huang Wei; Wei Wen-Bin; Li Sheng; Wang Yong</div><div class="citationInfo"><span class="NLM_cas:title">JAMA cardiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-684</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disease with high heritability; however, the bone morphogenetic protein receptor 2 (BMPR2) gene only accounts for 17% of IPAH.  The genetic basis of IPAH needs further investigation.  Objective:  To identify novel IPAH susceptibility genes other than BMPR2.  Design, Setting, and Participants:  This 2-stage, case-control genetic association study enrolled 230 patients with IPAH from 2 referral pulmonary hypertension centers in China.  Eligible patients had no BMPR2 variants and were compared with 968 healthy control participants.  Data were collected from January 1, 2000, to July 31, 2015, and analyzed from August 1, 2015, to May 30, 2018.  Exposures:  PTGIS rare variants.  Main Outcomes and Measures:  Whole-genome sequencing was performed to identify putative IPAH genes in a discovery cohort, with validation in an independent referral cohort.  Correlation of genotype and hemodynamic characteristics was then evaluated at baseline and after pulmonary vasodilator testing.  Functional assessments were conducted to analyze the effects of identified genetic variants on transcript splicing, enzymatic activity, and endothelial cell phenotypes.  Results:  Among 230 patients with IPAH (164 female [71.3%]; mean [SD] age, 34 [18] years), an enrichment of rare variants in a gene encoding prostacyclin synthase (PTGIS) was identified in the discovery cohort.  The association of PTGIS rare variants with IPAH was confirmed in the replication cohort.  In the combined data set, PTGIS rare variants were found in 14 of 230 cases (6.1%) and 8 of 968 controls (0.8%) (odds ratio, 7.8; 95% CI, 3.2-18.8; P = 5 × 10-6, logistic regression).  Compared with patients without PTGIS variants, inhaled iloprost induced a more significant decrease of pulmonary vascular resistance (difference in the least square mean, -21.7%; 95% CI, -31.4% to -12.0%; P < .001, linear regression model) and an increase of cardiac index (difference in the least square mean, 18.3%; 95% CI, 8.8%-27.8%; P < .001, linear regression model) in patients with PTGIS variants.  The minigene assay indicated that the c.521 + 1G>A variant resulted in aberrant messenger RNA transcripts.  The functional studies showed that the 2 missense rare variants (R252Q and A447T) resulted in a decrease in prostacyclin production and increased cell death of pulmonary microvascular endothelial cells.  Conclusions and Relevance:  This study identified 3 rare loss-of-function variants in the PTGIS gene from 2 independent cohorts with IPAH.  The genetic variants of PTGIS predispose pulmonary vascular responses to the iloprost stimulation.  These findings suggest that PTGIS variants may be involved in the pathogenesis of IPAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT15cswAg6LmP9pSBfyDvp7fW6udTcc2eagOEb6jDnaELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383pvVGnsA%253D%253D&md5=ac12399e5678f863f4fd54858328ad85</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjamacardio.2020.0479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamacardio.2020.0479%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-J.%26aulast%3DXu%26aufirst%3DX.-Q.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DK.-Q.%26aulast%3DLi%26aufirst%3DS.-Q.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DQ.-H.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DF.-H.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DW.-B.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.-H.%26aulast%3DLiu%26aufirst%3DQ.-Q.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Y.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DZ.-C.%26atitle%3DAssociation%2520of%2520rare%2520ptgis%2520variants%2520with%2520susceptibility%2520and%2520pulmonary%2520vascular%2520response%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJAMA%2520Cardiol.%26date%3D2020%26volume%3D5%26spage%3D677%26epage%3D684%26doi%3D10.1001%2Fjamacardio.2020.0479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benza, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farber, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krichman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raskob, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wason, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldkircher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span> <span> </span><span class="NLM_article-title">The changing picture of patients with pulmonary arterial hypertension in the united states how reveal differs from historic and non-us contemporary registries</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1378/chest.10-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.10-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20558556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FptVOjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2011&pages=128-137&author=A.+E.+Frostauthor=D.+B.+Badeschauthor=R.+J.+Barstauthor=R.+L.+Benzaauthor=G.+Elliottauthor=H.+W.+Farberauthor=A.+Krichmanauthor=T.+G.+Liouauthor=G.+E.+Raskobauthor=P.+Wasonauthor=K.+Feldkircherauthor=M.+Turnerauthor=M.+D.+McGoon&title=The+changing+picture+of+patients+with+pulmonary+arterial+hypertension+in+the+united+states+how+reveal+differs+from+historic+and+non-us+contemporary+registries&doi=10.1378%2Fchest.10-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries</span></div><div class="casAuthors">Frost Adaani E; Badesch David B; Barst Robyn J; Benza Raymond L; Elliott C Gregory; Farber Harrison W; Krichman Abby; Liou Theodore G; Raskob Gary E; Wason Prieya; Feldkircher Kathleen; Turner Michelle; McGoon Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  REVEAL (The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) provides current demographics of patients with group 1 pulmonary arterial hypertension (PAH) in the United States.  METHODS:  A total of 2,967 patients with PAH diagnosed based on right-sided heart catheterization were enrolled in REVEAL between March 2006 and September 2007.  Demographics from the REVEAL patient cohort and REVEAL subpopulations (matched by inclusion criteria to other registries) were compared with historic US registry data and other contemporary US and non-US national PAH registries by inclusion criteria, including the National Institutes of Health (NIH) PAH registry and the French PAH registry.  RESULTS:  REVEAL patients matched to NIH registry patients were older at diagnosis (mean ± SE, 44.9 ± 0.6 years vs 36.4 ± 1.1 years; difference, 8.5 ± 1.4; P < .001) and more likely to be women (78.7 ± 1.2% vs 63.1 ± 3.5%; P < .001).  REVEAL patients matched to French registry patients had similar age and severity at diagnosis, but REVEAL patients were more likely to be women (79.8 ± 0.8% vs 65.3 ± 1.8%; P < .001) and obese (BMI, ≥ 30 kg/m(2), 32.5 ± 1.0% vs 14.8 ± 1.4%; P < .001), whereas French patients were more likely to have HIV-associated PAH (6.2% vs 2.3%).  The female preponderance is similar to that in other US-based contemporary registries.  CONCLUSIONS:  At diagnosis, REVEAL patients were older than NIH registry patients and similar in age to patients enrolled in contemporary registries.  Compared with NIH and contemporary European and UK registries, there was a striking preponderance of women, and REVEAL patients were more likely to be obese.  These observations and the difference in HIV-associated PAH between REVEAL and other non-US contemporary registries warrant further investigation.  TRIAL REGISTRY:  ClinicalTrials.gov; No.: NCT00370214; URL: clinicaltrials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScBqtGyLoifAHqQV89nF-2fW6udTcc2eagOEb6jDnaELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FptVOjtg%253D%253D&md5=04d0a9732c3403a24c9937755e98c318</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1378%2Fchest.10-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.10-0075%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DFarber%26aufirst%3DH.%2BW.%26aulast%3DKrichman%26aufirst%3DA.%26aulast%3DLiou%26aufirst%3DT.%2BG.%26aulast%3DRaskob%26aufirst%3DG.%2BE.%26aulast%3DWason%26aufirst%3DP.%26aulast%3DFeldkircher%26aufirst%3DK.%26aulast%3DTurner%26aufirst%3DM.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26atitle%3DThe%2520changing%2520picture%2520of%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520in%2520the%2520united%2520states%2520how%2520reveal%2520differs%2520from%2520historic%2520and%2520non-us%2520contemporary%2520registries%26jtitle%3DChest%26date%3D2011%26volume%3D139%26spage%3D128%26epage%3D137%26doi%3D10.1378%2Fchest.10-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huscher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittrow, D.</span></span> <span> </span><span class="NLM_article-title">Incidence and prevalence of pulmonary arterial hypertension in Germany</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2015.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ijcard.2015.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26580339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28visl2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2016&pages=612-613&author=M.+M.+Hoeperauthor=D.+Huscherauthor=D.+Pittrow&title=Incidence+and+prevalence+of+pulmonary+arterial+hypertension+in+Germany&doi=10.1016%2Fj.ijcard.2015.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prevalence of pulmonary arterial hypertension in Germany</span></div><div class="casAuthors">Hoeper Marius M; Huscher Doerte; Pittrow David</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR25rnPVYfCKRFwe7cAcrfPfW6udTcc2eYsGgauWKIBnbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28visl2htw%253D%253D&md5=35bd403fa12ffb7bf70d0a98c419848c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2015.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2015.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DHuscher%26aufirst%3DD.%26aulast%3DPittrow%26aufirst%3DD.%26atitle%3DIncidence%2520and%2520prevalence%2520of%2520pulmonary%2520arterial%2520hypertension%2520in%2520Germany%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2016%26volume%3D203%26spage%3D612%26epage%3D613%26doi%3D10.1016%2Fj.ijcard.2015.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farber, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of disease: pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1665</span>, <span class="refDoi"> DOI: 10.1056/NEJMra035488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMra035488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15483284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1Whtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=1655-1665&author=H.+W.+Farberauthor=J.+Loscalzo&title=Mechanisms+of+disease%3A+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMra035488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary arterial hypertension</span></div><div class="casAuthors">Farber, Harrison W.; Loscalzo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1655-1665</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the developments in the pathogenesis of pulmonary arterial hypertension, focusing on the mol. genetics and cell biol. of idiopathic arterial hypertension, and relating them to other forms of pulmonary arterial hypertension, when appropriate.  It discusses the environmental factors assocd. with an increased risk of the development of pulmonary arterial hypertension, namely hypoxia, anorexigens, and central nervous system stimulants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw8ugQZXSH5LVg90H21EOLACvtfcHk0liJEJ095lHTdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1Whtbg%253D&md5=2bd6ffc505f1fcb986b45031ebb0a1b9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMra035488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra035488%26sid%3Dliteratum%253Aachs%26aulast%3DFarber%26aufirst%3DH.%2BW.%26aulast%3DLoscalzo%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520disease%253A%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D1655%26epage%3D1665%26doi%3D10.1056%2FNEJMra035488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of disease: pulmonary arterial hypertension</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2011.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnrcardio.2011.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21691314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlymsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=443-455&author=R.+T.+Schermulyauthor=H.+A.+Ghofraniauthor=M.+R.+Wilkinsauthor=F.+Grimminger&title=Mechanisms+of+disease%3A+pulmonary+arterial+hypertension&doi=10.1038%2Fnrcardio.2011.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of disease: pulmonary arterial hypertension</span></div><div class="casAuthors">Schermuly, Ralph T.; Ghofrani, Hossein A.; Wilkins, Martin R.; Grimminger, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">443-455</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the past decade or so, our understanding of pulmonary arterial hypertension has undergone a paradigm shift.  In this article, Dr Schermuly and colleagues discuss the known mol. mechanisms of the pathogenesis of this disease, and highlight the mol. technologies that are currently being used to further our understanding of these disease processes.  Our understanding of, and approach to, pulmonary arterial hypertension has undergone a paradigm shift in the past decade.  Once a condition thought to be dominated by increased vasoconstrictor tone and thrombosis, pulmonary arterial hypertension is now seen as a vasculopathy in which structural changes driven by excessive vascular cell growth and inflammation, with recruitment and infiltration of circulating cells, play a major role.  Perturbations of a no. of mol. mechanisms have been described, including pathways involving growth factors, cytokines, metabolic signaling, elastases, and proteases, that may underlie the pathogenesis of the disease.  Elucidating their contribution to the pathophysiol. of pulmonary arterial hypertension could offer new drug targets.  The role of progenitor cells in vascular repair is also under active investigation.  The right ventricular response to increased pressure load is recognized as crit. to survival and the mol. mechanisms involved are attracting increasing interest.  The challenge now is to integrate this new knowledge and explore how it can be used to categorize patients by mol. phenotype and tailor treatment more effectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX9Zk8oAL1YLVg90H21EOLACvtfcHk0liJEJ095lHTdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlymsb0%253D&md5=a7470d14839f757102531c233659dd2f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2011.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2011.87%26sid%3Dliteratum%253Aachs%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DMechanisms%2520of%2520disease%253A%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2011%26volume%3D8%26spage%3D443%26epage%3D455%26doi%3D10.1038%2Fnrcardio.2011.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1801887</span>, <span class="refDoi"> DOI: 10.1183/13993003.01887-2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01887-2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30545970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=1801887&author=M.+Humbertauthor=C.+Guignabertauthor=S.+Bonnetauthor=P.+Dorfmullerauthor=J.+R.+Klingerauthor=M.+R.+Nicollsauthor=A.+J.+Olschewskiauthor=S.+S.+Pullamsettiauthor=R.+T.+Schermulyauthor=K.+R.+Stenmarkauthor=M.+Rabinovitch&title=Pathology+and+pathobiology+of+pulmonary+hypertension%3A+state+of+the+art+and+research+perspectives&doi=10.1183%2F13993003.01887-2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives</span></div><div class="casAuthors">Humbert, Marc; Guignabert, Christophe; Bonnet, Sebastien; Dorfmuller, Peter; Klinger, James R.; Nicolls, Mark R.; Olschewski, Andrea J.; Pullamsetti, Soni S.; Schermuly, Ralph T.; Stenmark, Kurt R.; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1801887</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Clin. and translational research has played a major role in advancing our understanding of pulmonary hypertension (PH), including pulmonary arterial hypertension and other forms of PH with severe vascular remodeling (e.g. chronic thromboembolic PH and pulmonary veno-occlusive disease).  However, PH remains an incurable condition with a high mortality rate, underscoring the need for a better transfer of novel scientific knowledge into healthcare interventions.  Herein, we review recent findings in pathol. (with the questioning of the strict morphol. categorization of various forms of PH into pre- or post-capillary involvement of pulmonary vessels) and cellular mechanisms contributing to the onset and progression of pulmonary vascular remodeling assocd. with various forms of PH.  We also discuss ways to improve management and to support and optimize drug development in this research field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZGkp56pYK7Vg90H21EOLACvtfcHk0lgnecmRK9sSWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7zI&md5=96aa87aff972ffe284ddfebf843fad36</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1183%2F13993003.01887-2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01887-2018%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DBonnet%26aufirst%3DS.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DKlinger%26aufirst%3DJ.%2BR.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26aulast%3DOlschewski%26aufirst%3DA.%2BJ.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DPathology%2520and%2520pathobiology%2520of%2520pulmonary%2520hypertension%253A%2520state%2520of%2520the%2520art%2520and%2520research%2520perspectives%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2019%26volume%3D53%26spage%3D1801887%26doi%3D10.1183%2F13993003.01887-2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herve, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span> <span> </span><span class="NLM_article-title">Pathobiology of pulmonary hypertension - the role of platelets and thrombosis</span>. <i>Clin. Chest Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">475</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0272-5231%2805%2970283-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11590841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD3Mrktlajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=459-475&author=P.+Herveauthor=M.+Humbertauthor=O.+Sitbonauthor=F.+Parentauthor=H.+Nunesauthor=C.+Legalauthor=G.+Garciaauthor=G.+Simonneau&title=Pathobiology+of+pulmonary+hypertension+-+the+role+of+platelets+and+thrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for pulmonary arterial hypertension</span></div><div class="casAuthors">Humbert M; Nunes H; Sitbon O; Parent F; Herve P; Simonneau G</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-75</span>
        ISSN:<span class="NLM_cas:issn">0272-5231</span>.
    </div><div class="casAbstract">The present limitations in knowledge of the potential risk factors for PPH undoubtedly are attributable to the facts that PPH is a rare disease with an unknown pathogenesis and lacking large case series.  Moreover, definite epidemiologic data are rare and ideally should be obtained from epidemiologic surveys such as large case-control studies.  The increased incidence of the disease in young women, the familial cases, the association with autoimmune disorders, and the recent discovery that mutation of the PPH1 gene may not be restricted to familial PPH support the hypothesis that the development of pulmonary hypertension likely implies an individual susceptibility or predisposition, which is probably genetically determined.  It is also now commonly believed that the development of pulmonary hypertension in some of these predisposed individuals could be hastened or precipitated by various expression factors (some of them yet unrecognized), such as ingestion of certain drugs or diets, portal hypertension, or HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI33BB09iiM1m8bhe6roZYfW6udTcc2eYRdU7zxFjkWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mrktlajsg%253D%253D&md5=5b560a445f9067aa98d577873305656f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0272-5231%2805%2970283-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0272-5231%252805%252970283-5%26sid%3Dliteratum%253Aachs%26aulast%3DHerve%26aufirst%3DP.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DParent%26aufirst%3DF.%26aulast%3DNunes%26aufirst%3DH.%26aulast%3DLegal%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DPathobiology%2520of%2520pulmonary%2520hypertension%2520-%2520the%2520role%2520of%2520platelets%2520and%2520thrombosis%26jtitle%3DClin.%2520Chest%2520Med.%26date%3D2001%26volume%3D22%26spage%3D459%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corin, R. E.</span></span> <span> </span><span class="NLM_article-title">Prostacyclin: a vascular mediator</span>. <i>Eur. J. Vasc. Endovasc. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1016/S1078-5884(03)00385-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS1078-5884%2803%2900385-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=14603414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD3srisVKgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=571-578&author=J.+Vaneauthor=R.+E.+Corin&title=Prostacyclin%3A+a+vascular+mediator&doi=10.1016%2FS1078-5884%2803%2900385-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prostacyclin: a vascular mediator</span></div><div class="casAuthors">Vane J; Corin R E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">571-8</span>
        ISSN:<span class="NLM_cas:issn">1078-5884</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwGqFYbQqIpVQKX3ooHxWjfW6udTcc2eYNu8fqJ3Vjfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srisVKgsQ%253D%253D&md5=26b71cbbf5b7f8812576433070f9cb82</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1078-5884%2803%2900385-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1078-5884%252803%252900385-X%26sid%3Dliteratum%253Aachs%26aulast%3DVane%26aufirst%3DJ.%26aulast%3DCorin%26aufirst%3DR.%2BE.%26atitle%3DProstacyclin%253A%2520a%2520vascular%2520mediator%26jtitle%3DEur.%2520J.%2520Vasc.%2520Endovasc.%2520Surg.%26date%3D2003%26volume%3D26%26spage%3D571%26epage%3D578%26doi%3D10.1016%2FS1078-5884%2803%2900385-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyndman, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohan, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span> <span> </span><span class="NLM_article-title">Endothelin</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1124/pr.115.011833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fpr.115.011833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26956245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28josFaltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=357-418&author=A.+P.+Davenportauthor=K.+A.+Hyndmanauthor=N.+Dhaunauthor=C.+Southanauthor=D.+E.+Kohanauthor=J.+S.+Pollockauthor=D.+M.+Pollockauthor=D.+J.+Webbauthor=J.+J.+Maguire&title=Endothelin&doi=10.1124%2Fpr.115.011833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin</span></div><div class="casAuthors">Davenport Anthony P; Hyndman Kelly A; Dhaun Neeraj; Southan Christopher; Kohan Donald E; Pollock Jennifer S; Pollock David M; Webb David J; Maguire Janet J</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">357-418</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The endothelins comprise three structurally similar 21-amino acid peptides.  Endothelin-1 and -2 activate two G-protein coupled receptors, ETA and ETB, with equal affinity, whereas endothelin-3 has a lower affinity for the ETA subtype.  Genes encoding the peptides are present only among vertebrates.  The ligand-receptor signaling pathway is a vertebrate innovation and may reflect the evolution of endothelin-1 as the most potent vasoconstrictor in the human cardiovascular system with remarkably long lasting action.  Highly selective peptide ETA and ETB antagonists and ETB agonists together with radiolabeled analogs have accurately delineated endothelin pharmacology in humans and animal models, although surprisingly no ETA agonist has been discovered.  ET antagonists (bosentan, ambrisentan) have revolutionized the treatment of pulmonary arterial hypertension, with the next generation of antagonists exhibiting improved efficacy (macitentan).  Clinical trials continue to explore new applications, particularly in renal failure and for reducing proteinuria in diabetic nephropathy.  Translational studies suggest a potential benefit of ETB agonists in chemotherapy and neuroprotection.  However, demonstrating clinical efficacy of combined inhibitors of the endothelin converting enzyme and neutral endopeptidase has proved elusive.  Over 28 genetic modifications have been made to the ET system in mice through global or cell-specific knockouts, knock ins, or alterations in gene expression of endothelin ligands or their target receptors.  These studies have identified key roles for the endothelin isoforms and new therapeutic targets in development, fluid-electrolyte homeostasis, and cardiovascular and neuronal function.  For the future, novel pharmacological strategies are emerging via small molecule epigenetic modulators, biologicals such as ETB monoclonal antibodies and the potential of signaling pathway biased agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4KujB2a63gEodMGTatQ7LfW6udTcc2eYNu8fqJ3Vjfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28josFaltg%253D%253D&md5=9850fbcc0e84b749ce374f4ab885a11f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fpr.115.011833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.115.011833%26sid%3Dliteratum%253Aachs%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26aulast%3DHyndman%26aufirst%3DK.%2BA.%26aulast%3DDhaun%26aufirst%3DN.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DKohan%26aufirst%3DD.%2BE.%26aulast%3DPollock%26aufirst%3DJ.%2BS.%26aulast%3DPollock%26aufirst%3DD.%2BM.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26atitle%3DEndothelin%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D357%26epage%3D418%26doi%3D10.1124%2Fpr.115.011833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrige, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moncada, S.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor</span>. <i>Nature (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1038/327524a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F327524a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=3495737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL2sXktlCjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=1987&pages=524-526&author=R.+M.+J.+Palmerauthor=A.+G.+Ferrigeauthor=S.+Moncada&title=Nitric+oxide+release+accounts+for+the+biological+activity+of+endothelium-derived+relaxing+factor&doi=10.1038%2F327524a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor</span></div><div class="casAuthors">Palmer, R. M. J.; Ferrige, A. G.; Moncada, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">6122</span>),
    <span class="NLM_cas:pages">524-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The release of endothelium-derived relaxing factor (EDRF) and NO from porcine aortic endothelial cells in culture was examd.  NO was detd. as the chemiluminescent product of its reaction with ozone.  The biol. activity of EDRF and of NO was measured by bioassay.  The relaxation of the bioassay tissues induced by EDRF was indistinguishable from that induced by NO.  Both substances were equally unstable.  Bradykinin caused concn.-dependent release of NO from the cells in amts. sufficient to account for the biol. activity of EDRF.  The relaxations induced by EDRF and NO were inhibited by Hb and enhanced by superoxide dismutase to a similar degree.  Thus, NO released from endothelial cells is indistinguishable from EDRF in terms of biol. activity, stability, and susceptibility to an inhibitor and to a potentiator.  EDRF and NO are probably identical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1cVPcdhBb7Vg90H21EOLACvtfcHk0lgCbu5TKilMvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktlCjs70%253D&md5=6afcb0594f86da2a398d0b6b792a2d75</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2F327524a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F327524a0%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BM.%2BJ.%26aulast%3DFerrige%26aufirst%3DA.%2BG.%26aulast%3DMoncada%26aufirst%3DS.%26atitle%3DNitric%2520oxide%2520release%2520accounts%2520for%2520the%2520biological%2520activity%2520of%2520endothelium-derived%2520relaxing%2520factor%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D1987%26volume%3D327%26spage%3D524%26epage%3D526%26doi%3D10.1038%2F327524a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuder, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cool, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraci, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelkel, N. F.</span></span> <span> </span><span class="NLM_article-title">Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1932</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.159.6.9804054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm.159.6.9804054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10351941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK1M3otVKmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=1999&pages=1925-1932&author=R.+M.+Tuderauthor=C.+D.+Coolauthor=M.+W.+Geraciauthor=J.+Wangauthor=S.+H.+Abmanauthor=L.+Wrightauthor=D.+Badeschauthor=N.+F.+Voelkel&title=Prostacyclin+synthase+expression+is+decreased+in+lungs+from+patients+with+severe+pulmonary+hypertension&doi=10.1164%2Fajrccm.159.6.9804054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension</span></div><div class="casAuthors">Tuder R M; Cool C D; Geraci M W; Wang J; Abman S H; Wright L; Badesch D; Voelkel N F</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1925-32</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Prostacyclin is a powerful vasodilator and inhibits platelet adhesion and cell growth.  We hypothesized that a decrease in expression of the critical enzyme PGI2 synthase (PGI2-S) in the lung may represent an important manifestation of pulmonary endothelial dysfunction in severe pulmonary hypertension (PH).  Immunohistochemistry and Western blot analysis were used to assess lung PGI2-S protein expression, and in situ hybridization was used to assess PGI2-S mRNA expression.  In the normal pulmonary circulation (n = 7), PGI2-S was expressed in 48% of small, 67% of medium, and 76% of large pulmonary arteries as assessed by immunohistochemistry.  PPH (n = 12), cirrhosis-associated (n = 4) and HIV-associated PH (n = 2) lungs exhibited a marked reduction in PGI2-S expression, involving all size ranges of pulmonary arteries.  Vessels with concentric lesions showed complete lack of PGI2-S expression.  Congenital heart (n = 4) and CREST (n = 2) cases exhibited a more variable immunohistological pattern of PGI2-S expression.  These results were complemented by in situ hybridization and Western blots of representative lung samples.  We conclude that the different sizes of the pulmonary arteries express PGI2-S differently and that the loss of expression of PGI2-S represents one of the phenotypic alterations present in the pulmonary endothelial cells in severe PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1Hv-dp9-W-tLIORRPd5lbfW6udTcc2eaZGR-NSv3jALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3otVKmsQ%253D%253D&md5=b127ae703c27e7f073b13ffc90463eda</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.159.6.9804054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.159.6.9804054%26sid%3Dliteratum%253Aachs%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DCool%26aufirst%3DC.%2BD.%26aulast%3DGeraci%26aufirst%3DM.%2BW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAbman%26aufirst%3DS.%2BH.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DVoelkel%26aufirst%3DN.%2BF.%26atitle%3DProstacyclin%2520synthase%2520expression%2520is%2520decreased%2520in%2520lungs%2520from%2520patients%2520with%2520severe%2520pulmonary%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D159%26spage%3D1925%26epage%3D1932%26doi%3D10.1164%2Fajrccm.159.6.9804054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourge, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundage, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koerner, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uretsky, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobsis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, J. W.</span></span> <span> </span><span class="NLM_article-title">A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1056/NEJM199602013340504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJM199602013340504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=8532025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK28XhsVShs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1996&pages=296-301&author=R.+J.+Barstauthor=L.+J.+Rubinauthor=W.+A.+Longauthor=M.+D.+McGoonauthor=S.+Richauthor=D.+B.+Badeschauthor=B.+M.+Grovesauthor=V.+F.+Tapsonauthor=R.+C.+Bourgeauthor=B.+H.+Brundageauthor=S.+K.+Koernerauthor=D.+Langlebenauthor=C.+A.+Kellerauthor=S.+Muraliauthor=B.+F.+Uretskyauthor=L.+M.+Claytonauthor=M.+M.+Jobsisauthor=S.+D.+Blackburnauthor=D.+Shortinoauthor=J.+W.+Crow&title=A+comparison+of+continuous+intravenous+epoprostenol+%28prostacyclin%29+with+conventional+therapy+for+primary+pulmonary+hypertension&doi=10.1056%2FNEJM199602013340504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension</span></div><div class="casAuthors">Barst, Robyn J.; Rubin, Lewis J.; Long, Walker A.; McGoon, Michael D.; Rich, Stuart; Badesch, David B.; Groves, Bertron M.; Tapson, Victor F.; Bourge, Robert C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">296-301</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival.  The authors conducted a 12-wk prospective, randomized, multicenter open trial comparing the effects of the continuous i.v. infusion of epoprostenol (formerly called prostacyclin) plus conventional therapy with those of conventional therapy alone in 81 patients with severe primary pulmonary hypertension (New York Heart Assocn. functional class III or IV).  Exercise capacity was improved in the 41 patients treated with epoprostenol (median distance walked in six minutes, 362 m at 12 wk vs. 315 m at base line), but it decreased in the 40 patients treated with conventional therapy alone (204 m at 12 wk vs. 270 m at base line; for the comparison of the treatment groups).  Indexes of the quality of life were improved only in the epoprostenol group.  Hemodynamics improved at 12 wk in the epoprostenol-treated patients.  The changes in mean pulmonary-artery pressure for the epoprostenol and control groups were -8 % and +3 %, resp. (difference in mean change, -6.7 mm Hg; 95 % confidence interval, -10.7 to -2.6 mm Hg), and the mean changes in pulmonary vascular resistance for the epoprostenol and control groups were -21 % and +9 %, resp. (difference in mean change, -4.9 mm Hg per L per min; 95 % confidence interval, -7.6 to -2.3 mm Hg per L per min).  Eight patients died during the study, all of whom had been randomly assigned to conventional therapy.  Serious complications included four episodes of catheter-related sepsis and one thrombotic event.  As compared with conventional therapy, the continuous i.v. infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohxvdY8yCMD7Vg90H21EOLACvtfcHk0lg4wEkhI_tWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVShs70%253D&md5=09eaf0c73350f23954e2c90a2a19a72a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJM199602013340504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199602013340504%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DLong%26aufirst%3DW.%2BA.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DGroves%26aufirst%3DB.%2BM.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DBourge%26aufirst%3DR.%2BC.%26aulast%3DBrundage%26aufirst%3DB.%2BH.%26aulast%3DKoerner%26aufirst%3DS.%2BK.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DC.%2BA.%26aulast%3DMurali%26aufirst%3DS.%26aulast%3DUretsky%26aufirst%3DB.%2BF.%26aulast%3DClayton%26aufirst%3DL.%2BM.%26aulast%3DJobsis%26aufirst%3DM.%2BM.%26aulast%3DBlackburn%26aufirst%3DS.%2BD.%26aulast%3DShortino%26aufirst%3DD.%26aulast%3DCrow%26aufirst%3DJ.%2BW.%26atitle%3DA%2520comparison%2520of%2520continuous%2520intravenous%2520epoprostenol%2520%2528prostacyclin%2529%2520with%2520conventional%2520therapy%2520for%2520primary%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1996%26volume%3D334%26spage%3D296%26epage%3D301%26doi%3D10.1056%2FNEJM199602013340504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span> <span> </span><span class="NLM_article-title">Survival in primary pulmonary hypertension - the impact of epoprostenol therapy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000029100.82385.58</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.CIR.0000029100.82385.58" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12234951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=1477-1482&author=V.+V.+McLaughlinauthor=A.+Shillingtonauthor=S.+Rich&title=Survival+in+primary+pulmonary+hypertension+-+the+impact+of+epoprostenol+therapy&doi=10.1161%2F01.CIR.0000029100.82385.58"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Survival in Primary Pulmonary Hypertension, The Impact of Epoprostenol Therapy</span></div><div class="casAuthors">McLaughlin, Vallerie V.; Shillington, Alicia; Rich, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1482</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background - Primary pulmonary hypertension (PPH) is a severe and progressive disease.  Without treatment, the median survival is 2.8 yr, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 yr, resp.  Epoprostenol (i.v.) was the first Food and Drug Administration-approved therapy for PPH.  The long-term impact that epoprostenol has made on PPH remains to be defined.  Methods and Results - One hundred sixty-two consecutive patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 mo (median, 31 mo).  Data including functional class, exercise tolerance, and hemodynamics were recorded in a customized database.  Vital status was verified in each patient.  Obsd. survival with epoprostenol therapy at 1, 2, and 3 yr was 87.8%, 76.3%, and 62.8% and was significantly greater than the expected survival of 58.9%, 46.3%, and 35.4% based on historical data.  Baseline predictors of survival included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine.  Predictors of survival after the first year of therapy included functional class and improvement in exercise tolerance, cardiac index, and mean pulmonary artery pressure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLZq5WHeBbaLVg90H21EOLACvtfcHk0lg4wEkhI_tWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKksb0%253D&md5=faea3dbfef7bf10076786f83c5ea94c4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000029100.82385.58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000029100.82385.58%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DShillington%26aufirst%3DA.%26aulast%3DRich%26aufirst%3DS.%26atitle%3DSurvival%2520in%2520primary%2520pulmonary%2520hypertension%2520-%2520the%2520impact%2520of%2520epoprostenol%2520therapy%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D1477%26epage%3D1482%26doi%3D10.1161%2F01.CIR.0000029100.82385.58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickolson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorbruggen, H.</span></span> <span> </span><span class="NLM_article-title">Prostacyclin-analogs</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1002/med.2610050102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fmed.2610050102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=3884930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL2MXhtVKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1985&pages=1-53&author=R.+C.+Nickolsonauthor=M.+H.+Townauthor=H.+Vorbruggen&title=Prostacyclin-analogs&doi=10.1002%2Fmed.2610050102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Prostacyclin-analogs</span></div><div class="casAuthors">Nickolson, Robert C.; Town, Michael H.; Vorbrueggen, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-53</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    </div><div class="casAbstract">A review with 238 refs. is given on the chem. and biol. of new prostacyclin analogs.  Included is a summary of the biol., pharmacol., and chem. of natural prostacyclin  [35121-78-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQTiHFlSsubVg90H21EOLACvtfcHk0lg4wEkhI_tWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhtVKgsbo%253D&md5=966f023b425c68b7137bc7654845882d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmed.2610050102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.2610050102%26sid%3Dliteratum%253Aachs%26aulast%3DNickolson%26aufirst%3DR.%2BC.%26aulast%3DTown%26aufirst%3DM.%2BH.%26aulast%3DVorbruggen%26aufirst%3DH.%26atitle%3DProstacyclin-analogs%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1985%26volume%3D5%26spage%3D1%26epage%3D53%26doi%3D10.1002%2Fmed.2610050102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassard, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity-relationships associated with 3,4,5-triphenyl-1h-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1021/jm00080a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00080a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=389-397&author=N.+A.+Meanwellauthor=M.+J.+Rosenfeldauthor=J.+J.+K.+Wrightauthor=C.+L.+Brassardauthor=J.+O.+Buchananauthor=M.+E.+Federiciauthor=J.+S.+Flemingauthor=S.+M.+Seiler&title=Structure-activity-relationships+associated+with+3%2C4%2C5-triphenyl-1h-pyrazole-1-nonanoic+acid%2C+a+nonprostanoid+prostacyclin+mimetic&doi=10.1021%2Fjm00080a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span></div><div class="casAuthors">Meanwell, Nicholas A.; Rosenfeld, Michael J.; Wright, J. J. Kim; Brassard, Catherine L.; Buchanan, John O.; Federici, Marianne E.; Fleming, J. Stuart; Seiler, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-97</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of phenylated pyrazolealkanoic acids, e.g., I (R = (CH2)nCO2H, n = 5-10, R1, R3 = H, Ph, R2 = Ph, PhCH2, Et; R = (CH2)6XCH2CO2H, X = O, S, S(O), SO2, R1 = R2 = R3 = Ph) and related derivs. were prepd. as inhibitors of ADP-induced human platelet aggregation.  3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (II), with an IC50 of 0.4 μM, was the most potent inhibitor.  Biochem. studies detd. that II increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concn.-dependent fashion.  Displacement of [3H]iloprost by II from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biol. action.  Structure-activity studies demonstrated that the min. structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an ω-alkanoic acid side chain 8 or 9 atoms long.  Potency depended upon both side-chain length and its topol. relationship with the two Ph rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU40YZ6EI6OrVg90H21EOLACvtfcHk0ljb0cQu-R2qlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D&md5=00f2e4d0e07a45ebf9ad206a0c3c2de2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm00080a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00080a028%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRosenfeld%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%2BK.%26aulast%3DBrassard%26aufirst%3DC.%2BL.%26aulast%3DBuchanan%26aufirst%3DJ.%2BO.%26aulast%3DFederici%26aufirst%3DM.%2BE.%26aulast%3DFleming%26aufirst%3DJ.%2BS.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3DStructure-activity-relationships%2520associated%2520with%25203%252C4%252C5-triphenyl-1h-pyrazole-1-nonanoic%2520acid%252C%2520a%2520nonprostanoid%2520prostacyclin%2520mimetic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D389%26epage%3D397%26doi%3D10.1021%2Fjm00080a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higenbottam, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh-Xaun, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremona, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamine, S.</span></span> <span> </span><span class="NLM_article-title">Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost</span>. <i>Heart</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1136/hrt.79.2.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1136%2Fhrt.79.2.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=9538312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK1c7pvFWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1998&pages=175-179&author=T.+W.+Higenbottamauthor=A.+Y.+Buttauthor=A.+T.+Dinh-Xaunauthor=M.+Takaoauthor=G.+Cremonaauthor=S.+Akamine&title=Treatment+of+pulmonary+hypertension+with+the+continuous+infusion+of+a+prostacyclin+analogue%2C+iloprost&doi=10.1136%2Fhrt.79.2.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost</span></div><div class="casAuthors">Higenbottam T W; Butt A Y; Dinh-Xaun A T; Takao M; Cremona G; Akamine S</div><div class="citationInfo"><span class="NLM_cas:title">Heart (British Cardiac Society)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-9</span>
        ISSN:<span class="NLM_cas:issn">1355-6037</span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare prostacyclin with an analogue, iloprost, in treatment of severe pulmonary hypertension.  PATIENTS:  Eight patients with severe pulmonary hypertension: primary in five, thromboembolic pulmonary hypertension in three.  METHODS:  All patients underwent right heart catheterisation.  Mean (SEM) right atrial pressure was 9.9 (2.2) mm Hg, mean pulmonary artery pressure 67.4 (3.0) mm Hg, cardiac index 1.75 (0.13) l/min/m2 and mixed venous oxygen saturation 59.1(3.1)%.  Continuous intravenous epoprostenol (prostacyclin, PGI2) or iloprost was given for phase I (three to six weeks); the patients were then crossed over to receive the alternate drug in an equivalent phase II.  MAIN OUTCOME MEASURES:  Exercise tolerance was measured at baseline and at the end of phase I and II with a 12 minute walk; distance covered, rest period, percentage drop in arterial oxygen saturation (delta Sao2%) and percentage rise in heart rate (delta HR%).  RESULTS:  Walking distance covered rose from (mean (SEM)) 407.5 (73) to 591 (46) m with PGI2 (p = 0.004) and to 602.5 (60) m while on iloprost (p = 0.008).  Rest period decreased from 192 (73) seconds at baseline to 16 (16) seconds with PGI2 (p = 0.01) and to 58 (34) seconds with iloprost (p = 0.008).  Delta HR% was 37.5(6)% at baseline, 35(3)% on PGI2, and 24(6)% on iloprost (p = 0.04).  CONCLUSIONS:  Both intravenous PGI2 and iloprost caused significant improvement in exercise tolerance.  Iloprost offers an alternative to PGI2 treatment of severe pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT888cCbuZDlPtos8R3JUhXfW6udTcc2eanabJ1pMDx_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7pvFWisQ%253D%253D&md5=0cd839a9b8e72741462cbe5b5f3c9b7e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1136%2Fhrt.79.2.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fhrt.79.2.175%26sid%3Dliteratum%253Aachs%26aulast%3DHigenbottam%26aufirst%3DT.%2BW.%26aulast%3DButt%26aufirst%3DA.%2BY.%26aulast%3DDinh-Xaun%26aufirst%3DA.%2BT.%26aulast%3DTakao%26aufirst%3DM.%26aulast%3DCremona%26aufirst%3DG.%26aulast%3DAkamine%26aufirst%3DS.%26atitle%3DTreatment%2520of%2520pulmonary%2520hypertension%2520with%2520the%2520continuous%2520infusion%2520of%2520a%2520prostacyclin%2520analogue%252C%2520iloprost%26jtitle%3DHeart%26date%3D1998%26volume%3D79%26spage%3D175%26epage%3D179%26doi%3D10.1136%2Fhrt.79.2.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higenbottam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikkho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiely, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Sanchez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedentop, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span> <span> </span><span class="NLM_article-title">Inhaled iloprost for severe pulmonary hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa020204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12151469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslWqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=322-329&author=H.+Olschewskiauthor=G.+Simonneauauthor=N.+Galieauthor=T.+Higenbottamauthor=R.+Naeijeauthor=L.+J.+Rubinauthor=S.+Nikkhoauthor=R.+Speichauthor=M.+M.+Hoeperauthor=J.+Behrauthor=J.+Winklerauthor=O.+Sitbonauthor=W.+Popovauthor=H.+A.+Ghofraniauthor=A.+Manesauthor=D.+G.+Kielyauthor=R.+Ewertauthor=A.+Meyerauthor=P.+A.+Corrisauthor=M.+Delcroixauthor=M.+Gomez-Sanchezauthor=H.+Siedentopauthor=W.+Seeger&title=Inhaled+iloprost+for+severe+pulmonary+hypertension&doi=10.1056%2FNEJMoa020204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled iloprost for severe pulmonary hypertension</span></div><div class="casAuthors">Olschewski, Horst; Simonneau, Gerald; Galie, Nazzareno; Higenbottam, Timothy; Naeije, Robert; Rubin, Lewis J.; Nikkho, Syliva; Speich, Rudolf; Hoeper, Marius M.; Behr, Juergen; Winkler, Joerg; Sitbon, Olivier; Popov, Wladimir; Ghofrani, H. Ardeschir; Manes, Alessandra; Kiely, David G.; Ewert, Ralph; Meyer, Andreas; Corris, Paul A.; Delcroix, Marion; Gomez-Sanchez, Miguel; Siedentop, Harald; Seeger, Werner; Fabel, H.; Spiekerkoetter, E.; Grimminger, F.; Wiedemann, R.; Leuchte, H.; Aquilina, M.; Amsha, K.; Lawson, R.; Alcock, R.; Pforte, A.; Schauer, J.; Budts, W.; Escribano, P.; Lazaro, M.; Huchalla, E.; Borst, M.; Black, C. M.; Bravo, C.; Roman, A.; Monforte, V.; Peacock, A.; Boonstra, A.; Fracchia, C.; Marini, C.; Nicod, L.; Pepke-Zaba, J.; Sybrecht, G.; Wilkens, H.; Torbicki, A.; Diot, P.; Mota, T.; Pennaforte, J. L.; Perez, T.; Radenne, F.; Pison, C.; Vachiery, J. L.; Hallgren, P.; Kleber, F.-X.; Providencia, L.; Ribeiro, V. R. G.; Soler, M.; Stricker, H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Uncontrolled studies suggested that aerosolized iloprost, a stable analog of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension.  We compared repeated daily inhalations of 2.5 or 5.0 μg of iloprost (six or nine times per day; median inhaled dose, 30 μg per day) with inhalation of placebo.  A total of 203 patients with selected forms of severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (New York Heart Assocn. [NYHA] functional class III or IV) were included.  The primary end point was met if, after week 12, the NYHA class and distance walked in six minutes were improved by at least one class and at least 10 %, resp., in the absence of clin. deterioration according to predefined criteria and death.  The combined clin. end point was met by 16.8 % of the patients receiving iloprost, as compared with 4.9 % of the patients receiving placebo (P = 0.007).  There were increases in the distance walked in six minutes of 36.4 m in the iloprost group as a whole (P = 0.004) and of 58.8 m in the subgroup of patients with primary pulmonary hypertension.  Overall, 4.0 % of patients in the iloprost group (including one who died) and 13.7 % of those in the placebo group (including four who died) did not complete the study (P = 0.024); the most common reason for withdrawal was clin. deterioration.  As compared with base-line values, hemodynamic values were significantly improved at 12 wk when measured after iloprost inhalation (P<0.001), were largely unchanged when measured before iloprost inhalation, and were significantly worse in the placebo group.  Further significant beneficial effects of iloprost treatment included an improvement in the NYHA class (P = 0.03), dyspnea (P = 0.015), and quality of life (P = 0.026).  Syncope occurred with similar frequency in the two groups but was more frequently rated as serious in the iloprost group, although this adverse effect was not assocd. with clin. deterioration.  Inhaled iloprost is an effective therapy for patients with severe pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjzSDcfOk4BbVg90H21EOLACvtfcHk0lg27FG3ONwDYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslWqt7c%253D&md5=48ab0098d45ec99c4518476037cf610d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020204%26sid%3Dliteratum%253Aachs%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DHigenbottam%26aufirst%3DT.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DNikkho%26aufirst%3DS.%26aulast%3DSpeich%26aufirst%3DR.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DPopov%26aufirst%3DW.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DKiely%26aufirst%3DD.%2BG.%26aulast%3DEwert%26aufirst%3DR.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DCorris%26aufirst%3DP.%2BA.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DGomez-Sanchez%26aufirst%3DM.%26aulast%3DSiedentop%26aufirst%3DH.%26aulast%3DSeeger%26aufirst%3DW.%26atitle%3DInhaled%2520iloprost%2520for%2520severe%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D322%26epage%3D329%26doi%3D10.1056%2FNEJMoa020204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span> <span> </span><span class="NLM_article-title">Vasodilator actions of trk-100, a new prostaglandin-i2 analog</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">711</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1986.tb11174.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fj.1476-5381.1986.tb11174.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=3101928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL2sXksVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1986&pages=703-711&author=T.+Akibaauthor=M.+Miyazakiauthor=N.+Toda&title=Vasodilator+actions+of+trk-100%2C+a+new+prostaglandin-i2+analog&doi=10.1111%2Fj.1476-5381.1986.tb11174.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Vasodilator actions of TRK-100, a new prostaglandin I2 analog</span></div><div class="casAuthors">Akiba, Tetsuro; Miyazaki, Mizuo; Toda, Noboru</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">703-11</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">TRK-100 (I)  [88475-69-8] relaxed isolated canine arteries which were precontracted with PGF2α  [551-11-1] or K+; the relaxation was in the order of mesenteric and renal > coronary and femoral > basilar and middle cerebral arteries.  The relaxation by I was not affected by treatment with atropine, propranolol, cimetidine, aminophylline, and indomethacin, but was suppressed by diphloretin phosphate, a prostaglandin antagonist.  Treatment with I attenuated the contraction induced by PGF2α and Ca2+ in mesenteric and basilar arteries previously exposed to Ca2+-free medium, but did not significantly alter the contractile response to Ca2+ in the arteries exposed to Ca2+-free medium and depolarized by excess K+.  I and nitroglycerin  [55-63-0] relaxed isolated mesenteric arteries to a similar extent; however, when continuously infused into mesenteric arteries in anesthetized dogs, I produced greater vasodilatation than nitroglycerin.  Apparently, I relaxes dog mesenteric and renal arteries more than cerebral arteries; the relaxation appears to derive from interference with the release of Ca2+ from intracellular stores and with the transmembrane Ca2+ influx through a receptor-operated channel.  I may dilate large and small mesenteric arteries and resistance vessels to a similar extent, whereas nitroglycerin preferentially dilates the large artery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJfk3hKYGfOLVg90H21EOLACvtfcHk0ljvmxcn9aPYzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXksVGktg%253D%253D&md5=50b33581b124cc7029cfcb782f06555c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1986.tb11174.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1986.tb11174.x%26sid%3Dliteratum%253Aachs%26aulast%3DAkiba%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DToda%26aufirst%3DN.%26atitle%3DVasodilator%2520actions%2520of%2520trk-100%252C%2520a%2520new%2520prostaglandin-i2%2520analog%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1986%26volume%3D89%26spage%3D703%26epage%3D711%26doi%3D10.1111%2Fj.1476-5381.1986.tb11174.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branzi, A.</span></span> <span> </span><span class="NLM_article-title">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1183/09031936.02.05542002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.02.05542002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12412701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1037-1049&author=N.+Galieauthor=A.+Manesauthor=A.+Branzi&title=The+new+clinical+trials+on+pharmacological+treatment+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.02.05542002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Manes, A.; Branzi, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1049</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Past medical therapy for pulmonary arterial hypertension included the use of calcium-channel antagonists in acute vasoreactive subjects and oral anti-coagulants and continuous i.v. administration of epoprostenol in the more severe cases.  Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogs treprostinil, beraprost and iloprost, and the endothelin receptor antagonist bosentan have been tested in clin. trials in >1,100 patients.  Except for terbogrel, all compds. improved the mean exercise capacity by different degrees, as assessed by the 6-min walk test.  In the evaluation of the clin. relevance of exercise capacity improvements, addnl. elements need to be considered, such as baseline functional class and concomitant favorable effects on combined clin. events (including hospitalizations, mortality and rescue therapies), quality of life and hemodynamics.  No trials have shown effects on mortality, as the study protocols were not designed for assessing this end-point.  Each new compd. presents side-effects that are unpredictable in the individual patient and require appropriate attention upon treatment initiation and maintenance.  These new therapeutic options will be available in the near future and will allow tailoring of the most appropriate treatment to the single patient, according to an individualized benefit-to-risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4jEc_GhfAP7Vg90H21EOLACvtfcHk0ljvmxcn9aPYzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D&md5=40c0c3940d3ff20dd629afd5db22e416</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.05542002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.05542002%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DBranzi%26aufirst%3DA.%26atitle%3DThe%2520new%2520clinical%2520trials%2520on%2520pharmacological%2520treatment%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D20%26spage%3D1037%26epage%3D1049%26doi%3D10.1183%2F09031936.02.05542002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizza, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneussl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaouat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span> <span> </span><span class="NLM_article-title">Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1502</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(02)01786-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0735-1097%2802%2901786-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11985913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=1496-1502&author=N.+Galieauthor=M.+Humbertauthor=J.-L.+Vachieryauthor=C.+D.+Vizzaauthor=M.+Kneusslauthor=A.+Manesauthor=O.+Sitbonauthor=A.+Torbickiauthor=M.+Delcroixauthor=R.+Naeijeauthor=M.+Hoeperauthor=A.+Chaouatauthor=S.+Morandauthor=B.+Besseauthor=G.+Simonneau&title=Effects+of+beraprost+sodium%2C+an+oral+prostacyclin+analogue%2C+in+patients+with+pulmonary+arterial+hypertension%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS0735-1097%2802%2901786-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Galie, Nazzareno; Humbert, Marc; Vachiery, Jean-Luc; Vizza, Carmine Dario; Kneussl, Meinhard; Manes, Alessandra; Sitbon, Olivier; Torbicki, Adam; Delcroix, Marion; Naeije, Robert; Hoeper, Marius; Chaouat, Ari; Morand, Sophie; Besse, Bruno; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1496-1502</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to assess the efficacy and safety of beraprost sodium, an orally active prostacyclin analog, in New York Heart Assocn. (NYHA) functional class II and III patients with pulmonary arterial hypertension (PAH).  Pulmonary arterial hypertension is a life-threatening disease for which continuous i.v. infusion of prostacyclin has been proven effective.  However, this treatment is assocd. with serious complications arising from the complex delivery system.  In this double-blind, placebo-controlled study, 130 patients with PAH were randomized to the maximal tolerated dose of beraprost (median dose 80 μg four times a day) or to placebo for 12 wk.  The primary end point was the change in exercise capacity assessed by the 6-min walk test.  Secondary end points included changes in Borg dyspnea index, cardiopulmonary hemodynamics and NYHA functional class.  Patients treated with beraprost improved exercise capacity and symptoms.  The difference between treatment groups in the mean change of 6-min walking distance at week 12 was 25.1 m (95% confidence interval [CI]: 1.8 to 48.3, p = 0.036).  The difference in the mean change of Borg dyspnea index was -0.94 (95% CI: -1.63 to -0.24, p = 0.009).  In the sub-group of patients with primary pulmonary hypertension, the difference in the mean change of 6-min walking distance was 46.1 m (95% CI: 3.0 to 89.3, p = 0.035).  Cardiopulmonary hemodynamics and NYHA functional class had no statistically significant changes.  Drug-related adverse events were common in the titrn. phase and decreased in the maintenance period.  Beraprost improves exercise capacity and symptoms in NYHA functional class II and III patients with PAH and, in particular, in those with primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwooODR_ZS7Vg90H21EOLACvtfcHk0lgO0xw9vVfVvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKksbY%253D&md5=1aa9a4a5863c84a6f8b26b2743e9a6f4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2802%2901786-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252802%252901786-2%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.-L.%26aulast%3DVizza%26aufirst%3DC.%2BD.%26aulast%3DKneussl%26aufirst%3DM.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DHoeper%26aufirst%3DM.%26aulast%3DChaouat%26aufirst%3DA.%26aulast%3DMorand%26aufirst%3DS.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DEffects%2520of%2520beraprost%2520sodium%252C%2520an%2520oral%2520prostacyclin%2520analogue%252C%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2002%26volume%3D39%26spage%3D1496%26epage%3D1502%26doi%3D10.1016%2FS0735-1097%2802%2901786-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayburn, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinchbaugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arneson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffs, R.</span></span> <span> </span><span class="NLM_article-title">Beraprost therapy for pulmonary arterial hypertension</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(03)00463-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0735-1097%2803%2900463-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12821234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVSqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2003&pages=2119-2125&author=R.+J.+Barstauthor=M.+McGoonauthor=V.+McLaughlinauthor=V.+Tapsonauthor=R.+Oudizauthor=S.+Shapiroauthor=I.+M.+Robbinsauthor=R.+Channickauthor=D.+Badeschauthor=B.+K.+Rayburnauthor=R.+Flinchbaughauthor=J.+Sigmanauthor=C.+Arnesonauthor=R.+Jeffs&title=Beraprost+therapy+for+pulmonary+arterial+hypertension&doi=10.1016%2FS0735-1097%2803%2900463-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Beraprost therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Barst, Robyn J.; McGoon, Michael; McLaughlin, Vallerie; Tapson, Victor; Oudiz, Ronald; Shapiro, Shelley; Robbins, Ivan M.; Channick, Richard; Badesch, David; Rayburn, Barry K.; Flinchbaugh, Robin; Sigman, Jeff; Arneson, Carl; Jeffs, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2119-2125</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to assess the safety and efficacy of the oral prostacyclin analog beraprost sodium during a 12-mo double-blind, randomized, placebo-controlled trial in patients with pulmonary arterial hypertension (PAH).  Pulmonary arterial hypertension is a progressive disease that ultimately causes right heart failure and death.  Despite the risks from its delivery system, continuous i.v. epoprostenol remains the most efficacious treatment currently available.  A total of 116 patients with World Health Organization (WHO) functional class II or III primary pulmonary hypertension or PAH related to either collagen vascular diseases or congenital systemic to pulmonary shunts were enrolled.  Patients were randomized to receive the maximal tolerated dose of beraprost sodium (median dose 120 μg four times a day) or placebo for 12 mo.  The primary end point was disease progression; i.e., death, transplantation, epoprostenol rescue, or >25% decrease in peak oxygen consumption (VO2).  Secondary end points included exercise capacity assessed by 6-min walk test and peak VO2, Borg dyspnea score, hemodynamics, symptoms of PAH, and quality of life.  Patients treated with beraprost exhibited less evidence of disease progression at six months (p = 0.002), but this effect was not evident at either shorter or longer follow-up intervals.  Similarly, beraprost-treated patients had improved 6-min walk distance at 3 mo by 22 m from baseline and at 6 mo by 31 m (p = 0.010 and 0.016, resp.) compared with placebo, but not at either 9 or 12 mo.  Drug-related adverse events were common and were related to the disease and/or expected prostacyclin adverse events.  These data suggest that beneficial effects may occur during early phases of treatment with beraprost in WHO functional class II or III patients but that this effect attenuates with time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIw27g9t2f3LVg90H21EOLACvtfcHk0lgO0xw9vVfVvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVSqsLs%253D&md5=9169214f23faefb5a223cd8b6692dcc4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2803%2900463-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252803%252900463-7%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DMcGoon%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DTapson%26aufirst%3DV.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DChannick%26aufirst%3DR.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DRayburn%26aufirst%3DB.%2BK.%26aulast%3DFlinchbaugh%26aufirst%3DR.%26aulast%3DSigman%26aufirst%3DJ.%26aulast%3DArneson%26aufirst%3DC.%26aulast%3DJeffs%26aufirst%3DR.%26atitle%3DBeraprost%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2003%26volume%3D41%26spage%3D2119%26epage%3D2125%26doi%3D10.1016%2FS0735-1097%2803%2900463-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourge, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.165.6.2106079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm.165.6.2106079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11897647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD387psFCqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2002&pages=800-804&author=G.+Simonneauauthor=R.+J.+Barstauthor=N.+Galieauthor=R.+Naeijeauthor=S.+Richauthor=R.+C.+Bourgeauthor=A.+Keoghauthor=R.+Oudizauthor=A.+Frostauthor=S.+D.+Blackburnauthor=J.+W.+Crowauthor=L.+J.+Rubin&title=Continuous+subcutaneous+infusion+of+treprostinil%2C+a+prostacyclin+analogue%2C+in+patients+with+pulmonary+arterial+hypertension%3A+a+double-blind%2C+randomized%2C+placebo-controlled+trial&doi=10.1164%2Fajrccm.165.6.2106079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial</span></div><div class="casAuthors">Simonneau Gerald; Barst Robyn J; Galie Nazzareno; Naeije Robert; Rich Stuart; Bourge Robert C; Keogh Anne; Oudiz Ronald; Frost Adaani; Blackburn Shelmer D; Crow James W; Rubin Lewis J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">800-4</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous prostacyclin has proven to be effective.  However, this treatment requires a permanent central venous catheter with the associated risk of serious complications such as sepsis, thromboembolism, or syncope.  Treprostinil, a stable prostacyclin analogue, can be administered by a continuous subcutaneous infusion, avoiding these risks.  We conducted a 12-week, double-blind, placebo-controlled multicenter trial in 470 patients with pulmonary arterial hypertension, either primary or associated with connective tissue disease or congenital systemic-to-pulmonary shunts.  Exercise capacity improved with treprostinil and was unchanged with placebo; the between treatment group difference in median six-minute walking distance was 16 m (p = 0.006).  Improvement in exercise capacity was greater in the sicker patients and was dose-related, but independent of disease etiology.  Concomitantly, treprostinil significantly improved indices of dyspnea, signs and symptoms of pulmonary hypertension, and hemodynamics.  The most common side effect attributed to treprostinil was infusion site pain (85%) leading to premature discontinuation from the study in 8% of patients.  Three patients in the treprostinil treatment group presented with an episode of gastrointestinal hemorrhage.  We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR135dJKQFMM0wlCcfExbvbfW6udTcc2eYaZmrQQXnJSbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387psFCqtg%253D%253D&md5=345ab915c0849f46be7df9b1d34a2219</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.165.6.2106079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.165.6.2106079%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DBourge%26aufirst%3DR.%2BC.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DBlackburn%26aufirst%3DS.%2BD.%26aulast%3DCrow%26aufirst%3DJ.%2BW.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DContinuous%2520subcutaneous%2520infusion%2520of%2520treprostinil%252C%2520a%2520prostacyclin%2520analogue%252C%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%253A%2520a%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520trial%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2002%26volume%3D165%26spage%3D800%26epage%3D804%26doi%3D10.1164%2Fajrccm.165.6.2106079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span> <span> </span><span class="NLM_article-title">Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7128</span>– <span class="NLM_lpage">7137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7128-7137&author=T.+Asakiauthor=K.+Kuwanoauthor=K.+Morrisonauthor=J.+Gatfieldauthor=T.+Hamamotoauthor=M.+Clozel&title=Selexipag%3A+an+oral+and+selective+IP+prostacyclin+receptor+agonist+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.5b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Asaki, Tetsuo; Kuwano, Keiichi; Morrison, Keith; Gatfield, John; Hamamoto, Taisuke; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7128-7137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor.  Decreased prostacyclin prodn. occurs in several cardiovascular diseases.  However, the clin. use of prostacyclin and its analogs is complicated by their chem. and metabolic instability.  A medicinal chem. program searched for novel nonprostanoid prostacyclin receptor agonists not subject to these limitations.  A compd. with a diphenylpyrazine structural core was synthesized.  Metabolic stability and agonist potency were optimized through modification of the linear side chain.  Compd. 12b (MRE-269, ACT-333679) was identified as a potent and highly selective prostacyclin receptor agonist.  Replacement of the terminal carboxyl group with an N-acylsulfonamide group yielded parent compd. 26a (selexipag, NS-304, ACT-293987), which is orally active and provides sustained plasma exposure of 12b.  Compd. 26a was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouZjQo25LkGrVg90H21EOLACvtfcHk0lgbwZqUAmU_dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO&md5=4b09d302b4852c75be29c94578483d8d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00698%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DSelexipag%253A%2520an%2520oral%2520and%2520selective%2520IP%2520prostacyclin%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7128%26epage%3D7137%26doi%3D10.1021%2Facs.jmedchem.5b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">7720</span>– <span class="NLM_lpage">7725</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmc.2007.08.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17881233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7720-7725&author=A.+Nakamuraauthor=T.+Yamadaauthor=T.+Asaki&title=Synthesis+and+evaluation+of+N-acylsulfonamide+and+N-acylsulfonylurea+prodrugs+of+a+prostacyclin+receptor+agonist&doi=10.1016%2Fj.bmc.2007.08.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span></div><div class="casAuthors">Nakamura, Akio; Yamada, Tetsuhiro; Asaki, Tetsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7720-7725</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">N-Acylsulfonamide and N-acylsulfonylurea derivs. of the carboxylic acid prostacyclin receptor agonist 1 (I) were synthesized and their potential as prodrug forms of the carboxylic acid was evaluated in vitro and in vivo.  These compds. were converted to the active compd. 1 by hepatic microsomes from rats, dogs, monkeys, and humans, and some of the compds. were shown to yield sustained plasma concns. of 1 when they were orally administered to monkeys.  These types of analogs, including NS-304 (2a), are potentially useful prodrugs of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3pafmMVkL07Vg90H21EOLACvtfcHk0liP0Jrqtk0gSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF&md5=e48076b73d0c2bd9b4312dab5e0693ad</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DAsaki%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-acylsulfonamide%2520and%2520N-acylsulfonylurea%2520prodrugs%2520of%2520a%2520prostacyclin%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7720%26epage%3D7725%26doi%3D10.1016%2Fj.bmc.2007.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, K.</span></span> <span> </span><span class="NLM_article-title">2-{4- (5,6-diphenylpyrazin-2-yl)(isopropyl)amino butoxy}-N(methylsulfony l)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.124248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.107.124248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17545310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslKrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=1181-1188&author=K.+Kuwanoauthor=A.+Hashinoauthor=T.+Asakiauthor=T.+Hamamotoauthor=T.+Yamadaauthor=K.+Okuboauthor=K.+Kuwabara&title=2-%7B4-+%285%2C6-diphenylpyrazin-2-yl%29%28isopropyl%29amino+butoxy%7D-N%28methylsulfony+l%29acetamide+%28NS-304%29%2C+an+orally+available+and+long-acting+prostacyclin+receptor+agonist+prodrug&doi=10.1124%2Fjpet.107.124248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">2-{4-[5,6-(Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug</span></div><div class="casAuthors">Kuwano, Keiichi; Hashino, Asami; Asaki, Tetsuo; Hamamoto, Taisuke; Yamada, Tetsuhiro; Okubo, Kaori; Kuwabara, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1181-1188</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prostacyclin (PGI2) and its analogs are useful for the treatment of various vascular disorders, but their half-lives are too short for widespread clin. application.  To overcome this drawback, we have synthesized a novel diphenylpyrazine deriv., 2-{4-[5,6-(diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl)acetamide (NS-304), a prodrug of the active from {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269).  NS-304 is an orally available and potent agonist for the PGI2 receptor (IP receptor).  The inhibition const. (Ki) of MRE-269 for the human IP receptor was 20 nM; in contrast, the Ki values for other prostanoid receptors were >2.6 μM.  MRE-269 was therefore a highly selective agonist for the IP receptor.  The plasma concns. of MRE-269 remained near peak levels for more than 8 h after oral administration of NS-304 to rats and dogs, and NS-304 increased femoral skin blood flow in rats in a long-lasting manner without affecting the hemodynamics.  These findings indicate that NS-304 acts as a long-acting IP receptor agonist in vivo.  The continuous vasodilation evoked by NS-304 was not attenuated by repeated treatment, indicating that NS-304 is unlikely to cause severe desensitization of the IP receptor in rats.  Moreover, a microdose pharmacokinetic study in which NS-304 was orally administered to healthy male volunteers showed conversion of NS-304 to MRE-269 and a long plasma elimination half-life for MRE-269 (7.9 h).  In conclusion, NS-304 is an orally available and long-acting IP receptor agonist prodrug, and its active form, MRE-269, is highly selective for the IP receptor.  Therefore, NS-304 is a promising drug candidate for various vascular diseases, esp. pulmonary arterial hypertension and arteriosclerosis obliterans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvUgzrUBDOcrVg90H21EOLACvtfcHk0liP0Jrqtk0gSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslKrt78%253D&md5=d2adc101cf93d97d4812c5a21bd39ca8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.124248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.124248%26sid%3Dliteratum%253Aachs%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DHashino%26aufirst%3DA.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DOkubo%26aufirst%3DK.%26aulast%3DKuwabara%26aufirst%3DK.%26atitle%3D2-%257B4-%2520%25285%252C6-diphenylpyrazin-2-yl%2529%2528isopropyl%2529amino%2520butoxy%257D-N%2528methylsulfony%2520l%2529acetamide%2520%2528NS-304%2529%252C%2520an%2520orally%2520available%2520and%2520long-acting%2520prostacyclin%2520receptor%2520agonist%2520prodrug%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D1181%26epage%3D1188%26doi%3D10.1124%2Fjpet.107.124248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassard, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1021/jm00080a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00080a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=389-397&author=N.+A.+Meanwellauthor=M.+J.+Rosenfeldauthor=J.+J.+K.+Wrightauthor=C.+L.+Brassardauthor=J.+O.+Buchananauthor=M.+E.+Federiciauthor=J.+S.+Flemingauthor=S.+M.+Seiler&title=Structure-activity+relationships+associated+with+3%2C4%2C5-triphenyl-1H-pyrazole-1-nonanoic+acid%2C+a+nonprostanoid+prostacyclin+mimetic&doi=10.1021%2Fjm00080a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span></div><div class="casAuthors">Meanwell, Nicholas A.; Rosenfeld, Michael J.; Wright, J. J. Kim; Brassard, Catherine L.; Buchanan, John O.; Federici, Marianne E.; Fleming, J. Stuart; Seiler, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-97</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of phenylated pyrazolealkanoic acids, e.g., I (R = (CH2)nCO2H, n = 5-10, R1, R3 = H, Ph, R2 = Ph, PhCH2, Et; R = (CH2)6XCH2CO2H, X = O, S, S(O), SO2, R1 = R2 = R3 = Ph) and related derivs. were prepd. as inhibitors of ADP-induced human platelet aggregation.  3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (II), with an IC50 of 0.4 μM, was the most potent inhibitor.  Biochem. studies detd. that II increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concn.-dependent fashion.  Displacement of [3H]iloprost by II from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biol. action.  Structure-activity studies demonstrated that the min. structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an ω-alkanoic acid side chain 8 or 9 atoms long.  Potency depended upon both side-chain length and its topol. relationship with the two Ph rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU40YZ6EI6OrVg90H21EOLACvtfcHk0ljS6gBx0Hgmog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D&md5=00f2e4d0e07a45ebf9ad206a0c3c2de2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm00080a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00080a028%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRosenfeld%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%2BK.%26aulast%3DBrassard%26aufirst%3DC.%2BL.%26aulast%3DBuchanan%26aufirst%3DJ.%2BO.%26aulast%3DFederici%26aufirst%3DM.%2BE.%26aulast%3DFleming%26aufirst%3DJ.%2BS.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3DStructure-activity%2520relationships%2520associated%2520with%25203%252C4%252C5-triphenyl-1H-pyrazole-1-nonanoic%2520acid%252C%2520a%2520nonprostanoid%2520prostacyclin%2520mimetic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D389%26epage%3D397%26doi%3D10.1021%2Fjm00080a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, K.</span></span> <span> </span><span class="NLM_article-title">Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6692</span>– <span class="NLM_lpage">6704</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmc.2007.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17764960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=6692-6704&author=T.+Asakiauthor=T.+Hamamotoauthor=Y.+Sugiyamaauthor=K.+Kuwanoauthor=K.+Kuwabara&title=Structure-activity+studies+on+diphenylpyrazine+derivatives%3A+a+novel+class+of+prostacyclin+receptor+agonists&doi=10.1016%2Fj.bmc.2007.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists</span></div><div class="casAuthors">Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru; Kuwano, Keiichi; Kuwabara, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6692-6704</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivs. was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation.  Structure-activity relationship studies on the side chain contg. the carboxylic acid moiety of the lead compd. (I) showed that the length of the linker and the presence of the concatenating nitrogen atom adjacent to the pyrazine ring are crit. for the antiaggregatory activity.  This study led to the discovery of 2-amino-5,6-diphenylpyrazine derivs. (II, III, and IV), which showed potent inhibition of platelet aggregation with IC50 values of 0.2 μM.  Among these compds., IV is an orally available and long-lasting prostacyclin receptor agonist which is promising for the treatment of various vascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQelakXM9KLVg90H21EOLACvtfcHk0ljS6gBx0Hgmog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL&md5=e6abc169bee888ab0a33576a84eed962</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DKuwabara%26aufirst%3DK.%26atitle%3DStructure-activity%2520studies%2520on%2520diphenylpyrazine%2520derivatives%253A%2520a%2520novel%2520class%2520of%2520prostacyclin%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D6692%26epage%3D6704%26doi%3D10.1016%2Fj.bmc.2007.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlocai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonderman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzyna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efficace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I. M.</span></span> <span> </span><span class="NLM_article-title">Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1183/09031936.00137511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00137511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22362844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSksLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=874-880&author=G.+Simonneauauthor=A.+Torbickiauthor=M.+M.+Hoeperauthor=M.+Delcroixauthor=K.+Karlocaiauthor=N.+Galieauthor=B.+Deganoauthor=D.+Bondermanauthor=M.+Kurzynaauthor=M.+Efficaceauthor=R.+Giorginoauthor=I.+M.+Lang&title=Selexipag%3A+an+oral%2C+selective+prostacyclin+receptor+agonist+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.00137511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Simonneau, Gerald; Torbicki, Adam; Hoeper, Marius M.; Delcroix, Marion; Karlocai, Kristof; Galie, Nazzareno; Degano, Bruno; Bonderman, Diana; Kurzyna, Marcin; Efficace, Michela; Giorgino, Ruben; Lang, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">In this phase 2 proof-of-concept study we examd. the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH).  43 Adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor therapy) were randomized three to one to receive either selexipag or placebo.  Dosage was up-titrated in 200-μg increments from 200 μg twice daily on day 1 to the max. tolerated dose by day 35 (max. allowed dose of 800 μg twice daily).  Change in pulmonary vascular resistance at week 17 expressed as a percentage of the baseline value was the primary efficacy end-point, and was analyzed in the per protocol set first and then in the all-treated set to assess robustness of results.  A statistically significant 30.3% redn. in geometric mean pulmonary vascular resistance was obsd. after 17 wk' treatment with selexipag compared with placebo (95% confidence limits -44.7-12.2; p=0.0045, Wilcoxon rank sum test).  This was supported by a similar result from the all-treated set.  Selexipag was well tolerated with a safety profile in line with the expected pharmacol. effect.  Our results encourage the further investigation of selexipag for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBODCac2AG87Vg90H21EOLACvtfcHk0ljS6gBx0Hgmog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSksLfM&md5=ab8ed9d43ff5f02857f247aedbd7f8eb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1183%2F09031936.00137511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00137511%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DKarlocai%26aufirst%3DK.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DDegano%26aufirst%3DB.%26aulast%3DBonderman%26aufirst%3DD.%26aulast%3DKurzyna%26aufirst%3DM.%26aulast%3DEfficace%26aufirst%3DM.%26aulast%3DGiorgino%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DI.%2BM.%26atitle%3DSelexipag%253A%2520an%2520oral%252C%2520selective%2520prostacyclin%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2012%26volume%3D40%26spage%3D874%26epage%3D880%26doi%3D10.1183%2F09031936.00137511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Scala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzerikho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moiseeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span> <span> </span><span class="NLM_article-title">Selexipag for the treatment of pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2522</span>– <span class="NLM_lpage">2533</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1503184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1503184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26699168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2522-2533&author=O.+Sitbonauthor=R.+Channickauthor=K.+M.+Chinauthor=A.+Freyauthor=S.+Gaineauthor=N.+Galieauthor=H.-A.+Ghofraniauthor=M.+M.+Hoeperauthor=I.+M.+Langauthor=R.+Preissauthor=L.+J.+Rubinauthor=L.+Di+Scalaauthor=V.+Tapsonauthor=I.+Adzerikhoauthor=J.+Liuauthor=O.+Moiseevaauthor=X.+Zengauthor=G.+Simonneauauthor=V.+V.+McLaughlin&title=Selexipag+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1503184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Sitbon, Olivier; Channick, Richard; Chin, Kelly M.; Frey, Aline; Pharm, D.; Gaine, Sean; Galie, Nazzareno; Ghofrani, Hossein-Ardeschir; Hoeper, Marius M.; Lang, Irene M.; Preiss, Ralph; Rubin, Lewis J.; Di Scala, Lilla; Tapson, Victor; Adzerikho, Igor; Liu, Jinming; Moiseeva, Olga; Zeng, Xiaofeng; Simonneau, Gerald; McLaughlin, Vallerie V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2522-2533</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.  METHODS: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in individualized doses (max. dose, 1600 μg twice daily).  Patients were eligible for enrollment if they were not receiving treatment for pulmonary arterial hypertension or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both.  The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo).  RESULTS: A primary end-point event occurred in 397 patients - 41.6% of those in the placebo group and 27.0% of those in the selexipag group (hazard ratio in the selexipag group as compared with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P<0.001).  Disease progression and hospitalization accounted for 81.9% of the events.  The effect of selexipag with respect to the primary end point was similar in the subgroup of patients who were not receiving treatment for the disease at baseline and in the subgroup of patients who were already receiving treatment at baseline (including those who were receiving a combination of two therapies).  By the end of the study, 105 patients in the placebo group and 100 patients in the selexipag group had died from any cause.  Overall, 7.1% of patients in the placebo group and 14.3% of patients in the selexipag group discontinued their assigned regimen prematurely because of adverse events.  The most common adverse events in the selexipag group were consistent with the known side effects of prostacyclin, including headache, diarrhea, nausea, and jaw pain.  CONCLUSIONS: Among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo.  There was no significant difference in mortality between the two study groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqESCkOu3qJHrVg90H21EOLACvtfcHk0lgLkaT1YwAhRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjI&md5=226c0615071351060d286cb144e5dd28</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1503184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1503184%26sid%3Dliteratum%253Aachs%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DChannick%26aufirst%3DR.%26aulast%3DChin%26aufirst%3DK.%2BM.%26aulast%3DFrey%26aufirst%3DA.%26aulast%3DGaine%26aufirst%3DS.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.-A.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DLang%26aufirst%3DI.%2BM.%26aulast%3DPreiss%26aufirst%3DR.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DDi%2BScala%26aufirst%3DL.%26aulast%3DTapson%26aufirst%3DV.%26aulast%3DAdzerikho%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMoiseeva%26aufirst%3DO.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26atitle%3DSelexipag%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2522%26epage%3D2533%26doi%3D10.1056%2FNEJMoa1503184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boatman, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbaoui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behan, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shifrina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leakakos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (ralinepag): An orally active prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms12gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=913-927&author=T.-A.+Tranauthor=B.+Kramerauthor=Y.-J.+Shinauthor=P.+Vallarauthor=P.+D.+Boatmanauthor=N.+Zouauthor=C.+R.+Sageauthor=T.+Gharbaouiauthor=A.+Krishnanauthor=B.+Palauthor=S.+R.+Shakyaauthor=M.+A.+Garridoauthor=J.+W.+Adamsauthor=J.+Ramirezauthor=D.+P.+Behanauthor=A.+Shifrinaauthor=A.+Blackburnauthor=T.+Leakakosauthor=Y.+Shiauthor=M.+Morganauthor=A.+Sadequeauthor=W.+Chenauthor=D.+J.+Unettauthor=I.+Gaidarovauthor=X.+Chenauthor=S.+Changauthor=H.-H.+Shuauthor=S.-F.+Tungauthor=G.+Semple&title=Discovery+of+2-%28%28%281r%2C4r%29-4-%28%28%284-Chlorophenyl%29%28phenyl%29carbamoyl%29oxy%29methyl%29cyclohexyl%29methoxy%29acetate+%28ralinepag%29%3A+An+orally+active+prostacyclin+receptor+agonist+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.6b00871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Tran, Thuy-Anh; Kramer, Bryan; Shin, Young-Jun; Vallar, Pureza; Boatman, P. Douglas; Zou, Ning; Sage, Carleton R.; Gharbaoui, Tawfik; Krishnan, Ashwin; Pal, Biman; Shakya, Sagar R.; Garrido Montalban, Antonio; Adams, John W.; Ramirez, Juan; Behan, Dominic P.; Shifrina, Anna; Blackburn, Anthony; Leakakos, Tina; Shi, Yunqing; Morgan, Michael; Sadeque, Abu; Chen, Weichao; Unett, David J.; Gaidarov, Ibragim; Chen, Xiaohua; Chang, Steve; Shu, Hsin-Hui; Tung, Shiu-Feng; Semple, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">913-927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described.  Detailed profiling of a no. of analogs resulted in the identification of 5c (ralinepag) that has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family and a more modest 30- to 50-fold selectivity over the EP3 receptor.  In the authors' hands, its potency and efficacy are comparable or superior to MRE269 (the active metabolite of the clin. compd. NS-304) with respect to in vitro IP receptor dependent cAMP accumulation assays.  Ralinepag had an excellent PK profile across species.  Enterohepatic recirculation most probably contributes to a concn.-time profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough ratio.  Following the identification of an acceptable solid form, ralinepag was selected for further development for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvfp2ZN4i1bVg90H21EOLACvtfcHk0ljqCZDuIcfp5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms12gsw%253D%253D&md5=f37ba4106466f0ed724cd78db4b5b366</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00871%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.-A.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DVallar%26aufirst%3DP.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DZou%26aufirst%3DN.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DPal%26aufirst%3DB.%26aulast%3DShakya%26aufirst%3DS.%2BR.%26aulast%3DGarrido%26aufirst%3DM.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DShifrina%26aufirst%3DA.%26aulast%3DBlackburn%26aufirst%3DA.%26aulast%3DLeakakos%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DSadeque%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DH.-H.%26aulast%3DTung%26aufirst%3DS.-F.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DDiscovery%2520of%25202-%2528%2528%25281r%252C4r%2529-4-%2528%2528%25284-Chlorophenyl%2529%2528phenyl%2529carbamoyl%2529oxy%2529methyl%2529cyclohexyl%2529methoxy%2529acetate%2520%2528ralinepag%2529%253A%2520An%2520orally%2520active%2520prostacyclin%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D913%26epage%3D927%26doi%3D10.1021%2Facs.jmedchem.6b00871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ristic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klassen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribano
Subias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Souza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy results from a phase 2 randomized, parallel group, placebo-controlled trial</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1901030</span>, <span class="refDoi"> DOI: 10.1183/13993003.01030-2019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01030-2019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31391223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVKjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=1901030&author=F.+Torresauthor=H.+Farberauthor=A.+Risticauthor=V.+McLaughlinauthor=J.+Adamsauthor=J.+Zhangauthor=P.+Klassenauthor=W.+Shanahanauthor=J.+Grundyauthor=I.+Hoffmannauthor=C.+Cabellauthor=P.+Escribano%0ASubiasauthor=N.+Soodauthor=A.+Keoghauthor=G.+D%27Souzaauthor=L.+Rubin&title=Efficacy+and+safety+of+ralinepag%2C+a+novel+oral+IP+agonist%2C+in+PAH+patients+on+mono+or+dual+background+therapy+results+from+a+phase+2+randomized%2C+parallel+group%2C+placebo-controlled+trial&doi=10.1183%2F13993003.01030-2019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial</span></div><div class="casAuthors">Torres, Fernando; Farber, Harrison; Ristic, Arsen; McLaughlin, Vallerie; Adams, John; Zhang, Jinkun; Klassen, Preston; Shanahan, William; Grundy, John; Hoffmann, Ines; Cabell, Christopher; Subias, Pilar Escribano; Sood, Namita; Keogh, Anne; D'Souza, Gwyn; Rubin, Lewis</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1901030</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Purpose: This phase 2 study was designed to assess the efficacy, safety and tolerability of immediaterelease orally administered ralinepag, a selective, non-prostanoid prostacyclin receptor agonist with a 24-h terminal half-life, compared to placebo in adult patients with symptomatic pulmonary arterial hypertension (PAH).  Methods: 61 PAH patients who were receiving std. care, including mono or dual PAH-targeted background therapy were randomised 2:1 to ralinepag (n=40) or placebo (n=21).  The starting dose of ralinepag was 10 μg twice daily.  Dosage was then up-titrated as tolerated over the course of the 9-wk dose-titrn. period, to a max. total daily dose of 600 μg (300 μg twice daily).  The primary efficacy end-point was the abs. change in pulmonary vascular resistance (PVR) from baseline to week 22.  Addnl. end-points included percentage change in PVR from baseline, other haemodynamic parameters, 6-min walk distance (6MWD) and safety and tolerability.  Results: Ralinepag significantly decreased PVR by 163.9 dyn·s·cm-5 compared to an increase of 0.7 dyn·s·cm-5 with placebo ( p=0.02); the least-squares mean change from baseline PVR was -29.8% compared with placebo ( p=0.03). 6MWD increased from baseline by 36.2 m with ralinepag and 29.4 m with placebo ( p=0.90).  Serious adverse events occurred in 10% of ralinepag patients and 29% of placebo patients.  Study discontinuations occurred in 13% of ralinepag patients and 10% of placebo patients.  Summary: Ralinepag reduced PVR compared with placebo in PAH patients on mono (41%) or dual combination (59%) background therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1FRpt9_XiPrVg90H21EOLACvtfcHk0ljqCZDuIcfp5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVKjsbg%253D&md5=585ad038ae63c029c97b7ec2ee5b5068</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1183%2F13993003.01030-2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01030-2019%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DFarber%26aufirst%3DH.%26aulast%3DRistic%26aufirst%3DA.%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKlassen%26aufirst%3DP.%26aulast%3DShanahan%26aufirst%3DW.%26aulast%3DGrundy%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DI.%26aulast%3DCabell%26aufirst%3DC.%26aulast%3DEscribano%2BSubias%26aufirst%3DP.%26aulast%3DSood%26aufirst%3DN.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DD%2527Souza%26aufirst%3DG.%26aulast%3DRubin%26aufirst%3DL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ralinepag%252C%2520a%2520novel%2520oral%2520IP%2520agonist%252C%2520in%2520PAH%2520patients%2520on%2520mono%2520or%2520dual%2520background%2520therapy%2520results%2520from%2520a%2520phase%25202%2520randomized%252C%2520parallel%2520group%252C%2520placebo-controlled%2520trial%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2019%26volume%3D54%26spage%3D1901030%26doi%3D10.1183%2F13993003.01030-2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel prostacyclin mimetics with highly potent and selective IP receptor agonists</span>. <i>Yuki Gosei Kagaku Kyokaishi</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.5059/yukigoseikyokaishi.64.923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.5059%2Fyukigoseikyokaishi.64.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XpslejtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2006&pages=923-933&author=K.+Hattori&title=Discovery+of+novel+prostacyclin+mimetics+with+highly+potent+and+selective+IP+receptor+agonists&doi=10.5059%2Fyukigoseikyokaishi.64.923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel prostacyclin mimetics with highly potent and selective IP receptor agonists</span></div><div class="casAuthors">Hattori, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Yuki Gosei Kagaku Kyokaishi</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">923-933</span>CODEN:
                <span class="NLM_cas:coden">YGKKAE</span>;
        ISSN:<span class="NLM_cas:issn">0037-9980</span>.
    
            (<span class="NLM_cas:orgname">Yuki Gosei Kagaku Kyokai</span>)
        </div><div class="casAbstract">A review.  Prostacyclin (PGI2) is primarily secreted from vascular endothelium and plays an extremely important inhibitory role in platelet aggregation and as a vasodilator in maintaining homeostatic circulation.  Despite fascinating pharmacol. properties, the inherent instability and side effect of prostacyclin limit its therapeutic applicability.  In this paper, we described that discovery of three classes of prostacyclin mimetics without PG skeleton, which are cycloalkene skeleton type (FR 181560, FR 181157), tetrahydronaphthalene skeleton type (FK788), and amino acid type (FR 193264, FR 193262).  Several designed prostacyclin mimetics exhibited potent PGI2 agonistic activity with good selectivity for IP receptor and bioavailability.  The specific compds. were prepd. by asym. synthesis with high selectivity.  Furthermore, we also described metab. study using rat and human liver microsomes to lead new drug design (FR 223346, FR 232149).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUWjaUx6-6LVg90H21EOLACvtfcHk0lhvPkYiZ1pjvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpslejtLw%253D&md5=c74e05241bd94c0191272c62ecdaefb3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.5059%2Fyukigoseikyokaishi.64.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5059%252Fyukigoseikyokaishi.64.923%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520novel%2520prostacyclin%2520mimetics%2520with%2520highly%2520potent%2520and%2520selective%2520IP%2520receptor%2520agonists%26jtitle%3DYuki%2520Gosei%2520Kagaku%2520Kyokaishi%26date%3D2006%26volume%3D64%26spage%3D923%26epage%3D933%26doi%3D10.5059%2Fyukigoseikyokaishi.64.923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3091</span>– <span class="NLM_lpage">3095</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2005.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15914004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFWgurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3091-3095&author=K.+Hattoriauthor=A.+Tanakaauthor=O.+Okitsuauthor=S.+Tabuchiauthor=K.+Taniguchiauthor=M.+Nishioauthor=S.+Koyamaauthor=M.+Higakiauthor=J.+Sekiauthor=K.+Sakane&title=Discovery+of+diphenylcarbamate+derivatives+as+highly+potent+and+selective+IP+receptor+agonists%3A+Orally+active+prostacyclin+mimetics&doi=10.1016%2Fj.bmcl.2005.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3</span></div><div class="casAuthors">Hattori, Kouji; Tanaka, Akira; Okitsu, Osamu; Tabuchi, Seiichiro; Taniguchi, Kiyoshi; Nishio, Mie; Koyama, Satoshi; Higaki, Masahide; Seki, Jiro; Sakane, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3091-3095</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The new classes of diphenylcarbamate derivs. with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered.  The optimized diphenylcarbamate type compd. FK-788 (I) exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K i values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family.  I was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvW2aOaAtXMLVg90H21EOLACvtfcHk0lhvPkYiZ1pjvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFWgurw%253D&md5=1745006387eb0e3f6a1a57741ee84051</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DOkitsu%26aufirst%3DO.%26aulast%3DTabuchi%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DHigaki%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DJ.%26aulast%3DSakane%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520diphenylcarbamate%2520derivatives%2520as%2520highly%2520potent%2520and%2520selective%2520IP%2520receptor%2520agonists%253A%2520Orally%2520active%2520prostacyclin%2520mimetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3091%26epage%3D3095%26doi%3D10.1016%2Fj.bmcl.2005.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span> <span> </span><span class="NLM_article-title">Seki,Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6.</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4861</span>– <span class="NLM_lpage">4864</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2006.06.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16837197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlSgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4861-4864&author=A.+Tanakaauthor=K.+Hattoriauthor=K.+Taniguchiauthor=O.+Okitsuauthor=S.+Tabuchiauthor=M.+Nishioauthor=Y.+Nagakuraauthor=N.+Maedaauthor=H.+Muraiauthor=J.+Seki&title=Seki%2CReplacing+the+cyclohexene-linker+of+FR181157+leading+to+novel+IP+receptor+agonists%3A+orally+active+prostacyclin+mimetics.+Part+6.&doi=10.1016%2Fj.bmcl.2006.06.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6</span></div><div class="casAuthors">Tanaka, Akira; Hattori, Kouji; Taniguchi, Kiyoshi; Okitsu, Osamu; Tabuchi, Seiichiro; Nishio, Mie; Nagakura, Yasunori; Maeda, Noriaki; Murai, Hidetsugu; Seki, Jiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4861-4864</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and biol. activity of novel derivs. of the authors' previously reported IP receptor agonist FR181157 is described.  SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of 2-[3-[(2R)-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid monohydrochloride (FR207845) as a potent non-prostanoid PGI2 mimetic (IC50 for ADP-induced platelet aggregation inhibition = 58 nM for sodium salt) with good oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ-QLdxgnHsrVg90H21EOLACvtfcHk0lilvuzlI4e1yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlSgs7g%253D&md5=707791da7ccde815995406835a797121</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.076%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DOkitsu%26aufirst%3DO.%26aulast%3DTabuchi%26aufirst%3DS.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DNagakura%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DMurai%26aufirst%3DH.%26aulast%3DSeki%26aufirst%3DJ.%26atitle%3DSeki%252CReplacing%2520the%2520cyclohexene-linker%2520of%2520FR181157%2520leading%2520to%2520novel%2520IP%2520receptor%2520agonists%253A%2520orally%2520active%2520prostacyclin%2520mimetics.%2520Part%25206.%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4861%26epage%3D4864%26doi%3D10.1016%2Fj.bmcl.2006.06.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span> <span> </span><span class="NLM_article-title">Metabolism investigation leading to novel drug design 2: orally active prostacyclin mimetics. Part 5</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4475</span>– <span class="NLM_lpage">4478</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2006.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16824754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4475-4478&author=F.+Takamuraauthor=A.+Tanakaauthor=H.+Takasugiauthor=K.+Taniguchiauthor=M.+Nishioauthor=J.+Sekiauthor=K.+Hattori&title=Metabolism+investigation+leading+to+novel+drug+design+2%3A+orally+active+prostacyclin+mimetics.+Part+5&doi=10.1016%2Fj.bmcl.2006.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism investigation leading to novel drug design. Orally active prostacyclin mimetics.</span></div><div class="casAuthors">Takamura, Fujiko; Tanaka, Akira; Takasugi, Hisashi; Taniguchi, Kiyoshi; Nishio, Mie; Seki, Jiro; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4475-4478</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A metab. study of FK788 (2) led to the discovery of new diphenylcarbamoyl derivs. as prostacyclin mimetics without the PG skeleton.  The authors designed and evaluated PGI2 mimetics based on blocking the main metabolic pathway of FK788.  The new compd. (I) was found to be equipotent to FK788 towards PGI2 agonist activity and metabolically more stable than FK788.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplkJoawkTu6rVg90H21EOLACvtfcHk0lilvuzlI4e1yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOltrY%253D&md5=eca092560f1ebbfbf277214dfd5af817</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DTakasugi%26aufirst%3DH.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DMetabolism%2520investigation%2520leading%2520to%2520novel%2520drug%2520design%25202%253A%2520orally%2520active%2520prostacyclin%2520mimetics.%2520Part%25205%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4475%26epage%3D4478%26doi%3D10.1016%2Fj.bmcl.2006.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3279</span>– <span class="NLM_lpage">3283</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.04.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2005.04.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15935660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFSmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3279-3283&author=K.+Hattoriauthor=O.+Okitsuauthor=S.+Tabuchiauthor=K.+Taniguchiauthor=M.+Nishioauthor=S.+Koyamaauthor=J.+Sekiauthor=K.+Sakane&title=Discovery+of+new+diphenyloxazole+derivatives+containing+a+pyrrolidine+ring%3A+orally+active+prostacyclin+mimetics&doi=10.1016%2Fj.bmcl.2005.04.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2</span></div><div class="casAuthors">Hattori, Kouji; Okitsu, Osamu; Tabuchi, Seiichiro; Taniguchi, Kiyoshi; Nishio, Mie; Koyama, Satoshi; Seki, Jiro; Sakane, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3279-3283</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic and biol. evaluation of novel diphenyloxazole derivs. contg. a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described.  Asym. redn. of a ketone using a chiral Ru complex and reductive amination by NaBH4 produces four isomers of the tetrahydronaphthalene ring and the pyrrolidine ring with high stereoselectivity.  FR193262 (I), (R,R)-diphenyloxazolyl pyrrolidine deriv., displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJL07tHD9wKbVg90H21EOLACvtfcHk0liXARVIoRya1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFSmsr4%253D&md5=340aefaa7907f2e61728415dd3c4d118</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.04.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.04.042%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DOkitsu%26aufirst%3DO.%26aulast%3DTabuchi%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DSeki%26aufirst%3DJ.%26aulast%3DSakane%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520new%2520diphenyloxazole%2520derivatives%2520containing%2520a%2520pyrrolidine%2520ring%253A%2520orally%2520active%2520prostacyclin%2520mimetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3279%26epage%3D3283%26doi%3D10.1016%2Fj.bmcl.2005.04.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narumiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushikubi, F.</span></span> <span> </span><span class="NLM_article-title">Prostanoid receptors: structures, properties, and functions</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1152/physrev.1999.79.4.1193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1152%2Fphysrev.1999.79.4.1193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10508233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVymtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1999&pages=1193-1226&author=S.+Narumiyaauthor=Y.+Sugimotoauthor=F.+Ushikubi&title=Prostanoid+receptors%3A+structures%2C+properties%2C+and+functions&doi=10.1152%2Fphysrev.1999.79.4.1193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Prostanoid receptors: structures, properties, and functions</span></div><div class="casAuthors">Narumiya, Shuh; Sugimoto, Yukihiko; Ushikubi, Fumitaka</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1193-1226</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review, with 254 refs.  Prostanoids are the cyclooxygenase metabolites of arachidonic acid and include prostaglandin (PG) D2, PGE2, PGF2α, PGI2, and thromboxane A2.  They are synthesized and released upon cell stimulation and act on cells in the vicinity of their synthesis to exert their actions.  Receptors mediating the actions of prostanoids were recently identified and cloned.  They are G protein-coupled receptors with seven transmembrane domains.  There are eight types and subtypes of prostanoid receptors that are encoded by different genes but as a whole constitute a subfamily in the superfamily of the rhodopsin-type receptors.  Each of the receptors was expressed in cultured cells, and its ligand-binding properties and signal transduction pathways were characterized.  Moreover, domains and amino acid residues conferring the specificities of ligand binding and signal transduction are being clarified.  Information also is accumulating as to the distribution of these receptors in the body.  It is also becoming clear for some types of receptors how expression of their genes is regulated.  Furthermore, the gene for each of the eight types of prostanoid receptor has been disrupted, and mice deficient in each type of receptor are being examd. to identify and assess the roles played by each receptor under various physiol. and pathophysiol. conditions.  In this article, we summarize these findings and attempt to give an overview of the current status of research on the prostanoid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryyKYnqFDGUbVg90H21EOLACvtfcHk0lgTLh6Xz3if7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVymtL0%253D&md5=868b556bb0e6b8628efbc5bdc630025d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.1999.79.4.1193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.1999.79.4.1193%26sid%3Dliteratum%253Aachs%26aulast%3DNarumiya%26aufirst%3DS.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DUshikubi%26aufirst%3DF.%26atitle%3DProstanoid%2520receptors%253A%2520structures%252C%2520properties%252C%2520and%2520functions%26jtitle%3DPhysiol.%2520Rev.%26date%3D1999%26volume%3D79%26spage%3D1193%26epage%3D1226%26doi%3D10.1152%2Fphysrev.1999.79.4.1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavliv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Caestecker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1086/686140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1086%2F686140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27252848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=211-223&author=J.+D.+Westauthor=B.+M.+Vossauthor=L.+Pavlivauthor=M.+de+Caesteckerauthor=A.+R.+Hemnesauthor=E.+J.+Carrier&title=Antagonism+of+the+thromboxane-prostanoid+receptor+is+cardioprotective+against+right+ventricular+pressure+overload&doi=10.1086%2F686140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload</span></div><div class="casAuthors">West, James D.; Voss, Bryan M.; Pavliv, Leo; de Caestecker, Mark; Hemnes, Anna R.; Carrier, Erica J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-223</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH) and is a significant cause of morbidity and mortality in other forms of pulmonary hypertension.  There are no approved therapies directed at preserving RV function.  F-series and E-series isoprostanes are increased in heart failure and PAH, correlate to the severity of disease, and can signal through the thromboxane-prostanoid (TP) receptor, with effects from vasoconstriction to fibrosis.  The goal of these studies was to det. whether blockade of the TP receptor with the antagonist CPI211 was beneficial therapeutically in PAH-induced RV dysfunction.  Mice with RV dysfunction due to pressure overload by pulmonary artery banding (PAB) were given vehicle or CPI211.  Two weeks after PAB, CPI211-treated mice were protected from fibrosis with pressure overload.  Gene expression arrays and immunoblotting, quant. histol. and morphometry, and flow cytometric anal. were used to det. the mechanism of CPI211 protection.  TP receptor inhibition caused a near normalization of fibrotic area, prevented cellular hypertrophy while allowing increased RV mass, increased expression of antifibrotic thrombospondin-4, and blocked induction of the profibrotic transforming growth factor β (TGF-β) pathway.  A thromboxane synthase inhibitor or low-dose aspirin failed to replicate these results, which suggests that a ligand other than thromboxane mediates fibrosis through the TP receptor after pressure overload.  This study suggests that TP receptor antagonism may improve RV adaptation in situations of pressure overload by decreasing fibrosis and TGF-β signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbQ41GnagSPbVg90H21EOLACvtfcHk0lgTLh6Xz3if7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FI&md5=32f19f3327d2e10e4da0cd917c72cc63</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1086%2F686140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F686140%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DJ.%2BD.%26aulast%3DVoss%26aufirst%3DB.%2BM.%26aulast%3DPavliv%26aufirst%3DL.%26aulast%3Dde%2BCaestecker%26aufirst%3DM.%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26atitle%3DAntagonism%2520of%2520the%2520thromboxane-prostanoid%2520receptor%2520is%2520cardioprotective%2520against%2520right%2520ventricular%2520pressure%2520overload%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3D211%26epage%3D223%26doi%3D10.1086%2F686140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span> <span> </span><span class="NLM_article-title">Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2133</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-13-0107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1253%2Fcircj.CJ-13-0107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23676973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2013&pages=2127-2133&author=A.+Nakamuraauthor=N.+Nagayaauthor=H.+Obataauthor=K.+Sakaiauthor=Y.+Sakaiauthor=M.+Yoshikawaauthor=K.+Hamadaauthor=K.+Matsumotoauthor=H.+Kimura&title=Oral+administration+of+a+novel+long-acting+prostacyclin+agonist+with+thromboxane+synthase+inhibitory+activity+for+pulmonary+arterial+hypertension&doi=10.1253%2Fcircj.CJ-13-0107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary areterial hypertension</span></div><div class="casAuthors">Nakamura, Atsuhiro; Nagaya, Nirotoshi; Obata, Hiroaki; Sakai, Katsuya; Sakai, Yoshiki; Yoshikawa, Masanori; Hamada, Kaoru; Matsumoto, Kunio; Kimura, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2127-2133</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">Background: Continuous administration of prostacyclin has improved the survival of patients with pulmonary arterial hypertension (PAH).  However, this treatment has some problems, including its short duration of activity and difficult delivery.  Therefore, we developed ONO-1301, an orally active, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity.  Methods and Results: We investigated whether oral administration of ONO-1301 can both prevent and reverse monocrotaline (MCT)-induced PAH in rats.  Rats were randomly assigned to receive repeated oral administration of ONO-1301 twice daily beginning either 1 or 8 days after s.c. injection of MCT.  A control group received oral saline, and a sham group received a s.c. injection of saline instead of MCT.  MCT-treated controls developed significant pulmonary hypertension.  Treatment with ONO-1301 from day 1 or 8 significantly attenuated the increases in right ventricular systolic pressure and the increase in medial wall thickness of pulmonary arterioles.  Kaplan-Meier survival curves demonstrated that the effect of ONO-1301 was equiv. to that of an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor.  A single oral dose of ONO-1301 increased plasma cAMP levels for up to 6h.  Treatment with ONO-1301 significantly decreased urinary 11-dehydro-thromboxane B2 and increased the plasma hepatocyte growth factor concn.  Conclusions: Oral administration of ONO-1301 ameliorated PAH in rats, an effect that may occur through cAMP and hepatocyte growth factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRFjPboMpK4rVg90H21EOLACvtfcHk0lhgAa3fgBsG6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSltbjK&md5=441b73c368c0f1e787cbe3f209213183</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-13-0107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-13-0107%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DNagaya%26aufirst%3DN.%26aulast%3DObata%26aufirst%3DH.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DY.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DH.%26atitle%3DOral%2520administration%2520of%2520a%2520novel%2520long-acting%2520prostacyclin%2520agonist%2520with%2520thromboxane%2520synthase%2520inhibitory%2520activity%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirc.%2520J.%26date%3D2013%26volume%3D77%26spage%3D2127%26epage%3D2133%26doi%3D10.1253%2Fcircj.CJ-13-0107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pernow, J.</span></span> <span> </span><span class="NLM_article-title">The importance of endothelin-1 for vascular dysfunction in cardiovascular disease</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.cardiores.2007.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cardiores.2007.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17617392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2sris1entA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=8-18&author=F.+Bohmauthor=J.+Pernow&title=The+importance+of+endothelin-1+for+vascular+dysfunction+in+cardiovascular+disease&doi=10.1016%2Fj.cardiores.2007.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of endothelin-1 for vascular dysfunction in cardiovascular disease</span></div><div class="casAuthors">Bohm Felix; Pernow John</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-18</span>
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    </div><div class="casAbstract">Endothelin (ET)-1 is a potent vasoconstrictor peptide originally isolated from endothelial cells.  Its production is stimulated in a variety of different cell types under the influence of risk factors for cardiovascular disease and during the development of cardiovascular disease.  Based on these observations and the biological effects induced by ET-1, including profound vasoconstriction, pro-inflammatory actions, mitogenic and proliferative effects, stimulation of free radical formation and platelet activation, ET-1 has been implicated as an important factor in the development of vascular dysfunction and cardiovascular disease.  In the following the pathogenic role of ET-1, the mechanisms underlying the involvement of ET-1 for the development of vascular dysfunction and the potentially beneficial therapeutic effects of selective ET(A) and dual ET(A)/ET(B) receptor antagonists will be discussed.  In particular the changes of pathophysiological importance mediated by ET-1 in clinical studies are reviewed.  These changes may be of significance for the development of various cardiovascular diseases beyond pulmonary arterial hypertension which is the currently approved indication for ET receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7MJYJyhY7ypcXNb62YGmbfW6udTcc2eYGN2UmSM_K9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sris1entA%253D%253D&md5=d4a83638d857a87845f767a31f0dba5a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2007.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2007.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DBohm%26aufirst%3DF.%26aulast%3DPernow%26aufirst%3DJ.%26atitle%3DThe%2520importance%2520of%2520endothelin-1%2520for%2520vascular%2520dysfunction%2520in%2520cardiovascular%2520disease%26jtitle%3DCardiovasc.%2520Res.%26date%3D2007%26volume%3D76%26spage%3D8%26epage%3D18%26doi%3D10.1016%2Fj.cardiores.2007.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shennib, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duguid, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, D. J.</span></span> <span> </span><span class="NLM_article-title">Expression of endothelin-1 in the lungs of patients with pulmonary hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">1732</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJM199306173282402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJM199306173282402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=8497283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK3s3mvVensA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1993&pages=1732-1739&author=A.+Giaidauthor=M.+Yanagisawaauthor=D.+Langlebenauthor=R.+P.+Michelauthor=R.+Levyauthor=H.+Shennibauthor=S.+Kimuraauthor=T.+Masakiauthor=W.+P.+Duguidauthor=D.+J.+Stewart&title=Expression+of+endothelin-1+in+the+lungs+of+patients+with+pulmonary+hypertension&doi=10.1056%2FNEJM199306173282402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of endothelin-1 in the lungs of patients with pulmonary hypertension</span></div><div class="casAuthors">Giaid A; Yanagisawa M; Langleben D; Michel R P; Levy R; Shennib H; Kimura S; Masaki T; Duguid W P; Stewart D J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1732-9</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries.  Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties.  It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension.  We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension.  METHODS:  We studied the distribution of endothelin-1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3.  RESULTS:  In the controls, endothelin-1-like immunoreactivity was rarely seen in vascular endothelial cells.  In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis.  Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1-like immunoreactivity.  There was a strong correlation between the intensity of endothelin-1-like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension.  CONCLUSIONS:  Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm66l1sYsjv-R_TJajKxJDfW6udTcc2eb1ZvJj8tf-wrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s3mvVensA%253D%253D&md5=16ba9f2b5128052f096f08d695a7f73b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1056%2FNEJM199306173282402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199306173282402%26sid%3Dliteratum%253Aachs%26aulast%3DGiaid%26aufirst%3DA.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DMichel%26aufirst%3DR.%2BP.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DShennib%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DMasaki%26aufirst%3DT.%26aulast%3DDuguid%26aufirst%3DW.%2BP.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26atitle%3DExpression%2520of%2520endothelin-1%2520in%2520the%2520lungs%2520of%2520patients%2520with%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D328%26spage%3D1732%26epage%3D1739%26doi%3D10.1056%2FNEJM199306173282402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halank, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orzechowski, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeffken, G.</span></span> <span> </span><span class="NLM_article-title">Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1562</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.1378/chest.120.5.1562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.120.5.1562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11713135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2001&pages=1562-1569&author=C.+Rubensauthor=R.+Ewertauthor=M.+Halankauthor=R.+Wenselauthor=H.+D.+Orzechowskiauthor=H.+P.+Schultheissauthor=G.+Hoeffken&title=Big+endothelin-1+and+endothelin-1+plasma+levels+are+correlated+with+the+severity+of+primary+pulmonary+hypertension&doi=10.1378%2Fchest.120.5.1562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension</span></div><div class="casAuthors">Rubens, Christoph; Ewert, Ralf; Halank, Michael; Wensel, Roland; Orzechowski, Hans-Dieter; Schultheiss, Heinz-Peter; Hoeffken, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1562-1569</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension (PPH) is a rare disease of unknown etiol. that is characterized by a poor prognosis.  This study was undertaken to investigate possible correlations between endothelin (ET)-1 and big ET-1 plasma levels and the severity of PPH.  Sixteen consecutive patients with PPH were included.  Hemodynamics of patients with PPH were measured by right-heart catheterization, and a 6-min walk test was performed.  Plasma levels of the biol. active peptide ET-1 and its precursor big ET-1 were detd. in blood samples from the pulmonary artery, peripheral artery, and peripheral vein by RIA.  A strong correlation was shown between pulmonary vascular resistance, mean pulmonary artery pressure, cardiac output, cardiac index, 6-min walk data, and elevated plasma levels of big ET-1 as well as mature ET-1 plasma levels at all sites of blood sampling (p < 0.01 and p < 0.05, resp.).  Levels of circulating ET-1 might become a prognostic marker for patients with PPH and serve as a tool for the selection of patients who may benefit from treatment with ET-receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tVSTk7_7QrVg90H21EOLACvtfcHk0lgzRr3zZrCx8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Gkurg%253D&md5=c5ec3cbe3f5c3ccb4413adeecef51d15</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1378%2Fchest.120.5.1562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.120.5.1562%26sid%3Dliteratum%253Aachs%26aulast%3DRubens%26aufirst%3DC.%26aulast%3DEwert%26aufirst%3DR.%26aulast%3DHalank%26aufirst%3DM.%26aulast%3DWensel%26aufirst%3DR.%26aulast%3DOrzechowski%26aufirst%3DH.%2BD.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DHoeffken%26aufirst%3DG.%26atitle%3DBig%2520endothelin-1%2520and%2520endothelin-1%2520plasma%2520levels%2520are%2520correlated%2520with%2520the%2520severity%2520of%2520primary%2520pulmonary%2520hypertension%26jtitle%3DChest%26date%3D2001%26volume%3D120%26spage%3D1562%26epage%3D1569%26doi%3D10.1378%2Fchest.120.5.1562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Endothelin receptor antagonists for the treatment of pulmonary artery hypertension</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2012.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.lfs.2012.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22884806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OjtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=517-521&author=L.+J.+Rubin&title=Endothelin+receptor+antagonists+for+the+treatment+of+pulmonary+artery+hypertension&doi=10.1016%2Fj.lfs.2012.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor antagonists for the treatment of pulmonary artery hypertension</span></div><div class="casAuthors">Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">517-521</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The demonstration that endothelin prodn. is upregulated in pulmonary artery hypertension (PAH) served as the rationale for developing endothelin-receptor antagonists (ERAs) as a treatment for PAH.  This article reviews the primary studies demonstrating efficacy of ERAs in PAH.Multicenter, placebo-controlled trials and open-label extension studies.Two orally active ERAs are currently approved for the treatment of PAH - the dual receptor antagonist bosentan, and the more selective ETA receptor antagonist ambrisentan-based on multicenter randomized clin. trials demonstrating efficacy and safety.  Long-term experience with both agents supports maintenance of therapeutic effects in most patients.  Adverse effects, including altered liver function and edema may occur and require careful monitoring.Despite failure to demonstrate efficacy of ERAs in other cardiopulmonary conditions, ERAs have a major role in the treatment algorithm for PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN6RyKMLtSCbVg90H21EOLACvtfcHk0ljZ2nRV2fk_uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OjtrzP&md5=4417d2bd944627a484840c7137fe1ebf</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DEndothelin%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pulmonary%2520artery%2520hypertension%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D517%26epage%3D521%26doi%3D10.1016%2Fj.lfs.2012.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumo, F.</span></span> <span> </span><span class="NLM_article-title">Endothelin receptor subtype-b mediates synthesis of nitric-oxide by cultured bovine endothelial-cells</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1373</span>, <span class="refDoi"> DOI: 10.1172/JCI116338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI116338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7682570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK3sXisVymsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1993&pages=1367-1373&author=Y.+Hirataauthor=T.+Emoriauthor=S.+Eguchiauthor=K.+Kannoauthor=T.+Imaiauthor=K.+Ohtaauthor=F.+Marumo&title=Endothelin+receptor+subtype-b+mediates+synthesis+of+nitric-oxide+by+cultured+bovine+endothelial-cells&doi=10.1172%2FJCI116338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells</span></div><div class="casAuthors">Hirata, Yukio; Emori, Toshiaki; Eguchi, Satoru; Kanno, Kazuo; Imai, Taihei; Ohta, Kazuki; Marumo, Fumiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1367-73</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">Endothelins (ET) produce endothelium-dependent vasodilation through nitric oxide (NO) synthesis.  The cellular mechanism by which ET induces synthesis and release of endothelium-derived NO by cultured bovine endothelial cells (EC) was examd.  Binding studies revealed that bovine EC membrane had binding sites for a novel agonist (BQ3020) of the non-isopeptide-selective receptor subtype (ETB).  Affinity labeling studies showed a major labeled band with the apparent mol. mass of 50 kD.  Northern blot anal. demonstrated the expression of mRNA for the ETB receptor.  BQ3020 rapidly and dose dependently induced formation of inositol 1,4,5-triphosphate and increased intracellular Ca2+ concns. in fura-2-loaded cells.  Concomitantly, BQ3020 dose dependently stimulated prodn. of both nitrate/nitrite (NOx) and cyclic GMP; a highly significant correlation existed between NOx and cGMP prodn.  The stimulatory effect on NOx and cGMP prodn. by ETB agonist was inhibited by the NO synthase inhibitor monomethyl-L-arginine; this effect was reversed by coaddn. of L-arginine, but not D-arginine.  NOx and cGMP prodn. stimulated by BQ3020 was inhibited by pretreatment with pertussis toxin.  ETB agonist-induced NOx prodn. was blocked by a calmodulin inhibitor and an intracellular Ca2+ chelator, but not by an extracellular Ca2+ chelator or a Ca2+ channel blocker.  These data suggest that endothelins stimulate ETB receptor-mediated phosphoinositide breakdown via pertussis toxin-sensitive G-protein(s), which triggers release of intracellular Ca2+, thereby activating Ca2+/calmodulin-dependent NO synthase in EC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLhVM04QbfebVg90H21EOLACvtfcHk0ljZ2nRV2fk_uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVymsLs%253D&md5=bc94805a038db9977b2a7a254f87b5c8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1172%2FJCI116338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI116338%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DY.%26aulast%3DEmori%26aufirst%3DT.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DKanno%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DMarumo%26aufirst%3DF.%26atitle%3DEndothelin%2520receptor%2520subtype-b%2520mediates%2520synthesis%2520of%2520nitric-oxide%2520by%2520cultured%2520bovine%2520endothelial-cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1993%26volume%3D91%26spage%3D1367%26epage%3D1373%26doi%3D10.1172%2FJCI116338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neidhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bren, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramuz, H.</span></span> <span> </span><span class="NLM_article-title">The discovery of nonpeptide endothelin receptor antagonists. Progression towards bosentan</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1ygtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=519-524&author=W.+Neidhartauthor=V.+Brenauthor=D.+Burauthor=K.+Burriauthor=M.+Clozelauthor=G.+Hirthauthor=M.+Mullerauthor=H.+P.+Wesselauthor=H.+Ramuz&title=The+discovery+of+nonpeptide+endothelin+receptor+antagonists.+Progression+towards+bosentan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of nonpeptide endothelin receptor antagonists. Progression towards bosentan</span></div><div class="casAuthors">Neidhart, Werner; Breu, Volker; Bur, Daniel; Burri, Kaspar; Clozel, Martine; Hirth, Georges; Mueller, Marcel; Wessel, Hans P.; Ramuz, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">519-524</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>;
        ISSN:<span class="NLM_cas:issn">0009-4293</span>.
    
            (<span class="NLM_cas:orgname">Neue Schweizerische Chemische Gesellschaft</span>)
        </div><div class="casAbstract">A review with 23 refs., describing the development of a novel class of nonpeptide endothelin receptor antagonists based on a lead file screening with special investigations on bosentan in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR6LsyBs_RyLVg90H21EOLACvtfcHk0ljZ2nRV2fk_uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1ygtLo%253D&md5=4c38eb56ca6997fe10b92799f87cd120</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DBren%26aufirst%3DV.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DBurri%26aufirst%3DK.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DHirth%26aufirst%3DG.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWessel%26aufirst%3DH.%2BP.%26aulast%3DRamuz%26aufirst%3DH.%26atitle%3DThe%2520discovery%2520of%2520nonpeptide%2520endothelin%2520receptor%2520antagonists.%2520Progression%2520towards%2520bosentan%26jtitle%3DChimia%26date%3D1996%26volume%3D50%26spage%3D519%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hiti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, G. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusic-Pajic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span> <span> </span><span class="NLM_article-title">Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">2093</span>– <span class="NLM_lpage">2100</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)60919-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0140-6736%2808%2960919-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18572079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1cvgt12itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=2093-2100&author=N.+Galieauthor=L.+J.+Rubinauthor=M.+M.+Hoeperauthor=P.+Jansaauthor=H.+Al-Hitiauthor=G.+M.+B.+Meyerauthor=E.+Chiossiauthor=A.+Kusic-Pajicauthor=G.+Simonneau&title=Treatment+of+patients+with+mildly+symptomatic+pulmonary+arterial+hypertension+with+bosentan+%28EARLY+study%29%3A+a+double-blind%2C+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2808%2960919-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial</span></div><div class="casAuthors">Galie N; Rubin Lj; Hoeper Mm; Jansa P; Al-Hiti H; Meyer Gmb; Chiossi E; Kusic-Pajic A; Simonneau G</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9630</span>),
    <span class="NLM_cas:pages">2093-100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Treatments for pulmonary arterial hypertension have been mainly studied in patients with advanced disease (WHO functional class [FC] III and IV).  This study was designed to assess the effect of the dual endothelin receptor antagonist bosentan in patients with WHO FC II pulmonary arterial hypertension.  METHODS:  Patients with WHO FC II pulmonary arterial hypertension aged 12 years or over with 6-min walk distance of less than 80% of the normal predicted value or less than 500 m associated with a Borg dyspnoea index of 2 or greater were enrolled in this double-blind, placebo-controlled, multicentre trial. 185 patients were randomly assigned to receive bosentan (n=93) or placebo (n=92) for the 6-month double-blind treatment period via a centralised integrated voice recognition system.  Primary endpoints were pulmonary vascular resistance at month 6 expressed as percentage of baseline and change from baseline to month 6 in 6-min walk distance.  Analyses of the primary endpoints were done with all randomised patients who had a valid baseline assessment and an assessment or an imputed value for month 6.  This trial was registered with ClinicalTrials.gov, number NCT00091715.  FINDINGS:  Analyses were done with 168 patients (80 in the bosentan group, 88 in the placebo group) for pulmonary vascular resistance and with 177 (86 and 91) for 6-min walking distance.  At month 6, geometric mean pulmonary vascular resistance was 83.2% (95% CI 73.8-93.7) of the baseline value in the bosentan group and 107.5% (97.6-118.4) of the baseline value in the placebo group (treatment effect -22.6%, 95% CI -33.5 to -10.0; p<0.0001).  Mean 6-min walk distance increased from baseline in the bosentan group (11.2 m, 95% CI -4.6 to 27.0) and decreased in the placebo group (-7.9 m, -24.3 to 8.5), with a mean treatment effect of 19.1 m (95% CI 3.6-41.8; p=0.0758). 12 (13%) patients in the bosentan group and eight (9%) in the placebo group reported serious adverse events, the most common of which were syncope in the bosentan group and right ventricular failure in the placebo group.  INTERPRETATION:  Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThqEkH0P97IinGiHuhFGv8fW6udTcc2ea-5DNIMGQ4oLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvgt12itg%253D%253D&md5=db26e0a4a7898c0aaf0d20e8d05bfe70</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960919-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960919-8%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DAl-Hiti%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DG.%2BM.%2BB.%26aulast%3DChiossi%26aufirst%3DE.%26aulast%3DKusic-Pajic%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DTreatment%2520of%2520patients%2520with%2520mildly%2520symptomatic%2520pulmonary%2520arterial%2520hypertension%2520with%2520bosentan%2520%2528EARLY%2520study%2529%253A%2520a%2520double-blind%252C%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D2093%26epage%3D2100%26doi%3D10.1016%2FS0140-6736%2808%2960919-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2049</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2006.01.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jacc.2006.01.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16697324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=2049-2056&author=R.+J.+Barstauthor=D.+Langlebenauthor=D.+Badeschauthor=A.+Frostauthor=E.+C.+Lawrenceauthor=S.+Shapiroauthor=R.+Naeijeauthor=N.+Galie&title=Treatment+of+pulmonary+arterial+hypertension+with+the+selective+endothelin-a+receptor+antagonist+sitaxsentan&doi=10.1016%2Fj.jacc.2006.01.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan</span></div><div class="casAuthors">Barst, Robyn J.; Langleben, David; Badesch, David; Frost, Adaani; Lawrence, E. Clinton; Shapiro, Shelley; Naeije, Robert; Galie, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2049-2056</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We sought to det. the optimal dose of the selective endothelin A (ETA) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included.  Endothelin is a mediator of PAH.  In a preliminary PAH study, the selective ETA receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization (WHO) functional class (FC), and hemodynamics.  In this double-blind, placebo-controlled 18-wk study, 247 PAH patients (idiopathic, or assocd. with connective tissue disease or congenital heart disease) were randomized; 245 patients were treated: placebo (n = 62), sitaxsentan 50 mg (n = 62) or 100 mg (n = 61), or OL (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind) bosentan (n = 60).  The primary end point was change in 6MW distance from baseline to week 18.  Secondary end points included change in WHO FC, time to clin. worsening, and change in Borg dyspnea score.  At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compared with the placebo group (31.4 m, p = 0.03), and an improved WHO FC (p = 0.04).  The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p = 0.07) and for OL bosentan, 29.5 m (p = 0.05).  The incidence of elevated hepatic transaminases (>3× the upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.  Treatment with the selective ETA receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ8rFM0c55NLVg90H21EOLACvtfcHk0lhNOb2WBMaYWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D&md5=b68081ed4dccf86d36293b82f765a9b6</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2006.01.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2006.01.057%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DLawrence%26aufirst%3DE.%2BC.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DGalie%26aufirst%3DN.%26atitle%3DTreatment%2520of%2520pulmonary%2520arterial%2520hypertension%2520with%2520the%2520selective%2520endothelin-a%2520receptor%2520antagonist%2520sitaxsentan%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2006%26volume%3D47%26spage%3D2049%26epage%3D2056%26doi%3D10.1016%2Fj.jacc.2006.01.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vatter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, V.</span></span> <span> </span><span class="NLM_article-title">Ambrisentan, a non-peptide endothelin receptor antagonist</span>. <i>Cardiovasc. Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3466.2006.00063.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fj.1527-3466.2006.00063.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16939634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWjsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=63-76&author=H.+Vatterauthor=V.+Seifert&title=Ambrisentan%2C+a+non-peptide+endothelin+receptor+antagonist&doi=10.1111%2Fj.1527-3466.2006.00063.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan, a non-peptide endothelin receptor antagonist</span></div><div class="casAuthors">Vatter, Hartmut; Seifert, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-76</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Increasing nos. of exptl. investigations and recently also of clin. trials strongly suggest an integral involvement of the endothelin (ET)-system in the pathophysiol. of a variety of disease states, mainly of the cardiovascular system.  Ambrisentan (LU 208075), a selective ETA-receptor antagonist, is an orally active di-Ph propionic acid deriv.  It has been shown to have a very promising efficacy to safety ratio in the initial clin. trials.  Phase II and Phase III trials with ambrisentan in pulmonary arterial hypertension have been performed.  The pharmacol. properties and data from the exptl. investigations suggest addnl. possible uses of ambrisentan in the prevention of reperfusion injury after organ transplantation and in restenosis following coronary artery dilatation.  Furthermore, the pharmacol. profile of ambrisentan indicates that this drug may also be suitable in the treatment of cerebrovascular disorders.  In the present article basic investigations, animal studies and clin. trials with ambrisentan are reviewed.  This review may help to define pathophysiol. conditions, in which ambrisentan could be indicated and further evaluated in appropriate preclin. and clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnKVjoXdyMhLVg90H21EOLACvtfcHk0lhhikIa_kxeCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWjsrbO&md5=3120d9425067112ba5df2c25fe4c5f54</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.2006.00063.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.2006.00063.x%26sid%3Dliteratum%253Aachs%26aulast%3DVatter%26aufirst%3DH.%26aulast%3DSeifert%26aufirst%3DV.%26atitle%3DAmbrisentan%252C%2520a%2520non-peptide%2520endothelin%2520receptor%2520antagonist%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D2006%26volume%3D24%26spage%3D63%26epage%3D76%26doi%3D10.1111%2Fj.1527-3466.2006.00063.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roecker, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiens, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ambrisentan for the treatment of pulmonary arterial hypertension - results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3010</span>– <span class="NLM_lpage">3019</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.107.742510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.107.742510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18506008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFymu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2008&pages=3010-3019&author=N.+Galieauthor=H.+Olschewskiauthor=R.+J.+Oudizauthor=F.+Torresauthor=A.+Frostauthor=H.+A.+Ghofraniauthor=D.+B.+Badeschauthor=M.+D.+McGoonauthor=V.+V.+McLaughlinauthor=E.+B.+Roeckerauthor=M.+J.+Gerberauthor=C.+Duftonauthor=B.+L.+Wiensauthor=L.+J.+Rubin&title=Ambrisentan+for+the+treatment+of+pulmonary+arterial+hypertension+-+results+of+the+ambrisentan+in+pulmonary+arterial+hypertension%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+multicenter%2C+efficacy+%28ARIES%29+study+1+and+2&doi=10.1161%2FCIRCULATIONAHA.107.742510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Olschewski, Horst; Oudiz, Ronald J.; Torres, Fernando; Frost, Adaani; Ghofrani, Hossein A.; Badesch, David B.; McGoon, Michael D.; McLaughlin, Vallerie V.; Roecker, Ellen B.; Gerber, Michael J.; Dufton, Christopher; Wiens, Brian L.; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3010-3019</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension.  Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study 1 and 2 (ARIES-1 and ARIES-2) were concurrent, double-blind, placebo-controlled studies that randomized 202 and 192 patients with pulmonary arterial hypertension, resp., to placebo or ambrisentan (ARIES-1, 5 or 10 mg; ARIES-2, 2.5 or 5 mg) orally once daily for 12 wk.  The primary end point for each study was change in 6-min walk distance from baseline to week 12.  Clin. worsening, World Health Organization functional class, Short Form-36 Health Survey score, Borg dyspnea score, and B-type natriuretic peptide plasma concns. also were assessed.  In addn., a long-term extension study was performed.  The 6-min walk distance increased in all ambrisentan groups; mean placebo-cor. treatment effects were 31 m (P=0.008) and 51 m (P<0.001) in ARIES-1 for 5 and 10 mg ambrisentan, resp., and 32 m (P=0.022) and 59 m (P<0.001) in ARIES-2 for 2.5 and 5 mg ambrisentan, resp.  Improvements in time to clin. worsening (ARIES-2), World Health Organization functional class (ARIES-1), Short Form-36 score (ARIES-2), Borg dyspnea score (both studies), and B-type natriuretic peptide (both studies) were obsd.  No patient treated with ambrisentan developed aminotransferase concns. >3 times the upper limit of normal.  In 280 patients completing 48 wk of treatment with ambrisentan monotherapy, the improvement from baseline in 6-min walk at 48 wk was 39 m.  Ambrisentan improves exercise capacity in patients with pulmonary arterial hypertension.  Improvements were obsd. for several secondary end points in each of the studies, although statistical significance was more variable.  Ambrisentan is well tolerated and is assocd. with a low risk of aminotransferase abnormalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV0o6GSdBgGLVg90H21EOLACvtfcHk0lhhikIa_kxeCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFymu70%253D&md5=ebf9b6c539d3e5ab3df8bfec520b2a77</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.107.742510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.107.742510%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DRoecker%26aufirst%3DE.%2BB.%26aulast%3DGerber%26aufirst%3DM.%2BJ.%26aulast%3DDufton%26aufirst%3DC.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%2520-%2520results%2520of%2520the%2520ambrisentan%2520in%2520pulmonary%2520arterial%2520hypertension%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520multicenter%252C%2520efficacy%2520%2528ARIES%2529%2520study%25201%2520and%25202%26jtitle%3DCirculation%26date%3D2008%26volume%3D117%26spage%3D3010%26epage%3D3019%26doi%3D10.1161%2FCIRCULATIONAHA.107.742510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1378/chest.08-1028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.08-1028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18812445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvV2ltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2009&pages=122-129&author=M.+D.+McGoonauthor=A.+E.+Frostauthor=R.+J.+Oudizauthor=D.+B.+Badeschauthor=N.+Galieauthor=H.+Olschewskiauthor=V.+V.+McLaughlinauthor=M.+J.+Gerberauthor=C.+Duftonauthor=D.+J.+Despainauthor=L.+J.+Rubin&title=Ambrisentan+therapy+in+patients+with+pulmonary+arterial+hypertension+who+discontinued+bosentan+or+sitaxsentan+due+to+liver+function+test+abnormalities&doi=10.1378%2Fchest.08-1028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities</span></div><div class="casAuthors">McGoon, Michael D.; Frost, Adaani E.; Oudiz, Ronald J.; Badesch, David B.; Galie, Nazzareno; Olschewski, Horst; McLaughlin, Vallerie V.; Gerber, Michael J.; Dufton, Chris; Despain, Darrin J.; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">Background: Some endothelin receptor antagonists (ERAs) are assocd. with liver function test (LFT) result abnormalities.  However, ambrisentan has an incidence of serum aminotransferase levels more than three times the upper limit of normal (ULN), similar to that obsd. in PAH patients who are not receiving ERAs.  Because ambrisentan may provide benefits in PAH patients who have discontinued ERA therapy due to LFT abnormalities, we evaluated the safety and efficacy of ambrisentan in this patient population.  Methods: Patients who previously discontinued bosentan and/or sitaxsentan due to LFT abnormalities received ambrisentan, 2.5 mg qd, for 4 wk followed by 5 mg/d for 8 wk.  The primary end point was the incidence of aminotransferase levels more than three times ULN considered by the investigator to be related to ambrisentan and resulting in drug discontinuation.  Secondary end points included aminotransferase levels more than five times ULN requiring drug discontinuation and more than three times ULN requiring dose redn., as well as changes in 6-min walk distance (6MWD), Borg dyspnea index, World Health Organization functional class, and Short Form-36 health survey score.  Patients continued treatment beyond the 12-wk end point with monthly monitoring of LFTs.  Results: Thirty-six patients who previously discontinued bosentan (n = 31), sitaxsentan (n = 2), or both (n = 3) were enrolled.  At baseline, 69.4% of patients were receiving prostanoid and/or sildenafil therapy.  No patient had an aminotransferase level more than three times ULN that required ambrisentan discontinuation.  One patient had a transient aminotransferase level more than three times ULN that resolved following a temporary dose redn.  No addnl. aminotransferase levels more than three times ULN were obsd. with long-term treatment (median exposure, 102 wk), despite dose increases to 10 mg qd in more than half of the patients.  Significant improvements in 6MWD and other efficacy assessments were obsd.  Conclusions: Ambrisentan treatment may be an option for patients who have discontinued bosentan and/or sitaxsentan therapy due to LFT result abnormalities.  Trial registration: Clinicaltrials.gov Identifier NCT00423592.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWLH5SlJGaLVg90H21EOLACvtfcHk0lg7_W7QSOSCsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvV2ltrY%253D&md5=796bcc65870dd6ba5a253a6536ad4c55</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1378%2Fchest.08-1028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.08-1028%26sid%3Dliteratum%253Aachs%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DGerber%26aufirst%3DM.%2BJ.%26aulast%3DDufton%26aufirst%3DC.%26aulast%3DDespain%26aufirst%3DD.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520therapy%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520who%2520discontinued%2520bosentan%2520or%2520sitaxsentan%2520due%2520to%2520liver%2520function%2520test%2520abnormalities%26jtitle%3DChest%26date%3D2009%26volume%3D135%26spage%3D122%26epage%3D129%26doi%3D10.1378%2Fchest.08-1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasmin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernacek, P.</span></span> <span> </span><span class="NLM_article-title">Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1006/pupt.2000.0242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1006%2Fpupt.2000.0242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10873551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkt1KntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=135-140&author=J.+Dupuisauthor=J.+F.+Jasminauthor=S.+Prieauthor=P.+Cernacek&title=Importance+of+local+production+of+endothelin-1+and+of+the+ETB+receptor+in+the+regulation+of+pulmonary+vascular+tone&doi=10.1006%2Fpupt.2000.0242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone</span></div><div class="casAuthors">Dupuis, J.; Jasmin, J. F.; Prie, S.; Cernacek, P.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">135-140</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Interaction between locally released endothelin-1 (ET-1) and the endothelial ETB receptor could modulate pulmonary vascular tone.  The authors evaluated pulmonary ET-1 clearance and ET-1-ETB receptor interaction in the modulation of pulmonary vascular tone.  Controls and rats with Monocrotaline (MCT)-induced pulmonary hypertension (PH) were studied.  Lungs were isolated and perfused under const. pressure.  The effect of the selective ETB antagonist BQ-788 (10-12-10-8 mole) on perfusion flow rate and 125I-ET-1 extn. was detd.  Baseline 125I-ET-1 extn. was reduced from 62±5% in controls to 49±10% in PH (P=0.012).  BQ-788 inhibited extn. with a higher half-ID in the MCT group (-Log ID50= 8.9±0.4 vs. 9.5±0.1, P=0.03).  BQ-788 induced a mild redn. in perfusion flow rate of 0.7±0.3 mL/min in controls.  In the MCT group, this occurred at a lower dose and was more pronounced with a maximal redn. of 3.3±0.7 mL/min (P<0.01 vs. control).  ET-1 was undetectable in the effluent at baseline but was present in similar concns. in both groups after ETB blockade.  Addn. of 2 pg/mL ET-1 to lung perfusate did not modify pulmonary ET-1 clearance or the effect of BQ788 on perfusion flow rate in control lungs.  In normal rat lungs, the ETB receptor plays a minor regulatory role on vascular tone.  In MCT hypertension however, despite a redn. in ETB mediated extn., luminal prodn. of ET-1 attenuates the increase in pulmonary vascular tone.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD4QmKYo-8urVg90H21EOLACvtfcHk0lhNpwOgMNVN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkt1KntL0%253D&md5=3652b3318f2b8472dc41a89e51dc43cf</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1006%2Fpupt.2000.0242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fpupt.2000.0242%26sid%3Dliteratum%253Aachs%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DJasmin%26aufirst%3DJ.%2BF.%26aulast%3DPrie%26aufirst%3DS.%26aulast%3DCernacek%26aufirst%3DP.%26atitle%3DImportance%2520of%2520local%2520production%2520of%2520endothelin-1%2520and%2520of%2520the%2520ETB%2520receptor%2520in%2520the%2520regulation%2520of%2520pulmonary%2520vascular%2520tone%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D13%26spage%3D135%26epage%3D140%26doi%3D10.1006%2Fpupt.2000.0242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Endothelin-receptor antagonists beyond pulmonary arterial hypertension: cancer and fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8168</span>– <span class="NLM_lpage">8188</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8168-8188&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+antagonists+beyond+pulmonary+arterial+hypertension%3A+cancer+and+fibrosis&doi=10.1021%2Facs.jmedchem.5b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8168-8188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases.  Endothelin-receptor antagonists are in clin. use to treat pulmonary arterial hypertension and have been under clin. investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases.  In this Perspective, we review the mols. that have been evaluated in human clin. trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis.  We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists.  We will also consider which chem. characteristics are relevant to clin. use and the properties of mols. necessary for efficacy in treating diseases against which known mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfhFfiImWNbVg90H21EOLACvtfcHk0lhNpwOgMNVN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D&md5=b6f008d678c7e4ff5ded1db5f4a940c5</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01781%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520antagonists%2520beyond%2520pulmonary%2520arterial%2520hypertension%253A%2520cancer%2520and%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8168%26epage%3D8188%26doi%3D10.1021%2Facs.jmedchem.5b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, T.</span></span> <span> </span><span class="NLM_article-title">The discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7849</span>– <span class="NLM_lpage">7861</span>, <span class="refDoi"> DOI: 10.1021/jm3009103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7849-7861&author=M.+H.+Bolliauthor=C.+Bossauthor=C.+Binkertauthor=S.+Buchmannauthor=D.+Burauthor=P.+Hessauthor=M.+Iglarzauthor=S.+Meyerauthor=J.+Reinauthor=M.+Reyauthor=A.+Treiberauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=The+discovery+of+N-%5B5-%284-Bromophenyl%29-6-%5B2-%5B%285-bromo-2-pyrimidinyl%29oxy%5Dethoxy%5D-4-pyrimidinyl%5D-N%E2%80%99-propylsulfamide+%28macitentan%29%2C+an+orally+active%2C+potent+dual+endothelin+receptor+antagonist&doi=10.1021%2Fjm3009103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist</span></div><div class="casAuthors">Bolli, Martin H.; Boss, Christoph; Binkert, Christoph; Buchmann, Stephan; Bur, Daniel; Hess, Patrick; Iglarz, Marc; Meyer, Solange; Rein, Josiane; Rey, Markus; Treiber, Alexander; Clozel, Martine; Fischli, Walter; Weller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7849-7861</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the structure of bosentan (1), we embarked on a medicinal chem. program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.  This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines.  Among these, compd. 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ETB receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats.  Compd. 17 successfully completed a long-term phase III clin. trial for pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZxi30yihGrbVg90H21EOLACvtfcHk0ljwN-x1_NgP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP&md5=796cde2ff9ea36a2881dc58e46e903b7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm3009103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009103%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRein%26aufirst%3DJ.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DThe%2520discovery%2520of%2520N-%255B5-%25284-Bromophenyl%2529-6-%255B2-%255B%25285-bromo-2-pyrimidinyl%2529oxy%255Dethoxy%255D-4-pyrimidinyl%255D-N%25E2%2580%2599-propylsulfamide%2520%2528macitentan%2529%252C%2520an%2520orally%2520active%252C%2520potent%2520dual%2520endothelin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7849%26epage%3D7861%26doi%3D10.1021%2Fjm3009103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, T.</span></span> <span> </span><span class="NLM_article-title">The discovery of N- 5-(4-Bromophenyl)-6- 2-(5-bromo-2-pyrimidinyl)oxy ethoxy −4-pyrimidi nyl -N ’-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7849</span>– <span class="NLM_lpage">7861</span>, <span class="refDoi"> DOI: 10.1021/jm3009103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7849-7861&author=M.+H.+Bolliauthor=C.+Bossauthor=C.+Binkertauthor=S.+Buchmannauthor=D.+Burauthor=P.+Hessauthor=M.+Iglarzauthor=S.+Meyerauthor=J.+Reinauthor=M.+Reyauthor=A.+Treiberauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=The+discovery+of+N-+5-%284-Bromophenyl%29-6-+2-%285-bromo-2-pyrimidinyl%29oxy+ethoxy+%E2%88%924-pyrimidi+nyl+-N+%E2%80%99-propylsulfamide+%28macitentan%29%2C+an+orally+active%2C+potent+dual+endothelin+receptor+antagonist&doi=10.1021%2Fjm3009103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist</span></div><div class="casAuthors">Bolli, Martin H.; Boss, Christoph; Binkert, Christoph; Buchmann, Stephan; Bur, Daniel; Hess, Patrick; Iglarz, Marc; Meyer, Solange; Rein, Josiane; Rey, Markus; Treiber, Alexander; Clozel, Martine; Fischli, Walter; Weller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7849-7861</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the structure of bosentan (1), we embarked on a medicinal chem. program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.  This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines.  Among these, compd. 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ETB receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats.  Compd. 17 successfully completed a long-term phase III clin. trial for pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZxi30yihGrbVg90H21EOLACvtfcHk0ljwN-x1_NgP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP&md5=796cde2ff9ea36a2881dc58e46e903b7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm3009103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009103%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRein%26aufirst%3DJ.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DThe%2520discovery%2520of%2520N-%25205-%25284-Bromophenyl%2529-6-%25202-%25285-bromo-2-pyrimidinyl%2529oxy%2520ethoxy%2520%25E2%2588%25924-pyrimidi%2520nyl%2520-N%2520%25E2%2580%2599-propylsulfamide%2520%2528macitentan%2529%252C%2520an%2520orally%2520active%252C%2520potent%2520dual%2520endothelin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7849%26epage%3D7861%26doi%3D10.1021%2Fjm3009103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capeleto, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.142976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.108.142976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18780830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=736-745&author=M.+Iglarzauthor=C.+Binkertauthor=K.+Morrisonauthor=W.+Fischliauthor=J.+Gatfieldauthor=A.+Treiberauthor=T.+Wellerauthor=M.+H.+Bolliauthor=C.+Bossauthor=S.+Buchmannauthor=B.+Capeletoauthor=P.+Hessauthor=C.+Qiuauthor=M.+Clozel&title=Pharmacology+of+macitentan%2C+an+orally+active+tissue-targeting+dual+endothelin+receptor+antagonist&doi=10.1124%2Fjpet.108.142976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist</span></div><div class="casAuthors">Iglarz, Marc; Binkert, Christoph; Morrison, Keith; Fischli, Walter; Gatfield, John; Treiber, Alexander; Weller, Thomas; Bolli, Martin H.; Boss, Christoph; Buchmann, Stephan; Capeleto, Bruno; Hess, Patrick; Qiu, Changbin; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">736-745</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl]-N'-propylaminosulfonamide],is a new dual ETA/ETB endothelin (ET) receptor antagonist designed for tissue targeting.  Selection of macitentan was based on inhibitory potency on both ET receptors and optimization of physicochem. properties to achieve high affinity for lipophilic milieu.  In vivo, macitentan is metabolized into a major and pharmacol. active metabolite, ACT-132577.  Macitentan and its metabolite antagonized the specific binding of ET-1 on membranes of cells overexpressing ETA and ETB receptors and blunted ET-1-induced calcium mobilization in various natural cell lines, with inhibitory consts. within the nanomolar range.  In functional assays, macitentan and ACT-132577 inhibited ET-1-induced contractions in isolated endothelium-denuded rat aorta (ETA receptors) and sarafotoxin S6c-induced contractions in isolated rat trachea (ETB receptors).  In rats with pulmonary hypertension, macitentan prevented both the increase of pulmonary pressure and the right ventricle hypertrophy, and it markedly improved survival.  In diabetic rats, chronic administration of macitentan decreased blood pressure and proteinuria and prevented end-organ damage (renal vascular hypertrophy and structural injury).  In conclusion, macitentan, by its tissue-targeting properties and dual antagonism of ET receptors, protects against end-organ damage in diabetes and improves survival in pulmonary hypertensive rats.  This profile makes macitentan a new agent to treat cardiovascular disorders assocd. with chronic tissue ET system activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIo4YPpTRKFrVg90H21EOLACvtfcHk0lgiS-3NKEcafA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLvO&md5=00d0f8e55081e3851b8f9b5740b8d419</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142976%26sid%3Dliteratum%253Aachs%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DWeller%26aufirst%3DT.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DCapeleto%26aufirst%3DB.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DPharmacology%2520of%2520macitentan%252C%2520an%2520orally%2520active%2520tissue-targeting%2520dual%2520endothelin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D736%26epage%3D745%26doi%3D10.1124%2Fjpet.108.142976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzerikho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Brun, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittelholzer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perchenet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, B. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Macitentan and morbidity and mortality in pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1213917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1213917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23984728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=809-818&author=T.+Pulidoauthor=I.+Adzerikhoauthor=R.+N.+Channickauthor=M.+Delcroixauthor=N.+Galieauthor=H.+A.+Ghofraniauthor=P.+Jansaauthor=Z.+C.+Jingauthor=F.+O.+Le+Brunauthor=S.+Mehtaauthor=C.+M.+Mittelholzerauthor=L.+Perchenetauthor=B.+K.+S.+Sastryauthor=O.+Sitbonauthor=R.+Souzaauthor=A.+Torbickiauthor=X.+F.+Zengauthor=L.+J.+Rubinauthor=G.+Simonneau&title=Macitentan+and+morbidity+and+mortality+in+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1213917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan and morbidity and mortality in pulmonary arterial hypertension</span></div><div class="casAuthors">Pulido, Tomas; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galie, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loic; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogerio; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-818</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point.  We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.  METHODS We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg.  Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry.  The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with i.v. or s.c. prostanoids, or worsening of pulmonary arterial hypertension.  RESULTS A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.  The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, resp.  The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P = 0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001).  Worsening of pulmonary arterial hypertension was the most frequent primary end-point event.  The effect of macitentan on this end point was obsd. regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline.  Adverse events more frequently assocd. with macitentan than with placebo were headache, nasopharyngitis, and anemia.  CONCLUSIONS Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWzzZ3N-2NrVg90H21EOLACvtfcHk0lgiS-3NKEcafA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP&md5=430d59843298eaa407aa8a67acc84f81</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1213917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1213917%26sid%3Dliteratum%253Aachs%26aulast%3DPulido%26aufirst%3DT.%26aulast%3DAdzerikho%26aufirst%3DI.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DLe%2BBrun%26aufirst%3DF.%2BO.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DMittelholzer%26aufirst%3DC.%2BM.%26aulast%3DPerchenet%26aufirst%3DL.%26aulast%3DSastry%26aufirst%3DB.%2BK.%2BS.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DX.%2BF.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DMacitentan%2520and%2520morbidity%2520and%2520mortality%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D809%26epage%3D818%26doi%3D10.1056%2FNEJMoa1213917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S. Q.</span></span> <span> </span><span class="NLM_article-title">Therapeutic monoclonal antibody antagonizing endothelin receptor a for pulmonary arterial hypertension</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.252700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.118.252700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30992315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSgurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2019&pages=54-61&author=C.+Zhangauthor=X.+F.+Wangauthor=H.+Zhangauthor=C.+J.+Yaoauthor=H.+Panauthor=Y.+Guoauthor=K.+S.+Fanauthor=S.+Q.+Jing&title=Therapeutic+monoclonal+antibody+antagonizing+endothelin+receptor+a+for+pulmonary+arterial+hypertension&doi=10.1124%2Fjpet.118.252700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic monoclonal antibody antagonizing endothelin receptor A for pulmonary arterial hypertension</span></div><div class="casAuthors">Zhang, Cheng; Wang, Xiaofeng; Zhang, Hua; Yao, Chenjiang; Pan, Hao; Guo, Yong; Fan, Kesuo; Jing, Shuqian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Endothelin receptor A (ETA) is a G protein-coupled receptor and a major therapeutic target for pulmonary arterial hypertension (PAH).  We took a novel approach and developed an antagonistic monoclonal antibody, getagozumab, specifically against ETA.  Getagozumab displayed a Kd value of 8.7 nM and an IC50 value of 37.9 nM in the cell-based assays.  Getagozumab could significantly lower pulmonary arterial pressure in both hypoxia-induced and monocrotaline (MCT)-induced PAH monkey models and further attenuate the pulmonary arterial and right ventricular hypertrophy in MCT-induced PAH monkeys.  The preclin. studies demonstrated that getagozumab is safe, long lasting, and efficacious.  Getagozumab may provide a new and effective treatment for PAH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1AGncnKGFQ7Vg90H21EOLACvtfcHk0lgzTax-xkl4SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSgurzI&md5=e665e06b22c130e2757fa0d66af1dbf1</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.252700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.252700%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DC.%2BJ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DK.%2BS.%26aulast%3DJing%26aufirst%3DS.%2BQ.%26atitle%3DTherapeutic%2520monoclonal%2520antibody%2520antagonizing%2520endothelin%2520receptor%2520a%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D370%26spage%3D54%26epage%3D61%26doi%3D10.1124%2Fjpet.118.252700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammendola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlossmann, J.</span></span> <span> </span><span class="NLM_article-title">Rising behind NO: cGMP-dependent protein kinases</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1671</span>– <span class="NLM_lpage">1676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10769198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFGls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2000&pages=1671-1676&author=F.+Hofmannauthor=A.+Ammendolaauthor=J.+Schlossmann&title=Rising+behind+NO%3A+cGMP-dependent+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Rising behind NO: cGMP-dependent protein kinases</span></div><div class="casAuthors">Hofmann, Franz; Ammendola, Aldo; Schlossmann, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1671-1676</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Over the past few years, a wealth of biochem. and functional data has been gathered on mammalian cGMP-dependent protein kinases (cGKs).  In mammals, three different kinases are encoded by two genes.  Mutant and chimeric cGMP kinase proteins generated by mol. biol. techniques have yielded important biochem. knowledge, such as the function of the N-terminal domains of cGKI and cGKII, the identity of the cGMP-binding sites of cGKI, the substrate specificity of the enzymes and structural details of the catalytic center.  Genetic approaches have proved to be esp. useful for the anal. of the biol. function of cGKs.  Recently, some of the in vivo targets and mechanisms leading to smooth muscle relaxation have been identified.  In vivo targets are the myosin-binding subunit of myosin phosphatase (PP1M), a member of the protein phosphatase 1, the calcium-activated maxi K+ channel and a new protein named IRAG that forms a complex with the inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) receptor and cGKI.  Phosphorylation of PP1M by cGKIα activates myosin phosphatase, whereas phosphorylation of IRAG by cGKIβ decreases Ins(1,4,5)P3-induced calcium release.  The cGKII regulates in vivo intestinal fluid secretion by phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR), bone growth and renal renin secretion by phosphorylation of unknown proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNNtPIX1JkJrVg90H21EOLACvtfcHk0lgzTax-xkl4SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFGls7g%253D&md5=533206569aa2152c102c26c152256088</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DAmmendola%26aufirst%3DA.%26aulast%3DSchlossmann%26aufirst%3DJ.%26atitle%3DRising%2520behind%2520NO%253A%2520cGMP-dependent%2520protein%2520kinases%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2000%26volume%3D113%26spage%3D1671%26epage%3D1676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, D.</span></span> <span> </span><span class="NLM_article-title">Reduced expression of endothelial nitric-oxide synthase in the lungs of patients with pulmonary-hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1056/NEJM199507273330403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJM199507273330403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7540722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK2Mzht1Sgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1995&pages=214-221&author=A.+Giaidauthor=D.+Saleh&title=Reduced+expression+of+endothelial+nitric-oxide+synthase+in+the+lungs+of+patients+with+pulmonary-hypertension&doi=10.1056%2FNEJM199507273330403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension</span></div><div class="casAuthors">Giaid A; Saleh D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">214-21</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary hypertension is characterized by abnormal thickening of the pulmonary arteries and increased pulmonary vascular resistance.  Nitric oxide is a potent endothelium-derived vasorelaxant substance and an inhibitor of smooth-muscle-cell growth.  Nitric oxide is produced in various cell types by the action of an enzyme, nitric oxide synthase.  We compared the expression of endothelial nitric oxide synthase in the lungs of control subjects with that in the lungs of patients with pulmonary hypertension.  METHODS:  We investigated the expression of endothelial nitric oxide synthase by histochemical and immunohistochemical analysis, in situ hybridization, and Northern blot analysis in the lungs of 22 patients with plexogenic pulmonary arteriopathy (arteriopathy of grades 4 through 6), 24 patients with secondary pulmonary hypertension (arteriopathy of grades 1 through 3), and 23 control subjects.  RESULTS:  In the lungs of the control subjects, nitric oxide synthase was expressed at a high level in the vascular endothelium of all types of vessels and in the pulmonary epithelium.  In contrast, little or no expression of the enzyme was found in the vascular endothelium of pulmonary arteries with severe histologic abnormalities (i.e., plexiform lesions) in patients with pulmonary hypertension.  The intensity of the enzyme immunoreactivity correlated inversely with the severity of histologic changes.  There was an inverse correlation between the arterial expression of the enzyme and total pulmonary resistance in patients with plexogenic pulmonary arteriopathy (r = -0.766, P = 0.004).  CONCLUSIONS:  Pulmonary hypertension is associated with diminished expression of endothelial nitric oxide synthase.  It is possible that decreased expression of nitric oxide synthase may contribute to pulmonary vasoconstriction and to the excessive growth of the tunica media observed in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY84rBRawwM3qj_yg7twvpfW6udTcc2eZFNZ4NtP1xHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2Mzht1Sgtg%253D%253D&md5=13735159d034868a3edb9ac794521d86</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1056%2FNEJM199507273330403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199507273330403%26sid%3Dliteratum%253Aachs%26aulast%3DGiaid%26aufirst%3DA.%26aulast%3DSaleh%26aufirst%3DD.%26atitle%3DReduced%2520expression%2520of%2520endothelial%2520nitric-oxide%2520synthase%2520in%2520the%2520lungs%2520of%2520patients%2520with%2520pulmonary-hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D333%26spage%3D214%26epage%3D221%26doi%3D10.1056%2FNEJM199507273330403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisbois, E. J.</span></span> <span> </span><span class="NLM_article-title">Clinical use of inhaled nitric oxide: Local and systemic applications</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2019.11.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.freeradbiomed.2019.11.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31785330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSlurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=422-431&author=M.+Barnesauthor=E.+J.+Brisbois&title=Clinical+use+of+inhaled+nitric+oxide%3A+Local+and+systemic+applications&doi=10.1016%2Fj.freeradbiomed.2019.11.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical use of inhaled nitric oxide: Local and systemic applications</span></div><div class="casAuthors">Barnes, Megan; Brisbois, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">422-431</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Upon the FDA approval for inhaled nitric oxide (iNO) in 1999 to treat persistent pulmonary hypertension in neonates, iNO has proven to be a beneficial therapeutic in multiple diseases.  We aim to review applications of iNO that have modeled its protective and therapeutic attributes, as well as highlight preliminary studies that could allude to future avenues of use.  Numerous publications have reported specific incidences where iNO therapy has proved advantageous, while some applications have potential after further validation.  Establishing guidelines on dosing, duration, and defined clin. uses are crucial for the future of iNO.  Delivery of iNO has been controlled by a sole distributor, and comes with high cost, and lack of portability.  A shift in patents has allowed for new designs for iNO device synthesis, with many new developments of iNO medical devices that will likely change the future of iNO in a medical setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosbXJC5PB_rLVg90H21EOLACvtfcHk0lgT2SMaR2-oKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSlurrO&md5=2d60bc8853acaad82be702b446d59867</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2019.11.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2019.11.029%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DM.%26aulast%3DBrisbois%26aufirst%3DE.%2BJ.%26atitle%3DClinical%2520use%2520of%2520inhaled%2520nitric%2520oxide%253A%2520Local%2520and%2520systemic%2520applications%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2020%26volume%3D152%26spage%3D422%26epage%3D431%26doi%3D10.1016%2Fj.freeradbiomed.2019.11.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooldridge, K.</span></span> <span> </span><span class="NLM_article-title">Antiallergic activity of 8-azapurin-6-ones with heterocyclic 2-substituents</span>. <i>Eur. J. Med. Chem. - Chim. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaE28XhtlSitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1975&pages=447-449&author=A.+Hollandauthor=D.+Jacksonauthor=P.+Chaplenauthor=E.+Luntauthor=S.+Marshallauthor=D.+Painauthor=K.+Wooldridge&title=Antiallergic+activity+of+8-azapurin-6-ones+with+heterocyclic+2-substituents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Antiallergic activity of 8-azapurin-6-ones with heterocyclic 2-substituents</span></div><div class="casAuthors">Holland, Anthony; Jackson, David; Chaplen, Peter; Lunt, Edward; Marshall, Stewart; Pain, David; Wooldridge, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">447-9</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">The synthesis and antiallergic activity in the rat passive cutaneous anaphylactic reaction of a series of 2-heterocyclyl-8-azapurin-6-ones (I) is described.  No significant correlation with partition factors was obsd. but there is some evidence to suggest that activity is enhanced when the 2-substituent contains a group which is capable of forming a hydrogen bond with the 1-position of the azapurinone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-8X5iRsmlJrVg90H21EOLACvtfcHk0lgT2SMaR2-oKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhtlSitrc%253D&md5=0050a686a37e795b4ec7f38e13761557</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DA.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DChaplen%26aufirst%3DP.%26aulast%3DLunt%26aufirst%3DE.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DPain%26aufirst%3DD.%26aulast%3DWooldridge%26aufirst%3DK.%26atitle%3DAntiallergic%2520activity%2520of%25208-azapurin-6-ones%2520with%2520heterocyclic%25202-substituents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%2520-%2520Chim.%2520Ther.%26date%3D1975%26volume%3D10%26spage%3D447%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P.</span></span> <span> </span><span class="NLM_article-title">Sildenafil (VIAGRA(TM)), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1824</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(96)00323-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2F0960-894X%2896%2900323-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK2sXjsVyrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=1819-1824&author=N.+K.+Terrettauthor=A.+S.+Bellauthor=D.+Brownauthor=P.+Ellis&title=Sildenafil+%28VIAGRA%28TM%29%29%2C+a+potent+and+selective+inhibitor+of+type+5+cGMP+phosphodiesterase+with+utility+for+the+treatment+of+male+erectile+dysfunction&doi=10.1016%2F0960-894X%2896%2900323-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction</span></div><div class="casAuthors">Terrett, Nicholas K.; Bell, Andrew S.; Brown, David; Ellis, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1819-1824</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">5-(2'-Alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones, and in particular the authors' preferred compd., sildenafil (Viagra), discovered through a rational drug design program, are potent and selective inhibitors of the type 5 cGMP phosphodiesterase from both rabbit platelets and human corpus cavernosum.  Sildenafil is currently in the clinic for the oral treatment of male erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7W7FHK-wEJ7Vg90H21EOLACvtfcHk0lglfMi642ruFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsVyrtLw%253D&md5=2b2a31d0880dc0089a6253bcd7b182c9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900323-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900323-X%26sid%3Dliteratum%253Aachs%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DEllis%26aufirst%3DP.%26atitle%3DSildenafil%2520%2528VIAGRA%2528TM%2529%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520type%25205%2520cGMP%2520phosphodiesterase%2520with%2520utility%2520for%2520the%2520treatment%2520of%2520male%2520erectile%2520dysfunction%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D1819%26epage%3D1824%26doi%3D10.1016%2F0960-894X%2896%2900323-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sung, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeon Hwang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho Jeon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwan
Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min Yoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyun, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin Eum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyu Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung Cho, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>425</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1038/nature01914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnature01914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12955149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=98-102&author=B.-J.+Sungauthor=K.+Yeon+Hwangauthor=Y.+Ho+Jeonauthor=J.+I.+Leeauthor=Y.-S.+Heoauthor=J.+Hwan%0AKimauthor=J.+Moonauthor=J.+Min+Yoonauthor=Y.-L.+Hyunauthor=E.+Kimauthor=S.+Jin+Eumauthor=S.-Y.+Parkauthor=J.-O.+Leeauthor=T.+Gyu+Leeauthor=S.+Roauthor=J.+Myung+Cho&title=Structure+of+the+catalytic+domain+of+human+phosphodiesterase+5+with+bound+drug+molecules&doi=10.1038%2Fnature01914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules</span></div><div class="casAuthors">Sung, Byung-Je; Hwang, Kwang Yeon; Jeon, Young Ho; Lee, Jae Il; Heo, Yong-Seok; Kim, Jin Hwan; Moon, Jinho; Yoon, Jung Min; Hyun, Young-Lan; Kim, Eunmi; Eum, Sung Jin; Park, Sam-Yong; Lee, Jie-Oh; Lee, Tae Gyu; Ro, Seonggu; Cho, Joong Myung</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6953</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cAMP and cGMP.  As essential regulators of cyclic nucleotide signaling with diverse physiol. functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction.  Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolyzing activity in human corpus cavernosum tissue.  It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction.  Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available.  Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug mols. sildenafil, tadalafil (Cialis) and vardenafil (Levitra).  These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr5pTrMfa72rVg90H21EOLACvtfcHk0lglfMi642ruFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D&md5=8459333ee12ed3469f7b48d6e7f9fd5d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature01914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01914%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DB.-J.%26aulast%3DYeon%2BHwang%26aufirst%3DK.%26aulast%3DHo%2BJeon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DJ.%2BI.%26aulast%3DHeo%26aufirst%3DY.-S.%26aulast%3DHwan%2BKim%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DJ.%26aulast%3DMin%2BYoon%26aufirst%3DJ.%26aulast%3DHyun%26aufirst%3DY.-L.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DJin%2BEum%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.-Y.%26aulast%3DLee%26aufirst%3DJ.-O.%26aulast%3DGyu%2BLee%26aufirst%3DT.%26aulast%3DRo%26aufirst%3DS.%26aulast%3DMyung%2BCho%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520catalytic%2520domain%2520of%2520human%2520phosphodiesterase%25205%2520with%2520bound%2520drug%2520molecules%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D98%26epage%3D102%26doi%3D10.1038%2Fnature01914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of PDEs inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150825142134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F1568026615666150825142134" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=917-933&author=L.+Liauthor=W.+Chenauthor=T.+Chenauthor=J.+Renauthor=Y.+Xu&title=Structure-based+discovery+of+PDEs+inhibitors&doi=10.2174%2F1568026615666150825142134"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150825142134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150825142134%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DStructure-based%2520discovery%2520of%2520PDEs%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D16%26spage%3D917%26epage%3D933%26doi%3D10.2174%2F1568026615666150825142134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parpia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzyna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Sildenafil citrate therapy for pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">2148</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa050010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa050010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16291984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ajtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2148-2157&author=N.+Galieauthor=H.+A.+Ghofraniauthor=A.+Torbickiauthor=R.+J.+Barstauthor=L.+J.+Rubinauthor=D.+Badeschauthor=T.+Flemingauthor=T.+Parpiaauthor=G.+Burgessauthor=A.+Branziauthor=F.+Grimmingerauthor=M.+Kurzynaauthor=G.+Simonneau&title=Sildenafil+citrate+therapy+for+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa050010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil citrate therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Ghofrani, Hossein A.; Torbicki, Adam; Barst, Robyn J.; Rubin, Lewis J.; Badesch, David; Fleming, Thomas; Parpia, Tamiza; Burgess, Gary; Branzi, Angelo; Grimminger, Friedrich; Kurzyna, Marcin; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2148-2157</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cGMP, thereby enhancing the cGMP-mediated relaxation and growth inhibition of vascular smooth-muscle cells, including those in the lung.  METHODS: In this double-blind, placebo-controlled study, we randomly assigned 278 patients with symptomatic pulmonary arterial hypertension (either idiopathic or assocd. with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts) to placebo or sildenafil (20, 40, or 80 mg) orally three times daily for 12 wk.  The primary end point was the change from baseline to week 12 in the distance walked in six minutes.  The change in mean pulmonary-artery pressure and World Health Organization (WHO) functional class and the incidence of clin. worsening were also assessed, but the study was not powered to assess mortality.  Patients completing the 12-wk randomized study could enter a long-term extension study.  RESULTS: The distance walked in six minutes increased from baseline in all sildenafil groups; the mean placebo-cor. treatment effects were 45 m (+ 13.0 %), 46 m (+ 13.3 %), and 50 m (+ 14.7 %) for 20, 40, and 80 mg of sildenafil, resp. (P < 0.001 for all comparisons).  All sildenafil doses reduced the mean pulmonary-artery pressure (P = 0.04, P = 0.01, and P < 0.001, resp.), improved the WHO functional class (P = 0.003, P < 0.001, and P < 0.001, resp.), and were assocd. with side effects such as flushing, dyspepsia, and diarrhea.  The incidence of clin. worsening did not differ significantly between the patients treated with sildenafil and those treated with placebo.  Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m.  CONCLUSIONS: Sildenafil improves exercise capacity, WHO functional class, and hemodynamics in patients with symptomatic pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRmk6YHttM7Vg90H21EOLACvtfcHk0liM0MqYi42iuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ajtb%252FI&md5=98f9d612bdeb37178f0910263d9ca97f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050010%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DParpia%26aufirst%3DT.%26aulast%3DBurgess%26aufirst%3DG.%26aulast%3DBranzi%26aufirst%3DA.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DKurzyna%26aufirst%3DM.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DSildenafil%2520citrate%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2148%26epage%3D2157%26doi%3D10.1056%2FNEJMoa050010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayvergiya, R.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">851.e1</span>– <span class="NLM_lpage">851.e5</span>, <span class="refDoi"> DOI: 10.1016/j.ahj.2005.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ahj.2005.09.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2006&pages=851.e1-851.e5&author=T.+P.+Singhauthor=M.+Rohitauthor=A.+Groverauthor=D.+Malhotraauthor=R.+Vijayvergiya&title=A+randomized%2C+placebo-controlled%2C+double-blind%2C+crossover+study+to+evaluate+the+efficacy+of+oral+sildenafil+therapy+in+severe+pulmonary+artery+hypertension&doi=10.1016%2Fj.ahj.2005.09.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2005.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2005.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DT.%2BP.%26aulast%3DRohit%26aufirst%3DM.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DMalhotra%26aufirst%3DD.%26aulast%3DVijayvergiya%26aufirst%3DR.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520double-blind%252C%2520crossover%2520study%2520to%2520evaluate%2520the%2520efficacy%2520of%2520oral%2520sildenafil%2520therapy%2520in%2520severe%2520pulmonary%2520artery%2520hypertension%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2006%26volume%3D151%26spage%3D851.e1%26epage%3D851.e5%26doi%3D10.1016%2Fj.ahj.2005.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Monnier
de Gouville, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coste, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirilovsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyafil, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudinière, R.</span></span> <span> </span><span class="NLM_article-title">The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1H-imidazo[1‘,5‘:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4525</span>– <span class="NLM_lpage">4532</span>, <span class="refDoi"> DOI: 10.1021/jm030056e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030056e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4525-4532&author=A.+Dauganauthor=P.+Grondinauthor=C.+Ruaultauthor=A.-C.+Le+Monnier%0Ade+Gouvilleauthor=H.+Costeauthor=J.+Kirilovskyauthor=F.+Hyafilauthor=R.+Labaudini%C3%A8re&title=The+discovery+of+tadalafil%3A+A+novel+and+highly+selective+PDE5+inhibitor.+1%3A5%2C6%2C11%2C11a-tetrahydro-1H-imidazo%5B1%E2%80%98%2C5%E2%80%98%3A1%2C6%5Dpyrido%5B3%2C4-b%5Dindole-1%2C3%282H%29-dione+analogues&doi=10.1021%2Fjm030056e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues</span></div><div class="casAuthors">Daugan, Alain; Grondin, Pascal; Ruault, Cecile; Le Monnier de Gouville, Anne-Charlotte; Coste, Herve; Kirilovsky, Jorge; Hyafil, Francois; Labaudiniere, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4525-4532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from Et β-carboline-3-carboxylate (β-CCE), 1, a modest inhibitor of type 5 phosphodiesterase (PDE5), a series of functionalized tetrahydro-β-carboline derivs. has been identified as a novel chem. class of potent and selective PDE5 inhibitors.  Optimization of the side chain on the hydantoin ring of initial lead compd. 2 and of the arom. ring on position 5 led to the identification of compd. 6e, a highly potent and selective PDE5 inhibitor, with greater selectivity for PDE5 vs. PDE1-4 than sildenafil.  Compd. 6e demonstrated a long lasting and significant blood pressure lowering effect after iv administration in the spontaneously hypertensive rat model but showed only moderate oral in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0Ynxcj9_8rVg90H21EOLACvtfcHk0lhH9Skj-b00EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCju78%253D&md5=7c3b9aaf206cb18faaafc398c304357c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm030056e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030056e%26sid%3Dliteratum%253Aachs%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DGrondin%26aufirst%3DP.%26aulast%3DRuault%26aufirst%3DC.%26aulast%3DLe%2BMonnier%2Bde%2BGouville%26aufirst%3DA.-C.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DHyafil%26aufirst%3DF.%26aulast%3DLabaudini%25C3%25A8re%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520tadalafil%253A%2520A%2520novel%2520and%2520highly%2520selective%2520PDE5%2520inhibitor.%25201%253A5%252C6%252C11%252C11a-tetrahydro-1H-imidazo%255B1%25E2%2580%2598%252C5%25E2%2580%2598%253A1%252C6%255Dpyrido%255B3%252C4-b%255Dindole-1%252C3%25282H%2529-dione%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4525%26epage%3D4532%26doi%3D10.1021%2Fjm030056e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundage, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safdar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beardsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumkin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Resp. Tadalafil therapy for pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2894</span>– <span class="NLM_lpage">2903</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.108.839274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.108.839274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19470885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1alsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=2894-2903&author=N.+Galieauthor=B.+H.+Brundageauthor=H.+A.+Ghofraniauthor=R.+J.+Oudizauthor=G.+Simonneauauthor=Z.+Safdarauthor=S.+Shapiroauthor=R.+J.+Whiteauthor=M.+Chanauthor=A.+Beardsworthauthor=L.+Frumkinauthor=R.+J.+Barst&title=Resp.+Tadalafil+therapy+for+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.108.839274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil Therapy for Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Brundage, Bruce H.; Ghofrani, Hossein A.; Oudiz, Ronald J.; Simonneau, Gerald; Safdar, Zeenat; Shapiro, Shelley; White, R. James; Chan, Melanie; Beardsworth, Anthony; Frumkin, Lyn; Barst, Robyn J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2894-2903</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways.  Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway.  Methods and Results: In this 16-wk, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or assocd.), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily.  The primary end point was the change from baseline to week 16 in the distance walked in 6 min.  Changes in World Health Organization functional class, clin. worsening, and health-related quality of life were also assessed.  Patients completing the 16-wk study could enter a long-term extension study.  Tadalafil increased the distance walked in 6 min in a dose-dependent manner; only the 40-mg dose met the prespecified level of statistical significance (P<0.01).  Overall, the mean placebo-cor. treatment effect was 33 m (95% confidence interval, 15 to 50 m).  In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m) compared with 23 m (95% confidence interval, -2 to 48 m) in patients on background bosentan therapy.  Tadalafil 40 mg improved the time to clin. worsening (P=0.041), incidence of clin. worsening (68% relative risk redn.; P=0.038), and health-related quality of life.  The changes in World Health Organization functional class were not statistically significant.  The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing.  Conclusions: In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clin. worsening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRgmNAQBkSLVg90H21EOLACvtfcHk0lhH9Skj-b00EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1alsb0%253D&md5=64556d999b15e8a5269c03c810518ccc</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.108.839274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.108.839274%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DBrundage%26aufirst%3DB.%2BH.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSafdar%26aufirst%3DZ.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DR.%2BJ.%26aulast%3DChan%26aufirst%3DM.%26aulast%3DBeardsworth%26aufirst%3DA.%26aulast%3DFrumkin%26aufirst%3DL.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26atitle%3DResp.%2520Tadalafil%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2009%26volume%3D119%26spage%3D2894%26epage%3D2903%26doi%3D10.1161%2FCIRCULATIONAHA.108.839274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haning, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewohner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Es-Sayed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, E.</span></span> <span> </span><span class="NLM_article-title">Imidazo 5,1-f 1,2,4 triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00030-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0960-894X%2802%2900030-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11958981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslGkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=865-868&author=H.+Haningauthor=U.+Niewohnerauthor=T.+Schenkeauthor=M.+Es-Sayedauthor=G.+Schmidtauthor=T.+Lampeauthor=E.+Bischoff&title=Imidazo+5%2C1-f+1%2C2%2C4+triazin-4%283H%29-ones%2C+a+new+class+of+potent+PDE+5+inhibitors&doi=10.1016%2FS0960-894X%2802%2900030-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors</span></div><div class="casAuthors">Haning, Helmut; Niewohner, Ulrich; Schenke, Thomas; Es-Sayed, Mazen; Schmidt, Gunter; Lampe, Thomas; Bischoff, Erwin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">865-868</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">2-Aryl-substituted imidazo[5,1-f][1,2,4]triazin-4(3H)-ones represent a new class of potent cGMP-PDE 5 inhibitors that prove to be superior to other purine-isosteric inhibitors.  Subnanomolar inhibitors of PDE 5 with activity in in-vivo models for erectile dysfunction have been identified.  BAY 38-9456 (Vardenafil-hydrochloride) has been selected for clin. studies in the indication of erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpWwnsndy43rVg90H21EOLACvtfcHk0li5o1ekupTL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslGkt7c%253D&md5=cb00c9b2b1e68aa9ea254c4fe330b8a9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900030-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900030-6%26sid%3Dliteratum%253Aachs%26aulast%3DHaning%26aufirst%3DH.%26aulast%3DNiewohner%26aufirst%3DU.%26aulast%3DSchenke%26aufirst%3DT.%26aulast%3DEs-Sayed%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DLampe%26aufirst%3DT.%26aulast%3DBischoff%26aufirst%3DE.%26atitle%3DImidazo%25205%252C1-f%25201%252C2%252C4%2520triazin-4%25283H%2529-ones%252C%2520a%2520new%2520class%2520of%2520potent%2520PDE%25205%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D865%26epage%3D868%26doi%3D10.1016%2FS0960-894X%2802%2900030-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ormrod, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easthope, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figgitt, D. P.</span></span> <span> </span><span class="NLM_article-title">Vardenafil</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.2165/00002512-200219030-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2165%2F00002512-200219030-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12027779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsF2mtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=217-227&author=D.+Ormrodauthor=S.+E.+Easthopeauthor=D.+P.+Figgitt&title=Vardenafil&doi=10.2165%2F00002512-200219030-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Vardenafil</span></div><div class="casAuthors">Ormrod, Douglas; Easthope, Stephanie E.; Figgitt, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), an enzyme which hydrolyzes cyclic guanosine monophosphate in the cavernosum tissue of the penis.  Inhibition of PDE5 results in increased arterial blood flow leading to enlargement of the corpus cavernosum.  Because of the increased tumescence, veins are compressed between the corpus cavernosum and the tunica albuginea, resulting in an erection.  Vardenafil has a high bioavailability and is rapidly absorbed.  An erection of >60% rigidity was maintained for approx. twice as long following visual stimulation in patients treated with vardenafil 10 or 20mg than in recipients of placebo.  In a large, placebo-controlled trial in patients with mild to severe erectile dysfunction (ED), vardenafil 5, 10 or 20mg taken as needed over a 12-wk period significantly improved the scores in questions 3 and 4 of the International Index of Erectile Function (IIEF).  The rate of successful attempts at intercourse with ejaculation was also significantly higher with vardenafil (71 to 75%) than in the placebo group (39.5%), and significantly more patients treated with vardenafil than placebo responded 'yes' to a Global Assessment Question (GAQ) asking if treatment had improved erections.  In a 26-wk trial in 736 men with ED of varied etiologies and severity patients receiving vardenafil 5, 10 or 20mg experienced significantly improved erections with 85% of vardenafil 20mg recipients reporting improved erectile function (assessed using the GAQ) compared with 28% of placebo recipients.  Treatment with vardenafil also significantly improved scores in response to questions 3 and 4 of the IIEF compared with placebo.  A 12-wk trial in 452 men with ED assocd. with diabetes mellitus demonstrated that treatment with vardenafil 20mg compared with placebo significantly improved IIEF erectile function domain scores and the rate of pos. responders to the erectile improvement GAQ.  Similar results were reported in a placebo-controlled trial of vardenafil 10 to 20mg involving 440 patients with ED after radical prostatectomy.  Adverse events assocd. with vardenafil were those commonly assocd. with PDE5 inhibitors: headache, flushing, dyspepsia and rhinitis.  These were mostly dose-dependent and mild to moderate in intensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG-FWZ6nl6-bVg90H21EOLACvtfcHk0li5o1ekupTL2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsF2mtLc%253D&md5=88a0159222b6ca6d2de7b48615243704</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2165%2F00002512-200219030-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002512-200219030-00005%26sid%3Dliteratum%253Aachs%26aulast%3DOrmrod%26aufirst%3DD.%26aulast%3DEasthope%26aufirst%3DS.%2BE.%26aulast%3DFiggitt%26aufirst%3DD.%2BP.%26atitle%3DVardenafil%26jtitle%3DDrugs%2520Aging%26date%3D2002%26volume%3D19%26spage%3D217%26epage%3D227%26doi%3D10.2165%2F00002512-200219030-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Vardenafil in pulmonary arterial hypertension a randomized, double-blind, placebo-controlled study</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1729</span>, <span class="refDoi"> DOI: 10.1164/rccm.201101-0093OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201101-0093OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21471085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsF2nsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=1723-1729&author=Z.+C.+Jingauthor=Z.+X.+Yuauthor=J.+Y.+Shenauthor=B.+X.+Wuauthor=K.+F.+Xuauthor=X.+Y.+Zhuauthor=L.+Panauthor=Z.+L.+Zhangauthor=X.+Q.+Liuauthor=Y.+S.+Zhangauthor=X.+Jiangauthor=N.+Galie&title=Vardenafil+in+pulmonary+arterial+hypertension+a+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1164%2Frccm.201101-0093OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Vardenafil in pulmonary arterial hypertension</span></div><div class="casAuthors">Jing, Zhi-Cheng; Yu, Zai-Xin; Shen, Jie-Yan; Wu, Bing-Xiang; Xu, Kai-Feng; Zhu, Xian-Yang; Pan, Lei; Zhang, Zhuo-Li; Liu, Xue-Qin; Zhang, Yu-Shun; Jiang, Xin; Galie, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1723-1729</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Although the phosphodiesterase type 5 inhibitors sildenafil and tadalafil have demonstrated efficacy in patients with pulmonary arterial hypertension (PAH), monotherapy with these agents has not been conclusively shown to reduce clin. worsening events.  To evaluate the safety and efficacy of the phosphodiesterase type 5 inhibitor vardenafil in Chinese patients with PAH.  In a randomized, double-blind, placebo-controlled study, 66 patients with PAH were randomized 2:1 to vardenafil (5 mg once daily for 4 wk then 5 mg twice daily; n = 44) or placebo (n = 22) for 12 wk.  Patients completing this phase were then treated with open-label vardenafil (5 mg twice daily) for a further 12 wk.  At week 12, the mean placebo-cor. 6-min walking distance was increased with vardenafil (69 m; P < 0.001), and this improvement was maintained for at least 24 wk.  Vardenafil also increased the mean placebo-cor. cardiac index (0.39 L/min-1/m-2; P = 0.005) and decreased mean pulmonary arterial pressure and pulmonary vascular resistance (-5.3 mm Hg, P = 0.047; -4.7 Wood U, P = 0.003; resp.) at Week 12.  4 atients in the placebo group (20%) and one in the vardenafil group (2.3%) had clin. worsening events (hazard ratio 0.105; 95% confidence interval, 0.012-0.938; P = 0.044).  Vardenafil was assocd. with only mild and transient adverse events.  Vardenafil is effective and well tolerated in patients with PAH at a dose of 5 mg twice daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4vbfiG3EM7Vg90H21EOLACvtfcHk0lgp8G6_RGd2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsF2nsLs%253D&md5=c19b3a9b0a98c6ea2e86e955777f363c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1164%2Frccm.201101-0093OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201101-0093OC%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DYu%26aufirst%3DZ.%2BX.%26aulast%3DShen%26aufirst%3DJ.%2BY.%26aulast%3DWu%26aufirst%3DB.%2BX.%26aulast%3DXu%26aufirst%3DK.%2BF.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%2BL.%26aulast%3DLiu%26aufirst%3DX.%2BQ.%26aulast%3DZhang%26aufirst%3DY.%2BS.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGalie%26aufirst%3DN.%26atitle%3DVardenafil%2520in%2520pulmonary%2520arterial%2520hypertension%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D1723%26epage%3D1729%26doi%3D10.1164%2Frccm.201101-0093OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, K. S.</span></span> <span> </span><span class="NLM_article-title">Effects of renal impairment on the pharmacokinetics and safety of udenafil</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1002/jcph.1095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fjcph.1095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29537612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2murnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=905-912&author=Y.+S.+Choauthor=Y.+H.+Nohauthor=H.+S.+Limauthor=S.+H.+Choauthor=J.+L.+Ghimauthor=S.+Choeauthor=S.+B.+Kimauthor=J.+S.+Parkauthor=S.+K.+Leeauthor=W.+S.+Yangauthor=J.+W.+Changauthor=M.+Y.+Bahngauthor=K.+S.+Bae&title=Effects+of+renal+impairment+on+the+pharmacokinetics+and+safety+of+udenafil&doi=10.1002%2Fjcph.1095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil</span></div><div class="casAuthors">Cho, Yong-Soon; Noh, Yook-Hwan; Lim, Hyeong-Seok; Cho, Sang-Heon; Ghim, Jong-Lyul; Choe, Sangmin; Kim, Soon-Bae; Park, Jung-Sik; Lee, Sang-Koo; Yang, Won-Seok; Chang, Jai-Won; Bahng, Mi-Young; Bae, Kyun-Seop</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">905-912</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Udenafil is a phosphodiesterase-5 inhibitor used to treat erectile dysfunction.  Although udenafil is not predominantly eliminated by the kidney, renal impairment can alter its secretion/transport pathways.  Drug pharmacokinetics and safety must therefore be assessed in subjects with a renal impairment.  We investigated the effects of impaired renal function on the pharmacokinetics and safety of a single 100-mg oral dose of udenafil in a single-dose, open-label, parallel-group study of 31 subjects.  Cockcroft-Gault creatinine clearance was used to stratify these subjects into healthy controls (>80 mL·min-1) and individuals with mild (50 to ≤80 mL·min-1), moderate (30 to ≤50 mL·min-1), and severe (<30 mL·min-1) renal impairment.  Pharmacokinetic measurements and safety assessments indicated that the geometric mean of the area under the concn.-time curve to the last measurement in mildly, moderately, and severely renally impaired subjects was 1.30- (90% CI 1.05-1.60), 1.62- (90% CI 1.28-2.06), and 1.60- (90% CI 1.28-2.01) fold higher, resp., than the healthy controls.  The geometric mean of the max. obsd. concn. was 1.41- (90% CI 1.05-1.88), 2.02- (90% CI 1.47-2.79), and 1.65- (90% CI: 1.21-2.24) fold higher, resp.  Significant correlations were obsd. among the creatinine clearance, oral clearance, and max. concn. of udenafil (P < .01).  All adverse events were mild, and no subject discontinued the study.  Udenafil administration was well tolerated in all groups.  In view of the clin. relevance of drug exposure, our findings indicate that a dose adjustment of udenafil is warranted in subjects with moderate or severe renal impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJzpmGAdfoOrVg90H21EOLACvtfcHk0lgp8G6_RGd2Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2murnN&md5=aee92e306693a964d6235dd4a70e44f3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1095%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DNoh%26aufirst%3DY.%2BH.%26aulast%3DLim%26aufirst%3DH.%2BS.%26aulast%3DCho%26aufirst%3DS.%2BH.%26aulast%3DGhim%26aufirst%3DJ.%2BL.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DYang%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DBahng%26aufirst%3DM.%2BY.%26aulast%3DBae%26aufirst%3DK.%2BS.%26atitle%3DEffects%2520of%2520renal%2520impairment%2520on%2520the%2520pharmacokinetics%2520and%2520safety%2520of%2520udenafil%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D905%26epage%3D912%26doi%3D10.1002%2Fjcph.1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span> <span> </span><span class="NLM_article-title">Udenafil as a therapeutic option for pulmonary arterial hypertension</span>. <i>Korean Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.4070/kcj.2019.0023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.4070%2Fkcj.2019.0023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30808087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3cfnvVGjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=361-362&author=H.+Y.+Kimauthor=K.+H.+Kim&title=Udenafil+as+a+therapeutic+option+for+pulmonary+arterial+hypertension&doi=10.4070%2Fkcj.2019.0023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Udenafil as a Therapeutic Option for Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Kim Hyung Yoon; Kim Kye Hun</div><div class="citationInfo"><span class="NLM_cas:title">Korean circulation journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-362</span>
        ISSN:<span class="NLM_cas:issn">1738-5520</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8lEcRsF401sAKB7Fa-xrUfW6udTcc2eaepCjUxSj3tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfnvVGjtg%253D%253D&md5=b3d8bcd3407eb75a3bbddbca6c8d700f</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.4070%2Fkcj.2019.0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4070%252Fkcj.2019.0023%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BH.%26atitle%3DUdenafil%2520as%2520a%2520therapeutic%2520option%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DKorean%2520Circ.%2520J.%26date%3D2019%26volume%3D49%26spage%3D361%26epage%3D362%26doi%3D10.4070%2Fkcj.2019.0023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: a placebo-controlled, double-blind, phase IIb clinical trial</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.clinthera.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31202506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=1499-1507&author=H.-J.+Changauthor=S.+Songauthor=S.-A.+Changauthor=H.-K.+Kimauthor=H.-O.+Jungauthor=J.-H.+Choiauthor=J.+S.+Leeauthor=K.-H.+Kimauthor=J.-O.+Jeongauthor=J.+H.+Leeauthor=D.-K.+Kim&title=Efficacy+and+safety+of+udenafil+for+the+treatment+of+pulmonary+arterial+hypertension%3A+a+placebo-controlled%2C+double-blind%2C+phase+IIb+clinical+trial&doi=10.1016%2Fj.clinthera.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial</span></div><div class="casAuthors">Chang, Hyuk-Jae; Song, Shinjeong; Chang, Sung-A.; Kim, Hyung-Kwan; Jung, Hae-Ok; Choi, Jung-Hyun; Lee, Jae Seung; Kim, Kye-Hun; Jeong, Jin-Ok; Lee, Ju Hee; Kim, Duk-Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1499-1507</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Udenafil is an oral phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction.  In a multicenter, placebo-controlled, randomized Phase IIa study, the redn. of pulmonary vascular resistance index was greater with a 50-mg baseline dose of udenafil than with the 100-mg dose, the cardiac index did not decrease at most points, and the safety was excellent, suggesting that 50-mg udenafil could be used in a Phase IIb trial.In this 16-wk, double-blind, placebo-controlled study, 63 patients with pulmonary arterial hypertension were randomized to receive 50-mg udenafil or a placebo BID.  The primary efficacy end point was the 6-min walking distance.  The secondary efficacy end points were the Borg dyspnea score and time to clin. worsening.  Patients who completed the 16-wk study could participate in a long-term extension study.: In terms of the difference between the baseline and 16-wk 6-min walking distance in both groups, the mean placebo-cor. treatment effect was 25 (58) m (P = 0.0873).  Among the patients with a history of endothelin receptor antagonist therapy, the treatment effect at week 16 between the udenafil and placebo groups was 34 (60) m (P = 0.0460).  However, there were no significant differences in the Borg dyspnea score and time to clin. worsening between groups.  The safety profile and adverse effects of udenafil were similar to those of typical phosphodiesterase-5 inhibitors seen in previous studies.Udenafil has a favorable safety profile and improves exercise capacity in patients with pulmonary arterial hypertension.  ClinicalTrials.gov identifier: NCT01553721.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOGeG2uTI-rVg90H21EOLACvtfcHk0lgtzxcu9DDzGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKms7vJ&md5=84fa5486a1ed837c065de5f18801fd0b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.-J.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DH.-K.%26aulast%3DJung%26aufirst%3DH.-O.%26aulast%3DChoi%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DJeong%26aufirst%3DJ.-O.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DD.-K.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520udenafil%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%253A%2520a%2520placebo-controlled%252C%2520double-blind%252C%2520phase%2520IIb%2520clinical%2520trial%26jtitle%3DClin.%2520Ther.%26date%3D2019%26volume%3D41%26spage%3D1499%26epage%3D1507%26doi%3D10.1016%2Fj.clinthera.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. S.</span></span> <span> </span><span class="NLM_article-title">2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2777</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2009.03.125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19375311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2777-2779&author=H.+L.+Duanauthor=J.+Zhengauthor=Q.+L.+Laiauthor=Z.+Liuauthor=G.+H.+Tianauthor=Z.+Wangauthor=J.+F.+Liauthor=J.+S.+Shen&title=2-Phenylquinazolin-4%283H%29-one%2C+a+class+of+potent+PDE5+inhibitors+with+high+selectivity+versus+PDE6&doi=10.1016%2Fj.bmcl.2009.03.125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6</span></div><div class="casAuthors">Duan, Hongliang; Zheng, Jin; Lai, Qinglin; Liu, Zheng; Tian, Guanghui; Wang, Zhen; Li, Jianfeng; Shen, Jingshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2777-2779</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In our efforts to minimize the side effects assocd. with low selectivity against the other PDE isoenzymes, a novel class of 2-phenylquinazolin-4(3H)-one derivs. I (R1 = H, Me, Et, F, Cl, Br, I, vinyl, n-Pr, n-Bu; R2 = H, Me), were designed and prepd. as potent PDE5 inhibitors with high selectivity against PDE6.  The syntheses and SAR studies of such mols. were reported.  Particularly, compd. I (R1 = Cl; R2 = Me) exhibited more than 100-fold selectivity vs. PDE6 than sildenafil.  Moreover, this compd. also showed comparable efficacy with sildenafil in rat erection model in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcve_9fB6it7Vg90H21EOLACvtfcHk0lgtzxcu9DDzGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLk%253D&md5=37770ce876adebb1aad1b092f892275c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.125%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DH.%2BL.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DQ.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%2BF.%26aulast%3DShen%26aufirst%3DJ.%2BS.%26atitle%3D2-Phenylquinazolin-4%25283H%2529-one%252C%2520a%2520class%2520of%2520potent%2520PDE5%2520inhibitors%2520with%2520high%2520selectivity%2520versus%2520PDE6%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2777%26epage%3D2779%26doi%3D10.1016%2Fj.bmcl.2009.03.125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10540</span>– <span class="NLM_lpage">10550</span>, <span class="refDoi"> DOI: 10.1021/jm301159y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301159y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10540-10550&author=G.+Wangauthor=Z.+Liuauthor=T.+T.+Chenauthor=Z.+Wangauthor=H.+Y.+Yangauthor=M.+Y.+Zhengauthor=J.+Renauthor=G.+H.+Tianauthor=X.+J.+Yangauthor=L.+Liauthor=J.+F.+Liauthor=J.+Suoauthor=R.+X.+Zhangauthor=X.+R.+Jiangauthor=N.+K.+Terrettauthor=J.+S.+Shenauthor=Y.+C.+Xuauthor=H.+L.+Jiang&title=Design%2C+synthesis%2C+and+pharmacological+evaluation+of+monocyclic+pyrimidinones+as+novel+inhibitors+of+PDE5&doi=10.1021%2Fjm301159y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5</span></div><div class="casAuthors">Wang, Guan; Liu, Zheng; Chen, Tiantian; Wang, Zhen; Yang, Huaiyu; Zheng, Mingyue; Ren, Jing; Tian, Guanghui; Yang, Xiaojun; Li, Li; Li, Jianfeng; Suo, Jin; Zhang, Rongxia; Jiang, Xiangrui; Terrett, Nicholas Kenneth; Shen, Jingshan; Xu, Yechun; Jiang, Hualiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10540-10550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Piperazinylsulfonylphenyl pyrimidinones I [R = EtCH2, Bu, BuCH2CH2; R1 = H, MeCONH, F, Cl, Br, I, Me, Et, EtCH2; R2 = HO, H2N, MeCONH, Me, Et, EtCH2, Me2CH, Me2CHCH2, Ph, F3C; R1R2 = (CH2)3] were prepd. as inhibitors of phosphodiesterase 5 (PDE5) for potential use as drugs for the treatment of erectile dysfunction in men.  The inhibition of PDE5 by I was detd. in vitro.  I (R = EtCH2; R1 = R2 = Et) was the most potent compd. of those tested with an IC50 value of 1.6 nM against PDE5 and 25->5000 fold selectivity against ten other phosphodiesterases; the pharmacokinetics of I on i.v. and oral administration to rats and its activity in a rat model of erectile dysfunction were also detd.  The structures of I [R = EtCH2; R1R2 = (CH2)3] and of I (R = EtCH2; R1 = R2 = Et) bound to human PDE5 and including a water mol. responsible for important enzyme-substrate interactions were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjvKdEhRg2F7Vg90H21EOLACvtfcHk0lh5jXBW2R8deA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr%252FE&md5=55c3b0ef3e53d78c62a4833bcd13e69a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm301159y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301159y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%2BT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DZheng%26aufirst%3DM.%2BY.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DG.%2BH.%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%2BF.%26aulast%3DSuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%2BX.%26aulast%3DJiang%26aufirst%3DX.%2BR.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DShen%26aufirst%3DJ.%2BS.%26aulast%3DXu%26aufirst%3DY.%2BC.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520evaluation%2520of%2520monocyclic%2520pyrimidinones%2520as%2520novel%2520inhibitors%2520of%2520PDE5%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10540%26epage%3D10550%26doi%3D10.1021%2Fjm301159y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisa, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4979</span>– <span class="NLM_lpage">4990</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00123</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00123" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotl2nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4979-4990&author=Z.+Wangauthor=X.+R.+Jiangauthor=X.+L.+Zhangauthor=G.+H.+Tianauthor=R.+L.+Yangauthor=J.+Z.+Wuauthor=X.+L.+Zouauthor=Z.+Liuauthor=X.+J.+Yangauthor=C.+H.+Wuauthor=J.+Shiauthor=J.+F.+Liauthor=J.+Suoauthor=Y.+Wangauthor=R.+X.+Zhangauthor=Z.+J.+Xuauthor=X.+D.+Gongauthor=Y.+Heauthor=W.+L.+Zhuauthor=H.+A.+Aisaauthor=H.+L.+Jiangauthor=Y.+C.+Xuauthor=J.+S.+Shen&title=Pharmacokinetics-driven+optimization+of+4%283H%29-pyrimidinones+as+phosphodiesterase+type+5+inhibitors+leading+to+TPN171%2C+a+clinical+candidate+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.9b00123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Wang, Zhen; Jiang, Xiangrui; Zhang, Xianglei; Tian, Guanghui; Yang, Rulei; Wu, Jianzhong; Zou, Xiaoli; Liu, Zheng; Yang, Xiaojun; Wu, Chunhui; Shi, Jing; Li, Jianfeng; Suo, Jin; Wang, Yu; Zhang, Rongxia; Xu, Zhijian; Gong, Xudong; He, Yang; Zhu, Weiliang; Aisa, Haji Akber; Jiang, Hualiang; Xu, Yechun; Shen, Jingshan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4979-4990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase type 5 (PDE5) inhibitors are first-line therapy for pulmonary arterial hypertension (PAH) and erectile dysfunction.  As a continuing work to improve the terminal half-lives and oral bioavailabilities of our previously reported 4(3H)-pyrimidones, a pharmacokinetics-driven optimization focusing on the terminal substituent is described.  Two major congeneric series of 4(3H)-pyrimidones, the aminosulfonylphenylpyrimidones and acylaminophenylpyrimidones, were designed, synthesized, and pharmacol. assessed in vitro and in vivo.  Among them, compd. 15 (I) (CAS 1229018-87-4) (TPN171) with subnanomolar potency for PDE5 and good selectivity over PDE6 was finally recognized as a potential drug candidate, and its pharmacokinetic profiles in rats and dogs are significantly improved compared to the starting compd. (3).  Moreover, I was proven to exert a longer lasting effect than sildenafil in animal models, providing a foundation for a once-daily oral administration for its clin. use.  I Is currently being investigated in a phase II clin. trial for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSBJC7qO7NLVg90H21EOLACvtfcHk0lh5jXBW2R8deA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotl2nt78%253D&md5=5d0d84757d86a641744630c0f7739376</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00123%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DX.%2BR.%26aulast%3DZhang%26aufirst%3DX.%2BL.%26aulast%3DTian%26aufirst%3DG.%2BH.%26aulast%3DYang%26aufirst%3DR.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DZou%26aufirst%3DX.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%2BF.%26aulast%3DSuo%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DR.%2BX.%26aulast%3DXu%26aufirst%3DZ.%2BJ.%26aulast%3DGong%26aufirst%3DX.%2BD.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%2BL.%26aulast%3DAisa%26aufirst%3DH.%2BA.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DXu%26aufirst%3DY.%2BC.%26aulast%3DShen%26aufirst%3DJ.%2BS.%26atitle%3DPharmacokinetics-driven%2520optimization%2520of%25204%25283H%2529-pyrimidinones%2520as%2520phosphodiesterase%2520type%25205%2520inhibitors%2520leading%2520to%2520TPN171%252C%2520a%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4979%26epage%3D4990%26doi%3D10.1021%2Facs.jmedchem.9b00123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowitz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikka, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokman, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, W. J. G.</span></span> <span> </span><span class="NLM_article-title">Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.2174/138920013804870600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F138920013804870600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23140258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFagu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=265-269&author=S.+Gurauthor=P.+J.+Kadowitzauthor=A.+Gokceauthor=S.+C.+Sikkaauthor=U.+Lokmanauthor=W.+J.+G.+Hellstrom&title=Update+on+drug+interactions+with+phosphodiesterase-5+inhibitors+prescribed+as+first-line+therapy+for+patients+with+erectile+dysfunction+or+pulmonary+hypertension&doi=10.2174%2F138920013804870600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension</span></div><div class="casAuthors">Gur, Serap; Kadowitz, Philip J.; Gokce, Ahmet; Sikka, Suresh C.; Lokman, Utku; Hellstrom, Wayne J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-5 inhibitors (PDE5i, sildenafil, vardenafil, tadalafil and avanafil) are a first-line medical therapy for erectile dysfunction (ED).  In all likelihood, PDE5i usage will increase because sildenafil (Viagra and Revatio) and tadalafil (Cialis and Adcirca) have recently been recommended as first-line therapy for patients with pulmonary hypertension (PH).  PDE5i exhibit higher plasma concns. when co-administered with cytochrome P (CYP) 3A inhibitors, which influences their side-effect profile.  The higher PDE5i plasma concns., caused by CYP3A inhibitors, influence the severity and timing of PDE5i drug interactions and require dose adjustment.  PDE5i are safe when used with most antihypertensive agents, but co-administration with nitrates or α-blockers can cause severe hypotension and syncope.  Dose adjustment is also necessary when PDE5i are co-administered with CYP3A inducers.  The combination of oral tadalafil and bosentan (endothelin receptor antagonist) reduces tadalafil levels and requires dose adjustment.  Current literature reports a no. of interactions between PDE5i and other agents and further studies are needed to expand our knowledge base of these interactions.  This review discusses relevant PDE5i drug interactions, including those with CYP 450 inhibitors and inducers which are frequently used during the treatment of ED and PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraWOtrU04kSLVg90H21EOLACvtfcHk0lh5jXBW2R8deA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFagu7c%253D&md5=01a26a94eb0b30d89eeaf01bb35c8508</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2174%2F138920013804870600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920013804870600%26sid%3Dliteratum%253Aachs%26aulast%3DGur%26aufirst%3DS.%26aulast%3DKadowitz%26aufirst%3DP.%2BJ.%26aulast%3DGokce%26aufirst%3DA.%26aulast%3DSikka%26aufirst%3DS.%2BC.%26aulast%3DLokman%26aufirst%3DU.%26aulast%3DHellstrom%26aufirst%3DW.%2BJ.%2BG.%26atitle%3DUpdate%2520on%2520drug%2520interactions%2520with%2520phosphodiesterase-5%2520inhibitors%2520prescribed%2520as%2520first-line%2520therapy%2520for%2520patients%2520with%2520erectile%2520dysfunction%2520or%2520pulmonary%2520hypertension%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2013%26volume%3D14%26spage%3D265%26epage%3D269%26doi%3D10.2174%2F138920013804870600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Alija, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet-Buchholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feurer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furstner, C.</span></span> <span> </span><span class="NLM_article-title">NO-independent stimulators of soluble guanylate cyclase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00073-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0960-894X%2801%2900073-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11277519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=781-784&author=A.+Straubauthor=J.+P.+Staschauthor=C.+Alonso-Alijaauthor=J.+Benet-Buchholzauthor=B.+Duckeauthor=A.+Feurerauthor=C.+Furstner&title=NO-independent+stimulators+of+soluble+guanylate+cyclase&doi=10.1016%2FS0960-894X%2801%2900073-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">NO-Independent stimulators of soluble guanylate cyclase</span></div><div class="casAuthors">Straub, A.; Stasch, J.-P.; Alonso-Alija, C.; Benet-Buchholz, J.; Ducke, B.; Feurer, A.; Furstner, C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">781-784</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">SARs around a novel type of guanylate cyclase stimulator which act by a mechanism different from classical NO-donors are described.  Several pyrazolopyridinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application.  The SARs around a novel type of stimulators of sol. guanylate cyclase, their relaxing effects on preconstricted rabbit aortic rings (measured as IC50s) and their hypotensive properties are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog9vZU756NFbVg90H21EOLACvtfcHk0ljcy1-BnylbGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOjtLw%253D&md5=9abba586008935963c6124594b0fcb7a</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900073-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900073-7%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DBenet-Buchholz%26aufirst%3DJ.%26aulast%3DDucke%26aufirst%3DB.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DFurstner%26aufirst%3DC.%26atitle%3DNO-independent%2520stimulators%2520of%2520soluble%2520guanylate%2520cyclase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D781%26epage%3D784%26doi%3D10.1016%2FS0960-894X%2801%2900073-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Alija, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apeler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembowsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feurer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minuth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perzborn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleiss, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, M.</span></span> <span> </span><span class="NLM_article-title">NO-independent regulatory site on soluble guanylate cyclase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>410</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1038/35065611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F35065611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11242081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVyrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=2001&pages=212-215&author=J.+P.+Staschauthor=E.+M.+Beckerauthor=C.+Alonso-Alijaauthor=H.+Apelerauthor=K.+Dembowskyauthor=A.+Feurerauthor=R.+Gerzerauthor=T.+Minuthauthor=E.+Perzbornauthor=U.+Pleissauthor=H.+Schroderauthor=W.+Schroederauthor=E.+Stahlauthor=W.+Steinkeauthor=A.+Straubauthor=M.+Schramm&title=NO-independent+regulatory+site+on+soluble+guanylate+cyclase&doi=10.1038%2F35065611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent regulatory site on soluble guanylate cyclase</span></div><div class="casAuthors">Stasch, Johannes-Peter; Becker, Eva Maria; Alonso-Alija, Cristina; Apeler, Heiner; Dembowsky, Klaus; Feurer, Achim; Gerzer, Rupert; Minuth, Torsten; Perzborn, Elisabeth; Pleiss, Ulrich; Schroder, Henning; Schroeder, Werner; Stahl, Eike; Steinke, Wolfram; Straub, Alexander; Schramm, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">410</span>
        (<span class="NLM_cas:issue">6825</span>),
    <span class="NLM_cas:pages">212-215</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nitric oxide (NO) is a widespread, potent, biol. mediator that has many physiol. and pathophysiol. roles.  Research in the field of NO appears to have followed a straightforward path, and the findings have been progressive: NO and cGMP are involved in vasodilatation; glycerol trinitrate relaxes vascular smooth muscles by bioconversion to NO; mammalian cells synthesize NO; and last, NO mediates vasodilation by stimulating the sol. guanylate cyclase (sGC), a heterodimeric (α/β) heme protein that converts GTP to cGMP.  Here the authors report the discovery of a regulatory site on sGC.  Using photoaffinity labeling, the authors have identified the cysteine 238 and cysteine 243 region in the α1-subunit of sGC as the target for a new type of sGC stimulator.  Moreover, the authors present a pyrazolopyridine, BAY 41-2272, that potently stimulates sGC through this site by a mechanism that is independent of NO.  This results in antiplatelet activity, a strong decrease in blood pressure and an increase in survival in a low-NO rat model of hypertension, and as such may offer an approach for treating cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6lC7feiF4MLVg90H21EOLACvtfcHk0ljcy1-BnylbGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVyrur0%253D&md5=eb7d71bfc37767a0a371ba6fb0aec905</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2F35065611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35065611%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DBecker%26aufirst%3DE.%2BM.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DApeler%26aufirst%3DH.%26aulast%3DDembowsky%26aufirst%3DK.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DGerzer%26aufirst%3DR.%26aulast%3DMinuth%26aufirst%3DT.%26aulast%3DPerzborn%26aufirst%3DE.%26aulast%3DPleiss%26aufirst%3DU.%26aulast%3DSchroder%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DW.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DSchramm%26aufirst%3DM.%26atitle%3DNO-independent%2520regulatory%2520site%2520on%2520soluble%2520guanylate%2520cyclase%26jtitle%3DNature%26date%3D2001%26volume%3D410%26spage%3D212%26epage%3D215%26doi%3D10.1038%2F35065611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Alija, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apeler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembowsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feurer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minuth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perzborn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41–8543: in vitro studies</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0704484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fsj.bjp.0704484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11815368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1KrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=333-343&author=J.+P.+Staschauthor=C.+Alonso-Alijaauthor=H.+Apelerauthor=K.+Dembowskyauthor=A.+Feurerauthor=T.+Minuthauthor=E.+Perzbornauthor=M.+Schrammauthor=A.+Straub&title=Pharmacological+actions+of+a+novel+NO-independent+guanylyl+cyclase+stimulator%2C+BAY+41%E2%80%938543%3A+in+vitro+studies&doi=10.1038%2Fsj.bjp.0704484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies</span></div><div class="casAuthors">Stasch, Johannes-Peter; Alonso-Alija, Cristina; Apeler, Heiner; Dembowsky, Klaus; Feurer, Achim; Minuth, Torsten; Perzborn, Elisabeth; Schramm, Matthias; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-343</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BAY 41-8543 is a novel, highly specific and so far the most potent NO-independent stimulator of sGC.  Here we report the effects of BAY 41-8543 on the isolated enzyme, endothelial cells, platelets, isolated vessels and Langendorff heart prepn.  BAY 41-8543 stimulates the recombinant sGC concn.-dependently from 0.0001 μM to 100 μM up to 92-fold.  In combination, BAY 41-8543 and NO have synergistic effects over a wide range of concns.  Similar results are shown in implying that BAY 41-8543 stimulates the sGC directly and furthermore makes the enzyme more sensitive to its endogenous activator NO.  In vitro, BAY 41-8543 is a potent relaxing agent of aortas, saphenous arteries, coronary arteries and veins with IC50-values in the nM range.  In the rat heart Langendorff prepn., BAY 41-8543 potently reduces coronary perfusion pressure from 10-9 to 10-6 g ml-1 without any effect on left ventricular pressure and heart rate.  BAY 41-8543 is effective even under nitrate tolerance conditions proved by the same vasorelaxing effect on aortic rings taken either from normal or nitrate-tolerant rats.  BAY 41-8543 is a potent inhibitor of collagen-mediated aggregation in washed human platelets (IC50=0.09 μM).  In plasma, BAY 41-8543 inhibits collagen-mediated aggregation better than ADP-induced aggregation, but has no effect on the thrombin pathway.  BAY 41-8543 is also a potent direct stimulator of the cGMP/PKG/VASP pathway in platelets and synergizes with NO over a wide range of concns.  These results suggest that BAY 41-8543 is on the one hand an invaluable tool for studying sGC signaling in vitro and on the other hand its unique profile may offer a novel approach for treating cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqGtfBYQ5mtLVg90H21EOLACvtfcHk0ljcy1-BnylbGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1KrsLk%253D&md5=636596e7eb0ba2cf19b71b095a895e72</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704484%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DApeler%26aufirst%3DH.%26aulast%3DDembowsky%26aufirst%3DK.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DMinuth%26aufirst%3DT.%26aulast%3DPerzborn%26aufirst%3DE.%26aulast%3DSchramm%26aufirst%3DM.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DPharmacological%2520actions%2520of%2520a%2520novel%2520NO-independent%2520guanylyl%2520cyclase%2520stimulator%252C%2520BAY%252041%25E2%2580%25938543%253A%2520in%2520vitro%2520studies%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D333%26epage%3D343%26doi%3D10.1038%2Fsj.bjp.0704484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet-Buckholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frode, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlsdorfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siefert, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1717</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00034-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0968-0896%2802%2900034-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11937330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XisFWhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=1711-1717&author=A.+Straubauthor=J.+Benet-Buckholzauthor=R.+Frodeauthor=A.+Kernauthor=C.+Kohlsdorferauthor=P.+Schmittauthor=T.+Schwarzauthor=H.+M.+Siefertauthor=J.+P.+Stasch&title=Metabolites+of+orally+active+NO-independent+pyrazolopyridine+stimulators+of+soluble+guanylate+cyclase&doi=10.1016%2FS0968-0896%2802%2900034-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolites of Orally Active NO-Independent Pyrazolopyridine Stimulators of Soluble Guanylate Cyclase</span></div><div class="casAuthors">Straub, Alexander; Benet-Buckholz, Jordi; Frode, Rita; Kern, Armin; Kohlsdorfer, Christian; Schmitt, Peter; Schwarz, Thomas; Siefert, Hans-Martin; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1711-1717</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The pyrazolopyridine stimulators of sol. guanylate cyclase BAY 41-2272 and 41-8543 were oxidised in rats and dogs at their 5-pyrimidinyl-cyclopropyl and -morpholino residue.  These metabolites activate the sol. guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp41R8sAg7AVrVg90H21EOLACvtfcHk0lhSEdCj_XfGHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisFWhtL4%253D&md5=dd0c98bd41b083b218b85be30daabd5e</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900034-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900034-2%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DBenet-Buckholz%26aufirst%3DJ.%26aulast%3DFrode%26aufirst%3DR.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DKohlsdorfer%26aufirst%3DC.%26aulast%3DSchmitt%26aufirst%3DP.%26aulast%3DSchwarz%26aufirst%3DT.%26aulast%3DSiefert%26aufirst%3DH.%2BM.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DMetabolites%2520of%2520orally%2520active%2520NO-independent%2520pyrazolopyridine%2520stimulators%2520of%2520soluble%2520guanylate%2520cyclase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D1711%26epage%3D1717%26doi%3D10.1016%2FS0968-0896%2802%2900034-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilama, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Riociguat for the treatment of pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1209655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1209655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23883378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=330-340&author=H.+A.+Ghofraniauthor=N.+Galieauthor=F.+Grimmingerauthor=E.+Grunigauthor=M.+Humbertauthor=Z.+C.+Jingauthor=A.+M.+Keoghauthor=D.+Langlebenauthor=M.+O.+Kilamaauthor=A.+Fritschauthor=D.+Neuserauthor=L.+J.+Rubin&title=Riociguat+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1209655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; Galie, Nazzareno; Grimminger, Friedrich; Gruenig, Ekkehard; Humbert, Marc; Jing, Zhi-Cheng; Keogh, Anne M.; Langleben, David; Kilama, Michael Ochan; Fritsch, Arno; Neuser, Dieter; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">330-340</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Riociguat, a sol. guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension.  METHODS: In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-max. group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-max. group).  The 1.5 mg-max. group was included for exploratory purposes, and the data from that group were analyzed descriptively.  Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible.  The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 min.  Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clin. worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety.  RESULTS: By week 12, the 6-min walk distance had increased by a mean of 30 m in the 2.5 mg-max. group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P<0.001).  Prespecified subgroup analyses showed that riociguat improved the 6-min walk distance both in patients who were receiving no other treatment for the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.  There were significant improvements in pulmonary vascular resistance (P<0.001), NT-proBNP levels (P<0.001), WHO functional class (P = 0.003), time to clin. worsening (P = 0.005), and Borg dyspnea score (P = 0.002).  The most common serious adverse event in the placebo group and the 2.5 mg-max. group was syncope (4% and 1%, resp.).  CONCLUSIONS: Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCUP-sJMAaXrVg90H21EOLACvtfcHk0lhSEdCj_XfGHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K&md5=dc8f91183c5bfc8c1ec0d0f56b2ac0e2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209655%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DKeogh%26aufirst%3DA.%2BM.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DKilama%26aufirst%3DM.%2BO.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D330%26epage%3D340%26doi%3D10.1056%2FNEJMoa1209655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artmeier-Brandt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensing, G.</span></span> <span> </span><span class="NLM_article-title">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63–2521: An ascending-dose study in healthy male volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1177/0091270008319793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F0091270008319793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18519919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=926-934&author=R.+Freyauthor=W.+Muckauthor=S.+Ungerauthor=U.+Artmeier-Brandtauthor=G.+Weimannauthor=G.+Wensing&title=Single-dose+pharmacokinetics%2C+pharmacodynamics%2C+tolerability%2C+and+safety+of+the+soluble+guanylate+cyclase+stimulator+BAY+63%E2%80%932521%3A+An+ascending-dose+study+in+healthy+male+volunteers&doi=10.1177%2F0091270008319793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers</span></div><div class="casAuthors">Frey, Reiner; Mueck, Wolfgang; Unger, Sigrun; Artmeier-Brandt, Ulrike; Weimann, Gerrit; Wensing, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63-2521, a new drug in development for pulmonary hypertension.  Fifty-eight healthy male volunteers received a single oral dose of BAY 63-2521 (0.25-5 mg) or placebo.  No serious adverse events were reported; there were no life-threatening events.  Heart rate over 1 min, an indicator of the effect of a vasodilating agent on the cardiovascular system in healthy subjects, was increased dose dependently vs. placebo at BAY 63-2521 doses of 1 to 5 mg (P < .01).  Mean arterial and diastolic pressures were decreased vs. placebo at doses of 1 mg (P < .05) and 5 mg (P < .01).  Systolic pressure was not significantly affected.  BAY 63-2521 was readily absorbed and exhibited dose-proportional pharmacokinetics.  The pharmacodynamic and pharmacokinetic properties of BAY 63-2521 suggest that it can offer a unique mode of action in the treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom6tfQEA1oN7Vg90H21EOLACvtfcHk0liEJpHMWSGEog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D&md5=770d25ef69e46729dbf3a1bc2080d40f</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1177%2F0091270008319793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008319793%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DMuck%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DArtmeier-Brandt%26aufirst%3DU.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWensing%26aufirst%3DG.%26atitle%3DSingle-dose%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520tolerability%252C%2520and%2520safety%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520BAY%252063%25E2%2580%25932521%253A%2520An%2520ascending-dose%2520study%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D926%26epage%3D934%26doi%3D10.1177%2F0091270008319793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Follmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redlich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunder, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebenow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker-Pelster, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiss, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knorr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondritzki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trubel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5146</span>– <span class="NLM_lpage">5161</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00449</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5146-5161&author=M.+Follmannauthor=J.+Ackerstaffauthor=G.+Redlichauthor=F.+Wunderauthor=D.+Langauthor=A.+Kernauthor=P.+Feyauthor=N.+Griebenowauthor=W.+Krohauthor=E.+M.+Becker-Pelsterauthor=A.+Kretschmerauthor=V.+Geissauthor=V.+Liauthor=A.+Straubauthor=J.+Mittendorfauthor=R.+Jautelatauthor=H.+Schirokauthor=K.+H.+Schlemmerauthor=K.+Lustigauthor=M.+Gerischauthor=A.+Knorrauthor=H.+Tinelauthor=T.+Mondritzkiauthor=H.+Trubelauthor=P.+Sandnerauthor=J.+P.+Stasch&title=Discovery+of+the+soluble+guanylate+cyclase+stimulator+vericiguat+%28BAY+1021189%29+for+the+treatment+of+chronic+heart+failure&doi=10.1021%2Facs.jmedchem.7b00449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure</span></div><div class="casAuthors">Follmann, Markus; Ackerstaff, Jens; Redlich, Gorden; Wunder, Frank; Lang, Dieter; Kern, Armin; Fey, Peter; Griebenow, Nils; Kroh, Walter; Becker-Pelster, Eva-Maria; Kretschmer, Axel; Geiss, Volker; Li, Volkhart; Straub, Alexander; Mittendorf, Joachim; Jautelat, Rolf; Schirok, Hartmut; Schlemmer, Karl-Heinz; Lustig, Klemens; Gerisch, Michael; Knorr, Andreas; Tinel, Hanna; Mondritzki, Thomas; Truebel, Hubert; Sandner, Peter; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5146-5161</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first-in-class sol. guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension.  Despite its outstanding pharmacol. profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen.  In our efforts to further optimize the compd. class, we have uncovered interesting structure-activity relationships and were able to decrease oxidative metab. significantly.  These studies resulting in the discovery of once daily sGC stimulator vericiguat (compd. 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-r7F0gcVCrVg90H21EOLACvtfcHk0liEJpHMWSGEog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtb8%253D&md5=3b002cf2ab9fc92482fe08d6cac16302</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00449%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DAckerstaff%26aufirst%3DJ.%26aulast%3DRedlich%26aufirst%3DG.%26aulast%3DWunder%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DFey%26aufirst%3DP.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DKroh%26aufirst%3DW.%26aulast%3DBecker-Pelster%26aufirst%3DE.%2BM.%26aulast%3DKretschmer%26aufirst%3DA.%26aulast%3DGeiss%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DJautelat%26aufirst%3DR.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DKnorr%26aufirst%3DA.%26aulast%3DTinel%26aufirst%3DH.%26aulast%3DMondritzki%26aufirst%3DT.%26aulast%3DTrubel%26aufirst%3DH.%26aulast%3DSandner%26aufirst%3DP.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520vericiguat%2520%2528BAY%25201021189%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520heart%2520failure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5146%26epage%3D5161%26doi%3D10.1021%2Facs.jmedchem.7b00449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roessig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anstrom, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temple, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieske, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koglin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, C. M.</span></span> <span> </span><span class="NLM_article-title">A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator the VICTORIA trial</span>. <i>JACC-Heart Fail.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.jchf.2017.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jchf.2017.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29032136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1M7gslSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=96-104&author=P.+W.+Armstrongauthor=L.+Roessigauthor=M.+J.+Patelauthor=K.+J.+Anstromauthor=J.+Butlerauthor=A.+A.+Voorsauthor=C.+S.+P.+Lamauthor=P.+Ponikowskiauthor=T.+Templeauthor=B.+Pieskeauthor=J.+Ezekowitzauthor=A.+F.+Hernandezauthor=J.+Koglinauthor=C.+M.+O%E2%80%99Connor&title=A+multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+efficacy+and+safety+of+the+oral+soluble+guanylate+cyclase+stimulator+the+VICTORIA+trial&doi=10.1016%2Fj.jchf.2017.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial</span></div><div class="casAuthors">Armstrong Paul W; Roessig Lothar; Patel Mahesh J; Koglin Joerg; Anstrom Kevin J; Hernandez Adrian F; Butler Javed; Voors Adriaan A; Lam Carolyn S P; Ponikowski Piotr; Temple Tracy; Ezekowitz Justin; Pieske Burkert; O'Connor Christopher M</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Heart failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This trial sought to evaluate whether vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, was superior to placebo, on a background of standard of care, in increasing the time to the first occurrence of the composite endpoints of cardiovascular (CV) death and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction (HFrEF).  Deficiency in sGC-derived cyclic guanosine monophosphate (cGMP) causes both myocardial dysfunction and impaired endothelium-dependent vasomotor regulation that includes the myocardial microcirculation.  Experimental studies have suggested multiple potential benefits of sGC stimulators including prevention, or even reversal, of left ventricular hypertrophy and fibrosis, as well as reduction of ventricular afterload through both systemic and pulmonary vasodilation.  Hence, restoration of sufficient nitric oxide (NO)-sGC-cGMP signaling has been proposed as an important treatment target in HF.  Vericiguat has been shown to directly stimulate sGC and enhance sGC sensitivity to endogenous NO.  Available phase IIb data in HFrEF patients indicate vericiguat is safe and well-tolerated, and exploratory analyses indicate that it results in a dose-dependent, clinically significant reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at the highest tested dose.  VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) is a randomized, placebo-controlled, parallel group, multicenter, double-blind, event-driven phase 3 trial of vericiguat in subjects with HFrEF.  Approximately 4,872 subjects will be randomized to evaluate the efficacy and safety of vericiguat compared with placebo on a background of standard of care.  After a screening phase of up to 30 days, eligible subjects will be treated until the required number of cardiovascular deaths is observed.  The estimated median follow-up duration is approximately 18 months.  All subjects will be followed until study completion to assess for the occurrence of endpoint events.  VICTORIA will establish the efficacy and safety of vericiguat on cardiovascular death and HF hospitalization in patients with HFrEF. (A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction [HFrEF]-VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction [VICTORIA]; NCT02861534).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSuusnxBwex6-9TkgmBqTqfW6udTcc2eZEESueVZAbdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7gslSrsA%253D%253D&md5=c8e8bb390697ce18c89824cd9f758d44</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.jchf.2017.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchf.2017.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DRoessig%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DM.%2BJ.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DLam%26aufirst%3DC.%2BS.%2BP.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DTemple%26aufirst%3DT.%26aulast%3DPieske%26aufirst%3DB.%26aulast%3DEzekowitz%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DA.%2BF.%26aulast%3DKoglin%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DC.%2BM.%26atitle%3DA%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520the%2520oral%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520the%2520VICTORIA%2520trial%26jtitle%3DJACC-Heart%2520Fail.%26date%3D2018%26volume%3D6%26spage%3D96%26epage%3D104%26doi%3D10.1016%2Fj.jchf.2017.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Follmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebenow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mais, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span> <span> </span><span class="NLM_article-title">The chemistry and biology of soluble guanylate cyclase stimulators and activators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9462</span>, <span class="refDoi"> DOI: 10.1002/anie.201302588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fanie.201302588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9442-9462&author=M.+Follmannauthor=N.+Griebenowauthor=M.+G.+Hahnauthor=I.+Hartungauthor=F.-J.+Maisauthor=J.+Mittendorfauthor=M.+Schaeferauthor=H.+Schirokauthor=J.-P.+Staschauthor=F.+Stollauthor=A.+Straub&title=The+chemistry+and+biology+of+soluble+guanylate+cyclase+stimulators+and+activators&doi=10.1002%2Fanie.201302588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators</span></div><div class="casAuthors">Follmann, Markus; Griebenow, Nils; Hahn, Michael G.; Hartung, Ingo; Mais, Franz-Josef; Mittendorf, Joachim; Schaefer, Martina; Schirok, Hartmut; Stasch, Johannes-Peter; Stoll, Friederike; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9442-9462</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for more than 130 years.  Still today, NO-donor drugs are important in the management of cardiovascular diseases.  However, inhaled NO or drugs releasing NO and org. nitrates are assocd. with noteworthy therapeutic shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and nonspecific effects, such as post-translational modification of proteins.  The beneficial actions of NO are mediated by stimulation of sol. guanylate cyclase (sGC), a heme-contg. enzyme which produces the intracellular signaling mol. cGMP.  Recently, two classes of compds. have been discovered that amplify the function of sGC in a NO-independent manner, the so-called sGC stimulators and sGC activators.  The most advanced drug, the sGC stimulator riociguat, has successfully undergone Phase III clin. trials for different forms of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1k3LI-HnJc7Vg90H21EOLACvtfcHk0lg9957ztaDOSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K&md5=d84536785fcea442b23179a6d7bf7246</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302588%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DM.%2BG.%26aulast%3DHartung%26aufirst%3DI.%26aulast%3DMais%26aufirst%3DF.-J.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DStoll%26aufirst%3DF.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DThe%2520chemistry%2520and%2520biology%2520of%2520soluble%2520guanylate%2520cyclase%2520stimulators%2520and%2520activators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9442%26epage%3D9462%26doi%3D10.1002%2Fanie.201302588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakefield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chickering, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Profy, A. T.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, multiple-ascending-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects</span>. <i>Clin. Pharmacol. Drug Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1002/cpdd.627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fcpdd.627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30422390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=564-575&author=J.+P.+Hanrahanauthor=J.+D.+Wakefieldauthor=P.+J.+Wilsonauthor=M.+Mihovaauthor=J.+G.+Chickeringauthor=D.+Ruffauthor=M.+Hallauthor=G.+T.+Milneauthor=M.+G.+Currieauthor=A.+T.+Profy&title=A+randomized%2C+placebo-controlled%2C+multiple-ascending-dose+study+to+assess+the+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+the+soluble+guanylate+cyclase+stimulator+praliciguat+in+healthy+subjects&doi=10.1002%2Fcpdd.627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects</span></div><div class="casAuthors">Hanrahan, John P.; Wakefield, James D.; Wilson, Phebe J.; Mihova, Marina; Chickering, Jennifer G.; Ruff, Dennis; Hall, Michael; Milne, G. Todd; Currie, Mark G.; Profy, Albert T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">564-575</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Nitric oxide (NO)-sol. guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling is central to the regulation of several physiol. processes, including blood flow and inflammation.  Deficient NO signaling is implicated in multiple diseases. sGC stimulators are small mols. that enhance sGC activity, particularly in combination with NO.  In a randomized, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the sGC stimulator praliciguat were assessed in 44 healthy adults.  Four cohorts of 11 subjects (8 praliciguat, 3 placebo) received once-daily praliciguat for 14 days before up-titrating for 7 days (treatment sequences: 15/30 mg, 20/40 mg, 30/40 mg, and wt.-based).  All doses were tolerated.  No serious or severe adverse events (AEs) were reported.  The most common AEs in praliciguat recipients were headache and symptoms consistent with blood pressure (BP) lowering/vasodilation.  There were no lab., vital sign, electrocardiog., or platelet function findings indicative of a safety concern.  Pharmacokinetics were dose proportional, with an effective half-life of 24-37 h, supporting once-daily dosing.  Praliciguat produced dose-related increases in plasma cGMP consistent with stimulation of sGC.  Repeated once-daily dosing showed sustained decreases in BP.  Results support evaluation of praliciguat for the treatment of conditions assocd. with deficient NO signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbtRhsglmF7bVg90H21EOLACvtfcHk0lg9957ztaDOSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSju7nL&md5=5d984c96d74d4ceda4da9c310a229d5f</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.627%26sid%3Dliteratum%253Aachs%26aulast%3DHanrahan%26aufirst%3DJ.%2BP.%26aulast%3DWakefield%26aufirst%3DJ.%2BD.%26aulast%3DWilson%26aufirst%3DP.%2BJ.%26aulast%3DMihova%26aufirst%3DM.%26aulast%3DChickering%26aufirst%3DJ.%2BG.%26aulast%3DRuff%26aufirst%3DD.%26aulast%3DHall%26aufirst%3DM.%26aulast%3DMilne%26aufirst%3DG.%2BT.%26aulast%3DCurrie%26aufirst%3DM.%2BG.%26aulast%3DProfy%26aufirst%3DA.%2BT.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520multiple-ascending-dose%2520study%2520to%2520assess%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520praliciguat%2520in%2520healthy%2520subjects%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2019%26volume%3D8%26spage%3D564%26epage%3D575%26doi%3D10.1002%2Fcpdd.627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buys, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chickering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Profy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadcock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masferrer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential</span>. <i>Nitric Oxide</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.niox.2018.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.niox.2018.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29859918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyqurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=72-80&author=E.+S.+Buysauthor=D.+P.+Zimmerauthor=J.+Chickeringauthor=R.+Graulauthor=Y.+T.+Chienauthor=A.+Profyauthor=J.+R.+Hadcockauthor=J.+L.+Masferrerauthor=T.+Milne&title=Discovery+and+development+of+next+generation+sGC+stimulators+with+diverse+multidimensional+pharmacology+and+broad+therapeutic+potential&doi=10.1016%2Fj.niox.2018.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential</span></div><div class="casAuthors">Buys, E. S.; Zimmer, D. P.; Chickering, J.; Graul, R.; Chien, Y. T.; Profy, A.; Hadcock, J. R.; Masferrer, J. L.; Milne, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">Nitric Oxide</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-80</span>CODEN:
                <span class="NLM_cas:coden">NIOXF5</span>;
        ISSN:<span class="NLM_cas:issn">1089-8603</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO)-sensitive sol. guanylyl cyclase (sGC), an enzyme that catalyzes the conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophophate (cGMP), transduces many of the physiol. effects of the gasotransmitter NO.  Upon binding of NO to the prosthetic heme group of sGC, a conformational change occurs, resulting in enzymic activation and increased prodn. of cGMP. cGMP modulates several downstream cellular and physiol. responses, including but not limited to vasodilation.  Impairment of this signaling system and altered NO-cGMP homeostasis have been implicated in cardiovascular, pulmonary, renal, gastrointestinal, central nervous system, and hepatic pathologies. sGC stimulators, small mol. drugs that synergistically increase sGC enzyme activity with NO, have shown great potential to treat a variety of diseases via modulation of NO-sGC-cGMP signaling.  Here, we give an overview of novel, orally available sGC stimulators that Ironwood Pharmaceuticals is developing.  We outline the non-clin. and clin. studies, highlighting pharmacol. and pharmacokinetic (PK) profiles, including pharmacodynamic (PD) effects, and efficacy in a variety of disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjoqbbNZMdOLVg90H21EOLACvtfcHk0lj7JlgevKMPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyqurrF&md5=3eebb2810112cb030d53625d0f33ac42</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.niox.2018.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.niox.2018.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DBuys%26aufirst%3DE.%2BS.%26aulast%3DZimmer%26aufirst%3DD.%2BP.%26aulast%3DChickering%26aufirst%3DJ.%26aulast%3DGraul%26aufirst%3DR.%26aulast%3DChien%26aufirst%3DY.%2BT.%26aulast%3DProfy%26aufirst%3DA.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DMasferrer%26aufirst%3DJ.%2BL.%26aulast%3DMilne%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520development%2520of%2520next%2520generation%2520sGC%2520stimulators%2520with%2520diverse%2520multidimensional%2520pharmacology%2520and%2520broad%2520therapeutic%2520potential%26jtitle%3DNitric%2520Oxide%26date%3D2018%26volume%3D78%26spage%3D72%26epage%3D80%26doi%3D10.1016%2Fj.niox.2018.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00114-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2FS0092-8674%2800%2900114-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0lj7JlgevKMPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225%26doi%3D10.1016%2FS0092-8674%2800%2900114-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fartoukh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duroux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emilie, D.</span></span> <span> </span><span class="NLM_article-title">Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">559</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=9596101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK1c3lsFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=554-559&author=M.+Humbertauthor=G.+Montiauthor=M.+Fartoukhauthor=A.+Magnanauthor=F.+Brenotauthor=B.+Rainauthor=F.+Capronauthor=P.+Galanaudauthor=P.+Durouxauthor=G.+Simonneauauthor=D.+Emilie&title=Platelet-derived+growth+factor+expression+in+primary+pulmonary+hypertension%3A+comparison+of+HIV+seropositive+and+HIV+seronegative+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients</span></div><div class="casAuthors">Humbert M; Monti G; Fartoukh M; Magnan A; Brenot F; Rain B; Capron F; Galanaud P; Duroux P; Simonneau G; Emilie D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">554-9</span>
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    </div><div class="casAbstract">Primary pulmonary hypertension (PPH) is characterized by intimal fibrosis and cell proliferation (including fibroblasts, smooth muscle and endothelial cells) in the distal pulmonary arterial tree.  Considerable interest has been generated by recent reports of PPH in human immunodeficiency virus (HIV)-1-infected individuals.  Although the lack of evidence for a pulmonary artery infection has suggested that in such cases HIV may act through mediator release rather than by direct endothelial infection, the mechanisms underlying HIV-associated PPH remain poorly defined.  Platelet-derived growth factor (PDGF) has the ability to induce smooth muscle cell and fibroblast proliferation and migration.  Given these considerations, we have attempted to document a possible role for PDGF in PPH occurring in HIV seropositive and seronegative patients.  Using semiquantitative polymerase chain reaction (PCR), PDGF A-chain messenger ribonucleic acid (mRNA) expression was analysed in surgical lung biopsies from 13 HIV seronegative patients and one HIV seropositive patient, all displaying severe PPH.  In parallel, lung samples from two patients with HIV-1-associated PPH were studied by immunohistochemistry and in situ hybridization.  Results were compared to those obtained in three HIV-1-infected individuals with no pulmonary complication (as demonstrated by clinical, radiological, bacteriological, and necropsy findings) and five control lung biopsies.  As compared to controls, PDGF A-chain mRNA expression is elevated in lung biopsies from patients displaying PPH (p=0.029).  In HIV-1-associated PPH, interstitial perivascular cells expressing PDGF A-chain mRNA and protein could be detected by in situ hybridization and immunohistochemistry, respectively.  Platelet-derived growth factor expression is elevated in lung biopsies of patients displaying primary pulmonary hypertension.  Growth factors such as platelet-derived growth factor may play a part in the initiation and/or progression of primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiQHPFYGCsehdUSIfHIn4FfW6udTcc2ebNQjC_4bP06bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3lsFGnsg%253D%253D&md5=5ebf91f1c357b582fa71199365b90544</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DMonti%26aufirst%3DG.%26aulast%3DFartoukh%26aufirst%3DM.%26aulast%3DMagnan%26aufirst%3DA.%26aulast%3DBrenot%26aufirst%3DF.%26aulast%3DRain%26aufirst%3DB.%26aulast%3DCapron%26aufirst%3DF.%26aulast%3DGalanaud%26aufirst%3DP.%26aulast%3DDuroux%26aufirst%3DP.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DEmilie%26aufirst%3DD.%26atitle%3DPlatelet-derived%2520growth%2520factor%2520expression%2520in%2520primary%2520pulmonary%2520hypertension%253A%2520comparison%2520of%2520HIV%2520seropositive%2520and%2520HIV%2520seronegative%2520patients%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D1998%26volume%3D11%26spage%3D554%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramaniam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cras, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abman, S. H.</span></span> <span> </span><span class="NLM_article-title">Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus</span>. <i>Am. J. Physiol.-Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">L826</span>– <span class="NLM_lpage">L833</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00199.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1152%2Fajplung.00199.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12533438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=L826-L833&author=V.+Balasubramaniamauthor=T.+D.+Le+Crasauthor=D.+D.+Ivyauthor=T.+R.+Groverauthor=J.+P.+Kinsellaauthor=S.+H.+Abman&title=Role+of+platelet-derived+growth+factor+in+vascular+remodeling+during+pulmonary+hypertension+in+the+ovine+fetus&doi=10.1152%2Fajplung.00199.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus</span></div><div class="casAuthors">Balasubramaniam, Vivek; Le Cras, Timothy D.; Ivy, D. Dunbar; Grover, Theresa R.; Kinsella, John P.; Abman, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">5, Pt. 1</span>),
    <span class="NLM_cas:pages">L826-L833</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Platelet-derived growth factor (PDGF) is a potent smooth muscle cell mitogen that may contribute to smooth muscle hyperplasia during the development of chronic pulmonary hypertension (PH).  The authors studied changes in PDGFα- and β-receptor and ligand expression in lambs with chronic intrauterine PH induced by partial ligation of the ductus arteriosus (DA) at gestational age 124-128 days (term = 147 days).  Western blot anal. performed on whole lung homogenates from PH animals after 8 days of DA ligation showed a twofold increase in PDGFα- and β-receptor proteins compared with age-matched controls.  Lung PDGF-A and -B mRNA expression did not differ between PH and control animals.  The authors treated PH animals with NX1975, an aptamer that selectively inhibits PDGF-B, by infusion into the left pulmonary artery for 7 days after DA ligation.  NX1975 reduced the development of muscular thickening of small pulmonary arteries by 47% and right ventricular hypertrophy (RVH) by 66%.  Lung PDGFα- and β-receptor expression is increased in perinatal PH, and NX1975 reduces the increase in wall thickness of small pulmonary arteries and RVH in this model.  The authors speculate that PDGF signaling contributes to structural vascular remodeling in perinatal PH and that selective PDGF inhibition may provide a novel therapeutic strategy for the treatment of chronic PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmHQJEH3HWebVg90H21EOLACvtfcHk0lj7JlgevKMPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvFKjs7g%253D&md5=3c0c2ea001c5be85fe942c74d3245994</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00199.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00199.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramaniam%26aufirst%3DV.%26aulast%3DLe%2BCras%26aufirst%3DT.%2BD.%26aulast%3DIvy%26aufirst%3DD.%2BD.%26aulast%3DGrover%26aufirst%3DT.%2BR.%26aulast%3DKinsella%26aufirst%3DJ.%2BP.%26aulast%3DAbman%26aufirst%3DS.%2BH.%26atitle%3DRole%2520of%2520platelet-derived%2520growth%2520factor%2520in%2520vascular%2520remodeling%2520during%2520pulmonary%2520hypertension%2520in%2520the%2520ovine%2520fetus%26jtitle%3DAm.%2520J.%2520Physiol.-Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2003%26volume%3D284%26spage%3DL826%26epage%3DL833%26doi%3D10.1152%2Fajplung.00199.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dony, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydykov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span> <span> </span><span class="NLM_article-title">Reversal of experimental pulmonary hypertension by PDGF inhibition</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2821</span>, <span class="refDoi"> DOI: 10.1172/JCI24838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI24838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16200212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2811-2821&author=R.+T.+Schermulyauthor=E.+Donyauthor=H.+A.+Ghofraniauthor=S.+Pullamsettiauthor=R.+Savaiauthor=M.+Rothauthor=A.+Sydykovauthor=Y.+J.+Laiauthor=N.+Weissmannauthor=W.+Seegerauthor=F.+Grimminger&title=Reversal+of+experimental+pulmonary+hypertension+by+PDGF+inhibition&doi=10.1172%2FJCI24838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of experimental pulmonary hypertension by PDGF inhibition</span></div><div class="casAuthors">Schermuly, Ralph Theo; Dony, Eva; Ghofrani, Hossein Ardeschir; Pullamsetti, Soni; Savai, Rajkumar; Roth, Markus; Sydykov, Akylbek; Lai, Ying Ju; Weissmann, Norbert; Seeger, Werner; Grimminger, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2811-2821</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Progression of pulmonary hypertension is assocd. with increased proliferation and migration of pulmonary vascular smooth muscle cells.  PDGF is a potent mitogen and involved in this process.  We now report that the PDGF receptor antagonist STI571 (imatinib) reversed advanced pulmonary vascular disease in 2 animal models of pulmonary hypertension.  In rats with monocrotaline-induced pulmonary hypertension, therapy with daily administration of STI571 was started 28 days after induction of the disease.  A 2-wk treatment resulted in 100% survival, compared with only 50% in sham-treated rats.  The changes in RV pressure, measured continuously by telemetry, and right heart hypertrophy were reversed to near-normal levels.  STI571 prevented phosphorylation of the PDGF receptor and suppressed activation of downstream signaling pathways.  Similar results were obtained in chronically hypoxic mice, which were treated with STI571 after full establishment of pulmonary hypertension.  Moreover, expression of the PDGF receptor was significantly increased in lung tissue from pulmonary arterial hypertension patients compared with healthy donor lung tissue.  We conclude that STI571 reverses vascular remodeling and cor pulmonale in severe exptl. pulmonary hypertension regardless of the initiating stimulus.  This regimen offers a unique novel approach for antiremodeling therapy in progressed pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou65hFsYybr7Vg90H21EOLACvtfcHk0lgbnrxApB5fLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7bN&md5=467e940da906ab3fed2802b68e135c03</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1172%2FJCI24838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24838%26sid%3Dliteratum%253Aachs%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DDony%26aufirst%3DE.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DPullamsetti%26aufirst%3DS.%26aulast%3DSavai%26aufirst%3DR.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DSydykov%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BJ.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DReversal%2520of%2520experimental%2520pulmonary%2520hypertension%2520by%2520PDGF%2520inhibition%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2811%26epage%3D2821%26doi%3D10.1172%2FJCI24838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambaryan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambrecht, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Launay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Kaminsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span> <span> </span><span class="NLM_article-title">C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1164/rccm.201006-0905OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201006-0905OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21471108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnmt1ymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2011&pages=116-123&author=D.+Montaniauthor=F.+Perrosauthor=N.+Gambaryanauthor=B.+Girerdauthor=P.+Dorfmullerauthor=L.+C.+Priceauthor=A.+Huertasauthor=H.+Hammadauthor=B.+N.+Lambrechtauthor=G.+Simonneauauthor=J.+M.+Launayauthor=S.+Cohen-Kaminskyauthor=M.+Humbert&title=C-kit-positive+cells+accumulate+in+remodeled+vessels+of+idiopathic+pulmonary+arterial+hypertension&doi=10.1164%2Frccm.201006-0905OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension</span></div><div class="casAuthors">Montani David; Perros Frederic; Gambaryan Natalia; Girerd Barbara; Dorfmuller Peter; Price Laura C; Huertas Alice; Hammad Hamida; Lambrecht Bart; Simonneau Gerald; Launay Jean-Marie; Cohen-Kaminsky Sylvia; Humbert Marc</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  C-kit(+) cells, including bone marrow (BM)-derived progenitors and mast cells, may participate in vascular remodelling.  Because recent studies suggest that c-kit may be a target for innovative therapies in experimental pulmonary hypertension, we investigated the contribution of c-kit(+) cells in human idiopathic pulmonary arterial hypertension (IPAH).  OBJECTIVES:  To investigate the contribution of c-kit(+) cells in human IPAH.  METHODS:  Single c-kit, CXCL12/SDF-1α, CXCR4, CD34, and multiple c-kit, α-smooth muscle actin (α-SMA) and tryptase immunostainings were performed in IPAH lungs.  C-kit mRNA expression was quantified by real-time polymerase chain reaction in microdissected pulmonary arteries from patients with IPAH and control subjects.  Phenotype and function of circulating progenitors were analyzed by flow cytometry.  Plasma levels of soluble c-kit and CXCL12/SDF-1α were measured by ELISA.  MEASUREMENTS AND MAIN RESULTS:  Infiltration of c-kit(+) cells in pulmonary arterial lesions was associated with an increase in c-kit mRNA expression (P < 0.01 compared with control subjects).  Both c-kit(+)/tryptase(+) mast cells and c-kit(+)/tryptase(-) BM-derived cells were increased in pulmonary arteries of patients with IPAH compared with control subjects (106.6 ± 54.5 vs. 28 ± 16.8/mm(2) and 143.8 ± 101.1 vs. 23.3 ± 11.9/mm(2); all P<0.01).  Plasma-soluble c-kit was increased in IPAH compared with control subjects (27.4 ± 12.4 vs. 19.5 ± 5.8 ng/ml; P<0.05).  Two populations of circulating BM-derived cells (lin-CD34(high)CD133(high) [c-kit(high)CXCR4(low)] and lin-CD34(low)CD133(-) [c-kit(low)CXCR4(high)]) were increased in IPAH compared with control subjects (P=0.01).  Pulmonary arterial lesions were associated with vasa vasorum expansion expressing CXL12/SDF-1α that may recruit c-kit(+) cells.  CONCLUSIONS:  In IPAH, c-kit(+) cells infiltrate pulmonary arterial lesions and may participate to vascular remodeling.  Therefore, c-kit may represent a potential target for innovative PAH therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT47ixLTvkYifIW7hznt0zpfW6udTcc2eb9slCHbABARbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnmt1ymtw%253D%253D&md5=dac39aaf375a4707395ba94b699e432c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1164%2Frccm.201006-0905OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201006-0905OC%26sid%3Dliteratum%253Aachs%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DGambaryan%26aufirst%3DN.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DPrice%26aufirst%3DL.%2BC.%26aulast%3DHuertas%26aufirst%3DA.%26aulast%3DHammad%26aufirst%3DH.%26aulast%3DLambrecht%26aufirst%3DB.%2BN.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DLaunay%26aufirst%3DJ.%2BM.%26aulast%3DCohen-Kaminsky%26aufirst%3DS.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DC-kit-positive%2520cells%2520accumulate%2520in%2520remodeled%2520vessels%2520of%2520idiopathic%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D184%26spage%3D116%26epage%3D123%26doi%3D10.1164%2Frccm.201006-0905OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourge, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Sanchez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassoun, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span> <span> </span><span class="NLM_article-title">Imatinib mesylate as add-on therapy for pulmonary arterial hypertension results of the randomized IMPRES study</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1138</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.112.000765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.112.000765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23403476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFersbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2013&pages=1128-1138&author=M.+M.+Hoeperauthor=R.+J.+Barstauthor=R.+C.+Bourgeauthor=J.+Feldmanauthor=A.+E.+Frostauthor=N.+Galieauthor=M.+A.+Gomez-Sanchezauthor=F.+Grimmingerauthor=E.+Grunigauthor=P.+M.+Hassounauthor=N.+W.+Morrellauthor=A.+J.+Peacockauthor=T.+Satohauthor=G.+Simonneauauthor=V.+F.+Tapsonauthor=F.+Torresauthor=D.+Lawrenceauthor=D.+A.+Quinnauthor=H.+A.+Ghofrani&title=Imatinib+mesylate+as+add-on+therapy+for+pulmonary+arterial+hypertension+results+of+the+randomized+IMPRES+study&doi=10.1161%2FCIRCULATIONAHA.112.000765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study</span></div><div class="casAuthors">Hoeper, Marius M.; Barst, Robyn J.; Bourge, Robert C.; Feldman, Jeremy; Frost, Adaani E.; Galie, Nazzareno; Gomez-Sanchez, Miguel Angel; Grimminger, Friedrich; Gruenig, Ekkehard; Hassoun, Paul M.; Morrell, Nicholas W.; Peacock, Andrew J.; Satoh, Toru; Simonneau, Gerald; Tapson, Victor F.; Torres, Fernando; Lawrence, David; Quinn, Deborah A.; Ghofrani, Hossein-Ardeschir</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1128-1138</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH).  METHODS AND RESULTS: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-wk trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm symptomatic on ≥2 PAH therapies.  The primary outcome was change in 6-min walk distance.  Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clin. worsening.  After completion of the core study, patients could enter an open-label long-term extension study.  Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies.  After 24 wk, the mean placebo-cor. treatment effect on 6-min walk distance was 32 m (95% confidence interval, 12-52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib.  Pulmonary vascular resistance decreased by 379 dyne·s·cm (95% confidence interval, -502 to - 255; P<0.001, between-group difference).  Functional class, time to clin. worsening, and mortality did not differ between treatments.  Serious adverse events and discontinuations were more frequent with imatinib than placebo (44% vs. 30% and 33% vs. 18%, resp.).  Subdural hematoma occurred in 8 patients (2 in the core study, 6 in the extension) receiving imatinib and anticoagulation.  CONCLUSIONS: Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH, but serious adverse events and study drug discontinuations were common.  Further studies are needed to investigate the long-term safety and efficacy of imatinib in patients with PAH.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT00902174 (core study); NCT01392495 (extension).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSK-dic_4oALVg90H21EOLACvtfcHk0ljfYQqGYxs0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFersbo%253D&md5=1e5af4253848beee8181e4489c1cc8c0</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.000765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.000765%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DBourge%26aufirst%3DR.%2BC.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGomez-Sanchez%26aufirst%3DM.%2BA.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DHassoun%26aufirst%3DP.%2BM.%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DQuinn%26aufirst%3DD.%2BA.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26atitle%3DImatinib%2520mesylate%2520as%2520add-on%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%2520results%2520of%2520the%2520randomized%2520IMPRES%2520study%26jtitle%3DCirculation%26date%3D2013%26volume%3D127%26spage%3D1128%26epage%3D1138%26doi%3D10.1161%2FCIRCULATIONAHA.112.000765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juengel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriegsmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distler, J. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distler, O.</span></span> <span> </span><span class="NLM_article-title">Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1382</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2011-200940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1136%2Fannrheumdis-2011-200940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22523431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ont73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2012&pages=1382-1387&author=B.+Maurerauthor=N.+Reichauthor=A.+Juengelauthor=J.+Kriegsmannauthor=R.+E.+Gayauthor=G.+Schettauthor=B.+A.+Michelauthor=S.+Gayauthor=J.+H.+W.+Distlerauthor=O.+Distler&title=Fra-2+transgenic+mice+as+a+novel+model+of+pulmonary+hypertension+associated+with+systemic+sclerosis&doi=10.1136%2Fannrheumdis-2011-200940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis</span></div><div class="casAuthors">Maurer, Britta; Reich, Nicole; Juengel, Astrid; Kriegsmann, Joerg; Gay, Renate E.; Schett, Georg; Michel, Beat A.; Gay, Steffen; Distler, Joerg H. W.; Distler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1382-1387</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: Systemic sclerosis-assocd. pulmonary arterial hypertension differs from idiopathic pulmonary arterial hypertension with respect to histopathol., treatment responses and survival.  Medical progress on PAH is hampered by the lack of human biosamples and suitable animal models.  In this study, the authors evaluated fos-related antigen 2 (Fra-2) transgenic mice as a novel model for systemic sclerosis-assocd. pulmonary arterial hypertension.  Methods: Lung sections of Fra-2 transgenic (n=12) and wild-type mice (n=6) were analyzed at 16 wk by histol. using Dana Point criteria.  Cellular and mol. key players were assessed by immunohistochem.  To test the model's sensitivity to change over treatment, a subgroup of Fra-2 transgenic mice (n=6) was treated with the tyrosine kinase inhibitor nilotinib twice daily 37.5 mg orally from 8 wk of age.  Results: Fra-2 transgenic mice developed severe vascular remodelling of pulmonary arteries and nonspecific interstitial pneumonia-like interstitial lung disease resembling human systemic sclerosis-assocd. pulmonary hypertension.  Histol. features typical for systemic sclerosis-assocd. pulmonary arterial hypertension, such as intimal thickening with concentric laminar lesions, medial hypertrophy, perivascular inflammatory infiltrates, adventitial fibrosis, but not pulmonary occlusive venopathy were frequently detected.  Platelet-derived growth factor signalling pathways were activated in pulmonary vessels of Fra-2 transgenic compared with wild-type mice.  Since treatment with nilotinib strongly prevented the development of proliferative vasculopathy and lung fibrosis, the model proved to be sensitive to treatment.  Conclusions: This study suggests that Fra-2 transgenic mice as an animal model of systemic sclerosis-assocd. pulmonary arterial hypertension display main characteristic features of the human disease.  It therefore allows studying pathophysiol. aspects and might serve as a preclin. model for interventional proof-of-concept studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRM8WsXpuJW7Vg90H21EOLACvtfcHk0ljfYQqGYxs0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ont73E&md5=667e8d8cb815eac000650182cb39174b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2011-200940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2011-200940%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DReich%26aufirst%3DN.%26aulast%3DJuengel%26aufirst%3DA.%26aulast%3DKriegsmann%26aufirst%3DJ.%26aulast%3DGay%26aufirst%3DR.%2BE.%26aulast%3DSchett%26aufirst%3DG.%26aulast%3DMichel%26aufirst%3DB.%2BA.%26aulast%3DGay%26aufirst%3DS.%26aulast%3DDistler%26aufirst%3DJ.%2BH.%2BW.%26aulast%3DDistler%26aufirst%3DO.%26atitle%3DFra-2%2520transgenic%2520mice%2520as%2520a%2520novel%2520model%2520of%2520pulmonary%2520hypertension%2520associated%2520with%2520systemic%2520sclerosis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2012%26volume%3D71%26spage%3D1382%26epage%3D1387%26doi%3D10.1136%2Fannrheumdis-2011-200940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomberg-Maitland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coslet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrino, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Couture, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M. J.</span></span> <span> </span><span class="NLM_article-title">A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/clpt.2009.217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fclpt.2009.217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20010555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=303-310&author=M.+Gomberg-Maitlandauthor=M.+L.+Maitlandauthor=R.+J.+Barstauthor=L.+Sugengauthor=S.+Cosletauthor=T.+J.+Perrinoauthor=L.+Bondauthor=M.+E.+La+Coutureauthor=S.+L.+Archerauthor=M.+J.+Ratain&title=A+dosing%2Fcross-development+study+of+the+multikinase+inhibitor+sorafenib+in+patients+with+pulmonary+arterial+hypertension&doi=10.1038%2Fclpt.2009.217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Gomberg-Maitland, M.; Maitland, M. L.; Barst, R. J.; Sugeng, L.; Coslet, S.; Perrino, T. J.; Bond, L.; La Couture, M. E.; Archer, S. L.; Ratain, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-310</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) and cancer share elements of pathophysiol.  This provides an opportunity for the cross-development of anticancer agents that can be used in improving PAH care.  The adaptation of new drugs across these disease populations warrants a structured approach.  This study was a 16-wk, phase Ib, single-center, open-label trial of the multikinase/angiogenesis inhibitor sorafenib.  In order to assess the safety of sorafenib in PAH, patients with advanced but stable disease on parenteral prostanoids (with or without oral sildenafil) were initiated on treatment at the lowest active dosage administered to cancer patients: 200 mg daily.  Patients underwent weekly clin. evaluations and monthly functional testing and dose escalations to a final dosage of 400 mg twice daily.  Among 12 patients (10 of them women), sorafenib was well tolerated at 200 mg twice daily.  The most common adverse events were moderate skin reactions on the hands and feet and alopecia.  Our conclusion was therefore that this is a tolerable dosing regimen for testing the therapeutic activity of sorafenib in PAH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_iCSRXr2hLVg90H21EOLACvtfcHk0ljfYQqGYxs0sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbs%253D&md5=4640e523b547fd0502b0b16f8c1443ae</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.217%26sid%3Dliteratum%253Aachs%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DSugeng%26aufirst%3DL.%26aulast%3DCoslet%26aufirst%3DS.%26aulast%3DPerrino%26aufirst%3DT.%2BJ.%26aulast%3DBond%26aufirst%3DL.%26aulast%3DLa%2BCouture%26aufirst%3DM.%2BE.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26atitle%3DA%2520dosing%252Fcross-development%2520study%2520of%2520the%2520multikinase%2520inhibitor%2520sorafenib%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2010%26volume%3D87%26spage%3D303%26epage%3D310%26doi%3D10.1038%2Fclpt.2009.217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kataoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span> <span> </span><span class="NLM_article-title">Sorafenib as a potential strategy for refractory pulmonary arterial hypertension</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.pupt.2017.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28315488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVWnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=46-49&author=G.+Kimuraauthor=M.+Kataokaauthor=T.+Inamiauthor=K.+Fukudaauthor=H.+Yoshinoauthor=T.+Satoh&title=Sorafenib+as+a+potential+strategy+for+refractory+pulmonary+arterial+hypertension&doi=10.1016%2Fj.pupt.2017.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib as a potential strategy for refractory pulmonary arterial hypertension</span></div><div class="casAuthors">Kimura, Gou; Kataoka, Masaharu; Inami, Takumi; Fukuda, Keiichi; Yoshino, Hideaki; Satoh, Toru</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-49</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases.  We investigated the efficacy and safety of sorafenib for the treatment of patients with refractory pulmonary arterial hypertension (PAH).  Sorafenib was started in 9 patients (7 with idiopathic PAH, 2 with pulmonary veno-occlusive disease) who had severe PAH and right heart failure, in spite of treatment with vasodilators specific for PAH.  Sorafenib was started as an add-on therapy at a dose of 50 or 100 mg/day, and increased to 100-400 mg/day.  New York Heart Assocn. functional class improved in 8 patients and did not change in 1.  Mean pulmonary arterial pressure improved in 6 patients (14-28% decrease) and did not apparently change in 2 (follow-up catheterization was not performed in 1 patient).  The main adverse effects of sorafenib were skin reactions on the hands and feet, which appeared in 5 patients.  They were tolerable in 4 patients, but discontinuation of sorafenib was needed in only 1 patient.  In conclusion, sorafenib had favorable effects to improve symptoms and objective variables in patients with refractory PAH, with tolerable adverse events.  Sorafenib is an alternative strategy for patients with refractory PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTx8ugetoGdbVg90H21EOLACvtfcHk0lgntCHZ_cW7jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVWnt7o%253D&md5=a1bad595da6f14ee2ec3cd096c2740da</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DG.%26aulast%3DKataoka%26aufirst%3DM.%26aulast%3DInami%26aufirst%3DT.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DSatoh%26aufirst%3DT.%26atitle%3DSorafenib%2520as%2520a%2520potential%2520strategy%2520for%2520refractory%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D44%26spage%3D46%26epage%3D49%26doi%3D10.1016%2Fj.pupt.2017.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvaist, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canuet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poubeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natali, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jais, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Bitter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension in patients treated by dasatinib</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2128</span>– <span class="NLM_lpage">2137</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.079921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.111.079921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22451584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVegt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2128-2137&author=D.+Montaniauthor=E.+Bergotauthor=S.+Guntherauthor=L.+Savaleauthor=A.+Bergeronauthor=A.+Bourdinauthor=H.+Bouvaistauthor=M.+Canuetauthor=C.+Pisonauthor=M.+Macroauthor=P.+Poubeauauthor=B.+Girerdauthor=D.+Nataliauthor=C.+Guignabertauthor=F.+Perrosauthor=D.+S.+O%E2%80%99Callaghanauthor=X.+Jaisauthor=P.+Tubert-Bitterauthor=G.+Zalcmanauthor=O.+Sitbonauthor=G.+Simonneauauthor=M.+Humbert&title=Pulmonary+arterial+hypertension+in+patients+treated+by+dasatinib&doi=10.1161%2FCIRCULATIONAHA.111.079921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary Arterial Hypertension in Patients Treated by Dasatinib</span></div><div class="casAuthors">Montani, David; Bergot, Emmanuel; Guenther, Sven; Savale, Laurent; Bergeron, Anne; Bourdin, Arnaud; Bouvaist, Helene; Canuet, Matthieu; Pison, Christophe; Macro, Margareth; Poubeau, Patrice; Girerd, Barbara; Natali, Delphine; Guignabert, Christophe; Perros, Frederic; O'Callaghan, Dermot S.; Jais, Xavier; Tubert-Bitter, Pascale; Zalcman, Gerard; Sitbon, Olivier; Simonneau, Gerald; Humbert, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2128-2137</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: The French pulmonary hypertension (PH) registry allows the survey of epidemiol. trends.  Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib.  METHODS AND RESULTS-: This study was designed to describe incident cases of dasatinib-assocd. PH reported in the French PH registry.  From the approval of dasatinib (Nov. 2006) to Sept. 30, 2010, 9 incident cases treated by dasatinib at the time of PH diagnosis were identified.  At diagnosis, patients had moderate to severe precapillary PH with functional and hemodynamic impairment.  No other incident PH cases were exposed to other tyrosine kinase inhibitors at the time of PH diagnosis.  Clin., functional, or hemodynamic improvements were obsd. within 4 mo of dasatinib discontinuation in all but 1 patient.  Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1).  After a median follow-up of 9 mo (min-max 3-36), the majority of patients did not demonstrate complete clin. and hemodynamic recovery, and no patients reached a normal value of mean pulmonary artery pressure (≤20 mm Hg).  Two patients (22%) died at follow-up (1 of unexplained sudden death and 1 of cardiac failure in the context of septicemia, resp., 8 and 12 mo after dasatinib withdrawal).  The lowest est. of incident PH occurring in patients exposed to dasatinib in France was 0.45%.  CONCLUSIONS-: Dasatinib may induce severe precapillary PH fulfilling the criteria of pulmonary arterial hypertension, thus suggesting a direct and specific effect of dasatinib on pulmonary vessels.  Improvement is usually obsd. after withdrawal of dasatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOqwHaw1Dx_bVg90H21EOLACvtfcHk0lgntCHZ_cW7jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVegt7Y%253D&md5=057e7a4655f81f3ffea08b1bac332335</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.079921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.079921%26sid%3Dliteratum%253Aachs%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DBergot%26aufirst%3DE.%26aulast%3DGunther%26aufirst%3DS.%26aulast%3DSavale%26aufirst%3DL.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DBourdin%26aufirst%3DA.%26aulast%3DBouvaist%26aufirst%3DH.%26aulast%3DCanuet%26aufirst%3DM.%26aulast%3DPison%26aufirst%3DC.%26aulast%3DMacro%26aufirst%3DM.%26aulast%3DPoubeau%26aufirst%3DP.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DNatali%26aufirst%3DD.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DD.%2BS.%26aulast%3DJais%26aufirst%3DX.%26aulast%3DTubert-Bitter%26aufirst%3DP.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520in%2520patients%2520treated%2520by%2520dasatinib%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D2128%26epage%3D2137%26doi%3D10.1161%2FCIRCULATIONAHA.111.079921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Etienne-Manneville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span> <span> </span><span class="NLM_article-title">Rho GTPases in cell biology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1038/nature01148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnature01148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12478284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVSitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2002&pages=629-635&author=S.+Etienne-Mannevilleauthor=A.+Hall&title=Rho+GTPases+in+cell+biology&doi=10.1038%2Fnature01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Rho GTPases in cell biology</span></div><div class="casAuthors">Etienne-Manneville, Sandrine; Hall, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue">6916</span>),
    <span class="NLM_cas:pages">629-635</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rho GTPases are mol. switches that control a wide variety of signal transduction pathways in all eukaryotic cells.  They are known principally for their pivotal role in regulating the actin cytoskeleton, but their ability to influence cell polarity, microtubule dynamics, membrane transport pathways, and transcription factor activity is probably just as significant.  Underlying this biol. complexity is a simple biochem. idea, namely that by switching on a single GTPase, several distinct signaling pathways can be coordinately activated.  With spatial and temporal activation of multiple switches factored in, it is not surprising to find Rho GTPases having such a prominent role in eukaryotic cell biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo36ZCRk0eAD7Vg90H21EOLACvtfcHk0lgntCHZ_cW7jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVSitbw%253D&md5=87bec1cb1868fd1c13682c8e94260ee1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnature01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01148%26sid%3Dliteratum%253Aachs%26aulast%3DEtienne-Manneville%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DA.%26atitle%3DRho%2520GTPases%2520in%2520cell%2520biology%26jtitle%3DNature%26date%3D2002%26volume%3D420%26spage%3D629%26epage%3D635%26doi%3D10.1038%2Fnature01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do E, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1731</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-09-0135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1253%2Fcircj.CJ-09-0135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19590140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1MrnslyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=1731-1739&author=Z.+Do+Eauthor=Y.+Fukumotoauthor=A.+Takakiauthor=S.+Tawaraauthor=J.+Ohashiauthor=M.+Nakanoauthor=T.+Tadaauthor=K.+Sajiauthor=K.+Sugimuraauthor=H.+Fujitaauthor=Y.+Hoshikawaauthor=J.+Nawataauthor=T.+Kondoauthor=H.+Shimokawa&title=Evidence+for+Rho-kinase+activation+in+patients+with+pulmonary+arterial+hypertension&doi=10.1253%2Fcircj.CJ-09-0135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">Do e Zhulanqiqige; Fukumoto Yoshihiro; Takaki Aya; Tawara Shunsuke; Ohashi Junko; Nakano Makoto; Tada Tomohiro; Saji Kenya; Sugimura Kohichiro; Fujita Hiroshi; Hoshikawa Yasushi; Nawata Jun; Kondo Takashi; Shimokawa Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation journal : official journal of the Japanese Circulation Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1731-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Direct evidence for Rho-kinase activation in patients with pulmonary hypertension (PH) is still lacking.  METHODS AND RESULTS:  Rho-kinase activity in circulating neutrophils was examined by determining the ratio of phosphorylated/total forms of myosin-binding subunit, a substrate of Rho-kinase, in 40 consecutive PH patients and 40 healthy controls.  Next, Rho-kinase expression and activity was examined in isolated human lung tissues (5 patients with idiopathic pulmonary arterial hypertension [IPAH], 5 controls) and vascular reactivity of isolated small human pulmonary arteries in vitro (4 IPAH, 4 controls).  Rho-kinase activity in circulating neutrophils was significantly increased in the PH patients overall compared with controls (P<0.0001).  Significant correlations were noted between Rho-kinase activity and the severity and duration of PAH (all P<0.05).  Rho-kinase expression and activity in isolated lung tissues also were significantly increased in the IPAH patients compared with the controls (both P<0.0001).  Endothelium-dependent relaxation was markedly impaired and serotonin-induced contraction (in the absence of the endothelium) markedly enhanced in the PAH patients compared with the controls, and the hypercontraction to serotonin was abolished by hydroxyfasudil, a specific Rho-kinase inhibitor.  CONCLUSIONS:  These results provide the first direct evidence for Rho-kinase activation in patients with PAH, suggesting the therapeutic importance of Rho-kinase in the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4QU0u6YEfW8kU0YCbOU3EfW6udTcc2ea0wTadJh6C87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrnslyisQ%253D%253D&md5=cf309c992e0595588917041d836dfe2a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-09-0135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-09-0135%26sid%3Dliteratum%253Aachs%26aulast%3DDo%2BE%26aufirst%3DZ.%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DTakaki%26aufirst%3DA.%26aulast%3DTawara%26aufirst%3DS.%26aulast%3DOhashi%26aufirst%3DJ.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DT.%26aulast%3DSaji%26aufirst%3DK.%26aulast%3DSugimura%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DHoshikawa%26aufirst%3DY.%26aulast%3DNawata%26aufirst%3DJ.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DEvidence%2520for%2520Rho-kinase%2520activation%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirc.%2520J.%26date%3D2009%26volume%3D73%26spage%3D1731%26epage%3D1739%26doi%3D10.1253%2Fcircj.CJ-09-0135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mouchaers, K. T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalij, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postmus, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hinsbergh, V. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nieuw Amerongen, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laarse, W. J.</span></span> <span> </span><span class="NLM_article-title">Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1183/09031936.00130209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00130209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20351034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFSrtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=800-807&author=K.+T.+B.+Mouchaersauthor=I.+Schalijauthor=M.+A.+de+Boerauthor=P.+E.+Postmusauthor=V.+W.+M.+van+Hinsberghauthor=G.+P.+van+Nieuw+Amerongenauthor=A.+Vonk+Noordegraafauthor=W.+J.+van+der+Laarse&title=Fasudil+reduces+monocrotaline-induced+pulmonary+arterial+hypertension%3A+comparison+with+bosentan+and+sildenafil&doi=10.1183%2F09031936.00130209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil</span></div><div class="casAuthors">Mouchaers, K. T. B.; Schalij, I.; de Boer, M. A.; Postmus, P. E.; van Hinsbergh, V. W. M.; van Nieuw Amerongen, G. P.; Noordegraaf, A. Vonk; van der Laarse, W. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">800-807</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) still cannot be cured, warranting the search for novel treatments.  Fasudil (a Rho kinase inhibitor) was compared with bosentan (an endothelin receptor blocker) and sildenafil (a phosphodiesterase 5 inhibitor), with emphasis on right ventricular (RV) function, in a reversal rat model of monocrotaline (MCT)-induced PAH.  In addn., the effects of combining bosentan or sildenafil with fasudil were studied.  MCT (40 mg/kg body wt.-1) induced clear PAH in male Wistar rats (n = 9).  After 28 days, echocardiog., RV catheterization and histochem. showed that cardiac frequency, stroke vol. and RV contractility had deteriorated, accompanied by RV dilatation and hypertrophy, and marked pulmonary arterial wall thickening.  Mean pulmonary arterial pressure and pulmonary vascular resistance increased significantly compared to healthy rats (n = 9).  After 14 days, MCT-treated rats received a 14-day oral treatment with bosentan, sildenfil, fasudil or a combination of fasudil with either bosentan or sildenfil (all n = 9).  All treatments preserved cardiac frequency, stroke vol. and RV contractility, and reduced pulmonary vascular resistance and RV dilatation.  Fasudil lowered RV systolic pressure and mean pulmonary arterial pressure significantly, by reducing pulmonary arterial remodelling, which reduced RV hypertrophy.  Combining bosentan or sildenafil with fasudil had no synergistic effect.  Fasudil significantly improved PAH, to a greater degree than did bosentan and sildenafil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSaD9G1pFEz7Vg90H21EOLACvtfcHk0lgixXCoGI3FJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFSrtL7E&md5=ee112a35549c6f53fe46f157a02e85a4</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1183%2F09031936.00130209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00130209%26sid%3Dliteratum%253Aachs%26aulast%3DMouchaers%26aufirst%3DK.%2BT.%2BB.%26aulast%3DSchalij%26aufirst%3DI.%26aulast%3Dde%2BBoer%26aufirst%3DM.%2BA.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3Dvan%2BHinsbergh%26aufirst%3DV.%2BW.%2BM.%26aulast%3Dvan%2BNieuw%2BAmerongen%26aufirst%3DG.%2BP.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BLaarse%26aufirst%3DW.%2BJ.%26atitle%3DFasudil%2520reduces%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%253A%2520comparison%2520with%2520bosentan%2520and%2520sildenafil%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D36%26spage%3D800%26epage%3D807%26doi%3D10.1183%2F09031936.00130209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osanai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension - a pilot efficacy trial</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2619</span>– <span class="NLM_lpage">2625</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-13-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1253%2Fcircj.CJ-13-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23912836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2013&pages=2619-2625&author=Y.+Fukumotoauthor=N.+Yamadaauthor=H.+Matsubaraauthor=M.+Mizoguchiauthor=K.+Uchinoauthor=A.+Yaoauthor=Y.+Kiharaauthor=M.+Kawanoauthor=H.+Watanabeauthor=Y.+Takedaauthor=T.+Adachiauthor=S.+Osanaiauthor=N.+Tanabeauthor=T.+Inoueauthor=A.+Kuboauthor=Y.+Otaauthor=K.+Fukudaauthor=T.+Nakanoauthor=H.+Shimokawa&title=Double-blind%2C+placebo-controlled+clinical+trial+with+a+Rho-kinase+inhibitor+in+pulmonary+arterial+hypertension+-+a+pilot+efficacy+trial&doi=10.1253%2Fcircj.CJ-13-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension - a pilot efficacy trial -</span></div><div class="casAuthors">Fukumoto, Yoshihiro; Yamada, Norikazu; Matsubara, Hiromi; Mizoguchi, Minori; Uchino, Kazuaki; Yao, Atsushi; Kihara, Yasuki; Kawano, Mitsuhiro; Watanabe, Hiroshi; Takeda, Yutaka; Adachi, Takeshi; Osanai, Shinobu; Tanabe, Nobuhiro; Inoue, Teruo; Kubo, Akihiro; Ota, Yuri; Fukuda, Koichiro; Nakano, Takeshi; Shimokawa, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2619-2625</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">Background: We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models.  In the present study, we examd. the clin. effects of mid-term oral treatment with an extended release formulation of AT-877 (fasudil hydrochloride), a specific Rho-kinase inhibitor (AT-877ER) on PAH.  Methods and Results: 23 PAH patients were treated with either placebo (10/2 females/males, 51±16 years, idiopathic PAH (IPAH) in 6, PAH assocd. with connective tissue disease (CTD-PAH) in 3, PAH with congenital heart disease (CHD-PAH) in 2, and portal PAH in 1) or AT-877ER (6/5 females/males, 47±14 years, IPAH in 2, CTD-PAH in 5, and CHD-PAH in 4); 3 patients were excluded.  We performed a 6-min walk test and right heart catheterization in the remaining 20 patients, before and 3 mo after the treatment (placebo n=11, AT-877ER n=9).  Although there were no significant differences between the 2 groups for the 6-min walk distance, pulmonary hemodynamics tended to be improved in the AT-877ER group, esp. the prevalence of improved cardiac index from baseline, which was significantly higher in the AT-877ER than in the placebo group.  In the AT-877ER group, serum levels of hydroxyfasudil, an active metabolite of AT-877ER tended to correlate with improvements in the cardiac index and mean pulmonary artery pressure.  Conclusions: Mid-term treatment with oral AT-877ER showed addnl. improvement in pulmonary hemodynamics in patients with PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof001r8Pp19rVg90H21EOLACvtfcHk0lgixXCoGI3FJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I&md5=1f9a29ee6f6b0a9d40c80c883811f109</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-13-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-13-0443%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DMatsubara%26aufirst%3DH.%26aulast%3DMizoguchi%26aufirst%3DM.%26aulast%3DUchino%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DA.%26aulast%3DKihara%26aufirst%3DY.%26aulast%3DKawano%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DOsanai%26aufirst%3DS.%26aulast%3DTanabe%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DA.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DDouble-blind%252C%2520placebo-controlled%2520clinical%2520trial%2520with%2520a%2520Rho-kinase%2520inhibitor%2520in%2520pulmonary%2520arterial%2520hypertension%2520-%2520a%2520pilot%2520efficacy%2520trial%26jtitle%3DCirc.%2520J.%26date%3D2013%26volume%3D77%26spage%3D2619%26epage%3D2625%26doi%3D10.1253%2Fcircj.CJ-13-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demachi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension</span>. <i>Heart Vessels</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1007/s00380-009-1176-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1007%2Fs00380-009-1176-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20339976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3c3hsVGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2010&pages=144-149&author=H.+Fujitaauthor=Y.+Fukumotoauthor=K.+Sajiauthor=K.+Sugimuraauthor=J.+Demachiauthor=J.+Nawataauthor=H.+Shimokawa&title=Acute+vasodilator+effects+of+inhaled+fasudil%2C+a+specific+Rho-kinase+inhibitor%2C+in+patients+with+pulmonary+arterial+hypertension&doi=10.1007%2Fs00380-009-1176-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">Fujita Hiroshi; Fukumoto Yoshihiro; Saji Kenya; Sugimura Koichiro; Demachi Jun; Nawata Jun; Shimokawa Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Heart and vessels</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models.  In the present study, we examined acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, as a more feasible option to locally deliver the drug for PAH.  We examined 15 patients with PAH (13 women and 2 men, 45 +/- 4 years old), including idiopathic PAH (n = 5), PAH associated with connective tissue disease (n = 6), PAH with congenital heart disease (n = 3), and portal PAH (n = 1).  In those patients, we performed right heart catheterization with a Swan-Ganz catheter in the two protocols with inhalation of nitric oxide (NO) (40 ppm, 10 min) and fasudil (30 mg, 10 min) with a sufficient interval (>30 min).  Both NO and fasudil inhalation significantly reduced mean pulmonary arterial pressure (PAP) (NO: P < 0.01, fasudil: P < 0.05) and tended to decrease pulmonary vascular resistance (NO: P = 0.07, fasudil: P = 0.1), but did not affect cardiac index.  The ratio of pulmonary to systemic vascular resistance was significantly reduced both in NO and fasudil inhalation (NO: P < 0.01, fasudil: P < 0.05), indicating that both NO and fasudil inhalation selectively affect lung tissues.  Interestingly, there was no correlation in the vasodilator effects between NO and fasudil, and a positive correlation with serum levels of high-sensitivity C-reactive protein was noted for fasudil but not for NO.  These results suggest that inhalation of fasudil is as effective as NO in patients with PAH, possibly through different mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOIq-UL4l5qkbxh97K6Vt6fW6udTcc2eaZyyNa2OJPD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3hsVGkuw%253D%253D&md5=d915eaa82bda541ef775f2d3f3fb376b</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs00380-009-1176-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00380-009-1176-8%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DSaji%26aufirst%3DK.%26aulast%3DSugimura%26aufirst%3DK.%26aulast%3DDemachi%26aufirst%3DJ.%26aulast%3DNawata%26aufirst%3DJ.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DAcute%2520vasodilator%2520effects%2520of%2520inhaled%2520fasudil%252C%2520a%2520specific%2520Rho-kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DHeart%2520Vessels%26date%3D2010%26volume%3D25%26spage%3D144%26epage%3D149%26doi%3D10.1007%2Fs00380-009-1176-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morigi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leoni, A.</span></span> <span> </span><span class="NLM_article-title">Small-molecules targeting kinases involved in pulmonary hypertension: A patent review (2010–2015)</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3510</span>– <span class="NLM_lpage">3527</span>, <span class="refDoi"> DOI: 10.2174/0929867323666160809093451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F0929867323666160809093451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27516199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=3510-3527&author=R.+Morigiauthor=M.+Rambaldiauthor=A.+Locatelliauthor=A.+Leoni&title=Small-molecules+targeting+kinases+involved+in+pulmonary+hypertension%3A+A+patent+review+%282010%E2%80%932015%29&doi=10.2174%2F0929867323666160809093451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)</span></div><div class="casAuthors">Morigi, Rita; Rambaldi, Mirella; Locatelli, Alessandra; Leoni, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3510-3527</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Despite the fact that in recent years, a substantial progress has been made in the treatment of pulmonary hypertension, it is still a severe disease characterized by poor prognosis, and the search for new drugs remains a priority.  Current remedies address mainly the vasoconstrictor/ vasodilator imbalance in the pulmonary circulation, while the causes of the disease are only moderately affected.  Recently, the role of receptor and non receptor kinases in pulmonary hypertension has emerged and these targets were extensively considered for the development of new therapeutic strategies.  This review discusses the patents on small-mols. targeting kinases involved in the proliferation/apoptosis imbalance, typically present in pulmonary hypertension.  Methods: Bibliog. research for the inventions was carried out using Espacenet and Sci-Finder databases, "pulmonary hypertension and kinases" as research query and the range from 2010 to 2015.  Only patents published in English were considered.  A qual. anal. of the contents of each patent was made to examine the reported compds., the studies performed and the resulting conclusions.  Results: The review includes about thirty applications.  Moreover, in order to illustrate the pathophisiol. of the disease and the mechanisms of the targets, about forty addnl. papers were reported.  Considering that imatinib, a PDGF receptor inhibitor, entered the clin. trials for the treatment of pulmonary hypertension, the first patents were devoted to inhibitors of tyrosine kinase receptors, such as PDGFR and c-Kit.  Subsequently, in addn. to kinase receptors, the role of other pathways involved in pulmonary hypertension has emerged, and some research groups have focused their attention also on non-receptor kinases.  Fifteen patents on this topic reported these new targets and new derivs.  However, in most of the inventions, although the pulmonary hypertension is among the treatable diseases, the compds. were subjected only to antiproliferative assays and not to specific tests on animal models.  Conclusion: The studies reported in this review confirm the continuous research efforts aimed to identify new targets and new drugs for the treatment of pulmonary hypertension.  Several inhibitors of kinase were described.  These compds. could inhibit mainly important branching processes and pathol. growth of blood vessels, thereby might increase the lifespan of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XuriOHsVrLVg90H21EOLACvtfcHk0li0gtGN2QzTZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksb%252FN&md5=1678d159e602c532561ddc57f0ebea9d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160809093451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160809093451%26sid%3Dliteratum%253Aachs%26aulast%3DMorigi%26aufirst%3DR.%26aulast%3DRambaldi%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DA.%26aulast%3DLeoni%26aufirst%3DA.%26atitle%3DSmall-molecules%2520targeting%2520kinases%2520involved%2520in%2520pulmonary%2520hypertension%253A%2520A%2520patent%2520review%2520%25282010%25E2%2580%25932015%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D3510%26epage%3D3527%26doi%3D10.2174%2F0929867323666160809093451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. R.</span></span> <span> </span><span class="NLM_article-title">Molecular, pharmacological and functional diversity of 5-HT receptors</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1016/S0091-3057(01)00746-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0091-3057%2801%2900746-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11888546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVChtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=533-554&author=D.+Hoyerauthor=J.+P.+Hannonauthor=G.+R.+Martin&title=Molecular%2C+pharmacological+and+functional+diversity+of+5-HT+receptors&doi=10.1016%2FS0091-3057%2801%2900746-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular, pharmacological and functional diversity of 5-HT receptors</span></div><div class="casAuthors">Hoyer, Daniel; Hannon, Jason P.; Martin, Graeme R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-554</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-hydroxytryptamine, 5-HT) is probably unique among the monoamines in that its effects are subserved by as many as 13 distinct heptahelical, G-protein-coupled receptors (GPCRs) and one (presumably a family of) ligand-gated ion channel(s).  These receptors are divided into seven distinct classes (5-HT1 to 5-HT7) largely on the basis of their structural and operational characteristics.  While this degree of phys. diversity clearly underscores the physiol. importance of serotonin, evidence for an even greater degree of operational diversity continues to emerge.  The challenge for modern 5-HT research has therefore been to define more precisely the properties of the systems that make this incredible diversity possible.  Much progress in this regard has been made during the last decade with the realization that serotonin is possibly the least conservative monoamine transmitter and the cloning of its many receptors.  Coupled with the actions of an extremely avid and efficient reuptake system, this array of receptor subtypes provides almost limitless signaling capabilities to the extent that one might even question the need for other transmitter systems.  However, the complexity of the system appears endless, since posttranslational modifications, such as alternate splicing and RNA editing, increase the no. of proteins, oligomerization and heteromerization increase the no. of complexes, and multiple G-protein suggest receptor trafficking, allowing phenotypic switching and crosstalk within and possibly between receptor families.  Whether all these possibilities are used in vivo under physiol. or pathol. conditions remains to be firmly established, but in essence, such variety will keep the 5-HT community busy for quite some time.  Those who may have predicted that mol. biol. would largely simplify the life of pharmacologists have missed the point for 5-HT research in particular and, most probably, for many other transmitters.  This chapter is an attempt to summarize very briefly 5-HT receptor diversity.  The reward for unraveling this complex array of serotonin receptor-effector systems may be substantial, the ultimate prize being the development of important new drugs in a range of disease areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Nndw8IzJXLVg90H21EOLACvtfcHk0li0gtGN2QzTZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVChtb4%253D&md5=2fd7e3ea62256c616688b45794a7606a</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2801%2900746-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252801%252900746-8%26sid%3Dliteratum%253Aachs%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DHannon%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26atitle%3DMolecular%252C%2520pharmacological%2520and%2520functional%2520diversity%2520of%25205-HT%2520receptors%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D71%26spage%3D533%26epage%3D554%26doi%3D10.1016%2FS0091-3057%2801%2900746-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaumann, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, F. O.</span></span> <span> </span><span class="NLM_article-title">5-Hydroxytryptamine receptors in the human cardiovascular system</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.pharmthera.2005.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16960982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1Sks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2006&pages=674-706&author=A.+J.+Kaumannauthor=F.+O.+Levy&title=5-Hydroxytryptamine+receptors+in+the+human+cardiovascular+system&doi=10.1016%2Fj.pharmthera.2005.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">5-Hydroxytryptamine receptors in the human cardiovascular system</span></div><div class="casAuthors">Kaumann, Alberto J.; Levy, Finn Olav</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">674-706</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The human cardiovascular system is exposed to plasma 5-hydroxytryptamine (5-HT, serotonin), usually released from platelets. 5-HT can produce harmful acute and chronic effects.  The acute cardiac effects of 5-HT consist of tachycardia (preceded on occasion by a brief reflex bradycardia), increased atrial contractility and prodn. of atrial arrhythmias.  Acute inotropic, lusitropic and arrhythmic effects of 5-HT on human ventricle become conspicuous after inhibition of phosphodiesterase (PDE) activity.  Human cardiostimulation is mediated through 5-HT4 receptors.  Atrial and ventricular PDE3 activity exerts a protective role against potentially harmful cardiostimulation.  Chronic exposure to high levels of 5-HT (from metastatic carcinoid tumors), the anorectic drug fenfluramine and its metabolites, as well as the ecstasy drug 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA) are assocd. with proliferative disease and thickening of cardiac valves, mediated through 5-HT2B receptors.  5-HT2B receptors have an obligatory physiol. role in murine cardiac embryol. but whether this happens in humans requires research.  Congenital heart block (CHB) is, on occasion, assocd. with autoantibodies against 5-HT4 receptors.  Acute vascular constriction by 5-HT is usually shared by 5-HT1B and 5-HT2A receptors, except in intracranial arteries which constrict only through 5-HT1B receptors.  Both 5-HT1B and 5-HT2A receptors can mediate coronary artery spasm but only 5-HT1B receptors appear involved in coronary spasm of patients treated with triptans or with Prinzmetal angina.  5-HT2A receptors constrict the portal venous system including esophageal collaterals in cirrhosis.  Chronic exposure to 5-HT can contribute to pulmonary hypertension through activation of constrictor 5-HT1B receptors and proliferative 5-HT2B receptors, and possibly through direct intracellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Baa4LbQgzrVg90H21EOLACvtfcHk0ljwCWFJKnTUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1Sks70%253D&md5=ab1b7eaba55907f7e88bba89257b0908</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DKaumann%26aufirst%3DA.%2BJ.%26aulast%3DLevy%26aufirst%3DF.%2BO.%26atitle%3D5-Hydroxytryptamine%2520receptors%2520in%2520the%2520human%2520cardiovascular%2520system%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D111%26spage%3D674%26epage%3D706%26doi%3D10.1016%2Fj.pharmthera.2005.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillis, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, A. G. B.</span></span> <span> </span><span class="NLM_article-title">5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone</span>. <i>Pulm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1006/pulp.1994.1007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1006%2Fpulp.1994.1007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7516208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK2cXitlKrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1994&pages=65-72&author=M.+R.+MacLeanauthor=R.+A.+Claytonauthor=S.+W.+Hillisauthor=P.+D.+McIntyreauthor=A.+J.+Peacockauthor=A.+G.+B.+Templeton&title=5-HT1-receptor-mediated+vasoconstriction+in+bovine+isolated+pulmonary+arteries%3A+influences+of+vascular+endothelium+and+tone&doi=10.1006%2Fpulp.1994.1007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone</span></div><div class="casAuthors">MacLean, M. R.; Clayton, R. A.; Hillis, S. W.; McIntyre, P. D.; Peacock, A. J.; Templeton, A. G. B.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">PUPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0952-0600</span>.
    </div><div class="casAbstract">Vasoconstrictor responses to 5-hydroxytryptamine (5-HT) and the 5-HT1D receptor agonist sumatriptan were studied in isolated bovine pulmonary artery rings.  The effects of the antagonists, ketanserin (5-HT2A-receptors) and methiothepin (5-HT1- and 5-HT2A-receptors) on these responses were detd.  The influences of vascular tone and the effect of removal of the vascular endothelium and pretreatment with the inhibitor of nitric oxide synthase, Nω-nitro-L-arginine methylester, were also studied.  In the absence of tone, in majority of vessels, sumatriptan did not induce significant contractions.  5-HT-induced responses were concn.-dependent and ketanserin and methiothepin antagonized these in a competitive fashion.  Removal of the endothelium or inclusion of L-NAME potentiated responses to sumatriptan.  The sensitivity to sumatriptan was increased by L-NAME only in the presence of the endothelium while max. responses to sumatriptan were potentiated in both unrubbed and rubbed vessels.  Removal of the endothelium and/or inclusion of L-NAME had no significant effect on responses to 5-HT.  U46619-induced tone markedly increased sumatriptan-induced responses which were competitively antagonized by methiothepin but were relatively resistant to ketanserin, verifying activation of a 5-HT1D receptor.  Responses to 5-HT were also potentiated and competitively antagonized by ketanserin, and further antagonized by methiothepin.  With tone present, lower concns. of 5-HT were ketanserin-resistant and methiothepin-sensitive, indicating activation of a 5-HT1-like receptor.  The results indicate that, in bovine pulmonary arteries, in the absence of vascular tone, 5-HT mediates vasoconstriction via 5-HT2A receptors while with tone present, a 5-HT1D-like response to both 5-HT and sumatriptan is obsd.  The sumatriptan-induced response in potentiated by L-NAME and endothelium removal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWDuR9CUYeKLVg90H21EOLACvtfcHk0ljwCWFJKnTUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlKrtbc%253D&md5=4acaaa8e9e401c48b4678c3b0914267f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1006%2Fpulp.1994.1007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fpulp.1994.1007%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DClayton%26aufirst%3DR.%2BA.%26aulast%3DHillis%26aufirst%3DS.%2BW.%26aulast%3DMcIntyre%26aufirst%3DP.%2BD.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DTempleton%26aufirst%3DA.%2BG.%2BB.%26atitle%3D5-HT1-receptor-mediated%2520vasoconstriction%2520in%2520bovine%2520isolated%2520pulmonary%2520arteries%253A%2520influences%2520of%2520vascular%2520endothelium%2520and%2520tone%26jtitle%3DPulm.%2520Pharmacol.%26date%3D1994%26volume%3D7%26spage%3D65%26epage%3D72%26doi%3D10.1006%2Fpulp.1994.1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?</span>. <i>J. Lab. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/S0022-2143(99)90114-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0022-2143%2899%2990114-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10444023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXlsFegtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=1999&pages=105-114&author=M.+R.+MacLean&title=Endothelin-1+and+serotonin%3A+mediators+of+primary+and+secondary+pulmonary+hypertension%3F&doi=10.1016%2FS0022-2143%2899%2990114-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?</span></div><div class="casAuthors">MacLean, Margaret R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Laboratory and Clinical Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-114</span>CODEN:
                <span class="NLM_cas:coden">JLCMAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2143</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">A review with 133 refs.  Pulmonary hypertension (PHT) is a disease involving vasoconstriction and proliferation of the vascular smooth muscle.  ET-1 and serotonin are potent vasoconstrictors of the pulmonary arterial circulation and mitogens of pulmonary vascular smooth muscle cells.  Plasma levels of both serotonin and ET-1 are elevated in both primary and secondary PHT.  Hence they may contribute both to pulmonary vascular remodeling and the increased pulmonary vascular tone evident in PHT.  The influence of both mediators on the pulmonary vasculature and their putative roles in PHT is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogEGGVluxdeLVg90H21EOLACvtfcHk0ljwCWFJKnTUJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsFegtL0%253D&md5=b544eaa565ad39e68c24ccb27617e7e2</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2FS0022-2143%2899%2990114-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2143%252899%252990114-2%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DEndothelin-1%2520and%2520serotonin%253A%2520mediators%2520of%2520primary%2520and%2520secondary%2520pulmonary%2520hypertension%253F%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1999%26volume%3D134%26spage%3D105%26epage%3D114%26doi%3D10.1016%2FS0022-2143%2899%2990114-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porvasnik, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gannon, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shacham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mousily, F.</span></span> <span> </span><span class="NLM_article-title">PRX-08066, a novel 5-hydroxytryptamine receptor 2b antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.165001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.109.165001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20430844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KisLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=364-372&author=S.+L.+Porvasnikauthor=S.+Germainauthor=J.+Emburyauthor=K.+S.+Gannonauthor=V.+Jacquesauthor=J.+Murrayauthor=B.+J.+Byrneauthor=S.+Shachamauthor=F.+Al-Mousily&title=PRX-08066%2C+a+novel+5-hydroxytryptamine+receptor+2b+antagonist%2C+reduces+monocrotaline-induced+pulmonary+arterial+hypertension+and+right+ventricular+hypertrophy+in+rats&doi=10.1124%2Fjpet.109.165001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats</span></div><div class="casAuthors">Porvasnik, Stacy L.; Germain, Sean; Embury, Jennifer; Gannon, Kimberley S.; Jacques, Vincent; Murray, Justin; Byrne, Barry J.; Shacham, Sharon; Al-Mousily, Faris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-372</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a life-threatening disease that results in right ventricular failure.  5-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumarate (PRX-08066) is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist that causes selective vasodilation of pulmonary arteries.  In the current study, the effects of PRX-08066 were assessed by using the monocrotaline (MCT)-induced PAH rat model.  Male rats received 40 mg/kg MCT or phosphate-buffered saline and were treated orally twice a day with vehicle or 50 or 100 mg/kg PRX-08066 for 5 wk.  Pulmonary and cardiac functions were evaluated by hemodynamics, heart wt., magnetic resonance imaging (MRI), pulmonary artery (PA) morphol., and histol.  Cardiac MRI demonstrated that PRX-08066 (100 mg/kg) significantly (P < 0.05) improved right ventricular ejection fraction.  PRX-08066 significantly reduced peak PA pressure at 50 and 100 mg/kg (P < 0.05 and < 0.01, resp.) compared with MCT control animals.  PRX-08066 therapy also significantly reduced right ventricle (RV)/body wt. and RV/left ventricle + septum (P < 0.01 and < 0.001, resp.) compared with MCT-treated animals.  Morphometric assessment of pulmonary arterioles revealed a significant redn. in medial wall thickening and lumen occlusion assocd. with both doses of PRX-08066 (P < 0.01).  The 5-HT2BR antagonist PRX-08066 significantly attenuated the elevation in PA pressure and RV hypertrophy and maintained cardiac function.  Pulmonary vascular remodeling was also diminished compared with MCT control rats.  PRX-08066 prevents the severity of PAH in the MCT rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CaIqQmpIS7Vg90H21EOLACvtfcHk0lgGNLr_cZnPkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KisLbJ&md5=c00235e9c830eb3a3937fa3696dac88b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.165001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.165001%26sid%3Dliteratum%253Aachs%26aulast%3DPorvasnik%26aufirst%3DS.%2BL.%26aulast%3DGermain%26aufirst%3DS.%26aulast%3DEmbury%26aufirst%3DJ.%26aulast%3DGannon%26aufirst%3DK.%2BS.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DByrne%26aufirst%3DB.%2BJ.%26aulast%3DShacham%26aufirst%3DS.%26aulast%3DAl-Mousily%26aufirst%3DF.%26atitle%3DPRX-08066%252C%2520a%2520novel%25205-hydroxytryptamine%2520receptor%25202b%2520antagonist%252C%2520reduces%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520and%2520right%2520ventricular%2520hypertrophy%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D364%26epage%3D372%26doi%3D10.1124%2Fjpet.109.165001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumitrascu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulcke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konigshoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickelberg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S. S.</span></span> <span> </span><span class="NLM_article-title">Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1118</span>, <span class="refDoi"> DOI: 10.1183/09031936.00126010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00126010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20947677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFyrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=1104-1118&author=R.+Dumitrascuauthor=C.+Kulckeauthor=M.+Konigshoffauthor=F.+Kouriauthor=X.+Yangauthor=N.+Morrellauthor=H.+A.+Ghofraniauthor=N.+Weissmannauthor=R.+Reiterauthor=W.+Seegerauthor=F.+Grimmingerauthor=O.+Eickelbergauthor=R.+T.+Schermulyauthor=S.+S.+Pullamsetti&title=Terguride+ameliorates+monocrotaline-induced+pulmonary+hypertension+in+rats&doi=10.1183%2F09031936.00126010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats</span></div><div class="casAuthors">Dumitrascu, R.; Kulcke, C.; Koenigshoff, M.; Kouri, F.; Yang, X.; Morrell, N.; Ghofrani, H. A.; Weissmann, N.; Reiter, R.; Seeger, W.; Grimminger, F.; Eickelberg, O.; Schermuly, R. T.; Pullamsetti, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1104-1118</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a life-threatening disease characterised by vasoconstriction and remodelling of the pulmonary vasculature.  The serotonin (5-hydroxytryptamine (5-HT)) pathway has been shown to play a major role in the pathogenesis of PAH, but pharmacol. modulation of this pathway for treatment of PAH is, to date, at a pre-clin. level.  Terguride is a 5-HT receptor (5-HTR) antagonist that is well tolerated and clin. approved for ovulation disorders.  Immunohistochem. against 5-HTR2A/B on human lungs revealed their localisation to the vascular smooth muscle layer and quant. RT-PCR showed 5-HTR2B upregulation in pulmonary artery smooth muscle cells (PASMC) isolated from PAH patients.  Proliferation and migration of cultured primary human PASMC were dose-dependently blocked by terguride.  Therapeutic 5-HT signalling inhibition was 1) demonstrated in isolated, ventilated and perfused rat lungs and 2) by chronic terguride treatment of rats with monocrotaline (MCT)-induced pulmonary hypertension in a preventive or curative approach.  Terguride inhibited proliferation of PASMCs and abolished 5-HT-induced pulmonary vasoconstriction.  Chronic terguride treatment prevented dose-dependently the development and progression of MCT-induced PAH in rats.  Thus, terguride represents a valuable novel therapeutic approach in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsGNpNHdRcQLVg90H21EOLACvtfcHk0lgGNLr_cZnPkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFyrsLw%253D&md5=ee0d0587c29d605847294b963e32e2ab</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1183%2F09031936.00126010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00126010%26sid%3Dliteratum%253Aachs%26aulast%3DDumitrascu%26aufirst%3DR.%26aulast%3DKulcke%26aufirst%3DC.%26aulast%3DKonigshoff%26aufirst%3DM.%26aulast%3DKouri%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMorrell%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DReiter%26aufirst%3DR.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26atitle%3DTerguride%2520ameliorates%2520monocrotaline-induced%2520pulmonary%2520hypertension%2520in%2520rats%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D37%26spage%3D1104%26epage%3D1118%26doi%3D10.1183%2F09031936.00126010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schymura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novoyatleva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojonazarov, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wietelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luitel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krompiec, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span> <span> </span><span class="NLM_article-title">5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">438403</span>, <span class="refDoi"> DOI: 10.1155/2015/438403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1155%2F2015%2F438403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25667920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2MrktlChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=438403&author=W.+Janssenauthor=Y.+Schymuraauthor=T.+Novoyatlevaauthor=B.+Kojonazarovauthor=M.+Boehmauthor=A.+Wietelmannauthor=H.+Luitelauthor=K.+Murmannauthor=D.+R.+Krompiecauthor=A.+Tretynauthor=S.+S.+Pullamsettiauthor=N.+Weissmannauthor=W.+Seegerauthor=H.+A.+Ghofraniauthor=R.+T.+Schermuly&title=5-HT2B+receptor+antagonists+inhibit+fibrosis+and+protect+from+RV+heart+failure&doi=10.1155%2F2015%2F438403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure</span></div><div class="casAuthors">Janssen Wiebke; Novoyatleva Tatyana; Kojonazarov Baktybek; Boehm Mario; Luitel Himal; Murmann Kirsten; Krompiec Damian Richard; Weissmann Norbert; Ghofrani Hossein Ardeschir; Schermuly Ralph Theo; Schymura Yves; Wietelmann Astrid; Tretyn Aleksandra; Pullamsetti Soni Savai; Seeger Werner</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">438403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The serotonin (5-HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricular failure (RVF) remain poorly understood.  The aim of the current study was to investigate the effects of Terguride (5-HT2A and 2B receptor antagonist) or SB204741 (5-HT2B receptor antagonist) on right heart function and structure upon pulmonary artery banding (PAB) in mice.  METHODS:  Seven days after PAB, mice were treated for 14 days with Terguride (0.2 mg/kg bid) or SB204741 (5 mg/kg day).  Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods.  Total secreted collagen content was determined in mouse cardiac fibroblasts isolated from RV tissues.  RESULTS:  Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB.  Moreover, 5-HT2B receptor antagonists diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro.  CONCLUSION:  5-HT2B receptor antagonists reduce collagen deposition, thereby inhibiting right ventricular fibrosis.  Chronic treatment prevented the development and progression of pressure overload-induced RVF in mice.  Thus, 5-HT2B receptor antagonists represent a valuable novel therapeutic approach for RVF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFnL20FdRuuBpyrDyM_m9cfW6udTcc2eYhet7mploosrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrktlChtg%253D%253D&md5=9bccc5e39722aa7085103a62031abaa1</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1155%2F2015%2F438403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F438403%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DW.%26aulast%3DSchymura%26aufirst%3DY.%26aulast%3DNovoyatleva%26aufirst%3DT.%26aulast%3DKojonazarov%26aufirst%3DB.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DWietelmann%26aufirst%3DA.%26aulast%3DLuitel%26aufirst%3DH.%26aulast%3DMurmann%26aufirst%3DK.%26aulast%3DKrompiec%26aufirst%3DD.%2BR.%26aulast%3DTretyn%26aufirst%3DA.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26atitle%3D5-HT2B%2520receptor%2520antagonists%2520inhibit%2520fibrosis%2520and%2520protect%2520from%2520RV%2520heart%2520failure%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D438403%26doi%3D10.1155%2F2015%2F438403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hiti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halank, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaehler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkranz, S.</span></span> <span> </span><span class="NLM_article-title">Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase iia study</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">A2496</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2012&pages=A2496&author=H.+A.+Ghofraniauthor=H.+Al-Hitiauthor=A.+Vonk-Noordegraafauthor=J.+Behrauthor=C.+Neurohrauthor=P.+Jansaauthor=H.+Wilkensauthor=M.+M.+Hoeperauthor=E.+Gruenigauthor=C.+Opitzauthor=R.+Speichauthor=R.+Ewertauthor=M.+Halankauthor=A.+Torbickiauthor=C.+Kaehlerauthor=H.+Olschewskiauthor=A.+Filuschauthor=R.+Reiterauthor=S.+Rosenkranz&title=Proof-of-concept+study+to+investigate+the+efficacy%2C+hemodynamics+and+tolerability+of+terguride+vs.+placebo+in+subjects+with+pulmonary+arterial+hypertension%3A+results+of+a+double+blind%2C+randomised%2C+prospective+phase+iia+study&doi=10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DAl-Hiti%26aufirst%3DH.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DNeurohr%26aufirst%3DC.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DWilkens%26aufirst%3DH.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DGruenig%26aufirst%3DE.%26aulast%3DOpitz%26aufirst%3DC.%26aulast%3DSpeich%26aufirst%3DR.%26aulast%3DEwert%26aufirst%3DR.%26aulast%3DHalank%26aufirst%3DM.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DKaehler%26aufirst%3DC.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DFilusch%26aufirst%3DA.%26aulast%3DReiter%26aufirst%3DR.%26aulast%3DRosenkranz%26aufirst%3DS.%26atitle%3DProof-of-concept%2520study%2520to%2520investigate%2520the%2520efficacy%252C%2520hemodynamics%2520and%2520tolerability%2520of%2520terguride%2520vs.%2520placebo%2520in%2520subjects%2520with%2520pulmonary%2520arterial%2520hypertension%253A%2520results%2520of%2520a%2520double%2520blind%252C%2520randomised%252C%2520prospective%2520phase%2520iia%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D187%26spage%3DA2496%26doi%3D10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnichen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latte, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurad, B.</span></span> <span> </span><span class="NLM_article-title">Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: Absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis</span>. <i>Clin. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1097/00002826-200603000-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1097%2F00002826-200603000-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16614540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=80-86&author=C.+Hofmannauthor=U.+Pennerauthor=R.+Dorowauthor=H.+H.+Pertzauthor=S.+Jahnichenauthor=R.+Horowskiauthor=K.+P.+Latteauthor=D.+Pallaauthor=B.+Schurad&title=Lisuride%2C+a+dopamine+receptor+agonist+with+5-HT2B+receptor+antagonist+properties%3A+Absence+of+cardiac+valvulopathy+adverse+drug+reaction+reports+supports+the+concept+of+a+crucial+role+for+5-HT2B+receptor+agonism+in+cardiac+valvular+fibrosis&doi=10.1097%2F00002826-200603000-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis</span></div><div class="casAuthors">Hofmann, C.; Penner, U.; Dorow, R.; Pertz, H. H.; Jaehnichen, S.; Horowski, R.; Latte, K. P.; Palla, D.; Schurad, B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neuropharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-86</span>CODEN:
                <span class="NLM_cas:coden">CLNEDB</span>;
        ISSN:<span class="NLM_cas:issn">0362-5664</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Objectives: The high incidence of fibrotic cardiac valvulopathies reported in assocn. with the 8β-ergoline dopamine (DA) agonist, pergolide, and also case reports for cabergoline and bromocriptine have made it necessary to review the theor. basis and actual findings in the case of another DA agonist, the 8α-ergoline lisuride (used since the 1970s for migraine prophylaxis as well as since the 1980s for its prolactin-lowering and anti-Parkinson activity).  Methods: We have reviewed the pharmacol. of lisuride in relation to other DA agonists, and we have performed a throughout literature search as well as a search of our own and other adverse drug reaction databases for a possible relationship of lisuride with cardiac valvulopathy or for any reports of fibrosis in other locations.  Results: Our review of the pharmacol. and the literature strongly suggests that drug-induced cardiac valvulopathies are always related to a stimulatory drug effect on trophic 5-HT2B receptors.  As lisuride is devoid of such an effect, but on the contrary is an extremely potent 5-HT2B antagonist, an assocn. of lisuride therapy with cardiac valvulopathies seems to be highly unlikely.  In agreement with this hypothesis, not a single report of a cardiac valvulopathy assocd. with lisuride therapy has been identified in any database so far.Furthermore, against a background of an estd. 360,000 patient years, we have found only a very small no. of cases of any other form of fibrosis (1× retroperitoneal, 2× pleural, 2× pulmonary, 1× interstitial pulmonary changes), in part combined with other risk factors and confounding variables.  This closely matches 4 reports available from WHO (1× retroperitoneal, 3× pleural fibrosis).  In addn., only 5 other possibly related conditions (3× pleural effusion, 1× pleuritis, 1× pericarditis) were identified in the lisuride adverse drug reaction database of Schering, Berlin.  Conclusions: No link has been found between lisuride use and fibrotic cardiac valvulopathy, in agreement with the 5-HT2B receptor antagonist effect of this drug.  The very low incidence of spontaneous reports of any other fibrosis could be even compatible with an assocn. by chance in the population exposed to lisuride.  Although close monitoring for this kind of side effects is still to be recommended in the therapy with lisuride, our data do not support the concept of a class effect suggesting that all ergot-derived drugs and esp. DA receptor agonists with some chem. similarity to the ergot structure will cause or facilitate cardiac valvulopathies as obsd. with pergolide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO6Rsrw9jtzLVg90H21EOLACvtfcHk0lhGQ5on9E4Oow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsVersr4%253D&md5=a12de38613de4f88bf099762849ef0df</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1097%2F00002826-200603000-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002826-200603000-00005%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DC.%26aulast%3DPenner%26aufirst%3DU.%26aulast%3DDorow%26aufirst%3DR.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DJahnichen%26aufirst%3DS.%26aulast%3DHorowski%26aufirst%3DR.%26aulast%3DLatte%26aufirst%3DK.%2BP.%26aulast%3DPalla%26aufirst%3DD.%26aulast%3DSchurad%26aufirst%3DB.%26atitle%3DLisuride%252C%2520a%2520dopamine%2520receptor%2520agonist%2520with%25205-HT2B%2520receptor%2520antagonist%2520properties%253A%2520Absence%2520of%2520cardiac%2520valvulopathy%2520adverse%2520drug%2520reaction%2520reports%2520supports%2520the%2520concept%2520of%2520a%2520crucial%2520role%2520for%25205-HT2B%2520receptor%2520agonism%2520in%2520cardiac%2520valvular%2520fibrosis%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2006%26volume%3D29%26spage%3D80%26epage%3D86%26doi%3D10.1097%2F00002826-200603000-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herve, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span> <span> </span><span class="NLM_article-title">5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fsj.bjp.0703570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10991906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlGktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2000&pages=161-168&author=M.+R.+MacLeanauthor=P.+Herveauthor=S.+Eddahibiauthor=S.+Adnot&title=5-hydroxytryptamine+and+the+pulmonary+circulation%3A+receptors%2C+transporters+and+relevance+to+pulmonary+arterial+hypertension&doi=10.1038%2Fsj.bjp.0703570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">5-hydroxytryptamine and the pulmonary circulation: receptors, transporters, and relevance to pulmonary arterial hypertension</span></div><div class="casAuthors">MacLean, Margaret R.; Herve, Philippe; Eddahibi, Saadia; Adnot, Serge</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-168</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with few refs. is given on normal pulmonary circulation, the role of circulating 5-hydroxytryptamine (5-HT) in pulmonary arterial hypertension (PAH), 5-HT and pulmonary vascular remodeling, and 5-HT and pulmonary vasoconstriction.  Evidence suggests that there are crit. changes in platelet handling of 5-HT, and perhaps handling of platelets by the lung, combined with changes in the pulmonary vascular smooth muscle response to 5-HT, which can lead to PAH.  In primary PAH, 2ndary PAH, or after anorexigen intake, there may be deficiencies in 5-HT re-uptake into platelets which would lead to increased circulating or local 5-HT levels.  Where 5-HT release from platelets is stimulated or monoamine oxidase-B activity is compromised, this effect may be amplified.  Increased local levels of 5-HT, induced by platelet release or increased accumulation of platelets in the lung, would expose pulmonary vascular smooth muscle cells (SMCs) to elevated levels of 5-HT.  The effect of this would be to increase vascular pulmonary smooth muscle contraction and proliferation.  Contraction would result from increased stimulation of the 5-HT1B receptor, an effect which would be potentiated in PAH by increased vascular tone, increased Gq-/Gi-protein synergy, and decreased cyclic GMP levels.  Current evidence suggests that 5-HT-induced proliferation occurs primarily through 5-HT uptake by the 5-HT transporter (5-HTT).  In hypoxia, after anorexigen intake, and perhaps in genetically predisposed primary PAH patients and in 2ndary PAH, increased expression of 5-HTT may lead to further increases in the transport of 5-HT into the SMCs and increased proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzBoYsVVJ3xrVg90H21EOLACvtfcHk0lhGQ5on9E4Oow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlGktbo%253D&md5=d7e332a3868423f39714a405e021f2d1</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703570%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DHerve%26aufirst%3DP.%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DAdnot%26aufirst%3DS.%26atitle%3D5-hydroxytryptamine%2520and%2520the%2520pulmonary%2520circulation%253A%2520receptors%252C%2520transporters%2520and%2520relevance%2520to%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D131%26spage%3D161%26epage%3D168%26doi%3D10.1038%2Fsj.bjp.0703570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martres, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffestin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span> <span> </span><span class="NLM_article-title">Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells - relationship with the mitogenic action of serotonin</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1161/01.RES.84.3.329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.RES.84.3.329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10024307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXhsVaksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1999&pages=329-336&author=S.+Eddahibiauthor=V.+Fabreauthor=C.+Boniauthor=M.+P.+Martresauthor=B.+Raffestinauthor=M.+Hamonauthor=S.+Adnot&title=Induction+of+serotonin+transporter+by+hypoxia+in+pulmonary+vascular+smooth+muscle+cells+-+relationship+with+the+mitogenic+action+of+serotonin&doi=10.1161%2F01.RES.84.3.329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: Relationship with the mitogenic action of serotonin</span></div><div class="casAuthors">Eddahibi, S.; Fabre, V.; Boni, C.; Martres, M. P.; Raffestin, B.; Hamon, M.; Adnot, S.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The increased delivery of serotonin (5-hydroxytryptamine, 5-HT) to the lung aggravates the development of hypoxia-induced pulmonary hypertension in rats, possibly through stimulation of the proliferation of pulmonary artery smooth muscle cells (PA-SMCs).  In cultured rat PA-SMCs, 5-HT (10-8 to 10-6 M) induced DNA synthesis and potentiated the mitogenic effect of platelet-derived growth factor-BB (10 ng/mL).  This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10-6 M) and paroxetine (10-7 M), but it was unaltered by ketanserin (10-6 M), a 5-HT2A receptor antagonist.  In PA-SMCs exposed to hypoxia, the levels of 5-HTT mRNA (measured by competitive reverse transcriptase-polymerase chain reaction) increased by 240% within 2 h, followed by a 3-fold increase in the uptake of [3H]5-HT at 24 h.  Cotransfection of the cells with a construct of human 5-HTT promoter-luciferase gene reporter and of pCMV-β-galactosidase gene allowed the demonstration that exposure of cells to hypoxia produced a 5.5-fold increase in luciferase activity, with no change in β-galactosidase activity.  The increased expression of 5-HTT in hypoxic cells was assocd. with a greater mitogenic response to 5-HT (10-8 to 10-6 M) in the absence as well as in the presence of platelet-derived growth factor-BB.  5-HTT expression assessed by quant. reverse transcriptase-polymerase chain reaction and in situ hybridization in the lungs was found to predominate in the media of pulmonary artery, in which a marked increase was noted in rats that had been exposed to hypoxia for 15 days.  These data show that in vitro and in vivo exposure to hypoxia induces, via a transcriptional mechanism, 5-HTT expression in PA-SMCs, and that this effect contributes to the stimulatory action of 5-HT on PA-SMC proliferation.  In vivo expression of 5-HTT by PA-SMC may play a key role in serotonin-mediated pulmonary vascular remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpacqtF7lz_j7Vg90H21EOLACvtfcHk0ljhLdUTTANroQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsVaksb0%253D&md5=19a32c4f022c7bd14a8f9beeb2762934</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1161%2F01.RES.84.3.329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.84.3.329%26sid%3Dliteratum%253Aachs%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DFabre%26aufirst%3DV.%26aulast%3DBoni%26aufirst%3DC.%26aulast%3DMartres%26aufirst%3DM.%2BP.%26aulast%3DRaffestin%26aufirst%3DB.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdnot%26aufirst%3DS.%26atitle%3DInduction%2520of%2520serotonin%2520transporter%2520by%2520hypoxia%2520in%2520pulmonary%2520vascular%2520smooth%2520muscle%2520cells%2520-%2520relationship%2520with%2520the%2520mitogenic%2520action%2520of%2520serotonin%26jtitle%3DCirc.%2520Res.%26date%3D1999%26volume%3D84%26spage%3D329%26epage%3D336%26doi%3D10.1161%2F01.RES.84.3.329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuchar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morecroft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheward, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmar, A.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the 5-hydroxytryptamine transporter gene - effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2150</span>– <span class="NLM_lpage">2155</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000127375.56172.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.CIR.0000127375.56172.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15078799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=2150-2155&author=M.+R.+MacLeanauthor=G.+A.+Deucharauthor=M.+N.+Hicksauthor=I.+Morecroftauthor=S.+B.+Shenauthor=J.+Shewardauthor=J.+Colstonauthor=L.+Loughlinauthor=M.+Nilsenauthor=Y.+Dempsieauthor=A.+Harmar&title=Overexpression+of+the+5-hydroxytryptamine+transporter+gene+-+effect+on+pulmonary+hemodynamics+and+hypoxia-induced+pulmonary+hypertension&doi=10.1161%2F01.CIR.0000127375.56172.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the 5-hydroxytryptamine transporter gene. Effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension</span></div><div class="casAuthors">MacLean, Margaret R.; Deuchar, Graeme A.; Hicks, Martin N.; Morecroft, Ian; Shen, Sanbing; Sheward, John; Colston, Janet; Loughlin, Lynn; Nilsen, Margaret; Dempsie, Yvonne; Harmar, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2150-2155</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Increased serotonin (5-hydroxytryptamine, 5-HT) transporter activity has been obsd. in human familial pulmonary hypertension.  The authors investigated pulmonary hemodynamics and the development of hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in mice overexpressing the gene for the 5-HT transporter (5-HTT+ mice).  Right ventricular pressure was elevated 3-fold in normoxic 5-HTT+ mice compared with their wild-type controls.  Hypoxia-induced increases in right ventricular hypertrophy and pulmonary vascular remodeling were also potentiated in the 5-HTT+ mice.  5-HTT-like immunoreactivity, protein, and binding sites were markedly increased in the lungs from the 5-HTT+ mice.  Hypoxia, however, decreased 5-HT transporter immunoreactivity, mRNA transcription, protein, and binding sites in both wild-type and 5-HTT+ mice.  Thus, increased 5-HT transporter expression causes elevated right ventricular pressures, and this occurs before the onset of right ventricular hypertrophy or pulmonary arterial remodeling.  Hypoxia-induced remodeling is, however, increased in 5-HTT+ mice, whereas hypoxia inhibits 5-HTT expression.  This provides a unique model that demonstrates differential mechanisms for familial pulmonary arterial hypertension and pulmonary arterial hypertension with hypoxemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvHzyGg-PT_bVg90H21EOLACvtfcHk0ljhLdUTTANroQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVWqsr8%253D&md5=3919397704835d78387c5b0dea8169df</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000127375.56172.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000127375.56172.92%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DDeuchar%26aufirst%3DG.%2BA.%26aulast%3DHicks%26aufirst%3DM.%2BN.%26aulast%3DMorecroft%26aufirst%3DI.%26aulast%3DShen%26aufirst%3DS.%2BB.%26aulast%3DSheward%26aufirst%3DJ.%26aulast%3DColston%26aufirst%3DJ.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DDempsie%26aufirst%3DY.%26aulast%3DHarmar%26aufirst%3DA.%26atitle%3DOverexpression%2520of%2520the%25205-hydroxytryptamine%2520transporter%2520gene%2520-%2520effect%2520on%2520pulmonary%2520hemodynamics%2520and%2520hypoxia-induced%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2004%26volume%3D109%26spage%3D2150%26epage%3D2155%26doi%3D10.1161%2F01.CIR.0000127375.56172.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartevelle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span> <span> </span><span class="NLM_article-title">Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1263</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000126847.27660.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.RES.0000126847.27660.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15059929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ylurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2004&pages=1263-1270&author=E.+Marcosauthor=E.+Fadelauthor=O.+Sanchezauthor=M.+Humbertauthor=P.+Dartevelleauthor=G.+Simonneauauthor=M.+Hamonauthor=S.+Adnotauthor=S.+Eddahibi&title=Serotonin-induced+smooth+muscle+hyperplasia+in+various+forms+of+human+pulmonary+hypertension&doi=10.1161%2F01.RES.0000126847.27660.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension</span></div><div class="casAuthors">Marcos, Elisabeth; Fadel, Elie; Sanchez, Olivier; Humbert, Marc; Dartevelle, Philippe; Simonneau, Gerald; Hamon, Michel; Adnot, Serge; Eddahibi, Saadia</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1263-1270</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Hyperplasia of pulmonary artery smooth muscle cells (PA-SMCs) is a hallmark pathol. feature of pulmonary hypertension (PH).  Serotonin (5-HT) is involved in the hyperplasia through its interactions with specific receptors and internalization by a specific plasma membrane transporter.  We investigated the expression and role of the 5-HT transporter (5-HTT) and 5-HT1B, 5-HT2A, and 5-HT2B receptors in lungs and isolated PA-SMCs from patients with primary PH (n=14), pulmonary veno-occlusive disease (n=4), or secondary PH (SPH, n=8) and nonpulmonary hypertensive control subjects.  Whereas strong immunostaining for the three receptor types and 5-HTT was seen in remodeled pulmonary vessels from patients in all PH categories, only 5-HTT expression was increased in lungs and cultured PA-SMCs from patients vs. controls.  The increased growth response of PA-SMCs from patients with primary PH, pulmonary veno-occlusive disease, or SPH to 5-HT or serum was entirely attributable to 5-HTT overexpression, because 5-HTT inhibitors but not 5-HT receptor antagonists abolished 5-HT mitogenic activity and reduced the serum-induced growth response to similar levels in patients as in controls.  The L-allelic variant of the 5-HTT gene promoter, which is assocd. with 5-HTT overexpression, was present homozygously in 14 of 25 (56%) lung transplantation patients with SPH but in only 27% of controls.  Polymorphism of the 5-HTT gene promoter was only partly responsible for the increased 5-HTT expression in PH, because PA-SMCs from patients exhibited higher 5-HTT levels than same-genotype cells from controls and no addnl. promoter sequence alterations were found.  We conclude that 5-HTT overexpression is a common pathogenic mechanism in various forms of PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosAimQG2yqP7Vg90H21EOLACvtfcHk0ljhLdUTTANroQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ylurg%253D&md5=cefd064d9977e3650aa02e34cc5fd548</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000126847.27660.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000126847.27660.69%26sid%3Dliteratum%253Aachs%26aulast%3DMarcos%26aufirst%3DE.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DSanchez%26aufirst%3DO.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DDartevelle%26aufirst%3DP.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DEddahibi%26aufirst%3DS.%26atitle%3DSerotonin-induced%2520smooth%2520muscle%2520hyperplasia%2520in%2520various%2520forms%2520of%2520human%2520pulmonary%2520hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2004%26volume%3D94%26spage%3D1263%26epage%3D1270%26doi%3D10.1161%2F01.RES.0000126847.27660.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walther, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span> <span> </span><span class="NLM_article-title">A unique central tryptophan hydroxylase isoform</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1673</span>– <span class="NLM_lpage">1680</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(03)00556-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0006-2952%2803%2900556-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=14563478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVyktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2003&pages=1673-1680&author=D.+J.+Waltherauthor=M.+Bader&title=A+unique+central+tryptophan+hydroxylase+isoform&doi=10.1016%2FS0006-2952%2803%2900556-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">A unique central tryptophan hydroxylase isoform</span></div><div class="casAuthors">Walther, Diego J.; Bader, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1673-1680</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-hydroxytryptophan, 5-HT) is a neurotransmitter synthesized in the raphe nuclei of the brain stem and involved in the central control of food intake, sleep, and mood.  Accordingly, dysfunction of the serotonin system has been implicated in the pathogenesis of psychiatric diseases.  At the same time, serotonin is a peripheral hormone produced mainly by enterochromaffin cells in the intestine and stored in platelets, where it is involved in vasoconstriction, hemostasis, and the control of immune responses.  Moreover, serotonin is a precursor for melatonin and is therefore synthesized in high amts. in the pineal gland.  Tryptophan hydroxylase (TPH) catalyzes the rate limiting step in 5-HT synthesis.  Until recently, only one gene encoding TPH was described for vertebrates.  By gene targeting, we functionally ablated this gene in mice.  To our surprise, the resulting animals, although being deficient for serotonin in the periphery and in the pineal gland, exhibited close to normal levels of 5-HT in the brain stem.  This led us to the detection of a second TPH gene in the genome of humans, mice, and rats, called TPH2.  This gene is predominantly expressed in the brain stem, while the classical TPH gene, now called TPH1, is expressed in the gut, pineal gland, spleen, and thymus.  These findings clarify puzzling data, which have been collected over the last decades about partially purified TPH proteins with different characteristics and justify a new concept of the serotonin system.  In fact, there are two serotonin systems in vertebrates, independently regulated and with distinct functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz12marm0a7bVg90H21EOLACvtfcHk0lh2FLyUAhuxEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVyktr8%253D&md5=e936196cebd2fdf6a8fff9bd63bf3bc7</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2803%2900556-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252803%252900556-2%26sid%3Dliteratum%253Aachs%26aulast%3DWalther%26aufirst%3DD.%2BJ.%26aulast%3DBader%26aufirst%3DM.%26atitle%3DA%2520unique%2520central%2520tryptophan%2520hydroxylase%2520isoform%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2003%26volume%3D66%26spage%3D1673%26epage%3D1680%26doi%3D10.1016%2FS0006-2952%2803%2900556-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlier-Mur, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewachter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartevelle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanoun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span> <span> </span><span class="NLM_article-title">Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - critical role for serotonin-induced smooth muscle hyperplasia</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.105.591321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.105.591321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16606791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlCjurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2006&pages=1857-1864&author=S.+Eddahibiauthor=C.+Guignabertauthor=A.+M.+Barlier-Murauthor=L.+Dewachterauthor=E.+Fadelauthor=P.+Dartevelleauthor=M.+Humbertauthor=G.+Simonneauauthor=N.+Hanounauthor=F.+Sauriniauthor=M.+Hamonauthor=S.+Adnot&title=Cross+talk+between+endothelial+and+smooth+muscle+cells+in+pulmonary+hypertension+-+critical+role+for+serotonin-induced+smooth+muscle+hyperplasia&doi=10.1161%2FCIRCULATIONAHA.105.591321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension</span></div><div class="casAuthors">Eddahibi, Saadia; Guignabert, Christophe; Barlier-Mur, Anne-Marie; Dewachter, Laurence; Fadel, Elie; Dartevelle, Philippe; Humbert, Marc; Simonneau, Gerald; Hanoun, Naima; Saurini, Francoise; Hamon, Michel; Adnot, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background- The mechanism of pulmonary artery smooth muscle cell (PA-SMC) hyperplasia in idiopathic pulmonary artery hypertension (iPH) may involve both an inherent characteristic of PA-SMCs and abnormal control by external stimuli.  We investigated the role of pulmonary microvascular endothelial cells (P-ECs) in controlling PA-SMC growth.  Methods and Results- Serum-free medium of quiescent P-ECs elicited marked PA-SMC proliferation, and this effect was greater with P-ECs from patients with iPH than from control subjects and greater with PA-SMCs from these patients than from control subjects.  Fluoxetine, which inhibits serotonin-induced mitogenesis by blocking the serotonin transporter, and p-chlorophenylalanine, which inhibits serotonin synthesis by blocking tryptophan hydroxylase (TPH), caused a similar 60% redn. in the growth-promoting effect of P-EC media, whereas endothelin receptor blockers had no effect.  Assays of TPH activity in P-EC medium based on p-chlorophenylalanine-sensitive 5-hydroxytryptophan accumulation or serotonin detn. indicated serotonin synthesis by P-ECs and an increase in this TPH-dependent process in iPH.  Expression of the tph1 gene encoding the peripheral form of the TPH enzyme was increased in lungs and P-ECs from patients with iPH.  Lung TPH1 immunostaining was confined to the pulmonary vessel intima.  Conclusions- P-ECs produce paracrine factors governing PA-SMC growth.  Serotonin, the main P-EC-derived growth factor, is overproduced in iPH and contributes to PA-SMC hyperplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFS3T_5SojibVg90H21EOLACvtfcHk0lh2FLyUAhuxEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlCjurY%253D&md5=2e3804a104cd05f6b17f77da7c26b63b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.105.591321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.105.591321%26sid%3Dliteratum%253Aachs%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DBarlier-Mur%26aufirst%3DA.%2BM.%26aulast%3DDewachter%26aufirst%3DL.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DDartevelle%26aufirst%3DP.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHanoun%26aufirst%3DN.%26aulast%3DSaurini%26aufirst%3DF.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdnot%26aufirst%3DS.%26atitle%3DCross%2520talk%2520between%2520endothelial%2520and%2520smooth%2520muscle%2520cells%2520in%2520pulmonary%2520hypertension%2520-%2520critical%2520role%2520for%2520serotonin-induced%2520smooth%2520muscle%2520hyperplasia%26jtitle%3DCirculation%26date%3D2006%26volume%3D113%26spage%3D1857%26epage%3D1864%26doi%3D10.1161%2FCIRCULATIONAHA.105.591321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morecroft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotnik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000252210.58849.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.HYP.0000252210.58849.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17130306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD28jks1Okuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2007&pages=232-236&author=I.+Morecroftauthor=Y.+Dempsieauthor=M.+Baderauthor=D.+J.+Waltherauthor=K.+Kotnikauthor=L.+Loughlinauthor=M.+Nilsenauthor=M.+R.+MacLean&title=Effect+of+tryptophan+hydroxylase+1+deficiency+on+the+development+of+hypoxia-induced+pulmonary+hypertension&doi=10.1161%2F01.HYP.0000252210.58849.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension</span></div><div class="casAuthors">Morecroft Ian; Dempsie Yvonne; Bader Michael; Walther Diego J; Kotnik Katarina; Loughlin Lynn; Nilsen Margaret; MacLean Margaret R</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension (Dallas, Tex. : 1979)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tryptophan hydroxylase 1 catalyzes the rate-limiting step in the synthesis of serotonin in the periphery.  Recently, it has been shown that expression of the tryptophan hydroxylase 1 gene is increased in lungs and pulmonary endothelial cells from patients with idiopathic pulmonary arterial hypertension.  Here we investigated the effect of genetic deletion of tryptophan hydroxylase 1 on hypoxia-induced pulmonary arterial hypertension in mice by measuring pulmonary hemodynamics and pulmonary vascular remodeling before and after 2 weeks of hypoxia.  In wild-type mice, hypoxia increased right ventricular pressure and pulmonary vascular remodeling.  These effects of hypoxia were attenuated in the tryptophan hydroxylase 1-/-mice.  Hypoxia increased right ventricular hypertrophy in both wild-type and tryptophan hydroxylase 1-/-mice suggesting that in vivo peripheral serotonin has a differential effect on the pulmonary vasculature and right ventricular hypertrophy.  Contractile responses to serotonin were increased in pulmonary arteries from tryptophan hydroxylase 1-/-mice.  Hypoxia increased serotonin-mediated contraction in vessels from the wild-type mice, but this was not further increased by hypoxia in the tryptophan hydroxylase 1-/-mice.  In conclusion, these results indicate that tryptophan hydroxylase 1 and peripheral serotonin play an essential role in the development of hypoxia-induced elevations in pulmonary pressures and hypoxia-induced pulmonary vascular remodeling.  In addition, the results suggest that, in mice, serotonin has differential effects on the pulmonary vasculature and right ventricular hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpF0xWk9GDFP6AExegM5LLfW6udTcc2eZdmpGMGVXzmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jks1Okuw%253D%253D&md5=a8a3f072fa1b7d4cb051c01170f0a963</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000252210.58849.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000252210.58849.78%26sid%3Dliteratum%253Aachs%26aulast%3DMorecroft%26aufirst%3DI.%26aulast%3DDempsie%26aufirst%3DY.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DWalther%26aufirst%3DD.%2BJ.%26aulast%3DKotnik%26aufirst%3DK.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DEffect%2520of%2520tryptophan%2520hydroxylase%25201%2520deficiency%2520on%2520the%2520development%2520of%2520hypoxia-induced%2520pulmonary%2520hypertension%26jtitle%3DHypertension%26date%3D2007%26volume%3D49%26spage%3D232%26epage%3D236%26doi%3D10.1161%2F01.HYP.0000252210.58849.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavasin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V.</span></span> <span> </span><span class="NLM_article-title">Tryptophan hydroxylase 1 inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.237933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.116.237933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27927914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=267-279&author=R.+J.+Aielloauthor=P.+A.+Bourassaauthor=Q.+Zhangauthor=J.+Dubinsauthor=D.+R.+Goldbergauthor=S.+De+Lombaertauthor=M.+Humbertauthor=C.+Guignabertauthor=M.+A.+Cavasinauthor=T.+A.+McKinseyauthor=V.+Paralkar&title=Tryptophan+hydroxylase+1+inhibition+impacts+pulmonary+vascular+remodeling+in+two+rat+models+of+pulmonary+hypertension&doi=10.1124%2Fjpet.116.237933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan hydroxylase 1 inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension</span></div><div class="casAuthors">Aiello, Robert J.; Bourassa, Patricia-Ann; Zhang, Qing; Dubins, Jeffrey; Goldberg, Daniel R.; De Lombaert, Stephane; Humbert, Marc; Guignabert, Christophe; Cavasin, Maria A.; McKinsey, Timothy A.; Paralkar, Vishwas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-279</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a progressive disease defined by a chronic elevation in pulmonary arterial pressure with extensive pulmonary vascular remodeling and perivascular inflammation characterized by an accumulation of macrophages, lymphocytes, dendritic cells, and mast cells.  Although the exact etiol. of the disease is unknown, clin. as well as preclin. data strongly implicate a role for serotonin (5-HT) in the process.  Here, we investigated the chronic effects of pharmacol. inhibition of tryptophan hydroxylase 1 (TPH1), the rate-limiting enzyme in peripheral 5-HT biosynthesis, in two preclin. models of pulmonary hypertension (PH), the monocrotaline (MCT) rat and the semaxanib (SUGEN, Medinoah, Suzhou, China)-hypoxia rat.  In both PH models, Et (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate and Et (S)-8-(2-amino-6-((R)-1-(3',4'-dimethyl-3-(3-methyl-1 H-pyrazol-1-yl)-[1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, novel orally active TPH1 inhibitors with nanomolar in vitro potency, decreased serum, gut, and lung 5-HT levels in a dose-dependent manner and significantly reduced pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats.  In the MCT rat model, decreases in lung 5-HT significantly correlated with redns. in histamine levels and mast cell no. (P < 0.001, r2 = 0.88).  In contrast, neither ambrisentan nor tadalafil, which are vasodilators approved for the treatment of PAH, reduced mast cell no. or 5-HT levels, nor were they as effective in treating the vascular remodeling as were the TPH1 inhibitors.  When administered in combination with ambrisentan, the TPH1 inhibitors showed an additive effect on pulmonary vascular remodeling and pressures.  These data demonstrate that in addn. to reducing vascular remodeling, TPH1 inhibition has the added benefit of reducing the perivascular mast cell accumulation assocd. with PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoplnkLwVNX7bVg90H21EOLACvtfcHk0lg3yA7CGuSIhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjsLs%253D&md5=b128f38244f6bb26557f43b115bf335d</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.237933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.237933%26sid%3Dliteratum%253Aachs%26aulast%3DAiello%26aufirst%3DR.%2BJ.%26aulast%3DBourassa%26aufirst%3DP.%2BA.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DDubins%26aufirst%3DJ.%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DCavasin%26aufirst%3DM.%2BA.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DParalkar%26aufirst%3DV.%26atitle%3DTryptophan%2520hydroxylase%25201%2520inhibition%2520impacts%2520pulmonary%2520vascular%2520remodeling%2520in%2520two%2520rat%2520models%2520of%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D267%26epage%3D279%26doi%3D10.1124%2Fjpet.116.237933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span> <span> </span><span class="NLM_article-title">Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.113.301141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCRESAHA.113.301141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24951765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2014&pages=165-175&author=M.+Rabinovitchauthor=C.+Guignabertauthor=M.+Humbertauthor=M.+R.+Nicolls&title=Inflammation+and+immunity+in+the+pathogenesis+of+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCRESAHA.113.301141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Rabinovitch, Marlene; Guignabert, Christophe; Humbert, Marc; Nicolls, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-175</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension.  The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed.  Pre-clin. studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed.  In addn., we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development.  We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYuJ3RliFVC7Vg90H21EOLACvtfcHk0lg3yA7CGuSIhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL&md5=d3a2fe2798a44bdcdf4e5e0f8c71ab99</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.113.301141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.113.301141%26sid%3Dliteratum%253Aachs%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26atitle%3DInflammation%2520and%2520immunity%2520in%2520the%2520pathogenesis%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D115%26spage%3D165%26epage%3D175%26doi%3D10.1161%2FCIRCRESAHA.113.301141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrkina, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolliputi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, A. B.</span></span> <span> </span><span class="NLM_article-title">Interleukin-6 overexpression induces pulmonary hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.108.182014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCRESAHA.108.182014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19074475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2009&pages=236-244&author=M.+K.+Steinerauthor=O.+L.+Syrkinaauthor=N.+Kolliputiauthor=E.+J.+Markauthor=C.+A.+Halesauthor=A.+B.+Waxman&title=Interleukin-6+overexpression+induces+pulmonary+hypertension&doi=10.1161%2FCIRCRESAHA.108.182014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-6 Overexpression Induces Pulmonary Hypertension</span></div><div class="casAuthors">Steiner, M. Kathryn; Syrkina, Olga L.; Kolliputi, Narasaish; Mark, Eugene J.; Hales, Charles A.; Waxman, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-244</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Inflammatory cytokine interleukin (IL)-6 is elevated in the serum and lungs of patients with pulmonary artery hypertension (PAH).  Several animal models of PAH cite the potential role of inflammatory mediators.  We investigated role of IL-6 in the pathogenesis of pulmonary vascular disease.  Indexes of pulmonary vascular remodeling were measured in lung-specific IL-6-overexpressing transgenic mice (Tg+) and compared to wild-type (Tg-) controls in both normoxic and chronic hypoxic conditions.  The Tg+ mice exhibited elevated right ventricular systolic pressures and right ventricular hypertrophy with corresponding pulmonary vasculopathic changes, all of which were exacerbated by chronic hypoxia.  IL-6 overexpression increased muscularization of the proximal arterial tree, and hypoxia enhanced this effect.  It also reproduced the muscularization and proliferative arteriopathy seen in the distal arteriolar vessels of PAH patients.  The latter was characterized by the formation of occlusive neointimal angioproliferative lesions that worsened with hypoxia and were composed of endothelial cells and T-lymphocytes.  IL-6-induced arteriopathic changes were accompanied by activation of proangiogenic factor, vascular endothelial growth factor, the proproliferative kinase extracellular signal-regulated kinase, proproliferative transcription factors c-MYC and MAX, and the antiapoptotic proteins survivin and Bcl-2 and downregulation of the growth inhibitor transforming growth factor-β and proapoptotic kinases JNK and p38.  These findings suggest that IL-6 promotes the development and progression of pulmonary vascular remodeling and PAH through proproliferative antiapoptotic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1C-jlJztGbVg90H21EOLACvtfcHk0liHE_CYsnI8Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFahsQ%253D%253D&md5=4da16f129cada7855f50838de111ccd1</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.108.182014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.108.182014%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DM.%2BK.%26aulast%3DSyrkina%26aufirst%3DO.%2BL.%26aulast%3DKolliputi%26aufirst%3DN.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DHales%26aufirst%3DC.%2BA.%26aulast%3DWaxman%26aufirst%3DA.%2BB.%26atitle%3DInterleukin-6%2520overexpression%2520induces%2520pulmonary%2520hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2009%26volume%3D104%26spage%3D236%26epage%3D244%26doi%3D10.1161%2FCIRCRESAHA.108.182014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izziki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span> <span> </span><span class="NLM_article-title">Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-10-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-10-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19173740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1M7kvVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=6&author=L.+Savaleauthor=L.+Tuauthor=D.+Rideauauthor=M.+Izzikiauthor=B.+Maitreauthor=S.+Adnotauthor=S.+Eddahibi&title=Impact+of+interleukin-6+on+hypoxia-induced+pulmonary+hypertension+and+lung+inflammation+in+mice&doi=10.1186%2F1465-9921-10-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice</span></div><div class="casAuthors">Savale Laurent; Tu Ly; Rideau Dominique; Izziki Mohamed; Maitre Bernard; Adnot Serge; Eddahibi Saadia</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Inflammation may contribute to the pathogenesis of various forms of pulmonary hypertension (PH).  Recent studies in patients with idiopathic PH or PH associated with underlying diseases suggest a role for interleukin-6 (IL-6).  METHODS:  To determine whether endogenous IL-6 contributes to mediate hypoxic PH and lung inflammation, we studied IL-6-deficient (IL-6-/-) and wild-type (IL-6+/+) mice exposed to hypoxia for 2 weeks.  RESULTS:  Right ventricular systolic pressure, right ventricle hypertrophy, and the number and media thickness of muscular pulmonary vessels were decreased in IL-6-/- mice compared to wild-type controls after 2 weeks' hypoxia, although the pressure response to acute hypoxia was similar in IL-6+/+ and IL-6-/- mice.  Hypoxia exposure of IL-6+/+ mice led to marked increases in IL-6 mRNA and protein levels within the first week, with positive IL-6 immunostaining in the pulmonary vessel walls.  Lung IL-6 receptor and gp 130 (the IL-6 signal transducer) mRNA levels increased after 1 and 2 weeks' hypoxia.  In vitro studies of cultured human pulmonary-artery smooth-muscle-cells (PA-SMCs) and microvascular endothelial cells revealed prominent synthesis of IL-6 by PA-SMCs, with further stimulation by hypoxia.  IL-6 also markedly stimulated PA-SMC migration without affecting proliferation.  Hypoxic IL-6-/- mice showed less inflammatory cell recruitment in the lungs, compared to hypoxic wild-type mice, as assessed by lung protein levels and immunostaining for the specific macrophage marker F4/80, with no difference in lung expression of adhesion molecules or cytokines.  CONCLUSION:  These data suggest that IL-6 may be actively involved in hypoxia-induced lung inflammation and pulmonary vascular remodeling in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAwDSSNFgLuzAyhZbj3lKdfW6udTcc2eam6-eJYjnAmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7kvVyrtg%253D%253D&md5=05e1362bd7c29392099ae91149a9e800</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-10-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-10-6%26sid%3Dliteratum%253Aachs%26aulast%3DSavale%26aufirst%3DL.%26aulast%3DTu%26aufirst%3DL.%26aulast%3DRideau%26aufirst%3DD.%26aulast%3DIzziki%26aufirst%3DM.%26aulast%3DMaitre%26aufirst%3DB.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DEddahibi%26aufirst%3DS.%26atitle%3DImpact%2520of%2520interleukin-6%2520on%2520hypoxia-induced%2520pulmonary%2520hypertension%2520and%2520lung%2520inflammation%2520in%2520mice%26jtitle%3DRespir.%2520Res.%26date%3D2009%26volume%3D10%26spage%3D6%26doi%3D10.1186%2F1465-9921-10-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knightbridge, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunclark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corris, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toshner, M.</span></span> <span> </span><span class="NLM_article-title">Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterional hypertensi</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">204589321773582</span>, <span class="refDoi"> DOI: 10.1177/2045893217735820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F2045893217735820" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=204589321773582&author=J.+Hernandez-Sanchezauthor=L.+Harlowauthor=C.+Churchauthor=S.+Gaineauthor=E.+Knightbridgeauthor=K.+Bunclarkauthor=D.+Gorauthor=A.+Beddingauthor=N.+Morrellauthor=P.+Corrisauthor=M.+Toshner&title=Clinical+trial+protocol+for+TRANSFORM-UK%3A+A+therapeutic+open-label+study+of+tocilizumab+in+the+treatment+of+pulmonary+arterional+hypertensi&doi=10.1177%2F2045893217735820"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1177%2F2045893217735820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045893217735820%26sid%3Dliteratum%253Aachs%26aulast%3DHernandez-Sanchez%26aufirst%3DJ.%26aulast%3DHarlow%26aufirst%3DL.%26aulast%3DChurch%26aufirst%3DC.%26aulast%3DGaine%26aufirst%3DS.%26aulast%3DKnightbridge%26aufirst%3DE.%26aulast%3DBunclark%26aufirst%3DK.%26aulast%3DGor%26aufirst%3DD.%26aulast%3DBedding%26aufirst%3DA.%26aulast%3DMorrell%26aufirst%3DN.%26aulast%3DCorris%26aufirst%3DP.%26aulast%3DToshner%26aufirst%3DM.%26atitle%3DClinical%2520trial%2520protocol%2520for%2520TRANSFORM-UK%253A%2520A%2520therapeutic%2520open-label%2520study%2520of%2520tocilizumab%2520in%2520the%2520treatment%2520of%2520pulmonary%2520arterional%2520hypertensi%26jtitle%3DPulm.%2520Circ.%26date%3D2018%26volume%3D8%26spage%3D204589321773582%26doi%3D10.1177%2F2045893217735820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewska, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czajka, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stawski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isenberg, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browning, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowska, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyl fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41605</span>, <span class="refDoi"> DOI: 10.1038/srep41605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fsrep41605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28150703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVygtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=41605&author=A.+P.+Grzegorzewskaauthor=F.+Setaauthor=R.+Hanauthor=C.+A.+Czajkaauthor=K.+Makinoauthor=L.+Stawskiauthor=J.+S.+Isenbergauthor=J.+L.+Browningauthor=M.+Trojanowska&title=Dimethyl+fumarate+ameliorates+pulmonary+arterial+hypertension+and+lung+fibrosis+by+targeting+multiple+pathways&doi=10.1038%2Fsrep41605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways</span></div><div class="casAuthors">Grzegorzewska, Agnieszka P.; Seta, Francesca; Han, Rong; Czajka, Caitlin A.; Makino, Katsunari; Stawski, Lukasz; Isenberg, Jeffrey S.; Browning, Jeffrey L.; Trojanowska, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41605</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a fatal condition for which there is no cure.  Di-Me Fumarate (DMF) is an FDA approved anti-oxidative and anti-inflammatory agent with a favorable safety record.  The goal of this study was to assess the effectiveness of DMF as a therapy for PAH using patient-derived cells and murine models.  We show that DMF treatment is effective in reversing hemodynamic changes, reducing inflammation, oxidative damage, and fibrosis in the exptl. models of PAH and lung fibrosis.  Our findings indicate that effects of DMF are facilitated by inhibiting pro-inflammatory NFκB, STAT3 and cJUN signaling, as well as βTRCP-dependent degrdn. of the pro-fibrogenic mediators Sp1, TAZ and β-catenin.  These results provide a novel insight into the mechanism of its action.  Collectively, preclin. results demonstrate beneficial effects of DMF on key mol. pathways contributing to PAH, and support its testing in PAH treatment in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZiXCweVxYPbVg90H21EOLACvtfcHk0lhHkg6lyhCsGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVygtLw%253D&md5=632d10d6a023ec9484395e5281ff3699</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fsrep41605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep41605%26sid%3Dliteratum%253Aachs%26aulast%3DGrzegorzewska%26aufirst%3DA.%2BP.%26aulast%3DSeta%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DCzajka%26aufirst%3DC.%2BA.%26aulast%3DMakino%26aufirst%3DK.%26aulast%3DStawski%26aufirst%3DL.%26aulast%3DIsenberg%26aufirst%3DJ.%2BS.%26aulast%3DBrowning%26aufirst%3DJ.%2BL.%26aulast%3DTrojanowska%26aufirst%3DM.%26atitle%3DDimethyl%2520fumarate%2520ameliorates%2520pulmonary%2520arterial%2520hypertension%2520and%2520lung%2520fibrosis%2520by%2520targeting%2520multiple%2520pathways%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D41605%26doi%3D10.1038%2Fsrep41605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terry, M.</span></span> Reata Pharma Updates Business Operations and Clinical Trials in Light of COVID-19 Pandemic. <a href="https://www.biospace.com/article/reata-pharma-pauses-or-modifies-some-clinical-trials-in-response-to-covid-19/" class="extLink">https://www.biospace.com/article/reata-pharma-pauses-or-modifies-some-clinical-trials-in-response-to-covid-19/</a> (accessed Mar 31, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Terry%2C+M.+Reata+Pharma+Updates+Business+Operations+and+Clinical+Trials+in+Light+of+COVID-19+Pandemic.+https%3A%2F%2Fwww.biospace.com%2Farticle%2Freata-pharma-pauses-or-modifies-some-clinical-trials-in-response-to-covid-19%2F+%28accessed+Mar+31%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chieffo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorkasky, D. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic effects of oral cxa-10, a nitro fatty acid, after single and multiple ascending doses in healthy and obese subjects</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1111/cts.12672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fcts.12672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31343124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Oju7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=667-676&author=R.+M.+Garnerauthor=D.+R.+Mouldauthor=C.+Chieffoauthor=D.+K.+Jorkasky&title=Pharmacokinetic+and+pharmacodynamic+effects+of+oral+cxa-10%2C+a+nitro+fatty+acid%2C+after+single+and+multiple+ascending+doses+in+healthy+and+obese+subjects&doi=10.1111%2Fcts.12672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Pharmacodynamic Effects of Oral CXA-10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects</span></div><div class="casAuthors">Garner, Rachel M.; Mould, Diane R.; Chieffo, Carla; Jorkasky, Diane K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-676</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">10-nitro-9(E)-octadec-9-enoic acid (CXA-10), a novel nitro fatty acid compd., demonstrates potential as a therapeutic agent in multiple disease indications in which oxidative stress, inflammation, fibrosis, and/or direct tissue toxicity play significant roles.  Phase I studies were conducted in healthy and obese subjects to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of oral CXA-10 after single and multiple doses in the fed and fasted states that would confirm the mechanisms of action of CXA-10.  After single and multiple ascending doses, CXA-10 demonstrated dose-proportional increases in plasma exposure.  CXA-10 decreased levels of biomarkers assocd. with altered inflammation and metabolic stress obsd. from nonclin. studies.  In CXA-10-202, a consistent decrease from baseline was obsd. with CXA-10 150 mg dose, but not 25 or 450 mg doses, for biomarkers of altered inflammation and metabolic dysfunction, including leptin, triglycerides, cholesterol, MCP-1, and IL-6.  In CXA-10-203, after coadministration with CXA-10, geometric mean peak plasma concn. (Cmax) and area under the plasma concn.-time curve from time point 0 to the end of the dosing interval (AUC0-t) decreased 20% and 25% for pravastatin, increased 10% and 25% for simvastatin, and decreased 20% and 5% for ezetimibe.  These findings are consistent with the pharmacol. effects of CXA-10.  Adverse events (AEs) were dose-related, and the most frequently reported AEs (>10% of subjects) were diarrhea, abdominal pain, and nausea.  CXA-10 was safe and well-tolerated with no clin. significant abnormalities reported on phys. examn., vital signs, clin. lab. evaluations, or electrocardiog. evaluation.  Phase II studies are underway in patients with focal segmental glomerulosclerosis and pulmonary arterial hypertension to investigate the efficacy and tolerability of CXA-10 75-300 mg once daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohI0XxPv9aZLVg90H21EOLACvtfcHk0lhfmBlN-yHXSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Oju7rJ&md5=186578beba0cf48cb9b0ff785c7c8510</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1111%2Fcts.12672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12672%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DR.%2BM.%26aulast%3DMould%26aufirst%3DD.%2BR.%26aulast%3DChieffo%26aufirst%3DC.%26aulast%3DJorkasky%26aufirst%3DD.%2BK.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520effects%2520of%2520oral%2520cxa-10%252C%2520a%2520nitro%2520fatty%2520acid%252C%2520after%2520single%2520and%2520multiple%2520ascending%2520doses%2520in%2520healthy%2520and%2520obese%2520subjects%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D12%26spage%3D667%26epage%3D676%26doi%3D10.1111%2Fcts.12672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. K.</span></span> <span> </span><span class="NLM_article-title">Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-12-45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-12-45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21477377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltVWqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=45&author=D.+Wuauthor=D.+Leeauthor=Y.+K.+Sung&title=Prospect+of+vasoactive+intestinal+peptide+therapy+for+COPD%2FPAH+and+asthma%3A+a+review&doi=10.1186%2F1465-9921-12-45"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review</span></div><div class="casAuthors">Wu, Dongmei; Lee, Dongwon; Sung, Yong Kiel</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathol. features, including inflammation, smooth muscle contraction and remodeling.  No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation.  Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biol. actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions.  VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD.  Clin. application of VIP has been limited in the past for a no. of reasons, including its short plasma half-life and difficulty in administration routes.  The development of long-acting VIP analogs, in combination with appropriate drug delivery systems, may provide clin. useful agents for the treatment of PAH, asthma, and COPD.  This article reviews the physiol. significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_QNsDz7NQLVg90H21EOLACvtfcHk0lhfmBlN-yHXSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltVWqsLs%253D&md5=bac7eef73abdc56025e41b62edf37990</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-12-45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-12-45%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DSung%26aufirst%3DY.%2BK.%26atitle%3DProspect%2520of%2520vasoactive%2520intestinal%2520peptide%2520therapy%2520for%2520COPD%252FPAH%2520and%2520asthma%253A%2520a%2520review%26jtitle%3DRespir.%2520Res.%26date%3D2011%26volume%3D12%26spage%3D45%26doi%3D10.1186%2F1465-9921-12-45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosgoeller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziesche, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raderer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiebellehner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonbank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, L. H.</span></span> <span> </span><span class="NLM_article-title">Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1339</span>– <span class="NLM_lpage">1346</span>, <span class="refDoi"> DOI: 10.1172/JCI17500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI17500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12727925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=1339-1346&author=V.+Petkovauthor=W.+Mosgoellerauthor=R.+Ziescheauthor=M.+Radererauthor=L.+Stiebellehnerauthor=K.+Vonbankauthor=G.+C.+Funkauthor=G.+Hamiltonauthor=C.+Novotnyauthor=B.+Burianauthor=L.+H.+Block&title=Vasoactive+intestinal+peptide+as+a+new+drug+for+treatment+of+primary+pulmonary+hypertension&doi=10.1172%2FJCI17500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension</span></div><div class="casAuthors">Petkov, Ventzislav; Mosgoeller, Wilhelm; Ziesche, Rolf; Raderer, Markus; Stiebellehner, Leopold; Vonbank, Karin; Funk, Georg-Christian; Hamilton, Gerhard; Novotny, Clemens; Burian, Bernhard; Block, Lutz-Henning</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1339-1346</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension is a fatal disease causing progressive right heart failure within 3 yr after diagnosis.  The authors describe a new concept for treatment of the disease using vasoactive intestinal peptide, a neuropeptide primarily functioning as a neurotransmitter that acts as a potent systemic and pulmonary vasodilator.  The authors' rationale is based on the finding of a deficiency of the peptide in serum and lung tissue of patients with primary pulmonary hypertension, as evidenced by RIA and immunohistochem.  The relevance of this finding is underlined by an upregulation of corresponding receptor sites as shown by Northern blot anal., Western blot anal., and immunol. techniques.  Consequently, the substitution with the hormone results in substantial improvement of hemodynamic and prognostic parameters of the disease without side effects.  It decreased the mean pulmonary artery pressure in the eight study patients, increased cardiac output, and mixed venous oxygen satn.  The authors' data provide enough proof for further investigation of vasoactive intestinal peptide and its role in primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ZJeNEVtCgLVg90H21EOLACvtfcHk0li3MmDiO2FfpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFCrsrs%253D&md5=ce63b24000dd5a198351c9184f45ea95</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1172%2FJCI17500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI17500%26sid%3Dliteratum%253Aachs%26aulast%3DPetkov%26aufirst%3DV.%26aulast%3DMosgoeller%26aufirst%3DW.%26aulast%3DZiesche%26aufirst%3DR.%26aulast%3DRaderer%26aufirst%3DM.%26aulast%3DStiebellehner%26aufirst%3DL.%26aulast%3DVonbank%26aufirst%3DK.%26aulast%3DFunk%26aufirst%3DG.%2BC.%26aulast%3DHamilton%26aufirst%3DG.%26aulast%3DNovotny%26aufirst%3DC.%26aulast%3DBurian%26aufirst%3DB.%26aulast%3DBlock%26aufirst%3DL.%2BH.%26atitle%3DVasoactive%2520intestinal%2520peptide%2520as%2520a%2520new%2520drug%2520for%2520treatment%2520of%2520primary%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D111%26spage%3D1339%26epage%3D1346%26doi%3D10.1172%2FJCI17500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McBride, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuspiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasiak, S.</span></span> <span> </span><span class="NLM_article-title">Mitochondria: more than just a powerhouse</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">R551</span>– <span class="NLM_lpage">R560</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cub.2006.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16860735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlCrur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=R551-R560&author=H.+M.+McBrideauthor=M.+Neuspielauthor=S.+Wasiak&title=Mitochondria%3A+more+than+just+a+powerhouse&doi=10.1016%2Fj.cub.2006.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria: More Than Just a Powerhouse</span></div><div class="casAuthors">McBride, Heidi M.; Neuspiel, Margaret; Wasiak, Sylwia</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">R551-R560</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Pioneering biochem. studies have long forged the concept that the mitochondria are the 'energy powerhouse of the cell'.  These studies, combined with the unique evolutionary origin of the mitochondria, led the way to decades of research focusing on the organelle as an essential, yet independent, functional component of the cell.  Recently, however, this conceptual view of this isolated organelle has been profoundly altered with the discovery that mitochondria function within an integrated reticulum that is continually remodeled by both fusion and fission events.  The identification of a no. of proteins that regulate these activities is beginning to provide mechanistic details of mitochondrial membrane remodeling.  However, the broader question remains regarding the underlying purpose of mitochondrial dynamics and the translation of these morphol. transitions into altered functional output.  One hypothesis has been that mitochondrial respiration and metab. may be spatially and temporally regulated by the architecture and positioning of the organelle.  Recent evidence supports and expands this idea by demonstrating that mitochondria are an integral part of multiple cell signaling cascades.  Interestingly, proteins such as GTPases, kinases, and phosphatases are involved in bi-directional communication between the mitochondrial reticulum and the rest of the cell.  These proteins link mitochondrial function and dynamics to the regulation of metab., cell-cycle control, development, antiviral responses, and cell death.  Here, the authors highlight emerging evidence that provides mol. definition to mitochondria as a central platform in the execution of diverse cellular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHwM5rKw3FfrVg90H21EOLACvtfcHk0li3MmDiO2FfpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlCrur4%253D&md5=632f53eea50d01ed97079782f17a8aaa</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DMcBride%26aufirst%3DH.%2BM.%26aulast%3DNeuspiel%26aufirst%3DM.%26aulast%3DWasiak%26aufirst%3DS.%26atitle%3DMitochondria%253A%2520more%2520than%2520just%2520a%2520powerhouse%26jtitle%3DCurr.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3DR551%26epage%3DR560%26doi%3D10.1016%2Fj.cub.2006.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMurtry, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, J. R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haromy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelakis, E. D.</span></span> <span> </span><span class="NLM_article-title">Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000145360.16770.9f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.RES.0000145360.16770.9f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15375007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1aitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=830-840&author=M.+S.+McMurtryauthor=S.+Bonnetauthor=X.+C.+Wuauthor=J.+R.+B.+Dyckauthor=A.+Haromyauthor=K.+Hashimotoauthor=E.+D.+Michelakis&title=Dichloroacetate+prevents+and+reverses+pulmonary+hypertension+by+inducing+pulmonary+artery+smooth+muscle+cell+apoptosis&doi=10.1161%2F01.RES.0000145360.16770.9f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis</span></div><div class="casAuthors">McMurtry, M. Sean; Bonnet, Sebastien; Wu, Xichen; Dyck, Jason R. B.; Haromy, Alois; Hashimoto, Kyoko; Michelakis, Evangelos D.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">830-840</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The pulmonary arteries (PA) in pulmonary arterial hypertension (PAH) are constricted and remodeled.  They have suppressed apoptosis, partly attributable to suppression of the bone morphogenetic protein axis and selective downregulation of PA smooth muscle cell (PASMC) voltage-gated K+ channels, including Kv1.5.  The Kv downregulation-induced increase in [K+]i, tonically inhibits caspases, further suppressing apoptosis.  Mitochondria control apoptosis and produce activated oxygen species like H2O2, which regulate vascular tone by activating K+ channels, but their role in PAH is unknown.  We show that dichloroacetate (DCA), a metabolic modulator that increases mitochondrial oxidative phosphorylation, prevents and reverses established monocrotaline-induced PAH (MCT-PAH), significantly improving mortality.  Compared with MCT-PAH, DCA-treated rats (80 mg/kg per day in drinking water on day 14 after MCT, studied on day 21) have decreased pulmonary, but not systemic, vascular resistance (63% decrease, P<0.002), PA medial thickness (28% decrease, P<0.0001), and right ventricular hypertrophy (34% decrease, P<0.001).  DCA is similarly effective when given at day 1 or day 21 after MCT (studied day 28) but has no effect on normal rats.  DCA depolarizes MCT-PAH PASMC mitochondria and causes release of H2O2 and cytochrome c, inducing a 10-fold increase in apoptosis within the PA media (TUNEL and caspase 3 activity) and decreasing proliferation (proliferating-cell nuclear antigen and BrdU assays).  Immunoblots, immunohistochem., laser-captured microdissection-quant. reverse-transcription polymerase chain reaction and patch-clamping show that DCA reverses the Kv1.5 downregulation in resistance PAs.  In summary, DCA reverses PA remodeling by increasing the mitochondria-dependent apoptosis/proliferation ratio and upregulating Kv1.5 in the media.  We identify mitochondria-dependent apoptosis as a potential target for therapy and DCA as an effective and selective treatment for PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyP_V5-EJWBLVg90H21EOLACvtfcHk0li3MmDiO2FfpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1aitr8%253D&md5=82b4526a1abc7f5f881b7756877a7823</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000145360.16770.9f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000145360.16770.9f%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurtry%26aufirst%3DM.%2BS.%26aulast%3DBonnet%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%2BC.%26aulast%3DDyck%26aufirst%3DJ.%2BR.%2BB.%26aulast%3DHaromy%26aufirst%3DA.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26atitle%3DDichloroacetate%2520prevents%2520and%2520reverses%2520pulmonary%2520hypertension%2520by%2520inducing%2520pulmonary%2520artery%2520smooth%2520muscle%2520cell%2520apoptosis%26jtitle%3DCirc.%2520Res.%26date%3D2004%26volume%3D95%26spage%3D830%26epage%3D840%26doi%3D10.1161%2F01.RES.0000145360.16770.9f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michelakis, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurtu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Regan, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wharton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiely, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnaird, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukouris, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagendran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wort, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaao4583</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aao4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1126%2Fscitranslmed.aao4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29070699" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaao4583&author=E.+D.+Michelakisauthor=V.+Gurtuauthor=L.+Websterauthor=G.+Barnesauthor=G.+Watsonauthor=L.+Howardauthor=J.+Cupittauthor=I.+Patersonauthor=R.+B.+Thompsonauthor=K.+Chowauthor=D.+P.+O%E2%80%99Reganauthor=L.+Zhaoauthor=J.+Whartonauthor=D.+G.+Kielyauthor=A.+Kinnairdauthor=A.+E.+Boukourisauthor=C.+Whiteauthor=J.+Nagendranauthor=D.+H.+Freedauthor=S.+J.+Wortauthor=J.+S.+R.+Gibbsauthor=M.+R.+Wilkins&title=Inhibition+of+pyruvate+dehydrogenase+kinase+improves+pulmonary+arterial+hypertension+in+genetically+susceptible+patients&doi=10.1126%2Fscitranslmed.aao4583"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aao4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aao4583%26sid%3Dliteratum%253Aachs%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26aulast%3DGurtu%26aufirst%3DV.%26aulast%3DWebster%26aufirst%3DL.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DWatson%26aufirst%3DG.%26aulast%3DHoward%26aufirst%3DL.%26aulast%3DCupitt%26aufirst%3DJ.%26aulast%3DPaterson%26aufirst%3DI.%26aulast%3DThompson%26aufirst%3DR.%2BB.%26aulast%3DChow%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DD.%2BP.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWharton%26aufirst%3DJ.%26aulast%3DKiely%26aufirst%3DD.%2BG.%26aulast%3DKinnaird%26aufirst%3DA.%26aulast%3DBoukouris%26aufirst%3DA.%2BE.%26aulast%3DWhite%26aufirst%3DC.%26aulast%3DNagendran%26aufirst%3DJ.%26aulast%3DFreed%26aufirst%3DD.%2BH.%26aulast%3DWort%26aufirst%3DS.%2BJ.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%2BR.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DInhibition%2520of%2520pyruvate%2520dehydrogenase%2520kinase%2520improves%2520pulmonary%2520arterial%2520hypertension%2520in%2520genetically%2520susceptible%2520patients%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaao4583%26doi%3D10.1126%2Fscitranslmed.aao4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orriols, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Puerto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">BMP type II receptor as a therapeutic target in pulmonary arterial hypertension</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2979</span>– <span class="NLM_lpage">2995</span>, <span class="refDoi"> DOI: 10.1007/s00018-017-2510-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1007%2Fs00018-017-2510-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28447104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslaqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=2979-2995&author=M.+Orriolsauthor=M.+C.+Gomez-Puertoauthor=P.+ten+Dijke&title=BMP+type+II+receptor+as+a+therapeutic+target+in+pulmonary+arterial+hypertension&doi=10.1007%2Fs00018-017-2510-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">BMP type II receptor as a therapeutic target in pulmonary arterial hypertension</span></div><div class="casAuthors">Orriols, Mar; Gomez-Puerto, Maria Catalina; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2979-2995</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a chronic disease characterized by a progressive elevation in mean pulmonary arterial pressure.  This occurs due to abnormal remodeling of small peripheral lung vasculature resulting in progressive occlusion of the artery lumen that eventually causes right heart failure and death.  The most common cause of PAH is inactivating mutations in the gene encoding a bone morphogenetic protein type II receptor (BMPRII).  Current therapeutic options for PAH are limited and focused mainly on reversal of pulmonary vasoconstriction and proliferation of vascular cells.  Although these treatments can relieve disease symptoms, PAH remains a progressive lethal disease.  Emerging data suggest that restoration of BMPRII signaling in PAH is a promising alternative that could prevent and reverse pulmonary vascular remodeling.  Here we will focus on recent advances in rescuing BMPRII expression, function or signaling to prevent and reverse pulmonary vascular remodeling in PAH and its feasibility for clin. translation.  Furthermore, we summarize the role of described miRNAs that directly target the BMPR2 gene in blood vessels.  We discuss the therapeutic potential and the limitations of promising new approaches to restore BMPRII signaling in PAH patients.  Different mutations in BMPR2 and environmental/genetic factors make PAH a heterogeneous disease and it is thus likely that the best approach will be patient-tailored therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqmQOKKlgN-rVg90H21EOLACvtfcHk0licnef4EqV8-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslaqtro%253D&md5=5ecd1c04726b31366f8f33e5260a5c53</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1007%2Fs00018-017-2510-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-017-2510-4%26sid%3Dliteratum%253Aachs%26aulast%3DOrriols%26aufirst%3DM.%26aulast%3DGomez-Puerto%26aufirst%3DM.%2BC.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26atitle%3DBMP%2520type%2520II%2520receptor%2520as%2520a%2520therapeutic%2520target%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D2979%26epage%3D2995%26doi%3D10.1007%2Fs00018-017-2510-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beppu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. P.</span></span> <span> </span><span class="NLM_article-title">Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.107.736801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.107.736801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18663089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2008&pages=722-730&author=K.-H.+Hongauthor=Y.+J.+Leeauthor=E.+Leeauthor=S.+O.+Parkauthor=C.+Hanauthor=H.+Beppuauthor=E.+Liauthor=M.+K.+Raizadaauthor=K.+D.+Blochauthor=S.+P.+Oh&title=Genetic+ablation+of+the+Bmpr2+gene+in+pulmonary+endothelium+is+sufficient+to+predispose+to+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.107.736801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Hong, Kwon-Ho; Lee, Young Jae; Lee, Eunji; Park, Sung Ok; Han, Chul; Beppu, Hideyuki; Li, En; Raizada, Mohan K.; Bloch, Kenneth D.; Oh, S. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-730</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a rare but fatal lung disease of diverse origins.  PAH is now further subclassified as idiopathic PAH, familial PAH, and assocd. PAH varieties.  Heterozygous mutations in BMPR2 can be detected in 50% to 70% of patients with familial PAH and 10% to 40% of patients with idiopathic PAH.  Although endothelial cells have been suspected as the cellular origin of PAH pathogenesis, no direct in vivo evidence has been clearly presented.  The present study was designed to investigate whether endothelial Bmpr2 deletion can predispose to PAH.  The Bmpr2 gene was deleted in pulmonary endothelial cells using Bmpr2 conditional knockout mice and a novel endothelial Cre transgenic mouse line.  Wide ranges of right ventricular systolic pressure were obsd. in mice with heterozygous (21.7 to 44.1 mm Hg; median, 23.7 mm Hg) and homozygous (20.7 to 56.3 mm Hg; median, 27 mm Hg) conditional deletion of Bmpr2 in pulmonary endothelial cells compared with control mice (19.9 to 26.7 mm Hg; median, 23 mm Hg) at 2 to 7 mo of age.  A subset of mice with right ventricular systolic pressure >30 mm Hg exhibited right ventricular hypertrophy and an increase in the no. and wall thickness of muscularized distal pulmonary arteries.  In the lungs of these mice with high right ventricular systolic pressure, the expression of proteins involved in the pathogenesis of PAH such as serotonin transporter and tenascin-C was elevated in distal arteries and had a high incidence of perivascular leukocyte infiltration and in situ thrombosis.  Conditional heterozygous or homozygous Bmpr2 deletion in pulmonary endothelial cells predisposes mice to develop PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCVtZPvLz7bVg90H21EOLACvtfcHk0licnef4EqV8-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChsrc%253D&md5=65f0aafb8d74e90f3118ea5107544d2d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.107.736801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.107.736801%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DK.-H.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DS.%2BO.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DBeppu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DOh%26aufirst%3DS.%2BP.%26atitle%3DGenetic%2520ablation%2520of%2520the%2520Bmpr2%2520gene%2520in%2520pulmonary%2520endothelium%2520is%2520sufficient%2520to%2520predispose%2520to%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2008%26volume%3D118%26spage%3D722%26epage%3D730%26doi%3D10.1161%2FCIRCULATIONAHA.107.736801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauciulo, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhail, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higenbottam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crozier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allcock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corris, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembath, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, W. C.</span></span> <span> </span><span class="NLM_article-title">Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family</span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1136/jmg.37.10.741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1136%2Fjmg.37.10.741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11015450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVOisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2000&pages=741-745&author=J.+R.+Thomsonauthor=R.+D.+Machadoauthor=M.+W.+Pauciuloauthor=N.+V.+Morganauthor=M.+Humbertauthor=G.+C.+Elliottauthor=K.+Wardauthor=M.+Yacoubauthor=G.+Mikhailauthor=P.+Rogersauthor=J.+Newmanauthor=L.+Wheelerauthor=T.+Higenbottamauthor=J.+S.+R.+Gibbsauthor=J.+Eganauthor=A.+Crozierauthor=A.+Peacockauthor=R.+Allcockauthor=P.+Corrisauthor=J.+E.+Loydauthor=R.+C.+Trembathauthor=W.+C.+Nichols&title=Sporadic+primary+pulmonary+hypertension+is+associated+with+germline+mutations+of+the+gene+encoding+BMPR-II%2C+a+receptor+member+of+the+TGF-beta+family&doi=10.1136%2Fjmg.37.10.741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family</span></div><div class="casAuthors">Thomson, Jennifer R.; Machado, Rajiv D.; Pauciulo, Michael W.; Morgan, Neil V.; Humbert, Marc; Elliott, Greg C.; Ward, Ken; Yacoub, Magdi; Mikhail, Ghada; Rogers, Paula; Newman, John; Wheeler, Lisa; Higenbottam, Timothy; Gibbs, J. Simon R.; Egan, Jim; Crozier, Agnes; Peacock, Andrew; Allcock, Robert; Corris, Paul; Loyd, James E.; Trembath, Richard C.; Nichols, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">741-745</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension (PPH), resulting from occlusion of small pulmonary arteries, is a devastating condition.  Mutations of the bone morphogenetic protein receptor type II gene (BMPR2), a component of the transforming growth factor beta (TGF-β) family which plays a key role in cell growth, have recently been identified as causing familial PPH.  The authors have searched for BMPR2 gene mutations in sporadic PPH patients to det. whether the same genetic defect underlies the more common form of the disorder.  The authors investigated 50 unrelated patients, with a clin. diagnosis of PPH and no identifiable family history of pulmonary hypertension, by direct sequencing of the entire coding region and intron/exon boundaries of the BMPR2 gene.  DNA from available parent pairs was used to assess the occurrence of spontaneous (de novo) mutations contributing to sporadic PPH.  The authors found a total of 11 different heterozygous germline mutations of the BMPR2 gene in 13 of the 50 PPH patients studied, including missense, nonsense, and frameshift mutations each predicted to alter the cell signaling response to specific ligands.  Parental anal. showed three occurrences of paternal transmission and two of de novo mutation of the BMPR2 gene in sporadic PPH.  The sporadic form of PPH is assocd. with germline mutations of the gene encoding the receptor protein BMPR-II in at least 26% of cases.  A mol. classification of PPH, based upon the presence or absence of BMPR2 mutations, has important implications for patient management and screening of relatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-vtoLoka2dbVg90H21EOLACvtfcHk0lhMu4hdSA2PCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVOisrs%253D&md5=4bf7123d773053fc55eff0b65078c06d</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1136%2Fjmg.37.10.741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmg.37.10.741%26sid%3Dliteratum%253Aachs%26aulast%3DThomson%26aufirst%3DJ.%2BR.%26aulast%3DMachado%26aufirst%3DR.%2BD.%26aulast%3DPauciulo%26aufirst%3DM.%2BW.%26aulast%3DMorgan%26aufirst%3DN.%2BV.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DElliott%26aufirst%3DG.%2BC.%26aulast%3DWard%26aufirst%3DK.%26aulast%3DYacoub%26aufirst%3DM.%26aulast%3DMikhail%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DP.%26aulast%3DNewman%26aufirst%3DJ.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DHigenbottam%26aufirst%3DT.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%2BR.%26aulast%3DEgan%26aufirst%3DJ.%26aulast%3DCrozier%26aufirst%3DA.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DAllcock%26aufirst%3DR.%26aulast%3DCorris%26aufirst%3DP.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26aulast%3DNichols%26aufirst%3DW.%2BC.%26atitle%3DSporadic%2520primary%2520pulmonary%2520hypertension%2520is%2520associated%2520with%2520germline%2520mutations%2520of%2520the%2520gene%2520encoding%2520BMPR-II%252C%2520a%2520receptor%2520member%2520of%2520the%2520TGF-beta%2520family%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2000%26volume%3D37%26spage%3D741%26epage%3D745%26doi%3D10.1136%2Fjmg.37.10.741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palazzini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichstaedt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinderhofer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptoge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Angelantonio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N. W.</span></span> <span> </span><span class="NLM_article-title">BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(15)00544-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS2213-2600%2815%2900544-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26795434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=129-137&author=J.+D.+W.+Evansauthor=B.+Girerdauthor=D.+Montaniauthor=X.-J.+Wangauthor=N.+Galieauthor=E.+D.+Austinauthor=G.+Elliottauthor=K.+Asanoauthor=E.+Grunigauthor=Y.+Yanauthor=Z.-C.+Jingauthor=A.+Manesauthor=M.+Palazziniauthor=L.+A.+Wheelerauthor=I.+Nakayamaauthor=T.+Satohauthor=C.+Eichstaedtauthor=K.+Hinderhoferauthor=M.+Wolfauthor=E.+B.+Rosenzweigauthor=W.+K.+Chungauthor=F.+Soubrierauthor=G.+Simonneauauthor=O.+Sitbonauthor=S.+Grafauthor=S.+Kaptogeauthor=E.+Di+Angelantonioauthor=M.+Humbertauthor=N.+W.+Morrell&title=BMPR2+mutations+and+survival+in+pulmonary+arterial+hypertension%3A+an+individual+participant+data+meta-analysis&doi=10.1016%2FS2213-2600%2815%2900544-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis</span></div><div class="casAuthors">Evans, Jonathan D. W.; Girerd, Barbara; Montani, David; Wang, Xiao-Jian; Galie, Nazzareno; Austin, Eric D.; Elliott, Greg; Asano, Koichiro; Grunig, Ekkehard; Yan, Yi; Jing, Zhi-Cheng; Manes, Alessandra; Palazzini, Massimiliano; Wheeler, Lisa A.; Nakayama, Ikue; Satoh, Toru; Eichstaedt, Christina; Hinderhofer, Katrin; Wolf, Matthias; Rosenzweig, Erika B.; Chung, Wendy K.; Soubrier, Florent; Simonneau, Gerald; Sitbon, Olivier; Graf, Stefan; Kaptoge, Stephen; Di Angelantonio, Emanuele; Humbert, Marc; Morrell, Nicholas W.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-137</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH).  However, the effect of BMPR2 mutations on clin. phenotype and outcomes remains uncertain.  We analyzed individual participant data of 1550 patients with idiopathic, heritable, and anorexigen-assocd. PAH from eight cohorts that had been systematically tested for BMPR2 mutations.  The primary outcome was the composite of death or lung transplantation.  All-cause mortality was the secondary outcome.  Hazard ratios (HRs) for death or transplantation and all-cause mortality assocd. with the presence of BMPR2 mutation were calcd. using Cox proportional hazards models stratified by cohort.  Overall, 448 (29%) of 1550 patients had a BMPR2 mutation.  Mutation carriers were younger at diagnosis (mean age 35·4 [SD 14·8] vs 42·0 [17·8] years), had a higher mean pulmonary artery pressure (60·5 [13·8] vs 56·4 [15·3] mm Hg) and pulmonary vascular resistance (16·6 [8·3] vs 12·9 [8·3] Wood units), and lower cardiac index (2·11 [0·69] vs 2·51 [0·92] L/min per m2; all p<0·0001).  Patients with BMPR2 mutations were less likely to respond to acute vasodilator testing (3% [10 of 380] vs 16% [147 of 907]; p<0·0001).  Among the 1164 individuals with available survival data, age-adjusted and sex-adjusted HRs comparing BMPR2 mutation carriers with non-carriers were 1·42 (95% CI 1·15-1·75; p=0·0011) for the composite of death or lung transplantation and 1·27 (1·00-1·60; p=0·046) for all-cause mortality.  These HRs were attenuated after adjustment for potential mediators including pulmonary vascular resistance, cardiac index, and vasoreactivity.  HRs for death or transplantation and all-cause mortality assocd. with BMPR2 mutation were similar in men and women, but higher in patients with a younger age at diagnosis (p=0·0030 for death or transplantation, p=0·011 for all-cause mortality).  Patients with PAH and BMPR2 mutations present at a younger age with more severe disease, and are at increased risk of death, and death or transplantation, compared with those without BMPR2 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpil4DxmJ39dLVg90H21EOLACvtfcHk0lhMu4hdSA2PCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSrtbs%253D&md5=eaa90344770804008e9dee30b777d5a1</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2815%2900544-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252815%252900544-5%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%2BD.%2BW.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.-J.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DAsano%26aufirst%3DK.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DJing%26aufirst%3DZ.-C.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DPalazzini%26aufirst%3DM.%26aulast%3DWheeler%26aufirst%3DL.%2BA.%26aulast%3DNakayama%26aufirst%3DI.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DEichstaedt%26aufirst%3DC.%26aulast%3DHinderhofer%26aufirst%3DK.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DRosenzweig%26aufirst%3DE.%2BB.%26aulast%3DChung%26aufirst%3DW.%2BK.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DGraf%26aufirst%3DS.%26aulast%3DKaptoge%26aufirst%3DS.%26aulast%3DDi%2BAngelantonio%26aufirst%3DE.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26atitle%3DBMPR2%2520mutations%2520and%2520survival%2520in%2520pulmonary%2520arterial%2520hypertension%253A%2520an%2520individual%2520participant%2520data%2520meta-analysis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D129%26epage%3D137%26doi%3D10.1016%2FS2213-2600%2815%2900544-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiekerkoetter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudheendra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Bizri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haghighat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haghighat, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Perez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solow-Cordero, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beachy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">FK506 activates BMPR2 rescues endothelial dysfunction, and reverses pulmonary hypertension</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3600</span>– <span class="NLM_lpage">3613</span>, <span class="refDoi"> DOI: 10.1172/JCI65592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI65592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23867624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3600-3613&author=E.+Spiekerkoetterauthor=X.+Tianauthor=J.+Caiauthor=R.+K.+Hopperauthor=D.+Sudheendraauthor=C.+G.+Liauthor=N.+El-Bizriauthor=H.+Sawadaauthor=R.+Haghighatauthor=R.+Chanauthor=L.+Haghighatauthor=V.+de+Jesus+Perezauthor=L.+Wangauthor=S.+Reddyauthor=M.+Zhaoauthor=D.+Bernsteinauthor=D.+E.+Solow-Corderoauthor=P.+A.+Beachyauthor=T.+J.+Wandlessauthor=P.+ten+Dijkeauthor=M.+Rabinovitch&title=FK506+activates+BMPR2+rescues+endothelial+dysfunction%2C+and+reverses+pulmonary+hypertension&doi=10.1172%2FJCI65592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension</span></div><div class="casAuthors">Spiekerkoetter, Edda; Tian, Xuefei; Cai, Jie; Hopper, Rachel K.; Sudheendra, Deepti; Li, Caiyun G.; El-Bizri, Nesrine; Sawada, Hirofumi; Haghighat, Roxanna; Chan, Roshelle; Haghighat, Leila; Perez, Vinicio de Jesus; Wang, Lingli; Reddy, Sushma; Zhao, Mingming; Bernstein, Daniel; Solow-Cordero, David E.; Beachy, Philip A.; Wandless, Thomas J.; ten Dijke, Peter; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3600-3613</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Dysfunctional bone morphogenetic protein receptor-2 (BMPR2) signaling is implicated in the pathogenesis of pulmonary arterial hypertension (PAH).  We used a transcriptional high-throughput luciferase reporter assay to screen 3,756 FDA-approved drugs and bioactive compds. for induction of BMPR2 signaling.  The best response was achieved with FK506 (tacrolimus), via a dual mechanism of action as a calcineurin inhibitor that also binds FK-binding protein-12 (FKBP12), a repressor of BMP signaling.  FK506 released FKBP12 from type I receptors activin receptor-like kinase 1 (ALK1), ALK2, and ALK3 and activated downstream SMAD1/5 and MAPK signaling and ID1 gene regulation in a manner superior to the calcineurin inhibitor cyclosporine and the FKBP12 ligand rapamycin.  In pulmonary artery endothelial cells (ECs) from patients with idiopathic PAH, low-dose FK506 reversed dysfunctional BMPR2 signaling.  In mice with conditional Bmpr2 deletion in ECs, low-dose FK506 prevented exaggerated chronic hypoxic PAH assocd. with induction of EC targets of BMP signaling, such as apelin.  Low-dose FK506 also reversed severe PAH in rats with medial hypertrophy following monocrotaline and in rats with neointima formation following VEGF receptor blockade and chronic hypoxia.  Our studies indicate that low-dose FK506 could be useful in the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw2XivYtxF8bVg90H21EOLACvtfcHk0lhMu4hdSA2PCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtbbJ&md5=5ad349b62d39390a7bfcee1458bd8e12</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1172%2FJCI65592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65592%26sid%3Dliteratum%253Aachs%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DHopper%26aufirst%3DR.%2BK.%26aulast%3DSudheendra%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%2BG.%26aulast%3DEl-Bizri%26aufirst%3DN.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DHaghighat%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DHaghighat%26aufirst%3DL.%26aulast%3Dde%2BJesus%2BPerez%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DReddy%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DSolow-Cordero%26aufirst%3DD.%2BE.%26aulast%3DBeachy%26aufirst%3DP.%2BA.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DFK506%2520activates%2520BMPR2%2520rescues%2520endothelial%2520dysfunction%252C%2520and%2520reverses%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D3600%26epage%3D3613%26doi%3D10.1172%2FJCI65592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiekerkoetter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudheendra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long-Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanian, R. T.</span></span> <span> </span><span class="NLM_article-title">Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1602449</span>, <span class="refDoi"> DOI: 10.1183/13993003.02449-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.02449-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28893866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOqs7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1602449&author=E.+Spiekerkoetterauthor=Y.+K.+Sungauthor=D.+Sudheendraauthor=V.+Scottauthor=P.+Del+Rosarioauthor=M.+Billauthor=F.+Haddadauthor=J.+Long-Boyleauthor=H.+Hedlinauthor=R.+T.+Zamanian&title=Randomised+placebo-controlled+safety+and+tolerability+trial+of+FK506+%28tacrolimus%29+for+pulmonary+arterial+hypertension&doi=10.1183%2F13993003.02449-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension</span></div><div class="casAuthors">Spiekerkoetter, Edda; YSung, on K.; Sudheendra, Deepti; Scott, Valerie; Del Rosario, Patricia; Bill, Matthew; Haddad, Francois; Long-Boyle, Janel; Hedlin, Haley; Zamanian, Roham T.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1602449/1-1602449/12</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a devastating disease characterized by occlusive pulmonary vasculopathy.  Activation of bone morphogenetic protein receptor 2 (BMPR2) signalling by FK506 (tacrolimus) reverses occlusive vasculopathy in rodent PAH models.  Here, we detd. the safety and tolerability of low-level FK506 therapy in stable PAH patients.  We performed a randomized, double-blind, placebo-controlled, 16-wk, single-center, phase IIa trial in PAH patients with New York Heart Assocn. functional class II/III symptoms using three FK506 target levels (<2, 2-3 and 3-5 ng mL-1). 23 patients were randomized and 20 patients completed the trial.  FK506 was generally well tolerated, with nausea/diarrhoea being the most commonly reported adverse event and no observation of line infections in patients on i.v. prostacyclin therapy.  PAH patients had significantly lower BMPR2 expression in peripheral blood mononuclear cells vs. healthy controls (n=13; p=0.005), which improved after FK506 treatment.  While we obsd. that some patients responded with a pronounced increase in BMPR2 expression as well as improvement in 6-min walk distance, and serol. and echocardiog. parameters of heart failure, these changes were not significant.  Low-level FK506 is well tolerated and increases BMPR2 in subsets of PAH patients.  These results support the study of FK506 in a phase IIb efficacy trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIOKtxNjTCtLVg90H21EOLACvtfcHk0liSUfR-zUn39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOqs7%252FJ&md5=dd30eb06b5d86c95394d97c4be875ec8</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1183%2F13993003.02449-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02449-2016%26sid%3Dliteratum%253Aachs%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DSung%26aufirst%3DY.%2BK.%26aulast%3DSudheendra%26aufirst%3DD.%26aulast%3DScott%26aufirst%3DV.%26aulast%3DDel%2BRosario%26aufirst%3DP.%26aulast%3DBill%26aufirst%3DM.%26aulast%3DHaddad%26aufirst%3DF.%26aulast%3DLong-Boyle%26aufirst%3DJ.%26aulast%3DHedlin%26aufirst%3DH.%26aulast%3DZamanian%26aufirst%3DR.%2BT.%26atitle%3DRandomised%2520placebo-controlled%2520safety%2520and%2520tolerability%2520trial%2520of%2520FK506%2520%2528tacrolimus%2529%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2017%26volume%3D50%26spage%3D1602449%26doi%3D10.1183%2F13993003.02449-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, S. Y.</span></span> <span> </span><span class="NLM_article-title">Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1177/153537020623100507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F153537020623100507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XktlCqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2006&pages=534-544&author=Y.+G.+Chenauthor=Q.+Wangauthor=S.+L.+Linauthor=C.+D.+Changauthor=J.+Chungauthor=S.+Y.+Ying&title=Activin+signaling+and+its+role+in+regulation+of+cell+proliferation%2C+apoptosis%2C+and+carcinogenesis&doi=10.1177%2F153537020623100507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis</span></div><div class="casAuthors">Chen, Ye-Guang; Wang, Qiang; Lin, Shi-Lung; Chang, C. Donald; Chung, Jody; Ying, Shao-Yao</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (Maywood, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-544</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Society for Experimental Biology and Medicine</span>)
        </div><div class="casAbstract">A review.  Activins, cytokine members of the transforming growth factor-β superfamily, have various effects on many physiol. processes, including cell proliferation, cell death, metab., homeostasis, differentiation, immune responses endocrine function, etc.  Activins interact with two structurally related serine/threonine kinase receptors, type I and type II, and initiate downstream signaling via Smads to regulate gene expression.  Understanding how activin signaling is controlled extracellularly and intracellularly would not only lead to more complete understanding of cell growth and apoptosis, but would also provide the basis for therapeutic strategies to treat cancer and other related diseases.  This review focuses on the recent progress on activin-receptor interactions, regulations of activin signaling by ligand-binding proteins, receptor-binding proteins, and nucleocytoplasmic shuttling of Smad proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosDb2ITvjIZbVg90H21EOLACvtfcHk0liSUfR-zUn39Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktlCqs7g%253D&md5=2c97f63e0e704d808b22acfc1e73c82c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1177%2F153537020623100507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F153537020623100507%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BG.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DS.%2BL.%26aulast%3DChang%26aufirst%3DC.%2BD.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DYing%26aufirst%3DS.%2BY.%26atitle%3DActivin%2520signaling%2520and%2520its%2520role%2520in%2520regulation%2520of%2520cell%2520proliferation%252C%2520apoptosis%252C%2520and%2520carcinogenesis%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2006%26volume%3D231%26spage%3D534%26epage%3D544%26doi%3D10.1177%2F153537020623100507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchida, K.</span></span> <span> </span><span class="NLM_article-title">Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders</span>. <i>Curr. Drug Targets: Immune, Endocr. Metab. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.2174/1568008043339901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F1568008043339901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15180456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslCmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=157-166&author=K.+Tsuchida&title=Activins%2C+myostatin+and+related+TGF-%CE%B2+family+members+as+novel+therapeutic+targets+for+endocrine%2C+metabolic+and+immune+disorders&doi=10.2174%2F1568008043339901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders</span></div><div class="casAuthors">Tsuchida, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Immune, Endocrine and Metabolic Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">CDTIBT</span>;
        ISSN:<span class="NLM_cas:issn">1568-0088</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Activins and inhibins were first identified by virtue of their ability to regulate FSH secretion from the anterior pituitary.  Activins are also powerful regulators of gonadal functions.  However, the physiol. functions of activins are not restricted to reproductive tissues.  Activins are involved in apoptosis of hepatocytes and B cells, fibrosis, inflammation and neurogenesis.  Activins are regarded as novel drug targets since blocking activins would provide benefits by preventing apoptosis, fibrosis, inflammation and growth of several cancers.  Activins are members of the transforming growth factor-β (TGF-β) family, which has numerous peptide growth and differentiation factors including activins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and TGF-βs.  Among them, GDF8 is also known as myostatin and is structurally related to activins.  Myostatin is specifically expressed in the skeletal muscle lineage and is a candidate for muscle chalone neg. regulating the growth of myoblasts.  Myostatin is regarded as a good drug target since therapeutics that modulate skeletal muscle growth would be useful for disease conditions such as muscular dystrophy, sarcopenia, cachexia and even diabetes.  Recent studies have revealed that activins and myostatin signal through activin type II receptors (ActRIIA and ActRIIB) and their activities are regulated by extracellular binding proteins, follistatins and follistatin-related gene (FLRG).  Furthermore, signaling of activins, myostatin and related ligands is also controlled by intracellular receptor-interacting proteins by novel mechanisms.  In this review, I would like to show the current progress in the field emphasizing the importance of activins and myostatin as novel drug targets for immune, endocrine and metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2xmKCp92gFLVg90H21EOLACvtfcHk0lhBzYMqJMh0Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslCmsLg%253D&md5=0db8183320abb3a098713416bfe35597</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.2174%2F1568008043339901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568008043339901%26sid%3Dliteratum%253Aachs%26aulast%3DTsuchida%26aufirst%3DK.%26atitle%3DActivins%252C%2520myostatin%2520and%2520related%2520TGF-%25CE%25B2%2520family%2520members%2520as%2520novel%2520therapeutic%2520targets%2520for%2520endocrine%252C%2520metabolic%2520and%2520immune%2520disorders%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Immune%252C%2520Endocr.%2520Metab.%2520Disord.%26date%3D2004%26volume%3D4%26spage%3D157%26epage%3D166%26doi%3D10.2174%2F1568008043339901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augur, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocobo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli de Frias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosas, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sako, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearsall, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quisel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">eaaz5660</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaz5660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1126%2Fscitranslmed.aaz5660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=32404506" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eaaz5660&author=L.-M.+Yungauthor=P.+Yangauthor=S.+Joshiauthor=Z.+M.+Augurauthor=S.+S.+J.+Kimauthor=G.+A.+Bocoboauthor=T.+Dinterauthor=L.+Tronconeauthor=P.-S.+Chenauthor=M.+E.+McNeilauthor=M.+Southwoodauthor=S.+Poli+de+Friasauthor=J.+Knopfauthor=I.+O.+Rosasauthor=D.+Sakoauthor=R.+S.+Pearsallauthor=J.+D.+Quiselauthor=G.+Liauthor=R.+Kumarauthor=P.+B.+Yu&title=ACTRIIA-Fc+rebalances+activin%2FGDF+versus+BMP+signaling+in+pulmonary+hypertension&doi=10.1126%2Fscitranslmed.aaz5660"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaz5660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaz5660%26sid%3Dliteratum%253Aachs%26aulast%3DYung%26aufirst%3DL.-M.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DAugur%26aufirst%3DZ.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BS.%2BJ.%26aulast%3DBocobo%26aufirst%3DG.%2BA.%26aulast%3DDinter%26aufirst%3DT.%26aulast%3DTroncone%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DP.-S.%26aulast%3DMcNeil%26aufirst%3DM.%2BE.%26aulast%3DSouthwood%26aufirst%3DM.%26aulast%3DPoli%2Bde%2BFrias%26aufirst%3DS.%26aulast%3DKnopf%26aufirst%3DJ.%26aulast%3DRosas%26aufirst%3DI.%2BO.%26aulast%3DSako%26aufirst%3DD.%26aulast%3DPearsall%26aufirst%3DR.%2BS.%26aulast%3DQuisel%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DACTRIIA-Fc%2520rebalances%2520activin%252FGDF%2520versus%2520BMP%2520signaling%2520in%2520pulmonary%2520hypertension%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26spage%3Deaaz5660%26doi%3D10.1126%2Fscitranslmed.aaz5660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofovic, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzoubi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span> <span> </span><span class="NLM_article-title">Gender, sex hormones and pulmonary hypertension</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.4103/2045-8932.114756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.4103%2F2045-8932.114756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24015330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt1Grsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=294-314&author=E.+D.+Austinauthor=T.+Lahmauthor=J.+Westauthor=S.+P.+Tofovicauthor=A.+K.+Johansenauthor=M.+R.+MacLeanauthor=A.+Alzoubiauthor=M.+Oka&title=Gender%2C+sex+hormones+and+pulmonary+hypertension&doi=10.4103%2F2045-8932.114756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Gender, sex hormones and pulmonary hypertension</span></div><div class="casAuthors">Austin Eric D; Lahm Tim; West James; Tofovic Stevan P; Johansen Anne Katrine; Maclean Margaret R; Alzoubi Abdallah; Oka Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary circulation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">294-314</span>
        ISSN:<span class="NLM_cas:issn">2045-8932</span>.
    </div><div class="casAbstract">Most subtypes of pulmonary arterial hypertension (PAH) are characterized by a greater susceptibility to disease among females, although females with PAH appear to live longer after diagnosis.  While this "estrogen paradox  of enhanced female survival despite increased female susceptibility remains a mystery, recent progress has begun to shed light upon the interplay of sex hormones, the pathogenesis of pulmonary hypertension, and the right ventricular response to stress.  For example, emerging data in humans and experimental models suggest that estrogens or differential sex hormone metabolism may modify disease risk among susceptible subjects, and that estrogens may interact with additional local factors such as serotonin to enhance the potentially damaging chronic effects of estrogens on the pulmonary vasculature.  Regardless, it remains unclear why not all estrogenic compounds behave equally, nor why estrogens appear to be protective in certain settings but detrimental in others.  The contribution of androgens and other compounds, such as dehydroepiandrosterone, to pathogenesis and possibly treatment must be considered as well.  In this review, we will discuss the recent understandings on how estrogens, estrogen metabolism, dehydroepiandrosterone, and additional susceptibility factors may all contribute to the pathogenesis or potentially to the treatment of pulmonary hypertension, by evaluating current human, cell-based, and experimental model data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcUy7J5i-R9rGbPKh4T9eAfW6udTcc2eYnhxjYqx5QKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt1Grsg%253D%253D&md5=0516422de82cbf12a27578d2d9487c09</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.4103%2F2045-8932.114756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2045-8932.114756%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DLahm%26aufirst%3DT.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DTofovic%26aufirst%3DS.%2BP.%26aulast%3DJohansen%26aufirst%3DA.%2BK.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DAlzoubi%26aufirst%3DA.%26aulast%3DOka%26aufirst%3DM.%26atitle%3DGender%252C%2520sex%2520hormones%2520and%2520pulmonary%2520hypertension%26jtitle%3DPulm.%2520Circ.%26date%3D2013%26volume%3D3%26spage%3D294%26epage%3D314%26doi%3D10.4103%2F2045-8932.114756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciuclan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morecroft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mair, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1087</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.062927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.111.062927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22859684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kit73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=1087-1098&author=K.+Whiteauthor=A.+K.+Johansenauthor=M.+Nilsenauthor=L.+Ciuclanauthor=E.+Wallaceauthor=L.+Patonauthor=A.+Campbellauthor=I.+Morecroftauthor=L.+Loughlinauthor=J.+D.+McClureauthor=M.+Thomasauthor=K.+M.+Mairauthor=M.+R.+MacLean&title=Activity+of+the+estrogen-metabolizing+enzyme+cytochrome+P450+1B1+influences+the+development+of+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.111.062927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Estrogen-Metabolizing Enzyme Cytochrome P450 1B1 Influences the Development of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">White, Kevin; Johansen, Anne Katrine; Nilsen, Margaret; Ciuclan, Loredana; Wallace, Emma; Paton, Leigh; Campbell, Annabel; Morecroft, Ian; Loughlin, Lynn; McClure, John D.; Thomas, Matthew; Mair, Kirsty M.; MacLean, Margaret R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1087-1098</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Pulmonary arterial hypertension (PAH) is a hyperproliferative vascular disorder obsd. predominantly in women.  Estrogen is a potent mitogen in human pulmonary artery smooth muscle cells and contributes to PAH in vivo; however, the mechanisms attributed to this causation remain obscure.  Curiously, heightened expression of the estrogen-metabolizing enzyme cytochrome P 450 1B1 (CYP1B1) is reported in idiopathic PAH and murine models of PAH.  Methods and results: Here, we investigated the putative pathogenic role of CYP1B1 in PAH.  Quant. reverse transcription-polymerase chain reaction, immunoblotting, and in situ anal. revealed that pulmonary CYP1B1 is increased in hypoxic PAH, hypoxic+SU5416 PAH, and human PAH and is highly expressed within the pulmonary vascular wall.  PAH was assessed in mice via measurement of right ventricular hypertrophy, pulmonary vascular remodeling, and right ventricular systolic pressure.  Hypoxic PAH was attenuated in CYP1B1 mice, and the potent CYP1B1 inhibitor 2,3',4,5'-tetramethoxystilbene (TMS; 3 mg · kg · d IP) significantly attenuated hypoxic PAH and hypoxic+SU5416 PAH in vivo.  TMS also abolished estrogen-induced proliferation in human pulmonary artery smooth muscle cells and PAH-pulmonary artery smooth muscle cells.  The estrogen metabolite 16α-hydroxyestrone provoked human pulmonary artery smooth muscle cell proliferation, and this mitogenic effect was greatly pronounced in PAH-pulmonary artery smooth muscle cells.  ELISA anal. revealed that 16α-hydroxyestrone concn. was elevated in PAH, consistent with CYP1B1 overexpression and activity.  Finally, administration of the CYP1B1 metabolite 16α-hydroxyestrone (1.5 mg · kg · d IP) caused the development of PAH in mice.  Concusions: Increased CYP1B1-mediated estrogen metab. promotes the development of PAH, likely via the formation of mitogens, including 16α-hydroxyestrone.  Collectively, this study reveals a possible novel therapeutic target in clin. PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGTU4PCypUPrVg90H21EOLACvtfcHk0lhBzYMqJMh0Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kit73F&md5=ade99961b423dec036e0f0de164ec619</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.062927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.062927%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DJohansen%26aufirst%3DA.%2BK.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DCiuclan%26aufirst%3DL.%26aulast%3DWallace%26aufirst%3DE.%26aulast%3DPaton%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DMorecroft%26aufirst%3DI.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DMcClure%26aufirst%3DJ.%2BD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMair%26aufirst%3DK.%2BM.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DActivity%2520of%2520the%2520estrogen-metabolizing%2520enzyme%2520cytochrome%2520P450%25201B1%2520influences%2520the%2520development%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D1087%26epage%3D1098%26doi%3D10.1161%2FCIRCULATIONAHA.111.062927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaddipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, K. B.</span></span> <span> </span><span class="NLM_article-title">BMPR2 expression is suppressed by signaling through the estrogen receptor</span>. <i>Biol. Sex Differ.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.1186/2042-6410-3-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F2042-6410-3-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22348410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVKqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=6&author=E.+D.+Austinauthor=R.+Hamidauthor=A.+R.+Hemnesauthor=J.+E.+Loydauthor=T.+Blackwellauthor=C.+Yuauthor=J.+A.+Phillipsauthor=R.+Gaddipatiauthor=S.+Gladsonauthor=E.+Guauthor=J.+Westauthor=K.+B.+Lane&title=BMPR2+expression+is+suppressed+by+signaling+through+the+estrogen+receptor&doi=10.1186%2F2042-6410-3-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">BMPR2 expression is suppressed by signaling through the estrogen receptor</span></div><div class="casAuthors">Austin, Eric D.; Hamid, Rizwan; Hemnes, Anna R.; Loyd, James E.; Blackwell, Tom; Yu, Chang; Phillips, John A., III; Gaddipati, Radhika; Gladson, Santhi; Gu, Everett; West, James; Lane, Kirk B.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of Sex Differences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>CODEN:
                <span class="NLM_cas:coden">BSDIB9</span>;
        ISSN:<span class="NLM_cas:issn">2042-6410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Studies in multiple organ systems have shown cross-talk between signaling through the bone morphogenetic protein receptor type 2 (BMPR2) and estrogen pathways.  In humans, pulmonary arterial hypertension (PAH) has a female predominance, and is assocd. with decreased BMPR2 expression.  The goal of this study was to det. if estrogens suppress BMPR2 expression.  Methods: A variety of techniques were utilized across several model platforms to evaluate the relationship between estrogens and BMPR2 gene expression.  We used quant. RT-PCR, gel mobility shift, and luciferase activity assays in human samples, live mice, and cell culture.  Results: BMPR2 expression is reduced in lymphocytes from female patients compared with male patients, and in whole lungs from female mice compared with male mice.  There is an evolutionarily conserved estrogen receptor binding site in the BMPR2 promoter, which binds estrogen receptor by gel-shift assay.  Increased exogenous estrogen decreases BMPR2 expression in cell culture, particularly when induced to proliferate.  Transfection of increasing quantities of estrogen receptor alpha correlates strongly with decreasing expression of BMPR2.  Conclusions: BMPR2 gene expression is reduced in females compared to males in live humans and in mice, likely through direct estrogen receptor alpha binding to the BMPR2 promoter.  This reduced BMPR2 expression may contribute to the increased prevalence of PAH in females.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDjUDPfj-fN7Vg90H21EOLACvtfcHk0lirhx2DxsKlDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVKqsb4%253D&md5=b6110ad4045f57748aa935c619d5adcc</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1186%2F2042-6410-3-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2042-6410-3-6%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DHamid%26aufirst%3DR.%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DBlackwell%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DPhillips%26aufirst%3DJ.%2BA.%26aulast%3DGaddipati%26aufirst%3DR.%26aulast%3DGladson%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DE.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DK.%2BB.%26atitle%3DBMPR2%2520expression%2520is%2520suppressed%2520by%2520signaling%2520through%2520the%2520estrogen%2520receptor%26jtitle%3DBiol.%2520Sex%2520Differ.%26date%3D2012%26volume%3D3%26spage%3D6%26doi%3D10.1186%2F2042-6410-3-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farber-Eger, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span> <span> </span><span class="NLM_article-title">Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1602337</span>, <span class="refDoi"> DOI: 10.1183/13993003.02337-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.02337-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28775043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGisbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1602337&author=X.+P.+Chenauthor=E.+D.+Austinauthor=M.+Talatiauthor=J.+P.+Fesselauthor=E.+H.+Farber-Egerauthor=E.+L.+Brittainauthor=A.+R.+Hemnesauthor=J.+E.+Loydauthor=J.+West&title=Oestrogen+inhibition+reverses+pulmonary+arterial+hypertension+and+associated+metabolic+defects&doi=10.1183%2F13993003.02337-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects</span></div><div class="casAuthors">Chen, Xinping; Austin, Eric D.; Talati, Megha; Fessel, Joshua P.; Farber-Eger, Eric H.; Brittain, Evan L.; Hemnes, Anna R.; Loyd, James E.; West, James</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1602337/1-1602337/14</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Increased estrogen is a strong epidemiol. risk factor for development of pulmonary arterial hypertension (PAH) in patients, assocd. with metabolic defects.  In addn., estrogens drive penetrance in mice carrying mutations in bone morphogenetic protein receptor type II (BMPR2), the cause of most heritable PAH.  The goal of the present study was to det. whether inhibition of estrogens was effective in the treatment of PAH in these mice.  The estrogen inhibitors fulvestrant and anastrozole were used in a prevention and treatment paradigm in BMPR2 mutant mice, and tamoxifen was used for treatment.  In addn., BMPR2 mutant mice were crossed onto estrogen receptor (ESR)1 and ESR2 knockout backgrounds to assess receptor specificity.  Haemodynamic and metabolic outcomes were measured.  Estrogen inhibition both prevented and treated PAH in BMPR2 mutant mice.  This was assocd. with redn. in metabolic defects including oxidised lipid formation, insulin resistance and rescue of peroxisome proliferator-activated receptor-γ and CD36.  The effect was mediated primarily through ESR2, but partially through ESR1.  Our data suggest that trials of estrogen inhibition in human PAH are warranted, and may improve pulmonary vascular disease through amelioration of metabolic defects.  Although fulvestrant and anastrozole were more effective than tamoxifen, tamoxifen may be useful in premenopausal females, because of a reduced risk of induction of menopause.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI-goSKEPWGLVg90H21EOLACvtfcHk0lirhx2DxsKlDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGisbjO&md5=aab0f0b57fe92c0dc5a45bf1b19e70e1</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1183%2F13993003.02337-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02337-2016%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BP.%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DTalati%26aufirst%3DM.%26aulast%3DFessel%26aufirst%3DJ.%2BP.%26aulast%3DFarber-Eger%26aufirst%3DE.%2BH.%26aulast%3DBrittain%26aufirst%3DE.%2BL.%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DWest%26aufirst%3DJ.%26atitle%3DOestrogen%2520inhibition%2520reverses%2520pulmonary%2520arterial%2520hypertension%2520and%2520associated%2520metabolic%2520defects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2017%26volume%3D50%26spage%3D1602337%26doi%3D10.1183%2F13993003.02337-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champion, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleaves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. H.</span></span> <span> </span><span class="NLM_article-title">Testosterone negatively regulates right ventricular load stress responses in mice</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.4103/2045-8932.101647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.4103%2F2045-8932.101647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23130103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOrs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=352-358&author=A.+R.+Hemnesauthor=K.+B.+Maynardauthor=H.+C.+Championauthor=L.+Gleavesauthor=N.+Pennerauthor=J.+Westauthor=J.+H.+Newman&title=Testosterone+negatively+regulates+right+ventricular+load+stress+responses+in+mice&doi=10.4103%2F2045-8932.101647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Testosterone negatively regulates right ventricular load stress responses in mice</span></div><div class="casAuthors">Hemnes, Anna R.; Maynard, Karen B.; Champion, Hunter C.; Gleaves, Linda; Penner, Niki; West, James; Newman, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">352-358</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Right ventricular (RV) function is the major determinant of mortality in pulmonary arterial hypertension and male sex is a strong predictor of mortality in this disease.  The effects of testosterone on RV structure and function in load stress are presently unknown.  We tested whether testosterone levels affect RV hypertrophic responses, fibrosis and function.  Male C57BL/6 mice underwent castration or sham followed by pulmonary artery banding (PAB) or sham.  After recovery, testosterone pellets were placed in a subset of the castrated mice and mice were maintained for at least two weeks, when they underwent hemodynamic measurements and tissues were harvested.  Plasma levels of testosterone were reduced by castration and repleted by testosterone administration.  In PAB, castration resulted in lower right ventricle/left ventricle + septum (RV/LV + S) and myocyte diam. (P < 0.05).  Replacement of testosterone normalized these parameters and increased RV fibrosis (P < 0.05).  Two weeks of PAB resulted in increased RV systolic pressure in all groups with decreased markers of RV systolic and diastolic function, specifically reduced ejection fraction and increased time const. and dPdt min. (P < 0.05), though there was minimal effect of testosterone on hemodynamic parameters.  Survival was improved in mice that underwent castration with PAB compared with PAB alone (P < 0.05).  Testosterone affects RV hypertrophic response to load stress through increased myocyte size and increased fibrosis in mice.  Castration and testosterone replacement are not accompanied by significant alterations in RV in vivo hemodynamics, but testosterone deprivation appears to improve survival in PAB.  Further study of the role of testosterone in RV dysfunction is warranted to better understand these findings in the context of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSnxnznj6vwrVg90H21EOLACvtfcHk0lii21mHXt9Ohw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOrs7vK&md5=35798590ccecab369d1bea43deda0c80</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.4103%2F2045-8932.101647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2045-8932.101647%26sid%3Dliteratum%253Aachs%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DMaynard%26aufirst%3DK.%2BB.%26aulast%3DChampion%26aufirst%3DH.%2BC.%26aulast%3DGleaves%26aufirst%3DL.%26aulast%3DPenner%26aufirst%3DN.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26atitle%3DTestosterone%2520negatively%2520regulates%2520right%2520ventricular%2520load%2520stress%2520responses%2520in%2520mice%26jtitle%3DPulm.%2520Circ.%26date%3D2012%26volume%3D2%26spage%3D352%26epage%3D358%26doi%3D10.4103%2F2045-8932.101647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer-Chicko, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palevsky, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisciano, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Propert, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanczyk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittenhall, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventetuolo, C. E.</span></span> <span> </span><span class="NLM_article-title">Anastrozole in pulmonary arterial hypertension a randomized, double-blind, placebo-controlled trial</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1164/rccm.201605-1024OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201605-1024OC" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2016&pages=360-368&author=S.+M.+Kawutauthor=C.+L.+Archer-Chickoauthor=A.+DiMicheleauthor=J.+S.+Fritzauthor=J.+R.+Klingerauthor=B.+Kyauthor=H.+I.+Palevskyauthor=A.+J.+Palmiscianoauthor=M.+Patelauthor=D.+Pinderauthor=K.+J.+Propertauthor=K.+A.+Smithauthor=F.+Stanczykauthor=R.+Tracyauthor=A.+Vaidyaauthor=M.+E.+Whittenhallauthor=C.+E.+Ventetuolo&title=Anastrozole+in+pulmonary+arterial+hypertension+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1164%2Frccm.201605-1024OC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1164%2Frccm.201605-1024OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201605-1024OC%26sid%3Dliteratum%253Aachs%26aulast%3DKawut%26aufirst%3DS.%2BM.%26aulast%3DArcher-Chicko%26aufirst%3DC.%2BL.%26aulast%3DDiMichele%26aufirst%3DA.%26aulast%3DFritz%26aufirst%3DJ.%2BS.%26aulast%3DKlinger%26aufirst%3DJ.%2BR.%26aulast%3DKy%26aufirst%3DB.%26aulast%3DPalevsky%26aufirst%3DH.%2BI.%26aulast%3DPalmisciano%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPinder%26aufirst%3DD.%26aulast%3DPropert%26aufirst%3DK.%2BJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DStanczyk%26aufirst%3DF.%26aulast%3DTracy%26aufirst%3DR.%26aulast%3DVaidya%26aufirst%3DA.%26aulast%3DWhittenhall%26aufirst%3DM.%2BE.%26aulast%3DVentetuolo%26aufirst%3DC.%2BE.%26atitle%3DAnastrozole%2520in%2520pulmonary%2520arterial%2520hypertension%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2016%26volume%3D195%26spage%3D360%26epage%3D368%26doi%3D10.1164%2Frccm.201605-1024OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Naamani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palevsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankoff, D.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant for the treatment of pulmonary arterial hypertension</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1456</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201904-328RL</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1513%2FAnnalsATS.201904-328RL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31314997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3Mzot1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=1456-1459&author=S.+Kawutauthor=D.+Pinderauthor=N.+Al-Naamaniauthor=A.+McCormickauthor=H.+Palevskyauthor=J.+Fritzauthor=K.+Smithauthor=J.+Mazurekauthor=M.+Doyleauthor=M.+MacLeanauthor=A.+DeMicheleauthor=D.+Mankoff&title=Fulvestrant+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1513%2FAnnalsATS.201904-328RL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Kawut Steven M; Pinder Diane; Al-Naamani Nadine; McCormick Amber; Palevsky Harold I; Fritz Jason; Smith K Akaya; Mazurek Jeremy A; DeMichele Angela; Mankoff David A; Doyle Margaret F; MacLean Margaret R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1456-1459</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWZiQOqYuLoMzK395ZObgVfW6udTcc2ebr-DlSbZ6yR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mzot1Kqsg%253D%253D&md5=46e90f24e4dbe259b2da7150b4ab9ddf</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201904-328RL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201904-328RL%26sid%3Dliteratum%253Aachs%26aulast%3DKawut%26aufirst%3DS.%26aulast%3DPinder%26aufirst%3DD.%26aulast%3DAl-Naamani%26aufirst%3DN.%26aulast%3DMcCormick%26aufirst%3DA.%26aulast%3DPalevsky%26aufirst%3DH.%26aulast%3DFritz%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DMazurek%26aufirst%3DJ.%26aulast%3DDoyle%26aufirst%3DM.%26aulast%3DMacLean%26aufirst%3DM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DMankoff%26aufirst%3DD.%26atitle%3DFulvestrant%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2019%26volume%3D16%26spage%3D1456%26epage%3D1459%26doi%3D10.1513%2FAnnalsATS.201904-328RL" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maron, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, J. A.</span></span> <span> </span><span class="NLM_article-title">Emerging concepts in the molecular basis of pulmonary arterial hypertension part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2079</span>– <span class="NLM_lpage">2091</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.114.006980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.114.006980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26056345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2MbhvVyntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2015&pages=2079-2091&author=B.+A.+Maronauthor=J.+A.+Leopold&title=Emerging+concepts+in+the+molecular+basis+of+pulmonary+arterial+hypertension+part+II%3A+neurohormonal+signaling+contributes+to+the+pulmonary+vascular+and+right+ventricular+pathophenotype+of+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.114.006980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Maron Bradley A; Leopold Jane A</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2079-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSG1EvMG3_C9bHMBt0mMIXfW6udTcc2ebr-DlSbZ6yR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbhvVyntQ%253D%253D&md5=90439325950a5f24f31599ccf04a9221</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.114.006980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.114.006980%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DB.%2BA.%26aulast%3DLeopold%26aufirst%3DJ.%2BA.%26atitle%3DEmerging%2520concepts%2520in%2520the%2520molecular%2520basis%2520of%2520pulmonary%2520arterial%2520hypertension%2520part%2520II%253A%2520neurohormonal%2520signaling%2520contributes%2520to%2520the%2520pulmonary%2520vascular%2520and%2520right%2520ventricular%2520pathophenotype%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2015%26volume%3D131%26spage%3D2079%26epage%3D2091%26doi%3D10.1161%2FCIRCULATIONAHA.114.006980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theccanat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogoriler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaxall, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, S. L.</span></span> <span> </span><span class="NLM_article-title">GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy therapeutic implications in pulmonary hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">2859</span>– <span class="NLM_lpage">2869</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.112.109868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.112.109868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23124027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVeksr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=2859-2869&author=L.+Piaoauthor=Y.+H.+Fangauthor=K.+S.+Parikhauthor=J.+J.+Ryanauthor=K.+M.+D%E2%80%99Souzaauthor=T.+Theccanatauthor=P.+T.+Tothauthor=J.+Pogorilerauthor=J.+Paulauthor=B.+C.+Blaxallauthor=S.+A.+Akhterauthor=S.+L.+Archer&title=GRK2-mediated+inhibition+of+adrenergic+and+dopaminergic+signaling+in+right+ventricular+hypertrophy+therapeutic+implications+in+pulmonary+hypertension&doi=10.1161%2FCIRCULATIONAHA.112.109868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">GRK2-Mediated Inhibition of Adrenergic and Dopaminergic Signaling in Right Ventricular Hypertrophy: Therapeutic Implications in Pulmonary Hypertension</span></div><div class="casAuthors">Piao, Lin; Fang, Yong-Hu; Parikh, Kishan S.; Ryan, John J.; D'Souza, Karen M.; Theccanat, Tiju; Toth, Peter T.; Pogoriler, Jennifer; Paul, Jonathan; Blaxall, Burns C.; Akhter, Shahab A.; Archer, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2859-2869</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: The cause and consequences of impaired adrenergic signaling in right ventricular failure/hypertrophy (RVH) are poorly understood.  We hypothesized that G protein-coupled receptor kinase-2 (GRK2)-mediated uncoupling of β-adrenergic receptor signaling impairs inotropic reserve.  The implications of right ventricular (RV) adrenergic remodeling for inotrope selection and the therapeutic benefit of interrupting Gβγ-GRK2 interaction, using gallein, were tested.  METHODS AND RESULTS: Chamber-specificity and cellular localization of adrenergic remodeling were compared in rodent RVH assocd. with pulmonary arterial hypertension (PAH-RVH; SU5416+chronic-hypoxia or Monocrotaline) vs. pulmonary artery banding-induced RVH (PAB-RVH).  Results were corroborated in RV arrays from 10 PAH patients vs. controls.  Inotropic reserve was assessed in RV- and left ventricular-Langendorff models and in vivo.  Gallein therapy (1.8 mg/kg/day ×2-wk) was assessed.  Despite similar RVH, cardiac output (58.3±4.9 vs. 82.9±4.8 mL/min; P<0.001) and treadmill distance (41.5±11.6 vs. 244.1±12.4 m; P<0.001) were lower in PAH-RVH vs. PAB-RVH.  In PAH-RVH vs. PAB-RVH there was greater downregulation of β1-, α1- and dopamine-1 receptors, more left ventricular involvement, and greater impairment of RV contractile reserve.  RV GRK2 activity increased in parallel with a redn. in both adrenergic receptor expression and inotrope-stimulated cAMP levels (P<0.01). β1-receptor downregulation also occurred in human PAH-RVH.  Dobutamine was superior to dopamine as an RV inotrope, both ex vivo and in vivo.  CONCLUSIONS: GRK2-mediated desensitization-downregulation of adrenergic and dopaminergic receptors impairs inotropic reserve in PAH-RVH.  Acute inotropic support in RVH is best accomplished by dobutamine, reflecting its better coupling to adenylyl cyclase and the reliance of dopamine on dopamine-1-receptor signaling, which is impaired in RVH.  Inhibiting Gβγ-GRK2 interactions has therapeutic benefit in RVH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnSYQaT00wrVg90H21EOLACvtfcHk0lgNO_b-L1G6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVeksr%252FP&md5=768b029e33781eb8edd14e03ee1f0911</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.109868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.109868%26sid%3Dliteratum%253Aachs%26aulast%3DPiao%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DY.%2BH.%26aulast%3DParikh%26aufirst%3DK.%2BS.%26aulast%3DRyan%26aufirst%3DJ.%2BJ.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DK.%2BM.%26aulast%3DTheccanat%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DP.%2BT.%26aulast%3DPogoriler%26aufirst%3DJ.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DBlaxall%26aufirst%3DB.%2BC.%26aulast%3DAkhter%26aufirst%3DS.%2BA.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26atitle%3DGRK2-mediated%2520inhibition%2520of%2520adrenergic%2520and%2520dopaminergic%2520signaling%2520in%2520right%2520ventricular%2520hypertrophy%2520therapeutic%2520implications%2520in%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D2859%26epage%3D2869%26doi%3D10.1161%2FCIRCULATIONAHA.112.109868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogaard, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, V. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoke, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskauskas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelkel, N. F.</span></span> <span> </span><span class="NLM_article-title">Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1164/rccm.201003-0335OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201003-0335OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20508210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yhtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=652-660&author=H.+J.+Bogaardauthor=R.+Natarajanauthor=S.+Mizunoauthor=A.+Abbateauthor=P.+J.+Changauthor=V.+Q.+Chauauthor=N.+N.+Hokeauthor=D.+Kraskauskasauthor=M.+Kasperauthor=F.+N.+Salloumauthor=N.+F.+Voelkel&title=Adrenergic+receptor+blockade+reverses+right+heart+remodeling+and+dysfunction+in+pulmonary+hypertensive+rats&doi=10.1164%2Frccm.201003-0335OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats</span></div><div class="casAuthors">Bogaard, Harm J.; Natarajan, Ramesh; Mizuno, Shiro; Abbate, Antonio; Chang, Philip J.; Chau, Vinh Q.; Hoke, Nicholas N.; Kraskauskas, Donatas; Kasper, Michael; Salloum, Fadi N.; Voelkel, Norbert F.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-660</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Most patients with pulmonary arterial hypertension (PAH) die from right heart failure.  β-Adrenergic receptor blockade reduces mortality by about 30% in patients with left-sided systolic heart failure, but is not used in PAH.  Objectives: To assess the effect of the adrenergic receptor blocker carvedilol on the pulmonary circulation and right heart in exptl. pulmonary hypertension in rats.  Methods: Angioproliferative pulmonary hypertension was induced in rats by combined exposure to the vascular endothelial growth factor-receptor antagonist SU5416 and hypoxia.  Carvedilol treatment was started after establishment of pulmonary hypertension and right heart dysfunction.  Measurements and Main Results: Compared with vehicle-treated animals, treatment with carvedilol resulted in increased exercise endurance; improved right ventricular (RV) function (increased tricuspid annular plane systolic excursion and decreased RV dilatation); and an increased cardiac output.  The morphol. of the pulmonary vessels and the RV afterload were not affected by carvedilol.  Carvedilol treatment was assocd. with enhancement of RV fetal gene reactivation, increased protein kinase G (PKG) activity, and a redn. in capillary rarefaction and fibrosis.  Metoprolol had similar but less pronounced effects in the SU5416 and hypoxia model.  Cardioprotective effects were noted of both carvedilol and metoprolol in the monocrotaline model.  In the case of carvedilol, but not metoprolol, part of these effects resulted from a prevention of monocrotaline-induced lung remodeling.  Conclusions: Adrenergic receptor blockade reverses RV remodeling and improves RV function in exptl. pulmonary hypertension.  β-Adrenergic receptor blockers are not recommended in humans with PAH before their safety and efficacy are assessed in well-designed clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6wJ8_tfYGxLVg90H21EOLACvtfcHk0lgNO_b-L1G6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yhtrzJ&md5=cfc04844eb9ca5b533d9f7bbabcda90d</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1164%2Frccm.201003-0335OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201003-0335OC%26sid%3Dliteratum%253Aachs%26aulast%3DBogaard%26aufirst%3DH.%2BJ.%26aulast%3DNatarajan%26aufirst%3DR.%26aulast%3DMizuno%26aufirst%3DS.%26aulast%3DAbbate%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DP.%2BJ.%26aulast%3DChau%26aufirst%3DV.%2BQ.%26aulast%3DHoke%26aufirst%3DN.%2BN.%26aulast%3DKraskauskas%26aufirst%3DD.%26aulast%3DKasper%26aufirst%3DM.%26aulast%3DSalloum%26aufirst%3DF.%2BN.%26aulast%3DVoelkel%26aufirst%3DN.%2BF.%26atitle%3DAdrenergic%2520receptor%2520blockade%2520reverses%2520right%2520heart%2520remodeling%2520and%2520dysfunction%2520in%2520pulmonary%2520hypertensive%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D652%26epage%3D660%26doi%3D10.1164%2Frccm.201003-0335OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Man, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handoko, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Ballegoij, J. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalij, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaards, S. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postmus, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Velden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerhof, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulus, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span> <span> </span><span class="NLM_article-title">Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension</span>. <i>Circ.: Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1161/CIRCHEARTFAILURE.111.964494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCHEARTFAILURE.111.964494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22157723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=97-105&author=F.+S.+de+Manauthor=M.+L.+Handokoauthor=J.+J.+M.+van+Ballegoijauthor=I.+Schalijauthor=S.+J.+P.+Bogaardsauthor=P.+E.+Postmusauthor=J.+van+der%0AVeldenauthor=N.+Westerhofauthor=W.+J.+Paulusauthor=A.+Vonk-Noordegraaf&title=Bisoprolol+delays+progression+towards+right+heart+failure+in+experimental+pulmonary+hypertension&doi=10.1161%2FCIRCHEARTFAILURE.111.964494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension</span></div><div class="casAuthors">de Man, Frances S.; Handoko, M. Louis; van Ballegoij, Joris J. M.; Schalij, Ingrid; Bogaards, Sylvia J. P.; Postmus, Pieter E.; van der Velden, Jolanda; Westerhof, Nico; Paulus, Walter J.; Vonk-Noordegraaf, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Circulation: Heart Failure</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-105</span>CODEN:
                <span class="NLM_cas:coden">CHFICM</span>;
        ISSN:<span class="NLM_cas:issn">1941-3289</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: In pulmonary arterial hypertension (PH), sympathetic adrenergic activity is highly elevated.  Sympathetic overactivity is a compensatory mechanism at first, but might be detrimental for cardiac function in the long run.  We therefore investigated whether chronic low-dose treatment with bisoprolol (a cardioselective β-blocker) has beneficial effects on cardiac function in exptl. PH.  Methods and Results: PH was induced in rats by a single injection of monocrotaline (60 mg/kg).  Pressure telemetry in PH rats revealed that 10 mg/kg bisoprolol was the lowest dose that blunted heart rate response during daily activity.  Ten days after monocrotaline injection, echocardiog. was performed and PH rats were randomized for bisoprolol treatment (oral gavage) or vehicle (n=7/group).  At end of study (body mass loss >5%), echocardiog. was repeated, with addnl. pressure-vol. measurements and histomol. analyses.  Compared with control, right ventricular (RV) systolic pressure and arterial elastance (measure of vascular resistance) more than tripled in PH.  Bisoprolol delayed time to right heart failure (P<0.05).  RV afterload was unaffected, however, bisoprolol treatment increased RV contractility and filling (both P<0.01), and partially restored right ventriculo-arterial coupling and cardiac output (both P<0.05).  Bisoprolol restored RV β-adrenergic receptor signaling.  Histol. revealed significantly less RV fibrosis and myocardial inflammation in bisoprolol treated PH rats.  Conclusions: In exptl. PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function.  These promising results suggest a therapeutic role for β-blockers in PH that warrants further clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ4g99I61kR7Vg90H21EOLACvtfcHk0lgNO_b-L1G6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVCrt70%253D&md5=0c7bf27bad4692d06dc27cd4f9935653</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1161%2FCIRCHEARTFAILURE.111.964494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCHEARTFAILURE.111.964494%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMan%26aufirst%3DF.%2BS.%26aulast%3DHandoko%26aufirst%3DM.%2BL.%26aulast%3Dvan%2BBallegoij%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DSchalij%26aufirst%3DI.%26aulast%3DBogaards%26aufirst%3DS.%2BJ.%2BP.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DJ.%26aulast%3DWesterhof%26aufirst%3DN.%26aulast%3DPaulus%26aufirst%3DW.%2BJ.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26atitle%3DBisoprolol%2520delays%2520progression%2520towards%2520right%2520heart%2520failure%2520in%2520experimental%2520pulmonary%2520hypertension%26jtitle%3DCirc.%253A%2520Heart%2520Failure%26date%3D2012%26volume%3D5%26spage%3D97%26epage%3D105%26doi%3D10.1161%2FCIRCHEARTFAILURE.111.964494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asosingh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comhair, S. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highland, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erzurum, S. C.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">95240</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.95240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2Fjci.insight.95240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28814664" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=95240&author=S.+Farhaauthor=D.+Sayginauthor=M.+M.+Parkauthor=H.+I.+Cheongauthor=K.+Asosinghauthor=S.+A.+A.+Comhairauthor=O.+R.+Stephensauthor=E.+C.+Roachauthor=J.+Sharpauthor=K.+B.+Highlandauthor=F.+P.+DiFilippoauthor=D.+R.+Neumannauthor=W.+H.+W.+Tangauthor=S.+C.+Erzurum&title=Pulmonary+arterial+hypertension+treatment+with+carvedilol+for+heart+failure%3A+a+randomized+controlled+trial&doi=10.1172%2Fjci.insight.95240"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.95240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.95240%26sid%3Dliteratum%253Aachs%26aulast%3DFarha%26aufirst%3DS.%26aulast%3DSaygin%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DM.%2BM.%26aulast%3DCheong%26aufirst%3DH.%2BI.%26aulast%3DAsosingh%26aufirst%3DK.%26aulast%3DComhair%26aufirst%3DS.%2BA.%2BA.%26aulast%3DStephens%26aufirst%3DO.%2BR.%26aulast%3DRoach%26aufirst%3DE.%2BC.%26aulast%3DSharp%26aufirst%3DJ.%26aulast%3DHighland%26aufirst%3DK.%2BB.%26aulast%3DDiFilippo%26aufirst%3DF.%2BP.%26aulast%3DNeumann%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DW.%2BH.%2BW.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520treatment%2520with%2520carvedilol%2520for%2520heart%2520failure%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26spage%3D95240%26doi%3D10.1172%2Fjci.insight.95240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van Campen, J. S.J.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Veerdonk, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Bruggen, C. E.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaart, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raijmakers, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymans, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handoko, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaard, H.-J.</span></span> <span> </span><span class="NLM_article-title">Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1183/13993003.00090-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.00090-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27390285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2s7nvFOquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=787-796&author=J.+S.J.A.+van+Campenauthor=K.+de+Boerauthor=M.+C.+van+de+Veerdonkauthor=C.+E.E.+van+der+Bruggenauthor=C.+P.+Allaartauthor=P.+G.+Raijmakersauthor=M.+W.+Heymansauthor=J.+T.+Marcusauthor=H.+J.+Harmsauthor=M.+L.+Handokoauthor=F.+S.+de+Manauthor=A.+Vonk+Noordegraafauthor=H.-J.+Bogaard&title=Bisoprolol+in+idiopathic+pulmonary+arterial+hypertension%3A+an+explorative+study&doi=10.1183%2F13993003.00090-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study</span></div><div class="casAuthors">van Campen Jasmijn S J A; de Boer Karin; van de Veerdonk Marielle C; van der Bruggen Cathelijne E E; Vonk Noordegraaf Anton; Allaart Cor P; Handoko M Louis; Raijmakers Pieter G; Heymans Martijn W; Marcus J Tim; Harms Hendrik J; de Man Frances S; Bogaard Harm-Jan</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">787-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">While beta-blockers are considered contraindicated in pulmonary arterial hypertension (PAH), the prognostic significance of sympathetic nervous system over-activity suggests a potential benefit of beta-blocker therapy.  The aim of this randomised, placebo-controlled, crossover, single centre study was to determine the effects of bisoprolol on right ventricular ejection fraction (RVEF) in idiopathic PAH (iPAH) patients.  Additional efficacy and safety parameters were explored.Patients with optimally treated, stable iPAH (New York Heart Association functional class II/III) were randomised to placebo or bisoprolol.  Imaging and functional measurements were performed at baseline, crossover and end of study.18 iPAH patients were included, because inclusion faltered before enrolment of the targeted 25 patients. 17 patients completed 6 months of bisoprolol, 15 tolerated bisoprolol, one patient required intravenous diuretics.  Bisoprolol was associated with a lower heart rate (17 beats per minute, p=0.0001) but RVEF remained unchanged.  A drop in cardiac index (0.5 L·min(-1)·m(-2), p=0.015) was observed, along with a trend towards a decreased 6-min walking distance (6MWD).Although careful up-titration of bisoprolol was tolerated by most patients and resulted in a decreased heart rate, no benefit of bisoprolol in iPAH was demonstrated.  Decreases in cardiac index and 6MWD suggest a deteriorated cardiac function.  The results do not favour the use of bisoprolol in iPAH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_zHE52IrdNNTrvPZP1IpfW6udTcc2eas_SgEemitcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7nvFOquw%253D%253D&md5=917e7c1c05dda5ab5848185833efe972</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1183%2F13993003.00090-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.00090-2016%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BCampen%26aufirst%3DJ.%2BS.J.A.%26aulast%3Dde%2BBoer%26aufirst%3DK.%26aulast%3Dvan%2Bde%2BVeerdonk%26aufirst%3DM.%2BC.%26aulast%3Dvan%2Bder%2BBruggen%26aufirst%3DC.%2BE.E.%26aulast%3DAllaart%26aufirst%3DC.%2BP.%26aulast%3DRaijmakers%26aufirst%3DP.%2BG.%26aulast%3DHeymans%26aufirst%3DM.%2BW.%26aulast%3DMarcus%26aufirst%3DJ.%2BT.%26aulast%3DHarms%26aufirst%3DH.%2BJ.%26aulast%3DHandoko%26aufirst%3DM.%2BL.%26aulast%3Dde%2BMan%26aufirst%3DF.%2BS.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3DBogaard%26aufirst%3DH.-J.%26atitle%3DBisoprolol%2520in%2520idiopathic%2520pulmonary%2520arterial%2520hypertension%253A%2520an%2520explorative%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2016%26volume%3D48%26spage%3D787%26epage%3D796%26doi%3D10.1183%2F13993003.00090-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrario, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strawn, W. B.</span></span> <span> </span><span class="NLM_article-title">Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2006.01.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.amjcard.2006.01.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16784934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVOju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=121-128&author=C.+M.+Ferrarioauthor=W.+B.+Strawn&title=Role+of+the+renin-angiotensin-aldosterone+system+and+proinflammatory+mediators+in+cardiovascular+disease&doi=10.1016%2Fj.amjcard.2006.01.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Renin-Angiotensin-Aldosterone System and Proinflammatory Mediators in Cardiovascular Disease</span></div><div class="casAuthors">Ferrario, Carlos M.; Strawn, William B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Inflammation is a key mechanism in the initiation, progression, and clin. sequelae of cardiovascular diseases (CVDs), including atherosclerosis, nephropathy, and cardiomyopathy.  Angiotensin II, the major effector peptide of the renin-angiotensin-aldosterone system (RAAS), plays a significant role in the advent and perpetuation of these inflammatory diseases, most notably in atherogenesis.  Consequently, suppression of the influence of angiotensin II by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce or potentially reverse atherosclerosis and other inflammation-assocd. CVDs.  Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors exert anti-inflammatory actions and prevent or reduce the development of atherosclerosis in animal models.  Clin., RAAS suppression reduces common carotid and femoral artery intima-media thickness, thus indicating moderation of the vascular disease process.  These clin. benefits likely involve restraint of the deleterious effects of angiotensin II in addn. to, or independent of, lowering blood pressure.  Increasing evidence that the detection and monitoring of vascular inflammation are important tools in the management of atherosclerosis also implicates the RAAS in this pathogenic process.  Inflammatory mols. such as intercellular adhesion mol.-1, vascular cell adhesion mol.-1, monocyte chemoattractant protein-1, tumor necrosis factor-α, and C-reactive protein have potential diagnostic and prognostic values in CVD and are modified by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.  Monitoring these markers may be crucial for detg. which agents, or combinations of agents, will result in the most clin. beneficial outcomes for patients.  Large-scale trials are still required to det. the effects of the long-term suppression of inflammation on CVDs through the use of RAAS modulating agents, as well as to det. how closely markers of inflammatory activity may correlate with CVD outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosh0yQAEuVR7Vg90H21EOLACvtfcHk0liUklQvtdVESg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVOju7w%253D&md5=b9843797edf7a0e38d78e690d720efa7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2006.01.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2006.01.059%26sid%3Dliteratum%253Aachs%26aulast%3DFerrario%26aufirst%3DC.%2BM.%26aulast%3DStrawn%26aufirst%3DW.%2BB.%26atitle%3DRole%2520of%2520the%2520renin-angiotensin-aldosterone%2520system%2520and%2520proinflammatory%2520mediators%2520in%2520cardiovascular%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2006%26volume%3D98%26spage%3D121%26epage%3D128%26doi%3D10.1016%2Fj.amjcard.2006.01.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Man, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handoko, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalij, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonstra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postmus, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velden, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span> <span> </span><span class="NLM_article-title">Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1164/rccm.201203-0411OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201203-0411OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22859525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslynsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2012&pages=780-789&author=F.+S.+de+Manauthor=L.+Tuauthor=M.+L.+Handokoauthor=S.+Rainauthor=G.+Ruiterauthor=C.+Francoisauthor=I.+Schalijauthor=P.+Dorfmullerauthor=G.+Simonneauauthor=E.+Fadelauthor=F.+Perrosauthor=A.+Boonstraauthor=P.+E.+Postmusauthor=I.+van+der+Veldenauthor=A.+Vonk-Noordegraafauthor=M.+Humbertauthor=S.+Eddahibiauthor=C.+Guignabert&title=Dysregulated+renin-angiotensin-aldosterone+system+contributes+to+pulmonary+arterial+hypertension&doi=10.1164%2Frccm.201203-0411OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension</span></div><div class="casAuthors">de Man, Frances S.; Tu, Ly; Handoko, M. Louis; Rain, Silvia; Ruiter, Gerrina; Francois, Charlene; Schalij, Ingrid; Dorfmuller, Peter; Simonneau, Gerald; Fadel, Elie; Perros, Frederic; Boonstra, Anco; Postmus, Piet E.; van der Velden, Jolanda; Vonk-Noordegraaf, Anton; Humbert, Marc; Eddahibi, Saadia; Guignabert, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">780-789</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Patients with idiopathic pulmonary arterial hypertension (iPAH) often have a low cardiac output.  To compensate, neurohormonal systems such as the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system are up-regulated, but this may have long-term neg. effects on the progression of iPAH.  Objectives: Assess systemic and pulmonary RAAS activity in patients with iPAH and det. the efficacy of chronic RAAS inhibition in exptl. PAH.  Methods: We collected 79 blood samples from 58 patients with iPAH in the VU University Medical Center Amsterdam (between 2004 and 2010) to det. systemic RAAS activity.  Measurements and Main Results: We obsd. increased levels of renin, angiotensin (Ang)I, and AngII, which were assocd. with disease progression (P < 0.05) and mortality (P < 0.05).  To det. pulmonary RAAS activity, lung specimens were obtained from patients with iPAH (during lung transplantation, n = 13) and control subjects (during lobectomy or pneumonectomy for cancer, n = 14).  Local RAAS activity in pulmonary arteries of patients with iPAH was increased, demonstrated by elevated angiotensin-converting enzyme activity in pulmonary endothelial cells and increased AngII type 1 (AT1) receptor expression and signaling.  In addn., local RAAS up-regulation was assocd. with increased pulmonary artery smooth muscle cell proliferation via enhanced AT1 receptor signaling in patients with iPAH compared with control subjects.  Finally, to det. the therapeutic potential of RAAS activity, we assessed the chronic effects of an AT1 receptor antagonist (losartan) in the monocrotaline PAH rat model (60 mg/kg).  Losartan delayed disease progression, decreased right ventricular afterload and pulmonary vascular remodeling, and restored right ventricular-arterial coupling in rats with PAH.  Conclusions: Systemic and pulmonary RAAS activities are increased in patients with iPAH and are assocd. with increased pulmonary vascular remodeling.  Chronic inhibition of RAAS by losartan is beneficial in exptl. PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraIen40FBoKbVg90H21EOLACvtfcHk0liUklQvtdVESg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslynsrfJ&md5=a4a0689ac69e3f81289e0ecbba1a3e0a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1164%2Frccm.201203-0411OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201203-0411OC%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMan%26aufirst%3DF.%2BS.%26aulast%3DTu%26aufirst%3DL.%26aulast%3DHandoko%26aufirst%3DM.%2BL.%26aulast%3DRain%26aufirst%3DS.%26aulast%3DRuiter%26aufirst%3DG.%26aulast%3DFrancois%26aufirst%3DC.%26aulast%3DSchalij%26aufirst%3DI.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DI.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DGuignabert%26aufirst%3DC.%26atitle%3DDysregulated%2520renin-angiotensin-aldosterone%2520system%2520contributes%2520to%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D186%26spage%3D780%26epage%3D789%26doi%3D10.1164%2Frccm.201203-0411OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maron, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opotowsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landzberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, J. A.</span></span> <span> </span><span class="NLM_article-title">Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1093/eurjhf/hfs173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1093%2Feurjhf%2Fhfs173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23111998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=277-283&author=B.+A.+Maronauthor=A.+R.+Opotowskyauthor=M.+J.+Landzbergauthor=J.+Loscalzoauthor=A.+B.+Waxmanauthor=J.+A.+Leopold&title=Plasma+aldosterone+levels+are+elevated+in+patients+with+pulmonary+arterial+hypertension+in+the+absence+of+left+ventricular+heart+failure%3A+a+pilot+study&doi=10.1093%2Feurjhf%2Fhfs173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study</span></div><div class="casAuthors">Maron, Bradley A.; Opotowsky, Alexander R.; Landzberg, Michael J.; Loscalzo, Joseph; Waxman, Aaron B.; Leopold, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-283</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Elevated levels of the mineralocorticoid hormone aldosterone are recognized as a modifiable contributor to the pathophysiol. of select cardiovascular diseases due to left heart failure.  In pulmonary arterial hypertension (PAH), pulmonary vascular remodelling induces right ventricular dysfunction and heart failure in the absence of left ventricular (LV) dysfunction.  Hyperaldosteronism has emerged as a promoter of pulmonary vascular disease in exptl. animal models of PAH; however, the extent to which hyperaldosteronism is assocd. with PAH in patients is unknown.  Thus, the central aim of the current study is to det. if hyperaldosteronism is an unrecognized component of the PAH clin. syndrome.  Methods and results: Plasma aldosterone levels and invasive cardiopulmonary haemodynamic measurements were obtained for 25 patients referred for evaluation of unexplained dyspnoea or pulmonary hypertension.  Compared with controls (n = 5), patients with PAH (n = 18) demonstrated significantly increased plasma aldosterone levels (1200.4 ± 423.9 vs. 5959.1 ± 2817.9 pg/mL, P < 0.02), mean pulmonary artery pressure (21.4 ± 5.0 vs. 45.5 ± 10.4 mmHg, P < 0.002), and pulmonary vascular resistance (PVR) (1.41 ± 0.6 vs. 7.3 ± 3.8 Wood units, P < 0.003) without differences in LV ejection fraction or pulmonary capillary wedge pressure between groups.  Among patients not prescribed PAH-specific pharmacotherapy prior to cardiac catheterization, a subgroup of the cohort with severe pulmonary hypertension, aldosterone levels correlated pos. with PVR (r = 0.72, P < 0.02) and transpulmonary gradient (r = 0.69, P < 0.02), but correlated inversely with cardiac output (r = -0.79, P < 0.005).  Conclusions: These data demonstrate a novel cardiopulmonary haemodynamic profile assocd. with hyperaldosteronism in patients: diminished cardiac output due to pulmonary vascular disease in the absence of LV heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mixfV2NH8LVg90H21EOLACvtfcHk0liUklQvtdVESg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFGhtrc%253D&md5=bbcd872a845014dee58962200cb6cda8</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfs173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfs173%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DB.%2BA.%26aulast%3DOpotowsky%26aufirst%3DA.%2BR.%26aulast%3DLandzberg%26aufirst%3DM.%2BJ.%26aulast%3DLoscalzo%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DA.%2BB.%26aulast%3DLeopold%26aufirst%3DJ.%2BA.%26atitle%3DPlasma%2520aldosterone%2520levels%2520are%2520elevated%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520in%2520the%2520absence%2520of%2520left%2520ventricular%2520heart%2520failure%253A%2520a%2520pilot%2520study%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2013%26volume%3D15%26spage%3D277%26epage%3D283%26doi%3D10.1093%2Feurjhf%2Fhfs173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maron, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, J. A.</span></span> <span> </span><span class="NLM_article-title">Aldosterone inactivates the endothelin-B Receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.112.094722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.112.094722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22787113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=963-974&author=B.+A.+Maronauthor=Y.+Y.+Zhangauthor=K.+Whiteauthor=S.+Y.+Chanauthor=D.+E.+Handyauthor=C.+E.+Mahoneyauthor=J.+Loscalzoauthor=J.+A.+Leopold&title=Aldosterone+inactivates+the+endothelin-B+Receptor+via+a+cysteinyl+thiol+redox+switch+to+decrease+pulmonary+endothelial+nitric+oxide+levels+and+modulate+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.112.094722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Maron, Bradley A.; Zhang, Ying-Yi; White, Kevin; Chan, Stephen Y.; Handy, Diane E.; Mahoney, Christopher E.; Loscalzo, Joseph; Leopold, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: Pulmonary arterial hypertension (PAH) is characterized, in part, by decreased endothelial nitric oxide (NO) prodn. and elevated levels of endothelin-1.  Endothelin-1 is known to stimulate endothelial nitric oxide synthase (eNOS) via the endothelin-B receptor (ETB), suggesting that this signaling pathway is perturbed in PAH.  Endothelin-1 also stimulates adrenal aldosterone synthesis; in systemic blood vessels, hyperaldosteronism induces vascular dysfunction by increasing endothelial reactive oxygen species generation and decreasing NO levels.  We hypothesized that aldosterone modulates PAH by disrupting ETB-eNOS signaling through a mechanism involving increased pulmonary endothelial oxidant stress.  METHODS AND RESULTS-: In rats with PAH, elevated endothelin-1 levels were assocd. with elevated aldosterone levels in plasma and lung tissue and decreased lung NO metabolites in the absence of left-sided heart failure.  In human pulmonary artery endothelial cells, endothelin-1 increased aldosterone levels via peroxisome proliferator-activated receptor gamma coactivator-1α/steroidogenesis factor-1-dependent upregulation of aldosterone synthase.  Aldosterone also increased reactive oxygen species prodn., which oxidatively modified cysteinyl thiols in the eNOS-activating region of ETB to decrease endothelin-1-stimulated eNOS activity.  Substitution of ETB-Cys405 with alanine improved ETB-dependent NO synthesis under conditions of oxidant stress, confirming that Cys405 is a redox-sensitive thiol that is necessary for ETB-eNOS signaling.  In human pulmonary artery endothelial cells, mineralocorticoid receptor antagonism with spironolactone decreased aldosterone-mediated reactive oxygen species generation and restored ETB-dependent NO prodn.  Spironolactone or eplerenone prevented or reversed pulmonary vascular remodeling and improved cardiopulmonary hemodynamics in 2 animal models of PAH in vivo.  CONCLUSIONS-: Our findings demonstrate that aldosterone modulates an ETB cysteinyl thiol redox switch to decrease pulmonary endothelium-derived NO and promote PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lo1WeB8Nm7Vg90H21EOLACvtfcHk0lh_XkerkY05fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjP&md5=673b9f1c4b352ba3acfb2a0991c35f5e</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.094722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.094722%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DB.%2BA.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DS.%2BY.%26aulast%3DHandy%26aufirst%3DD.%2BE.%26aulast%3DMahoney%26aufirst%3DC.%2BE.%26aulast%3DLoscalzo%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DJ.%2BA.%26atitle%3DAldosterone%2520inactivates%2520the%2520endothelin-B%2520Receptor%2520via%2520a%2520cysteinyl%2520thiol%2520redox%2520switch%2520to%2520decrease%2520pulmonary%2520endothelial%2520nitric%2520oxide%2520levels%2520and%2520modulate%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D963%26epage%3D974%26doi%3D10.1161%2FCIRCULATIONAHA.112.094722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X. L.</span></span> <span> </span><span class="NLM_article-title">The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease</span>. <i>Cardiology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1159/000346884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1159%2F000346884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23548773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslartbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2013&pages=208-212&author=H.+L.+Daiauthor=Y.+Guoauthor=X.+F.+Guangauthor=Z.+C.+Xiaoauthor=M.+Zhangauthor=X.+L.+Yin&title=The+changes+of+serum+angiotensin-converting+enzyme+2+in+patients+with+pulmonary+arterial+hypertension+due+to+congenital+heart+disease&doi=10.1159%2F000346884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">The Changes of Serum Angiotensin-Converting Enzyme 2 in Patients with Pulmonary Arterial Hypertension due to Congenital Heart Disease</span></div><div class="casAuthors">Dai, Hai-long; Guo, Yue; Guang, Xue-feng; Xiao, Zhi-cheng; Zhang, Ming; Yin, Xiao-long</div><div class="citationInfo"><span class="NLM_cas:title">Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">208-212</span>CODEN:
                <span class="NLM_cas:coden">CAGYAO</span>;
        ISSN:<span class="NLM_cas:issn">0008-6312</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Angiotensin-converting enzyme 2 (ACE2), a primary component of the vasoprotective axis in the renin-angiotensin system (RAS), has recently been found to have regulatory actions in hypoxic pulmonary hypertension and monocrotaline-induced pulmonary hypertension.  We explored the hypothesis that the level of ACE2 protein contents may be decreased in patients with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD).  Objective: We obsd. the serum ACE2 protein contents in patients with PAH due to CHD (CHD-PAH), and investigated their correlation with mean pulmonary arterial pressure (mPAP).  Methods: One hundred and four patients with CHD and 33 normal control patients (group A) were involved in the research.  The patients with CHD were divided into 55 cases of nonpulmonary hypertension (group B), 25 cases of mild to moderate pulmonary hypertension (group C) and 24 cases of severe pulmonary hypertension (group D).  The serum level of ACE2 protein contents were detected by ELISA (ELISA), and the relationship between these contents and mPAP were analyzed.  Results: ACE2 protein contents significantly declined as mPAP increased.  The mPAP was neg. correlated with the level of ACE2 protein contents.  Conclusions: These results demonstrated that ACE2 may play an important regulatory role in CHD-PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpycMoNtADxrbVg90H21EOLACvtfcHk0lh_XkerkY05fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslartbs%253D&md5=614d9b8abbc835d937b593fc52e5553f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1159%2F000346884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000346884%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%2BL.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGuang%26aufirst%3DX.%2BF.%26aulast%3DXiao%26aufirst%3DZ.%2BC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYin%26aufirst%3DX.%2BL.%26atitle%3DThe%2520changes%2520of%2520serum%2520angiotensin-converting%2520enzyme%25202%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520due%2520to%2520congenital%2520heart%2520disease%26jtitle%3DCardiology%26date%3D2013%26volume%3D124%26spage%3D208%26epage%3D212%26doi%3D10.1159%2F000346884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, D. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Buhr, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heringer-Walther, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, S. V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnole-Santos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">8258</span>– <span class="NLM_lpage">8263</span>, <span class="refDoi"> DOI: 10.1073/pnas.1432869100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1073%2Fpnas.1432869100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12829792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFGnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=8258-8263&author=R.+A.+S.+Santosauthor=A.+Silvaauthor=C.+Maricauthor=D.+M.+R.+Silvaauthor=R.+P.+Machadoauthor=I.+de+Buhrauthor=S.+Heringer-Waltherauthor=S.+V.+B.+Pinheiroauthor=M.+T.+Lopesauthor=M.+Baderauthor=E.+P.+Mendesauthor=V.+S.+Lemosauthor=M.+J.+Campagnole-Santosauthor=H.+P.+Schultheissauthor=R.+Spethauthor=T.+Walther&title=Angiotensin-%281%E2%80%937%29+is+an+endogenous+ligand+for+the+G+protein-coupled+receptor+Mas&doi=10.1073%2Fpnas.1432869100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas</span></div><div class="casAuthors">Santos, Robson A. S.; Simoes e Silva, Ana C.; Maric, Christine; Silva, Denise M. R.; Machado, Raquel Pillar; de Buhr, Insa; Heringer-Walther, Silvia; Pinheiro, Sergio Veloso B.; Lopes, Myriam Teresa; Bader, Michael; Mendes, Elizabeth P.; Lemos, Virgina Soares; Campagnole-Santos, Maria Jose; Schultheiss, Heinz-Peter; Speth, Robert; Walther, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">8258-8263</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The renin-angiotensin system plays a crit. role in blood pressure control and body fluid and electrolyte homeostasis.  Besides angiotensin (Ang) II, other Ang peptides, such as Ang III [Ang-(2-8)], Ang IV [Ang-(3-8)], and Ang-(1-7) may also have important biol. activities.  Ang-(1-7) has become an angiotensin of interest in the past few years, because its cardiovascular and baroreflex actions counteract those of Ang II.  Unique angiotensin-binding sites specific for this heptapeptide and studies with a selective Ang-(1-7) antagonist indicated the existence of a distinct Ang-(1-7) receptor.  The authors demonstrate that genetic deletion of the G protein coupled receptor encoded by the Mas protooncogene abolishes the binding of Ang-(1-7) to mouse kidneys.  Accordingly, Mas-deficient mice completely lack the antidiuretic action of Ang-(1-7) after an acute water load.  Ang-(1-7) binds to Mas-transfected cells and elicits arachidonic acid release.  Furthermore, Mas-deficient aortas lose their Ang-(1-7)-induced relaxation response.  Collectively, these findings identify Mas as a functional receptor for Ang-(1-7) and provide a clear mol. basis for the physiol. actions of this biol. active peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEGDVMsUC2rVg90H21EOLACvtfcHk0lh_XkerkY05fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFGnsbc%253D&md5=cf5e4154ac09053f2c2633ba398186ab</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1432869100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1432869100%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%2BA.%2BS.%26aulast%3DSilva%26aufirst%3DA.%26aulast%3DMaric%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DD.%2BM.%2BR.%26aulast%3DMachado%26aufirst%3DR.%2BP.%26aulast%3Dde%2BBuhr%26aufirst%3DI.%26aulast%3DHeringer-Walther%26aufirst%3DS.%26aulast%3DPinheiro%26aufirst%3DS.%2BV.%2BB.%26aulast%3DLopes%26aufirst%3DM.%2BT.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DMendes%26aufirst%3DE.%2BP.%26aulast%3DLemos%26aufirst%3DV.%2BS.%26aulast%3DCampagnole-Santos%26aufirst%3DM.%2BJ.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DSpeth%26aufirst%3DR.%26aulast%3DWalther%26aufirst%3DT.%26atitle%3DAngiotensin-%25281%25E2%2580%25937%2529%2520is%2520an%2520endogenous%2520ligand%2520for%2520the%2520G%2520protein-coupled%2520receptor%2520Mas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D8258%26epage%3D8263%26doi%3D10.1073%2Fpnas.1432869100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinasabapathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katovich, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span> <span> </span><span class="NLM_article-title">Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1–7) bioencapsulated in plant cells attenuates pulmonary hypertension</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.114.03871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FHYPERTENSIONAHA.114.03871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25225206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=1248-1259&author=V.+Shenoyauthor=K.+C.+Kwonauthor=A.+Rathinasabapathyauthor=S.+N.+Linauthor=G.+Y.+Jinauthor=C.+J.+Songauthor=P.+Shilauthor=A.+Nairauthor=Y.+F.+Qiauthor=Q.+H.+Liauthor=J.+Francisauthor=M.+J.+Katovichauthor=H.+Daniellauthor=M.+K.+Raizada&title=Oral+delivery+of+angiotensin-converting+enzyme+2+and+angiotensin-%281%E2%80%937%29+bioencapsulated+in+plant+cells+attenuates+pulmonary+hypertension&doi=10.1161%2FHYPERTENSIONAHA.114.03871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension</span></div><div class="casAuthors">Shenoy, Vinayak; Kwon, Kwang-Chul; Rathinasabapathy, Anandharajan; Lin, Shina; Jin, Guiying; Song, Chunjuan; Shil, Pollob; Nair, Anand; Qi, Yanfei; Li, Qiuhong; Francis, Joseph; Katovich, Michael J.; Daniell, Henry; Raizada, Mohan K.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1248-1259</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Emerging evidences indicate that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin-converting enzyme 2 (ACE2) and its enzymic product, angiotensin-(1-7) [Ang-(1-7)] contribute to the pathogenesis of pulmonary hypertension (PH).  However, long-term repetitive delivery of ACE2 or Ang-(1-7) would require enhanced protein stability and ease of administration to improve patient compliance.  Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect against gastric enzymic degrdn. and facilitates long-term storage at room temp.  Besides, fusion to a transmucosal carrier helps effective systemic absorption from the intestine on oral delivery.  We hypothesized that bioencapsulating ACE2 or Ang-(1-7) fused to the cholera nontoxin B subunit would enable development of an oral delivery system that is effective in treating PH.  PH was induced in male Sprague Dawley rats by monocrotaline administration.  Subset of animals was simultaneously treated with bioencapsulaed ACE2 or Ang-(1-7) (prevention protocol).  In a sep. set of expts., drug treatment was initiated after 2 wk of PH induction (reversal protocol).  Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) prevented the development of monocrotaline-induced PH and improved assocd. cardiopulmonary pathophysiol.  Furthermore, in the reversal protocol, oral ACE2 or Ang-(1-7) treatment significantly arrested disease progression, along with improvement in right heart function, and decrease in pulmonary vessel wall thickness.  In addn., a combination therapy with ACE2 and Ang-(1-7) augmented the beneficial effects against monocrotaline-induced lung injury.  Our study provides proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technol. for pulmonary disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzZ3vAloHfbVg90H21EOLACvtfcHk0li6Ma8le7NKYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLrE&md5=9369d6b29a8334de869b428938a128bc</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03871%26sid%3Dliteratum%253Aachs%26aulast%3DShenoy%26aufirst%3DV.%26aulast%3DKwon%26aufirst%3DK.%2BC.%26aulast%3DRathinasabapathy%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DS.%2BN.%26aulast%3DJin%26aufirst%3DG.%2BY.%26aulast%3DSong%26aufirst%3DC.%2BJ.%26aulast%3DShil%26aufirst%3DP.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DY.%2BF.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DKatovich%26aufirst%3DM.%2BJ.%26aulast%3DDaniell%26aufirst%3DH.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26atitle%3DOral%2520delivery%2520of%2520angiotensin-converting%2520enzyme%25202%2520and%2520angiotensin-%25281%25E2%2580%25937%2529%2520bioencapsulated%2520in%2520plant%2520cells%2520attenuates%2520pulmonary%2520hypertension%26jtitle%3DHypertension%26date%3D2014%26volume%3D64%26spage%3D1248%26epage%3D1259%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinasabapathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fike, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortune, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerszten, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span> <span> </span><span class="NLM_article-title">A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1702638</span>, <span class="refDoi"> DOI: 10.1183/13993003.02638-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.02638-2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29903860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1eqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=1702638&author=A.+R.+Hemnesauthor=A.+Rathinasabapathyauthor=E.+A.+Austinauthor=E.+L.+Brittainauthor=E.+J.+Carrierauthor=X.+P.+Chenauthor=J.+P.+Fesselauthor=C.+D.+Fikeauthor=P.+Fongauthor=N.+Fortuneauthor=R.+E.+Gersztenauthor=J.+A.+Johnsonauthor=M.+Kaplowitzauthor=J.+H.+Newmanauthor=R.+Pianaauthor=M.+E.+Pughauthor=T.+W.+Riceauthor=I.+M.+Robbinsauthor=L.+Wheelerauthor=C.+Yuauthor=J.+E.+Loydauthor=J.+West&title=A+potential+therapeutic+role+for+angiotensin-converting+enzyme+2+in+human+pulmonary+arterial+hypertension&doi=10.1183%2F13993003.02638-2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension</span></div><div class="casAuthors">Hemnes, Anna R.; Rathinasabapathy, Anandharajan; Austin, Eric A.; Brittain, Evan L.; Carrier, Erica J.; Chen, Xinping; Fessel, Joshua P.; Fike, Candice D.; Fong, Peter; Fortune, Niki; Gerszten, Robert E.; Johnson, Jennifer A.; Kaplowitz, Mark; Newman, John H.; Piana, Robert; Pugh, Meredith E.; Rice, Todd W.; Robbins, Ivan M.; Wheeler, Lisa; Yu, Chang; Loyd, James E.; West, James</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1702638/1-1702638/12</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a deadly disease with no cure.  Alternate conversion of angiotensin II (AngII) to angiotensin-(1-7) (Ang-(1-7)) by angiotensin-converting enzyme 2 (ACE2) resulting in Mas receptor (Mas1) activation improves rodent models of PAH.  Effects of recombinant human (rh) ACE2 in human PAH are unknown.  Our objective was to det. the effects of rhACE2 in PAH.  We defined the mol. effects of Mas1 activation using porcine pulmonary arteries, measured AngII/Ang-(1-7) levels in human PAH and conducted a phase IIa, open-label pilot study of a single infusion of rhACE2 (GSK2586881, 0.2 or 0.4 mg·kg-1 i.v.).  Superoxide dismutase 2 (SOD2) and inflammatory gene expression were identified as markers of Mas1 activation.  After confirming reduced plasma ACE2 activity in human PAH, five patients were enrolled in the trial.  GSK2586881 was well tolerated with significant improvement in cardiac output and pulmonary vascular resistance.  GSK2586881 infusion was assocd. with reduced plasma markers of inflammation within 2-4 h and increased SOD2 plasma protein at 2 wk.  PAH is characterised by reduced ACE2 activity.  Augmentation of ACE2 in a pilot study was well tolerated, assocd. with improved pulmonary haemodynamics and reduced markers of oxidant and inflammatory mediators.  Targeting this pathway may be beneficial in human PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxLA3NjqcCf7Vg90H21EOLACvtfcHk0li6Ma8le7NKYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1eqtL4%253D&md5=ff85f764b3a641f60fc7f2d9de088bea</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1183%2F13993003.02638-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02638-2017%26sid%3Dliteratum%253Aachs%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DRathinasabapathy%26aufirst%3DA.%26aulast%3DAustin%26aufirst%3DE.%2BA.%26aulast%3DBrittain%26aufirst%3DE.%2BL.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26aulast%3DChen%26aufirst%3DX.%2BP.%26aulast%3DFessel%26aufirst%3DJ.%2BP.%26aulast%3DFike%26aufirst%3DC.%2BD.%26aulast%3DFong%26aufirst%3DP.%26aulast%3DFortune%26aufirst%3DN.%26aulast%3DGerszten%26aufirst%3DR.%2BE.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKaplowitz%26aufirst%3DM.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26aulast%3DPiana%26aufirst%3DR.%26aulast%3DPugh%26aufirst%3DM.%2BE.%26aulast%3DRice%26aufirst%3DT.%2BW.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DWest%26aufirst%3DJ.%26atitle%3DA%2520potential%2520therapeutic%2520role%2520for%2520angiotensin-converting%2520enzyme%25202%2520in%2520human%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2018%26volume%3D51%26spage%3D1702638%26doi%3D10.1183%2F13993003.02638-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrell, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurell, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boswell, D. R.</span></span> <span> </span><span class="NLM_article-title">Structure and variation of human alpha-1-antitrypsin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1038/298329a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F298329a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7045697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL3sXhs12k" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=1982&pages=329-334&author=R.+W.+Carrellauthor=J.+O.+Jeppssonauthor=C.+B.+Laurellauthor=S.+O.+Brennanauthor=M.+C.+Owenauthor=L.+Vaughanauthor=D.+R.+Boswell&title=Structure+and+variation+of+human+alpha-1-antitrypsin&doi=10.1038%2F298329a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and variation of human α1-antitrypsin</span></div><div class="casAuthors">Carrell, Robin W.; Jeppsson, Jan-Olof; Laurell, Carl Bertil; Brennan, Stephen O.; Owen, Maurice C.; Vaughan, Lloyd; Boswell, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5872</span>),
    <span class="NLM_cas:pages">329-34</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A review with 71 refs., discussing the sequence of α1-antitrypsin in relation to its role as a tissue scavenger of leukocyte elastase and how 2 abnormal variants commonly present in Europeans cause a deficiency that predisposes them to a progressive loss of lung elasticity.  The nature of the reactive center helps explain why cigarette smoking greatly accelerates the onset and severity of this degenerative process to give the disease emphysema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZGzYirKtcyrVg90H21EOLACvtfcHk0lghgDa2Rl6gGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhs12k&md5=d44c54f9c44ee8da29cef9b7c22f1403</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2F298329a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F298329a0%26sid%3Dliteratum%253Aachs%26aulast%3DCarrell%26aufirst%3DR.%2BW.%26aulast%3DJeppsson%26aufirst%3DJ.%2BO.%26aulast%3DLaurell%26aufirst%3DC.%2BB.%26aulast%3DBrennan%26aufirst%3DS.%2BO.%26aulast%3DOwen%26aufirst%3DM.%2BC.%26aulast%3DVaughan%26aufirst%3DL.%26aulast%3DBoswell%26aufirst%3DD.%2BR.%26atitle%3DStructure%2520and%2520variation%2520of%2520human%2520alpha-1-antitrypsin%26jtitle%3DNature%26date%3D1982%26volume%3D298%26spage%3D329%26epage%3D334%26doi%3D10.1038%2F298329a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldabbous, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Salam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duluc, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepke-Zaba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainscough, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadinnapola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toshner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciak-Stothard, B.</span></span> <span> </span><span class="NLM_article-title">Neutrophil extracellular traps promote angiogenesis: evidence from vascular pathology in pulmonary hypertension</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1161/ATVBAHA.116.307634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FATVBAHA.116.307634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27470511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFensrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=2078-2087&author=L.+Aldabbousauthor=V.+Abdul-Salamauthor=T.+McKinnonauthor=L.+Dulucauthor=J.+Pepke-Zabaauthor=M.+Southwoodauthor=A.+J.+Ainscoughauthor=C.+Hadinnapolaauthor=M.+R.+Wilkinsauthor=M.+Toshnerauthor=B.+Wojciak-Stothard&title=Neutrophil+extracellular+traps+promote+angiogenesis%3A+evidence+from+vascular+pathology+in+pulmonary+hypertension&doi=10.1161%2FATVBAHA.116.307634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension</span></div><div class="casAuthors">Aldabbous, Lulwah; Abdul-Salam, Vahitha; McKinnon, Tom; Duluc, Lucie; Pepke-Zaba, Joanna; Southwood, Mark; Ainscough, Alexander J.; Hadinnapola, Charaka; Wilkins, Martin R.; Toshner, Mark; Wojciak-Stothard, Beata</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2078-2087</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: Inflammation and dysregulated angiogenesis are features of endothelial dysfunction in pulmonary hypertension.  Neutrophil extracellular traps (NETs), produced by dying neutrophils, contribute to pathogenesis of numerous vascular disorders but their role in pulmonary hypertension has not been studied.  We sought evidence of (NETs) formation in pulmonary hypertension and investigated the effect of NETs on endothelial function.  APPROACH AND RESULTS-: Plasma and lung tissues of patients with pulmonary hypertension were analyzed for NET markers.  The effects of NETs on endothelial function were studied in vitro and in vivo.  Patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension showed elevated plasma levels of DNA, neutrophil elastase, and myeloperoxidase.  NET-forming neutrophils and extensive areas of NETosis were found in the occlusive plexiform lesions and vascularized intrapulmonary thrombi.  NETs induced nuclear factor κB-dependent endothelial angiogenesis in vitro and increased vascularization of matrigel plugs in vivo.  Angiogenic responses were assocd. with increased release of matrix metalloproteinase-9, heparin-binding epidermal growth factor-like growth factor, latency-assocd. peptide of the transforming growth factor β1, and urokinase-type plasminogen activator, accompanied by increased endothelial permeability and cell motility.  NETs-induced responses depended on myeloperoxidase/H2O2-dependent activation of Toll-like receptor 4/nuclear factor κB signaling.  NETs stimulated the release of endothelin-1 in HPAECs (human pulmonary artery endothelial cells) and stimulated pulmonary smooth muscle cell proliferation in vitro.  CONCLUSIONS-: We are the first to implicate NETs in angiogenesis and provide a functional link between NETs and inflammatory angiogenesis in vitro and in vivo.  We demonstrate the potential pathol. relevance of this in 2 diseases of disordered vascular homeostasis, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd9VtkXZ7XFbVg90H21EOLACvtfcHk0lghgDa2Rl6gGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFensrnL&md5=b6c7506cfe5b41d4af6d434745c306de</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.116.307634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.116.307634%26sid%3Dliteratum%253Aachs%26aulast%3DAldabbous%26aufirst%3DL.%26aulast%3DAbdul-Salam%26aufirst%3DV.%26aulast%3DMcKinnon%26aufirst%3DT.%26aulast%3DDuluc%26aufirst%3DL.%26aulast%3DPepke-Zaba%26aufirst%3DJ.%26aulast%3DSouthwood%26aufirst%3DM.%26aulast%3DAinscough%26aufirst%3DA.%2BJ.%26aulast%3DHadinnapola%26aufirst%3DC.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DToshner%26aufirst%3DM.%26aulast%3DWojciak-Stothard%26aufirst%3DB.%26atitle%3DNeutrophil%2520extracellular%2520traps%2520promote%2520angiogenesis%253A%2520evidence%2520from%2520vascular%2520pathology%2520in%2520pulmonary%2520hypertension%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2016%26volume%3D36%26spage%3D2078%26epage%3D2087%26doi%3D10.1161%2FATVBAHA.116.307634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilbut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humpl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1038/76282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F76282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10835689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkt12isbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=698-702&author=K.+N.+Cowanauthor=A.+Heilbutauthor=T.+Humplauthor=C.+Lamauthor=S.+Itoauthor=M.+Rabinovitch&title=Complete+reversal+of+fatal+pulmonary+hypertension+in+rats+by+a+serine+elastase+inhibitor&doi=10.1038%2F76282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor</span></div><div class="casAuthors">Cowan, Kyle Northcote; Heilbut, Adrian; Humpl, Tilman; Lam, Catherine; Ito, Shinya; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">698-702</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Progression of pulmonary hypertension is assocd. with increased serine elastase activity and the proteinase-dependent deposition of the extracellular matrix smooth muscle cell survival factor tenascin-C.  Tenascin-C amplifies the response of smooth muscle cells to growth factors, which are also liberated through matrix proteolysis.  Recent organ culture studies using hypertrophied rat pulmonary arteries have shown that elastase inhibitors suppress tenascin-C and induce smooth muscle cell apoptosis.  This initiates complete regression of the hypertrophied vessel wall by a coordinated loss of cellularity and extracellular matrix.  We now report that elastase inhibitors can reverse advanced pulmonary vascular disease produced in rats by injecting monocrotaline, an endothelial toxin.  We began oral administration of the peptidyl trifluoromethylketone serine elastase inhibitors M249314 or ZD0892 21 days after injection of monocrotaline.  A 1-wk treatment resulted in 92% survival, compared with 39% survival in untreated or vehicle-treated rats.  Pulmonary artery pressure and muscularization were reduced by myocyte apoptosis and loss of extracellular matrix, specifically elastin and tenascin-C.  After 2 wk, pulmonary artery pressure and structure normalized, and survival was 86%, compared with 0% in untreated or vehicle-treated rats.  Although concomitant treatment with various agents can reduce pulmonary hypertension, we have documented complete regression after establishment of malignant monocrotaline-induced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJEvNkrAhGLVg90H21EOLACvtfcHk0lghgDa2Rl6gGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkt12isbc%253D&md5=09b5ecab8278b8439ff21cc1c9d47cfd</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2F76282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F76282%26sid%3Dliteratum%253Aachs%26aulast%3DCowan%26aufirst%3DK.%2BN.%26aulast%3DHeilbut%26aufirst%3DA.%26aulast%3DHumpl%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DC.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DComplete%2520reversal%2520of%2520fatal%2520pulmonary%2520hypertension%2520in%2520rats%2520by%2520a%2520serine%2520elastase%2520inhibitor%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D698%26epage%3D702%26doi%3D10.1038%2F76282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1161/hc0402.102866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2Fhc0402.102866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11815437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVGmurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2002&pages=516-521&author=S.+H.+E.+Zaidiauthor=X.+M.+Youauthor=S.+Ciuraauthor=M.+Husainauthor=M.+Rabinovitch&title=Overexpression+of+the+serine+elastase+inhibitor+elafin+protects+transgenic+mice+from+hypoxic+pulmonary+hypertension&doi=10.1161%2Fhc0402.102866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension</span></div><div class="casAuthors">Zaidi, Syed H. E.; You, Xiao-Mang; Ciura, Sorana; Husain, Mansoor; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-521</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Increased serine elastase activity has been implicated in the vascular remodeling assocd. with chronic hypoxia-related pulmonary hypertension in rats.  In this study we detd. the time course of hypoxia-induced serine elastase activity in the murine lung and related this to initiation of a proteolytic cascade characterized by an increase in matrix metalloproteinases (MMPs).  We then used transgenic mice in which overexpression of the selective serine elastase inhibitor elafin was targeted to the cardiovascular system to det. whether upregulation of a naturally occurring serine elastase inhibitor suppresses MMPs and the hemodynamic and structural response to chronic hypoxia (air at 380 mm Hg).  In nontransgenic but not in elafin-transgenic mice, we documented a transient increase in serine elastase activity after 12 h of hypoxic exposure attributed to a 30-kDa protein as detd. by elastin zymog. and fluorophosphonate/fluorophosphate-biotin labeling.  Two days after hypoxia, the pro-forms of MMP-2 and MMP-9 were induced in the nontransgenic mice, but MMP-9 was suppressed in elafin-transgenic mice.  Acute hypoxic vasoconstriction was similar in nontransgenic and elafin-transgenic littermates.  Chronic hypoxia for 26 days resulted in > 1-fold increase in right ventricular pressure (P<0.004) in nontransgenic compared with control or elafin-transgenic littermates.  In the latter mice, normalization of the right ventricular pressure was assocd. with reduced muscularization and preservation of the no. of distal vessels (P<0.04 for both comparisons).  Modulation of the severity of chronic hypoxia-induced pulmonary vascular disease could be a function of endogenously expressed serine elastase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4gZPiZXntQrVg90H21EOLACvtfcHk0ljyE2_KCwNovA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVGmurw%253D&md5=78af2fdea41a6490063abb1dd67da8c7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1161%2Fhc0402.102866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhc0402.102866%26sid%3Dliteratum%253Aachs%26aulast%3DZaidi%26aufirst%3DS.%2BH.%2BE.%26aulast%3DYou%26aufirst%3DX.%2BM.%26aulast%3DCiura%26aufirst%3DS.%26aulast%3DHusain%26aufirst%3DM.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DOverexpression%2520of%2520the%2520serine%2520elastase%2520inhibitor%2520elafin%2520protects%2520transgenic%2520mice%2520from%2520hypoxic%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2002%26volume%3D105%26spage%3D516%26epage%3D521%26doi%3D10.1161%2Fhc0402.102866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekerkoetter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschwich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennigs, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sa, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockstill, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanian, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bland, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1286</span>, <span class="refDoi"> DOI: 10.1164/rccm.201412-2291OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201412-2291OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25853696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=1273-1286&author=N.+P.+Nickelauthor=E.+Spiekerkoetterauthor=M.+X.+Guauthor=C.+Y.+G.+Liauthor=H.+Liauthor=M.+Kaschwichauthor=I.+Dieboldauthor=J.+K.+Hennigsauthor=K.+Y.+Kimauthor=K.+Miyagawaauthor=L.+L.+Wangauthor=A.+Q.+Caoauthor=S.+L.+Saauthor=X.+G.+Jiangauthor=R.+W.+Stockstillauthor=M.+R.+Nicollsauthor=R.+T.+Zamanianauthor=R.+D.+Blandauthor=M.+Rabinovitch&title=Elafin+reverses+pulmonary+hypertension+via+caveolin-1-dependent+bone+morphogenetic+protein+signaling&doi=10.1164%2Frccm.201412-2291OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling</span></div><div class="casAuthors">Nickel, Nils P.; Spiekerkoetter, Edda; Gu, Mingxia; Li, Caiyun G.; Li, Hai; Kaschwich, Mark; Diebold, Isabel; Hennigs, Jan K.; Kim, Ki-Yoon; Miyagawa, Kazuya; Wang, Lingli; Cao, Aiqin; Sa, Silin; Jiang, Xinguo; Stockstill, Raymond W.; Nicolls, Mark R.; Zamanian, Roham T.; Bland, Richard D.; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1273-1286</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Pulmonary arterial hypertension is characterized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling, and increased elastase activity.  Synthetic elastase inhibitors reverse exptl. pulmonary hypertension but cause hepatotoxicity in clin. studies.  The endogenous elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to improve endothelial function and BMPR2 signaling, and to reverse severe exptl. pulmonary hypertension or vascular pathol. in the human disease was unknown.  Objectives: To assess elafin-mediated regression of pulmonary vascular pathol. in rats and in lung explants from patients with pulmonary hypertension.  To det. if elafin amplifies BMPR2 signaling in pulmonary artery endothelial cells and to elucidate the underlying mechanism.  Methods: Rats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia (Sugen/hypoxia) as well as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediated reversibility of pulmonary vascular disease.  Pulmonary arterial endothelial cells from patients and control subjects were used to det. the efficacy and mechanism of elafin-mediated BMPR2 signaling.  Measurements and Main Results: In Sugen/hypoxia rats, elafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ventricular systolic pressure and hypertrophy and pulmonary artery occlusive changes.  Elafin improved endothelial function by increasing apelin, a BMPR2 target.  Elafin induced apoptosis in human pulmonary arterial smooth muscle cells and decreased neointimal lesions in lung organ culture.  In normal and patient pulmonary artery endothelial cells, elafin promoted angiogenesis by increasing pSMAD-dependent and -independent BMPR2 signaling.  This was linked mechanistically to augmented interaction of BMPR2 with caveolin-1 via elafin-mediated stabilization of endothelial surface caveolin-1.  Conclusions: Elafin reverses obliterative changes in pulmonary arteries via elastase inhibition and caveolin-1-dependent amplification of BMPR2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_aA0F6wxMv7Vg90H21EOLACvtfcHk0ljyE2_KCwNovA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb7M&md5=f03a10eb726fec9372a3a01f13eddb2c</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1164%2Frccm.201412-2291OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201412-2291OC%26sid%3Dliteratum%253Aachs%26aulast%3DNickel%26aufirst%3DN.%2BP.%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DGu%26aufirst%3DM.%2BX.%26aulast%3DLi%26aufirst%3DC.%2BY.%2BG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DKaschwich%26aufirst%3DM.%26aulast%3DDiebold%26aufirst%3DI.%26aulast%3DHennigs%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DK.%2BY.%26aulast%3DMiyagawa%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DCao%26aufirst%3DA.%2BQ.%26aulast%3DSa%26aufirst%3DS.%2BL.%26aulast%3DJiang%26aufirst%3DX.%2BG.%26aulast%3DStockstill%26aufirst%3DR.%2BW.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26aulast%3DZamanian%26aufirst%3DR.%2BT.%26aulast%3DBland%26aufirst%3DR.%2BD.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DElafin%2520reverses%2520pulmonary%2520hypertension%2520via%2520caveolin-1-dependent%2520bone%2520morphogenetic%2520protein%2520signaling%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26spage%3D1273%26epage%3D1286%26doi%3D10.1164%2Frccm.201412-2291OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Federici, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigelsky, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNelly, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comhair, S. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erzurum, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldred, M. A.</span></span> <span> </span><span class="NLM_article-title">Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1164/rccm.201411-2128OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201411-2128OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25918951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVynu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=219-228&author=C.+Federiciauthor=K.+M.+Drakeauthor=C.+M.+Rigelskyauthor=L.+N.+McNellyauthor=S.+L.+Meadeauthor=S.+A.+A.+Comhairauthor=S.+C.+Erzurumauthor=M.+A.+Aldred&title=Increased+mutagen+sensitivity+and+DNA+damage+in+pulmonary+arterial+hypertension&doi=10.1164%2Frccm.201411-2128OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension</span></div><div class="casAuthors">Federici, Chiara; Drake, Kylie M.; Rigelsky, Christina M.; McNellyl, Lauren N.; Meade, Sirena L.; Comhair, Suzy A. A.; Erzurum, Serpil C.; Aldred, Micheala A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Pulmonary arterial hypertension (PAH) is a serious lung condition characterized by vascular remodeling in the precapillary pulmonary arterioles.  We and others have demonstrated chromosomal abnormalities and increased DNA damage in PAH lung vascular cells, but their timing and role in disease pathogenesis is unknown.  Objectives: We hypothesized that if DNA damage predates PAH, it might he an intrinsic cell property that is present outside the diseased lung.  Methods: We measured DNA damage, mutagen sensitivity, and reactive oxygen species (ROS) in lung and blood cells from patients with Group 1 PAH, their relatives, and unrelated control subjects.  Measurements and Main Results: Baseline DNA damage was significantly elevated in PAH, both in pulmonary artery endothelial cells (P < 0.05) and peripheral blood mononuclear cells (PBMC) (P < 0.001).  Remarkably, PBMC from unaffected relatives showed similar increases, indicating this is not related to PAH treatments.  ROS levels were also higher (P < 0.01).  DNA damage correlated with ROS prodn. and was suppressed by antioxidants (P < 0.001).  PBMC from patients and relatives also showed markedly increased sensitivity to two chemotherapeutic drugs, bleomycin and etoposide (P < 0.001).  Results were consistent across idiopathic, heritable, and assocd. PAH groups.  Conclusions: Levels of baseline and mutagen-induced DNA damage are intrinsically higher in PAH cells.  Similar results in PBMC from unaffected relatives suggest this may he a genetically detd. trait that predates disease onset and may act as a risk factor contributing to lung vascular remodeling following endothelial cell injury.  Further studies are required to fully characterize mutagen sensitivity, which could have important implications for clin. management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8qjI4maJxebVg90H21EOLACvtfcHk0ljyE2_KCwNovA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVynu77N&md5=8054e5749fbec03e90a8f76b2b30f004</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1164%2Frccm.201411-2128OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201411-2128OC%26sid%3Dliteratum%253Aachs%26aulast%3DFederici%26aufirst%3DC.%26aulast%3DDrake%26aufirst%3DK.%2BM.%26aulast%3DRigelsky%26aufirst%3DC.%2BM.%26aulast%3DMcNelly%26aufirst%3DL.%2BN.%26aulast%3DMeade%26aufirst%3DS.%2BL.%26aulast%3DComhair%26aufirst%3DS.%2BA.%2BA.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26aulast%3DAldred%26aufirst%3DM.%2BA.%26atitle%3DIncreased%2520mutagen%2520sensitivity%2520and%2520DNA%2520damage%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D192%26spage%3D219%26epage%3D228%26doi%3D10.1164%2Frccm.201411-2128OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranchoux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucherat, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span> <span> </span><span class="NLM_article-title">Review DNA damage and pulmonary hypertension</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">990</span>, <span class="refDoi"> DOI: 10.3390/ijms17060990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fijms17060990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=990&author=B.+Ranchouxauthor=J.+Melocheauthor=R.+Paulinauthor=O.+Boucheratauthor=S.+Provencherauthor=S.+Bonnet&title=Review+DNA+damage+and+pulmonary+hypertension&doi=10.3390%2Fijms17060990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">DNA damage and pulmonary hypertension</span></div><div class="casAuthors">Ranchoux, Benoit; Meloche, Jolyane; Paulin, Roxane; Boucherat, Olivier; Provencher, Steeve; Bonnet, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">990/1-990/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pulmonary hypertension (PH) is defined by a mean pulmonary arterial pressure over 25 mmHg at rest and is diagnosed by right heart catheterization.  Among the different groups of PH, pulmonary arterial hypertension (PAH) is characterized by a progressive obstruction of distal pulmonary arteries, related to endothelial cell dysfunction and vascular cell proliferation, which leads to an increased pulmonary vascular resistance, right ventricular hypertrophy, and right heart failure.  Although the primary trigger of PAH remains unknown, oxidative stress and inflammation have been shown to play a key role in the development and progression of vascular remodeling.  These factors are known to increase DNA damage that might favor the emergence of the proliferative and apoptosis-resistant phenotype obsd. in PAH vascular cells.  High levels of DNA damage were reported to occur in PAH lungs and remodeled arteries as well as in animal models of PH.  Moreover, recent studies have demonstrated that impaired DNA-response mechanisms may lead to an increased mutagen sensitivity in PAH patients.  Finally, PAH was linked with decreased breast cancer 1 protein (BRCA1) and DNA topoisomerase 2-binding protein 1 (TopBP1) expression, both involved in maintaining genome integrity.  This review aims to provide an overview of recent evidence of DNA damage and DNA repair deficiency and their implication in PAH pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtqqa2DNyVprVg90H21EOLACvtfcHk0ljPvn_4L3Y4Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtbvK&md5=27ff03edee07462cba41c03c4d98142b</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.3390%2Fijms17060990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17060990%26sid%3Dliteratum%253Aachs%26aulast%3DRanchoux%26aufirst%3DB.%26aulast%3DMeloche%26aufirst%3DJ.%26aulast%3DPaulin%26aufirst%3DR.%26aulast%3DBoucherat%26aufirst%3DO.%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DS.%26atitle%3DReview%2520DNA%2520damage%2520and%2520pulmonary%2520hypertension%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26spage%3D990%26doi%3D10.3390%2Fijms17060990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meloche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potus, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zervopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graydon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courboulin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuils-Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelakis, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span> <span> </span><span class="NLM_article-title">Role for DNA damage signaling in pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.113.006167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.113.006167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24270264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=786-797&author=J.+Melocheauthor=A.+Pfliegerauthor=M.+Vaillancourtauthor=R.+Paulinauthor=F.+Potusauthor=S.+Zervopoulosauthor=C.+Graydonauthor=A.+Courboulinauthor=S.+Breuils-Bonnetauthor=E.+Tremblayauthor=C.+Coutureauthor=E.+D.+Michelakisauthor=S.+Provencherauthor=S.+Bonnet&title=Role+for+DNA+damage+signaling+in+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.113.006167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Role for DNA Damage Signaling in Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Meloche, Jolyane; Pflieger, Aude; Vaillancourt, Mylene; Paulin, Roxane; Potus, Francois; Zervopoulos, Sotirios; Graydon, Colin; Courboulin, Audrey; Breuils-Bonnet, Sandra; Tremblay, Eve; Couture, Christian; Michelakis, Evangelos D.; Provencher, Steeve; Bonnet, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">786-797</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: Pulmonary arterial hypertension (PAH) is assocd. with sustained inflammation known to promote DNA damage.  Despite these unfavorable environmental conditions, PAH pulmonary arterial smooth muscle cells (PASMCs) exhibit, in contrast to healthy PASMCs, a pro-proliferative and anti-apoptotic phenotype, sustained in time by the activation of miR-204, nuclear factor of activated T cells, and hypoxia-inducible factor 1-α.  We hypothesized that PAH-PASMCs have increased the activation of poly(ADP-ribose) polymerase-1 (PARP-1), a crit. enzyme implicated in DNA repair, allowing proliferation despite the presence of DNA-damaging insults, eventually leading to PAH.  METHODS AND RESULTS: Human PAH distal pulmonary arteries and cultured PAH-PASMCs exhibit increased DNA damage markers (53BP1 and γ-H2AX) and an overexpression of PARP-1 (immunoblot and activity assay), in comparison with healthy tissues/cells.  Healthy PASMCs treated with a clin. relevant dose of tumor necrosis factor-α harbored a similar phenotype, suggesting that inflammation induces DNA damage and PARP-1 activation in PAH.  We also showed that PARP-1 activation accounts for miR-204 downregulation (quant. reverse transcription polymerase chain reaction) and the subsequent activation of the transcription factors nuclear factor of activated T cells and hypoxia-inducible factor 1-α in PAH-PASMCs, previously shown to be crit. for PAH in several models.  These effects resulted in PASMC proliferation (Ki67, proliferating cell nuclear antigen, and WST1 assays) and resistance to apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling and Annexin V assays).  In vivo, the clin. available PARP inhibitor ABT-888 reversed PAH in 2 exptl. rat models (Sugen/hypoxia and monocrotaline).  CONCLUSIONS: These results show for the first time that the DNA damage/PARP-1 signaling pathway is important for PAH development and provide a new therapeutic target for this deadly disease with high translational potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktJ97sIdRjLVg90H21EOLACvtfcHk0ljPvn_4L3Y4Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSnsrY%253D&md5=f5cef653a9c6286f494685ac2d32f9c6</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.113.006167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.113.006167%26sid%3Dliteratum%253Aachs%26aulast%3DMeloche%26aufirst%3DJ.%26aulast%3DPflieger%26aufirst%3DA.%26aulast%3DVaillancourt%26aufirst%3DM.%26aulast%3DPaulin%26aufirst%3DR.%26aulast%3DPotus%26aufirst%3DF.%26aulast%3DZervopoulos%26aufirst%3DS.%26aulast%3DGraydon%26aufirst%3DC.%26aulast%3DCourboulin%26aufirst%3DA.%26aulast%3DBreuils-Bonnet%26aufirst%3DS.%26aulast%3DTremblay%26aufirst%3DE.%26aulast%3DCouture%26aufirst%3DC.%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DS.%26atitle%3DRole%2520for%2520DNA%2520damage%2520signaling%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2014%26volume%3D129%26spage%3D786%26epage%3D797%26doi%3D10.1161%2FCIRCULATIONAHA.113.006167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span> <span> </span><span class="NLM_article-title">Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension</span>. <i>Mol. Cells</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.14348/molcells.2014.2308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.14348%2Fmolcells.2014.2308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24608803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1GgtL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=196-201&author=J.+Kim&title=Apelin-APJ+signaling%3A+a+potential+therapeutic+target+for+pulmonary+arterial+hypertension&doi=10.14348%2Fmolcells.2014.2308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension</span></div><div class="casAuthors">Kim, Jongmin</div><div class="citationInfo"><span class="NLM_cas:title">Molecules and Cells</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">196-201, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOCEEK</span>;
        ISSN:<span class="NLM_cas:issn">1016-8478</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Molecular and Cellular Biology</span>)
        </div><div class="casAbstract">A review.  Pulmonary arterial hypertension (PAH) is a progressive disease characterized by the vascular remodeling of the pulmonary arterioles, including formation of plexiform and concentric lesions comprised of proliferative vascular cells.  Clin., PAH leads to increased pulmonary arterial pressure and subsequent right ventricular failure.  Existing therapies have improved the outcome but mortality still remains exceedingly high.  There is emerging evidence that the seven-transmembrane G-protein coupled receptor APJ and its cognate endogenous ligand apelin are important in the maintenance of pulmonary vascular homeostasis through the targeting of crit. mediators, such as Kruppel-like factor 2 (KLF2), endothelial nitric oxide synthase (eNOS), and microRNAs (miRNAs).  Disruption of this pathway plays a major part in the pathogenesis of PAH.  Given its role in the maintenance of pulmonary vascular homeostasis, the apelin-APJ pathway is a potential target for PAH therapy.  This review highlights the current state in the understanding of the apelin-APJ axis related to PAH and discusses the therapeutic potential of this signaling pathway as a novel paradigm of PAH therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNqPZpqOXMXLVg90H21EOLACvtfcHk0ljPvn_4L3Y4Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1GgtL7P&md5=65161f80f7231d8cf13d501a70d7318c</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.14348%2Fmolcells.2014.2308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14348%252Fmolcells.2014.2308%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DApelin-APJ%2520signaling%253A%2520a%2520potential%2520therapeutic%2520target%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DMol.%2520Cells%26date%3D2014%26volume%3D37%26spage%3D196%26epage%3D201%26doi%3D10.14348%2Fmolcells.2014.2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatemoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimiya, M.</span></span> <span> </span><span class="NLM_article-title">The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/S0167-0115(01)00236-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0167-0115%2801%2900236-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11384769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvV2rtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2001&pages=87-92&author=K.+Tatemotoauthor=K.+Takayamaauthor=M.+X.+Zouauthor=I.+Kumakiauthor=W.+Zhangauthor=K.+Kumanoauthor=M.+Fujimiya&title=The+novel+peptide+apelin+lowers+blood+pressure+via+a+nitric+oxide-dependent+mechanism&doi=10.1016%2FS0167-0115%2801%2900236-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism</span></div><div class="casAuthors">Tatemoto, K.; Takayama, K.; Zou, M.-X.; Kumaki, I.; Zhang, W.; Kumano, K.; Fujimiya, M.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Apelin is an endogenous ligand of the human orphan receptor APJ.  The authors detected apelin-like immunoreactivity in the adipocytes, gastric mucosa, and Kupffer cells in the liver.  The authors also detected apelin-like immunoreactivity localized within the endothelia of small arteries in various organs.  Further, it was found that mean arterial pressure after the administration of apelin-12, apelin-13, and apelin-36 at a dose of 10 nmol/kg in anesthetized rats was reduced by 26, 11, and 5 mm Hg, resp.  In the presence of a nitric oxide (NO) synthase inhibitor, the effect of apelin-12 on blood pressure was abolished.  Furthermore, the administration of apelin-12 (10 nmol/kg) in rats produced a transitory elevation of the plasma nitrite/nitrate concn. from a basal level of 21.4 to 27.0 μM.  Thus, apelin may lower blood pressure via a nitric oxide-dependent mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr13vFqdwNahbVg90H21EOLACvtfcHk0li03OqqOwKzjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvV2rtrY%253D&md5=af0d7ea0f8481a76a57d5207730a39e1</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2FS0167-0115%2801%2900236-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-0115%252801%252900236-1%26sid%3Dliteratum%253Aachs%26aulast%3DTatemoto%26aufirst%3DK.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DZou%26aufirst%3DM.%2BX.%26aulast%3DKumaki%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKumano%26aufirst%3DK.%26aulast%3DFujimiya%26aufirst%3DM.%26atitle%3DThe%2520novel%2520peptide%2520apelin%2520lowers%2520blood%2520pressure%2520via%2520a%2520nitric%2520oxide-dependent%2520mechanism%26jtitle%3DRegul.%2520Pept.%26date%3D2001%26volume%3D99%26spage%3D87%26epage%3D92%26doi%3D10.1016%2FS0167-0115%2801%2900236-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alastalo, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Perez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskenvuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">3735</span>– <span class="NLM_lpage">3746</span>, <span class="refDoi"> DOI: 10.1172/JCI43382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI43382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21821917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=3735-3746&author=T.-P.+Alastaloauthor=M.+Liauthor=V.+de+Jesus+Perezauthor=D.+Phamauthor=H.+Sawadaauthor=J.+K.+Wangauthor=M.+Koskenvuoauthor=L.+Wangauthor=B.+A.+Freemanauthor=H.+Y.+Changauthor=M.+Rabinovitch&title=Disruption+of+PPAR%CE%B3%2F%CE%B2-catenin-mediated+regulation+of+apelin+impairs+BMP-induced+mouse+and+human+pulmonary+arterial+EC+survival&doi=10.1172%2FJCI43382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival</span></div><div class="casAuthors">Alastalo, Tero-Pekka; Li, Molong; de Jesus Perez, Vinicio; Pham, David; Sawada, Hirofumi; Wang, Jordon K.; Koskenvuo, Minna; Wang, Lingli; Freeman, Bruce A.; Chang, Howard Y.; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3735-3746</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Reduced bone morphogenetic protein receptor 2 (BMPR2) expression in patients with pulmonary arterial hypertension (PAH) can impair pulmonary arterial EC (PAEC) function.  This can adversely affect EC survival and promote SMC proliferation.  We hypothesized that interventions to normalize expression of genes that are targets of BMPR2 signaling could restore PAEC function and prevent or reverse PAH.  Here we have characterized, in human PAECs, a BMPR2-mediated transcriptional complex between PPARγ and β-catenin and shown that disruption of this complex impaired BMP-mediated PAEC survival.  Using whole genome-wide ChIP-Chip promoter anal. and gene expression microarrays, we delineated PPARγ/β-catenin-dependent transcription of target genes including APLN, which encodes apelin.  We documented reduced PAEC expression of apelin in PAH patients vs. controls.  In cell culture expts., we showed that apelin-deficient PAECs were prone to apoptosis and promoted pulmonary arterial SMC (PASMC) proliferation.  Conversely, we established that apelin, like BMPR2 ligands, suppressed proliferation and induced apoptosis of PASMCs.  Consistent with these functions, administration of apelin reversed PAH in mice with reduced prodn. of apelin resulting from deletion of PPARγ in ECs.  Taken together, our findings suggest that apelin could be effective in treating PAH by rescuing BMPR2 and PAEC dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZixAy3nCZDrVg90H21EOLACvtfcHk0li03OqqOwKzjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOhtr7P&md5=cb1311168b02baf1eb1173ade2739aec</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1172%2FJCI43382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI43382%26sid%3Dliteratum%253Aachs%26aulast%3DAlastalo%26aufirst%3DT.-P.%26aulast%3DLi%26aufirst%3DM.%26aulast%3Dde%2BJesus%2BPerez%26aufirst%3DV.%26aulast%3DPham%26aufirst%3DD.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%2BK.%26aulast%3DKoskenvuo%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFreeman%26aufirst%3DB.%2BA.%26aulast%3DChang%26aufirst%3DH.%2BY.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DDisruption%2520of%2520PPAR%25CE%25B3%252F%25CE%25B2-catenin-mediated%2520regulation%2520of%2520apelin%2520impairs%2520BMP-induced%2520mouse%2520and%2520human%2520pulmonary%2520arterial%2520EC%2520survival%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D3735%26epage%3D3746%26doi%3D10.1172%2FJCI43382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayasekera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, L. S. G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onorato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirrat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newby, D. E.</span></span> <span> </span><span class="NLM_article-title">Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension</span>. <i>JACC Basic Transl Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.jacbts.2018.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jacbts.2018.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29876530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbkslelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=176-186&author=L.+Brashauthor=M.+J.+Brewisauthor=A.+C.+Churchauthor=G.+Jayasekeraauthor=M.+K.+Johnsonauthor=N.+McGlincheyauthor=J.+Simpsonauthor=S.+Thomsonauthor=D.+J.+Welshauthor=A.+J.+Peacockauthor=G.+D.+Barnesauthor=S.+J.+Gibbsauthor=L.+S.+G.+E.+Howardauthor=G.+Watsonauthor=M.+R.+Wilkinsauthor=J.+Onoratoauthor=C.+Xuauthor=C.+Stirratauthor=D.+E.+Newby&title=Short-term+hemodynamic+effects+of+apelin+in+patients+with+pulmonary+arterial+hypertension&doi=10.1016%2Fj.jacbts.2018.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Brash Lauren; Brewis Melanie J; Church A Colin; Jayasekera Geeshath; Johnson Martin K; McGlinchey Neil; Simpson Joanne; Thomson Stephen; Welsh David J; Peacock Andrew J; Barnes Gareth D; Gibbs Simon J; Howard Luke S G E; Watson Geoffrey; Wilkins Martin R; Onorato Joelle; Xu Carrie; Stirrat Colin; Newby David E</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Basic to translational science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-186</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models.  Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH.  In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr(1))apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr(1))apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output.  This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition.  Apelin agonism is a novel potential therapeutic target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNTM0d67PiEN-cVm4E2RlLfW6udTcc2ea6tfhw1SeuV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbkslelsg%253D%253D&md5=617243dd6dff4a6f05bb555b7c10deb5</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.jacbts.2018.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacbts.2018.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DBrash%26aufirst%3DL.%26aulast%3DBrewis%26aufirst%3DM.%2BJ.%26aulast%3DChurch%26aufirst%3DA.%2BC.%26aulast%3DJayasekera%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DM.%2BK.%26aulast%3DMcGlinchey%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DWelsh%26aufirst%3DD.%2BJ.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DBarnes%26aufirst%3DG.%2BD.%26aulast%3DGibbs%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DL.%2BS.%2BG.%2BE.%26aulast%3DWatson%26aufirst%3DG.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DOnorato%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DStirrat%26aufirst%3DC.%26aulast%3DNewby%26aufirst%3DD.%2BE.%26atitle%3DShort-term%2520hemodynamic%2520effects%2520of%2520apelin%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJACC%2520Basic%2520Transl%2520Sci.%26date%3D2018%26volume%3D3%26spage%3D176%26epage%3D186%26doi%3D10.1016%2Fj.jacbts.2018.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengers, R. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laghmani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkerts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenaar, G. T. M.</span></span> <span> </span><span class="NLM_article-title">Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response</span>. <i>Am. J. Physiol.: Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">L262</span>– <span class="NLM_lpage">L270</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00389.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1152%2Fajplung.00389.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26047641" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=L262-L270&author=X.+Y.+Chenauthor=F.+J.+Waltherauthor=R.+M.+A.+Sengersauthor=E.+Laghmaniauthor=A.+Salamauthor=G.+Folkertsauthor=T.+Peraauthor=G.+T.+M.+Wagenaar&title=Metformin+attenuates+hyperoxia-induced+lung+injury+in+neonatal+rats+by+reducing+the+inflammatory+response&doi=10.1152%2Fajplung.00389.2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00389.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00389.2014%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BY.%26aulast%3DWalther%26aufirst%3DF.%2BJ.%26aulast%3DSengers%26aufirst%3DR.%2BM.%2BA.%26aulast%3DLaghmani%26aufirst%3DE.%26aulast%3DSalam%26aufirst%3DA.%26aulast%3DFolkerts%26aufirst%3DG.%26aulast%3DPera%26aufirst%3DT.%26aulast%3DWagenaar%26aufirst%3DG.%2BT.%2BM.%26atitle%3DMetformin%2520attenuates%2520hyperoxia-induced%2520lung%2520injury%2520in%2520neonatal%2520rats%2520by%2520reducing%2520the%2520inflammatory%2520response%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2015%26volume%3D309%26spage%3DL262%26epage%3DL270%26doi%3D10.1152%2Fajplung.00389.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sartoretto, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melo, G. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, M. H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaglia, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scavone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuman, R. K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortes, Z. B.</span></span> <span> </span><span class="NLM_article-title">Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2676</span>– <span class="NLM_lpage">2689</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2005.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.lfs.2005.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15964597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=2676-2689&author=J.+L.+Sartorettoauthor=G.+A.+N.+Meloauthor=M.+H.+C.+Carvalhoauthor=D.+Nigroauthor=R.+T.+Passagliaauthor=C.+Scavoneauthor=R.+K.+N.+Cumanauthor=Z.+B.+Fortes&title=Metformin+treatment+restores+the+altered+microvascular+reactivity+in+neonatal+streptozotocin-induced+diabetic+rats+increasing+NOS+activity%2C+but+not+NOS+expression&doi=10.1016%2Fj.lfs.2005.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression</span></div><div class="casAuthors">Sartoretto, Juliano Luiz; Melo, Gessilda A. N.; Carvalho, Maria H. C.; Nigro, Dorothy; Passaglia, Rita T.; Scavone, Cristoforo; Cuman, Roberto K. N.; Fortes, Zuleica B.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2676-2689</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Abnormalities in vascular function are well recognized in diabetes.  Hyperglycemia may be central to the pathogenesis of vascular dysfunction but is not certain whether improvements in glycemic control will improve vascular function.  The effects of metformin, an antidiabetic agent that improves insulin sensitivity and glycemic control, on the microvascular reactivity have not been reported in neonatal streptozotocin-induced (n-STZ) diabetes.  Diabetes was induced by STZ injection (160 mg/kg, i.p.) in neonates (2-day-old) Wistar rats.  N-STZ diabetic rats were treated with metformin (300 mg/kg, 15 d, by gavage).  Using intravital microscopy the changes in mesenteric arteriolar and venular diams. were detd. in anesthetized control and n-STZ diabetic rats, before and after topical application of endothelium-dependent vasodilator agents, mediators or not of the inflammatory response, and endothelium-independent vasodilator agent.  We also detd. the total nitric oxide synthase (NOS) activity (conversion of -arginine to citrulline) and endothelial(e), inducible(i), and neuronal(n) NOS expression (using polymerase chain reaction after reverse transcription of the mRNAs into cDNAs) in the mesentery of metformin-treated n-STZ diabetic and vehicle-treated n-STZ diabetic and control rats.  Although metformin treatment did not correct the high glycemic levels and the impaired glucose tolerance, the reduced vasodilator responses and total NOS activity in n-STZ diabetic rats were cor. by the treatment.  Neither diabetes nor metformin treatment altered the expression of the three NOS isoforms.  We concluded that metformin restores the reduced response to vasodilator agents, independently of the correction of the metabolic alterations.  Improvement of total NOS activity might be in part responsible for the correction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBpo7orSU5Y7Vg90H21EOLACvtfcHk0lghP6syymUxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFersrc%253D&md5=b4d0f631cfd2a3426fec47526955a052</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2005.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2005.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DSartoretto%26aufirst%3DJ.%2BL.%26aulast%3DMelo%26aufirst%3DG.%2BA.%2BN.%26aulast%3DCarvalho%26aufirst%3DM.%2BH.%2BC.%26aulast%3DNigro%26aufirst%3DD.%26aulast%3DPassaglia%26aufirst%3DR.%2BT.%26aulast%3DScavone%26aufirst%3DC.%26aulast%3DCuman%26aufirst%3DR.%2BK.%2BN.%26aulast%3DFortes%26aufirst%3DZ.%2BB.%26atitle%3DMetformin%2520treatment%2520restores%2520the%2520altered%2520microvascular%2520reactivity%2520in%2520neonatal%2520streptozotocin-induced%2520diabetic%2520rats%2520increasing%2520NOS%2520activity%252C%2520but%2520not%2520NOS%2520expression%26jtitle%3DLife%2520Sci.%26date%3D2005%26volume%3D77%26spage%3D2676%26epage%3D2689%26doi%3D10.1016%2Fj.lfs.2005.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salt, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Metformin reverses development of pulmonary hypertension via aromatase inhibition</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.116.07353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FHYPERTENSIONAHA.116.07353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27296990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=446-454&author=A.+Deanauthor=M.+Nilsenauthor=L.+Loughlinauthor=I.+P.+Saltauthor=M.+R.+MacLean&title=Metformin+reverses+development+of+pulmonary+hypertension+via+aromatase+inhibition&doi=10.1161%2FHYPERTENSIONAHA.116.07353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition</span></div><div class="casAuthors">Dean, Afshan; Nilsen, Margaret; Loughlin, Lynn; Salt, Ian P.; MacLean, Margaret R.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">446-454</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Females are more susceptible to pulmonary arterial hypertension than males, although the reasons remain unclear.  The hypoglycemic drug, metformin, is reported to have multiple actions, including the inhibition of aromatase and stimulation of AMP-activated protein kinase.  Inhibition of aromatase using anastrazole is protective in exptl. pulmonary hypertension but whether metformin attenuates pulmonary hypertension through this mechanism remains unknown.  We investigated whether metformin affected aromatase activity and if it could reduce the development of pulmonary hypertension in the sugen 5416/hypoxic rat model.  We also investigated its influence on proliferation in human pulmonary arterial smooth muscle cells.  Metformin reversed right ventricular systolic pressure, right ventricular hypertrophy, and decreased pulmonary vascular remodeling in the rat.  Furthermore, metformin increased rat lung AMP-activated protein kinase signaling, decreased lung and circulating estrogen levels, levels of aromatase, the estrogen metabolizing enzyme; cytochrome P 450 1B1 and its transcription factor; the aryl hydrocarbon receptor.  In human pulmonary arterial smooth muscle cells, metformin decreased proliferation and decreased estrogen synthesis by decreasing aromatase activity through the PII promoter site of Cyp19a1.  Thus, we report for the first time that metformin can reverse pulmonary hypertension through inhibition of aromatase and estrogen synthesis in a manner likely to be mediated by AMP-activated protein kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_x4Ml4x6vHLVg90H21EOLACvtfcHk0lghP6syymUxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmsrfJ&md5=218ae77676c664641b751d24823082d5</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.116.07353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.116.07353%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DA.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DSalt%26aufirst%3DI.%2BP.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DMetformin%2520reverses%2520development%2520of%2520pulmonary%2520hypertension%2520via%2520aromatase%2520inhibition%26jtitle%3DHypertension%26date%3D2016%26volume%3D68%26spage%3D446%26epage%3D454%26doi%3D10.1161%2FHYPERTENSIONAHA.116.07353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolli-Derkinderen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumas-de-La-Roque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savineau, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loirand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacaud, P.</span></span> <span> </span><span class="NLM_article-title">Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00445.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fj.1476-5381.2009.00445.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19814724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=1285-1294&author=C.+Agardauthor=M.+Rolli-Derkinderenauthor=E.+Dumas-de-La-Roqueauthor=M.+Rioauthor=C.+Saganauthor=J.+P.+Savineauauthor=G.+Loirandauthor=P.+Pacaud&title=Protective+role+of+the+antidiabetic+drug+metformin+against+chronic+experimental+pulmonary+hypertension&doi=10.1111%2Fj.1476-5381.2009.00445.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension</span></div><div class="casAuthors">Agard, C.; Rolli-Derkinderen, M.; Dumas-de-La-Roque, E.; Rio, M.; Sagan, C.; Savineau, J. P.; Loirand, G.; Pacaud, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1285-1294</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is assocd. with increased contraction and proliferation of pulmonary vascular smooth muscle cells.  The anti-diabetic drug metformin has been shown to have relaxant and anti-proliferation properties.  We thus examd. the effect of metformin in PAH.  Metformin effects were analyzed in hypoxia- and monocrotaline-induced PAH in rats.  Ex vivo and in vitro analyses were performed in lungs, pulmonary artery rings and cells.  In hypoxia- and monocrotaline-induced PAH, the changes in mean pulmonary arterial pressure and right heart hypertrophy were nearly normalized by metformin treatment (100 mg/kg-1/day-1).  Pulmonary arterial remodelling occurring in both exptl. models of PAH was also inhibited by metformin treatment.  In rats with monocrotaline-induced PAH, treatment with metformin significantly increased survival.  Metformin increased endothelial nitric oxide synthase phosphorylation and decreased Rho kinase activity in pulmonary artery from rats with PAH.  These effects are assocd. with an improvement of carbachol-induced relaxation and redn. of phenylephrine-induced contraction of pulmonary artery.  In addn., metformin inhibited mitogen-activated protein kinase activation and strongly reduced pulmonary arterial cell proliferation during PAH.  In vitro, metformin directly inhibited pulmonary artery smooth muscle cell growth.  Metformin protected against PAH, regardless of the initiating stimulus.  This protective effect may be related to its anti-remodelling property involving improvement of endothelial function, vasodilatory and anti-proliferative actions.  As metformin is currently prescribed to treat diabetic patients, assessment of its use as a therapy against PAH in humans should be easier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTjiKlQR3ObVg90H21EOLACvtfcHk0lghP6syymUxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSksL7N&md5=efa7ad4365379282cfcc38e4a76dd9da</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00445.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00445.x%26sid%3Dliteratum%253Aachs%26aulast%3DAgard%26aufirst%3DC.%26aulast%3DRolli-Derkinderen%26aufirst%3DM.%26aulast%3DDumas-de-La-Roque%26aufirst%3DE.%26aulast%3DRio%26aufirst%3DM.%26aulast%3DSagan%26aufirst%3DC.%26aulast%3DSavineau%26aufirst%3DJ.%2BP.%26aulast%3DLoirand%26aufirst%3DG.%26aulast%3DPacaud%26aufirst%3DP.%26atitle%3DProtective%2520role%2520of%2520the%2520antidiabetic%2520drug%2520metformin%2520against%2520chronic%2520experimental%2520pulmonary%2520hypertension%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D1285%26epage%3D1294%26doi%3D10.1111%2Fj.1476-5381.2009.00445.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0lhK7wRAu5ODwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncharov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudryashova, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihida-Stansbury, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLisser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krymskaya, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuder, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharova, E. A.</span></span> <span> </span><span class="NLM_article-title">Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.113.004581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.113.004581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24270265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlShsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=864-874&author=D.+A.+Goncharovauthor=T.+V.+Kudryashovaauthor=H.+Ziaiauthor=K.+Ihida-Stansburyauthor=H.+DeLisserauthor=V.+P.+Krymskayaauthor=R.+M.+Tuderauthor=S.+M.+Kawutauthor=E.+A.+Goncharova&title=Mammalian+target+of+rapamycin+complex+2+%28mTORC2%29+coordinates+pulmonary+artery+smooth+muscle+cell+metabolism%2C+proliferation%2C+and+survival+in+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.113.004581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian Target of Rapamycin Complex 2 (mTORC2) Coordinates Pulmonary Artery Smooth Muscle Cell Metabolism, Proliferation, and Survival in Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Goncharov, Dmitry A.; Kudryashova, Tatiana V.; Ziai, Houman; Ihida-Stansbury, Kaori; De Lisser, Horace; Krymskaya, Vera P.; Tuder, Rubin M.; Kawut, Steven M.; Goncharova, Elena A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">864-874</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: Enhanced proliferation, resistance to apoptosis, and metabolic shift to glycolysis of pulmonary arterial vascular smooth muscle cells (PAVSMCs) are key pathophysiol. components of pulmonary vascular remodeling in idiopathic pulmonary arterial hypertension (PAH).  The role of the distinct mammalian target of rapamycin (mTOR) complexes mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor) in PAVSMC proliferation and survival in PAH and their therapeutic relevance are unknown.  METHODS AND RESULTS: Immunohistochem. and immunoblot analyses revealed that mTORC1 and mTORC2 pathways are markedly upregulated in small remodeled pulmonary arteries and isolated distal PAVSMCs from subjects with idiopathic PAH that have increased ATP levels, proliferation, and survival that depend on glycolytic metab.  Small interfering RNA- and pharmacol.-based anal. showed that although both mTORC1 and mTORC2 contribute to proliferation, only mTORC2 is required for ATP generation and survival of idiopathic PAH PAVSMCs.  MTORC2 downregulated the energy sensor AMP-activated protein kinase, which led to activation of mTORC1-S6 and increased proliferation, as well as a deficiency of the proapoptotic protein Bim and idiopathic PAH PAVSMC survival.  NADPH oxidase 4 (Nox4) protein levels were increased in idiopathic PAH PAVSMCs, which was necessary for mTORC2 activation, proliferation, and survival.  Nox4 levels and mTORC2 signaling were significantly upregulated in small pulmonary arteries from hypoxia-exposed rats at days 2 to 28 of hypoxia.  Treatment with the mTOR kinase inhibitor PP242 at days 15 to 28 suppressed mTORC2 but not Nox4, induced smooth muscle-specific apoptosis in small pulmonary arteries, and reversed hypoxia-induced pulmonary vascular remodeling in rats.  CONCLUSIONS: These data provide a novel mechanistic link of Nox4-dependent activation of mTORC2 via the energy sensor AMP-activated protein kinase to increased proliferation and survival of PAVSMCs in PAH, which suggests a new potential pathway for therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruk0h6H0v-47Vg90H21EOLACvtfcHk0lhK7wRAu5ODwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlShsLY%253D&md5=7f796541aa267234775122dc776e5340</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.113.004581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.113.004581%26sid%3Dliteratum%253Aachs%26aulast%3DGoncharov%26aufirst%3DD.%2BA.%26aulast%3DKudryashova%26aufirst%3DT.%2BV.%26aulast%3DZiai%26aufirst%3DH.%26aulast%3DIhida-Stansbury%26aufirst%3DK.%26aulast%3DDeLisser%26aufirst%3DH.%26aulast%3DKrymskaya%26aufirst%3DV.%2BP.%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DKawut%26aufirst%3DS.%2BM.%26aulast%3DGoncharova%26aufirst%3DE.%2BA.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520complex%25202%2520%2528mTORC2%2529%2520coordinates%2520pulmonary%2520artery%2520smooth%2520muscle%2520cell%2520metabolism%252C%2520proliferation%252C%2520and%2520survival%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2014%26volume%3D129%26spage%3D864%26epage%3D874%26doi%3D10.1161%2FCIRCULATIONAHA.113.004581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paddenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Lilien, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulhammer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillmanns, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun-Dullaeus, R. C.</span></span> <span> </span><span class="NLM_article-title">Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-8-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-8-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17319968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2s7lslChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=15&author=R.+Paddenbergauthor=P.+Stiegerauthor=A.+L.+von+Lilienauthor=P.+Faulhammerauthor=A.+Goldenbergauthor=H.+H.+Tillmannsauthor=W.+Kummerauthor=R.+C.+Braun-Dullaeus&title=Rapamycin+attenuates+hypoxia-induced+pulmonary+vascular+remodeling+and+right+ventricular+hypertrophy+in+mice&doi=10.1186%2F1465-9921-8-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice</span></div><div class="casAuthors">Paddenberg Renate; Stieger Philipp; von Lilien Anna-Laura; Faulhammer Petra; Goldenberg Anna; Tillmanns Harald H; Kummer Wolfgang; Braun-Dullaeus Ruediger C</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic hypoxia induces pulmonary arterial hypertension (PAH).  Smooth muscle cell (SMC) proliferation and hypertrophy are important contributors to the remodeling that occurs in chronic hypoxic pulmonary vasculature.  We hypothesized that rapamycin (RAPA), a potent cell cycle inhibitor, prevents pulmonary hypertension in chronic hypoxic mice.  METHODS:  Mice were held either at normoxia (N; 21% O2) or at hypobaric hypoxia (H; 0.5 atm; ~10% O2).  RAPA-treated animals (3 mg/kg*d, i.p.) were compared to animals injected with vehicle alone.  Proliferative activity within the pulmonary arteries was quantified by staining for Ki67 (positive nuclei/vessel) and media area was quantified by computer-aided planimetry after immune-labeling for alpha-smooth muscle actin (pixel/vessel).  The ratio of right ventricle to left ventricle plus septum (RV/[LV+S]) was used to determine right ventricular hypertrophy.  RESULTS:  Proliferative activity increased by 34% at day 4 in mice held under H (median: 0.38) compared to N (median: 0.28, p = 0.028) which was completely blocked by RAPA (median HO+RAPA: 0.23, p = 0.003).  H-induced proliferation had leveled off within 3 weeks.  At this time point media area had, however, increased by 53% from 91 (N) to 139 (H, p < 0.001) which was prevented by RAPA (H+RAPA: 102; p < 0.001).  RV/[LV+S] ratio which had risen from 0.17 (N) to 0.26 (H, p < 0.001) was attenuated in the H+RAPA group (0.22, p = 0.041).  For a therapeutic approach animals were exposed to H for 21 days followed by 21 days in H +/- RAPA.  Forty two days of H resulted in a media area of 129 (N: 83) which was significantly attenuated in RAPA-treated mice (H+RAPA: 92).  RV/[LV+S] ratios supported prevention of PH (N 0.13; H 0.27; H+RAPA 0.17).  RAPA treatment of N mice did not influence any parameter examined.  CONCLUSION:  Therapy with rapamycin may represent a new strategy for the treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGyRcywODD80PI-fCgwosgfW6udTcc2eazOHHz5pM9Xbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7lslChsQ%253D%253D&md5=4e2cdad1e0fccddfa68f40661b08a7cd</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-8-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-8-15%26sid%3Dliteratum%253Aachs%26aulast%3DPaddenberg%26aufirst%3DR.%26aulast%3DStieger%26aufirst%3DP.%26aulast%3Dvon%2BLilien%26aufirst%3DA.%2BL.%26aulast%3DFaulhammer%26aufirst%3DP.%26aulast%3DGoldenberg%26aufirst%3DA.%26aulast%3DTillmanns%26aufirst%3DH.%2BH.%26aulast%3DKummer%26aufirst%3DW.%26aulast%3DBraun-Dullaeus%26aufirst%3DR.%2BC.%26atitle%3DRapamycin%2520attenuates%2520hypoxia-induced%2520pulmonary%2520vascular%2520remodeling%2520and%2520right%2520ventricular%2520hypertrophy%2520in%2520mice%26jtitle%3DRespir.%2520Res.%26date%3D2007%26volume%3D8%26spage%3D15%26doi%3D10.1186%2F1465-9921-8-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bru-Mercier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courboulin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quatredeniers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker-Martin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antigny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakhleh, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranchoux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouadon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinhas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Kaminsky, S.</span></span> <span> </span><span class="NLM_article-title">NMDA-type glutamate receptor activation promotes vascular remodeling and pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.117.029930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.117.029930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29444988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVagsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2018&pages=2371-2389&author=S.+J.+Dumasauthor=G.+Bru-Mercierauthor=A.+Courboulinauthor=M.+Quatredeniersauthor=C.+Rucker-Martinauthor=F.+Antignyauthor=M.+K.+Nakhlehauthor=B.+Ranchouxauthor=E.+Gouadonauthor=M.+C.+Vinhasauthor=M.+Vocelleauthor=N.+Raymondauthor=P.+Dorfmullerauthor=E.+Fadelauthor=F.+Perrosauthor=M.+Humbertauthor=S.+Cohen-Kaminsky&title=NMDA-type+glutamate+receptor+activation+promotes+vascular+remodeling+and+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.117.029930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Dumas, Sebastien J.; Bru-Mercier, Gilles; Courboulin, Audrey; Quatredeniers, Marceau; Ruecker-Martin, Catherine; Antigny, Fabrice; Nakhleh, Morad K.; Ranchoux, Benoit; Gouadon, Elodie; Vinhas, Maria-Candida; Vocelle, Matthieu; Raymond, Nicolas; Dorfmueller, Peter; Fadel, Elie; Perros, Frederic; Humbert, Marc; Cohen-Kaminsky, Sylvia</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2371-2389</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Excessive proliferation and apoptosis resistance in pulmonary vascular cells underlie vascular remodeling in pulmonary arterial hypertension (PAH).  Specific treatments for PAH exist, mostly targeting endothelial dysfunction, but high pulmonary arterial pressure still causes heart failure and death.  Pulmonary vascular remodeling may be driven by metabolic reprogramming of vascular cells to increase glutaminolysis and glutamate prodn.  The N-methyl-D-aspartate receptor (NMDAR), a major neuronal glutamate receptor, is also expressed on vascular cells, but its role in PAH is unknown.  Methods: We assessed the status of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and controls through mass spectrometry imaging, Western blotting, and immunohistochem.  We measured the glutamate release from cultured pulmonary vascular cells using enzymic assays and analyzed NMDAR regulation/phosphorylation through Western blot expts.  The effect of NMDAR blockade on human pulmonary arterial smooth muscle cell proliferation was detd. using a BrdU incorporation assay.  We assessed the role of NMDARs in vascular remodeling assocd. to pulmonary hypertension, in both smooth muscle-specific NMDAR knockout mice exposed to chronic hypoxia and the monocrotaline rat model of pulmonary hypertension using NMDAR blockers.  Results: We report glutamate accumulation, upregulation of the NMDAR, and NMDAR engagement reflected by increases in GluN1-subunit phosphorylation in the pulmonary arteries of human patients with PAH.  Kv channel inhibition and type A-selective endothelin receptor activation amplified calcium-dependent glutamate release from human pulmonary arterial smooth muscle cell, and type A-selective endothelin receptor and platelet-derived growth factor receptor activation led to NMDAR engagement, highlighting crosstalk between the glutamate-NMDAR axis and major PAH-assocd. pathways.  The platelet-derived growth factor-BB-induced proliferation of human pulmonary arterial smooth muscle cells involved NMDAR activation and phosphorylated GluN1 subunit localization to cell-cell contacts, consistent with glutamatergic communication between proliferating human pulmonary arterial smooth muscle cells via NMDARs.  Smooth-muscle NMDAR deficiency in mice attenuated the vascular remodeling triggered by chronic hypoxia, highlighting the role of vascular NMDARs in pulmonary hypertension.  Pharmacol. NMDAR blockade in the monocrotaline rat model of pulmonary hypertension had beneficial effects on cardiac and vascular remodeling, decreasing endothelial dysfunction, cell proliferation, and apoptosis resistance while disrupting the glutamate-NMDAR pathway in pulmonary arteries.  Conclusions: These results reveal a dysregulation of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and identify vascular NMDARs as targets for antiremodeling treatments in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWbl26iE6Q7Vg90H21EOLACvtfcHk0lgql7TkekVMfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVagsrbJ&md5=a515464a510fe449334c29bc5b8330ae</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.117.029930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.117.029930%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DS.%2BJ.%26aulast%3DBru-Mercier%26aufirst%3DG.%26aulast%3DCourboulin%26aufirst%3DA.%26aulast%3DQuatredeniers%26aufirst%3DM.%26aulast%3DRucker-Martin%26aufirst%3DC.%26aulast%3DAntigny%26aufirst%3DF.%26aulast%3DNakhleh%26aufirst%3DM.%2BK.%26aulast%3DRanchoux%26aufirst%3DB.%26aulast%3DGouadon%26aufirst%3DE.%26aulast%3DVinhas%26aufirst%3DM.%2BC.%26aulast%3DVocelle%26aufirst%3DM.%26aulast%3DRaymond%26aufirst%3DN.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DCohen-Kaminsky%26aufirst%3DS.%26atitle%3DNMDA-type%2520glutamate%2520receptor%2520activation%2520promotes%2520vascular%2520remodeling%2520and%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2018%26volume%3D137%26spage%3D2371%26epage%3D2389%26doi%3D10.1161%2FCIRCULATIONAHA.117.029930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel hybridization from isosorbide 5-mononitrate and bardoxolone methyl with dual activities of pulmonary vasodilation and vascular remodeling inhibition on pulmonary arterial hypertension rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1474</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1474-1482&author=Y.+Chengauthor=Y.+Gongauthor=S.+Qianauthor=Y.+Mouauthor=H.+Liauthor=X.+Chenauthor=H.+Kongauthor=W.+Xieauthor=H.+Wangauthor=Y.+Zhangauthor=Z.+Huang&title=Identification+of+a+novel+hybridization+from+isosorbide+5-mononitrate+and+bardoxolone+methyl+with+dual+activities+of+pulmonary+vasodilation+and+vascular+remodeling+inhibition+on+pulmonary+arterial+hypertension+rats&doi=10.1021%2Facs.jmedchem.7b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats</span></div><div class="casAuthors">Cheng, Yusheng; Gong, Yan; Qian, Shuai; Mou, Yi; Li, Hanrui; Chen, Xijing; Kong, Hui; Xie, Weiping; Wang, Hong; Zhang, Yihua; Huang, Zhangjian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1474-1482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given the clin. therapeutic efficacy of oral-dosed bardoxolone Me (1) and the selective vasodilatory effect caused by inhalation of nitric oxide (NO) on pulmonary arterial hypertension (PAH) patients, a new hybrid (CDDO-NO, 2) from 1 and NO donor isosorbide 5-mononitrate (3) was designed and synthesized.  This hybrid could liberate 1 and NO in the lungs of rats after trachea injection.  Significantly, 2 lowered mean pulmonary artery pressure (mPAP) and right ventricular systolic pressure (RVSP), decreased right ventricular hypertrophy (RVH), and attenuated pulmonary artery medial thickness (PAMT) and vascular muscularization in monocrotaline (MCT)-induced PAH rats.  Meanwhile, 2 inhibited overproliferation of perivascular cells and diminished macrophage infiltration and oxidative stress by inactivation of NOX4.  In addn., 2 markedly reduced cardiac hypertrophy and fibrosis in the PAH rats.  Overall, 2 exhibited potent dual activities of pulmonary vasodilation and vascular remodeling inhibition, suggesting that it may be a promising agent for PAH intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokAmpHGp1f87Vg90H21EOLACvtfcHk0lgql7TkekVMfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGls70%253D&md5=1c6572d25d398bfbdc35173e9b59a377</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01153%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DS.%26aulast%3DMou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DIdentification%2520of%2520a%2520novel%2520hybridization%2520from%2520isosorbide%25205-mononitrate%2520and%2520bardoxolone%2520methyl%2520with%2520dual%2520activities%2520of%2520pulmonary%2520vasodilation%2520and%2520vascular%2520remodeling%2520inhibition%2520on%2520pulmonary%2520arterial%2520hypertension%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1474%26epage%3D1482%26doi%3D10.1021%2Facs.jmedchem.7b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pyrazolo[3,4-b] pyridine derivatives with dual activities of vascular remodeling inhibition and vasodilation for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11215</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVWhtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11215&author=L.+Huauthor=L.+Liauthor=Q.+Changauthor=S.+Fuauthor=J.+Qinauthor=Z.+Chenauthor=X.+Liauthor=Q.+Liuauthor=G.+Huauthor=Q.+Li&title=Discovery+of+novel+pyrazolo%5B3%2C4-b%5D+pyridine+derivatives+with+dual+activities+of+vascular+remodeling+inhibition+and+vasodilation+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.0c01132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pyrazolo[3,4-b]Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Hu, Liqing; Li, Lijun; Chang, Qi; Fu, Songsen; Qin, Jia; Chen, Zhuo; Li, Xiaohui; Liu, Qinglian; Hu, Gaoyun; Li, Qianbin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11215-11234</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Current pulmonary arterial hypertension (PAH) therapeutic strategies mainly focus on vascular relaxation with less emphasis on vascular remodeling, which results in poor prognosis.  Hence, dual pathway regulators with vasodilation effect via sol. guanylate cyclase (sGC) stimulation and vascular remodeling regulation effect by AMP-activated protein kinase (AMPK) inhibition provide more advantages and potentialities.  Herein, we designed and synthesized a series of novel pyrazolo[3,4-b]pyridine derivs. based on sGC stimulator and AMPK inhibitor scaffolds.  In vitro, 2 exhibited moderate vasodilation activity and higher proliferation and migration suppressive effects compared to riociguat.  In vivo, 2 significantly decreased right ventricular systolic pressure (RVSP), attenuated pulmonary artery medial thickness (PAMT), and right ventricular hypertrophy (RVH) in hypoxia-induced PAH rat models (i.g.).  Given the unique advantages of significant vascular remodeling inhibition and moderate vascular relaxation based on the dual pathway regulation, we proposed 2 as a promising lead for anti-PAH drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxCtw-vcP3wrVg90H21EOLACvtfcHk0liN4FBf35INKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVWhtr%252FJ&md5=1d1fa972aeb8b6e08b0ac40c8e4d0f57</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01132%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520novel%2520pyrazolo%255B3%252C4-b%255D%2520pyridine%2520derivatives%2520with%2520dual%2520activities%2520of%2520vascular%2520remodeling%2520inhibition%2520and%2520vasodilation%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11215%26doi%3D10.1021%2Facs.jmedchem.0c01132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. J.</span></span> <span> </span><span class="NLM_article-title">Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2012-0071OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1165%2Frcmb.2012-0071OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23065131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Kntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=125-134&author=J.+Wangauthor=Q.+Jiangauthor=L.+M.+Wanauthor=K.+Yangauthor=Y.+Zhangauthor=Y.+Q.+Chenauthor=E.+Wangauthor=N.+Laiauthor=L.+Zhaoauthor=H.+Jiangauthor=Y.+Q.+Sunauthor=N.+S.+Zhongauthor=P.+X.+Ranauthor=W.+J.+Lu&title=Sodium+tanshinone+IIA+sulfonate+inhibits+canonical+transient+receptor+potential+expression+in+pulmonary+arterial+smooth+muscle+from+pulmonary+hypertensive+rats&doi=10.1165%2Frcmb.2012-0071OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats</span></div><div class="casAuthors">Wang, Jian; Jiang, Qian; Wan, Limei; Yang, Kai; Zhang, Yi; Chen, Yuqin; Wang, Elizabeth; Lai, Ning; Zhao, Lei; Jiang, Hua; Sun, Yueqian; Zhong, Nanshan; Ran, Pixin; Lu, Wenju</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Danshen, the dried root of Salvia miltiorrhiza, is widely used in clinics in China for treating various diseases, including cardiovascular diseases.  Sodium tanshinone IIA sulfonate (STS), a water-sol. deriv. of tanshinone IIA isolated as the major active component from Danshen, was recently reported to be effective in attenuating the characteristic pulmonary vascular changes assocd. with chronically hypoxic pulmonary hypertension (CHPH); however, the underlying detailed mechanisms are poorly understood.  In this study, we investigated the effects of STS on basal intracellular Ca2+ concn. ([Ca2+]i) and store-operated Ca2+ entry (SOCE) in distal pulmonary arterial smooth muscle cells (PASMCs) exposed to prolonged hypoxia or isolated from CHPH rats.  SOCE measured by Mn2+ quenching of Fura-2 fluorescence in PASMCs from rats exposed to chronic hypoxia (10% O2, 21 d) was increased by 59%, and basal [Ca2+]i was increased by 119%; this effect was inhibited by i.p. injection of STS.  These inhibitory effects of STS on hypoxic increases of SOCE and basal [Ca2+]i were assocd. with reduced expression of canonical transient receptor potential (TRPC)1 and TRPC6 in distal pulmonary arterial smooth muscle and decreases on right ventricular pressure, right ventricular hypertrophy, and peripheral pulmonary vessel thickening.  In ex vivo cultured distal PASMCs from normoxic rats, STS (0-25 μM) dose-dependently inhibited hypoxia-induced cell proliferation and migration, paralleled with attenuation in increases of basal [Ca2+]i, SOCE, mRNA, and protein expression of TRPC1 and TRPC6.  STS also relieved right ventricular systolic pressure, right ventricular hypertrophy, and TRPC1 and TRPC6 protein expression in distal pulmonary arteries in a monocrotaline-induced rat model of pulmonary arterial hypertension.  These results indicate that STS prevents pulmonary arterial hypertension development likely by inhibiting TRPC1 and TRPC6 expression, resulting in normalized basal [Ca2+]i and attenuated proliferation and migration of PASMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocO4lRhKI0AbVg90H21EOLACvtfcHk0liN4FBf35INKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Kntw%253D%253D&md5=ade066de6af0e4531fb20fa28c74705d</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2012-0071OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2012-0071OC%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWan%26aufirst%3DL.%2BM.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DLai%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DY.%2BQ.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26aulast%3DRan%26aufirst%3DP.%2BX.%26aulast%3DLu%26aufirst%3DW.%2BJ.%26atitle%3DSodium%2520tanshinone%2520IIA%2520sulfonate%2520inhibits%2520canonical%2520transient%2520receptor%2520potential%2520expression%2520in%2520pulmonary%2520arterial%2520smooth%2520muscle%2520from%2520pulmonary%2520hypertensive%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2013%26volume%3D48%26spage%3D125%26epage%3D134%26doi%3D10.1165%2Frcmb.2012-0071OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span> <span> </span><span class="NLM_article-title">Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23585945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3srlt1CisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=169-172&author=J.+Wangauthor=W.+J.+Luauthor=W.+Wangauthor=N.+F.+Zhangauthor=H.+Wuauthor=C.+L.+Liuauthor=X.+Q.+Chenauthor=Y.+H.+Chenauthor=Y.+Q.+Chenauthor=Q.+Jiangauthor=L.+Xuauthor=L.+C.+Tianauthor=P.+X.+Ranauthor=N.+S.+Zhong&title=Promising+therapeutic+effects+of+sodium+tanshinone+IIA+sulfonate+towards+pulmonary+arterial+hypertension+in+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients</span></div><div class="casAuthors">Wang Jian; Lu Wenju; Wang Wei; Zhang Nuofu; Wu Hua; Liu Chunli; Chen Xiuqing; Chen Yonghua; Chen Yuqin; Jiang Qian; Xu Lei; Tian Lichun; Ran Pixin; Zhong Nanshan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-72</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary hypertension (PH) is a lethal disease with no cure currently available.  Sodium Tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the major active component from salvia miltiorrhiza, a kind of Chinese herbal medicine.  We investigate the efficacy of STS towards treatment of PH patients.  METHODS AND RESULTS:  Five hospitalized patients were randomly enrolled for this study.  These patients were suffering from various types of serious PH without getting sufficient benefits from sildenafil treatment (20 mg tid) for at least three months.  The efficacy of STS on PH was evaluated by measuring the pulmonary arterial systolic pressure (PASP), RV size by echocardiography, 6-minute walking distance (6MWD), Borg dyspnea score, and WHO functional class of PH.  Patients aged from 17 to 46 (average 33±11) years old, pulmonary arterial systolic pressure (PASP) ranged from 60 to 140 mmHg, RV size ranged from 25 to 39 mm were included in study.  At the endpoint of observation for 8 weeks of STS infusion, they obtained reduction of PASP in the range of 14-45 (average 28.6±12.5) mmHg, RV size in the range of 0-10 (average 4.2±1.6).  All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II.  CONCLUSIONS:  These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmAHSB1C2JF3WEEzDrymxmfW6udTcc2ebVBtZvD8zKebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srlt1CisQ%253D%253D&md5=2ac29f6ae8197f3a5aa510174cdb8716</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%2BF.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DL.%2BC.%26aulast%3DRan%26aufirst%3DP.%2BX.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26atitle%3DPromising%2520therapeutic%2520effects%2520of%2520sodium%2520tanshinone%2520IIA%2520sulfonate%2520towards%2520pulmonary%2520arterial%2520hypertension%2520in%2520patients%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2013%26volume%3D5%26spage%3D169%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and clinical application of tetramethylpyrazine (an interesting natural compound isolated from ligusticum wallichii): Current status and perspective</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">2124638</span>, <span class="refDoi"> DOI: 10.1155/2016/2124638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1155%2F2016%2F2124638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27668034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FitFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=2124638&author=Y.+K.+Zhaoauthor=Y.+Liuauthor=K.+J.+Chen&title=Mechanisms+and+clinical+application+of+tetramethylpyrazine+%28an+interesting+natural+compound+isolated+from+ligusticum+wallichii%29%3A+Current+status+and+perspective&doi=10.1155%2F2016%2F2124638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective</span></div><div class="casAuthors">Zhao Yingke; Liu Yue; Chen Keji</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2124638</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tetramethylpyrazine, a natural compound from Ligusticum wallichii (Chuan Xiong), has been extensively used in China for cardiovascular and cerebrovascular diseases for about 40 years.  Because of its effectiveness in multisystems, especially in cardiovascular, its pharmacological action, clinical application, and the structural modification have attracted broad attention.  In this paper its mechanisms of action, the clinical status, and synthetic derivatives will be reviewed briefly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnh5xfR2y40kGy1nwu7K2mfW6udTcc2ebVBtZvD8zKebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FitFersw%253D%253D&md5=d75cf8fdc81fde0aa8e0ed3da7504af2</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2124638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2124638%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%2BJ.%26atitle%3DMechanisms%2520and%2520clinical%2520application%2520of%2520tetramethylpyrazine%2520%2528an%2520interesting%2520natural%2520compound%2520isolated%2520from%2520ligusticum%2520wallichii%2529%253A%2520Current%2520status%2520and%2520perspective%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2016%26volume%3D2016%26spage%3D2124638%26doi%3D10.1155%2F2016%2F2124638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naruse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y. F.</span></span> <span> </span><span class="NLM_article-title">Effects of tetramethylpyrazine, a Chinese medicine, on plasma endothelin-1 levels during acute pulmonary hypoxia in anesthetized dogs</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">S456</span>– <span class="NLM_lpage">S459</span>, <span class="refDoi"> DOI: 10.1097/00005344-199800001-00130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1097%2F00005344-199800001-00130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=9595511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=S456-S459&author=W.+B.+Caoauthor=Z.+P.+Zengauthor=Y.+J.+Zhuauthor=W.+C.+Luoauthor=H.+Demuraauthor=M.+Naruseauthor=Y.+F.+Shi&title=Effects+of+tetramethylpyrazine%2C+a+Chinese+medicine%2C+on+plasma+endothelin-1+levels+during+acute+pulmonary+hypoxia+in+anesthetized+dogs&doi=10.1097%2F00005344-199800001-00130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of tetramethylpyrazine, a Chinese medicine, on plasma endothelin-1 levels during acute pulmonary hypoxia in anesthetized dogs</span></div><div class="casAuthors">Cao, Wei-Biao; Zeng, Zheng-Pei; Zhu, Yuan-Jue; Luo, Wei-Ci; Demura, Hiroshi; Naruse, Mitsuhide; Shi, Yi-Fan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">Suppl. 1, Endothelin V</span>),
    <span class="NLM_cas:pages">S456-S459</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Our study was designed to elucidate the effects of tetramethylpyrazine (TMP), a Chinese medicine, on plasma endothelin-1 (ET-1) levels in dogs with acute pulmonary alveolar hypoxia.  Anesthetized dogs were used under artificial ventilation with room air or a hypoxic gas mixt. (10% O2 and 90% N2) (n = 10) for 60 min.  Effects of TMP (80 mg/kg) were studied by i.v. injection of TMP before exposure to hypoxia (n = 8).  Mean pulmonary arterial pressure (PAPm), systemic arterial pressure (SAPm), right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and heart rate (HR) were measured.  The pulmonary vascular resistance (PVR) was calcd. by the equation of (PAPm-PCWP) × 8/CO.  Plasma ET-1 levels were detd. in the abdominal aorta and pulmonary artery by RIA.  The effects of TMP on PAP and plasma ET-1 level were evaluated by using percent increase in PAPm and the change of Da-pET (ΔET) before and after hypoxia.  Both PAPm and PVR were significantly elevated 5 min after acute hypoxia over a period of 60 min, whereas CO and PCWP did not change.  Plasma ET-1 levels in the abdominal aorta and Da-pET showed a significant increase.  Administration of TMP significantly decreased the hypoxia-induced increase in the PAPm, PVR, and ΔET.  These results suggest that TMP could be a useful therapeutic agent in the treatment of pulmonary hypertension induced by acute hypoxia through decrease of plasma ET-1 levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzZaZTgEs_7Vg90H21EOLACvtfcHk0lhZJIFt-pAUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFartbc%253D&md5=c095548f63818356e292c59437c485ca</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1097%2F00005344-199800001-00130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199800001-00130%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DW.%2BB.%26aulast%3DZeng%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DY.%2BJ.%26aulast%3DLuo%26aufirst%3DW.%2BC.%26aulast%3DDemura%26aufirst%3DH.%26aulast%3DNaruse%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BF.%26atitle%3DEffects%2520of%2520tetramethylpyrazine%252C%2520a%2520Chinese%2520medicine%252C%2520on%2520plasma%2520endothelin-1%2520levels%2520during%2520acute%2520pulmonary%2520hypoxia%2520in%2520anesthetized%2520dogs%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1998%26volume%3D31%26spage%3DS456%26epage%3DS459%26doi%3D10.1097%2F00005344-199800001-00130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z. X.</span></span> <span> </span><span class="NLM_article-title">Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation</span>. <i>Chin. J. Appl. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2MfotVyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2014&pages=532-537&author=E.+Z.+Fengauthor=S.+Y.+Yangauthor=N.+X.+Huangauthor=H.+Yinauthor=Y.+Zhangauthor=Z.+X.+Tian&title=Plasma+endothelin-1+and+nitric+oxide+correlate+with+ligustrazine+alleviation+of+pulmonary+artery+hypertension+in+patients+of+chronic+cor+pulmonale+from+high+altitude+plateau+during+acute+exacerbation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation</span></div><div class="casAuthors">Feng En-Zhi; Yang Sheng-Yue; Huang Ning-Xia; Yin He; Zhang Ying; Tian Zhong-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">532-7</span>
        ISSN:<span class="NLM_cas:issn">1000-6834</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore the mechanisms involved in the ligustrazine alleviation of the pulmonary artery hypertension (PAH) in patients of chronic obstructive pulmonary disease (COPD) associated with chronic cor pulmonale (CCP) during exacerbation.  METHODS:  Seventy patients of COPD and CCP with acute exacerbation were randomly and equally divided into control group and treatment group.  The control group received standard treatment with antibiotics, antiasthmatic and expectorant medications, and oxygenation; and the ligustrazine treatment group received ligustrazine treatment (80 mg/d; i.v.; for 2 weeks) in addition to the standard treatment.  Before and at the end of 2 week treatment, the clinic responses of the two regimens were evaluated, plasma levels of endothelin-1 (ET-1) and nitric oxide (NO) were determined; arterial oxygen partial pressure (PaO2, mean pulmonary arterial pressure (mPAP), outflow tract of right ventricle (RVOT), and internal diameter of right ventricle (RV) were measured.  RESULTS:  Good clinic benefits were achieved in both the standard and ligustrazine regimens, plasma level of ET-1, values of mPAP, RV and RVOT decreased significantly, plasma level of NO and PaO2 values decreased (all P < 0.01 vs pre-treatment to all parameters).  Compared with the control group, ligustrazine greatly enhanced the clinic efficacy from 77.1% to 97.1% (P < 0.05), and also resulted in more significant changes of all these parameters (P < 0.01 vs control group for all parameters).  For both groups, the levels of plasma ET-1 were positively correlated with values of mPAP, RVOT, and RV (r = 0.710, 0.853, and 0.766, respectively, all P = 0.000), and negatively correlated with plasma NO and PaO2 (r = - 0.823, and - 0.752, respectively, all P = 0.000).  CONCLUSION:  Ligustrazine is effective in treating pulmonary artery hypertension during acute exacerbation of COPD and CCP in patients from the plateau area.  The observed changes in the plasma levels of NO and ET-1 in response to ligustrazine treatment suggest that ligustrazine may act through the selective effect on pulmonary blood vessels to enhance the synthesis and release of NO and suppress those of ET-1 from lung vascular endothelial cells, thus reducing pulmonary artery pressure and decreasing pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYL82f4RkqVjToTC3aBaesfW6udTcc2eb6vZUii1wcvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfotVyisA%253D%253D&md5=366a254a5f0286e5300c2717a56545c6</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DE.%2BZ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DHuang%26aufirst%3DN.%2BX.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DZ.%2BX.%26atitle%3DPlasma%2520endothelin-1%2520and%2520nitric%2520oxide%2520correlate%2520with%2520ligustrazine%2520alleviation%2520of%2520pulmonary%2520artery%2520hypertension%2520in%2520patients%2520of%2520chronic%2520cor%2520pulmonale%2520from%2520high%2520altitude%2520plateau%2520during%2520acute%2520exacerbation%26jtitle%3DChin.%2520J.%2520Appl.%2520Physiol.%26date%3D2014%26volume%3D30%26spage%3D532%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clifford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howatson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, E. J.</span></span> <span> </span><span class="NLM_article-title">The potential benefits of red beetroot supplementation in health and disease</span>. <i>Nutrients</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2801</span>– <span class="NLM_lpage">2822</span>, <span class="refDoi"> DOI: 10.3390/nu7042801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fnu7042801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25875121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFKhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2801-2822&author=T.+Cliffordauthor=G.+Howatsonauthor=D.+J.+Westauthor=E.+J.+Stevenson&title=The+potential+benefits+of+red+beetroot+supplementation+in+health+and+disease&doi=10.3390%2Fnu7042801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">The potential benefits of red beetroot supplementation in health and disease</span></div><div class="casAuthors">Clifford, Tom; Howatson, Glyn; West, Daniel J.; Stevenson, Emma J.</div><div class="citationInfo"><span class="NLM_cas:title">Nutrients</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2801-2822</span>CODEN:
                <span class="NLM_cas:coden">NUTRHU</span>;
        ISSN:<span class="NLM_cas:issn">2072-6643</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In recent years there has been a growing interest in the biol. activity of red beetroot (Beta vulgaris rubra) and its potential utility as a health promoting and disease preventing functional food.  As a source of nitrate, beetroot ingestion provides a natural means of increasing in vivo nitric oxide (NO) availability and has emerged as a potential strategy to prevent and manage pathologies assocd. with diminished NO bioavailability, notably hypertension and endothelial function.  Beetroot is also being considered as a promising therapeutic treatment in a range of clin. pathologies assocd. with oxidative stress and inflammation.  Its constituents, most notably the betalain pigments, display potent antioxidant, anti-inflammatory and chemo-preventive activity in vitro and in vivo.  The purpose of this review is to discuss beetroot's biol. activity and to evaluate evidence from studies that specifically investigated the effect of beetroot supplementation on inflammation, oxidative stress, cognition and endothelial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMfhI0Tw0fPrVg90H21EOLACvtfcHk0lhZJIFt-pAUUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFKhtLw%253D&md5=6f3d3b75aa8e2ee00520780249ed8e3d</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.3390%2Fnu7042801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnu7042801%26sid%3Dliteratum%253Aachs%26aulast%3DClifford%26aufirst%3DT.%26aulast%3DHowatson%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DD.%2BJ.%26aulast%3DStevenson%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520potential%2520benefits%2520of%2520red%2520beetroot%2520supplementation%2520in%2520health%2520and%2520disease%26jtitle%3DNutrients%26date%3D2015%26volume%3D7%26spage%3D2801%26epage%3D2822%26doi%3D10.3390%2Fnu7042801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henrohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkstrand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granstam, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingimarsdottir, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedenstrom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinovschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernroth, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, G.</span></span> <span> </span><span class="NLM_article-title">Effects of oral supplementation with nitrate-rich beetroot juice in patients with pulmonary arterial hypertension- results from BEET-PAH, an exploratory randomized, double-blind, placebo-controlled, crossover study</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2018.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cardfail.2018.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30244181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=640-653&author=D.+Henrohnauthor=K.+Bjorkstrandauthor=J.+O.+Lundbergauthor=S.-O.+Granstamauthor=T.+Baronauthor=I.+J.+Ingimarsdottirauthor=H.+Hedenstromauthor=A.+Malinovschiauthor=M.-L.+Wernrothauthor=M.+Janssonauthor=M.+Hedelandauthor=G.+Wikstrom&title=Effects+of+oral+supplementation+with+nitrate-rich+beetroot+juice+in+patients+with+pulmonary+arterial+hypertension-+results+from+BEET-PAH%2C+an+exploratory+randomized%2C+double-blind%2C+placebo-controlled%2C+crossover+study&doi=10.1016%2Fj.cardfail.2018.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension-Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study</span></div><div class="casAuthors">Henrohn, Dan; Bjoerkstrand, Kristoffer; Lundberg, Jon O.; Granstam, Sven-Olof; Baron, Tomasz; Ingimarsdottir, Inga J.; Hedenstroem, Hans; Malinovschi, Andrei; Wernroth, Mona-Lisa; Jansson, Martin; Hedeland, Mikael; Wikstroem, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">640-653</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The nitrate-nitrite-nitric oxide (NO) pathway may represent a potential therapeutic target in patients with pulmonary arterial hypertension (PAH).  We explored the effects of dietary nitrate supplementation, with the use of nitrate-rich beetroot juice (BRJ), in patients with PAH.  We prospectively studied 15 patients with PAH in an exploratory randomized, double-blind, placebo-controlled, crossover trial.  The patients received nitrate-rich beetroot juice and placebo in 2 treatment periods of 7 days each.  Compared with placebo ingestion of BRJ resulted in increases in; fractional exhaled NO at all flow-rates, alveolar NO concns. and bronchial NO flux, and plasma and salivary levels of nitrate and nitrite.  Plasma ornithine levels decreased and indexes of relative arginine availability increased after BRJ compared to placebo.  A decrease in breathing frequency was obsd. during ergospirometry after BRJ.  A tendency for an improvement in right ventricular function was obsd. after ingestion of BRJ.  In addn. a tendency for an increase in the peak power output to peak oxygen consumption ratio was obsd., which became significant in patients reaching an increase of plasma nitrite >30% (responders).  An increase in the W peak/VO2 peak ratio was obsd. after BRJ ingestion in plasma nitrite responders.  These findings indicate that supplementation with inorg. nitrate increase NO synthase-independent NO prodn. from the nitrate-nitrite-NO pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok5_Ul2yZS-7Vg90H21EOLACvtfcHk0lhkZ7G-oIYyxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOqsrzM&md5=0a5dc6c576884dd5c065d993c4867497</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2018.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2018.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DHenrohn%26aufirst%3DD.%26aulast%3DBjorkstrand%26aufirst%3DK.%26aulast%3DLundberg%26aufirst%3DJ.%2BO.%26aulast%3DGranstam%26aufirst%3DS.-O.%26aulast%3DBaron%26aufirst%3DT.%26aulast%3DIngimarsdottir%26aufirst%3DI.%2BJ.%26aulast%3DHedenstrom%26aufirst%3DH.%26aulast%3DMalinovschi%26aufirst%3DA.%26aulast%3DWernroth%26aufirst%3DM.-L.%26aulast%3DJansson%26aufirst%3DM.%26aulast%3DHedeland%26aufirst%3DM.%26aulast%3DWikstrom%26aufirst%3DG.%26atitle%3DEffects%2520of%2520oral%2520supplementation%2520with%2520nitrate-rich%2520beetroot%2520juice%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension-%2520results%2520from%2520BEET-PAH%252C%2520an%2520exploratory%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520crossover%2520study%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2018%26volume%3D24%26spage%3D640%26epage%3D653%26doi%3D10.1016%2Fj.cardfail.2018.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nan, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhaxi, D. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D. X.</span></span> <span> </span><span class="NLM_article-title">Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1016/j.jep.2018.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jep.2018.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29325918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2018&pages=175-183&author=X.+M.+Nanauthor=S.+S.+Suauthor=K.+Maauthor=X.+D.+Maauthor=X.+M.+Wangauthor=D.+Z.+Zhaxiauthor=R.+L.+Geauthor=Z.+Q.+Liauthor=D.+X.+Lu&title=Bioactive+fraction+of+Rhodiola+algida+against+chronic+hypoxia-induced+pulmonary+arterial+hypertension+and+its+anti-proliferation+mechanism+in+rats&doi=10.1016%2Fj.jep.2018.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats</span></div><div class="casAuthors">Nan, Xingmei; Su, Shanshan; Ma, Ke; Ma, Xiaodong; Wang, Ximeng; Zhaxi, Dongzhu; Ge, Rili; Li, Zhanqiang; Lu, Dianxiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-183</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Rhodiola algida var. tangutica (Maxim.) S. H. Fu is a perennial plant of the Crassulaceae family that grows in the mountainous regions of Asia.  The rhizome and roots of this plant have been long used as Tibetan folk medicine for preventing high altitude sickness.  The aim of this study was to det. the effect of bioactive fraction from R. algida (ACRT) on chronic hypoxia-induced pulmonary arterial hypertension (HPAH) and to understand the possible mechanism of its pharmacodynamic actions.  Male Sprague-Dawley rats were sepd. into five groups: control group, hypoxia group, and hypoxia+ACRT groups (62.5, 125, and 250 mg/kg/day of ACRT).  The chronic hypoxic environment was created in a hypobaric chamber by adjusting the inner pressure and oxygen content for 4 wk.  After 4 wk, major physiol. parameters of pulmonary arterial hypertension such as mPAP, right ventricle index (RV/LV+S, RVHI), hematocrit (Hct) levels and the medial vessel thickness (wt%) were measured.  Protein and mRNA expression levels of proliferating cell nuclear antigen (PCNA), cyclin D1, p27Kip1 and cyclin-dependent kinase 4 (CDK4) were detected by western blotting and real time PCR resp.  Chem. profile of ACRT was revealed by ultra performance liq. chromatog. coupled with quadrupole time of flight mass spectrometry (UHPLC-Q-TOF-MS/MS).  The results showed that a successful HPAH rat model was established in a hypobaric chamber for 4 wk, as indicated by the significant increase in mPAP, RV/LV+S, RV/BW and wt%.  Compared with the normal group, administration of ACRT reduced mPAP, right ventricular hypertrophy, pulmonary small artery wall thickness, and damage in ultrastructure induced by hypoxia in rats.  PCNA, cyclin D1, and CDK4 expression was reduced (p<0.05), and p27Kip1 expression increased (p<0.05) in hypoxia+ACRT groups compared to hypoxia. 38 constituents in bioactive fraction were identified by UHPLC-Q-TOF-MS/MS.  Our results suggest that ACRT could alleviate chronic hypoxia-induced pulmonary arterial hypertension.  And its anti-proliferation mechanism in rats based on decreasing PCNA, cyclin D1, CDK4 expression level and inhibiting p27Kip1 degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKTDWnOZiR_rVg90H21EOLACvtfcHk0ljOfVaBDS70EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFels7s%253D&md5=e9653dcef57fc9a19b6514bf38565901</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2018.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2018.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DNan%26aufirst%3DX.%2BM.%26aulast%3DSu%26aufirst%3DS.%2BS.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DX.%2BD.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DZhaxi%26aufirst%3DD.%2BZ.%26aulast%3DGe%26aufirst%3DR.%2BL.%26aulast%3DLi%26aufirst%3DZ.%2BQ.%26aulast%3DLu%26aufirst%3DD.%2BX.%26atitle%3DBioactive%2520fraction%2520of%2520Rhodiola%2520algida%2520against%2520chronic%2520hypoxia-induced%2520pulmonary%2520arterial%2520hypertension%2520and%2520its%2520anti-proliferation%2520mechanism%2520in%2520rats%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2018%26volume%3D216%26spage%3D175%26epage%3D183%26doi%3D10.1016%2Fj.jep.2018.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosanovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seimetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, B. K.</span></span> <span> </span><span class="NLM_article-title">Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1086/674303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1086%2F674303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24618536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2crhvFaitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=499-506&author=D.+Kosanovicauthor=X.+Tianauthor=O.+Pakauthor=Y.+J.+Laiauthor=Y.+L.+Hsiehauthor=M.+Seimetzauthor=N.+Weissmannauthor=R.+T.+Schermulyauthor=B.+K.+Dahal&title=Rhodiola%3A+an+ordinary+plant+or+a+promising+future+therapy+for+pulmonary+hypertension%3F+a+brief+review&doi=10.1086%2F674303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review</span></div><div class="casAuthors">Kosanovic Djuro; Tian Xia; Pak Oleg; Lai Ying-Ju; Hsieh Yi-Ling; Seimetz Michael; Weissmann Norbert; Schermuly Ralph Theo; Dahal Bhola Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary circulation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-506</span>
        ISSN:<span class="NLM_cas:issn">2045-8932</span>.
    </div><div class="casAbstract">Abstract Pulmonary hypertension (PH) is a chronic, complex, and progressive disease that eventuates in fatality.  Research efforts over the past decades have resulted in therapeutic options that improve quality of life and prolong survival of patients, but they do not offer a cure.  We propose a philosophical model that a disturbed balance of yin and yang results in pulmonary vascular remodeling, the hallmark of PH pathology.  The model may be useful in exploring the wisdom of traditional Chinese medicine and incorporating it into mainstream PH research.  In this context, the medicinal plant Rhodiola can be of profound interest owing to its variety of health-friendly attributes.  Rhodiola has been shown to be beneficial in high-altitude-related symptoms and acute exacerbation of PH; moreover, improvement of PH has been demonstrated experimentally in chronically hypoxic rats.  The beneficial effects of Rhodiola in PH may be attributable to its potential targeting of the signaling pathways, such as endothelin-1, nitric oxide, vascular endothelial growth factor, angiotensin-converting enzyme, nuclear factor κ-B, tumor necrosis factor α, and interleukin-6.  Alterations in these mediators are implicated in PH pathogenesis, the characteristics of which include chronic pulmonary vasoconstriction, vasoproliferation, and vascular inflammation.  Salidroside, one of the compounds extracted from Rhodiola, has been found to provide therapeutic benefits in experimental PH.  As the data are limited and the field is in its infancy, further studies including in-depth analysis of the therapeutic effects on various animal models of PH are desirable.  We believe that future PH research should place an adequate and special emphasis on exploring and promoting the potential of traditional Chinese medicine, and to this end, the medicinal plant Rhodiola offers a promising field on which to embark.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzT7ePq8oZyzEwO064Z95rfW6udTcc2eagAucTWKQGYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crhvFaitQ%253D%253D&md5=3286794ff26fa50e4b4b3e7911366907</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1086%2F674303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F674303%26sid%3Dliteratum%253Aachs%26aulast%3DKosanovic%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DPak%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DY.%2BJ.%26aulast%3DHsieh%26aufirst%3DY.%2BL.%26aulast%3DSeimetz%26aufirst%3DM.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DDahal%26aufirst%3DB.%2BK.%26atitle%3DRhodiola%253A%2520an%2520ordinary%2520plant%2520or%2520a%2520promising%2520future%2520therapy%2520for%2520pulmonary%2520hypertension%253F%2520a%2520brief%2520review%26jtitle%3DPulm.%2520Circ.%26date%3D2013%26volume%3D3%26spage%3D499%26epage%3D506%26doi%3D10.1086%2F674303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span> <span> </span><span class="NLM_article-title">Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway</span>. <i>BMC Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">191</span>, <span class="refDoi"> DOI: 10.1186/s12890-017-0477-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2Fs12890-017-0477-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29233105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=191&author=D.+Guiauthor=Z.+Cuiauthor=L.+Zhangauthor=C.+Yuauthor=D.+Yaoauthor=M.+Xuauthor=M.+Chenauthor=P.+Wuauthor=G.+Liauthor=L.+Wangauthor=X.+Huang&title=Salidroside+attenuates+hypoxia-induced+pulmonary+arterial+smooth+muscle+cell+proliferation+and+apoptosis+resistance+by+upregulating+autophagy+through+the+AMPK-mTOR-ULK1+pathway&doi=10.1186%2Fs12890-017-0477-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway</span></div><div class="casAuthors">Gui, Di; Cui, Zhimin; Zhang, Lin; Yu, Chang; Yao, Dan; Xu, Min; Chen, Mayun; Wu, Peiliang; Li, Guoping; Wang, Liangxing; Huang, Xiaoying</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">191/1-191/12</span>CODEN:
                <span class="NLM_cas:coden">BPMMBB</span>;
        ISSN:<span class="NLM_cas:issn">1471-2466</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Recent studies have shown that both adenosine monophosphate activated protein kinase (AMPK) and the mammalian target of rapamycin (mTOR) are energy sensors and are related to autophagy.  Our recent reports have shown that salidroside can exert protective effects against hypoxia-induced pulmonary arterial smooth muscle cell (PASMC) proliferation and apoptosis resistance through the AMPK pathway.  This study aims to explore the relationship among AMPK, mTOR and ULK1 in PASMCs under hypoxic conditions and to investigate whether the protective effects of salidroside are related to the autophagic cell death pathway.  Rat PASMCs were cultured and divided into five groups: the normoxia, hypoxia, hypoxia + MHY1485 (mTOR agonist), hypoxia + rapamycin (mTOR inhibitor) and hypoxia + salidroside groups.  Hypoxic cells were treated as indicated for 24 h.  Cell viability was evaluated by the CCK-8 assay.  Cell apoptosis was measured by the TUNEL assay.  The autophagy flux of PASMCs was evaluated with tandem mRFP-GFP fluorescence microscopy.  Autophagosomes were detected by electron microscopy.  Protein expression of LC3, p62, AMPK, P-AMPK (Thr 172), P-ULK1 (Ser 555 and Ser 317), mTOR, P-mTOR (Ser 2448), ULK1 and P-ULK1 (Ser 757) was detected by western blot assay.  PASMC proliferation and apoptosis resistance were obsd. under hypoxic conditions.  Autophagy flux, the no. of autophagosomes and the LC3II/LC3I ratio were increased in the hypoxia group compared with the normoxia group, whereas p62 expression was decreased.  Treatment with rapamycin or salidroside reversed hypoxia-induced PASMC proliferation and apoptosis resistance and further increased autophagy flux, autophagosome levels and the LC3II/LC3I ratio but decreased p62 expression.  Treatment with MHY1485 reversed hypoxia-induced PASMC apoptosis resistance and decreased autophagy flux as well as increased autophagosome levels, the LC3II/LC3I ratio and p62 expression.  P-AMPK (Thr 172) and P-ULK1 (Ser 555) of the AMPK-ULK1 pathway were increased in the hypoxia group and were further increased in the salidroside group.  Rapamycin and MHY1485 had no effect on either P-AMPK (Thr 172) or P-ULK1 (Ser 555).  Phosphorylation of ULK1 at serine 317 did not significantly affect the five groups.  Furthermore, P-mTOR (Ser 2448) and P-ULK1 (Ser 757) of the AMPK-mTOR-ULK1 pathway were decreased in the hypoxia group and were further decreased in the salidroside group.  MHY1485 increased the expression of both P-mTOR(Ser 2448) and P-ULK1(Ser 757), whereas rapamycin had the opposite effect.  Salidroside might inhibit hypoxia-induced PASMC proliferation and reverse apoptosis resistance via the upregulation of autophagy through both the AMPKa1-ULK1 and AMPKa1-mTOR-ULK1 pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPnYD3yg58kLVg90H21EOLACvtfcHk0ljOfVaBDS70EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyhsr4%253D&md5=e6fe05dcb9370c330979018413a3f91e</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1186%2Fs12890-017-0477-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12890-017-0477-4%26sid%3Dliteratum%253Aachs%26aulast%3DGui%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DX.%26atitle%3DSalidroside%2520attenuates%2520hypoxia-induced%2520pulmonary%2520arterial%2520smooth%2520muscle%2520cell%2520proliferation%2520and%2520apoptosis%2520resistance%2520by%2520upregulating%2520autophagy%2520through%2520the%2520AMPK-mTOR-ULK1%2520pathway%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2017%26volume%3D17%26spage%3D191%26doi%3D10.1186%2Fs12890-017-0477-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilfeather, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Effects of tetrandrine on growth factor-induced DNA synthesis and proliferative response of rat pulmonary artery smooth muscle cells</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1006/pupt.2000.0230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1006%2Fpupt.2000.0230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10799282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFentr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=53-60&author=H.+L.+Wangauthor=S.+A.+Kilfeatherauthor=G.+R.+Martinauthor=C.+P.+Page&title=Effects+of+tetrandrine+on+growth+factor-induced+DNA+synthesis+and+proliferative+response+of+rat+pulmonary+artery+smooth+muscle+cells&doi=10.1006%2Fpupt.2000.0230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Tetrandrine on Growth Factor-induced DNA Synthesis and Proliferative Response of Rat Pulmonary Artery Smooth Muscle Cells</span></div><div class="casAuthors">Wang, H. L.; Kilfeather, S. A.; Martin, G. R.; Page, C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-60</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The objective of the present study was to investigate the effect of tetrandrine (a plant alkaloid isolated from Stephenia tetrandra) on growth factor-induced DNA synthesis and proliferative responses of rat pulmonary artery smooth muscle cells.  Male rat and bovine pulmonary artery smooth muscle cells (PASMC) were cultured in Medium 199 contg. FBS (10%).  DNA synthesis was monitored from [3H]-thymidine uptake and cell proliferation by direct cell counting.  In the present study FBS (1% vol./vol.) caused a small increase in DNA synthesis above basal levels in rat and bovine PASMC (6% and 11% resp.).  Platelet-derived growth factor (PDGF, 50 ng/mL), fibroblast growth factor (FGF, 50 ng/mL) or interleukin-1α (IL-1α, 100 pg/mL) alone increased rat PASMC proliferation (69-85%) and DNA synthesis above basal levels (76-92%).  The addn. of these growth factors in combination with FBS (1%) resulted in higher increases in DNA synthesis above basal levels (rat PASMC:PDGF, 465%; FGF, 421%; IL-1α, 406%; bovine PASMC:PDGF, 279%).  Tetrandrine (10-5 M) inhibited FBS (10%)-induced rat PASMC proliferation (90.5%) and DNA synthesis (89.0%).  Tetrandrine significantly inhibited cell proliferation (86.5-98.5%) and DNA synthesis (79.9-89.0%) induced by FBS (1%) in combination with one of the following mitogens; PDGF (50 ng/mL), FGF (50 ng/mL), IL-1α (100 pg/mL).  The inhibitory effects of tetrandrine were obsd. between 10-6 and 10-5 M and PASMC viability was not affected by tetrandrine below 3×10-5 m.  In summary, these results suggest that tetrandrine can exert anti-proliferative effects against a range of mitogenic stimuli for vascular smooth muscle cells in vitro.  Such effects may contribute to the inhibitory effect of tetrandrine on pulmonary vascular remodeling assocd. with pulmonary hypertension.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSl6HIAaGyhrVg90H21EOLACvtfcHk0lgQnDwGVog61g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFentr8%253D&md5=15410c8ee04fa9c3ec61f2792964ab12</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1006%2Fpupt.2000.0230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fpupt.2000.0230%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DKilfeather%26aufirst%3DS.%2BA.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DEffects%2520of%2520tetrandrine%2520on%2520growth%2520factor-induced%2520DNA%2520synthesis%2520and%2520proliferative%2520response%2520of%2520rat%2520pulmonary%2520artery%2520smooth%2520muscle%2520cells%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D13%26spage%3D53%26epage%3D60%26doi%3D10.1006%2Fpupt.2000.0230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W. P.</span></span> <span> </span><span class="NLM_article-title">Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1</span>. <i>J. Vasc. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1468</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1016/j.jvs.2015.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jvs.2015.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26527422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28znvFKrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=1468-1477&author=X.+W.+Wangauthor=Y.+C.+Yangauthor=D.+P.+Yangauthor=G.+Tongauthor=S.+S.+Lvauthor=X.+Linauthor=C.+F.+Chenauthor=W.+P.+Dong&title=Tetrandrine+prevents+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats+through+regulation+of+the+protein+expression+of+inducible+nitric+oxide+synthase+and+cyclic+guanosine+monophosphate-dependent+protein+kinase+type+1&doi=10.1016%2Fj.jvs.2015.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1</span></div><div class="casAuthors">Wang Xiaowu; Yang Dongpeng; Tong Guang; Lv Shanshan; Lin Xi; Chen Changfu; Yang Yongchao; Dong Wenpeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of vascular surgery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1468-1477</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Pulmonary arterial hypertension (PAH) is a fatal disease characterized by a persistent elevation of pulmonary artery pressure and ventricular hypertrophy.  Tetrandrine is a bisbenzylisoquinoline alkaloid that can decrease blood pressure, inhibit the proliferation of vascular smooth muscle cells, and block cardiac hypertrophy, but whether it has a therapeutic effect on PAH remains poorly defined.  This study was undertaken to investigate the efficacy of tetrandrine on PAH.  METHODS:  Forty-eight male Sprague-Dawley rats were randomly and equally divided into four groups.  The control group was injected with normal saline; the others were injected with monocrotaline (MCT) to induce PAH, then treated with saline, tetrandrine, and vardenafil, respectively, from day 21 to day 42.  On day 43, we measured the mean pulmonary artery pressure under general anesthesia, dissected the rat, and calculated the right ventricular hypertrophy index [right ventricle/(left ventricle plus septum)].  Later we observed the changes in the pulmonary vascular wall; measured the expression of cyclic guanosine monophosphate-dependent protein kinase type 1 and inducible nitric oxide synthase; measured the levels of superoxide dismutase, glutathione, malondialdehyde, and catalase; and then compared the results among groups.  RESULTS:  Compared with the MCT group, rats treated with tetrandrine had attenuated mean pulmonary artery pressure (20.48 ± 1.49 vs 30.07 ± 1.51; P < .01) and right ventricular hypertrophy index (49.19 ± 2.45 vs 68.50 ± 1.95; P < .01), inhibited proliferation of pulmonary artery smooth muscle cells, and improved endothelial function.  Tetrandrine also upregulated the expression of protein kinase type 1 (90.86 ± 1.95 vs 67.34 ± 1.50; P < .01); downregulated the expression of inducible nitric oxide synthase (74.76 ± 1.48 vs 80.19 ± 0.28; P < .01); increased levels of superoxide dismutase (245.54 ± 12.98 vs 166.16 ± 21.42; P < .01), glutathione (0.699 ± 0.032 vs 0.514 ± 0.056; P < .01), and catalase (32.13 ± 2.33 vs 27.19 ± 2.72; P < .01); and decreased malondialdehyde (1.027 ± 0.039 vs 1.462 ± 0.055; P < .01).  CONCLUSIONS:  Tetrandrine alleviated MCT-induced PAH through regulation of nitric oxide signaling pathway and antioxidant and antiproliferation effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9xHanSufiLq69lAbTj9rGfW6udTcc2eaamsCtMXyQprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28znvFKrsw%253D%253D&md5=5cc9af001cb0b115da465e74838296e8</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.jvs.2015.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jvs.2015.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BW.%26aulast%3DYang%26aufirst%3DY.%2BC.%26aulast%3DYang%26aufirst%3DD.%2BP.%26aulast%3DTong%26aufirst%3DG.%26aulast%3DLv%26aufirst%3DS.%2BS.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%2BF.%26aulast%3DDong%26aufirst%3DW.%2BP.%26atitle%3DTetrandrine%2520prevents%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%2520through%2520regulation%2520of%2520the%2520protein%2520expression%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520and%2520cyclic%2520guanosine%2520monophosphate-dependent%2520protein%2520kinase%2520type%25201%26jtitle%3DJ.%2520Vasc.%2520Surg.%26date%3D2016%26volume%3D64%26spage%3D1468%26epage%3D1477%26doi%3D10.1016%2Fj.jvs.2015.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faul, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, P. N.</span></span> <span> </span><span class="NLM_article-title">Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">2252</span>– <span class="NLM_lpage">2258</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.162.6.2002018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm.162.6.2002018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11112148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD3M7gt1yqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2000&pages=2252-2258&author=J.+L.+Faulauthor=T.+Nishimuraauthor=G.+J.+Berryauthor=G.+V.+Bensonauthor=R.+G.+Pearlauthor=P.+N.+Kao&title=Triptolide+attenuates+pulmonary+arterial+hypertension+and+neointimal+formation+in+rats&doi=10.1164%2Fajrccm.162.6.2002018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats</span></div><div class="casAuthors">Faul J L; Nishimura T; Berry G J; Benson G V; Pearl R G; Kao P N</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2252-8</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">This paper reports the effect of triptolide (a diterpenoid triepoxide) on the development of monocrotaline (MCT)-induced pulmonary hypertension in pneumonectomized rats.  Male Sprague- Dawley rats were injected with MCT (60 mg/kg) on Day 7 after left pneumonectomy.  Rats received therapy from Day 5 to 35 with triptolide (0.25 mg/kg intraperitoneally, every other day, n = 10), or vehicle (0.1 ml of ethanol/cremophor intraperitoneally, every other day, n = 10).  By Day 35, triptolide-treated rats demonstrated lower mean pulmonary arterial pressure (mPAP) than vehicle-treated rats (mPAP 21 +/- 3 versus 42 +/- 5 mm Hg, p < 0.001).  Triptolide-treated rats also had significantly less right ventricular hypertrophy (RVH) and pulmonary arterial neointimal formation.  In a rescue experiment, rats initiated therapy on Day 21.  At Day 35, vehicle-treated rats (n = 4) had higher mPAP (40 +/- 9 mm Hg), greater RVH, and more severe pulmonary arterial neointimal formation than rats that received triptolide (0.25 mg/kg every other day, n = 7, mPAP 30 +/- 4 mm Hg) and rats that received triptolide (0.2 mg/kg daily, n = 7, mPAP 25 +/- 5 mm Hg, p < 0.01).  In pneumonectomized rats that receive MCT, triptolide attenuates the development of pulmonary hypertension and RVH, and promotes regression of pulmonary arterial neointimal formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLXhP7c5JA32x8TEN9K18QfW6udTcc2eaamsCtMXyQprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7gt1yqtA%253D%253D&md5=6e7c00f7c5b810fa40126a7deca304d8</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.162.6.2002018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.162.6.2002018%26sid%3Dliteratum%253Aachs%26aulast%3DFaul%26aufirst%3DJ.%2BL.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DBerry%26aufirst%3DG.%2BJ.%26aulast%3DBenson%26aufirst%3DG.%2BV.%26aulast%3DPearl%26aufirst%3DR.%2BG.%26aulast%3DKao%26aufirst%3DP.%2BN.%26atitle%3DTriptolide%2520attenuates%2520pulmonary%2520arterial%2520hypertension%2520and%2520neointimal%2520formation%2520in%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2000%26volume%3D162%26spage%3D2252%26epage%3D2258%26doi%3D10.1164%2Fajrccm.162.6.2002018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-B.</span></span> <span> </span><span class="NLM_article-title">The effect of breviscapine on the pulmonary arterial pressure and the expression of Rho-kinase in pulmonary arterioles of hypoxic rats</span>. <i>Chin. J. Tuberc. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">830</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FjtFKgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=826-830&author=L.+Yangauthor=B.-X.+Zhengauthor=D.-Y.+Chengauthor=Q.-L.+Suauthor=L.-L.+Fanauthor=Y.-J.+Yangauthor=M.+Muauthor=W.-B.+Chen&title=The+effect+of+breviscapine+on+the+pulmonary+arterial+pressure+and+the+expression+of+Rho-kinase+in+pulmonary+arterioles+of+hypoxic+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of breviscapine on the pulmonary arterial pressure and the expression of Rho-kinase in pulmonary arterioles of hypoxic rats</span></div><div class="casAuthors">Yang Li; Zheng Bi-Xia; Cheng De-Yun; Su Qiao-Li; Fan Li-Li; Yang Yan-Juan; Mu Mao; Chen Wen-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">826-30</span>
        ISSN:<span class="NLM_cas:issn">1001-0939</span>.
    </div><div class="casAbstract">OBJECTIVE:  To observe the effect of breviscapine on the pulmonary artery pressure and the Rho-kinase and Rho-kinase mRNA in pulmonary arterioles of rats treated with hypoxia, and therefore to explore the mechanisms of breviscapine on hypoxic pulmonary hypertension.  METHODS:  Eighteen adult male SD rats were randomly divided into 3 groups.  One group was exposed to air (normal group), the second group was exposed to isobaric hypoxia for 3 weeks (hypoxic group), and the third group was exposed to hypoxia for 3 weeks and treated with breviscapine (preventive group).  Cardiac catheterization was used to measure the mean pulmonary arterial pressure (mPAP).  The heart was isolated, and the right ventricle (RV), left ventricle plus ventricular septum (LV + S) were weighed to calculate the ratio RV/(LV + S).  The ratio of vascular wall thickness/vascular external diameter (WT%) and the ratio of vascular wall area/total vascular area (WA%) were measured by image analysis.  The quantity of Rho-kinase and Rho-kinase mRNA in rat pulmonary arterioles were determined by immunohistochemistry and in situ hybridization respectively.  RESULTS:  The mPAP in the preventive group [(19.83 +/- 1.47) mm Hg, 1 mm Hg = 0.133 kPa] was significantly lower than that of the hypoxic group [(27.3 +/- 5.0) mm Hg], t = 4.28, P < 0.05.  The RV/(LV + S) in the preventive group (0.29 +/- 0.03) was significantly lower than that in the hypoxic group (0.34 +/- 0.05, t = 2.39, P < 0.05).  The WT% and WA% in the preventive group (25 +/- 5 and 45 +/- 5, respectively) were significantly lower than those in the hypoxic group (36 +/- 12 and 59 +/- 13, respectively, t = 4.89, 5.89, P < 0.05).  The positive staining of ROCKI and ROCKII on pulmonary arterioles in the preventive group (1.18 +/- 0.10 and 1.30 +/- 0.12, respectively) were significantly lower than those in the hypoxic group (1.29 +/- 0.08 and 1.63 +/- 0.24, respectively, t = 3.90, 5.82, P < 0.05).  The positive staining of ROCKI mRNA and ROCKII mRNA in the preventive group (1.23 +/- 0.13 and 1.22 +/- 0.06, respectively) were significantly lower than those in the hypoxic group (1.37 +/- 0.13 and 1.59 +/- 0.31, respectively, t = 3.94, 5.83, P < 0.05).  CONCLUSION:  Breviscapine was shown to prevent hypoxic pulmonary hypertension and decrease Rho-kinase and Rho-kinase mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTf9N__5pX2OEH3Rlp_k91zfW6udTcc2eaRp2MXukNpcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FjtFKgtg%253D%253D&md5=e9b20bd925e0e4c775058ad883bdfb56</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DB.-X.%26aulast%3DCheng%26aufirst%3DD.-Y.%26aulast%3DSu%26aufirst%3DQ.-L.%26aulast%3DFan%26aufirst%3DL.-L.%26aulast%3DYang%26aufirst%3DY.-J.%26aulast%3DMu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.-B.%26atitle%3DThe%2520effect%2520of%2520breviscapine%2520on%2520the%2520pulmonary%2520arterial%2520pressure%2520and%2520the%2520expression%2520of%2520Rho-kinase%2520in%2520pulmonary%2520arterioles%2520of%2520hypoxic%2520rats%26jtitle%3DChin.%2520J.%2520Tuberc.%2520Respir.%2520Dis.%26date%3D2008%26volume%3D31%26spage%3D826%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. J.</span></span> <span> </span><span class="NLM_article-title">Effect of erigeron breviscapini on chronic hypoxic pulmonary hypertension and serumnitric oxide and endothel in-1 in rats</span>. <i>J. Huazhong Acta Med. Univ. Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2001&pages=224-226&author=Y.+P.+Dingauthor=Y.+J.+Xu&title=Effect+of+erigeron+breviscapini+on+chronic+hypoxic+pulmonary+hypertension+and+serumnitric+oxide+and+endothel+in-1+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%2BP.%26aulast%3DXu%26aufirst%3DY.%2BJ.%26atitle%3DEffect%2520of%2520erigeron%2520breviscapini%2520on%2520chronic%2520hypoxic%2520pulmonary%2520hypertension%2520and%2520serumnitric%2520oxide%2520and%2520endothel%2520in-1%2520in%2520rats%26jtitle%3DJ.%2520Huazhong%2520Acta%2520Med.%2520Univ.%2520Sci.%2520Technol.%26date%3D2001%26volume%3D30%26spage%3D224%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadipour, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalantar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, Z. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmanullah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalantar, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. G.</span></span> <span> </span><span class="NLM_article-title">Hawthorn (crataegus oxyacantha) flavonoid extract as an effective medicinal plant derivative to prevent pulmonary hypertension and heart failure in broiler chickens</span>. <i>Open Access J. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=321-328&author=B.+Ahmadipourauthor=M.+Kalantarauthor=S.+M.+Hosseiniauthor=Z.+U.+Rehmanauthor=F.+Farmanullahauthor=M.+H.+Kalantarauthor=L.+G.+Yang&title=Hawthorn+%28crataegus+oxyacantha%29+flavonoid+extract+as+an+effective+medicinal+plant+derivative+to+prevent+pulmonary+hypertension+and+heart+failure+in+broiler+chickens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAhmadipour%26aufirst%3DB.%26aulast%3DKalantar%26aufirst%3DM.%26aulast%3DHosseini%26aufirst%3DS.%2BM.%26aulast%3DRehman%26aufirst%3DZ.%2BU.%26aulast%3DFarmanullah%26aufirst%3DF.%26aulast%3DKalantar%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DL.%2BG.%26atitle%3DHawthorn%2520%2528crataegus%2520oxyacantha%2529%2520flavonoid%2520extract%2520as%2520an%2520effective%2520medicinal%2520plant%2520derivative%2520to%2520prevent%2520pulmonary%2520hypertension%2520and%2520heart%2520failure%2520in%2520broiler%2520chickens%26jtitle%3DOpen%2520Access%2520J.%2520Sci.%26date%3D2019%26volume%3D25%26spage%3D321%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. C.</span></span> <span> </span><span class="NLM_article-title">Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats</span>. <i>Int. J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.7150/ijms.16810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.7150%2Fijms.16810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27994500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FmsVGlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=942-954&author=D.+Q.+Xuauthor=Y.+Liauthor=B.+Zhangauthor=Y.+X.+Wangauthor=Y.+Liuauthor=Y.+Luoauthor=W.+Niuauthor=M.+Q.+Dongauthor=M.+L.+Liuauthor=H.+Y.+Dongauthor=P.+T.+Zhaoauthor=Z.+C.+Li&title=Resveratrol+alleviate+hypoxic+pulmonary+hypertension+via+anti-inflammation+and+anti-oxidant+pathways+in+rats&doi=10.7150%2Fijms.16810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats</span></div><div class="casAuthors">Xu Dunquan; Li Yan; Zhang Bo; Wang Yanxia; Liu Yi; Luo Ying; Niu Wen; Dong Mingqing; Liu Manling; Dong Haiying; Zhao Pengtao; Li Zhichao</div><div class="citationInfo"><span class="NLM_cas:title">International journal of medical sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">942-954</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resveratrol, a plant-derived polyphenolic compound and a phytoestrogen, was shown to possess multiple protective effects including anti-inflammatory response and anti-oxidative stress.  Hypoxic pulmonary hypertension (HPH) is a progressive disease characterized by sustained vascular resistance and marked pulmonary vascular remodeling.  The exact mechanisms of HPH are still unclear, but inflammatory response and oxidative stress was demonstrated to participate in the progression of HPH.  The present study was designed to investigate the effects of resveratrol on HPH development.  Sprague-Dawley rats were challenged by hypoxia exposure for 28 days to mimic hypoxic pulmonary hypertension along with treating resveratrol (40 mg/kg/day).  Hemodynamic and pulmonary pathomorphology data were then obtained, and the anti-proliferation effect of resveratrol was determined by in vitro assays.  The anti-inflammation and anti-oxidative effects of resveratrol were investigated in vivo and in vitro.  The present study showed that resveratrol treatment alleviated right ventricular systolic pressure and pulmonary arterial remodeling induced by hypoxia.  In vitro experiments showed that resveratrol notably inhibited proliferation of pulmonary arterial smooth muscle cells in an ER-independent manner.  Data showed that resveratrol administration inhibited HIF-1 α expression in vivo and in vitro, suppressed inflammatory cells infiltration around the pulmonary arteries, and decreased ROS production induced by hypoxia in PAMSCs.  The inflammatory cytokines' mRNA levels of tumor necrosis factor α, interleukin 6, and interleukin 1β were all suppressed by resveratrol treatment.  The in vitro assays showed that resveratrol inhibited the expression of HIF-1 α via suppressing the MAPK/ERK1 and PI3K/AKT pathways.  The antioxidant axis of Nuclear factor erythroid-2 related factor 2/ Thioredoxin 1 (Nrf-2/Trx-1) was up-regulated both in lung tissues and in cultured PASMCs.  In general, the current study demonstrated that resveratrol may prevent pulmonary hypertension through its anti-proliferation, anti-inflammation and antioxidant effects.  Hence, the present data may offer novel targets and promising pharmacological perspective for treating hypoxic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEn6Xj-1_1wpHZzFRCXxVKfW6udTcc2eaRp2MXukNpcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FmsVGlug%253D%253D&md5=8019e9e2f7172112a3c28590b599c8cf</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.7150%2Fijms.16810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijms.16810%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%2BQ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DM.%2BQ.%26aulast%3DLiu%26aufirst%3DM.%2BL.%26aulast%3DDong%26aufirst%3DH.%2BY.%26aulast%3DZhao%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DZ.%2BC.%26atitle%3DResveratrol%2520alleviate%2520hypoxic%2520pulmonary%2520hypertension%2520via%2520anti-inflammation%2520and%2520anti-oxidant%2520pathways%2520in%2520rats%26jtitle%3DInt.%2520J.%2520Med.%2520Sci.%26date%3D2016%26volume%3D13%26spage%3D942%26epage%3D954%26doi%3D10.7150%2Fijms.16810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Polydatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein kinase C mechanisms</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">7776</span>– <span class="NLM_lpage">7787</span>, <span class="refDoi"> DOI: 10.3390/ijms13067776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fijms13067776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22837726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFSksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=7776-7787&author=Q.+Miaoauthor=X.+P.+Shiauthor=M.+X.+Yeauthor=J.+Zhangauthor=S.+Miaoauthor=S.+W.+Wangauthor=B.+Liauthor=X.+X.+Jiangauthor=S.+Zhangauthor=N.+Huauthor=J.+Liauthor=J.+Zhang&title=Polydatin+attenuates+hypoxic+pulmonary+hypertension+and+reverses+remodeling+through+protein+kinase+C+mechanisms&doi=10.3390%2Fijms13067776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Polydatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein kinase C mechanisms</span></div><div class="casAuthors">Miao, Qing; Shi, Xiao-Peng; Ye, Ming-Xiang; Zhang, Jin; Miao, Shan; Wang, Si-Wang; Li, Bo; Jiang, Xiu-Xiu; Zhang, Song; Hu, Nan; Li, Juan; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7776-7787</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hypoxic pulmonary hypertension is a life-threatening emergency if untreated.  Consistent pulmonary hypertension also leads to arteries and ventricular remodeling.  The clin. therapeutic strategy for pulmonary hypertension and the corresponding remodeling mainly interacts with NO, angiotensin II (Ang II) and elevated endothelin (ET) targets.  In the present study, we evaluated the effects of polydatin on hypoxia-induced pulmonary hypertension.  It was obsd. that polydatin attenuated hypoxic pulmonary hypertension, reversed remodeling, and regulated NO, Ang II, ET contents in the serum and lung samples.  However, forced activation of PKC signaling by its selective activator thymeleatoxin (THX) could abate the effects of polydatain.  These results suggest that polydatin might be a promising candidate for hypoxic pulmonary treatment through interaction with PKC mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv9UQgVkjAObVg90H21EOLACvtfcHk0lgzNpQ_Gy7uCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFSksrc%253D&md5=cb2809f7c22f094ea1ca142287d1ad43</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.3390%2Fijms13067776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms13067776%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DX.%2BP.%26aulast%3DYe%26aufirst%3DM.%2BX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DX.%2BX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPolydatin%2520attenuates%2520hypoxic%2520pulmonary%2520hypertension%2520and%2520reverses%2520remodeling%2520through%2520protein%2520kinase%2520C%2520mechanisms%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D13%26spage%3D7776%26epage%3D7787%26doi%3D10.3390%2Fijms13067776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. L.</span></span> <span> </span><span class="NLM_article-title">Icariin Inhibits pulmonary hypertension induced by monocrotaline through enhancement of NO/cGMP signaling pathway in rats</span>. <i>Evid.-based Complement Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2016/7915415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1155%2F2016%2F7915415" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=1-10&author=L.+S.+Liauthor=Y.+M.+Luoauthor=J.+Liuauthor=Y.+Zhangauthor=X.+X.+Fuauthor=D.+L.+Yang&title=Icariin+Inhibits+pulmonary+hypertension+induced+by+monocrotaline+through+enhancement+of+NO%2FcGMP+signaling+pathway+in+rats&doi=10.1155%2F2016%2F7915415"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1155%2F2016%2F7915415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F7915415%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DLuo%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%2BX.%26aulast%3DYang%26aufirst%3DD.%2BL.%26atitle%3DIcariin%2520Inhibits%2520pulmonary%2520hypertension%2520induced%2520by%2520monocrotaline%2520through%2520enhancement%2520of%2520NO%252FcGMP%2520signaling%2520pathway%2520in%2520rats%26jtitle%3DEvid.-based%2520Complement%2520Altern.%2520Med.%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2016%2F7915415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, T.</span></span> <span> </span><span class="NLM_article-title">Relaxant effects of pyranocoumarin compounds isolated from a Chinese medical plant, Bai-Hua Qian-Hu, on isolated rabbit tracheas and pulmonary arteries</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1248/bpb.22.984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1248%2Fbpb.22.984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10513627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXmtFCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=984-987&author=N.+C.+Zhaoauthor=W.+B.+Jinauthor=X.+H.+Zhangauthor=F.+L.+Guanauthor=Y.+B.+Sunauthor=H.+Adachiauthor=T.+Okuyama&title=Relaxant+effects+of+pyranocoumarin+compounds+isolated+from+a+Chinese+medical+plant%2C+Bai-Hua+Qian-Hu%2C+on+isolated+rabbit+tracheas+and+pulmonary+arteries&doi=10.1248%2Fbpb.22.984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Relaxant effects of pyranocoumarin compounds isolated from a chinese medical plant, Bai-Hua Qian-Hu, on isolated rabbit tracheas and pulmonary arteries</span></div><div class="casAuthors">Zhao, Nai-Cai; Jin, Wan-Bao; Zhang, Xin-Hua; Guan, Fu-Lan; Sun, Yu-Bin; Adachi, Hideyuki; Okuyama, Toru</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">984-987</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Qian-Hu is a well-known traditional Chinese medicine used for the treatment of respiratory diseases and pulmonary hypertension.  We compared the relaxant effects of pyranocoumarin compds., including (+)-praeruptorin A (Pra-C), Pd-Ia (=(±)-praeruptorin A), pteryxin, peucedanocoumarin II (P-II) and 8-methoxypsoralen (8-MOP) purified from Bai-Hua Qian-Hu (BQ) in isolated rabbit tracheas and pulmonary arteries.  Pra-C, pteryxin and Pd-Ia produced significant relaxant effects in tracheal prepns. constricted with 40 mM KCl or 10 μM acetylcholine.  The relaxant response to Pra-C, pteryxin or Pd-Ia in prepns. constricted with KCl was significantly more potent than that in prepns. constricted with acetylcholine.  Pra-C, pteryxin or Pd-Ia at a concn. of 30 μM completely relaxed tracheas constricted with 40 mM KCl, whereas P-II at the same concn. showed only partial relaxation.  In pulmonary arterial prepns., 8-MOP produced a significant relaxant effect on contractions by 10 μM phenylephrine, without any effect on the contraction by 40 mM KCl.  These results suggest that Pd-Ia, pteryxin and Pra-C for their calcium antagonistic action, and 8-MOP for its inhibitory effect on contraction induced by phenylephrine, may be the active principles of BQ for relaxing the smooth muscle of tracheas and pulmonary arteries, and the principle may produce a synergistic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1-CMHpK-HLVg90H21EOLACvtfcHk0lgzNpQ_Gy7uCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtFCmt70%253D&md5=14296394de549cd03e6a17f4a128d969</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1248%2Fbpb.22.984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.22.984%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DN.%2BC.%26aulast%3DJin%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DX.%2BH.%26aulast%3DGuan%26aufirst%3DF.%2BL.%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DAdachi%26aufirst%3DH.%26aulast%3DOkuyama%26aufirst%3DT.%26atitle%3DRelaxant%2520effects%2520of%2520pyranocoumarin%2520compounds%2520isolated%2520from%2520a%2520Chinese%2520medical%2520plant%252C%2520Bai-Hua%2520Qian-Hu%252C%2520on%2520isolated%2520rabbit%2520tracheas%2520and%2520pulmonary%2520arteries%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D1999%26volume%3D22%26spage%3D984%26epage%3D987%26doi%3D10.1248%2Fbpb.22.984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. L.</span></span> <span> </span><span class="NLM_article-title">Osthole attenuates pulmonary arterial hypertension in monocrotaline-treated rats</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2823</span>– <span class="NLM_lpage">2829</span>, <span class="refDoi"> DOI: 10.3892/mmr.2017.6876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3892%2Fmmr.2017.6876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28677726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2htr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2823-2829&author=Y.+L.+Liauthor=Y.+W.+Wangauthor=Y.+Q.+Liauthor=Z.+Q.+Qianauthor=L.+Zhuauthor=D.+L.+Yang&title=Osthole+attenuates+pulmonary+arterial+hypertension+in+monocrotaline-treated+rats&doi=10.3892%2Fmmr.2017.6876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Osthole attenuates pulmonary arterial hypertension in monocrotaline-treated rats</span></div><div class="casAuthors">Li, Yeli; Wang, Yingwan; Li, Yiqi; Qian, Zhiqiang; Zhu, Ling; Yang, Danli</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2823-2829</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is an insidious and progressive disease that is triggered by various cardiopulmonary diseases.  Inflammation has an important role in the progression of PAH.  Osthole (Ost) is a coumarin that has clear anti-inflammatory properties.  The present study aimed to investigate the effects of Ost on PAH, and to explore the mechanism underlying this effect.  Using the monocrota- line (MCT)-induced PAH rat model, the effects of Ost on PAH were investigated.  Rats were s.c. administered a single dose of MCT (50 mg/kg) to establish the PAH model, followed by daily treatment with Ost (10 or 20 mg/kg) by gavage for 28 days.  The mean pulmonary arterial pressure (mPAP) was measured and histol. anal. was performed.  The results demonstrated that Ost significantly decreased mPAP, and reduced thickening of the pulmonary artery, compared with in rats in the MCT group.  To further det. whether the effects of Ost on MCT-induced PAH were assocd. with inflammatory responses, the nuclear factor-κB (NF-κB) p65 signaling pathway was investigated by western blot anal.  The results demonstrated that Ost increased inhibition of the NF-κB p65 signaling pathway.  In conclusion, the results of the present study demonstrate that Ost may suppress the progression of MCT-induced PAH in rats, which may be, at least partially, mediated through modulation of the NF-κB p65 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ftR9Qn-cjrVg90H21EOLACvtfcHk0lgzNpQ_Gy7uCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2htr0%253D&md5=44d2028ab7d42898c6fde006dcd14881</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2017.6876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2017.6876%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DQian%26aufirst%3DZ.%2BQ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%2BL.%26atitle%3DOsthole%2520attenuates%2520pulmonary%2520arterial%2520hypertension%2520in%2520monocrotaline-treated%2520rats%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2017%26volume%3D16%26spage%3D2823%26epage%3D2829%26doi%3D10.3892%2Fmmr.2017.6876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-L.</span></span> <span> </span><span class="NLM_article-title">Osthole inhibits cell proliferation by regulating the TGF-β1/Smad/p38 signaling pathways in pulmonary arterial smooth muscle cells</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">109640</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2019.109640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.biopha.2019.109640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31810114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Ois7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2020&pages=109640&author=Y.+Yueauthor=Y.-Q.+Liauthor=S.+Fuauthor=Y.-T.+Wuauthor=L.+Zhuauthor=L.+Huaauthor=J.-Y.+Lvauthor=Y.-L.+Liauthor=D.-L.+Yang&title=Osthole+inhibits+cell+proliferation+by+regulating+the+TGF-%CE%B21%2FSmad%2Fp38+signaling+pathways+in+pulmonary+arterial+smooth+muscle+cells&doi=10.1016%2Fj.biopha.2019.109640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Osthole inhibits cell proliferation by regulating the TGF-β1/Smad/p38 signaling pathways in pulmonary arterial smooth muscle cells</span></div><div class="casAuthors">Yue, Yun; Li, Yi-qi; Fu, Shu; Wu, Yu-Ting; Zhu, Ling; Hua, Liang; Lv, Jun-Yuan; Li, Ye-Li; Yang, Dan-Li</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109640</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Pulmonary artery smooth muscle cell (PASMC) proliferation contributes to pulmonary vascular remodeling, which ultimately leads to pulmonary arterial hypertension (PAH).  Osthole has been previously shown to inhibit tumor cell growth.  Our previous expts. demonstrated that osthole could prevent monocrotaline-induced PAH and pulmonary artery remodeling in rats and that its effects might be assocd. with inhibiting PASMC proliferation.  However, the exact mechanism remains unclear.  In this study, we obsd. the inhibitory effect of osthole on platelet-derived growth factor (PDGF)-BB-induced rat PASMC growth, cell cycle progression and proliferating cell nuclear antigen (PCNA) expression, as measured by CCK-8 assay, flow cytometric anal. and western blotting, resp.  We also detected the expression and activities of the cell cycle regulators cyclin D1/CDK4, cyclin E1/CDK2, p53, p27 and p21 and the TGF-β1/Smad/p38 signaling pathways in rat PASMCs by western blotting.  Our results show that osthole effectively suppressed PDGF-BB-stimulated proliferation, PCNA protein expression, and cell cycle progression in rat PASMCs in vitro.  We further demonstrated that treatment with osthole significantly induced cell cycle arrest at the G0/G1 phase in PASMCs, which was supported by the finding that osthole significantly decreased cyclin D1/CDK4 and cyclin E1/CDK2 protein levels and increased p53, p27 and p21 protein levels.  These effects may partly be attributed to the downregulation of TGF-β1/Smad/p38 signaling pathway activation.  Our findings suggest that osthole is a potential therapeutic candidate that warrants further investigation regarding its potential use for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZCwyfqz5MirVg90H21EOLACvtfcHk0ljRcmeedHsgoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Ois7jK&md5=5a039a640a6fdf4a8ae57f5763c61256</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.109640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.109640%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.-Q.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.-T.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHua%26aufirst%3DL.%26aulast%3DLv%26aufirst%3DJ.-Y.%26aulast%3DLi%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DD.-L.%26atitle%3DOsthole%2520inhibits%2520cell%2520proliferation%2520by%2520regulating%2520the%2520TGF-%25CE%25B21%252FSmad%252Fp38%2520signaling%2520pathways%2520in%2520pulmonary%2520arterial%2520smooth%2520muscle%2520cells%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2020%26volume%3D121%26spage%3D109640%26doi%3D10.1016%2Fj.biopha.2019.109640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q. H.</span></span> <span> </span><span class="NLM_article-title">Astragalus polysaccharides attenuate monocrotaline-induced pulmonary arterial hypertension in rats</span>. <i>Am. J. Chin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1142/S0192415X17500410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1142%2FS0192415X17500410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28521513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVGmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=773-789&author=L.+B.+Yuanauthor=C.+Y.+Huaauthor=S.+Gaoauthor=Y.+L.+Yinauthor=M.+Daiauthor=H.+Y.+Mengauthor=P.+P.+Liauthor=Z.+X.+Yangauthor=Q.+H.+Hu&title=Astragalus+polysaccharides+attenuate+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats&doi=10.1142%2FS0192415X17500410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Astragalus Polysaccharides Attenuate Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats</span></div><div class="casAuthors">Yuan, Lin-Bo; Hua, Chun-Yan; Gao, Sheng; Yin, Ya-Ling; Dai, Mao; Meng, Han-Yan; Li, Piao-Piao; Yang, Zhong-Xin; Hu, Qing-Hua</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Chinese Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">773-789</span>CODEN:
                <span class="NLM_cas:coden">AJCMBA</span>;
        ISSN:<span class="NLM_cas:issn">0192-415X</span>.
    
            (<span class="NLM_cas:orgname">World Scientific Publishing Co. Pte. Ltd.</span>)
        </div><div class="casAbstract">Astragalus polysaccharides (APS) have been shown to possess a variety of biol. activities including anti-oxidant and anti-inflammation functions in a no. of diseases.  However, their function in pulmonary arterial hypertension (PAH) is still unknown.  Rats received APS (200mg/kg once two days) for 2 wk after being injected with monocrotaline (MCT; 60mg/kg).  The pulmonary hemodynamic index, right ventricular hypertrophy, and lung morphol. features of the rat models were examd., as well as the NO/eNOS ratio of wet lung and dry lung wt. and MPO.  A qRT-PCR and p-IκB was used to assess IL-1β, IL-6 and TNF-α and WB was used to detect the total IκB.  Based on these measurements, it was found that APS reversed the MCT-induced increase in mean pulmonary arterial pressure (mPAP) (from 32.731mmHg to 26.707mmHg), decreased pulmonary vascular resistance (PVR) (from 289.021mmHg× min/L to 246.351mmHg×min/L), and reduced right ventricular hypertrophy (from 289.021mmHg×min/L to 246.351 mmHg×min/L) (p<0.05).  In terms of pulmonary artery remodeling, the WT% and WA% decreased with the addn. of APS.  In addn., it was found that APS promoted the synthesis of eNOS and the secretion of NO, promoting vasodilation and APS decreased the MCT-induced elevation of MPO, IL-1β, IL-6 and TNF-α, reducing inflammation.  Furthermore, APS was able to inhibit the activation of pho-IκBα.  In couclusion, APS ameliorates MCT-induced pulmonary artery hypertension by inhibiting pulmonary arterial remodeling partially via eNOS/NO and NF-κB signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0FFEQOpEK1LVg90H21EOLACvtfcHk0ljRcmeedHsgoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVGmt7o%253D&md5=636be119a4d7ac7e01128ed82c993f4b</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1142%2FS0192415X17500410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1142%252FS0192415X17500410%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%2BB.%26aulast%3DHua%26aufirst%3DC.%2BY.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DY.%2BL.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DP.%2BP.%26aulast%3DYang%26aufirst%3DZ.%2BX.%26aulast%3DHu%26aufirst%3DQ.%2BH.%26atitle%3DAstragalus%2520polysaccharides%2520attenuate%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%26jtitle%3DAm.%2520J.%2520Chin.%2520Med.%26date%3D2017%26volume%3D45%26spage%3D773%26epage%3D789%26doi%3D10.1142%2FS0192415X17500410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, T.</span></span> <span> </span><span class="NLM_article-title">Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">79</span>, <span class="refDoi"> DOI: 10.1186/s12931-019-1041-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2Fs12931-019-1041-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31023308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fpt1CrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=79&author=T.+Zhangauthor=N.+Kawaguchiauthor=K.+Yoshiharaauthor=E.+Hayamaauthor=Y.+Furutaniauthor=K.+Kawaguchiauthor=T.+Tanakaauthor=T.+Nakanishi&title=Silibinin+efficacy+in+a+rat+model+of+pulmonary+arterial+hypertension+using+monocrotaline+and+chronic+hypoxia&doi=10.1186%2Fs12931-019-1041-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia</span></div><div class="casAuthors">Zhang Tingting; Kawaguchi Nanako; Yoshihara Kenji; Hayama Emiko; Furutani Yoshiyuki; Kawaguchi Kayoko; Tanaka Takeshi; Nakanishi Toshio; Zhang Tingting</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  C-X-C chemokine receptor type 4 (CXCR4) may be involved in the development of pulmonary arterial hypertension (PAH).  CXCR4 inhibitor AMD3100 was described to have a positive effect on the prevention of pulmonary arterial muscularization in PAH models.  Silibinin is a traditional medicine that has an antagonistic effect on CXCR4.  We investigated the effect of silibinin using rat models of PAH.  METHODS:  PAH was induced by a single subcutaneous injection of monocrotaline.  The rats were maintained in a chronic hypoxic condition (10% O2) with or without silibinin.  To evaluate the efficacy of silibinin on PAH, right ventricular systolic pressure (RVSP), Fulton index (weight ratio of right ventricle to the left ventricle and septum), percent medial wall thickness (% MT), and vascular occlusion score (VOS) were measured and calculated.  Immunohistochemical analysis was performed targeting CXCR4 and c-Kit.  Reverse transcription-quantitative polymerase chain reaction was performed for the stem cell markers CXCR4, stromal cell derived factor-1 (SDF-1), c-Kit, and stem cell factor (SCF), and the inflammatory markers monocyte chemoattractant protein 1 (MCP1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFα).  Statistical analyses were performed using t-test and one-way analysis of variance with Bonferroni's post hoc test.  RESULTS:  Silibinin treatment for 1 week reduced RVSP and Fulton index.  Treatment for 2 weeks reduced RVSP, Fulton index, % MT, and VOS, as well as downregulating the expression of CXCR4, SDF-1, and TNFα in pulmonary arteries.  In contrast, treatment for 3 weeks failed to ameliorate PAH.  The time-course study demonstrated that RVSP, Fulton index, % MT, and VOS gradually increased over time, with a decrease in the expression of CXCR4 and TNFα occurring after 2 weeks of PAH development.  After 3 weeks, SDF-1, c-Kit, and SCF began to decrease and, after 5 weeks, MCP1 and IL-6 gradually accumulated.  CONCLUSIONS:  The CXCR4 inhibitor silibinin can ameliorate PAH, possibly through the suppression of the CXCR4/SDF-1 axis, until the point where PAH becomes a severe and irreversible condition.  Silibinin results in reduced pulmonary arterial pressure and delays pulmonary arteriolar occlusion and pulmonary vascular remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVkeWJ1Fp8_srRqEXsZufAfW6udTcc2eYNcnfsjLm2Jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fpt1CrtQ%253D%253D&md5=beeebd17b13886f3b88f65092d65e120</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1186%2Fs12931-019-1041-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-019-1041-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKawaguchi%26aufirst%3DN.%26aulast%3DYoshihara%26aufirst%3DK.%26aulast%3DHayama%26aufirst%3DE.%26aulast%3DFurutani%26aufirst%3DY.%26aulast%3DKawaguchi%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DT.%26atitle%3DSilibinin%2520efficacy%2520in%2520a%2520rat%2520model%2520of%2520pulmonary%2520arterial%2520hypertension%2520using%2520monocrotaline%2520and%2520chronic%2520hypoxia%26jtitle%3DRespir.%2520Res.%26date%3D2019%26volume%3D20%26spage%3D79%26doi%3D10.1186%2Fs12931-019-1041-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span> <span> </span><span class="NLM_article-title">Protective effects of 18β-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">108749</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2019.108749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cbi.2019.108749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31325423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSrsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2019&pages=108749&author=M.+Zhangauthor=Z.+Changauthor=P.+Zhangauthor=Z.+Jingauthor=L.+Yanauthor=J.+Fengauthor=Z.+Huauthor=Q.+Xuauthor=W.+Zhouauthor=P.+Maauthor=Y.+Haoauthor=R.+Zhou&title=Protective+effects+of+18%CE%B2-glycyrrhetinic+acid+on+pulmonary+arterial+hypertension+via+regulation+of+Rho+A%2FRho+kinsase+pathway&doi=10.1016%2Fj.cbi.2019.108749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of 18beta-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway</span></div><div class="casAuthors">Zhang, Min; Chang, Zhi; Zhang, Peng; Jing, Zhicheng; Yan, Lin; Feng, Jun; Hu, Zhiqiang; Xu, Qingbin; Zhou, Wei; Ma, Ping; Hao, Yinju; Zhou, Ru</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108749</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Excessive proliferation, migration and anti-apoptosis of pulmonary artery smooth muscle cells (PASMCs) are the basis for the development of pulmonary vascular remodeling, and it is the driving force for pulmonary arterial hypertension (PAH). 18beta-glycyrrhetinic acid is the main active substance extd. from Chinese herbal medicine licorice, with outstanding anti-inflammatory, anti-oxidn. and anti-proliferative effects.  Our team found in previous studies that 18beta-GA has protective effects on monocrotaline-induced PAH in rats.  However, the anti-angiogenic effect of 18beta-GA on PAH remains unclear.  Therefore, in order to further investigate whether the beneficial effects of 18beta-GA on PAH are related to its antiproliferative effect, we conducted expts. in vivo and in vitro.  In vivo, 18beta-GA relieved mean pulmonary arterial pressure, right ventricular systolic pressure, and right ventricular hypertrophy index, improving pulmonary remodeling.  Furthermore, after treatment with 18beta-GA, the expression of Rho A, ROCK1, ROCK2 was decreased and ROCK activity was inhibited in HPASMC.  In addn., 18beta-GA also attenuated PDGF-induced changes in p27kip1, Bax and Bcl-2.  In summary, these results indicate that 18beta-GA regulates the activity of RhoA-ROCK signaling pathway, inhibits the proliferation of HPASMCs, and has potential value in the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiCEft5wUvrVg90H21EOLACvtfcHk0ljwys4oEAOlJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSrsLnJ&md5=27b8ac4fdccf1e535417048b1d3c9901</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2019.108749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2019.108749%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DR.%26atitle%3DProtective%2520effects%2520of%252018%25CE%25B2-glycyrrhetinic%2520acid%2520on%2520pulmonary%2520arterial%2520hypertension%2520via%2520regulation%2520of%2520Rho%2520A%252FRho%2520kinsase%2520pathway%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2019%26volume%3D311%26spage%3D108749%26doi%3D10.1016%2Fj.cbi.2019.108749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span> <span> </span><span class="NLM_article-title">Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">63430</span>– <span class="NLM_lpage">63441</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.18632%2Foncotarget.18825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28969002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FksVSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=63430-63441&author=Z.+Zhangauthor=L.+Zhangauthor=C.+Sunauthor=F.+Kongauthor=J.+Wangauthor=Q.+Xinauthor=W.+Jiangauthor=K.+Liauthor=O.+Chenauthor=Y.+Luan&title=Baicalin+attenuates+monocrotaline-induced+pulmonary+hypertension+through+bone+morphogenetic+protein+signaling+pathway&doi=10.18632%2Foncotarget.18825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway</span></div><div class="casAuthors">Zhang Zhaohua; Zhang Luan; Sun Chao; Kong Feng; Wang Jue; Xin Qian; Jiang Wen; Li Kaili; Chen Ou; Luan Yun</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">63430-63441</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Baicalin, a flavonoid compound extracted from roots of Scutellaria baicalensis Georgi (huang qin), it has been shown to effectively attenuates pulmonary hypertension (PH), however, the potential mechanism remains unexplored.  In this study, we investigated the potential mechanism of baicalin on monocrotaline (MCT)-induced PH in rats.  The results showed that baicalin attenuated lung damage in PH rat model through inhibiting the pulmonary arterial smooth muscle cell proliferation and induction of cells apoptosis.  Furthermore, we demonstrated that baicalin inhibition the expression of nuclear factor-κB (NF-κB) p65 and bone morphogenetic protein (BMP) antagonists gremlin-1, but increased the expression of inhibitor of NF-κB (I-κBα), BMPR2, BMP-4, BMP-9 and Smad1/5/8.  Additionally, baicalin suppression endothelial-to-mesenchymal transition in PH lung tissue.  Collectively, we confirmed that baicalin via inhibition of NF-κB signaling to further activation of BMP signaling to have a therapeutic effect on PH and providing a promising therapeutic strategy for PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLSKkSsKMGSHthwrmtH4OBfW6udTcc2eZrai10YGB6J7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FksVSlsQ%253D%253D&md5=cbdf388c963985efd6df07e5a68d1b63</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18825%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DO.%26aulast%3DLuan%26aufirst%3DY.%26atitle%3DBaicalin%2520attenuates%2520monocrotaline-induced%2520pulmonary%2520hypertension%2520through%2520bone%2520morphogenetic%2520protein%2520signaling%2520pathway%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D63430%26epage%3D63441%26doi%3D10.18632%2Foncotarget.18825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, W.</span></span> <span> </span><span class="NLM_article-title">Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1177/2045894019878599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F2045894019878599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOntr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1-10&author=G.+Yanauthor=J.+Wangauthor=T.+Yiauthor=J.+Chengauthor=H.+Guoauthor=Y.+Heauthor=X.+Shuiauthor=Z.+Wuauthor=S.+Huangauthor=W.+Lei&title=Baicalin+prevents+pulmonary+arterial+remodeling+in+vivo+via+the+AKT%2FERK%2FNF-%CE%BAB+signaling+pathways&doi=10.1177%2F2045894019878599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways</span></div><div class="casAuthors">Yan, Guosen; Wang, Jinxia; Yi, Tao; Cheng, Junfen; Guo, Haixu; He, Yuan; Shui, Xiaorong; Wu, Zeyong; Huang, Shian; Lei, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">This study investigated the effects and mechanism of baicalin on vascular remodeling in rats with pulmonary arterial hypertension.  A rat pulmonary arterial hypertension model was constructed using i.p. injection of monocrotaline, and different doses of baicalin were used to treat these rats.  The mean pulmonary arterial pressure (mPAP) and right ventricular systolic pressure (RVSP) were measured with a right heart catheter.  Moreover, the hearts were dissected to det. the right ventricular hypertrophy index (RVHI).  The lung tissues were stained with H&E and Masson's staining to est. the pulmonary vascular remodeling and collagen fibrosis, and the expression of proteins in the AKT, ERK, and NF-κB p65 phosphorylation (p-AKT, p-ERK, p-p65) was examd. by Western blot anal.  We found that compared with untreated pulmonary arterial hypertension rats, baicalin ameliorated pulmonary vascular remodeling and cardiorespiratory injury, inhibited p-p65 and p-ERK expression, and promoted p-AKT and p-eNOS expression.  In conclusion, baicalin interfered with pulmonary vascular remodeling and pulmonary arterial hypertension development in rats through the AKT/eNOS, ERK and NF-κB signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOISajJ6mKrVg90H21EOLACvtfcHk0ljwys4oEAOlJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOntr7O&md5=73d210a96cdff297e1ef39c36db7200e</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1177%2F2045894019878599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045894019878599%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DShui%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DLei%26aufirst%3DW.%26atitle%3DBaicalin%2520prevents%2520pulmonary%2520arterial%2520remodeling%2520in%2520vivo%2520via%2520the%2520AKT%252FERK%252FNF-%25CE%25BAB%2520signaling%2520pathways%26jtitle%3DPulm.%2520Circ.%26date%3D2019%26volume%3D9%26spage%3D1%26epage%3D10%26doi%3D10.1177%2F2045894019878599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic effects of aloperine on the pulmonary arterial hypertension</span>. <i>Farmacia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.31925/farmacia.2019.4.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.31925%2Ffarmacia.2019.4.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Chu7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=691-701&author=S.+Liauthor=F.+Zhouauthor=J.+Dongauthor=Q.+Dongauthor=H.+Luanauthor=L.+Liauthor=Y.+Hao&title=Therapeutic+effects+of+aloperine+on+the+pulmonary+arterial+hypertension&doi=10.31925%2Ffarmacia.2019.4.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic effects of aloperine on the pulmonary arterial hypertension</span></div><div class="casAuthors">Li, Shuang; Zhou, Fubo; Dong, Jianjiang; Dong, Qi; Luan, Hairong; Li, Li; Hao, Yankun</div><div class="citationInfo"><span class="NLM_cas:title">Farmacia (Bucharest, Romania)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">FRMBAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-8237</span>.
    
            (<span class="NLM_cas:orgname">Societatea de Stiinte Farmaceutice din Romania</span>)
        </div><div class="casAbstract">In order to study the therapeutic effect of aloperine (ALO) on the pulmonary arterial hypertension (PAH), 90 male Sprague Dawley (SD) rats were divided into six groups: sham group, PAH group, PAH + 25 mg/kg bw ALO group, PAH + 50 mg/kg bw ALO group, PAH + 100 mg/kg bw ALOgroup, and PAH + 25 mg/kg bw sildenafil group.  The hemodynamic parameters, pulmonary fibrosis, vascular endothelial cell structure, intercellular monocyte chemotactic protein-1 (MCP-1) (adhesion factor-1) and ET-1 (endothelin-1) expression levels, and the expression levels of nuclear factor kappa light chain enhancer of activated B cells (NF-κB), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) pathways were assayed by Western blotting in order to evaluate the influence of ALO on PAH.  It was revealed that after the successful establishment of monocrotaline-induced PAH models in rats, rats showed decreased wall thickness of pulmonary arterioles, vascular stenosis, irregular swelling of vascular endothelial cells, proliferation of pulmonary fibrous tissues, disordered arrangement, increased no. of MCP-1 and ET-1 cells, and increased expression levels of NF-κB, TNF-α, and IL-1β pathways.  Sildenafil is well known to have protective effects on PAH.  According to the achieved results, it can be concluded that ALO also has protective effects on PAH.  ALO could improve the development of PAH through the NF-κB p65 signalling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiQbnvWu4j4bVg90H21EOLACvtfcHk0li4Lk3tuTBU8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Chu7nN&md5=2d127939a2a97d9f5bc1925e737281fb</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.31925%2Ffarmacia.2019.4.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.31925%252Ffarmacia.2019.4.19%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DLuan%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DY.%26atitle%3DTherapeutic%2520effects%2520of%2520aloperine%2520on%2520the%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DFarmacia%26date%3D2019%26volume%3D67%26spage%3D691%26epage%3D701%26doi%3D10.31925%2Ffarmacia.2019.4.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wann, S.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-C.</span></span> <span> </span><span class="NLM_article-title">Caffeic acid phenethyl ester rescues pulmonary arterial hypertension through the inhibition of AKT/ERK-dependent PDGF/HIF-1α in vitro and in vivo</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1468</span>, <span class="refDoi"> DOI: 10.3390/ijms20061468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fijms20061468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1468&author=C.-C.+Chengauthor=P.-L.+Chiauthor=M.-C.+Shenauthor=C.-W.+Shuauthor=S.-R.+Wannauthor=C.-P.+Liuauthor=C.-J.+Tsengauthor=W.-C.+Huang&title=Caffeic+acid+phenethyl+ester+rescues+pulmonary+arterial+hypertension+through+the+inhibition+of+AKT%2FERK-dependent+PDGF%2FHIF-1%CE%B1+in+vitro+and+in+vivo&doi=10.3390%2Fijms20061468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeic acid phenethyl ester rescues pulmonary arterial hypertension through the inhibition of AKT/ERK-dependent PDGF/HIF-1α in vitro and in vivo</span></div><div class="casAuthors">Cheng, Chin-Chang; Chi, Pei-Ling; Shen, Min-Ci; Shu, Chih-Wen; Wann, Shue-Ren; Liu, Chun-Peng; Tseng, Ching-Jiunn; Huang, Wei-Chun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is characterized by pulmonary arterial proliferation and remodeling, resulting in a specific increase in right ventricle systolic pressure (RVSP) and, ultimately right ventricular failure.  Recent studies have demonstrated that caffeic acid phenethyl ester (CAPE) exerts a protective role in NF- κB-mediated inflammatory diseases.  However, the effect of CAPE on PAH remains to be elucidated.  In this study, monocrotaline (MCT) was used to establish PAH in rats.  Two weeks after the induction of PAH by MCT, CAPE was administrated by i.p. injection once a day for two weeks.  Pulmonary hemodynamic measurements and pulmonary artery morphol. assessments were examd.  Our results showed that administration of CAPE significantly suppressed MCT-induced vascular remodeling by decreasing the HIF-1α expression and PDGF-BB prodn., and improved in vivo RV systolic performance in rats.  Furthermore, CAPE inhibits hypoxia- and PDGF-BB-induced HIF-1α expression by decreasing the activation of the AKT/ERK pathway, which results in the inhibition of human pulmonary artery smooth muscle cells (hPASMCs) proliferation and prevention of cells resistant to apoptosis.  Overall, our data suggest that HIF-1α is regarded as an alternative target for CAPE in addn. to NF- κB, and may represent a promising therapeutic agent for the treatment of PAH diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCGH9JCmTeD7Vg90H21EOLACvtfcHk0li4Lk3tuTBU8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWltL8%253D&md5=c9b749591edcd825995439d638b76f40</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.3390%2Fijms20061468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20061468%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.-C.%26aulast%3DChi%26aufirst%3DP.-L.%26aulast%3DShen%26aufirst%3DM.-C.%26aulast%3DShu%26aufirst%3DC.-W.%26aulast%3DWann%26aufirst%3DS.-R.%26aulast%3DLiu%26aufirst%3DC.-P.%26aulast%3DTseng%26aufirst%3DC.-J.%26aulast%3DHuang%26aufirst%3DW.-C.%26atitle%3DCaffeic%2520acid%2520phenethyl%2520ester%2520rescues%2520pulmonary%2520arterial%2520hypertension%2520through%2520the%2520inhibition%2520of%2520AKT%252FERK-dependent%2520PDGF%252FHIF-1%25CE%25B1%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1468%26doi%3D10.3390%2Fijms20061468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.-r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.-q.</span></span> <span> </span><span class="NLM_article-title">Betaine attenuates monocrotaline-induced pulmonary arterial hypertension in rats via inhibiting inflammatory response</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1274</span>, <span class="refDoi"> DOI: 10.3390/molecules23061274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fmolecules23061274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1274&author=J.-m.+Yangauthor=R.+Zhouauthor=M.+Zhangauthor=H.-r.+Tanauthor=J.-q.+Yu&title=Betaine+attenuates+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats+via+inhibiting+inflammatory+response&doi=10.3390%2Fmolecules23061274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Betaine attenuates monocrotaline-induced pulmonary arterial hypertension in rats via inhibiting inflammatory response</span></div><div class="casAuthors">Yang, Jia-mei; Zhou, Ru; Zhang, Min; Tan, Huan-ran; Yu, Jian-qiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1274/1-1274/15</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, leading to right ventricular failure and death.  Recent studies have suggested that chronic inflammatory processes are involved in the pathogenesis of PAH.  To test our hypothesis, we aimed to investigate the effects of betaine on monocrotaline-induced PAH in rats and attempted to further clarify the possible mechanisms.  PAH was induced by monocrotaline (50 mg/kg) and oral administration of betaine (100, 200, and 400 mg/kg/day).  The mean pulmonary arterial pressure, right ventricular systolic pressure, and right ventricle hypertrophy index were used to evaluate the development of PAH.  Nuclear factor-kappaB, tumor necrosis factor alpha (TNF-a), and interleukin-1beta were assessed by Western blot.  This study showed that betaine improved the abnormalities in right ventricular systolic pressure, mean pulmonary arterial pressure, right ventricle hypertrophy index, and pulmonary arterial remodeling induced by monocrotaline compared with the PAH group.  The levels of MCP-1 and ET-1 also decreased.  Western blot indicated that the protein expression levels of NF-kappaB, TNF-a, and IL-1beta significantly decreased (p < 0.01).  Our study demonstrated that betaine attenuated PAH through its anti-inflammatory effects.  Hence, the present data may offer novel targets and promising pharmacol. perspectives for treating monocrotaline-induced PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwzIYSjSh7GLVg90H21EOLACvtfcHk0li4Lk3tuTBU8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWksb3P&md5=ba29b457ba33a6abdcfc04f9400314bd</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23061274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23061274%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-m.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DH.-r.%26aulast%3DYu%26aufirst%3DJ.-q.%26atitle%3DBetaine%2520attenuates%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%2520via%2520inhibiting%2520inflammatory%2520response%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D1274%26doi%3D10.3390%2Fmolecules23061274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the NG, NG-dimethyl-L-arginine metabolism pathways in rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>842</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ejphar.2018.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30419238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Crur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=842&publication_year=2019&pages=338-344&author=G.+Daiauthor=B.+Liauthor=Y.+Xuauthor=Z.+Zengauthor=H.+Yang&title=Oxymatrine+prevents+the+development+of+monocrotaline-induced+pulmonary+hypertension+via+regulation+of+the+NG%2C+NG-dimethyl-L-arginine+metabolism+pathways+in+rats&doi=10.1016%2Fj.ejphar.2018.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the NG, NG-dimethyl-L-arginine metabolism pathways in rats</span></div><div class="casAuthors">Dai, Guidong; Li, Benpeng; Xu, Yuping; Zeng, Zhuliang; Yang, Hongyun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">842</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">338-344</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the potential effect of oxymatrine in monocrotaline-induced pulmonary hypertension and its possible influence on the NG,NG-dimethyl-L-arginine (ADMA) metab. pathway.  Pulmonary hypertension was induced in rats by a single-dose injection of monocrotaline (60 mg/kg).  Daily oral administration of oxymatrine (25, 50 and 100 mg/kg) was started on the day following the monocrotaline injection for 28 days.  Oxymatrine (50 and 100 mg/kg) significantly attenuated monocrotaline-induced lung and right ventricular hypertrophy, right ventricular systolic pressure elevation, and right ventricular dysfunction.  Meanwhile, oxymatrine normalized the level of pulmonary asym. ADMA and attenuated the upregulated expression of protein arginine methyltransferase 1 (PRMT1).  Oxymatrine had no effect on the expression of protein arginine methyltransferase 2 (PRMT2) and NG,NG-Dimethylarginine dimethylaminohydrolase 1 (DDAH1), which were upregulated in monocrotaline-induced pulmonary arterial hypertensive rats.  However, the expression of the protein NG,NG-Dimethylarginine dimethylaminohydrolase 2 (DDAH2) did not differ among all groups (all P>0.05).  These results suggest that oxymatrine may offer protective effects on the development of pulmonary hypertension by ameliorating pulmonary remodeling and modulating the ADMA metab. pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL-e5boppvb7Vg90H21EOLACvtfcHk0lhNfyM58-S_ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Crur7I&md5=d572ac3747abba051afbd64582c07118</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DOxymatrine%2520prevents%2520the%2520development%2520of%2520monocrotaline-induced%2520pulmonary%2520hypertension%2520via%2520regulation%2520of%2520the%2520NG%252C%2520NG-dimethyl-L-arginine%2520metabolism%2520pathways%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D842%26spage%3D338%26epage%3D344%26doi%3D10.1016%2Fj.ejphar.2018.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2017.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.biopha.2017.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29078260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1yltbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=825-833&author=Q.+Liauthor=J.+Wangauthor=X.+Zhuauthor=Z.+Zengauthor=X.+Wuauthor=Y.+Xuauthor=J.+Xieauthor=J.+Yu&title=Dihydromyricetin+prevents+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats&doi=10.1016%2Fj.biopha.2017.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats</span></div><div class="casAuthors">Li, Qinghai; Wang, Jun; Zhu, Xianying; Zeng, Zhilin; Wu, Xiaomei; Xu, Yongjian; Xie, Jungang; Yu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">825-833</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Pulmonary artery hypertension (PAH) is a chronic and deadly disease, for which effective medical treatments are lacking.  Here, we investigated whether 2R,3R-dihydromyricetin (DHM) could prevent monocrotaline (MCT)-induced PAH in rats.  The MCT-injected rats were treated with normal saline or DHM (100 mg/kg body wt./d) for 4 wk, followed by measurements of right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RVHI), pulmonary arterial remodeling (PAR), and expression levels of IL-6, TNF-α, and IL-10.  In vitro, we assessed the role of DHM on IL-6-induced migration of primary human pulmonary arterial smooth muscle cells (HPASMCs).  We found that DHM treatment attenuated changes in RVSP, RVHI, and PAR in MCT-injected PAH rats.  The obsd. increase of IL-6 levels in PAH rats was inhibited by DHM treatment.  In vitro, DHM pretreatment reduced IL-6-induced HPASMC migration.  Furthermore, MCT- and IL-6-mediated increases in MMP9 and P-STAT3 (tyr705) PY-STAT3 levels were suppressed by DHM treatment in vivo and in vitro.  These results suggest that DHM could prevent MCT-induced rat PAH and IL-6-induced HPASMC migration through a mechanism involving inhibiting of the STAT3/MMP9 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPsUYmgkl9t7Vg90H21EOLACvtfcHk0lhNfyM58-S_ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1yltbzO&md5=9518191da3a3d2cf9ba8b0987ee04cf5</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2017.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2017.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DDihydromyricetin%2520prevents%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2017%26volume%3D96%26spage%3D825%26epage%3D833%26doi%3D10.1016%2Fj.biopha.2017.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucherat, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span> <span> </span><span class="NLM_article-title">The cancer theory of pulmonary arterial hypertension</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1177/2045893217701438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F2045893217701438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28597757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlCgurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=285-299&author=O.+Boucheratauthor=G.+Vitryauthor=I.+Trinhauthor=R.+Paulinauthor=S.+Provencherauthor=S.+Bonnet&title=The+cancer+theory+of+pulmonary+arterial+hypertension&doi=10.1177%2F2045893217701438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">The cancer theory of pulmonary arterial hypertension</span></div><div class="casAuthors">Boucherat, Olivier; Vitry, Geraldine; Trinh, Isabelle; Paulin, Roxane; Provencher, Steeve; Bonnet, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) remains a mysterious killer that, like cancer, is characterized by tremendous complexity.  PAH development occurs under sustained and persistent environmental stress, such as inflammation, shear stress, pseudo-hypoxia, and more.  After inducing an initial death of the endothelial cells, these environmental stresses contribute with time to the development of hyper-proliferative and apoptotic resistant clone of cells including pulmonary artery smooth muscle cells, fibroblasts, and even pulmonary artery endothelial cells allowing vascular remodeling and PAH development.  Molecularly, these cells exhibit many features common to cancer cells offering the opportunity to exploit therapeutic strategies used in cancer to treat PAH.  In this review, we outline the signaling pathways and mechanisms described in cancer that drive PAH cells' survival and proliferation and discuss the therapeutic potential of antineoplastic drugs in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAogNU0qVfVrVg90H21EOLACvtfcHk0lhNfyM58-S_ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlCgurw%253D&md5=1a0e3aeb31030c1a9465fedf441eda30</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1177%2F2045893217701438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045893217701438%26sid%3Dliteratum%253Aachs%26aulast%3DBoucherat%26aufirst%3DO.%26aulast%3DVitry%26aufirst%3DG.%26aulast%3DTrinh%26aufirst%3DI.%26aulast%3DPaulin%26aufirst%3DR.%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DS.%26atitle%3DThe%2520cancer%2520theory%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DPulm.%2520Circ.%26date%3D2017%26volume%3D7%26spage%3D285%26epage%3D299%26doi%3D10.1177%2F2045893217701438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbera, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1413687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26308684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=834-844&author=N.+Galieauthor=J.+A.+Barberaauthor=A.+E.+Frostauthor=H.+A.+Ghofraniauthor=M.+M.+Hoeperauthor=V.+V.+McLaughlinauthor=A.+J.+Peacockauthor=G.+Simonneauauthor=J.+L.+Vachieryauthor=E.+Grunigauthor=R.+J.+Oudizauthor=A.+Vonk-Noordegraafauthor=R.+J.+Whiteauthor=C.+Blairauthor=H.+Gilliesauthor=K.+L.+Millerauthor=J.+H.+N.+Harrisauthor=J.+Langleyauthor=L.+J.+Rubin&title=Initial+use+of+ambrisentan+plus+tadalafil+in+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1413687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Barbera, J. A.; Frost, A. E.; Ghofrani, H.-A.; Hoeper, M. M.; McLaughlin, V. V.; Peacock, A. J.; Simonneau, G.; Vachiery, J.-L.; Grunig, E.; Oudiz, R. J.; Vonk-Noordegraaf, A.; White, R. J.; Blair, C.; Gillies, H.; Miller, K. L.; Harris, J. H. N.; Langley, J.; Rubin, L. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">834-844</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.  Methods: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentanmonotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily.  The primary end point in a time-to-event anal. was the first event of clin. failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clin. response.  Results: The primary anal. included 500 participants; 253 were assigned to the combination- therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group.  A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, resp., and in 31% of the pooledmonotherapy group (the two monotherapy groups combined).  The hazard ratio for the primary end point in the combination-therapy group vs. the pooled-monotherapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001).  At week 24, the combination-therapy group had greater redns. from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monotherapy group (mean change, -67.2% vs. -50.4%; P<0.001), as well as a higher percentage of patients with a satisfactory clin. response (39% vs. 29%; odds ratio, 1.56 [95% CI, 1.05 to 2.32]; P = 0.03) and a greater improvement in the 6-min walk distance (median change from baseline, 48.98 m vs. 23.80 m; P<0.001).  The adverse events that occurred more frequently in the combination-therapy group than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia.  Conclusions: Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clin.-failure events than the risk with ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and GlaxoSmithKline; AMBITION ClinicalTrials.gov no., NCT01178073).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4zQLE95kVbVg90H21EOLACvtfcHk0lippxlj4p6AsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D&md5=018dd6202fa784e3570c7dd6395218e4</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413687%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DBarbera%26aufirst%3DJ.%2BA.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DR.%2BJ.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DGillies%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DK.%2BL.%26aulast%3DHarris%26aufirst%3DJ.%2BH.%2BN.%26aulast%3DLangley%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DInitial%2520use%2520of%2520ambrisentan%2520plus%2520tadalafil%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D834%26epage%3D844%26doi%3D10.1056%2FNEJMoa1413687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaine, S.</span></span> <span> </span><span class="NLM_article-title">Beyond a single pathway: combination therapy in pulmonary arterial hypertension</span>. <i>Eur. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1183/16000617.0085-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F16000617.0085-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27903663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2sjitVOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=408-417&author=O.+Sitbonauthor=S.+Gaine&title=Beyond+a+single+pathway%3A+combination+therapy+in+pulmonary+arterial+hypertension&doi=10.1183%2F16000617.0085-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond a single pathway: combination therapy in pulmonary arterial hypertension</span></div><div class="casAuthors">Sitbon Olivier; Sitbon Olivier; Sitbon Olivier; Gaine Sean</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">142</span>),
    <span class="NLM_cas:pages">408-417</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is a strong rationale for combining therapies to simultaneously target three of the key pathways implicated in the pathogenesis of pulmonary arterial hypertension (PAH).  Evidence to support this strategy is growing, and a number of studies have demonstrated that combination therapy, administered as either a sequential or an initial regimen, can improve long-term outcomes in PAH.  Dual combination therapy with a phosphodiesterase-5 inhibitor and an endothelin receptor antagonist is the most widely utilised combination regimen.  However, some patients fail to achieve their treatment goals on dual therapy and may benefit from the addition of a third drug.  The use of triple therapy in clinical practice was previously reserved for patients with severe disease due to the need for parenteral administration of prostanoids.  Although triple therapy with parenteral prostanoids plays a key role in the management of severe PAH, the approval of oral therapies that target the prostacyclin pathway means that all three pathways can now be targeted with oral drugs at an earlier disease stage.  Furthermore, there is evidence demonstrating that this approach can delay disease progression.  Based on the evidence available, it is becoming increasingly clear that all PAH patients should be offered the benefits of combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnSocOUykyg-qrn-c4Of3KfW6udTcc2eZMsAUu2d3ezrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjitVOitA%253D%253D&md5=8e436a77a02e54bb63f5a76e8144d5e8</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1183%2F16000617.0085-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.0085-2016%26sid%3Dliteratum%253Aachs%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DGaine%26aufirst%3DS.%26atitle%3DBeyond%2520a%2520single%2520pathway%253A%2520combination%2520therapy%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2016%26volume%3D25%26spage%3D408%26epage%3D417%26doi%3D10.1183%2F16000617.0085-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragg, G. M.</span></span> <span> </span><span class="NLM_article-title">Natural products as sources of new drugs from 1981 to 2014</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.5b01055</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.5b01055" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1Kqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=629-661&author=D.+J.+Newmanauthor=G.+M.+Cragg&title=Natural+products+as+sources+of+new+drugs+from+1981+to+2014&doi=10.1021%2Facs.jnatprod.5b01055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Natural Products as Sources of New Drugs from 1981 to 2014</span></div><div class="casAuthors">Newman, David J.; Cragg, Gordon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-661</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">This contribution is a completely updated and expanded version of the four prior analogous reviews that were published in this journal in 1997, 2003, 2007, and 2012.  In the case of all approved therapeutic agents, the time frame has been extended to cover the 34 years from Jan. 1, 1981, to Dec. 31, 2014, for all diseases worldwide, and from 1950 (earliest so far identified) to Dec. 2014 for all approved antitumor drugs worldwide.  As mentioned in the 2012 review, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions and the designation "natural product botanical", or "NB", to cover those botanical "defined mixts." now recognized as drug entities by the U.S. FDA (and similar organizations).  From the data presented in this review, the utilization of natural products and/or their novel structures, in order to discover and develop the final drug entity, is still alive and well.  For example, in the area of cancer, over the time frame from around the 1940s to the end of 2014, of the 175 small mols. approved, 131, or 75%, are other than "S" (synthetic), with 85, or 49%, actually being either natural products or directly derived therefrom.  In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the anti-infective area being dependent on natural products and their structures.  We wish to draw the attention of readers to the rapidly evolving recognition that a significant no. of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore it is considered that this area of natural product research should be expanded significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMgEvq9fVY8bVg90H21EOLACvtfcHk0lippxlj4p6AsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1Kqu7k%253D&md5=c9f2a44ab6b66331b7ef6ca64029328a</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.5b01055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.5b01055%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26atitle%3DNatural%2520products%2520as%2520sources%2520of%2520new%2520drugs%2520from%25201981%2520to%25202014%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2016%26volume%3D79%26spage%3D629%26epage%3D661%26doi%3D10.1021%2Facs.jnatprod.5b01055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Nature brings new avenues to the therapy of central nervous system diseases-An overview of possible treatments derived from natural products</span>. <i>Sci. China: Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1332</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1007/s11427-019-9587-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1007%2Fs11427-019-9587-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31444682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3MrhtFGrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1332-1367&author=J.+Zhangauthor=Y.+Heauthor=X.+Jiangauthor=H.+Jiangauthor=J.+Shen&title=Nature+brings+new+avenues+to+the+therapy+of+central+nervous+system+diseases-An+overview+of+possible+treatments+derived+from+natural+products&doi=10.1007%2Fs11427-019-9587-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Nature brings new avenues to the therapy of central nervous system diseases-An overview of possible treatments derived from natural products</span></div><div class="casAuthors">Zhang Junchi; He Yang; Jiang Xiangrui; Jiang Hualiang; Shen Jingshan; Zhang Junchi</div><div class="citationInfo"><span class="NLM_cas:title">Science China. Life sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1332-1367</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Natural products (NPs), including traditional Chinese medicine (TCM), have been long and widely used in the prevention and treatment of central nervous system (CNS) diseases by virtue of their abundant sources, diverse structures, and novel activities.  In this review article, we intend to summarize and discuss the situation or status of the clinical employments or trials of the NPs and their derivatives with CNS activities.  NPs that have been extensively studied in preclinical research in recent years are also included.  The compounds presented in this review are classified according to their indications and followed by details such as natural sources, possible biological mechanisms, and development status, while a considerable proportion of them are found in TCM.  In addition, some drug combinations with synergistic effects are also mentioned.  According to their impressive therapeutic effects and novel chemical structures, NPs are not only effective therapeutic remedies in clinic, but also lead compounds for structural modification, which indicate that nature brings new avenues to the therapy of CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzf-JpvpvX-OkdrW1FkXG-fW6udTcc2eZMsAUu2d3ezrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrhtFGrsg%253D%253D&md5=42cc72913f5a721a72d785ec7f626a65</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1007%2Fs11427-019-9587-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11427-019-9587-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DNature%2520brings%2520new%2520avenues%2520to%2520the%2520therapy%2520of%2520central%2520nervous%2520system%2520diseases-An%2520overview%2520of%2520possible%2520treatments%2520derived%2520from%2520natural%2520products%26jtitle%3DSci.%2520China%253A%2520Life%2520Sci.%26date%3D2019%26volume%3D62%26spage%3D1332%26epage%3D1367%26doi%3D10.1007%2Fs11427-019-9587-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Counting on natural products for drug design</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1038/nchem.2479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnchem.2479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27219696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=531-541&author=T.+Rodriguesauthor=D.+Rekerauthor=P.+Schneiderauthor=G.+Schneider&title=Counting+on+natural+products+for+drug+design&doi=10.1038%2Fnchem.2479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Counting on natural products for drug design</span></div><div class="casAuthors">Rodrigues, Tiago; Reker, Daniel; Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">531-541</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products and their mol. frameworks have a long tradition as valuable starting points for medicinal chem. and drug discovery.  Recently, there has been a revitalization of interest in the inclusion of these chemotypes in compd. collections for screening and achieving selective target modulation.  Here the authors discuss natural-product-inspired drug discovery with a focus on recent advances in the design of synthetically tractable small mols. that mimic nature's chem.  The authors highlight the potential of innovative computational tools in processing structurally complex natural products to predict their macromol. targets and attempt to forecast the role that natural-product-derived fragments and fragment-like natural products will play in next-generation drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNR16z66-NgLVg90H21EOLACvtfcHk0lh0hhTJ9YVt1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D&md5=3f6391192d648de2a54524afafd6203a</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2479%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DCounting%2520on%2520natural%2520products%2520for%2520drug%2520design%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D531%26epage%3D541%26doi%3D10.1038%2Fnchem.2479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongjie  Qian</span>, <span class="hlFld-ContribAuthor ">Qian  Chen</span>, <span class="hlFld-ContribAuthor ">Liyu  Liang</span>, <span class="hlFld-ContribAuthor ">Yang  Zou</span>, <span class="hlFld-ContribAuthor ">Huahua  Pu</span>, <span class="hlFld-ContribAuthor ">Liang  Xin</span>, <span class="hlFld-ContribAuthor ">Rong  Song</span>, <span class="hlFld-ContribAuthor ">Tingting  Li</span>, <span class="hlFld-ContribAuthor ">Huijuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Guanghui  Tian</span>, <span class="hlFld-ContribAuthor ">Jingshan  Shen</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Chen  Yu</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>, <span class="hlFld-ContribAuthor ">Jingying  Jia</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. </span><span class="cited-content_cbyCitation_journal-name">Drug Design, Development and Therapy</span><span> <strong>2021,</strong> <em>Volume 15 </em>, 2947-2959. <a href="https://doi.org/10.2147/DDDT.S308610" title="DOI URL">https://doi.org/10.2147/DDDT.S308610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/DDDT.S308610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FDDDT.S308610%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Design%252C%2520Development%2520and%2520Therapy%26atitle%3DA%252BPhase%252BI%252BStudy%252Bto%252BEvaluate%252Bthe%252BSafety%25252C%252BTolerability%25252C%252Band%252BPharmacokinetics%252Bof%252BTPN171H%25252C%252Ba%252BNovel%252BPhosphodiesterase%252BType%252B5%252BInhibitor%25252C%252Bin%252BHealthy%252BSubjects%26aulast%3DQian%26aufirst%3DHongjie%26date%3D2021%26date%3D2021%26volume%3DVolume%252015%26spage%3D2947%26epage%3D2959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0036.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Endogenous substances and related pathways that are associated with the development of PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PGI<sub>2</sub> pathway and potential targets of PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0028.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Metabolism of PGI<sub>2</sub></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of some PGI<sub>2</sub> analogues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Development of PGI<sub>2</sub> drugs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0029.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Design of Selexipag</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures of PGI<sub>2</sub> receptor agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Biosynthetic pathway of TXA<sub>2</sub> and PGI<sub>2</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Imbalance between TXA<sub>2</sub> and PGI<sub>2</sub> in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of ifetroban, NTP-42, Onoono-1301, and TRA-418.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Roles of the ET receptor in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of ERAs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Development of an ERA.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0030.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Design of Bosentan</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0012.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. NO pathway and potential molecular targets for PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0013.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Development of drugs in the NO pathway for PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0014.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Chemical structures of PDE5 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0031.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Design of Sildenafil</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0015.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Crystal structure of the catalytic domain of PDE5 in complex with sildenafil. Sildenafil is shown in green, zinc ions are shown as gray spheres, H-bond interactions are shown as yellow dashed lines, and Π–Π stacking interactions are shown as purple dashed lines (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2h42">2h42</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0039.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Design of Riociguat</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0016.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Chemical structures of other sGC activators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0017.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Roles of ROCK in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0018.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure of fasudil.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0019.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Roles of the 5-HT pathway in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0020.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Chemical structures of 5-HT receptor antagonists, selective 5-HT reuptake inhibitors, and a tryptophan hydroxylase (TPH) inhibitor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0021.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Chemical structures of PDK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0022.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structure of tacrolimus.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0023.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Roles of the RAAS in PAH.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0024.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structures of losartan and spironolactone.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0025.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure of olaparib.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0026.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structures of metformin, rapamycin, MN-08, CDDO-NO, and compound <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/medium/jm0c01093_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0027.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structures of natural products for PAH treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01093/20201218/images/large/jm0c01093_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01093&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 237 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noordegraaf, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, M. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancellotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonagh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierard, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zompatori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M.</span></span> <span> </span><span class="NLM_article-title">2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">903</span>– <span class="NLM_lpage">975</span>, <span class="refDoi"> DOI: 10.1183/13993003.01032-2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01032-2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26318161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslSiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2015&pages=903-975&author=N.+Galieauthor=M.+Humbertauthor=J.-L.+Vachieryauthor=S.+Gibbsauthor=I.+Langauthor=A.+Torbickiauthor=G.+Simonneauauthor=A.+Peacockauthor=A.+V.+Noordegraafauthor=M.+Beghettiauthor=A.+Ghofraniauthor=M.+A.+G.+Sanchezauthor=G.+Hansmannauthor=W.+Klepetkoauthor=P.+Lancellottiauthor=M.+Matucciauthor=T.+McDonaghauthor=L.+A.+Pierardauthor=P.+T.+Trindadeauthor=M.+Zompatoriauthor=M.+Hoeper&title=2015+ESC%2FERS+guidelines+for+the+diagnosis+and+treatment+of+pulmonary+hypertension&doi=10.1183%2F13993003.01032-2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Humbert, Marc; Vachiery, Jean-Luc; Gibbs, Simon; Lang, Irene; Torbicki, Adam; Simonneau, Gerald; Peacock, Andrew; Noordegraaf, Anton Vonk; Beghetti, Maurice; Ghofrani, Ardeschir; Sanchez, Miguel Angel Gomez; Hansmann, Georg; Klepetko, Walter; Lancellotti, Patrizio; Matucci, Marco; McDonagh, Theresa; Pierard, Luc A.; Trindade, Pedro T.; Zompatori, Maurizio; Hoeper, Marius</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">903-975</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">This article describes on 2015 ESC/ERS guidelines for diagnosis and treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorK3std3OPyrVg90H21EOLACvtfcHk0lhchRZAjghm1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslSiu74%253D&md5=b8fbd51d60af38c30146a8e3c60de880</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1183%2F13993003.01032-2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01032-2015%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.-L.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DNoordegraaf%26aufirst%3DA.%2BV.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DA.%26aulast%3DSanchez%26aufirst%3DM.%2BA.%2BG.%26aulast%3DHansmann%26aufirst%3DG.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMatucci%26aufirst%3DM.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DPierard%26aufirst%3DL.%2BA.%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DZompatori%26aufirst%3DM.%26aulast%3DHoeper%26aufirst%3DM.%26atitle%3D2015%2520ESC%252FERS%2520guidelines%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520pulmonary%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D46%26spage%3D903%26epage%3D975%26doi%3D10.1183%2F13993003.01032-2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celermajer, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatzoulis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krowka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span> <span> </span><span class="NLM_article-title">Haemodynamic definitions and updated clinical classification of pulmonary hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1801913</span>, <span class="refDoi"> DOI: 10.1183/13993003.01913-2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01913-2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30545968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=1801913&author=G.+Simonneauauthor=D.+Montaniauthor=D.+S.+Celermajerauthor=C.+P.+Dentonauthor=M.+A.+Gatzoulisauthor=M.+Krowkaauthor=P.+G.+Williamsauthor=R.+Souza&title=Haemodynamic+definitions+and+updated+clinical+classification+of+pulmonary+hypertension&doi=10.1183%2F13993003.01913-2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Haemodynamic definitions and updated clinical classification of pulmonary hypertension</span></div><div class="casAuthors">Simonneau, Gerald; Montani, David; Celermajer, David S.; Denton, Christopher P.; Gatzoulis, Michael A.; Krowka, Michael; Williams, Paul G.; Souza, Rogerio</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1801913</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest, measured by right heart catheterisation.  Recent data from normal subjects has shown that normal mPAP was 14.0 ± 3.3 mmHg.  Two std. deviations above this mean value would suggest mPAP >20 mmHg as above the upper limit of normal (above the 97.5th percentile).  This definition is no longer arbitrary, but based on a scientific approach.  However, this abnormal elevation of mPAP is not sufficient to define pulmonary vascular disease as it can be due to an increase in cardiac output or pulmonary arterial wedge pressure.  Thus, this 6th WSPH Task Force proposes to include pulmonary vascular resistance ≥3 Wood Units in the definition of all forms of pre-capillary PH assocd. with mPAP >20 mmHg.  Prospective trials are required to det. whether this PH population might benefit from specific management.  Regarding clin. classification, the main Task Force changes were the inclusion in group 1 of a subgroup "pulmonary arterial hypertension (PAH) long-term responders to calcium channel blockers", due to the specific prognostic and management of these patients, and a subgroup "PAH with overt features of venous/capillaries (pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis) involvement", due to evidence suggesting a continuum between arterial, capillary and vein involvement in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_4e3AX60qrVg90H21EOLACvtfcHk0lhchRZAjghm1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7rL&md5=3864bf280a8c2d38ebf6710debf9287e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1183%2F13993003.01913-2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01913-2018%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DCelermajer%26aufirst%3DD.%2BS.%26aulast%3DDenton%26aufirst%3DC.%2BP.%26aulast%3DGatzoulis%26aufirst%3DM.%2BA.%26aulast%3DKrowka%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DP.%2BG.%26aulast%3DSouza%26aufirst%3DR.%26atitle%3DHaemodynamic%2520definitions%2520and%2520updated%2520clinical%2520classification%2520of%2520pulmonary%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2019%26volume%3D53%26spage%3D1801913%26doi%3D10.1183%2F13993003.01913-2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galiè, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beghetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez Sanchez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lancellotti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonagh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierard, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trindade, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zompatori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M.</span></span> <span> </span><span class="NLM_article-title">2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS): endorsed by: association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)</span>. <i>Eur. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehv317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1093%2Feurheartj%2Fehv317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26320113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC287nt1Gitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=67-119&author=N.+Gali%C3%A8author=M.+Humbertauthor=J.-L.+Vachieryauthor=S.+Gibbsauthor=I.+Langauthor=A.+Torbickiauthor=G.+Simonneauauthor=A.+Peacockauthor=A.+Vonk+Noordegraafauthor=M.+Beghettiauthor=A.+Ghofraniauthor=M.+A.+Gomez+Sanchezauthor=G.+Hansmannauthor=W.+Klepetkoauthor=P.+Lancellottiauthor=M.+Matucciauthor=T.+McDonaghauthor=L.+A.+Pierardauthor=P.+T.+Trindadeauthor=M.+Zompatoriauthor=M.+Hoeper&title=2015+ESC%2FERS+guidelines+for+the+diagnosis+and+treatment+of+pulmonary+hypertension%3A+the+joint+task+force+for+the+diagnosis+and+treatment+of+pulmonary+hypertension+of+the+european+society+of+cardiology+%28ESC%29+and+the+european+respiratory+society+%28ERS%29%3A+endorsed+by%3A+association+for+european+paediatric+and+congenital+cardiology+%28AEPC%29%2C+international+society+for+heart+and+lung+transplantation+%28ISHLT%29&doi=10.1093%2Feurheartj%2Fehv317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</span></div><div class="casAuthors">Galie Nazzareno; Humbert Marc; Vachiery Jean-Luc; Gibbs Simon; Lang Irene; Torbicki Adam; Simonneau Gerald; Peacock Andrew; Vonk Noordegraaf Anton; Beghetti Maurice; Ghofrani Ardeschir; Gomez Sanchez Miguel Angel; Hansmann Georg; Klepetko Walter; Lancellotti Patrizio; Matucci Marco; McDonagh Theresa; Pierard Luc A; Trindade Pedro T; Zompatori Maurizio; Hoeper Marius</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-119</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcJiEtRxzflCnGiHuhFGv8fW6udTcc2eaxQ4eaj7o4krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nt1Gitg%253D%253D&md5=8ef6fec63bd8bb337bec7485660ea933</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehv317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehv317%26sid%3Dliteratum%253Aachs%26aulast%3DGali%25C3%25A8%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.-L.%26aulast%3DGibbs%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DI.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3DBeghetti%26aufirst%3DM.%26aulast%3DGhofrani%26aufirst%3DA.%26aulast%3DGomez%2BSanchez%26aufirst%3DM.%2BA.%26aulast%3DHansmann%26aufirst%3DG.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DLancellotti%26aufirst%3DP.%26aulast%3DMatucci%26aufirst%3DM.%26aulast%3DMcDonagh%26aufirst%3DT.%26aulast%3DPierard%26aufirst%3DL.%2BA.%26aulast%3DTrindade%26aufirst%3DP.%2BT.%26aulast%3DZompatori%26aufirst%3DM.%26aulast%3DHoeper%26aufirst%3DM.%26atitle%3D2015%2520ESC%252FERS%2520guidelines%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520pulmonary%2520hypertension%253A%2520the%2520joint%2520task%2520force%2520for%2520the%2520diagnosis%2520and%2520treatment%2520of%2520pulmonary%2520hypertension%2520of%2520the%2520european%2520society%2520of%2520cardiology%2520%2528ESC%2529%2520and%2520the%2520european%2520respiratory%2520society%2520%2528ERS%2529%253A%2520endorsed%2520by%253A%2520association%2520for%2520european%2520paediatric%2520and%2520congenital%2520cardiology%2520%2528AEPC%2529%252C%2520international%2520society%2520for%2520heart%2520and%2520lung%2520transplantation%2520%2528ISHLT%2529%26jtitle%3DEur.%2520Heart%2520J.%26date%3D2016%26volume%3D37%26spage%3D67%26epage%3D119%26doi%3D10.1093%2Feurheartj%2Fehv317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benza, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span> <span> </span><span class="NLM_article-title">An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1378/chest.11-1460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.11-1460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22281797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC38vht12iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2012&pages=448-456&author=R.+L.+Benzaauthor=D.+P.+Millerauthor=R.+J.+Barstauthor=D.+B.+Badeschauthor=A.+E.+Frostauthor=M.+D.+McGoon&title=An+evaluation+of+long-term+survival+from+time+of+diagnosis+in+pulmonary+arterial+hypertension+from+the+REVEAL+registry&doi=10.1378%2Fchest.11-1460"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry</span></div><div class="casAuthors">Benza Raymond L; Miller Dave P; Barst Robyn J; Badesch David B; Frost Adaani E; McGoon Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">448-456</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) was established to characterize the clinical course, treatment, and predictors of outcomes in patients with pulmonary arterial hypertension (PAH) in the United States.  To date, estimated survival based on time of patient enrollment has been established and reported.  To determine whether the survival of patients with PAH has improved over recent decades, we assessed survival from time of diagnosis for the REVEAL Registry cohort and compared these results to the estimated survival using the National Institutes of Health (NIH) prognostic equation.  METHODS:  Newly or previously diagnosed patients (aged ≥ 3 months at diagnosis) with PAH enrolled from March 2006 to December 2009 at 55 US centers were included in the current analysis.  RESULTS:  A total of 2,635 patients qualified for this analysis.  One-, 3-, 5-, and 7-year survival rates from time of diagnostic right-sided heart catheterization were 85%, 68%, 57%, and 49%, respectively.  For patients with idiopathic/familial PAH, survival rates were 91% ± 2%, 74% ± 2%, 65% ± 3%, and 59% ± 3% compared with estimated survival rates of 68%, 47%, 36%, and 32%, respectively, using the NIH equation.  CONCLUSIONS:  Comprehensive analysis of survival from time of diagnosis in a large cohort of patients with PAH suggests considerable improvements in survival in the past 2 decades since the establishment of the NIH registry, the effects of which most likely reflect a combination of changes in treatments, improved patient support strategies, and possibly a PAH population at variance with other cohorts</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKENQHdcnpUBe4jJGKT5N0fW6udTcc2eZvsXR5nEXPELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vht12iuw%253D%253D&md5=1c56fc60b035ab670af101300c0ee76f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1378%2Fchest.11-1460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.11-1460%26sid%3Dliteratum%253Aachs%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DMiller%26aufirst%3DD.%2BP.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26atitle%3DAn%2520evaluation%2520of%2520long-term%2520survival%2520from%2520time%2520of%2520diagnosis%2520in%2520pulmonary%2520arterial%2520hypertension%2520from%2520the%2520REVEAL%2520registry%26jtitle%3DChest%26date%3D2012%26volume%3D142%26spage%3D448%26epage%3D456%26doi%3D10.1378%2Fchest.11-1460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idrees, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwa-Hahnle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S. R.</span></span> <span> </span><span class="NLM_article-title">A global view of pulmonary hypertension</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">306</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(15)00543-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS2213-2600%2815%2900543-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26975810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28fgtFKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=306-322&author=M.+M.+Hoeperauthor=M.+Humbertauthor=R.+Souzaauthor=M.+Idreesauthor=S.+M.+Kawutauthor=K.+Sliwa-Hahnleauthor=Z.+C.+Jingauthor=J.+S.+R.+Gibbs&title=A+global+view+of+pulmonary+hypertension&doi=10.1016%2FS2213-2600%2815%2900543-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A global view of pulmonary hypertension</span></div><div class="casAuthors">Hoeper Marius M; Humbert Marc; Souza Rogerio; Idrees Majdy; Kawut Steven M; Sliwa-Hahnle Karen; Jing Zhi-Cheng; Gibbs J Simon R</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Respiratory medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">306-22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pulmonary hypertension is a substantial global health issue.  All age groups are affected with rapidly growing importance in elderly people, particularly in countries with ageing populations.  Present estimates suggest a pulmonary hypertension prevalence of about 1% of the global population, which increases up to 10% in individuals aged more than 65 years.  In almost all parts of the world, left-sided heart and lung diseases have become the most frequent causes of pulmonary hypertension.  About 80% of affected patients live in developing countries, where pulmonary hypertension is frequently associated with congenital heart disease and various infectious disorders, including schistosomiasis, HIV, and rheumatic heart disease.  These forms of pulmonary hypertension occur predominantly in those younger than 65 years.  Independently of the underlying disease, the development of pulmonary hypertension is associated with clinical deterioration and a substantially increased mortality risk.  Global research efforts are needed to establish preventive strategies and treatments for the various types of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL7LiBqZ0M-DToTC3aBaesfW6udTcc2eZvsXR5nEXPELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fgtFKntg%253D%253D&md5=597061e505456222734077cee4fc9112</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2815%2900543-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252815%252900543-3%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DIdrees%26aufirst%3DM.%26aulast%3DKawut%26aufirst%3DS.%2BM.%26aulast%3DSliwa-Hahnle%26aufirst%3DK.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%2BR.%26atitle%3DA%2520global%2520view%2520of%2520pulmonary%2520hypertension%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D306%26epage%3D322%26doi%3D10.1016%2FS2213-2600%2815%2900543-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duffels, M.G.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelfriet, P.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, R.M.F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Loon, R.L.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoendermis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vriend, J.W.J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velde, E.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bresser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulder, B.J.M.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2006.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ijcard.2006.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17182132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2svgvF2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2007&pages=198-204&author=M.G.J.+Duffelsauthor=P.M.+Engelfrietauthor=R.M.F.+Bergerauthor=R.L.E.+van+Loonauthor=E.+Hoendermisauthor=J.W.J.+Vriendauthor=E.T.+van+der+Veldeauthor=P.+Bresserauthor=B.J.M.+Mulder&title=Pulmonary+arterial+hypertension+in+congenital+heart+disease%3A+an+epidemiologic+perspective+from+a+Dutch+registry&doi=10.1016%2Fj.ijcard.2006.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry</span></div><div class="casAuthors">Duffels M G J; Engelfriet P M; Berger R M F; van Loon R L E; Hoendermis E; Vriend J W J; van der Velde E T; Bresser P; Mulder B J M</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-204</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary arterial hypertension (PAH) associated with congenital heart disease is usually the result of a large systemic-to-pulmonary shunt, and often leads to right ventricular failure and early death.  The purpose of this study was to determine the prevalence of PAH among adult patients included in a national registry of congenital heart disease and to assess the relation between patient characteristics and PAH.  METHODS:  Patients with PAH associated with a septal defect were identified from the registry.  Gender, age, underlying diagnosis, previous closure, age at repair and NYHA classification were recorded.  PAH was defined as a systolic pulmonary arterial pressure (sPAP) greater than 40 mm Hg, estimated by means of echocardiographical evaluation.  RESULTS:  The prevalence of PAH among all 5970 registered adult patients with congenital heart disease was 4.2%.  Of 1824 patients with a septal defect in the registry, 112 patients (6.1%) had PAH.  Median age of these patients was 38 years (range 18-81 years) and 40% were male.  Of these patients, 58% had the Eisenmenger syndrome.  Among the patients with a previously closed septal defect, 30 had PAH (3%).  Ventricular septal defect (VSD) was the most frequent underlying defect (42%) among patients with PAH and a septal defect.  Female sex (Odds ratio=1.5, p=0.001) and sPAP (Odds ratio=0.04, p<0.001) were independently associated with a decreased functional class.  CONCLUSION:  PAH is common in adult patients with congenital heart disease.  In our registry the prevalence of PAH in septal defects is around 6%.  More than half of these patients have the Eisenmenger syndrome, which accounts for 1% of the total population in the CONCOR registry.  Whether the prevalence of PAH will decrease in the future as a result of early detection and intervention remains to be awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX_lSrZ52mf_IW7hznt0zpfW6udTcc2eZPOJijHMrPb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svgvF2htQ%253D%253D&md5=21ff12220d90b72ab10a01c12f14927d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2006.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2006.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DDuffels%26aufirst%3DM.G.J.%26aulast%3DEngelfriet%26aufirst%3DP.M.%26aulast%3DBerger%26aufirst%3DR.M.F.%26aulast%3Dvan%2BLoon%26aufirst%3DR.L.E.%26aulast%3DHoendermis%26aufirst%3DE.%26aulast%3DVriend%26aufirst%3DJ.W.J.%26aulast%3Dvan%2Bder%2BVelde%26aufirst%3DE.T.%26aulast%3DBresser%26aufirst%3DP.%26aulast%3DMulder%26aufirst%3DB.J.M.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520in%2520congenital%2520heart%2520disease%253A%2520an%2520epidemiologic%2520perspective%2520from%2520a%2520Dutch%2520registry%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2007%26volume%3D120%26spage%3D198%26epage%3D204%26doi%3D10.1016%2Fj.ijcard.2006.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, L.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.-C.</span></span> <span> </span><span class="NLM_article-title">Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1378/chest.10-2327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.10-2327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21330386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3MjjsVejtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2011&pages=301-309&author=R.+Zhangauthor=L.-Z.+Daiauthor=P.+Yuanauthor=X.+Jiangauthor=J.+Heauthor=W.-P.+Xieauthor=Z.-X.+Yuauthor=B.-X.+Wuauthor=L.+Panauthor=M.+Humbertauthor=Z.-C.+Jing&title=Survival+of+Chinese+patients+with+pulmonary+arterial+hypertension+in+the+modern+treatment+era&doi=10.1378%2Fchest.10-2327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era</span></div><div class="casAuthors">Zhang Rui; Dai Li-Zhi; Yuan Ping; Jiang Xin; He Jing; Xie Wei-Ping; Yu Zai-Xin; Wu Bing-Xiang; Pan Lei; Humbert Marc; Jing Zhi-Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">301-309</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In a previous study of Chinese patients with idiopathic pulmonary arterial hypertension (IPAH) in the nontargeted therapy era (defined as the time before 2006 when new pulmonary arterial hypertension-specific drugs were not available in China), we reported 1- and 3-year survival estimates of only 68% and 39%, respectively.  However, it is not yet known whether the survival of patients with pulmonary arterial hypertension is improved in the modern treatment era (defined in China as after 2006).  METHODS:  A retrospective cohort study was undertaken in 276 consecutive patients with newly diagnosed incident IPAH and connective tissue disease-related pulmonary arterial hypertension (CTDPAH) who were referred between 2007 and 2009.  Baseline characteristics and survival rates in the two groups were compared.  RESULTS:  The 1- and 3-year survival estimates were 92.1% and 75.1%, respectively, in patients with IPAH, and 85.4% and 53.6%, respectively, in patients with CTDPAH.  Patients with CTDPAH had a significantly lower mean pulmonary artery pressure, more pericardial effusion, and more severe impairment of the diffusion capacity of the lung for carbon monoxide than patients with IPAH.  A diagnosis of CTDPAH, World Health Organization functional class III or IV, single-breath diffusion capacity of the lung for carbon monoxide < 80% predicted, and the presence of pericardial effusion were independent predictors of mortality.  The 1- and 3-year survival rates of male patients were 93.5% and 77.5%, respectively, in those with IPAH, and 71.1% and 47.4%, respectively, in those with CTDPAH.  CONCLUSIONS:  The survival rates of patients with pulmonary arterial hypertension have improved in China in the modern treatment era, despite the high costs of treatment and financial constraints.  However, the survival rates of patients with CTDPAH are inferior to those of patients with IPAH.  Our study also indicates poorer survival rates in male patients with CTDPAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlooHjtlZHBczK395ZObgVfW6udTcc2eZPOJijHMrPb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjjsVejtA%253D%253D&md5=e76725c02d6e5e4b04ae7e7f38a4093e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1378%2Fchest.10-2327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.10-2327%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DDai%26aufirst%3DL.-Z.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DW.-P.%26aulast%3DYu%26aufirst%3DZ.-X.%26aulast%3DWu%26aufirst%3DB.-X.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DJing%26aufirst%3DZ.-C.%26atitle%3DSurvival%2520of%2520Chinese%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520in%2520the%2520modern%2520treatment%2520era%26jtitle%3DChest%26date%3D2011%26volume%3D140%26spage%3D301%26epage%3D309%26doi%3D10.1378%2Fchest.10-2327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thenappan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomberg-Maitland, M.</span></span> <span> </span><span class="NLM_article-title">A USA-based registry for pulmonary arterial hypertension: 1982–2006</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1103</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1183/09031936.00042107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00042107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17804449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2sjhs1aisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=1103-1110&author=T.+Thenappanauthor=S.+J.+Shahauthor=S.+Richauthor=M.+Gomberg-Maitland&title=A+USA-based+registry+for+pulmonary+arterial+hypertension%3A+1982%E2%80%932006&doi=10.1183%2F09031936.00042107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A USA-based registry for pulmonary arterial hypertension: 1982-2006</span></div><div class="casAuthors">Thenappan T; Shah S J; Rich S; Gomberg-Maitland M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1103-10</span>
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    </div><div class="casAbstract">The aim of this study was to define the epidemiology of World Health Organization (WHO) Group I pulmonary arterial hypertension (PAH) in a large referral centre in the USA.  The Pulmonary Hypertension Connection registry, initiated in 2004, evaluated all patients in a single USA practice from 1982-2006.  For comparison, the authors divided the group by incident versus prevalent cohorts, aetiology and by treatment era.  In total, 578 patients (77% female) aged 48+/-14 yrs were entered.  Of these, 80% had class III or IV symptoms.  Over time, connective tissue disease-associated PAH increased, while referrals for HIV remained low.  One-third of patients were referred on calcium channel blocker therapy even though only 4.6% had an acute response to vasodilator challenge.  When compared by treatment era, there were no differences in the severity of PAH.  However, survival had improved over time, with a 1-yr survival of 85% in the incident cohort.  In the USA, pulmonary arterial hypertension patients are still referred to tertiary centres too late.  Referral of connective tissue disease is increasing, while referral of HIV remains low.  Inappropriate calcium channel blocker treatment is common.  Survival rates have increased but remain low suggesting that prognosis is improving but PAH is still a progressive, fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI4aZiQhHccedfST00W0BcfW6udTcc2eZPOJijHMrPb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjhs1aisg%253D%253D&md5=4339a0d226727687947e35be0a8eb78e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1183%2F09031936.00042107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00042107%26sid%3Dliteratum%253Aachs%26aulast%3DThenappan%26aufirst%3DT.%26aulast%3DShah%26aufirst%3DS.%2BJ.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26atitle%3DA%2520USA-based%2520registry%2520for%2520pulmonary%2520arterial%2520hypertension%253A%25201982%25E2%2580%25932006%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2007%26volume%3D30%26spage%3D1103%26epage%3D1110%26doi%3D10.1183%2F09031936.00042107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alves, J. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavilanes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jardim, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, C. J. C. D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dias, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morinaga, L. T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">501</span>, <span class="refDoi"> DOI: 10.1378/chest.14-1036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.14-1036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25317567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2M3gsFKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=495-501&author=J.+L.+Alvesauthor=F.+Gavilanesauthor=C.+Jardimauthor=C.+J.+C.+D.+S.+Fernandesauthor=B.+Diasauthor=S.+Hoetteauthor=L.+T.+K.+Morinagaauthor=M.+Humbertauthor=R.+Souza&title=Pulmonary+arterial+hypertension+in+the+southern+hemisphere%3A+results+from+a+registry+of+incident+Brazilian+cases&doi=10.1378%2Fchest.14-1036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary arterial hypertension in the southern hemisphere: results from a registry of incident Brazilian cases</span></div><div class="casAuthors">Alves Jose Leonidas Jr; Gavilanes Francisca; Jardim Carlos; Fernandes Caio Julio Cesar Dos Santos; Dias Bruno; Hoette Susana; Morinaga Luciana Tamie Kato; Humbert Marc; Souza Rogerio</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">495-501</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary arterial hypertension (PAH) is a rare and ultimately fatal disorder of the pulmonary vasculature.  There is increasing interest in the worldwide characteristics of patients with PAH, although data coming from the Southern Hemisphere remain scarce.  The objective of this study was to describe a cohort of incident patients with PAH from a large reference center in Brazil.  METHODS:  All consecutive patients who received a diagnosis of PAH by right-sided heart catheterization between 2008 and 2013 were included in the study.  RESULTS:  A total of 178 patients with newly diagnosed PAH were enrolled in the study (mean age, 46 years; female/male ratio, 3.3:1; 45.5% in New York Heart Association functional class III or IV).  Idiopathic PAH (IPAH), connective tissue disease (CTD), and schistosomiasis-associated PAH (Sch-PAH) accounted for 28.7%, 25.8%, and 19.7% of all cases, respectively.  The patients were treated with phosphodiesterase type 5 inhibitors (66%), endothelin receptor antagonists (27%), or a combination of both (5%).  For the PAH group as a whole, the estimated survival rate 3 years after diagnosis was 73.9%.  The prognosis for the patients with CTD was worse than that for the patients with IPAH and Sch-PAH (P = .03).  CONCLUSIONS:  The distribution of PAH causes and the baseline characteristics in our registry clearly differ from the previously published European and US-based registries.  These differences highlight the importance of regional registries and also raise questions regarding the need to better account for such differences in future clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSQ_TzsVWqSnEGy1nwu7K2mfW6udTcc2eaAj4azf_RQs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M3gsFKgtQ%253D%253D&md5=aa653375cc31c01b00c7609b5d77ebc6</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1378%2Fchest.14-1036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.14-1036%26sid%3Dliteratum%253Aachs%26aulast%3DAlves%26aufirst%3DJ.%2BL.%26aulast%3DGavilanes%26aufirst%3DF.%26aulast%3DJardim%26aufirst%3DC.%26aulast%3DFernandes%26aufirst%3DC.%2BJ.%2BC.%2BD.%2BS.%26aulast%3DDias%26aufirst%3DB.%26aulast%3DHoette%26aufirst%3DS.%26aulast%3DMorinaga%26aufirst%3DL.%2BT.%2BK.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSouza%26aufirst%3DR.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520in%2520the%2520southern%2520hemisphere%253A%2520results%2520from%2520a%2520registry%2520of%2520incident%2520Brazilian%2520cases%26jtitle%3DChest%26date%3D2015%26volume%3D147%26spage%3D495%26epage%3D501%26doi%3D10.1378%2Fchest.14-1036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaici, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sztrymf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span> <span> </span><span class="NLM_article-title">Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">73</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-11-73</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-11-73" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20534176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3cnltlCjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=73&author=B.+Girerdauthor=D.+Montaniauthor=M.+Eyriesauthor=A.+Yaiciauthor=B.+Sztrymfauthor=F.+Couletauthor=O.+Sitbonauthor=G.+Simonneauauthor=F.+Soubrierauthor=M.+Humbert&title=Absence+of+influence+of+gender+and+BMPR2+mutation+type+on+clinical+phenotypes+of+pulmonary+arterial+hypertension&doi=10.1186%2F1465-9921-11-73"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension</span></div><div class="casAuthors">Girerd Barbara; Montani David; Eyries Melanie; Yaici Azzedine; Sztrymf Benjamin; Coulet Florence; Sitbon Olivier; Simonneau Gerald; Soubrier Florent; Humbert Marc</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Previous studies indicate that patients with pulmonary arterial hypertension (PAH) carrying a mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene, develop the disease 10 years earlier than non-carriers, and have a more severe hemodynamic compromise at diagnosis.  A recent report has suggested that this may only be the case for females and that patients with missense mutations in BMPR2 gene have more severe disease than patients with truncating mutations.  METHODS:  We reviewed data from all patients with PAH considered as idiopathic and patients with a family history of PAH, who underwent genetic counselling in the French PAH network between January, 1st 2004 and April, 1st 2010.  We compared clinical, functional, and hemodynamic characteristics between carriers and non-carriers of a BMPR2 mutation, according to gender or BMPR2 mutation type.  RESULTS:  PAH patients carrying a BMPR2 mutation (n = 115) were significantly younger at diagnosis than non-carriers (n = 267) (35.8 +/- 15.4 and 47.5 +/- 16.2 respectively, p < 0.0001).  The presence of a BMPR2 mutation was associated with a younger age at diagnosis in females (36.4 +/- 14.9 in BMPR2 mutation carriers and 47.4 +/- 15.8 in non-carriers, p < 0.0001), and males (34.6 +/- 16.8 in BMPR2 mutation carriers and 47.8 +/- 17.1 in non-carriers, p < 0.0001).  BMPR2 mutation carriers had a more severe hemodynamic compromise at diagnosis, but this was not influenced by gender.  No differences in survival and time to death or lung transplantation were found in male and female PAH patients carrying a BMPR2 mutation.  No differences were observed in clinical outcomes according to the type of BMPR2 mutations (missense, truncating, large rearrangement or splice defect).  CONCLUSION:  When compared to non-carriers, BMPR2 mutation carriers from the French PAH network are younger at diagnosis and present with a more severe hemodynamic compromise, irrespective of gender.  Moreover, BMPR2 mutation type had no influence on clinical phenotypes in our patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRS3xCW_uwW7FU0A1HOshhfW6udTcc2eaAj4azf_RQs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnltlCjtg%253D%253D&md5=fb95b84821fb87adddc23018d4e56f7f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-11-73&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-11-73%26sid%3Dliteratum%253Aachs%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DEyries%26aufirst%3DM.%26aulast%3DYaici%26aufirst%3DA.%26aulast%3DSztrymf%26aufirst%3DB.%26aulast%3DCoulet%26aufirst%3DF.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DAbsence%2520of%2520influence%2520of%2520gender%2520and%2520BMPR2%2520mutation%2520type%2520on%2520clinical%2520phenotypes%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DRespir.%2520Res.%26date%3D2010%26volume%3D11%26spage%3D73%26doi%3D10.1186%2F1465-9921-11-73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ventetuolo, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praestgaard, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palevsky, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halpern, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span> <span> </span><span class="NLM_article-title">Sex and haemodynamics in pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1183/09031936.00027613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00027613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23949961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3sbgsFCrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=523-530&author=C.+E.+Ventetuoloauthor=A.+Praestgaardauthor=H.+I.+Palevskyauthor=J.+R.+Klingerauthor=S.+D.+Halpernauthor=S.+M.+Kawut&title=Sex+and+haemodynamics+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.00027613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Sex and haemodynamics in pulmonary arterial hypertension</span></div><div class="casAuthors">Ventetuolo Corey E; Praestgaard Amy; Palevsky Harold I; Klinger James R; Halpern Scott D; Kawut Steven M</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">523-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Female sex is a risk factor for pulmonary arterial hypertension (PAH), yet females have better survival than males.  We sought to determine if sex was associated with baseline haemodynamics in subjects with PAH, and whether age modified these relationships.  We conducted a pooled analysis from 11 randomised trials submitted to the US Food and Drug Administration.  The study sample included 1211 subjects with idiopathic PAH, 25% of whom were males, and 489 subjects with connective tissue disease-associated PAH, 13% of whom were males.  After multivariable adjustment, right atrial pressure was 1.36 mmHg higher (95% CI 0.44-2.27, p=0.004), cardiac index was -0.14 L · min(-1) · m(-2) lower (95% CI -0.23-0.04, p=0.01) and pulmonary vascular resistance was 1.23 Wood units higher (95% CI 0.18-2.27, p=0.02) in males compared with females.  Younger males had 5.43 mmHg (95% CI 2.20-8.66, p=0.001) higher mean pulmonary arterial pressures than younger females, but these relationships were attenuated after age 45 years.  In the subgroup of connective tissue disease-associated PAH, males may have had higher right atrial pressure.  These findings implicate age as a modifier and provide further evidence of sexual dimorphism in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIxZz-_QwTccvLc4ARHEmzfW6udTcc2ea3Ctow7JfTrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbgsFCrtA%253D%253D&md5=e3f78e675238be6fdadf7b750785e257</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1183%2F09031936.00027613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00027613%26sid%3Dliteratum%253Aachs%26aulast%3DVentetuolo%26aufirst%3DC.%2BE.%26aulast%3DPraestgaard%26aufirst%3DA.%26aulast%3DPalevsky%26aufirst%3DH.%2BI.%26aulast%3DKlinger%26aufirst%3DJ.%2BR.%26aulast%3DHalpern%26aufirst%3DS.%2BD.%26aulast%3DKawut%26aufirst%3DS.%2BM.%26atitle%3DSex%2520and%2520haemodynamics%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D523%26epage%3D530%26doi%3D10.1183%2F09031936.00027613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickelberg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraci, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanaoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembath, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span> <span> </span><span class="NLM_article-title">Genetics and genomics of pulmonary arterial hypertension</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">S32</span>– <span class="NLM_lpage">S42</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2009.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jacc.2009.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19555857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVOks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=S32-S42&author=R.+D.+Machadoauthor=O.+Eickelbergauthor=C.+G.+Elliottauthor=M.+W.+Geraciauthor=M.+Hanaokaauthor=J.+E.+Loydauthor=J.+H.+Newmanauthor=J.+A.+Phillipsauthor=F.+Soubrierauthor=R.+C.+Trembathauthor=W.+K.+Chung&title=Genetics+and+genomics+of+pulmonary+arterial+hypertension&doi=10.1016%2Fj.jacc.2009.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Genetics and genomics of pulmonary arterial hypertension</span></div><div class="casAuthors">Machado, Rajiv D.; Eickelberg, Oliver; Elliott, C. Gregory; Geraci, Mark W.; Hanaoka, Masayuki; Loyd, James E.; Newman, John H.; Phillips, John A., III; Soubrier, Florent; Trembath, Richard C.; Chung, Wendy K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1, Suppl. S</span>),
    <span class="NLM_cas:pages">S32-S42</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Pulmonary arterial hypertension (PAH) is a rare disorder that may be hereditable (HPAH), idiopathic (IPAH), or assocd. with either drug-toxin exposures or other medical conditions.  Familial cases have long been recognized and are usually due to mutations in the bone morphogenetic protein receptor type 2 gene (BMPR2), or, much less commonly, 2 other members of the transforming growth factor-β superfamily, activin-like kinase-type 1 (ALK1) and endoglin (ENG), which are assocd. with hereditary hemorrhagic telangiectasia.  In addn., approx. 20% of patients with IPAH carry mutations in BMPR2.  We provide a summary of BMPR2 mutations assocd. with HPAH, most of which are unique to each family and are presumed to result in loss of function.  We review the finding of missense variants and variants of unknown significance in BMPR2 in IPAH/HPAH, fenfluramine exposure, and PAH assocd. with congenital heart disease.  Clin. testing for BMPR2 mutations is available and may be offered to HPAH and IPAH patients but should be preceded by genetic counseling, since lifetime penetrance is only 10% to 20%, and there are currently no known effective preventative measures.  Identification of a familial mutation can be valuable in reproductive planning and identifying family members who are not mutation carriers and thus will not require lifelong surveillance.  With advances in genomic technol. and with international collaborative efforts, genome-wide assocn. studies will be conducted to identify addnl. genes for HPAH, genetic modifiers for BMPR2 penetrance and genetic susceptibility to IPAH.  In addn., collaborative studies of BMPR2 mutation carriers should enable identification of environmental modifiers, biomarkers for disease development and progression, and surrogate markers for efficacy end points in clin. drug development, thereby providing an invaluable resource for trials of PAH prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowGr7nzbP5HbVg90H21EOLACvtfcHk0ljxHBxqh-89vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVOks7k%253D&md5=e1f7082de0347dec4a97b2767a53fb5b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2009.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2009.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DMachado%26aufirst%3DR.%2BD.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DElliott%26aufirst%3DC.%2BG.%26aulast%3DGeraci%26aufirst%3DM.%2BW.%26aulast%3DHanaoka%26aufirst%3DM.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26aulast%3DPhillips%26aufirst%3DJ.%2BA.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26aulast%3DChung%26aufirst%3DW.%2BK.%26atitle%3DGenetics%2520and%2520genomics%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2009%26volume%3D54%26spage%3DS32%26epage%3DS42%26doi%3D10.1016%2Fj.jacc.2009.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman-Campos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyries, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tregouet, D.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borczuk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span> <span> </span><span class="NLM_article-title">A novel channelopathy in pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1211097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1211097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23883380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=351-361&author=L.+Maauthor=D.+Roman-Camposauthor=E.+D.+Austinauthor=M.+Eyriesauthor=K.+S.+Sampsonauthor=F.+Soubrierauthor=M.+Germainauthor=D.-A.+Tregouetauthor=A.+Borczukauthor=E.+B.+Rosenzweigauthor=B.+Girerdauthor=D.+Montaniauthor=M.+Humbertauthor=J.+E.+Loydauthor=R.+S.+Kassauthor=W.+K.+Chung&title=A+novel+channelopathy+in+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1211097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A novel channelopathy in pulmonary arterial hypertension</span></div><div class="casAuthors">Ma, Lijiang; Roman-Campos, Danilo; Austin, Eric D.; Eyries, Melanie; Sampson, Kevin S.; Soubrier, Florent; Germain, Marine; Tregouet, David-Alexandre; Borczuk, Alain; Rosenzweig, Erika Berman; Girerd, Barbara; Montani, David; Humbert, Marc; Loyd, James E.; Kass, Robert S.; Chung, Wendy K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-361</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Pulmonary arterial hypertension is a devastating disease with high mortality.  Familial cases of pulmonary arterial hypertension are usually characterized by autosomal dominant transmission with reduced penetrance, and some familial cases have unknown genetic causes.  METHODS We studied a family in which multiple members had pulmonary arterial hypertension without identifiable mutations in any of the genes known to be assocd. with the disease, including BMPR2, ALK1, ENG, SMAD9, and CAV1.  Three family members were studied with whole-exome sequencing.  Addnl. patients with familial or idiopathic pulmonary arterial hypertension were screened for the mutations in the gene that was identified on whole-exome sequencing.  All variants were expressed in COS-7 cells, and channel function was studied by means of patch-clamp anal.  RESULTS We identified a novel heterozygous missense variant c.608 G→A (G203D) in KCNK3 (the gene encoding potassium channel subfamily K, member 3) as a disease-causing candidate gene in the family.  Five addnl. heterozygous missense variants in KCNK3 were independently identified in 92 unrelated patients with familial pulmonary arterial hypertension and 230 patients with idiopathic pulmonary arterial hypertension.  We used in silico bioinformatic tools to predict that all six novel variants would be damaging.  Electrophysiol. studies of the channel indicated that all these missense mutations resulted in loss of function, and the redn. in the potassium-channel current was remedied by the application of the phospholipase inhibitor ONO-RS-082.  CONCLUSIONS Our study identified the assocn. of a novel gene, KCNK3, with familial and idiopathic pulmonary arterial hypertension.  Mutations in this gene produced reduced potassium-channel current, which was successfully remedied by pharmacol. manipulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUvoY6Pc_sj7Vg90H21EOLACvtfcHk0ljxHBxqh-89vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7E&md5=497004fe0de551415ca15fbeb9ebdaf6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1211097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1211097%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DRoman-Campos%26aufirst%3DD.%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DEyries%26aufirst%3DM.%26aulast%3DSampson%26aufirst%3DK.%2BS.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DGermain%26aufirst%3DM.%26aulast%3DTregouet%26aufirst%3DD.-A.%26aulast%3DBorczuk%26aufirst%3DA.%26aulast%3DRosenzweig%26aufirst%3DE.%2BB.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DKass%26aufirst%3DR.%2BS.%26aulast%3DChung%26aufirst%3DW.%2BK.%26atitle%3DA%2520novel%2520channelopathy%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D351%26epage%3D361%26doi%3D10.1056%2FNEJMoa1211097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, F.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.-C.</span></span> <span> </span><span class="NLM_article-title">Association of rare ptgis variants with susceptibility and pulmonary vascular response in patients with idiopathic pulmonary arterial hypertension</span>. <i>JAMA Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1001/jamacardio.2020.0479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1001%2Fjamacardio.2020.0479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=32236489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB383pvVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=677-684&author=X.-J.+Wangauthor=X.-Q.+Xuauthor=K.+Sunauthor=K.-Q.+Liuauthor=S.-Q.+Liauthor=X.+Jiangauthor=Q.-H.+Zhaoauthor=L.+Wangauthor=F.-H.+Pengauthor=J.+Yeauthor=Y.+Wuauthor=R.+Jiangauthor=J.+Zhangauthor=W.+Huangauthor=W.-B.+Weiauthor=Y.+Yanauthor=J.-H.+Liauthor=Q.-Q.+Liuauthor=S.+Liauthor=Y.+Wangauthor=S.-Y.+Zhangauthor=X.+Zhangauthor=Z.-C.+Jing&title=Association+of+rare+ptgis+variants+with+susceptibility+and+pulmonary+vascular+response+in+patients+with+idiopathic+pulmonary+arterial+hypertension&doi=10.1001%2Fjamacardio.2020.0479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Wang Xiao-Jian; Xu Xi-Qi; Sun Kai; Li Su-Qi; Jiang Xin; Peng Fu-Hua; Ye Jue; Wu Yan; Yan Yi; Li Jing-Hui; Liu Qian-Qian; Xu Xi-Qi; Sun Kai; Jiang Xin; Zhang Shu-Yang; Jing Zhi-Cheng; Liu Ke-Qiang; Zhang Xue; Zhao Qin-Hua; Wang Lan; Jiang Rui; Zhang Jin; Huang Wei; Wei Wen-Bin; Li Sheng; Wang Yong</div><div class="citationInfo"><span class="NLM_cas:title">JAMA cardiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-684</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Idiopathic pulmonary arterial hypertension (IPAH) is a fatal disease with high heritability; however, the bone morphogenetic protein receptor 2 (BMPR2) gene only accounts for 17% of IPAH.  The genetic basis of IPAH needs further investigation.  Objective:  To identify novel IPAH susceptibility genes other than BMPR2.  Design, Setting, and Participants:  This 2-stage, case-control genetic association study enrolled 230 patients with IPAH from 2 referral pulmonary hypertension centers in China.  Eligible patients had no BMPR2 variants and were compared with 968 healthy control participants.  Data were collected from January 1, 2000, to July 31, 2015, and analyzed from August 1, 2015, to May 30, 2018.  Exposures:  PTGIS rare variants.  Main Outcomes and Measures:  Whole-genome sequencing was performed to identify putative IPAH genes in a discovery cohort, with validation in an independent referral cohort.  Correlation of genotype and hemodynamic characteristics was then evaluated at baseline and after pulmonary vasodilator testing.  Functional assessments were conducted to analyze the effects of identified genetic variants on transcript splicing, enzymatic activity, and endothelial cell phenotypes.  Results:  Among 230 patients with IPAH (164 female [71.3%]; mean [SD] age, 34 [18] years), an enrichment of rare variants in a gene encoding prostacyclin synthase (PTGIS) was identified in the discovery cohort.  The association of PTGIS rare variants with IPAH was confirmed in the replication cohort.  In the combined data set, PTGIS rare variants were found in 14 of 230 cases (6.1%) and 8 of 968 controls (0.8%) (odds ratio, 7.8; 95% CI, 3.2-18.8; P = 5 × 10-6, logistic regression).  Compared with patients without PTGIS variants, inhaled iloprost induced a more significant decrease of pulmonary vascular resistance (difference in the least square mean, -21.7%; 95% CI, -31.4% to -12.0%; P < .001, linear regression model) and an increase of cardiac index (difference in the least square mean, 18.3%; 95% CI, 8.8%-27.8%; P < .001, linear regression model) in patients with PTGIS variants.  The minigene assay indicated that the c.521 + 1G>A variant resulted in aberrant messenger RNA transcripts.  The functional studies showed that the 2 missense rare variants (R252Q and A447T) resulted in a decrease in prostacyclin production and increased cell death of pulmonary microvascular endothelial cells.  Conclusions and Relevance:  This study identified 3 rare loss-of-function variants in the PTGIS gene from 2 independent cohorts with IPAH.  The genetic variants of PTGIS predispose pulmonary vascular responses to the iloprost stimulation.  These findings suggest that PTGIS variants may be involved in the pathogenesis of IPAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT15cswAg6LmP9pSBfyDvp7fW6udTcc2ebAECxsGGM0urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383pvVGnsA%253D%253D&md5=ac12399e5678f863f4fd54858328ad85</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjamacardio.2020.0479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamacardio.2020.0479%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-J.%26aulast%3DXu%26aufirst%3DX.-Q.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DK.-Q.%26aulast%3DLi%26aufirst%3DS.-Q.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DQ.-H.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DF.-H.%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DW.-B.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.-H.%26aulast%3DLiu%26aufirst%3DQ.-Q.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Y.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJing%26aufirst%3DZ.-C.%26atitle%3DAssociation%2520of%2520rare%2520ptgis%2520variants%2520with%2520susceptibility%2520and%2520pulmonary%2520vascular%2520response%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJAMA%2520Cardiol.%26date%3D2020%26volume%3D5%26spage%3D677%26epage%3D684%26doi%3D10.1001%2Fjamacardio.2020.0479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benza, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farber, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krichman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raskob, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wason, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldkircher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span> <span> </span><span class="NLM_article-title">The changing picture of patients with pulmonary arterial hypertension in the united states how reveal differs from historic and non-us contemporary registries</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1378/chest.10-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.10-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20558556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FptVOjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2011&pages=128-137&author=A.+E.+Frostauthor=D.+B.+Badeschauthor=R.+J.+Barstauthor=R.+L.+Benzaauthor=G.+Elliottauthor=H.+W.+Farberauthor=A.+Krichmanauthor=T.+G.+Liouauthor=G.+E.+Raskobauthor=P.+Wasonauthor=K.+Feldkircherauthor=M.+Turnerauthor=M.+D.+McGoon&title=The+changing+picture+of+patients+with+pulmonary+arterial+hypertension+in+the+united+states+how+reveal+differs+from+historic+and+non-us+contemporary+registries&doi=10.1378%2Fchest.10-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries</span></div><div class="casAuthors">Frost Adaani E; Badesch David B; Barst Robyn J; Benza Raymond L; Elliott C Gregory; Farber Harrison W; Krichman Abby; Liou Theodore G; Raskob Gary E; Wason Prieya; Feldkircher Kathleen; Turner Michelle; McGoon Michael D</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-37</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  REVEAL (The Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) provides current demographics of patients with group 1 pulmonary arterial hypertension (PAH) in the United States.  METHODS:  A total of 2,967 patients with PAH diagnosed based on right-sided heart catheterization were enrolled in REVEAL between March 2006 and September 2007.  Demographics from the REVEAL patient cohort and REVEAL subpopulations (matched by inclusion criteria to other registries) were compared with historic US registry data and other contemporary US and non-US national PAH registries by inclusion criteria, including the National Institutes of Health (NIH) PAH registry and the French PAH registry.  RESULTS:  REVEAL patients matched to NIH registry patients were older at diagnosis (mean ± SE, 44.9 ± 0.6 years vs 36.4 ± 1.1 years; difference, 8.5 ± 1.4; P < .001) and more likely to be women (78.7 ± 1.2% vs 63.1 ± 3.5%; P < .001).  REVEAL patients matched to French registry patients had similar age and severity at diagnosis, but REVEAL patients were more likely to be women (79.8 ± 0.8% vs 65.3 ± 1.8%; P < .001) and obese (BMI, ≥ 30 kg/m(2), 32.5 ± 1.0% vs 14.8 ± 1.4%; P < .001), whereas French patients were more likely to have HIV-associated PAH (6.2% vs 2.3%).  The female preponderance is similar to that in other US-based contemporary registries.  CONCLUSIONS:  At diagnosis, REVEAL patients were older than NIH registry patients and similar in age to patients enrolled in contemporary registries.  Compared with NIH and contemporary European and UK registries, there was a striking preponderance of women, and REVEAL patients were more likely to be obese.  These observations and the difference in HIV-associated PAH between REVEAL and other non-US contemporary registries warrant further investigation.  TRIAL REGISTRY:  ClinicalTrials.gov; No.: NCT00370214; URL: clinicaltrials.gov.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScBqtGyLoifAHqQV89nF-2fW6udTcc2ebAECxsGGM0urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FptVOjtg%253D%253D&md5=04d0a9732c3403a24c9937755e98c318</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1378%2Fchest.10-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.10-0075%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DBenza%26aufirst%3DR.%2BL.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DFarber%26aufirst%3DH.%2BW.%26aulast%3DKrichman%26aufirst%3DA.%26aulast%3DLiou%26aufirst%3DT.%2BG.%26aulast%3DRaskob%26aufirst%3DG.%2BE.%26aulast%3DWason%26aufirst%3DP.%26aulast%3DFeldkircher%26aufirst%3DK.%26aulast%3DTurner%26aufirst%3DM.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26atitle%3DThe%2520changing%2520picture%2520of%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520in%2520the%2520united%2520states%2520how%2520reveal%2520differs%2520from%2520historic%2520and%2520non-us%2520contemporary%2520registries%26jtitle%3DChest%26date%3D2011%26volume%3D139%26spage%3D128%26epage%3D137%26doi%3D10.1378%2Fchest.10-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huscher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittrow, D.</span></span> <span> </span><span class="NLM_article-title">Incidence and prevalence of pulmonary arterial hypertension in Germany</span>. <i>Int. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">612</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1016/j.ijcard.2015.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ijcard.2015.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26580339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28visl2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2016&pages=612-613&author=M.+M.+Hoeperauthor=D.+Huscherauthor=D.+Pittrow&title=Incidence+and+prevalence+of+pulmonary+arterial+hypertension+in+Germany&doi=10.1016%2Fj.ijcard.2015.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Incidence and prevalence of pulmonary arterial hypertension in Germany</span></div><div class="casAuthors">Hoeper Marius M; Huscher Doerte; Pittrow David</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612-3</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR25rnPVYfCKRFwe7cAcrfPfW6udTcc2eaZyth2Fyt2Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28visl2htw%253D%253D&md5=35bd403fa12ffb7bf70d0a98c419848c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ijcard.2015.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijcard.2015.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DHuscher%26aufirst%3DD.%26aulast%3DPittrow%26aufirst%3DD.%26atitle%3DIncidence%2520and%2520prevalence%2520of%2520pulmonary%2520arterial%2520hypertension%2520in%2520Germany%26jtitle%3DInt.%2520J.%2520Cardiol.%26date%3D2016%26volume%3D203%26spage%3D612%26epage%3D613%26doi%3D10.1016%2Fj.ijcard.2015.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farber, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of disease: pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1665</span>, <span class="refDoi"> DOI: 10.1056/NEJMra035488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMra035488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15483284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1Whtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2004&pages=1655-1665&author=H.+W.+Farberauthor=J.+Loscalzo&title=Mechanisms+of+disease%3A+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMra035488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary arterial hypertension</span></div><div class="casAuthors">Farber, Harrison W.; Loscalzo, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">351</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1655-1665</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review on the developments in the pathogenesis of pulmonary arterial hypertension, focusing on the mol. genetics and cell biol. of idiopathic arterial hypertension, and relating them to other forms of pulmonary arterial hypertension, when appropriate.  It discusses the environmental factors assocd. with an increased risk of the development of pulmonary arterial hypertension, namely hypoxia, anorexigens, and central nervous system stimulants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw8ugQZXSH5LVg90H21EOLACvtfcHk0lhG9-L3cVNk0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1Whtbg%253D&md5=2bd6ffc505f1fcb986b45031ebb0a1b9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMra035488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra035488%26sid%3Dliteratum%253Aachs%26aulast%3DFarber%26aufirst%3DH.%2BW.%26aulast%3DLoscalzo%26aufirst%3DJ.%26atitle%3DMechanisms%2520of%2520disease%253A%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D351%26spage%3D1655%26epage%3D1665%26doi%3D10.1056%2FNEJMra035488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of disease: pulmonary arterial hypertension</span>. <i>Nat. Rev. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1038/nrcardio.2011.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnrcardio.2011.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21691314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlymsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=443-455&author=R.+T.+Schermulyauthor=H.+A.+Ghofraniauthor=M.+R.+Wilkinsauthor=F.+Grimminger&title=Mechanisms+of+disease%3A+pulmonary+arterial+hypertension&doi=10.1038%2Fnrcardio.2011.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of disease: pulmonary arterial hypertension</span></div><div class="casAuthors">Schermuly, Ralph T.; Ghofrani, Hossein A.; Wilkins, Martin R.; Grimminger, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cardiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">443-455</span>CODEN:
                <span class="NLM_cas:coden">NRCAE6</span>;
        ISSN:<span class="NLM_cas:issn">1759-5002</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the past decade or so, our understanding of pulmonary arterial hypertension has undergone a paradigm shift.  In this article, Dr Schermuly and colleagues discuss the known mol. mechanisms of the pathogenesis of this disease, and highlight the mol. technologies that are currently being used to further our understanding of these disease processes.  Our understanding of, and approach to, pulmonary arterial hypertension has undergone a paradigm shift in the past decade.  Once a condition thought to be dominated by increased vasoconstrictor tone and thrombosis, pulmonary arterial hypertension is now seen as a vasculopathy in which structural changes driven by excessive vascular cell growth and inflammation, with recruitment and infiltration of circulating cells, play a major role.  Perturbations of a no. of mol. mechanisms have been described, including pathways involving growth factors, cytokines, metabolic signaling, elastases, and proteases, that may underlie the pathogenesis of the disease.  Elucidating their contribution to the pathophysiol. of pulmonary arterial hypertension could offer new drug targets.  The role of progenitor cells in vascular repair is also under active investigation.  The right ventricular response to increased pressure load is recognized as crit. to survival and the mol. mechanisms involved are attracting increasing interest.  The challenge now is to integrate this new knowledge and explore how it can be used to categorize patients by mol. phenotype and tailor treatment more effectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX9Zk8oAL1YLVg90H21EOLACvtfcHk0lhUvdXTRSbHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlymsb0%253D&md5=a7470d14839f757102531c233659dd2f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrcardio.2011.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrcardio.2011.87%26sid%3Dliteratum%253Aachs%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DMechanisms%2520of%2520disease%253A%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DNat.%2520Rev.%2520Cardiol.%26date%3D2011%26volume%3D8%26spage%3D443%26epage%3D455%26doi%3D10.1038%2Fnrcardio.2011.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1801887</span>, <span class="refDoi"> DOI: 10.1183/13993003.01887-2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01887-2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30545970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2019&pages=1801887&author=M.+Humbertauthor=C.+Guignabertauthor=S.+Bonnetauthor=P.+Dorfmullerauthor=J.+R.+Klingerauthor=M.+R.+Nicollsauthor=A.+J.+Olschewskiauthor=S.+S.+Pullamsettiauthor=R.+T.+Schermulyauthor=K.+R.+Stenmarkauthor=M.+Rabinovitch&title=Pathology+and+pathobiology+of+pulmonary+hypertension%3A+state+of+the+art+and+research+perspectives&doi=10.1183%2F13993003.01887-2018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives</span></div><div class="casAuthors">Humbert, Marc; Guignabert, Christophe; Bonnet, Sebastien; Dorfmuller, Peter; Klinger, James R.; Nicolls, Mark R.; Olschewski, Andrea J.; Pullamsetti, Soni S.; Schermuly, Ralph T.; Stenmark, Kurt R.; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1801887</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Clin. and translational research has played a major role in advancing our understanding of pulmonary hypertension (PH), including pulmonary arterial hypertension and other forms of PH with severe vascular remodeling (e.g. chronic thromboembolic PH and pulmonary veno-occlusive disease).  However, PH remains an incurable condition with a high mortality rate, underscoring the need for a better transfer of novel scientific knowledge into healthcare interventions.  Herein, we review recent findings in pathol. (with the questioning of the strict morphol. categorization of various forms of PH into pre- or post-capillary involvement of pulmonary vessels) and cellular mechanisms contributing to the onset and progression of pulmonary vascular remodeling assocd. with various forms of PH.  We also discuss ways to improve management and to support and optimize drug development in this research field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodZGkp56pYK7Vg90H21EOLACvtfcHk0lhUvdXTRSbHwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKns7zI&md5=96aa87aff972ffe284ddfebf843fad36</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1183%2F13993003.01887-2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01887-2018%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DBonnet%26aufirst%3DS.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DKlinger%26aufirst%3DJ.%2BR.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26aulast%3DOlschewski%26aufirst%3DA.%2BJ.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DPathology%2520and%2520pathobiology%2520of%2520pulmonary%2520hypertension%253A%2520state%2520of%2520the%2520art%2520and%2520research%2520perspectives%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2019%26volume%3D53%26spage%3D1801887%26doi%3D10.1183%2F13993003.01887-2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herve, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span> <span> </span><span class="NLM_article-title">Pathobiology of pulmonary hypertension - the role of platelets and thrombosis</span>. <i>Clin. Chest Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">475</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0272-5231%2805%2970283-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11590841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD3Mrktlajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=459-475&author=P.+Herveauthor=M.+Humbertauthor=O.+Sitbonauthor=F.+Parentauthor=H.+Nunesauthor=C.+Legalauthor=G.+Garciaauthor=G.+Simonneau&title=Pathobiology+of+pulmonary+hypertension+-+the+role+of+platelets+and+thrombosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for pulmonary arterial hypertension</span></div><div class="casAuthors">Humbert M; Nunes H; Sitbon O; Parent F; Herve P; Simonneau G</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in chest medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-75</span>
        ISSN:<span class="NLM_cas:issn">0272-5231</span>.
    </div><div class="casAbstract">The present limitations in knowledge of the potential risk factors for PPH undoubtedly are attributable to the facts that PPH is a rare disease with an unknown pathogenesis and lacking large case series.  Moreover, definite epidemiologic data are rare and ideally should be obtained from epidemiologic surveys such as large case-control studies.  The increased incidence of the disease in young women, the familial cases, the association with autoimmune disorders, and the recent discovery that mutation of the PPH1 gene may not be restricted to familial PPH support the hypothesis that the development of pulmonary hypertension likely implies an individual susceptibility or predisposition, which is probably genetically determined.  It is also now commonly believed that the development of pulmonary hypertension in some of these predisposed individuals could be hastened or precipitated by various expression factors (some of them yet unrecognized), such as ingestion of certain drugs or diets, portal hypertension, or HIV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI33BB09iiM1m8bhe6roZYfW6udTcc2eYaNW5l5aZZD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3Mrktlajsg%253D%253D&md5=5b560a445f9067aa98d577873305656f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0272-5231%2805%2970283-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0272-5231%252805%252970283-5%26sid%3Dliteratum%253Aachs%26aulast%3DHerve%26aufirst%3DP.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DParent%26aufirst%3DF.%26aulast%3DNunes%26aufirst%3DH.%26aulast%3DLegal%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DPathobiology%2520of%2520pulmonary%2520hypertension%2520-%2520the%2520role%2520of%2520platelets%2520and%2520thrombosis%26jtitle%3DClin.%2520Chest%2520Med.%26date%3D2001%26volume%3D22%26spage%3D459%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vane, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corin, R. E.</span></span> <span> </span><span class="NLM_article-title">Prostacyclin: a vascular mediator</span>. <i>Eur. J. Vasc. Endovasc. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">571</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1016/S1078-5884(03)00385-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS1078-5884%2803%2900385-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=14603414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD3srisVKgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=571-578&author=J.+Vaneauthor=R.+E.+Corin&title=Prostacyclin%3A+a+vascular+mediator&doi=10.1016%2FS1078-5884%2803%2900385-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prostacyclin: a vascular mediator</span></div><div class="casAuthors">Vane J; Corin R E</div><div class="citationInfo"><span class="NLM_cas:title">European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">571-8</span>
        ISSN:<span class="NLM_cas:issn">1078-5884</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRwGqFYbQqIpVQKX3ooHxWjfW6udTcc2eYaNW5l5aZZD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3srisVKgsQ%253D%253D&md5=26b71cbbf5b7f8812576433070f9cb82</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS1078-5884%2803%2900385-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1078-5884%252803%252900385-X%26sid%3Dliteratum%253Aachs%26aulast%3DVane%26aufirst%3DJ.%26aulast%3DCorin%26aufirst%3DR.%2BE.%26atitle%3DProstacyclin%253A%2520a%2520vascular%2520mediator%26jtitle%3DEur.%2520J.%2520Vasc.%2520Endovasc.%2520Surg.%26date%3D2003%26volume%3D26%26spage%3D571%26epage%3D578%26doi%3D10.1016%2FS1078-5884%2803%2900385-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyndman, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhaun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohan, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, J. J.</span></span> <span> </span><span class="NLM_article-title">Endothelin</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">418</span>, <span class="refDoi"> DOI: 10.1124/pr.115.011833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fpr.115.011833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26956245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28josFaltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=357-418&author=A.+P.+Davenportauthor=K.+A.+Hyndmanauthor=N.+Dhaunauthor=C.+Southanauthor=D.+E.+Kohanauthor=J.+S.+Pollockauthor=D.+M.+Pollockauthor=D.+J.+Webbauthor=J.+J.+Maguire&title=Endothelin&doi=10.1124%2Fpr.115.011833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin</span></div><div class="casAuthors">Davenport Anthony P; Hyndman Kelly A; Dhaun Neeraj; Southan Christopher; Kohan Donald E; Pollock Jennifer S; Pollock David M; Webb David J; Maguire Janet J</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">357-418</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The endothelins comprise three structurally similar 21-amino acid peptides.  Endothelin-1 and -2 activate two G-protein coupled receptors, ETA and ETB, with equal affinity, whereas endothelin-3 has a lower affinity for the ETA subtype.  Genes encoding the peptides are present only among vertebrates.  The ligand-receptor signaling pathway is a vertebrate innovation and may reflect the evolution of endothelin-1 as the most potent vasoconstrictor in the human cardiovascular system with remarkably long lasting action.  Highly selective peptide ETA and ETB antagonists and ETB agonists together with radiolabeled analogs have accurately delineated endothelin pharmacology in humans and animal models, although surprisingly no ETA agonist has been discovered.  ET antagonists (bosentan, ambrisentan) have revolutionized the treatment of pulmonary arterial hypertension, with the next generation of antagonists exhibiting improved efficacy (macitentan).  Clinical trials continue to explore new applications, particularly in renal failure and for reducing proteinuria in diabetic nephropathy.  Translational studies suggest a potential benefit of ETB agonists in chemotherapy and neuroprotection.  However, demonstrating clinical efficacy of combined inhibitors of the endothelin converting enzyme and neutral endopeptidase has proved elusive.  Over 28 genetic modifications have been made to the ET system in mice through global or cell-specific knockouts, knock ins, or alterations in gene expression of endothelin ligands or their target receptors.  These studies have identified key roles for the endothelin isoforms and new therapeutic targets in development, fluid-electrolyte homeostasis, and cardiovascular and neuronal function.  For the future, novel pharmacological strategies are emerging via small molecule epigenetic modulators, biologicals such as ETB monoclonal antibodies and the potential of signaling pathway biased agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT4KujB2a63gEodMGTatQ7LfW6udTcc2eYaNW5l5aZZD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28josFaltg%253D%253D&md5=9850fbcc0e84b749ce374f4ab885a11f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1124%2Fpr.115.011833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.115.011833%26sid%3Dliteratum%253Aachs%26aulast%3DDavenport%26aufirst%3DA.%2BP.%26aulast%3DHyndman%26aufirst%3DK.%2BA.%26aulast%3DDhaun%26aufirst%3DN.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DKohan%26aufirst%3DD.%2BE.%26aulast%3DPollock%26aufirst%3DJ.%2BS.%26aulast%3DPollock%26aufirst%3DD.%2BM.%26aulast%3DWebb%26aufirst%3DD.%2BJ.%26aulast%3DMaguire%26aufirst%3DJ.%2BJ.%26atitle%3DEndothelin%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D357%26epage%3D418%26doi%3D10.1124%2Fpr.115.011833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, R. M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrige, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moncada, S.</span></span> <span> </span><span class="NLM_article-title">Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor</span>. <i>Nature (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1038/327524a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F327524a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=3495737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL2sXktlCjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=1987&pages=524-526&author=R.+M.+J.+Palmerauthor=A.+G.+Ferrigeauthor=S.+Moncada&title=Nitric+oxide+release+accounts+for+the+biological+activity+of+endothelium-derived+relaxing+factor&doi=10.1038%2F327524a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor</span></div><div class="casAuthors">Palmer, R. M. J.; Ferrige, A. G.; Moncada, S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">6122</span>),
    <span class="NLM_cas:pages">524-6</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The release of endothelium-derived relaxing factor (EDRF) and NO from porcine aortic endothelial cells in culture was examd.  NO was detd. as the chemiluminescent product of its reaction with ozone.  The biol. activity of EDRF and of NO was measured by bioassay.  The relaxation of the bioassay tissues induced by EDRF was indistinguishable from that induced by NO.  Both substances were equally unstable.  Bradykinin caused concn.-dependent release of NO from the cells in amts. sufficient to account for the biol. activity of EDRF.  The relaxations induced by EDRF and NO were inhibited by Hb and enhanced by superoxide dismutase to a similar degree.  Thus, NO released from endothelial cells is indistinguishable from EDRF in terms of biol. activity, stability, and susceptibility to an inhibitor and to a potentiator.  EDRF and NO are probably identical.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1cVPcdhBb7Vg90H21EOLACvtfcHk0liO3LzYaBqYYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktlCjs70%253D&md5=6afcb0594f86da2a398d0b6b792a2d75</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2F327524a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F327524a0%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DR.%2BM.%2BJ.%26aulast%3DFerrige%26aufirst%3DA.%2BG.%26aulast%3DMoncada%26aufirst%3DS.%26atitle%3DNitric%2520oxide%2520release%2520accounts%2520for%2520the%2520biological%2520activity%2520of%2520endothelium-derived%2520relaxing%2520factor%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D1987%26volume%3D327%26spage%3D524%26epage%3D526%26doi%3D10.1038%2F327524a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuder, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cool, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geraci, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abman, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelkel, N. F.</span></span> <span> </span><span class="NLM_article-title">Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>159</i></span>,  <span class="NLM_fpage">1925</span>– <span class="NLM_lpage">1932</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.159.6.9804054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm.159.6.9804054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10351941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK1M3otVKmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=1999&pages=1925-1932&author=R.+M.+Tuderauthor=C.+D.+Coolauthor=M.+W.+Geraciauthor=J.+Wangauthor=S.+H.+Abmanauthor=L.+Wrightauthor=D.+Badeschauthor=N.+F.+Voelkel&title=Prostacyclin+synthase+expression+is+decreased+in+lungs+from+patients+with+severe+pulmonary+hypertension&doi=10.1164%2Fajrccm.159.6.9804054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension</span></div><div class="casAuthors">Tuder R M; Cool C D; Geraci M W; Wang J; Abman S H; Wright L; Badesch D; Voelkel N F</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1925-32</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Prostacyclin is a powerful vasodilator and inhibits platelet adhesion and cell growth.  We hypothesized that a decrease in expression of the critical enzyme PGI2 synthase (PGI2-S) in the lung may represent an important manifestation of pulmonary endothelial dysfunction in severe pulmonary hypertension (PH).  Immunohistochemistry and Western blot analysis were used to assess lung PGI2-S protein expression, and in situ hybridization was used to assess PGI2-S mRNA expression.  In the normal pulmonary circulation (n = 7), PGI2-S was expressed in 48% of small, 67% of medium, and 76% of large pulmonary arteries as assessed by immunohistochemistry.  PPH (n = 12), cirrhosis-associated (n = 4) and HIV-associated PH (n = 2) lungs exhibited a marked reduction in PGI2-S expression, involving all size ranges of pulmonary arteries.  Vessels with concentric lesions showed complete lack of PGI2-S expression.  Congenital heart (n = 4) and CREST (n = 2) cases exhibited a more variable immunohistological pattern of PGI2-S expression.  These results were complemented by in situ hybridization and Western blots of representative lung samples.  We conclude that the different sizes of the pulmonary arteries express PGI2-S differently and that the loss of expression of PGI2-S represents one of the phenotypic alterations present in the pulmonary endothelial cells in severe PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1Hv-dp9-W-tLIORRPd5lbfW6udTcc2eZbweYK_BIqbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M3otVKmsQ%253D%253D&md5=b127ae703c27e7f073b13ffc90463eda</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.159.6.9804054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.159.6.9804054%26sid%3Dliteratum%253Aachs%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DCool%26aufirst%3DC.%2BD.%26aulast%3DGeraci%26aufirst%3DM.%2BW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAbman%26aufirst%3DS.%2BH.%26aulast%3DWright%26aufirst%3DL.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DVoelkel%26aufirst%3DN.%2BF.%26atitle%3DProstacyclin%2520synthase%2520expression%2520is%2520decreased%2520in%2520lungs%2520from%2520patients%2520with%2520severe%2520pulmonary%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D159%26spage%3D1925%26epage%3D1932%26doi%3D10.1164%2Fajrccm.159.6.9804054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groves, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourge, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundage, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koerner, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uretsky, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jobsis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shortino, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, J. W.</span></span> <span> </span><span class="NLM_article-title">A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">296</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1056/NEJM199602013340504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJM199602013340504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=8532025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK28XhsVShs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=1996&pages=296-301&author=R.+J.+Barstauthor=L.+J.+Rubinauthor=W.+A.+Longauthor=M.+D.+McGoonauthor=S.+Richauthor=D.+B.+Badeschauthor=B.+M.+Grovesauthor=V.+F.+Tapsonauthor=R.+C.+Bourgeauthor=B.+H.+Brundageauthor=S.+K.+Koernerauthor=D.+Langlebenauthor=C.+A.+Kellerauthor=S.+Muraliauthor=B.+F.+Uretskyauthor=L.+M.+Claytonauthor=M.+M.+Jobsisauthor=S.+D.+Blackburnauthor=D.+Shortinoauthor=J.+W.+Crow&title=A+comparison+of+continuous+intravenous+epoprostenol+%28prostacyclin%29+with+conventional+therapy+for+primary+pulmonary+hypertension&doi=10.1056%2FNEJM199602013340504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension</span></div><div class="casAuthors">Barst, Robyn J.; Rubin, Lewis J.; Long, Walker A.; McGoon, Michael D.; Rich, Stuart; Badesch, David B.; Groves, Bertron M.; Tapson, Victor F.; Bourge, Robert C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">296-301</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension is a progressive disease for which no treatment has been shown in a prospective, randomized trial to improve survival.  The authors conducted a 12-wk prospective, randomized, multicenter open trial comparing the effects of the continuous i.v. infusion of epoprostenol (formerly called prostacyclin) plus conventional therapy with those of conventional therapy alone in 81 patients with severe primary pulmonary hypertension (New York Heart Assocn. functional class III or IV).  Exercise capacity was improved in the 41 patients treated with epoprostenol (median distance walked in six minutes, 362 m at 12 wk vs. 315 m at base line), but it decreased in the 40 patients treated with conventional therapy alone (204 m at 12 wk vs. 270 m at base line; for the comparison of the treatment groups).  Indexes of the quality of life were improved only in the epoprostenol group.  Hemodynamics improved at 12 wk in the epoprostenol-treated patients.  The changes in mean pulmonary-artery pressure for the epoprostenol and control groups were -8 % and +3 %, resp. (difference in mean change, -6.7 mm Hg; 95 % confidence interval, -10.7 to -2.6 mm Hg), and the mean changes in pulmonary vascular resistance for the epoprostenol and control groups were -21 % and +9 %, resp. (difference in mean change, -4.9 mm Hg per L per min; 95 % confidence interval, -7.6 to -2.3 mm Hg per L per min).  Eight patients died during the study, all of whom had been randomly assigned to conventional therapy.  Serious complications included four episodes of catheter-related sepsis and one thrombotic event.  As compared with conventional therapy, the continuous i.v. infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohxvdY8yCMD7Vg90H21EOLACvtfcHk0lhURX_j7gJHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhsVShs70%253D&md5=09eaf0c73350f23954e2c90a2a19a72a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1056%2FNEJM199602013340504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199602013340504%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DLong%26aufirst%3DW.%2BA.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DGroves%26aufirst%3DB.%2BM.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DBourge%26aufirst%3DR.%2BC.%26aulast%3DBrundage%26aufirst%3DB.%2BH.%26aulast%3DKoerner%26aufirst%3DS.%2BK.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DKeller%26aufirst%3DC.%2BA.%26aulast%3DMurali%26aufirst%3DS.%26aulast%3DUretsky%26aufirst%3DB.%2BF.%26aulast%3DClayton%26aufirst%3DL.%2BM.%26aulast%3DJobsis%26aufirst%3DM.%2BM.%26aulast%3DBlackburn%26aufirst%3DS.%2BD.%26aulast%3DShortino%26aufirst%3DD.%26aulast%3DCrow%26aufirst%3DJ.%2BW.%26atitle%3DA%2520comparison%2520of%2520continuous%2520intravenous%2520epoprostenol%2520%2528prostacyclin%2529%2520with%2520conventional%2520therapy%2520for%2520primary%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1996%26volume%3D334%26spage%3D296%26epage%3D301%26doi%3D10.1056%2FNEJM199602013340504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shillington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span> <span> </span><span class="NLM_article-title">Survival in primary pulmonary hypertension - the impact of epoprostenol therapy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000029100.82385.58</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.CIR.0000029100.82385.58" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12234951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVKksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2002&pages=1477-1482&author=V.+V.+McLaughlinauthor=A.+Shillingtonauthor=S.+Rich&title=Survival+in+primary+pulmonary+hypertension+-+the+impact+of+epoprostenol+therapy&doi=10.1161%2F01.CIR.0000029100.82385.58"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Survival in Primary Pulmonary Hypertension, The Impact of Epoprostenol Therapy</span></div><div class="casAuthors">McLaughlin, Vallerie V.; Shillington, Alicia; Rich, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1477-1482</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background - Primary pulmonary hypertension (PPH) is a severe and progressive disease.  Without treatment, the median survival is 2.8 yr, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 yr, resp.  Epoprostenol (i.v.) was the first Food and Drug Administration-approved therapy for PPH.  The long-term impact that epoprostenol has made on PPH remains to be defined.  Methods and Results - One hundred sixty-two consecutive patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 mo (median, 31 mo).  Data including functional class, exercise tolerance, and hemodynamics were recorded in a customized database.  Vital status was verified in each patient.  Obsd. survival with epoprostenol therapy at 1, 2, and 3 yr was 87.8%, 76.3%, and 62.8% and was significantly greater than the expected survival of 58.9%, 46.3%, and 35.4% based on historical data.  Baseline predictors of survival included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine.  Predictors of survival after the first year of therapy included functional class and improvement in exercise tolerance, cardiac index, and mean pulmonary artery pressure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLZq5WHeBbaLVg90H21EOLACvtfcHk0lhURX_j7gJHEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVKksb0%253D&md5=faea3dbfef7bf10076786f83c5ea94c4</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000029100.82385.58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000029100.82385.58%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DShillington%26aufirst%3DA.%26aulast%3DRich%26aufirst%3DS.%26atitle%3DSurvival%2520in%2520primary%2520pulmonary%2520hypertension%2520-%2520the%2520impact%2520of%2520epoprostenol%2520therapy%26jtitle%3DCirculation%26date%3D2002%26volume%3D106%26spage%3D1477%26epage%3D1482%26doi%3D10.1161%2F01.CIR.0000029100.82385.58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickolson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorbruggen, H.</span></span> <span> </span><span class="NLM_article-title">Prostacyclin-analogs</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1002/med.2610050102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fmed.2610050102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=3884930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL2MXhtVKgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1985&pages=1-53&author=R.+C.+Nickolsonauthor=M.+H.+Townauthor=H.+Vorbruggen&title=Prostacyclin-analogs&doi=10.1002%2Fmed.2610050102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Prostacyclin-analogs</span></div><div class="casAuthors">Nickolson, Robert C.; Town, Michael H.; Vorbrueggen, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-53</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    </div><div class="casAbstract">A review with 238 refs. is given on the chem. and biol. of new prostacyclin analogs.  Included is a summary of the biol., pharmacol., and chem. of natural prostacyclin  [35121-78-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQTiHFlSsubVg90H21EOLACvtfcHk0lidAqD6cONqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhtVKgsbo%253D&md5=966f023b425c68b7137bc7654845882d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fmed.2610050102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.2610050102%26sid%3Dliteratum%253Aachs%26aulast%3DNickolson%26aufirst%3DR.%2BC.%26aulast%3DTown%26aufirst%3DM.%2BH.%26aulast%3DVorbruggen%26aufirst%3DH.%26atitle%3DProstacyclin-analogs%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1985%26volume%3D5%26spage%3D1%26epage%3D53%26doi%3D10.1002%2Fmed.2610050102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassard, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity-relationships associated with 3,4,5-triphenyl-1h-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1021/jm00080a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00080a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=389-397&author=N.+A.+Meanwellauthor=M.+J.+Rosenfeldauthor=J.+J.+K.+Wrightauthor=C.+L.+Brassardauthor=J.+O.+Buchananauthor=M.+E.+Federiciauthor=J.+S.+Flemingauthor=S.+M.+Seiler&title=Structure-activity-relationships+associated+with+3%2C4%2C5-triphenyl-1h-pyrazole-1-nonanoic+acid%2C+a+nonprostanoid+prostacyclin+mimetic&doi=10.1021%2Fjm00080a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span></div><div class="casAuthors">Meanwell, Nicholas A.; Rosenfeld, Michael J.; Wright, J. J. Kim; Brassard, Catherine L.; Buchanan, John O.; Federici, Marianne E.; Fleming, J. Stuart; Seiler, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-97</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of phenylated pyrazolealkanoic acids, e.g., I (R = (CH2)nCO2H, n = 5-10, R1, R3 = H, Ph, R2 = Ph, PhCH2, Et; R = (CH2)6XCH2CO2H, X = O, S, S(O), SO2, R1 = R2 = R3 = Ph) and related derivs. were prepd. as inhibitors of ADP-induced human platelet aggregation.  3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (II), with an IC50 of 0.4 μM, was the most potent inhibitor.  Biochem. studies detd. that II increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concn.-dependent fashion.  Displacement of [3H]iloprost by II from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biol. action.  Structure-activity studies demonstrated that the min. structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an ω-alkanoic acid side chain 8 or 9 atoms long.  Potency depended upon both side-chain length and its topol. relationship with the two Ph rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU40YZ6EI6OrVg90H21EOLACvtfcHk0lidAqD6cONqQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D&md5=00f2e4d0e07a45ebf9ad206a0c3c2de2</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm00080a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00080a028%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRosenfeld%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%2BK.%26aulast%3DBrassard%26aufirst%3DC.%2BL.%26aulast%3DBuchanan%26aufirst%3DJ.%2BO.%26aulast%3DFederici%26aufirst%3DM.%2BE.%26aulast%3DFleming%26aufirst%3DJ.%2BS.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3DStructure-activity-relationships%2520associated%2520with%25203%252C4%252C5-triphenyl-1h-pyrazole-1-nonanoic%2520acid%252C%2520a%2520nonprostanoid%2520prostacyclin%2520mimetic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D389%26epage%3D397%26doi%3D10.1021%2Fjm00080a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Higenbottam, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh-Xaun, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremona, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akamine, S.</span></span> <span> </span><span class="NLM_article-title">Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost</span>. <i>Heart</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1136/hrt.79.2.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1136%2Fhrt.79.2.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=9538312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK1c7pvFWisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1998&pages=175-179&author=T.+W.+Higenbottamauthor=A.+Y.+Buttauthor=A.+T.+Dinh-Xaunauthor=M.+Takaoauthor=G.+Cremonaauthor=S.+Akamine&title=Treatment+of+pulmonary+hypertension+with+the+continuous+infusion+of+a+prostacyclin+analogue%2C+iloprost&doi=10.1136%2Fhrt.79.2.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost</span></div><div class="casAuthors">Higenbottam T W; Butt A Y; Dinh-Xaun A T; Takao M; Cremona G; Akamine S</div><div class="citationInfo"><span class="NLM_cas:title">Heart (British Cardiac Society)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">175-9</span>
        ISSN:<span class="NLM_cas:issn">1355-6037</span>.
    </div><div class="casAbstract">OBJECTIVE:  To compare prostacyclin with an analogue, iloprost, in treatment of severe pulmonary hypertension.  PATIENTS:  Eight patients with severe pulmonary hypertension: primary in five, thromboembolic pulmonary hypertension in three.  METHODS:  All patients underwent right heart catheterisation.  Mean (SEM) right atrial pressure was 9.9 (2.2) mm Hg, mean pulmonary artery pressure 67.4 (3.0) mm Hg, cardiac index 1.75 (0.13) l/min/m2 and mixed venous oxygen saturation 59.1(3.1)%.  Continuous intravenous epoprostenol (prostacyclin, PGI2) or iloprost was given for phase I (three to six weeks); the patients were then crossed over to receive the alternate drug in an equivalent phase II.  MAIN OUTCOME MEASURES:  Exercise tolerance was measured at baseline and at the end of phase I and II with a 12 minute walk; distance covered, rest period, percentage drop in arterial oxygen saturation (delta Sao2%) and percentage rise in heart rate (delta HR%).  RESULTS:  Walking distance covered rose from (mean (SEM)) 407.5 (73) to 591 (46) m with PGI2 (p = 0.004) and to 602.5 (60) m while on iloprost (p = 0.008).  Rest period decreased from 192 (73) seconds at baseline to 16 (16) seconds with PGI2 (p = 0.01) and to 58 (34) seconds with iloprost (p = 0.008).  Delta HR% was 37.5(6)% at baseline, 35(3)% on PGI2, and 24(6)% on iloprost (p = 0.04).  CONCLUSIONS:  Both intravenous PGI2 and iloprost caused significant improvement in exercise tolerance.  Iloprost offers an alternative to PGI2 treatment of severe pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT888cCbuZDlPtos8R3JUhXfW6udTcc2ebUv6cIRgJNOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7pvFWisQ%253D%253D&md5=0cd839a9b8e72741462cbe5b5f3c9b7e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1136%2Fhrt.79.2.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fhrt.79.2.175%26sid%3Dliteratum%253Aachs%26aulast%3DHigenbottam%26aufirst%3DT.%2BW.%26aulast%3DButt%26aufirst%3DA.%2BY.%26aulast%3DDinh-Xaun%26aufirst%3DA.%2BT.%26aulast%3DTakao%26aufirst%3DM.%26aulast%3DCremona%26aufirst%3DG.%26aulast%3DAkamine%26aufirst%3DS.%26atitle%3DTreatment%2520of%2520pulmonary%2520hypertension%2520with%2520the%2520continuous%2520infusion%2520of%2520a%2520prostacyclin%2520analogue%252C%2520iloprost%26jtitle%3DHeart%26date%3D1998%26volume%3D79%26spage%3D175%26epage%3D179%26doi%3D10.1136%2Fhrt.79.2.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higenbottam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikkho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiely, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corris, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Sanchez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedentop, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span> <span> </span><span class="NLM_article-title">Inhaled iloprost for severe pulmonary hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">322</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa020204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12151469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XlslWqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=322-329&author=H.+Olschewskiauthor=G.+Simonneauauthor=N.+Galieauthor=T.+Higenbottamauthor=R.+Naeijeauthor=L.+J.+Rubinauthor=S.+Nikkhoauthor=R.+Speichauthor=M.+M.+Hoeperauthor=J.+Behrauthor=J.+Winklerauthor=O.+Sitbonauthor=W.+Popovauthor=H.+A.+Ghofraniauthor=A.+Manesauthor=D.+G.+Kielyauthor=R.+Ewertauthor=A.+Meyerauthor=P.+A.+Corrisauthor=M.+Delcroixauthor=M.+Gomez-Sanchezauthor=H.+Siedentopauthor=W.+Seeger&title=Inhaled+iloprost+for+severe+pulmonary+hypertension&doi=10.1056%2FNEJMoa020204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled iloprost for severe pulmonary hypertension</span></div><div class="casAuthors">Olschewski, Horst; Simonneau, Gerald; Galie, Nazzareno; Higenbottam, Timothy; Naeije, Robert; Rubin, Lewis J.; Nikkho, Syliva; Speich, Rudolf; Hoeper, Marius M.; Behr, Juergen; Winkler, Joerg; Sitbon, Olivier; Popov, Wladimir; Ghofrani, H. Ardeschir; Manes, Alessandra; Kiely, David G.; Ewert, Ralph; Meyer, Andreas; Corris, Paul A.; Delcroix, Marion; Gomez-Sanchez, Miguel; Siedentop, Harald; Seeger, Werner; Fabel, H.; Spiekerkoetter, E.; Grimminger, F.; Wiedemann, R.; Leuchte, H.; Aquilina, M.; Amsha, K.; Lawson, R.; Alcock, R.; Pforte, A.; Schauer, J.; Budts, W.; Escribano, P.; Lazaro, M.; Huchalla, E.; Borst, M.; Black, C. M.; Bravo, C.; Roman, A.; Monforte, V.; Peacock, A.; Boonstra, A.; Fracchia, C.; Marini, C.; Nicod, L.; Pepke-Zaba, J.; Sybrecht, G.; Wilkens, H.; Torbicki, A.; Diot, P.; Mota, T.; Pennaforte, J. L.; Perez, T.; Radenne, F.; Pison, C.; Vachiery, J. L.; Hallgren, P.; Kleber, F.-X.; Providencia, L.; Ribeiro, V. R. G.; Soler, M.; Stricker, H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Uncontrolled studies suggested that aerosolized iloprost, a stable analog of prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and exercise capacity in patients with pulmonary hypertension.  We compared repeated daily inhalations of 2.5 or 5.0 μg of iloprost (six or nine times per day; median inhaled dose, 30 μg per day) with inhalation of placebo.  A total of 203 patients with selected forms of severe pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (New York Heart Assocn. [NYHA] functional class III or IV) were included.  The primary end point was met if, after week 12, the NYHA class and distance walked in six minutes were improved by at least one class and at least 10 %, resp., in the absence of clin. deterioration according to predefined criteria and death.  The combined clin. end point was met by 16.8 % of the patients receiving iloprost, as compared with 4.9 % of the patients receiving placebo (P = 0.007).  There were increases in the distance walked in six minutes of 36.4 m in the iloprost group as a whole (P = 0.004) and of 58.8 m in the subgroup of patients with primary pulmonary hypertension.  Overall, 4.0 % of patients in the iloprost group (including one who died) and 13.7 % of those in the placebo group (including four who died) did not complete the study (P = 0.024); the most common reason for withdrawal was clin. deterioration.  As compared with base-line values, hemodynamic values were significantly improved at 12 wk when measured after iloprost inhalation (P<0.001), were largely unchanged when measured before iloprost inhalation, and were significantly worse in the placebo group.  Further significant beneficial effects of iloprost treatment included an improvement in the NYHA class (P = 0.03), dyspnea (P = 0.015), and quality of life (P = 0.026).  Syncope occurred with similar frequency in the two groups but was more frequently rated as serious in the iloprost group, although this adverse effect was not assocd. with clin. deterioration.  Inhaled iloprost is an effective therapy for patients with severe pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjzSDcfOk4BbVg90H21EOLACvtfcHk0liSSbip1JI37w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlslWqt7c%253D&md5=48ab0098d45ec99c4518476037cf610d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020204%26sid%3Dliteratum%253Aachs%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DHigenbottam%26aufirst%3DT.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DNikkho%26aufirst%3DS.%26aulast%3DSpeich%26aufirst%3DR.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DPopov%26aufirst%3DW.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DKiely%26aufirst%3DD.%2BG.%26aulast%3DEwert%26aufirst%3DR.%26aulast%3DMeyer%26aufirst%3DA.%26aulast%3DCorris%26aufirst%3DP.%2BA.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DGomez-Sanchez%26aufirst%3DM.%26aulast%3DSiedentop%26aufirst%3DH.%26aulast%3DSeeger%26aufirst%3DW.%26atitle%3DInhaled%2520iloprost%2520for%2520severe%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D322%26epage%3D329%26doi%3D10.1056%2FNEJMoa020204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toda, N.</span></span> <span> </span><span class="NLM_article-title">Vasodilator actions of trk-100, a new prostaglandin-i2 analog</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">711</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1986.tb11174.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fj.1476-5381.1986.tb11174.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=3101928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL2sXksVGktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1986&pages=703-711&author=T.+Akibaauthor=M.+Miyazakiauthor=N.+Toda&title=Vasodilator+actions+of+trk-100%2C+a+new+prostaglandin-i2+analog&doi=10.1111%2Fj.1476-5381.1986.tb11174.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Vasodilator actions of TRK-100, a new prostaglandin I2 analog</span></div><div class="casAuthors">Akiba, Tetsuro; Miyazaki, Mizuo; Toda, Noboru</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">703-11</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">TRK-100 (I)  [88475-69-8] relaxed isolated canine arteries which were precontracted with PGF2α  [551-11-1] or K+; the relaxation was in the order of mesenteric and renal > coronary and femoral > basilar and middle cerebral arteries.  The relaxation by I was not affected by treatment with atropine, propranolol, cimetidine, aminophylline, and indomethacin, but was suppressed by diphloretin phosphate, a prostaglandin antagonist.  Treatment with I attenuated the contraction induced by PGF2α and Ca2+ in mesenteric and basilar arteries previously exposed to Ca2+-free medium, but did not significantly alter the contractile response to Ca2+ in the arteries exposed to Ca2+-free medium and depolarized by excess K+.  I and nitroglycerin  [55-63-0] relaxed isolated mesenteric arteries to a similar extent; however, when continuously infused into mesenteric arteries in anesthetized dogs, I produced greater vasodilatation than nitroglycerin.  Apparently, I relaxes dog mesenteric and renal arteries more than cerebral arteries; the relaxation appears to derive from interference with the release of Ca2+ from intracellular stores and with the transmembrane Ca2+ influx through a receptor-operated channel.  I may dilate large and small mesenteric arteries and resistance vessels to a similar extent, whereas nitroglycerin preferentially dilates the large artery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJfk3hKYGfOLVg90H21EOLACvtfcHk0liLtBf6H65LMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXksVGktg%253D%253D&md5=50b33581b124cc7029cfcb782f06555c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1986.tb11174.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1986.tb11174.x%26sid%3Dliteratum%253Aachs%26aulast%3DAkiba%26aufirst%3DT.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DToda%26aufirst%3DN.%26atitle%3DVasodilator%2520actions%2520of%2520trk-100%252C%2520a%2520new%2520prostaglandin-i2%2520analog%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1986%26volume%3D89%26spage%3D703%26epage%3D711%26doi%3D10.1111%2Fj.1476-5381.1986.tb11174.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branzi, A.</span></span> <span> </span><span class="NLM_article-title">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1037</span>– <span class="NLM_lpage">1049</span>, <span class="refDoi"> DOI: 10.1183/09031936.02.05542002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.02.05542002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12412701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1037-1049&author=N.+Galieauthor=A.+Manesauthor=A.+Branzi&title=The+new+clinical+trials+on+pharmacological+treatment+in+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.02.05542002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The new clinical trials on pharmacological treatment in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Manes, A.; Branzi, A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1037-1049</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  Past medical therapy for pulmonary arterial hypertension included the use of calcium-channel antagonists in acute vasoreactive subjects and oral anti-coagulants and continuous i.v. administration of epoprostenol in the more severe cases.  Recently, the thromboxane inhibitor terbogrel, the prostacyclin analogs treprostinil, beraprost and iloprost, and the endothelin receptor antagonist bosentan have been tested in clin. trials in >1,100 patients.  Except for terbogrel, all compds. improved the mean exercise capacity by different degrees, as assessed by the 6-min walk test.  In the evaluation of the clin. relevance of exercise capacity improvements, addnl. elements need to be considered, such as baseline functional class and concomitant favorable effects on combined clin. events (including hospitalizations, mortality and rescue therapies), quality of life and hemodynamics.  No trials have shown effects on mortality, as the study protocols were not designed for assessing this end-point.  Each new compd. presents side-effects that are unpredictable in the individual patient and require appropriate attention upon treatment initiation and maintenance.  These new therapeutic options will be available in the near future and will allow tailoring of the most appropriate treatment to the single patient, according to an individualized benefit-to-risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4jEc_GhfAP7Vg90H21EOLACvtfcHk0liLtBf6H65LMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVGkt7w%253D&md5=40c0c3940d3ff20dd629afd5db22e416</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.05542002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.05542002%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DBranzi%26aufirst%3DA.%26atitle%3DThe%2520new%2520clinical%2520trials%2520on%2520pharmacological%2520treatment%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D20%26spage%3D1037%26epage%3D1049%26doi%3D10.1183%2F09031936.02.05542002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vizza, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneussl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaouat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span> <span> </span><span class="NLM_article-title">Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1496</span>– <span class="NLM_lpage">1502</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(02)01786-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0735-1097%2802%2901786-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11985913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2002&pages=1496-1502&author=N.+Galieauthor=M.+Humbertauthor=J.-L.+Vachieryauthor=C.+D.+Vizzaauthor=M.+Kneusslauthor=A.+Manesauthor=O.+Sitbonauthor=A.+Torbickiauthor=M.+Delcroixauthor=R.+Naeijeauthor=M.+Hoeperauthor=A.+Chaouatauthor=S.+Morandauthor=B.+Besseauthor=G.+Simonneau&title=Effects+of+beraprost+sodium%2C+an+oral+prostacyclin+analogue%2C+in+patients+with+pulmonary+arterial+hypertension%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2FS0735-1097%2802%2901786-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial</span></div><div class="casAuthors">Galie, Nazzareno; Humbert, Marc; Vachiery, Jean-Luc; Vizza, Carmine Dario; Kneussl, Meinhard; Manes, Alessandra; Sitbon, Olivier; Torbicki, Adam; Delcroix, Marion; Naeije, Robert; Hoeper, Marius; Chaouat, Ari; Morand, Sophie; Besse, Bruno; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1496-1502</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to assess the efficacy and safety of beraprost sodium, an orally active prostacyclin analog, in New York Heart Assocn. (NYHA) functional class II and III patients with pulmonary arterial hypertension (PAH).  Pulmonary arterial hypertension is a life-threatening disease for which continuous i.v. infusion of prostacyclin has been proven effective.  However, this treatment is assocd. with serious complications arising from the complex delivery system.  In this double-blind, placebo-controlled study, 130 patients with PAH were randomized to the maximal tolerated dose of beraprost (median dose 80 μg four times a day) or to placebo for 12 wk.  The primary end point was the change in exercise capacity assessed by the 6-min walk test.  Secondary end points included changes in Borg dyspnea index, cardiopulmonary hemodynamics and NYHA functional class.  Patients treated with beraprost improved exercise capacity and symptoms.  The difference between treatment groups in the mean change of 6-min walking distance at week 12 was 25.1 m (95% confidence interval [CI]: 1.8 to 48.3, p = 0.036).  The difference in the mean change of Borg dyspnea index was -0.94 (95% CI: -1.63 to -0.24, p = 0.009).  In the sub-group of patients with primary pulmonary hypertension, the difference in the mean change of 6-min walking distance was 46.1 m (95% CI: 3.0 to 89.3, p = 0.035).  Cardiopulmonary hemodynamics and NYHA functional class had no statistically significant changes.  Drug-related adverse events were common in the titrn. phase and decreased in the maintenance period.  Beraprost improves exercise capacity and symptoms in NYHA functional class II and III patients with PAH and, in particular, in those with primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwooODR_ZS7Vg90H21EOLACvtfcHk0liLtBf6H65LMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKksbY%253D&md5=1aa9a4a5863c84a6f8b26b2743e9a6f4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2802%2901786-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252802%252901786-2%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DVachiery%26aufirst%3DJ.-L.%26aulast%3DVizza%26aufirst%3DC.%2BD.%26aulast%3DKneussl%26aufirst%3DM.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DHoeper%26aufirst%3DM.%26aulast%3DChaouat%26aufirst%3DA.%26aulast%3DMorand%26aufirst%3DS.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DEffects%2520of%2520beraprost%2520sodium%252C%2520an%2520oral%2520prostacyclin%2520analogue%252C%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2002%26volume%3D39%26spage%3D1496%26epage%3D1502%26doi%3D10.1016%2FS0735-1097%2802%2901786-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayburn, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinchbaugh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arneson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffs, R.</span></span> <span> </span><span class="NLM_article-title">Beraprost therapy for pulmonary arterial hypertension</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2119</span>– <span class="NLM_lpage">2125</span>, <span class="refDoi"> DOI: 10.1016/S0735-1097(03)00463-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0735-1097%2803%2900463-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12821234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVSqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2003&pages=2119-2125&author=R.+J.+Barstauthor=M.+McGoonauthor=V.+McLaughlinauthor=V.+Tapsonauthor=R.+Oudizauthor=S.+Shapiroauthor=I.+M.+Robbinsauthor=R.+Channickauthor=D.+Badeschauthor=B.+K.+Rayburnauthor=R.+Flinchbaughauthor=J.+Sigmanauthor=C.+Arnesonauthor=R.+Jeffs&title=Beraprost+therapy+for+pulmonary+arterial+hypertension&doi=10.1016%2FS0735-1097%2803%2900463-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Beraprost therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Barst, Robyn J.; McGoon, Michael; McLaughlin, Vallerie; Tapson, Victor; Oudiz, Ronald; Shapiro, Shelley; Robbins, Ivan M.; Channick, Richard; Badesch, David; Rayburn, Barry K.; Flinchbaugh, Robin; Sigman, Jeff; Arneson, Carl; Jeffs, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2119-2125</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to assess the safety and efficacy of the oral prostacyclin analog beraprost sodium during a 12-mo double-blind, randomized, placebo-controlled trial in patients with pulmonary arterial hypertension (PAH).  Pulmonary arterial hypertension is a progressive disease that ultimately causes right heart failure and death.  Despite the risks from its delivery system, continuous i.v. epoprostenol remains the most efficacious treatment currently available.  A total of 116 patients with World Health Organization (WHO) functional class II or III primary pulmonary hypertension or PAH related to either collagen vascular diseases or congenital systemic to pulmonary shunts were enrolled.  Patients were randomized to receive the maximal tolerated dose of beraprost sodium (median dose 120 μg four times a day) or placebo for 12 mo.  The primary end point was disease progression; i.e., death, transplantation, epoprostenol rescue, or >25% decrease in peak oxygen consumption (VO2).  Secondary end points included exercise capacity assessed by 6-min walk test and peak VO2, Borg dyspnea score, hemodynamics, symptoms of PAH, and quality of life.  Patients treated with beraprost exhibited less evidence of disease progression at six months (p = 0.002), but this effect was not evident at either shorter or longer follow-up intervals.  Similarly, beraprost-treated patients had improved 6-min walk distance at 3 mo by 22 m from baseline and at 6 mo by 31 m (p = 0.010 and 0.016, resp.) compared with placebo, but not at either 9 or 12 mo.  Drug-related adverse events were common and were related to the disease and/or expected prostacyclin adverse events.  These data suggest that beneficial effects may occur during early phases of treatment with beraprost in WHO functional class II or III patients but that this effect attenuates with time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIw27g9t2f3LVg90H21EOLACvtfcHk0ljcz-umXWjbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVSqsLs%253D&md5=9169214f23faefb5a223cd8b6692dcc4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2FS0735-1097%2803%2900463-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0735-1097%252803%252900463-7%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DMcGoon%26aufirst%3DM.%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DTapson%26aufirst%3DV.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DChannick%26aufirst%3DR.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DRayburn%26aufirst%3DB.%2BK.%26aulast%3DFlinchbaugh%26aufirst%3DR.%26aulast%3DSigman%26aufirst%3DJ.%26aulast%3DArneson%26aufirst%3DC.%26aulast%3DJeffs%26aufirst%3DR.%26atitle%3DBeraprost%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2003%26volume%3D41%26spage%3D2119%26epage%3D2125%26doi%3D10.1016%2FS0735-1097%2803%2900463-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourge, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.165.6.2106079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm.165.6.2106079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11897647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD387psFCqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2002&pages=800-804&author=G.+Simonneauauthor=R.+J.+Barstauthor=N.+Galieauthor=R.+Naeijeauthor=S.+Richauthor=R.+C.+Bourgeauthor=A.+Keoghauthor=R.+Oudizauthor=A.+Frostauthor=S.+D.+Blackburnauthor=J.+W.+Crowauthor=L.+J.+Rubin&title=Continuous+subcutaneous+infusion+of+treprostinil%2C+a+prostacyclin+analogue%2C+in+patients+with+pulmonary+arterial+hypertension%3A+a+double-blind%2C+randomized%2C+placebo-controlled+trial&doi=10.1164%2Fajrccm.165.6.2106079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial</span></div><div class="casAuthors">Simonneau Gerald; Barst Robyn J; Galie Nazzareno; Naeije Robert; Rich Stuart; Bourge Robert C; Keogh Anne; Oudiz Ronald; Frost Adaani; Blackburn Shelmer D; Crow James W; Rubin Lewis J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">800-4</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Pulmonary arterial hypertension is a life-threatening disease for which continuous intravenous prostacyclin has proven to be effective.  However, this treatment requires a permanent central venous catheter with the associated risk of serious complications such as sepsis, thromboembolism, or syncope.  Treprostinil, a stable prostacyclin analogue, can be administered by a continuous subcutaneous infusion, avoiding these risks.  We conducted a 12-week, double-blind, placebo-controlled multicenter trial in 470 patients with pulmonary arterial hypertension, either primary or associated with connective tissue disease or congenital systemic-to-pulmonary shunts.  Exercise capacity improved with treprostinil and was unchanged with placebo; the between treatment group difference in median six-minute walking distance was 16 m (p = 0.006).  Improvement in exercise capacity was greater in the sicker patients and was dose-related, but independent of disease etiology.  Concomitantly, treprostinil significantly improved indices of dyspnea, signs and symptoms of pulmonary hypertension, and hemodynamics.  The most common side effect attributed to treprostinil was infusion site pain (85%) leading to premature discontinuation from the study in 8% of patients.  Three patients in the treprostinil treatment group presented with an episode of gastrointestinal hemorrhage.  We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR135dJKQFMM0wlCcfExbvbfW6udTcc2ebJTzNb3NyxCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD387psFCqtg%253D%253D&md5=345ab915c0849f46be7df9b1d34a2219</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.165.6.2106079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.165.6.2106079%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DRich%26aufirst%3DS.%26aulast%3DBourge%26aufirst%3DR.%2BC.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DOudiz%26aufirst%3DR.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DBlackburn%26aufirst%3DS.%2BD.%26aulast%3DCrow%26aufirst%3DJ.%2BW.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DContinuous%2520subcutaneous%2520infusion%2520of%2520treprostinil%252C%2520a%2520prostacyclin%2520analogue%252C%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%253A%2520a%2520double-blind%252C%2520randomized%252C%2520placebo-controlled%2520trial%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2002%26volume%3D165%26spage%3D800%26epage%3D804%26doi%3D10.1164%2Fajrccm.165.6.2106079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span> <span> </span><span class="NLM_article-title">Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7128</span>– <span class="NLM_lpage">7137</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7128-7137&author=T.+Asakiauthor=K.+Kuwanoauthor=K.+Morrisonauthor=J.+Gatfieldauthor=T.+Hamamotoauthor=M.+Clozel&title=Selexipag%3A+an+oral+and+selective+IP+prostacyclin+receptor+agonist+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.5b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Asaki, Tetsuo; Kuwano, Keiichi; Morrison, Keith; Gatfield, John; Hamamoto, Taisuke; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7128-7137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor.  Decreased prostacyclin prodn. occurs in several cardiovascular diseases.  However, the clin. use of prostacyclin and its analogs is complicated by their chem. and metabolic instability.  A medicinal chem. program searched for novel nonprostanoid prostacyclin receptor agonists not subject to these limitations.  A compd. with a diphenylpyrazine structural core was synthesized.  Metabolic stability and agonist potency were optimized through modification of the linear side chain.  Compd. 12b (MRE-269, ACT-333679) was identified as a potent and highly selective prostacyclin receptor agonist.  Replacement of the terminal carboxyl group with an N-acylsulfonamide group yielded parent compd. 26a (selexipag, NS-304, ACT-293987), which is orally active and provides sustained plasma exposure of 12b.  Compd. 26a was developed for the treatment of pulmonary arterial hypertension and shown to reduce the risk of the composite morbidity/mortality end point in a phase 3 event-driven clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouZjQo25LkGrVg90H21EOLACvtfcHk0ljcz-umXWjbwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlOjurzO&md5=4b09d302b4852c75be29c94578483d8d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00698%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DSelexipag%253A%2520an%2520oral%2520and%2520selective%2520IP%2520prostacyclin%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7128%26epage%3D7137%26doi%3D10.1021%2Facs.jmedchem.5b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">7720</span>– <span class="NLM_lpage">7725</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmc.2007.08.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17881233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=7720-7725&author=A.+Nakamuraauthor=T.+Yamadaauthor=T.+Asaki&title=Synthesis+and+evaluation+of+N-acylsulfonamide+and+N-acylsulfonylurea+prodrugs+of+a+prostacyclin+receptor+agonist&doi=10.1016%2Fj.bmc.2007.08.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist</span></div><div class="casAuthors">Nakamura, Akio; Yamada, Tetsuhiro; Asaki, Tetsuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7720-7725</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">N-Acylsulfonamide and N-acylsulfonylurea derivs. of the carboxylic acid prostacyclin receptor agonist 1 (I) were synthesized and their potential as prodrug forms of the carboxylic acid was evaluated in vitro and in vivo.  These compds. were converted to the active compd. 1 by hepatic microsomes from rats, dogs, monkeys, and humans, and some of the compds. were shown to yield sustained plasma concns. of 1 when they were orally administered to monkeys.  These types of analogs, including NS-304 (2a), are potentially useful prodrugs of 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3pafmMVkL07Vg90H21EOLACvtfcHk0liZSYXInbgJRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2msLzF&md5=e48076b73d0c2bd9b4312dab5e0693ad</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.052%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DAsaki%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-acylsulfonamide%2520and%2520N-acylsulfonylurea%2520prodrugs%2520of%2520a%2520prostacyclin%2520receptor%2520agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D7720%26epage%3D7725%26doi%3D10.1016%2Fj.bmc.2007.08.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okubo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, K.</span></span> <span> </span><span class="NLM_article-title">2-{4- (5,6-diphenylpyrazin-2-yl)(isopropyl)amino butoxy}-N(methylsulfony l)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1188</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.124248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.107.124248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17545310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpslKrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=1181-1188&author=K.+Kuwanoauthor=A.+Hashinoauthor=T.+Asakiauthor=T.+Hamamotoauthor=T.+Yamadaauthor=K.+Okuboauthor=K.+Kuwabara&title=2-%7B4-+%285%2C6-diphenylpyrazin-2-yl%29%28isopropyl%29amino+butoxy%7D-N%28methylsulfony+l%29acetamide+%28NS-304%29%2C+an+orally+available+and+long-acting+prostacyclin+receptor+agonist+prodrug&doi=10.1124%2Fjpet.107.124248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">2-{4-[5,6-(Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug</span></div><div class="casAuthors">Kuwano, Keiichi; Hashino, Asami; Asaki, Tetsuo; Hamamoto, Taisuke; Yamada, Tetsuhiro; Okubo, Kaori; Kuwabara, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1181-1188</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Prostacyclin (PGI2) and its analogs are useful for the treatment of various vascular disorders, but their half-lives are too short for widespread clin. application.  To overcome this drawback, we have synthesized a novel diphenylpyrazine deriv., 2-{4-[5,6-(diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N- (methylsulfonyl)acetamide (NS-304), a prodrug of the active from {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269).  NS-304 is an orally available and potent agonist for the PGI2 receptor (IP receptor).  The inhibition const. (Ki) of MRE-269 for the human IP receptor was 20 nM; in contrast, the Ki values for other prostanoid receptors were >2.6 μM.  MRE-269 was therefore a highly selective agonist for the IP receptor.  The plasma concns. of MRE-269 remained near peak levels for more than 8 h after oral administration of NS-304 to rats and dogs, and NS-304 increased femoral skin blood flow in rats in a long-lasting manner without affecting the hemodynamics.  These findings indicate that NS-304 acts as a long-acting IP receptor agonist in vivo.  The continuous vasodilation evoked by NS-304 was not attenuated by repeated treatment, indicating that NS-304 is unlikely to cause severe desensitization of the IP receptor in rats.  Moreover, a microdose pharmacokinetic study in which NS-304 was orally administered to healthy male volunteers showed conversion of NS-304 to MRE-269 and a long plasma elimination half-life for MRE-269 (7.9 h).  In conclusion, NS-304 is an orally available and long-acting IP receptor agonist prodrug, and its active form, MRE-269, is highly selective for the IP receptor.  Therefore, NS-304 is a promising drug candidate for various vascular diseases, esp. pulmonary arterial hypertension and arteriosclerosis obliterans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvUgzrUBDOcrVg90H21EOLACvtfcHk0liZSYXInbgJRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpslKrt78%253D&md5=d2adc101cf93d97d4812c5a21bd39ca8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.124248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.124248%26sid%3Dliteratum%253Aachs%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DHashino%26aufirst%3DA.%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DT.%26aulast%3DOkubo%26aufirst%3DK.%26aulast%3DKuwabara%26aufirst%3DK.%26atitle%3D2-%257B4-%2520%25285%252C6-diphenylpyrazin-2-yl%2529%2528isopropyl%2529amino%2520butoxy%257D-N%2528methylsulfony%2520l%2529acetamide%2520%2528NS-304%2529%252C%2520an%2520orally%2520available%2520and%2520long-acting%2520prostacyclin%2520receptor%2520agonist%2520prodrug%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26spage%3D1181%26epage%3D1188%26doi%3D10.1124%2Fjpet.107.124248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenfeld, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassard, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federici, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiler, S. M.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">397</span>, <span class="refDoi"> DOI: 10.1021/jm00080a028</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00080a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=389-397&author=N.+A.+Meanwellauthor=M.+J.+Rosenfeldauthor=J.+J.+K.+Wrightauthor=C.+L.+Brassardauthor=J.+O.+Buchananauthor=M.+E.+Federiciauthor=J.+S.+Flemingauthor=S.+M.+Seiler&title=Structure-activity+relationships+associated+with+3%2C4%2C5-triphenyl-1H-pyrazole-1-nonanoic+acid%2C+a+nonprostanoid+prostacyclin+mimetic&doi=10.1021%2Fjm00080a028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic</span></div><div class="casAuthors">Meanwell, Nicholas A.; Rosenfeld, Michael J.; Wright, J. J. Kim; Brassard, Catherine L.; Buchanan, John O.; Federici, Marianne E.; Fleming, J. Stuart; Seiler, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">389-97</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of phenylated pyrazolealkanoic acids, e.g., I (R = (CH2)nCO2H, n = 5-10, R1, R3 = H, Ph, R2 = Ph, PhCH2, Et; R = (CH2)6XCH2CO2H, X = O, S, S(O), SO2, R1 = R2 = R3 = Ph) and related derivs. were prepd. as inhibitors of ADP-induced human platelet aggregation.  3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (II), with an IC50 of 0.4 μM, was the most potent inhibitor.  Biochem. studies detd. that II increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concn.-dependent fashion.  Displacement of [3H]iloprost by II from platelet membranes indicated that the platelet prostacyclin (PGI2) receptor is the locus of biol. action.  Structure-activity studies demonstrated that the min. structural requirements for binding to the platelet PGI2 receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an ω-alkanoic acid side chain 8 or 9 atoms long.  Potency depended upon both side-chain length and its topol. relationship with the two Ph rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU40YZ6EI6OrVg90H21EOLACvtfcHk0liZSYXInbgJRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvFaluw%253D%253D&md5=00f2e4d0e07a45ebf9ad206a0c3c2de2</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm00080a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00080a028%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DRosenfeld%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DJ.%2BJ.%2BK.%26aulast%3DBrassard%26aufirst%3DC.%2BL.%26aulast%3DBuchanan%26aufirst%3DJ.%2BO.%26aulast%3DFederici%26aufirst%3DM.%2BE.%26aulast%3DFleming%26aufirst%3DJ.%2BS.%26aulast%3DSeiler%26aufirst%3DS.%2BM.%26atitle%3DStructure-activity%2520relationships%2520associated%2520with%25203%252C4%252C5-triphenyl-1H-pyrazole-1-nonanoic%2520acid%252C%2520a%2520nonprostanoid%2520prostacyclin%2520mimetic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D389%26epage%3D397%26doi%3D10.1021%2Fjm00080a028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwabara, K.</span></span> <span> </span><span class="NLM_article-title">Structure-activity studies on diphenylpyrazine derivatives: a novel class of prostacyclin receptor agonists</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">6692</span>– <span class="NLM_lpage">6704</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2007.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmc.2007.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17764960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2007&pages=6692-6704&author=T.+Asakiauthor=T.+Hamamotoauthor=Y.+Sugiyamaauthor=K.+Kuwanoauthor=K.+Kuwabara&title=Structure-activity+studies+on+diphenylpyrazine+derivatives%3A+a+novel+class+of+prostacyclin+receptor+agonists&doi=10.1016%2Fj.bmc.2007.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists</span></div><div class="casAuthors">Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru; Kuwano, Keiichi; Kuwabara, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6692-6704</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivs. was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation.  Structure-activity relationship studies on the side chain contg. the carboxylic acid moiety of the lead compd. (I) showed that the length of the linker and the presence of the concatenating nitrogen atom adjacent to the pyrazine ring are crit. for the antiaggregatory activity.  This study led to the discovery of 2-amino-5,6-diphenylpyrazine derivs. (II, III, and IV), which showed potent inhibition of platelet aggregation with IC50 values of 0.2 μM.  Among these compds., IV is an orally available and long-lasting prostacyclin receptor agonist which is promising for the treatment of various vascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQelakXM9KLVg90H21EOLACvtfcHk0lis-yYEmfp4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCisbfL&md5=e6abc169bee888ab0a33576a84eed962</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2007.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2007.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAsaki%26aufirst%3DT.%26aulast%3DHamamoto%26aufirst%3DT.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DKuwabara%26aufirst%3DK.%26atitle%3DStructure-activity%2520studies%2520on%2520diphenylpyrazine%2520derivatives%253A%2520a%2520novel%2520class%2520of%2520prostacyclin%2520receptor%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2007%26volume%3D15%26spage%3D6692%26epage%3D6704%26doi%3D10.1016%2Fj.bmc.2007.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlocai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonderman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzyna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efficace, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgino, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I. M.</span></span> <span> </span><span class="NLM_article-title">Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1183/09031936.00137511</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00137511" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22362844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslSksLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=874-880&author=G.+Simonneauauthor=A.+Torbickiauthor=M.+M.+Hoeperauthor=M.+Delcroixauthor=K.+Karlocaiauthor=N.+Galieauthor=B.+Deganoauthor=D.+Bondermanauthor=M.+Kurzynaauthor=M.+Efficaceauthor=R.+Giorginoauthor=I.+M.+Lang&title=Selexipag%3A+an+oral%2C+selective+prostacyclin+receptor+agonist+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1183%2F09031936.00137511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Simonneau, Gerald; Torbicki, Adam; Hoeper, Marius M.; Delcroix, Marion; Karlocai, Kristof; Galie, Nazzareno; Degano, Bruno; Bonderman, Diana; Kurzyna, Marcin; Efficace, Michela; Giorgino, Ruben; Lang, Irene M.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">In this phase 2 proof-of-concept study we examd. the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH).  43 Adult patients with symptomatic PAH (receiving stable endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor therapy) were randomized three to one to receive either selexipag or placebo.  Dosage was up-titrated in 200-μg increments from 200 μg twice daily on day 1 to the max. tolerated dose by day 35 (max. allowed dose of 800 μg twice daily).  Change in pulmonary vascular resistance at week 17 expressed as a percentage of the baseline value was the primary efficacy end-point, and was analyzed in the per protocol set first and then in the all-treated set to assess robustness of results.  A statistically significant 30.3% redn. in geometric mean pulmonary vascular resistance was obsd. after 17 wk' treatment with selexipag compared with placebo (95% confidence limits -44.7-12.2; p=0.0045, Wilcoxon rank sum test).  This was supported by a similar result from the all-treated set.  Selexipag was well tolerated with a safety profile in line with the expected pharmacol. effect.  Our results encourage the further investigation of selexipag for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBODCac2AG87Vg90H21EOLACvtfcHk0lis-yYEmfp4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslSksLfM&md5=ab8ed9d43ff5f02857f247aedbd7f8eb</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1183%2F09031936.00137511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00137511%26sid%3Dliteratum%253Aachs%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DKarlocai%26aufirst%3DK.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DDegano%26aufirst%3DB.%26aulast%3DBonderman%26aufirst%3DD.%26aulast%3DKurzyna%26aufirst%3DM.%26aulast%3DEfficace%26aufirst%3DM.%26aulast%3DGiorgino%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DI.%2BM.%26atitle%3DSelexipag%253A%2520an%2520oral%252C%2520selective%2520prostacyclin%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2012%26volume%3D40%26spage%3D874%26epage%3D880%26doi%3D10.1183%2F09031936.00137511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Scala, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzerikho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moiseeva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span> <span> </span><span class="NLM_article-title">Selexipag for the treatment of pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">2522</span>– <span class="NLM_lpage">2533</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1503184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1503184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26699168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=2522-2533&author=O.+Sitbonauthor=R.+Channickauthor=K.+M.+Chinauthor=A.+Freyauthor=S.+Gaineauthor=N.+Galieauthor=H.-A.+Ghofraniauthor=M.+M.+Hoeperauthor=I.+M.+Langauthor=R.+Preissauthor=L.+J.+Rubinauthor=L.+Di+Scalaauthor=V.+Tapsonauthor=I.+Adzerikhoauthor=J.+Liuauthor=O.+Moiseevaauthor=X.+Zengauthor=G.+Simonneauauthor=V.+V.+McLaughlin&title=Selexipag+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1503184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Selexipag for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Sitbon, Olivier; Channick, Richard; Chin, Kelly M.; Frey, Aline; Pharm, D.; Gaine, Sean; Galie, Nazzareno; Ghofrani, Hossein-Ardeschir; Hoeper, Marius M.; Lang, Irene M.; Preiss, Ralph; Rubin, Lewis J.; Di Scala, Lilla; Tapson, Victor; Adzerikho, Igor; Liu, Jinming; Moiseeva, Olga; Zeng, Xiaofeng; Simonneau, Gerald; McLaughlin, Vallerie V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2522-2533</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.  METHODS: In this event-driven, phase 3, randomized, double-blind, placebo-controlled trial, we randomly assigned 1156 patients with pulmonary arterial hypertension to receive placebo or selexipag in individualized doses (max. dose, 1600 μg twice daily).  Patients were eligible for enrollment if they were not receiving treatment for pulmonary arterial hypertension or if they were receiving a stable dose of an endothelin-receptor antagonist, a phosphodiesterase type 5 inhibitor, or both.  The primary end point was a composite of death from any cause or a complication related to pulmonary arterial hypertension up to the end of the treatment period (defined for each patient as 7 days after the date of the last intake of selexipag or placebo).  RESULTS: A primary end-point event occurred in 397 patients - 41.6% of those in the placebo group and 27.0% of those in the selexipag group (hazard ratio in the selexipag group as compared with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P<0.001).  Disease progression and hospitalization accounted for 81.9% of the events.  The effect of selexipag with respect to the primary end point was similar in the subgroup of patients who were not receiving treatment for the disease at baseline and in the subgroup of patients who were already receiving treatment at baseline (including those who were receiving a combination of two therapies).  By the end of the study, 105 patients in the placebo group and 100 patients in the selexipag group had died from any cause.  Overall, 7.1% of patients in the placebo group and 14.3% of patients in the selexipag group discontinued their assigned regimen prematurely because of adverse events.  The most common adverse events in the selexipag group were consistent with the known side effects of prostacyclin, including headache, diarrhea, nausea, and jaw pain.  CONCLUSIONS: Among patients with pulmonary arterial hypertension, the risk of the primary composite end point of death or a complication related to pulmonary arterial hypertension was significantly lower with selexipag than with placebo.  There was no significant difference in mortality between the two study groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqESCkOu3qJHrVg90H21EOLACvtfcHk0lis-yYEmfp4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlurjI&md5=226c0615071351060d286cb144e5dd28</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1503184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1503184%26sid%3Dliteratum%253Aachs%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DChannick%26aufirst%3DR.%26aulast%3DChin%26aufirst%3DK.%2BM.%26aulast%3DFrey%26aufirst%3DA.%26aulast%3DGaine%26aufirst%3DS.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.-A.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DLang%26aufirst%3DI.%2BM.%26aulast%3DPreiss%26aufirst%3DR.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DDi%2BScala%26aufirst%3DL.%26aulast%3DTapson%26aufirst%3DV.%26aulast%3DAdzerikho%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMoiseeva%26aufirst%3DO.%26aulast%3DZeng%26aufirst%3DX.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26atitle%3DSelexipag%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D2522%26epage%3D2533%26doi%3D10.1056%2FNEJMoa1503184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boatman, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbaoui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakya, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behan, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shifrina, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leakakos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeque, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unett, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaidarov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (ralinepag): An orally active prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00871</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00871" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXms12gsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=913-927&author=T.-A.+Tranauthor=B.+Kramerauthor=Y.-J.+Shinauthor=P.+Vallarauthor=P.+D.+Boatmanauthor=N.+Zouauthor=C.+R.+Sageauthor=T.+Gharbaouiauthor=A.+Krishnanauthor=B.+Palauthor=S.+R.+Shakyaauthor=M.+A.+Garridoauthor=J.+W.+Adamsauthor=J.+Ramirezauthor=D.+P.+Behanauthor=A.+Shifrinaauthor=A.+Blackburnauthor=T.+Leakakosauthor=Y.+Shiauthor=M.+Morganauthor=A.+Sadequeauthor=W.+Chenauthor=D.+J.+Unettauthor=I.+Gaidarovauthor=X.+Chenauthor=S.+Changauthor=H.-H.+Shuauthor=S.-F.+Tungauthor=G.+Semple&title=Discovery+of+2-%28%28%281r%2C4r%29-4-%28%28%284-Chlorophenyl%29%28phenyl%29carbamoyl%29oxy%29methyl%29cyclohexyl%29methoxy%29acetate+%28ralinepag%29%3A+An+orally+active+prostacyclin+receptor+agonist+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.6b00871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Tran, Thuy-Anh; Kramer, Bryan; Shin, Young-Jun; Vallar, Pureza; Boatman, P. Douglas; Zou, Ning; Sage, Carleton R.; Gharbaoui, Tawfik; Krishnan, Ashwin; Pal, Biman; Shakya, Sagar R.; Garrido Montalban, Antonio; Adams, John W.; Ramirez, Juan; Behan, Dominic P.; Shifrina, Anna; Blackburn, Anthony; Leakakos, Tina; Shi, Yunqing; Morgan, Michael; Sadeque, Abu; Chen, Weichao; Unett, David J.; Gaidarov, Ibragim; Chen, Xiaohua; Chang, Steve; Shu, Hsin-Hui; Tung, Shiu-Feng; Semple, Graeme</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">913-927</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design and synthesis of a new series of potent non-prostanoid IP receptor agonists that showed oral efficacy in the rat monocrotaline model of pulmonary arterial hypertension (PAH) are described.  Detailed profiling of a no. of analogs resulted in the identification of 5c (ralinepag) that has good selectivity in both binding and functional assays with respect to most members of the prostanoid receptor family and a more modest 30- to 50-fold selectivity over the EP3 receptor.  In the authors' hands, its potency and efficacy are comparable or superior to MRE269 (the active metabolite of the clin. compd. NS-304) with respect to in vitro IP receptor dependent cAMP accumulation assays.  Ralinepag had an excellent PK profile across species.  Enterohepatic recirculation most probably contributes to a concn.-time profile after oral administration in the cynomolgus monkey that showed a very low peak-to-trough ratio.  Following the identification of an acceptable solid form, ralinepag was selected for further development for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXvfp2ZN4i1bVg90H21EOLACvtfcHk0ljtz3v_f9PMXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXms12gsw%253D%253D&md5=f37ba4106466f0ed724cd78db4b5b366</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00871%26sid%3Dliteratum%253Aachs%26aulast%3DTran%26aufirst%3DT.-A.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3DShin%26aufirst%3DY.-J.%26aulast%3DVallar%26aufirst%3DP.%26aulast%3DBoatman%26aufirst%3DP.%2BD.%26aulast%3DZou%26aufirst%3DN.%26aulast%3DSage%26aufirst%3DC.%2BR.%26aulast%3DGharbaoui%26aufirst%3DT.%26aulast%3DKrishnan%26aufirst%3DA.%26aulast%3DPal%26aufirst%3DB.%26aulast%3DShakya%26aufirst%3DS.%2BR.%26aulast%3DGarrido%26aufirst%3DM.%2BA.%26aulast%3DAdams%26aufirst%3DJ.%2BW.%26aulast%3DRamirez%26aufirst%3DJ.%26aulast%3DBehan%26aufirst%3DD.%2BP.%26aulast%3DShifrina%26aufirst%3DA.%26aulast%3DBlackburn%26aufirst%3DA.%26aulast%3DLeakakos%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DMorgan%26aufirst%3DM.%26aulast%3DSadeque%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DUnett%26aufirst%3DD.%2BJ.%26aulast%3DGaidarov%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DH.-H.%26aulast%3DTung%26aufirst%3DS.-F.%26aulast%3DSemple%26aufirst%3DG.%26atitle%3DDiscovery%2520of%25202-%2528%2528%25281r%252C4r%2529-4-%2528%2528%25284-Chlorophenyl%2529%2528phenyl%2529carbamoyl%2529oxy%2529methyl%2529cyclohexyl%2529methoxy%2529acetate%2520%2528ralinepag%2529%253A%2520An%2520orally%2520active%2520prostacyclin%2520receptor%2520agonist%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D913%26epage%3D927%26doi%3D10.1021%2Facs.jmedchem.6b00871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ristic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klassen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escribano
Subias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Souza, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy results from a phase 2 randomized, parallel group, placebo-controlled trial</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1901030</span>, <span class="refDoi"> DOI: 10.1183/13993003.01030-2019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.01030-2019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31391223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVKjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=1901030&author=F.+Torresauthor=H.+Farberauthor=A.+Risticauthor=V.+McLaughlinauthor=J.+Adamsauthor=J.+Zhangauthor=P.+Klassenauthor=W.+Shanahanauthor=J.+Grundyauthor=I.+Hoffmannauthor=C.+Cabellauthor=P.+Escribano%0ASubiasauthor=N.+Soodauthor=A.+Keoghauthor=G.+D%27Souzaauthor=L.+Rubin&title=Efficacy+and+safety+of+ralinepag%2C+a+novel+oral+IP+agonist%2C+in+PAH+patients+on+mono+or+dual+background+therapy+results+from+a+phase+2+randomized%2C+parallel+group%2C+placebo-controlled+trial&doi=10.1183%2F13993003.01030-2019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial</span></div><div class="casAuthors">Torres, Fernando; Farber, Harrison; Ristic, Arsen; McLaughlin, Vallerie; Adams, John; Zhang, Jinkun; Klassen, Preston; Shanahan, William; Grundy, John; Hoffmann, Ines; Cabell, Christopher; Subias, Pilar Escribano; Sood, Namita; Keogh, Anne; D'Souza, Gwyn; Rubin, Lewis</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1901030</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Purpose: This phase 2 study was designed to assess the efficacy, safety and tolerability of immediaterelease orally administered ralinepag, a selective, non-prostanoid prostacyclin receptor agonist with a 24-h terminal half-life, compared to placebo in adult patients with symptomatic pulmonary arterial hypertension (PAH).  Methods: 61 PAH patients who were receiving std. care, including mono or dual PAH-targeted background therapy were randomised 2:1 to ralinepag (n=40) or placebo (n=21).  The starting dose of ralinepag was 10 μg twice daily.  Dosage was then up-titrated as tolerated over the course of the 9-wk dose-titrn. period, to a max. total daily dose of 600 μg (300 μg twice daily).  The primary efficacy end-point was the abs. change in pulmonary vascular resistance (PVR) from baseline to week 22.  Addnl. end-points included percentage change in PVR from baseline, other haemodynamic parameters, 6-min walk distance (6MWD) and safety and tolerability.  Results: Ralinepag significantly decreased PVR by 163.9 dyn·s·cm-5 compared to an increase of 0.7 dyn·s·cm-5 with placebo ( p=0.02); the least-squares mean change from baseline PVR was -29.8% compared with placebo ( p=0.03). 6MWD increased from baseline by 36.2 m with ralinepag and 29.4 m with placebo ( p=0.90).  Serious adverse events occurred in 10% of ralinepag patients and 29% of placebo patients.  Study discontinuations occurred in 13% of ralinepag patients and 10% of placebo patients.  Summary: Ralinepag reduced PVR compared with placebo in PAH patients on mono (41%) or dual combination (59%) background therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1FRpt9_XiPrVg90H21EOLACvtfcHk0ljtz3v_f9PMXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVKjsbg%253D&md5=585ad038ae63c029c97b7ec2ee5b5068</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1183%2F13993003.01030-2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.01030-2019%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DFarber%26aufirst%3DH.%26aulast%3DRistic%26aufirst%3DA.%26aulast%3DMcLaughlin%26aufirst%3DV.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DKlassen%26aufirst%3DP.%26aulast%3DShanahan%26aufirst%3DW.%26aulast%3DGrundy%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DI.%26aulast%3DCabell%26aufirst%3DC.%26aulast%3DEscribano%2BSubias%26aufirst%3DP.%26aulast%3DSood%26aufirst%3DN.%26aulast%3DKeogh%26aufirst%3DA.%26aulast%3DD%2527Souza%26aufirst%3DG.%26aulast%3DRubin%26aufirst%3DL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ralinepag%252C%2520a%2520novel%2520oral%2520IP%2520agonist%252C%2520in%2520PAH%2520patients%2520on%2520mono%2520or%2520dual%2520background%2520therapy%2520results%2520from%2520a%2520phase%25202%2520randomized%252C%2520parallel%2520group%252C%2520placebo-controlled%2520trial%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2019%26volume%3D54%26spage%3D1901030%26doi%3D10.1183%2F13993003.01030-2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel prostacyclin mimetics with highly potent and selective IP receptor agonists</span>. <i>Yuki Gosei Kagaku Kyokaishi</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.5059/yukigoseikyokaishi.64.923</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.5059%2Fyukigoseikyokaishi.64.923" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XpslejtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2006&pages=923-933&author=K.+Hattori&title=Discovery+of+novel+prostacyclin+mimetics+with+highly+potent+and+selective+IP+receptor+agonists&doi=10.5059%2Fyukigoseikyokaishi.64.923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel prostacyclin mimetics with highly potent and selective IP receptor agonists</span></div><div class="casAuthors">Hattori, Koji</div><div class="citationInfo"><span class="NLM_cas:title">Yuki Gosei Kagaku Kyokaishi</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">923-933</span>CODEN:
                <span class="NLM_cas:coden">YGKKAE</span>;
        ISSN:<span class="NLM_cas:issn">0037-9980</span>.
    
            (<span class="NLM_cas:orgname">Yuki Gosei Kagaku Kyokai</span>)
        </div><div class="casAbstract">A review.  Prostacyclin (PGI2) is primarily secreted from vascular endothelium and plays an extremely important inhibitory role in platelet aggregation and as a vasodilator in maintaining homeostatic circulation.  Despite fascinating pharmacol. properties, the inherent instability and side effect of prostacyclin limit its therapeutic applicability.  In this paper, we described that discovery of three classes of prostacyclin mimetics without PG skeleton, which are cycloalkene skeleton type (FR 181560, FR 181157), tetrahydronaphthalene skeleton type (FK788), and amino acid type (FR 193264, FR 193262).  Several designed prostacyclin mimetics exhibited potent PGI2 agonistic activity with good selectivity for IP receptor and bioavailability.  The specific compds. were prepd. by asym. synthesis with high selectivity.  Furthermore, we also described metab. study using rat and human liver microsomes to lead new drug design (FR 223346, FR 232149).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqUWjaUx6-6LVg90H21EOLACvtfcHk0lgEbo1ygHJLdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpslejtLw%253D&md5=c74e05241bd94c0191272c62ecdaefb3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.5059%2Fyukigoseikyokaishi.64.923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5059%252Fyukigoseikyokaishi.64.923%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520novel%2520prostacyclin%2520mimetics%2520with%2520highly%2520potent%2520and%2520selective%2520IP%2520receptor%2520agonists%26jtitle%3DYuki%2520Gosei%2520Kagaku%2520Kyokaishi%26date%3D2006%26volume%3D64%26spage%3D923%26epage%3D933%26doi%3D10.5059%2Fyukigoseikyokaishi.64.923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3091</span>– <span class="NLM_lpage">3095</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2005.04.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15914004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFWgurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3091-3095&author=K.+Hattoriauthor=A.+Tanakaauthor=O.+Okitsuauthor=S.+Tabuchiauthor=K.+Taniguchiauthor=M.+Nishioauthor=S.+Koyamaauthor=M.+Higakiauthor=J.+Sekiauthor=K.+Sakane&title=Discovery+of+diphenylcarbamate+derivatives+as+highly+potent+and+selective+IP+receptor+agonists%3A+Orally+active+prostacyclin+mimetics&doi=10.1016%2Fj.bmcl.2005.04.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3</span></div><div class="casAuthors">Hattori, Kouji; Tanaka, Akira; Okitsu, Osamu; Tabuchi, Seiichiro; Taniguchi, Kiyoshi; Nishio, Mie; Koyama, Satoshi; Higaki, Masahide; Seki, Jiro; Sakane, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3091-3095</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The new classes of diphenylcarbamate derivs. with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered.  The optimized diphenylcarbamate type compd. FK-788 (I) exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K i values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family.  I was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvW2aOaAtXMLVg90H21EOLACvtfcHk0lgEbo1ygHJLdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFWgurw%253D&md5=1745006387eb0e3f6a1a57741ee84051</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DOkitsu%26aufirst%3DO.%26aulast%3DTabuchi%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DHigaki%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DJ.%26aulast%3DSakane%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520diphenylcarbamate%2520derivatives%2520as%2520highly%2520potent%2520and%2520selective%2520IP%2520receptor%2520agonists%253A%2520Orally%2520active%2520prostacyclin%2520mimetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3091%26epage%3D3095%26doi%3D10.1016%2Fj.bmcl.2005.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span> <span> </span><span class="NLM_article-title">Seki,Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6.</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4861</span>– <span class="NLM_lpage">4864</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2006.06.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16837197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlSgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4861-4864&author=A.+Tanakaauthor=K.+Hattoriauthor=K.+Taniguchiauthor=O.+Okitsuauthor=S.+Tabuchiauthor=M.+Nishioauthor=Y.+Nagakuraauthor=N.+Maedaauthor=H.+Muraiauthor=J.+Seki&title=Seki%2CReplacing+the+cyclohexene-linker+of+FR181157+leading+to+novel+IP+receptor+agonists%3A+orally+active+prostacyclin+mimetics.+Part+6.&doi=10.1016%2Fj.bmcl.2006.06.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: Orally active prostacyclin mimetics. Part 6</span></div><div class="casAuthors">Tanaka, Akira; Hattori, Kouji; Taniguchi, Kiyoshi; Okitsu, Osamu; Tabuchi, Seiichiro; Nishio, Mie; Nagakura, Yasunori; Maeda, Noriaki; Murai, Hidetsugu; Seki, Jiro</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4861-4864</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The synthesis and biol. activity of novel derivs. of the authors' previously reported IP receptor agonist FR181157 is described.  SAR studies to replace the cyclohexene-linker of FR181157 led to the discovery of 2-[3-[(2R)-[2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid monohydrochloride (FR207845) as a potent non-prostanoid PGI2 mimetic (IC50 for ADP-induced platelet aggregation inhibition = 58 nM for sodium salt) with good oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ-QLdxgnHsrVg90H21EOLACvtfcHk0lgEbo1ygHJLdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlSgs7g%253D&md5=707791da7ccde815995406835a797121</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.076%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DOkitsu%26aufirst%3DO.%26aulast%3DTabuchi%26aufirst%3DS.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DNagakura%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DN.%26aulast%3DMurai%26aufirst%3DH.%26aulast%3DSeki%26aufirst%3DJ.%26atitle%3DSeki%252CReplacing%2520the%2520cyclohexene-linker%2520of%2520FR181157%2520leading%2520to%2520novel%2520IP%2520receptor%2520agonists%253A%2520orally%2520active%2520prostacyclin%2520mimetics.%2520Part%25206.%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4861%26epage%3D4864%26doi%3D10.1016%2Fj.bmcl.2006.06.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takasugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span> <span> </span><span class="NLM_article-title">Metabolism investigation leading to novel drug design 2: orally active prostacyclin mimetics. Part 5</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4475</span>– <span class="NLM_lpage">4478</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2006.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16824754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4475-4478&author=F.+Takamuraauthor=A.+Tanakaauthor=H.+Takasugiauthor=K.+Taniguchiauthor=M.+Nishioauthor=J.+Sekiauthor=K.+Hattori&title=Metabolism+investigation+leading+to+novel+drug+design+2%3A+orally+active+prostacyclin+mimetics.+Part+5&doi=10.1016%2Fj.bmcl.2006.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism investigation leading to novel drug design. Orally active prostacyclin mimetics.</span></div><div class="casAuthors">Takamura, Fujiko; Tanaka, Akira; Takasugi, Hisashi; Taniguchi, Kiyoshi; Nishio, Mie; Seki, Jiro; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4475-4478</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A metab. study of FK788 (2) led to the discovery of new diphenylcarbamoyl derivs. as prostacyclin mimetics without the PG skeleton.  The authors designed and evaluated PGI2 mimetics based on blocking the main metabolic pathway of FK788.  The new compd. (I) was found to be equipotent to FK788 towards PGI2 agonist activity and metabolically more stable than FK788.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplkJoawkTu6rVg90H21EOLACvtfcHk0lh-zW3_nVUnkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOltrY%253D&md5=eca092560f1ebbfbf277214dfd5af817</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DTakamura%26aufirst%3DF.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DTakasugi%26aufirst%3DH.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DSeki%26aufirst%3DJ.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DMetabolism%2520investigation%2520leading%2520to%2520novel%2520drug%2520design%25202%253A%2520orally%2520active%2520prostacyclin%2520mimetics.%2520Part%25205%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4475%26epage%3D4478%26doi%3D10.1016%2Fj.bmcl.2006.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hattori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3279</span>– <span class="NLM_lpage">3283</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.04.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2005.04.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15935660" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFSmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3279-3283&author=K.+Hattoriauthor=O.+Okitsuauthor=S.+Tabuchiauthor=K.+Taniguchiauthor=M.+Nishioauthor=S.+Koyamaauthor=J.+Sekiauthor=K.+Sakane&title=Discovery+of+new+diphenyloxazole+derivatives+containing+a+pyrrolidine+ring%3A+orally+active+prostacyclin+mimetics&doi=10.1016%2Fj.bmcl.2005.04.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2</span></div><div class="casAuthors">Hattori, Kouji; Okitsu, Osamu; Tabuchi, Seiichiro; Taniguchi, Kiyoshi; Nishio, Mie; Koyama, Satoshi; Seki, Jiro; Sakane, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3279-3283</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic and biol. evaluation of novel diphenyloxazole derivs. contg. a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described.  Asym. redn. of a ketone using a chiral Ru complex and reductive amination by NaBH4 produces four isomers of the tetrahydronaphthalene ring and the pyrrolidine ring with high stereoselectivity.  FR193262 (I), (R,R)-diphenyloxazolyl pyrrolidine deriv., displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJL07tHD9wKbVg90H21EOLACvtfcHk0lh-zW3_nVUnkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFSmsr4%253D&md5=340aefaa7907f2e61728415dd3c4d118</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.04.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.04.042%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DOkitsu%26aufirst%3DO.%26aulast%3DTabuchi%26aufirst%3DS.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DS.%26aulast%3DSeki%26aufirst%3DJ.%26aulast%3DSakane%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520new%2520diphenyloxazole%2520derivatives%2520containing%2520a%2520pyrrolidine%2520ring%253A%2520orally%2520active%2520prostacyclin%2520mimetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3279%26epage%3D3283%26doi%3D10.1016%2Fj.bmcl.2005.04.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narumiya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushikubi, F.</span></span> <span> </span><span class="NLM_article-title">Prostanoid receptors: structures, properties, and functions</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1226</span>, <span class="refDoi"> DOI: 10.1152/physrev.1999.79.4.1193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1152%2Fphysrev.1999.79.4.1193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10508233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXmvVymtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1999&pages=1193-1226&author=S.+Narumiyaauthor=Y.+Sugimotoauthor=F.+Ushikubi&title=Prostanoid+receptors%3A+structures%2C+properties%2C+and+functions&doi=10.1152%2Fphysrev.1999.79.4.1193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Prostanoid receptors: structures, properties, and functions</span></div><div class="casAuthors">Narumiya, Shuh; Sugimoto, Yukihiko; Ushikubi, Fumitaka</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1193-1226</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review, with 254 refs.  Prostanoids are the cyclooxygenase metabolites of arachidonic acid and include prostaglandin (PG) D2, PGE2, PGF2α, PGI2, and thromboxane A2.  They are synthesized and released upon cell stimulation and act on cells in the vicinity of their synthesis to exert their actions.  Receptors mediating the actions of prostanoids were recently identified and cloned.  They are G protein-coupled receptors with seven transmembrane domains.  There are eight types and subtypes of prostanoid receptors that are encoded by different genes but as a whole constitute a subfamily in the superfamily of the rhodopsin-type receptors.  Each of the receptors was expressed in cultured cells, and its ligand-binding properties and signal transduction pathways were characterized.  Moreover, domains and amino acid residues conferring the specificities of ligand binding and signal transduction are being clarified.  Information also is accumulating as to the distribution of these receptors in the body.  It is also becoming clear for some types of receptors how expression of their genes is regulated.  Furthermore, the gene for each of the eight types of prostanoid receptor has been disrupted, and mice deficient in each type of receptor are being examd. to identify and assess the roles played by each receptor under various physiol. and pathophysiol. conditions.  In this article, we summarize these findings and attempt to give an overview of the current status of research on the prostanoid receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryyKYnqFDGUbVg90H21EOLACvtfcHk0lh-zW3_nVUnkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvVymtL0%253D&md5=868b556bb0e6b8628efbc5bdc630025d</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.1999.79.4.1193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.1999.79.4.1193%26sid%3Dliteratum%253Aachs%26aulast%3DNarumiya%26aufirst%3DS.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DUshikubi%26aufirst%3DF.%26atitle%3DProstanoid%2520receptors%253A%2520structures%252C%2520properties%252C%2520and%2520functions%26jtitle%3DPhysiol.%2520Rev.%26date%3D1999%26volume%3D79%26spage%3D1193%26epage%3D1226%26doi%3D10.1152%2Fphysrev.1999.79.4.1193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavliv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Caestecker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1086/686140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1086%2F686140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27252848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=211-223&author=J.+D.+Westauthor=B.+M.+Vossauthor=L.+Pavlivauthor=M.+de+Caesteckerauthor=A.+R.+Hemnesauthor=E.+J.+Carrier&title=Antagonism+of+the+thromboxane-prostanoid+receptor+is+cardioprotective+against+right+ventricular+pressure+overload&doi=10.1086%2F686140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload</span></div><div class="casAuthors">West, James D.; Voss, Bryan M.; Pavliv, Leo; de Caestecker, Mark; Hemnes, Anna R.; Carrier, Erica J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-223</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Right ventricular (RV) failure is the primary cause of death in pulmonary arterial hypertension (PAH) and is a significant cause of morbidity and mortality in other forms of pulmonary hypertension.  There are no approved therapies directed at preserving RV function.  F-series and E-series isoprostanes are increased in heart failure and PAH, correlate to the severity of disease, and can signal through the thromboxane-prostanoid (TP) receptor, with effects from vasoconstriction to fibrosis.  The goal of these studies was to det. whether blockade of the TP receptor with the antagonist CPI211 was beneficial therapeutically in PAH-induced RV dysfunction.  Mice with RV dysfunction due to pressure overload by pulmonary artery banding (PAB) were given vehicle or CPI211.  Two weeks after PAB, CPI211-treated mice were protected from fibrosis with pressure overload.  Gene expression arrays and immunoblotting, quant. histol. and morphometry, and flow cytometric anal. were used to det. the mechanism of CPI211 protection.  TP receptor inhibition caused a near normalization of fibrotic area, prevented cellular hypertrophy while allowing increased RV mass, increased expression of antifibrotic thrombospondin-4, and blocked induction of the profibrotic transforming growth factor β (TGF-β) pathway.  A thromboxane synthase inhibitor or low-dose aspirin failed to replicate these results, which suggests that a ligand other than thromboxane mediates fibrosis through the TP receptor after pressure overload.  This study suggests that TP receptor antagonism may improve RV adaptation in situations of pressure overload by decreasing fibrosis and TGF-β signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbQ41GnagSPbVg90H21EOLACvtfcHk0lg3W60Zk_eG2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFSrsb%252FI&md5=32f19f3327d2e10e4da0cd917c72cc63</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1086%2F686140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F686140%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DJ.%2BD.%26aulast%3DVoss%26aufirst%3DB.%2BM.%26aulast%3DPavliv%26aufirst%3DL.%26aulast%3Dde%2BCaestecker%26aufirst%3DM.%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26atitle%3DAntagonism%2520of%2520the%2520thromboxane-prostanoid%2520receptor%2520is%2520cardioprotective%2520against%2520right%2520ventricular%2520pressure%2520overload%26jtitle%3DPulm.%2520Circ.%26date%3D2016%26volume%3D6%26spage%3D211%26epage%3D223%26doi%3D10.1086%2F686140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span> <span> </span><span class="NLM_article-title">Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2127</span>– <span class="NLM_lpage">2133</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-13-0107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1253%2Fcircj.CJ-13-0107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23676973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSltbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2013&pages=2127-2133&author=A.+Nakamuraauthor=N.+Nagayaauthor=H.+Obataauthor=K.+Sakaiauthor=Y.+Sakaiauthor=M.+Yoshikawaauthor=K.+Hamadaauthor=K.+Matsumotoauthor=H.+Kimura&title=Oral+administration+of+a+novel+long-acting+prostacyclin+agonist+with+thromboxane+synthase+inhibitory+activity+for+pulmonary+arterial+hypertension&doi=10.1253%2Fcircj.CJ-13-0107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary areterial hypertension</span></div><div class="casAuthors">Nakamura, Atsuhiro; Nagaya, Nirotoshi; Obata, Hiroaki; Sakai, Katsuya; Sakai, Yoshiki; Yoshikawa, Masanori; Hamada, Kaoru; Matsumoto, Kunio; Kimura, Hiroshi</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2127-2133</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">Background: Continuous administration of prostacyclin has improved the survival of patients with pulmonary arterial hypertension (PAH).  However, this treatment has some problems, including its short duration of activity and difficult delivery.  Therefore, we developed ONO-1301, an orally active, long-acting prostacyclin agonist with thromboxane synthase inhibitory activity.  Methods and Results: We investigated whether oral administration of ONO-1301 can both prevent and reverse monocrotaline (MCT)-induced PAH in rats.  Rats were randomly assigned to receive repeated oral administration of ONO-1301 twice daily beginning either 1 or 8 days after s.c. injection of MCT.  A control group received oral saline, and a sham group received a s.c. injection of saline instead of MCT.  MCT-treated controls developed significant pulmonary hypertension.  Treatment with ONO-1301 from day 1 or 8 significantly attenuated the increases in right ventricular systolic pressure and the increase in medial wall thickness of pulmonary arterioles.  Kaplan-Meier survival curves demonstrated that the effect of ONO-1301 was equiv. to that of an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor.  A single oral dose of ONO-1301 increased plasma cAMP levels for up to 6h.  Treatment with ONO-1301 significantly decreased urinary 11-dehydro-thromboxane B2 and increased the plasma hepatocyte growth factor concn.  Conclusions: Oral administration of ONO-1301 ameliorated PAH in rats, an effect that may occur through cAMP and hepatocyte growth factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRFjPboMpK4rVg90H21EOLACvtfcHk0lg3W60Zk_eG2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSltbjK&md5=441b73c368c0f1e787cbe3f209213183</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-13-0107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-13-0107%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DNagaya%26aufirst%3DN.%26aulast%3DObata%26aufirst%3DH.%26aulast%3DSakai%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DY.%26aulast%3DYoshikawa%26aufirst%3DM.%26aulast%3DHamada%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DH.%26atitle%3DOral%2520administration%2520of%2520a%2520novel%2520long-acting%2520prostacyclin%2520agonist%2520with%2520thromboxane%2520synthase%2520inhibitory%2520activity%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirc.%2520J.%26date%3D2013%26volume%3D77%26spage%3D2127%26epage%3D2133%26doi%3D10.1253%2Fcircj.CJ-13-0107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pernow, J.</span></span> <span> </span><span class="NLM_article-title">The importance of endothelin-1 for vascular dysfunction in cardiovascular disease</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.cardiores.2007.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cardiores.2007.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17617392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2sris1entA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=8-18&author=F.+Bohmauthor=J.+Pernow&title=The+importance+of+endothelin-1+for+vascular+dysfunction+in+cardiovascular+disease&doi=10.1016%2Fj.cardiores.2007.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The importance of endothelin-1 for vascular dysfunction in cardiovascular disease</span></div><div class="casAuthors">Bohm Felix; Pernow John</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-18</span>
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    </div><div class="casAbstract">Endothelin (ET)-1 is a potent vasoconstrictor peptide originally isolated from endothelial cells.  Its production is stimulated in a variety of different cell types under the influence of risk factors for cardiovascular disease and during the development of cardiovascular disease.  Based on these observations and the biological effects induced by ET-1, including profound vasoconstriction, pro-inflammatory actions, mitogenic and proliferative effects, stimulation of free radical formation and platelet activation, ET-1 has been implicated as an important factor in the development of vascular dysfunction and cardiovascular disease.  In the following the pathogenic role of ET-1, the mechanisms underlying the involvement of ET-1 for the development of vascular dysfunction and the potentially beneficial therapeutic effects of selective ET(A) and dual ET(A)/ET(B) receptor antagonists will be discussed.  In particular the changes of pathophysiological importance mediated by ET-1 in clinical studies are reviewed.  These changes may be of significance for the development of various cardiovascular diseases beyond pulmonary arterial hypertension which is the currently approved indication for ET receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7MJYJyhY7ypcXNb62YGmbfW6udTcc2eZjDaLRuZnAxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sris1entA%253D%253D&md5=d4a83638d857a87845f767a31f0dba5a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.cardiores.2007.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardiores.2007.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DBohm%26aufirst%3DF.%26aulast%3DPernow%26aufirst%3DJ.%26atitle%3DThe%2520importance%2520of%2520endothelin-1%2520for%2520vascular%2520dysfunction%2520in%2520cardiovascular%2520disease%26jtitle%3DCardiovasc.%2520Res.%26date%3D2007%26volume%3D76%26spage%3D8%26epage%3D18%26doi%3D10.1016%2Fj.cardiores.2007.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shennib, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duguid, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, D. J.</span></span> <span> </span><span class="NLM_article-title">Expression of endothelin-1 in the lungs of patients with pulmonary hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">1732</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1056/NEJM199306173282402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJM199306173282402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=8497283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK3s3mvVensA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1993&pages=1732-1739&author=A.+Giaidauthor=M.+Yanagisawaauthor=D.+Langlebenauthor=R.+P.+Michelauthor=R.+Levyauthor=H.+Shennibauthor=S.+Kimuraauthor=T.+Masakiauthor=W.+P.+Duguidauthor=D.+J.+Stewart&title=Expression+of+endothelin-1+in+the+lungs+of+patients+with+pulmonary+hypertension&doi=10.1056%2FNEJM199306173282402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of endothelin-1 in the lungs of patients with pulmonary hypertension</span></div><div class="casAuthors">Giaid A; Yanagisawa M; Langleben D; Michel R P; Levy R; Shennib H; Kimura S; Masaki T; Duguid W P; Stewart D J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">1732-9</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries.  Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties.  It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension.  We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension.  METHODS:  We studied the distribution of endothelin-1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3.  RESULTS:  In the controls, endothelin-1-like immunoreactivity was rarely seen in vascular endothelial cells.  In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis.  Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1-like immunoreactivity.  There was a strong correlation between the intensity of endothelin-1-like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension.  CONCLUSIONS:  Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTm66l1sYsjv-R_TJajKxJDfW6udTcc2eZjDaLRuZnAxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s3mvVensA%253D%253D&md5=16ba9f2b5128052f096f08d695a7f73b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1056%2FNEJM199306173282402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199306173282402%26sid%3Dliteratum%253Aachs%26aulast%3DGiaid%26aufirst%3DA.%26aulast%3DYanagisawa%26aufirst%3DM.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DMichel%26aufirst%3DR.%2BP.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DShennib%26aufirst%3DH.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DMasaki%26aufirst%3DT.%26aulast%3DDuguid%26aufirst%3DW.%2BP.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26atitle%3DExpression%2520of%2520endothelin-1%2520in%2520the%2520lungs%2520of%2520patients%2520with%2520pulmonary%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D328%26spage%3D1732%26epage%3D1739%26doi%3D10.1056%2FNEJM199306173282402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halank, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orzechowski, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeffken, G.</span></span> <span> </span><span class="NLM_article-title">Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1562</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.1378/chest.120.5.1562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.120.5.1562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11713135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1Gkurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2001&pages=1562-1569&author=C.+Rubensauthor=R.+Ewertauthor=M.+Halankauthor=R.+Wenselauthor=H.+D.+Orzechowskiauthor=H.+P.+Schultheissauthor=G.+Hoeffken&title=Big+endothelin-1+and+endothelin-1+plasma+levels+are+correlated+with+the+severity+of+primary+pulmonary+hypertension&doi=10.1378%2Fchest.120.5.1562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension</span></div><div class="casAuthors">Rubens, Christoph; Ewert, Ralf; Halank, Michael; Wensel, Roland; Orzechowski, Hans-Dieter; Schultheiss, Heinz-Peter; Hoeffken, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1562-1569</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension (PPH) is a rare disease of unknown etiol. that is characterized by a poor prognosis.  This study was undertaken to investigate possible correlations between endothelin (ET)-1 and big ET-1 plasma levels and the severity of PPH.  Sixteen consecutive patients with PPH were included.  Hemodynamics of patients with PPH were measured by right-heart catheterization, and a 6-min walk test was performed.  Plasma levels of the biol. active peptide ET-1 and its precursor big ET-1 were detd. in blood samples from the pulmonary artery, peripheral artery, and peripheral vein by RIA.  A strong correlation was shown between pulmonary vascular resistance, mean pulmonary artery pressure, cardiac output, cardiac index, 6-min walk data, and elevated plasma levels of big ET-1 as well as mature ET-1 plasma levels at all sites of blood sampling (p < 0.01 and p < 0.05, resp.).  Levels of circulating ET-1 might become a prognostic marker for patients with PPH and serve as a tool for the selection of patients who may benefit from treatment with ET-receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3tVSTk7_7QrVg90H21EOLACvtfcHk0lhxcqG1ztSvig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1Gkurg%253D&md5=c5ec3cbe3f5c3ccb4413adeecef51d15</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1378%2Fchest.120.5.1562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.120.5.1562%26sid%3Dliteratum%253Aachs%26aulast%3DRubens%26aufirst%3DC.%26aulast%3DEwert%26aufirst%3DR.%26aulast%3DHalank%26aufirst%3DM.%26aulast%3DWensel%26aufirst%3DR.%26aulast%3DOrzechowski%26aufirst%3DH.%2BD.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DHoeffken%26aufirst%3DG.%26atitle%3DBig%2520endothelin-1%2520and%2520endothelin-1%2520plasma%2520levels%2520are%2520correlated%2520with%2520the%2520severity%2520of%2520primary%2520pulmonary%2520hypertension%26jtitle%3DChest%26date%3D2001%26volume%3D120%26spage%3D1562%26epage%3D1569%26doi%3D10.1378%2Fchest.120.5.1562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Endothelin receptor antagonists for the treatment of pulmonary artery hypertension</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2012.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.lfs.2012.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22884806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OjtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2012&pages=517-521&author=L.+J.+Rubin&title=Endothelin+receptor+antagonists+for+the+treatment+of+pulmonary+artery+hypertension&doi=10.1016%2Fj.lfs.2012.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor antagonists for the treatment of pulmonary artery hypertension</span></div><div class="casAuthors">Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">13-14</span>),
    <span class="NLM_cas:pages">517-521</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The demonstration that endothelin prodn. is upregulated in pulmonary artery hypertension (PAH) served as the rationale for developing endothelin-receptor antagonists (ERAs) as a treatment for PAH.  This article reviews the primary studies demonstrating efficacy of ERAs in PAH.Multicenter, placebo-controlled trials and open-label extension studies.Two orally active ERAs are currently approved for the treatment of PAH - the dual receptor antagonist bosentan, and the more selective ETA receptor antagonist ambrisentan-based on multicenter randomized clin. trials demonstrating efficacy and safety.  Long-term experience with both agents supports maintenance of therapeutic effects in most patients.  Adverse effects, including altered liver function and edema may occur and require careful monitoring.Despite failure to demonstrate efficacy of ERAs in other cardiopulmonary conditions, ERAs have a major role in the treatment algorithm for PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN6RyKMLtSCbVg90H21EOLACvtfcHk0lhjkUjetcG_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OjtrzP&md5=4417d2bd944627a484840c7137fe1ebf</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2012.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2012.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DEndothelin%2520receptor%2520antagonists%2520for%2520the%2520treatment%2520of%2520pulmonary%2520artery%2520hypertension%26jtitle%3DLife%2520Sci.%26date%3D2012%26volume%3D91%26spage%3D517%26epage%3D521%26doi%3D10.1016%2Fj.lfs.2012.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumo, F.</span></span> <span> </span><span class="NLM_article-title">Endothelin receptor subtype-b mediates synthesis of nitric-oxide by cultured bovine endothelial-cells</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">1367</span>– <span class="NLM_lpage">1373</span>, <span class="refDoi"> DOI: 10.1172/JCI116338</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI116338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7682570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK3sXisVymsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1993&pages=1367-1373&author=Y.+Hirataauthor=T.+Emoriauthor=S.+Eguchiauthor=K.+Kannoauthor=T.+Imaiauthor=K.+Ohtaauthor=F.+Marumo&title=Endothelin+receptor+subtype-b+mediates+synthesis+of+nitric-oxide+by+cultured+bovine+endothelial-cells&doi=10.1172%2FJCI116338"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells</span></div><div class="casAuthors">Hirata, Yukio; Emori, Toshiaki; Eguchi, Satoru; Kanno, Kazuo; Imai, Taihei; Ohta, Kazuki; Marumo, Fumiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1367-73</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">Endothelins (ET) produce endothelium-dependent vasodilation through nitric oxide (NO) synthesis.  The cellular mechanism by which ET induces synthesis and release of endothelium-derived NO by cultured bovine endothelial cells (EC) was examd.  Binding studies revealed that bovine EC membrane had binding sites for a novel agonist (BQ3020) of the non-isopeptide-selective receptor subtype (ETB).  Affinity labeling studies showed a major labeled band with the apparent mol. mass of 50 kD.  Northern blot anal. demonstrated the expression of mRNA for the ETB receptor.  BQ3020 rapidly and dose dependently induced formation of inositol 1,4,5-triphosphate and increased intracellular Ca2+ concns. in fura-2-loaded cells.  Concomitantly, BQ3020 dose dependently stimulated prodn. of both nitrate/nitrite (NOx) and cyclic GMP; a highly significant correlation existed between NOx and cGMP prodn.  The stimulatory effect on NOx and cGMP prodn. by ETB agonist was inhibited by the NO synthase inhibitor monomethyl-L-arginine; this effect was reversed by coaddn. of L-arginine, but not D-arginine.  NOx and cGMP prodn. stimulated by BQ3020 was inhibited by pretreatment with pertussis toxin.  ETB agonist-induced NOx prodn. was blocked by a calmodulin inhibitor and an intracellular Ca2+ chelator, but not by an extracellular Ca2+ chelator or a Ca2+ channel blocker.  These data suggest that endothelins stimulate ETB receptor-mediated phosphoinositide breakdown via pertussis toxin-sensitive G-protein(s), which triggers release of intracellular Ca2+, thereby activating Ca2+/calmodulin-dependent NO synthase in EC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLhVM04QbfebVg90H21EOLACvtfcHk0lhjkUjetcG_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXisVymsLs%253D&md5=bc94805a038db9977b2a7a254f87b5c8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1172%2FJCI116338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI116338%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DY.%26aulast%3DEmori%26aufirst%3DT.%26aulast%3DEguchi%26aufirst%3DS.%26aulast%3DKanno%26aufirst%3DK.%26aulast%3DImai%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DMarumo%26aufirst%3DF.%26atitle%3DEndothelin%2520receptor%2520subtype-b%2520mediates%2520synthesis%2520of%2520nitric-oxide%2520by%2520cultured%2520bovine%2520endothelial-cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1993%26volume%3D91%26spage%3D1367%26epage%3D1373%26doi%3D10.1172%2FJCI116338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neidhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bren, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessel, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramuz, H.</span></span> <span> </span><span class="NLM_article-title">The discovery of nonpeptide endothelin receptor antagonists. Progression towards bosentan</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">524</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK28Xnt1ygtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=519-524&author=W.+Neidhartauthor=V.+Brenauthor=D.+Burauthor=K.+Burriauthor=M.+Clozelauthor=G.+Hirthauthor=M.+Mullerauthor=H.+P.+Wesselauthor=H.+Ramuz&title=The+discovery+of+nonpeptide+endothelin+receptor+antagonists.+Progression+towards+bosentan"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of nonpeptide endothelin receptor antagonists. Progression towards bosentan</span></div><div class="casAuthors">Neidhart, Werner; Breu, Volker; Bur, Daniel; Burri, Kaspar; Clozel, Martine; Hirth, Georges; Mueller, Marcel; Wessel, Hans P.; Ramuz, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">519-524</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>;
        ISSN:<span class="NLM_cas:issn">0009-4293</span>.
    
            (<span class="NLM_cas:orgname">Neue Schweizerische Chemische Gesellschaft</span>)
        </div><div class="casAbstract">A review with 23 refs., describing the development of a novel class of nonpeptide endothelin receptor antagonists based on a lead file screening with special investigations on bosentan in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR6LsyBs_RyLVg90H21EOLACvtfcHk0lhjkUjetcG_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xnt1ygtLo%253D&md5=4c38eb56ca6997fe10b92799f87cd120</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeidhart%26aufirst%3DW.%26aulast%3DBren%26aufirst%3DV.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DBurri%26aufirst%3DK.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DHirth%26aufirst%3DG.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWessel%26aufirst%3DH.%2BP.%26aulast%3DRamuz%26aufirst%3DH.%26atitle%3DThe%2520discovery%2520of%2520nonpeptide%2520endothelin%2520receptor%2520antagonists.%2520Progression%2520towards%2520bosentan%26jtitle%3DChimia%26date%3D1996%26volume%3D50%26spage%3D519%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hiti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, G. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiossi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusic-Pajic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span> <span> </span><span class="NLM_article-title">Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">2093</span>– <span class="NLM_lpage">2100</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)60919-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0140-6736%2808%2960919-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18572079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1cvgt12itg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=2093-2100&author=N.+Galieauthor=L.+J.+Rubinauthor=M.+M.+Hoeperauthor=P.+Jansaauthor=H.+Al-Hitiauthor=G.+M.+B.+Meyerauthor=E.+Chiossiauthor=A.+Kusic-Pajicauthor=G.+Simonneau&title=Treatment+of+patients+with+mildly+symptomatic+pulmonary+arterial+hypertension+with+bosentan+%28EARLY+study%29%3A+a+double-blind%2C+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2808%2960919-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial</span></div><div class="casAuthors">Galie N; Rubin Lj; Hoeper Mm; Jansa P; Al-Hiti H; Meyer Gmb; Chiossi E; Kusic-Pajic A; Simonneau G</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">9630</span>),
    <span class="NLM_cas:pages">2093-100</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Treatments for pulmonary arterial hypertension have been mainly studied in patients with advanced disease (WHO functional class [FC] III and IV).  This study was designed to assess the effect of the dual endothelin receptor antagonist bosentan in patients with WHO FC II pulmonary arterial hypertension.  METHODS:  Patients with WHO FC II pulmonary arterial hypertension aged 12 years or over with 6-min walk distance of less than 80% of the normal predicted value or less than 500 m associated with a Borg dyspnoea index of 2 or greater were enrolled in this double-blind, placebo-controlled, multicentre trial. 185 patients were randomly assigned to receive bosentan (n=93) or placebo (n=92) for the 6-month double-blind treatment period via a centralised integrated voice recognition system.  Primary endpoints were pulmonary vascular resistance at month 6 expressed as percentage of baseline and change from baseline to month 6 in 6-min walk distance.  Analyses of the primary endpoints were done with all randomised patients who had a valid baseline assessment and an assessment or an imputed value for month 6.  This trial was registered with ClinicalTrials.gov, number NCT00091715.  FINDINGS:  Analyses were done with 168 patients (80 in the bosentan group, 88 in the placebo group) for pulmonary vascular resistance and with 177 (86 and 91) for 6-min walking distance.  At month 6, geometric mean pulmonary vascular resistance was 83.2% (95% CI 73.8-93.7) of the baseline value in the bosentan group and 107.5% (97.6-118.4) of the baseline value in the placebo group (treatment effect -22.6%, 95% CI -33.5 to -10.0; p<0.0001).  Mean 6-min walk distance increased from baseline in the bosentan group (11.2 m, 95% CI -4.6 to 27.0) and decreased in the placebo group (-7.9 m, -24.3 to 8.5), with a mean treatment effect of 19.1 m (95% CI 3.6-41.8; p=0.0758). 12 (13%) patients in the bosentan group and eight (9%) in the placebo group reported serious adverse events, the most common of which were syncope in the bosentan group and right ventricular failure in the placebo group.  INTERPRETATION:  Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThqEkH0P97IinGiHuhFGv8fW6udTcc2eZz1j4n2qDziLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvgt12itg%253D%253D&md5=db26e0a4a7898c0aaf0d20e8d05bfe70</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2960919-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252960919-8%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DAl-Hiti%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DG.%2BM.%2BB.%26aulast%3DChiossi%26aufirst%3DE.%26aulast%3DKusic-Pajic%26aufirst%3DA.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DTreatment%2520of%2520patients%2520with%2520mildly%2520symptomatic%2520pulmonary%2520arterial%2520hypertension%2520with%2520bosentan%2520%2528EARLY%2520study%2529%253A%2520a%2520double-blind%252C%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D2093%26epage%3D2100%26doi%3D10.1016%2FS0140-6736%2808%2960919-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naeije, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2049</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2006.01.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jacc.2006.01.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16697324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=2049-2056&author=R.+J.+Barstauthor=D.+Langlebenauthor=D.+Badeschauthor=A.+Frostauthor=E.+C.+Lawrenceauthor=S.+Shapiroauthor=R.+Naeijeauthor=N.+Galie&title=Treatment+of+pulmonary+arterial+hypertension+with+the+selective+endothelin-a+receptor+antagonist+sitaxsentan&doi=10.1016%2Fj.jacc.2006.01.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan</span></div><div class="casAuthors">Barst, Robyn J.; Langleben, David; Badesch, David; Frost, Adaani; Lawrence, E. Clinton; Shapiro, Shelley; Naeije, Robert; Galie, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2049-2056</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We sought to det. the optimal dose of the selective endothelin A (ETA) receptor antagonist sitaxsentan for the treatment of pulmonary arterial hypertension (PAH); for observation only, an open-label (OL) bosentan arm was included.  Endothelin is a mediator of PAH.  In a preliminary PAH study, the selective ETA receptor antagonist sitaxsentan improved six-min walk (6MW) distance, World Health Organization (WHO) functional class (FC), and hemodynamics.  In this double-blind, placebo-controlled 18-wk study, 247 PAH patients (idiopathic, or assocd. with connective tissue disease or congenital heart disease) were randomized; 245 patients were treated: placebo (n = 62), sitaxsentan 50 mg (n = 62) or 100 mg (n = 61), or OL (6MW tests, Borg dyspnea scores, and WHO FC assessments third-party blind) bosentan (n = 60).  The primary end point was change in 6MW distance from baseline to week 18.  Secondary end points included change in WHO FC, time to clin. worsening, and change in Borg dyspnea score.  At week 18, patients treated with sitaxsentan 100 mg had an increased 6MW distance compared with the placebo group (31.4 m, p = 0.03), and an improved WHO FC (p = 0.04).  The placebo-subtracted treatment effect for sitaxsentan 50 mg was 24.2 m (p = 0.07) and for OL bosentan, 29.5 m (p = 0.05).  The incidence of elevated hepatic transaminases (>3× the upper limit of normal) was 6% for placebo, 5% for sitaxsentan 50 mg, 3% for sitaxsentan 100 mg, and 11% for bosentan.  Treatment with the selective ETA receptor antagonist sitaxsentan, orally once daily at a dose of 100 mg, improves exercise capacity and WHO FC in PAH patients, with a low incidence of hepatic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ8rFM0c55NLVg90H21EOLACvtfcHk0ljuZ4yzKVV_Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFalsbs%253D&md5=b68081ed4dccf86d36293b82f765a9b6</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2006.01.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2006.01.057%26sid%3Dliteratum%253Aachs%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DLawrence%26aufirst%3DE.%2BC.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DNaeije%26aufirst%3DR.%26aulast%3DGalie%26aufirst%3DN.%26atitle%3DTreatment%2520of%2520pulmonary%2520arterial%2520hypertension%2520with%2520the%2520selective%2520endothelin-a%2520receptor%2520antagonist%2520sitaxsentan%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2006%26volume%3D47%26spage%3D2049%26epage%3D2056%26doi%3D10.1016%2Fj.jacc.2006.01.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vatter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifert, V.</span></span> <span> </span><span class="NLM_article-title">Ambrisentan, a non-peptide endothelin receptor antagonist</span>. <i>Cardiovasc. Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3466.2006.00063.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fj.1527-3466.2006.00063.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16939634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWjsrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=63-76&author=H.+Vatterauthor=V.+Seifert&title=Ambrisentan%2C+a+non-peptide+endothelin+receptor+antagonist&doi=10.1111%2Fj.1527-3466.2006.00063.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan, a non-peptide endothelin receptor antagonist</span></div><div class="casAuthors">Vatter, Hartmut; Seifert, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Drug Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-76</span>CODEN:
                <span class="NLM_cas:coden">CDREEA</span>;
        ISSN:<span class="NLM_cas:issn">0897-5957</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Increasing nos. of exptl. investigations and recently also of clin. trials strongly suggest an integral involvement of the endothelin (ET)-system in the pathophysiol. of a variety of disease states, mainly of the cardiovascular system.  Ambrisentan (LU 208075), a selective ETA-receptor antagonist, is an orally active di-Ph propionic acid deriv.  It has been shown to have a very promising efficacy to safety ratio in the initial clin. trials.  Phase II and Phase III trials with ambrisentan in pulmonary arterial hypertension have been performed.  The pharmacol. properties and data from the exptl. investigations suggest addnl. possible uses of ambrisentan in the prevention of reperfusion injury after organ transplantation and in restenosis following coronary artery dilatation.  Furthermore, the pharmacol. profile of ambrisentan indicates that this drug may also be suitable in the treatment of cerebrovascular disorders.  In the present article basic investigations, animal studies and clin. trials with ambrisentan are reviewed.  This review may help to define pathophysiol. conditions, in which ambrisentan could be indicated and further evaluated in appropriate preclin. and clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnKVjoXdyMhLVg90H21EOLACvtfcHk0ljuZ4yzKVV_Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWjsrbO&md5=3120d9425067112ba5df2c25fe4c5f54</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3466.2006.00063.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3466.2006.00063.x%26sid%3Dliteratum%253Aachs%26aulast%3DVatter%26aufirst%3DH.%26aulast%3DSeifert%26aufirst%3DV.%26atitle%3DAmbrisentan%252C%2520a%2520non-peptide%2520endothelin%2520receptor%2520antagonist%26jtitle%3DCardiovasc.%2520Drug%2520Rev.%26date%3D2006%26volume%3D24%26spage%3D63%26epage%3D76%26doi%3D10.1111%2Fj.1527-3466.2006.00063.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roecker, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiens, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ambrisentan for the treatment of pulmonary arterial hypertension - results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3010</span>– <span class="NLM_lpage">3019</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.107.742510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.107.742510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18506008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFymu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2008&pages=3010-3019&author=N.+Galieauthor=H.+Olschewskiauthor=R.+J.+Oudizauthor=F.+Torresauthor=A.+Frostauthor=H.+A.+Ghofraniauthor=D.+B.+Badeschauthor=M.+D.+McGoonauthor=V.+V.+McLaughlinauthor=E.+B.+Roeckerauthor=M.+J.+Gerberauthor=C.+Duftonauthor=B.+L.+Wiensauthor=L.+J.+Rubin&title=Ambrisentan+for+the+treatment+of+pulmonary+arterial+hypertension+-+results+of+the+ambrisentan+in+pulmonary+arterial+hypertension%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+multicenter%2C+efficacy+%28ARIES%29+study+1+and+2&doi=10.1161%2FCIRCULATIONAHA.107.742510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Olschewski, Horst; Oudiz, Ronald J.; Torres, Fernando; Frost, Adaani; Ghofrani, Hossein A.; Badesch, David B.; McGoon, Michael D.; McLaughlin, Vallerie V.; Roecker, Ellen B.; Gerber, Michael J.; Dufton, Christopher; Wiens, Brian L.; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3010-3019</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension.  Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study 1 and 2 (ARIES-1 and ARIES-2) were concurrent, double-blind, placebo-controlled studies that randomized 202 and 192 patients with pulmonary arterial hypertension, resp., to placebo or ambrisentan (ARIES-1, 5 or 10 mg; ARIES-2, 2.5 or 5 mg) orally once daily for 12 wk.  The primary end point for each study was change in 6-min walk distance from baseline to week 12.  Clin. worsening, World Health Organization functional class, Short Form-36 Health Survey score, Borg dyspnea score, and B-type natriuretic peptide plasma concns. also were assessed.  In addn., a long-term extension study was performed.  The 6-min walk distance increased in all ambrisentan groups; mean placebo-cor. treatment effects were 31 m (P=0.008) and 51 m (P<0.001) in ARIES-1 for 5 and 10 mg ambrisentan, resp., and 32 m (P=0.022) and 59 m (P<0.001) in ARIES-2 for 2.5 and 5 mg ambrisentan, resp.  Improvements in time to clin. worsening (ARIES-2), World Health Organization functional class (ARIES-1), Short Form-36 score (ARIES-2), Borg dyspnea score (both studies), and B-type natriuretic peptide (both studies) were obsd.  No patient treated with ambrisentan developed aminotransferase concns. >3 times the upper limit of normal.  In 280 patients completing 48 wk of treatment with ambrisentan monotherapy, the improvement from baseline in 6-min walk at 48 wk was 39 m.  Ambrisentan improves exercise capacity in patients with pulmonary arterial hypertension.  Improvements were obsd. for several secondary end points in each of the studies, although statistical significance was more variable.  Ambrisentan is well tolerated and is assocd. with a low risk of aminotransferase abnormalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV0o6GSdBgGLVg90H21EOLACvtfcHk0liVi41rw25nnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFymu70%253D&md5=ebf9b6c539d3e5ab3df8bfec520b2a77</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.107.742510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.107.742510%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DRoecker%26aufirst%3DE.%2BB.%26aulast%3DGerber%26aufirst%3DM.%2BJ.%26aulast%3DDufton%26aufirst%3DC.%26aulast%3DWiens%26aufirst%3DB.%2BL.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%2520-%2520results%2520of%2520the%2520ambrisentan%2520in%2520pulmonary%2520arterial%2520hypertension%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520multicenter%252C%2520efficacy%2520%2528ARIES%2529%2520study%25201%2520and%25202%26jtitle%3DCirculation%26date%3D2008%26volume%3D117%26spage%3D3010%26epage%3D3019%26doi%3D10.1161%2FCIRCULATIONAHA.107.742510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGoon, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1378/chest.08-1028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1378%2Fchest.08-1028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18812445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvV2ltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2009&pages=122-129&author=M.+D.+McGoonauthor=A.+E.+Frostauthor=R.+J.+Oudizauthor=D.+B.+Badeschauthor=N.+Galieauthor=H.+Olschewskiauthor=V.+V.+McLaughlinauthor=M.+J.+Gerberauthor=C.+Duftonauthor=D.+J.+Despainauthor=L.+J.+Rubin&title=Ambrisentan+therapy+in+patients+with+pulmonary+arterial+hypertension+who+discontinued+bosentan+or+sitaxsentan+due+to+liver+function+test+abnormalities&doi=10.1378%2Fchest.08-1028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities</span></div><div class="casAuthors">McGoon, Michael D.; Frost, Adaani E.; Oudiz, Ronald J.; Badesch, David B.; Galie, Nazzareno; Olschewski, Horst; McLaughlin, Vallerie V.; Gerber, Michael J.; Dufton, Chris; Despain, Darrin J.; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">122-129</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">Background: Some endothelin receptor antagonists (ERAs) are assocd. with liver function test (LFT) result abnormalities.  However, ambrisentan has an incidence of serum aminotransferase levels more than three times the upper limit of normal (ULN), similar to that obsd. in PAH patients who are not receiving ERAs.  Because ambrisentan may provide benefits in PAH patients who have discontinued ERA therapy due to LFT abnormalities, we evaluated the safety and efficacy of ambrisentan in this patient population.  Methods: Patients who previously discontinued bosentan and/or sitaxsentan due to LFT abnormalities received ambrisentan, 2.5 mg qd, for 4 wk followed by 5 mg/d for 8 wk.  The primary end point was the incidence of aminotransferase levels more than three times ULN considered by the investigator to be related to ambrisentan and resulting in drug discontinuation.  Secondary end points included aminotransferase levels more than five times ULN requiring drug discontinuation and more than three times ULN requiring dose redn., as well as changes in 6-min walk distance (6MWD), Borg dyspnea index, World Health Organization functional class, and Short Form-36 health survey score.  Patients continued treatment beyond the 12-wk end point with monthly monitoring of LFTs.  Results: Thirty-six patients who previously discontinued bosentan (n = 31), sitaxsentan (n = 2), or both (n = 3) were enrolled.  At baseline, 69.4% of patients were receiving prostanoid and/or sildenafil therapy.  No patient had an aminotransferase level more than three times ULN that required ambrisentan discontinuation.  One patient had a transient aminotransferase level more than three times ULN that resolved following a temporary dose redn.  No addnl. aminotransferase levels more than three times ULN were obsd. with long-term treatment (median exposure, 102 wk), despite dose increases to 10 mg qd in more than half of the patients.  Significant improvements in 6MWD and other efficacy assessments were obsd.  Conclusions: Ambrisentan treatment may be an option for patients who have discontinued bosentan and/or sitaxsentan therapy due to LFT result abnormalities.  Trial registration: Clinicaltrials.gov Identifier NCT00423592.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXWLH5SlJGaLVg90H21EOLACvtfcHk0liVi41rw25nnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvV2ltrY%253D&md5=796bcc65870dd6ba5a253a6536ad4c55</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1378%2Fchest.08-1028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.08-1028%26sid%3Dliteratum%253Aachs%26aulast%3DMcGoon%26aufirst%3DM.%2BD.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%2BB.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DGerber%26aufirst%3DM.%2BJ.%26aulast%3DDufton%26aufirst%3DC.%26aulast%3DDespain%26aufirst%3DD.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DAmbrisentan%2520therapy%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520who%2520discontinued%2520bosentan%2520or%2520sitaxsentan%2520due%2520to%2520liver%2520function%2520test%2520abnormalities%26jtitle%3DChest%26date%3D2009%26volume%3D135%26spage%3D122%26epage%3D129%26doi%3D10.1378%2Fchest.08-1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dupuis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasmin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernacek, P.</span></span> <span> </span><span class="NLM_article-title">Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1006/pupt.2000.0242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1006%2Fpupt.2000.0242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10873551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkt1KntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=135-140&author=J.+Dupuisauthor=J.+F.+Jasminauthor=S.+Prieauthor=P.+Cernacek&title=Importance+of+local+production+of+endothelin-1+and+of+the+ETB+receptor+in+the+regulation+of+pulmonary+vascular+tone&doi=10.1006%2Fpupt.2000.0242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Importance of local production of endothelin-1 and of the ETB receptor in the regulation of pulmonary vascular tone</span></div><div class="casAuthors">Dupuis, J.; Jasmin, J. F.; Prie, S.; Cernacek, P.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">135-140</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Interaction between locally released endothelin-1 (ET-1) and the endothelial ETB receptor could modulate pulmonary vascular tone.  The authors evaluated pulmonary ET-1 clearance and ET-1-ETB receptor interaction in the modulation of pulmonary vascular tone.  Controls and rats with Monocrotaline (MCT)-induced pulmonary hypertension (PH) were studied.  Lungs were isolated and perfused under const. pressure.  The effect of the selective ETB antagonist BQ-788 (10-12-10-8 mole) on perfusion flow rate and 125I-ET-1 extn. was detd.  Baseline 125I-ET-1 extn. was reduced from 62±5% in controls to 49±10% in PH (P=0.012).  BQ-788 inhibited extn. with a higher half-ID in the MCT group (-Log ID50= 8.9±0.4 vs. 9.5±0.1, P=0.03).  BQ-788 induced a mild redn. in perfusion flow rate of 0.7±0.3 mL/min in controls.  In the MCT group, this occurred at a lower dose and was more pronounced with a maximal redn. of 3.3±0.7 mL/min (P<0.01 vs. control).  ET-1 was undetectable in the effluent at baseline but was present in similar concns. in both groups after ETB blockade.  Addn. of 2 pg/mL ET-1 to lung perfusate did not modify pulmonary ET-1 clearance or the effect of BQ788 on perfusion flow rate in control lungs.  In normal rat lungs, the ETB receptor plays a minor regulatory role on vascular tone.  In MCT hypertension however, despite a redn. in ETB mediated extn., luminal prodn. of ET-1 attenuates the increase in pulmonary vascular tone.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD4QmKYo-8urVg90H21EOLACvtfcHk0liVi41rw25nnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkt1KntL0%253D&md5=3652b3318f2b8472dc41a89e51dc43cf</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1006%2Fpupt.2000.0242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fpupt.2000.0242%26sid%3Dliteratum%253Aachs%26aulast%3DDupuis%26aufirst%3DJ.%26aulast%3DJasmin%26aufirst%3DJ.%2BF.%26aulast%3DPrie%26aufirst%3DS.%26aulast%3DCernacek%26aufirst%3DP.%26atitle%3DImportance%2520of%2520local%2520production%2520of%2520endothelin-1%2520and%2520of%2520the%2520ETB%2520receptor%2520in%2520the%2520regulation%2520of%2520pulmonary%2520vascular%2520tone%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D13%26spage%3D135%26epage%3D140%26doi%3D10.1006%2Fpupt.2000.0242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juillerat-Jeanneret, L.</span></span> <span> </span><span class="NLM_article-title">Endothelin-receptor antagonists beyond pulmonary arterial hypertension: cancer and fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8168</span>– <span class="NLM_lpage">8188</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01781</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01781" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8168-8188&author=J.+D.+Aubertauthor=L.+Juillerat-Jeanneret&title=Endothelin-receptor+antagonists+beyond+pulmonary+arterial+hypertension%3A+cancer+and+fibrosis&doi=10.1021%2Facs.jmedchem.5b01781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis</span></div><div class="casAuthors">Aubert, John-David; Juillerat-Jeanneret, Lucienne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8168-8188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for therapeutic intervention in human diseases.  Endothelin-receptor antagonists are in clin. use to treat pulmonary arterial hypertension and have been under clin. investigation for the treatment of several other diseases, such as systemic hypertension, cancer, vasospasm, and fibrogenic diseases.  In this Perspective, we review the mols. that have been evaluated in human clin. trials for the treatment of pulmonary arterial hypertension, as well as other cardiovascular diseases, cancer, and fibrosis.  We will also discuss the therapeutic consequences of receptor selectivity with regard to ETA-selective, ETB-selective, or dual ETA/ETB antagonists.  We will also consider which chem. characteristics are relevant to clin. use and the properties of mols. necessary for efficacy in treating diseases against which known mols. displayed suboptimal efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKfhFfiImWNbVg90H21EOLACvtfcHk0lhdBk2PH_HSCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVClsrs%253D&md5=b6f008d678c7e4ff5ded1db5f4a940c5</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01781%26sid%3Dliteratum%253Aachs%26aulast%3DAubert%26aufirst%3DJ.%2BD.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26atitle%3DEndothelin-receptor%2520antagonists%2520beyond%2520pulmonary%2520arterial%2520hypertension%253A%2520cancer%2520and%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8168%26epage%3D8188%26doi%3D10.1021%2Facs.jmedchem.5b01781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, T.</span></span> <span> </span><span class="NLM_article-title">The discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7849</span>– <span class="NLM_lpage">7861</span>, <span class="refDoi"> DOI: 10.1021/jm3009103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7849-7861&author=M.+H.+Bolliauthor=C.+Bossauthor=C.+Binkertauthor=S.+Buchmannauthor=D.+Burauthor=P.+Hessauthor=M.+Iglarzauthor=S.+Meyerauthor=J.+Reinauthor=M.+Reyauthor=A.+Treiberauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=The+discovery+of+N-%5B5-%284-Bromophenyl%29-6-%5B2-%5B%285-bromo-2-pyrimidinyl%29oxy%5Dethoxy%5D-4-pyrimidinyl%5D-N%E2%80%99-propylsulfamide+%28macitentan%29%2C+an+orally+active%2C+potent+dual+endothelin+receptor+antagonist&doi=10.1021%2Fjm3009103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist</span></div><div class="casAuthors">Bolli, Martin H.; Boss, Christoph; Binkert, Christoph; Buchmann, Stephan; Bur, Daniel; Hess, Patrick; Iglarz, Marc; Meyer, Solange; Rein, Josiane; Rey, Markus; Treiber, Alexander; Clozel, Martine; Fischli, Walter; Weller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7849-7861</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the structure of bosentan (1), we embarked on a medicinal chem. program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.  This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines.  Among these, compd. 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ETB receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats.  Compd. 17 successfully completed a long-term phase III clin. trial for pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZxi30yihGrbVg90H21EOLACvtfcHk0lhdBk2PH_HSCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP&md5=796cde2ff9ea36a2881dc58e46e903b7</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm3009103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009103%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRein%26aufirst%3DJ.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DThe%2520discovery%2520of%2520N-%255B5-%25284-Bromophenyl%2529-6-%255B2-%255B%25285-bromo-2-pyrimidinyl%2529oxy%255Dethoxy%255D-4-pyrimidinyl%255D-N%25E2%2580%2599-propylsulfamide%2520%2528macitentan%2529%252C%2520an%2520orally%2520active%252C%2520potent%2520dual%2520endothelin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7849%26epage%3D7861%26doi%3D10.1021%2Fjm3009103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bur, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, T.</span></span> <span> </span><span class="NLM_article-title">The discovery of N- 5-(4-Bromophenyl)-6- 2-(5-bromo-2-pyrimidinyl)oxy ethoxy −4-pyrimidi nyl -N ’-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7849</span>– <span class="NLM_lpage">7861</span>, <span class="refDoi"> DOI: 10.1021/jm3009103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3009103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7849-7861&author=M.+H.+Bolliauthor=C.+Bossauthor=C.+Binkertauthor=S.+Buchmannauthor=D.+Burauthor=P.+Hessauthor=M.+Iglarzauthor=S.+Meyerauthor=J.+Reinauthor=M.+Reyauthor=A.+Treiberauthor=M.+Clozelauthor=W.+Fischliauthor=T.+Weller&title=The+discovery+of+N-+5-%284-Bromophenyl%29-6-+2-%285-bromo-2-pyrimidinyl%29oxy+ethoxy+%E2%88%924-pyrimidi+nyl+-N+%E2%80%99-propylsulfamide+%28macitentan%29%2C+an+orally+active%2C+potent+dual+endothelin+receptor+antagonist&doi=10.1021%2Fjm3009103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist</span></div><div class="casAuthors">Bolli, Martin H.; Boss, Christoph; Binkert, Christoph; Buchmann, Stephan; Bur, Daniel; Hess, Patrick; Iglarz, Marc; Meyer, Solange; Rein, Josiane; Rey, Markus; Treiber, Alexander; Clozel, Martine; Fischli, Walter; Weller, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7849-7861</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the structure of bosentan (1), we embarked on a medicinal chem. program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy.  This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines.  Among these, compd. 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ETB receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats.  Compd. 17 successfully completed a long-term phase III clin. trial for pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZxi30yihGrbVg90H21EOLACvtfcHk0lhdBk2PH_HSCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFClurjP&md5=796cde2ff9ea36a2881dc58e46e903b7</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fjm3009103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3009103%26sid%3Dliteratum%253Aachs%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DS.%26aulast%3DRein%26aufirst%3DJ.%26aulast%3DRey%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DClozel%26aufirst%3DM.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DT.%26atitle%3DThe%2520discovery%2520of%2520N-%25205-%25284-Bromophenyl%2529-6-%25202-%25285-bromo-2-pyrimidinyl%2529oxy%2520ethoxy%2520%25E2%2588%25924-pyrimidi%2520nyl%2520-N%2520%25E2%2580%2599-propylsulfamide%2520%2528macitentan%2529%252C%2520an%2520orally%2520active%252C%2520potent%2520dual%2520endothelin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7849%26epage%3D7861%26doi%3D10.1021%2Fjm3009103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iglarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binkert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatfield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolli, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boss, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capeleto, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clozel, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.142976</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.108.142976" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18780830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=736-745&author=M.+Iglarzauthor=C.+Binkertauthor=K.+Morrisonauthor=W.+Fischliauthor=J.+Gatfieldauthor=A.+Treiberauthor=T.+Wellerauthor=M.+H.+Bolliauthor=C.+Bossauthor=S.+Buchmannauthor=B.+Capeletoauthor=P.+Hessauthor=C.+Qiuauthor=M.+Clozel&title=Pharmacology+of+macitentan%2C+an+orally+active+tissue-targeting+dual+endothelin+receptor+antagonist&doi=10.1124%2Fjpet.108.142976"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist</span></div><div class="casAuthors">Iglarz, Marc; Binkert, Christoph; Morrison, Keith; Fischli, Walter; Gatfield, John; Treiber, Alexander; Weller, Thomas; Bolli, Martin H.; Boss, Christoph; Buchmann, Stephan; Capeleto, Bruno; Hess, Patrick; Qiu, Changbin; Clozel, Martine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">736-745</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Macitentan, also called Actelion-1 or ACT-064992 [N-[5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl]-N'-propylaminosulfonamide],is a new dual ETA/ETB endothelin (ET) receptor antagonist designed for tissue targeting.  Selection of macitentan was based on inhibitory potency on both ET receptors and optimization of physicochem. properties to achieve high affinity for lipophilic milieu.  In vivo, macitentan is metabolized into a major and pharmacol. active metabolite, ACT-132577.  Macitentan and its metabolite antagonized the specific binding of ET-1 on membranes of cells overexpressing ETA and ETB receptors and blunted ET-1-induced calcium mobilization in various natural cell lines, with inhibitory consts. within the nanomolar range.  In functional assays, macitentan and ACT-132577 inhibited ET-1-induced contractions in isolated endothelium-denuded rat aorta (ETA receptors) and sarafotoxin S6c-induced contractions in isolated rat trachea (ETB receptors).  In rats with pulmonary hypertension, macitentan prevented both the increase of pulmonary pressure and the right ventricle hypertrophy, and it markedly improved survival.  In diabetic rats, chronic administration of macitentan decreased blood pressure and proteinuria and prevented end-organ damage (renal vascular hypertrophy and structural injury).  In conclusion, macitentan, by its tissue-targeting properties and dual antagonism of ET receptors, protects against end-organ damage in diabetes and improves survival in pulmonary hypertensive rats.  This profile makes macitentan a new agent to treat cardiovascular disorders assocd. with chronic tissue ET system activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIo4YPpTRKFrVg90H21EOLACvtfcHk0ljQmf12ig_lPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtLvO&md5=00d0f8e55081e3851b8f9b5740b8d419</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.142976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.142976%26sid%3Dliteratum%253Aachs%26aulast%3DIglarz%26aufirst%3DM.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DMorrison%26aufirst%3DK.%26aulast%3DFischli%26aufirst%3DW.%26aulast%3DGatfield%26aufirst%3DJ.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DWeller%26aufirst%3DT.%26aulast%3DBolli%26aufirst%3DM.%2BH.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DBuchmann%26aufirst%3DS.%26aulast%3DCapeleto%26aufirst%3DB.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DQiu%26aufirst%3DC.%26aulast%3DClozel%26aufirst%3DM.%26atitle%3DPharmacology%2520of%2520macitentan%252C%2520an%2520orally%2520active%2520tissue-targeting%2520dual%2520endothelin%2520receptor%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D736%26epage%3D745%26doi%3D10.1124%2Fjpet.108.142976" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulido, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adzerikho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Channick, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcroix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Brun, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittelholzer, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perchenet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, B. K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souza, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Macitentan and morbidity and mortality in pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">809</span>– <span class="NLM_lpage">818</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1213917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1213917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23984728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=809-818&author=T.+Pulidoauthor=I.+Adzerikhoauthor=R.+N.+Channickauthor=M.+Delcroixauthor=N.+Galieauthor=H.+A.+Ghofraniauthor=P.+Jansaauthor=Z.+C.+Jingauthor=F.+O.+Le+Brunauthor=S.+Mehtaauthor=C.+M.+Mittelholzerauthor=L.+Perchenetauthor=B.+K.+S.+Sastryauthor=O.+Sitbonauthor=R.+Souzaauthor=A.+Torbickiauthor=X.+F.+Zengauthor=L.+J.+Rubinauthor=G.+Simonneau&title=Macitentan+and+morbidity+and+mortality+in+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1213917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Macitentan and morbidity and mortality in pulmonary arterial hypertension</span></div><div class="casAuthors">Pulido, Tomas; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galie, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loic; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogerio; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-818</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point.  We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.  METHODS We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg.  Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry.  The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with i.v. or s.c. prostanoids, or worsening of pulmonary arterial hypertension.  RESULTS A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.  The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, resp.  The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P = 0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001).  Worsening of pulmonary arterial hypertension was the most frequent primary end-point event.  The effect of macitentan on this end point was obsd. regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline.  Adverse events more frequently assocd. with macitentan than with placebo were headache, nasopharyngitis, and anemia.  CONCLUSIONS Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAWzzZ3N-2NrVg90H21EOLACvtfcHk0ljQmf12ig_lPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyis7fP&md5=430d59843298eaa407aa8a67acc84f81</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1213917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1213917%26sid%3Dliteratum%253Aachs%26aulast%3DPulido%26aufirst%3DT.%26aulast%3DAdzerikho%26aufirst%3DI.%26aulast%3DChannick%26aufirst%3DR.%2BN.%26aulast%3DDelcroix%26aufirst%3DM.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DLe%2BBrun%26aufirst%3DF.%2BO.%26aulast%3DMehta%26aufirst%3DS.%26aulast%3DMittelholzer%26aufirst%3DC.%2BM.%26aulast%3DPerchenet%26aufirst%3DL.%26aulast%3DSastry%26aufirst%3DB.%2BK.%2BS.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSouza%26aufirst%3DR.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DX.%2BF.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DMacitentan%2520and%2520morbidity%2520and%2520mortality%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D809%26epage%3D818%26doi%3D10.1056%2FNEJMoa1213917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S. Q.</span></span> <span> </span><span class="NLM_article-title">Therapeutic monoclonal antibody antagonizing endothelin receptor a for pulmonary arterial hypertension</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">54</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.252700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.118.252700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30992315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSgurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2019&pages=54-61&author=C.+Zhangauthor=X.+F.+Wangauthor=H.+Zhangauthor=C.+J.+Yaoauthor=H.+Panauthor=Y.+Guoauthor=K.+S.+Fanauthor=S.+Q.+Jing&title=Therapeutic+monoclonal+antibody+antagonizing+endothelin+receptor+a+for+pulmonary+arterial+hypertension&doi=10.1124%2Fjpet.118.252700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic monoclonal antibody antagonizing endothelin receptor A for pulmonary arterial hypertension</span></div><div class="casAuthors">Zhang, Cheng; Wang, Xiaofeng; Zhang, Hua; Yao, Chenjiang; Pan, Hao; Guo, Yong; Fan, Kesuo; Jing, Shuqian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-61</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Endothelin receptor A (ETA) is a G protein-coupled receptor and a major therapeutic target for pulmonary arterial hypertension (PAH).  We took a novel approach and developed an antagonistic monoclonal antibody, getagozumab, specifically against ETA.  Getagozumab displayed a Kd value of 8.7 nM and an IC50 value of 37.9 nM in the cell-based assays.  Getagozumab could significantly lower pulmonary arterial pressure in both hypoxia-induced and monocrotaline (MCT)-induced PAH monkey models and further attenuate the pulmonary arterial and right ventricular hypertrophy in MCT-induced PAH monkeys.  The preclin. studies demonstrated that getagozumab is safe, long lasting, and efficacious.  Getagozumab may provide a new and effective treatment for PAH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1AGncnKGFQ7Vg90H21EOLACvtfcHk0lg-mg56HdmOBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSgurzI&md5=e665e06b22c130e2757fa0d66af1dbf1</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.252700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.252700%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DC.%2BJ.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DK.%2BS.%26aulast%3DJing%26aufirst%3DS.%2BQ.%26atitle%3DTherapeutic%2520monoclonal%2520antibody%2520antagonizing%2520endothelin%2520receptor%2520a%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D370%26spage%3D54%26epage%3D61%26doi%3D10.1124%2Fjpet.118.252700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammendola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlossmann, J.</span></span> <span> </span><span class="NLM_article-title">Rising behind NO: cGMP-dependent protein kinases</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1671</span>– <span class="NLM_lpage">1676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10769198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFGls7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2000&pages=1671-1676&author=F.+Hofmannauthor=A.+Ammendolaauthor=J.+Schlossmann&title=Rising+behind+NO%3A+cGMP-dependent+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Rising behind NO: cGMP-dependent protein kinases</span></div><div class="casAuthors">Hofmann, Franz; Ammendola, Aldo; Schlossmann, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1671-1676</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Over the past few years, a wealth of biochem. and functional data has been gathered on mammalian cGMP-dependent protein kinases (cGKs).  In mammals, three different kinases are encoded by two genes.  Mutant and chimeric cGMP kinase proteins generated by mol. biol. techniques have yielded important biochem. knowledge, such as the function of the N-terminal domains of cGKI and cGKII, the identity of the cGMP-binding sites of cGKI, the substrate specificity of the enzymes and structural details of the catalytic center.  Genetic approaches have proved to be esp. useful for the anal. of the biol. function of cGKs.  Recently, some of the in vivo targets and mechanisms leading to smooth muscle relaxation have been identified.  In vivo targets are the myosin-binding subunit of myosin phosphatase (PP1M), a member of the protein phosphatase 1, the calcium-activated maxi K+ channel and a new protein named IRAG that forms a complex with the inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) receptor and cGKI.  Phosphorylation of PP1M by cGKIα activates myosin phosphatase, whereas phosphorylation of IRAG by cGKIβ decreases Ins(1,4,5)P3-induced calcium release.  The cGKII regulates in vivo intestinal fluid secretion by phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR), bone growth and renal renin secretion by phosphorylation of unknown proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNNtPIX1JkJrVg90H21EOLACvtfcHk0lg-mg56HdmOBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFGls7g%253D&md5=533206569aa2152c102c26c152256088</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DAmmendola%26aufirst%3DA.%26aulast%3DSchlossmann%26aufirst%3DJ.%26atitle%3DRising%2520behind%2520NO%253A%2520cGMP-dependent%2520protein%2520kinases%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2000%26volume%3D113%26spage%3D1671%26epage%3D1676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giaid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, D.</span></span> <span> </span><span class="NLM_article-title">Reduced expression of endothelial nitric-oxide synthase in the lungs of patients with pulmonary-hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1056/NEJM199507273330403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJM199507273330403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7540722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK2Mzht1Sgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1995&pages=214-221&author=A.+Giaidauthor=D.+Saleh&title=Reduced+expression+of+endothelial+nitric-oxide+synthase+in+the+lungs+of+patients+with+pulmonary-hypertension&doi=10.1056%2FNEJM199507273330403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension</span></div><div class="casAuthors">Giaid A; Saleh D</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">214-21</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary hypertension is characterized by abnormal thickening of the pulmonary arteries and increased pulmonary vascular resistance.  Nitric oxide is a potent endothelium-derived vasorelaxant substance and an inhibitor of smooth-muscle-cell growth.  Nitric oxide is produced in various cell types by the action of an enzyme, nitric oxide synthase.  We compared the expression of endothelial nitric oxide synthase in the lungs of control subjects with that in the lungs of patients with pulmonary hypertension.  METHODS:  We investigated the expression of endothelial nitric oxide synthase by histochemical and immunohistochemical analysis, in situ hybridization, and Northern blot analysis in the lungs of 22 patients with plexogenic pulmonary arteriopathy (arteriopathy of grades 4 through 6), 24 patients with secondary pulmonary hypertension (arteriopathy of grades 1 through 3), and 23 control subjects.  RESULTS:  In the lungs of the control subjects, nitric oxide synthase was expressed at a high level in the vascular endothelium of all types of vessels and in the pulmonary epithelium.  In contrast, little or no expression of the enzyme was found in the vascular endothelium of pulmonary arteries with severe histologic abnormalities (i.e., plexiform lesions) in patients with pulmonary hypertension.  The intensity of the enzyme immunoreactivity correlated inversely with the severity of histologic changes.  There was an inverse correlation between the arterial expression of the enzyme and total pulmonary resistance in patients with plexogenic pulmonary arteriopathy (r = -0.766, P = 0.004).  CONCLUSIONS:  Pulmonary hypertension is associated with diminished expression of endothelial nitric oxide synthase.  It is possible that decreased expression of nitric oxide synthase may contribute to pulmonary vasoconstriction and to the excessive growth of the tunica media observed in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY84rBRawwM3qj_yg7twvpfW6udTcc2ebYTfiSpyMbp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2Mzht1Sgtg%253D%253D&md5=13735159d034868a3edb9ac794521d86</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1056%2FNEJM199507273330403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199507273330403%26sid%3Dliteratum%253Aachs%26aulast%3DGiaid%26aufirst%3DA.%26aulast%3DSaleh%26aufirst%3DD.%26atitle%3DReduced%2520expression%2520of%2520endothelial%2520nitric-oxide%2520synthase%2520in%2520the%2520lungs%2520of%2520patients%2520with%2520pulmonary-hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1995%26volume%3D333%26spage%3D214%26epage%3D221%26doi%3D10.1056%2FNEJM199507273330403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisbois, E. J.</span></span> <span> </span><span class="NLM_article-title">Clinical use of inhaled nitric oxide: Local and systemic applications</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1016/j.freeradbiomed.2019.11.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.freeradbiomed.2019.11.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31785330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSlurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=422-431&author=M.+Barnesauthor=E.+J.+Brisbois&title=Clinical+use+of+inhaled+nitric+oxide%3A+Local+and+systemic+applications&doi=10.1016%2Fj.freeradbiomed.2019.11.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical use of inhaled nitric oxide: Local and systemic applications</span></div><div class="casAuthors">Barnes, Megan; Brisbois, Elizabeth J.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">422-431</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Upon the FDA approval for inhaled nitric oxide (iNO) in 1999 to treat persistent pulmonary hypertension in neonates, iNO has proven to be a beneficial therapeutic in multiple diseases.  We aim to review applications of iNO that have modeled its protective and therapeutic attributes, as well as highlight preliminary studies that could allude to future avenues of use.  Numerous publications have reported specific incidences where iNO therapy has proved advantageous, while some applications have potential after further validation.  Establishing guidelines on dosing, duration, and defined clin. uses are crucial for the future of iNO.  Delivery of iNO has been controlled by a sole distributor, and comes with high cost, and lack of portability.  A shift in patents has allowed for new designs for iNO device synthesis, with many new developments of iNO medical devices that will likely change the future of iNO in a medical setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosbXJC5PB_rLVg90H21EOLACvtfcHk0lgH2Blrc65HGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSlurrO&md5=2d60bc8853acaad82be702b446d59867</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.freeradbiomed.2019.11.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.freeradbiomed.2019.11.029%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DM.%26aulast%3DBrisbois%26aufirst%3DE.%2BJ.%26atitle%3DClinical%2520use%2520of%2520inhaled%2520nitric%2520oxide%253A%2520Local%2520and%2520systemic%2520applications%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2020%26volume%3D152%26spage%3D422%26epage%3D431%26doi%3D10.1016%2Fj.freeradbiomed.2019.11.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaplen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooldridge, K.</span></span> <span> </span><span class="NLM_article-title">Antiallergic activity of 8-azapurin-6-ones with heterocyclic 2-substituents</span>. <i>Eur. J. Med. Chem. - Chim. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">449</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaE28XhtlSitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1975&pages=447-449&author=A.+Hollandauthor=D.+Jacksonauthor=P.+Chaplenauthor=E.+Luntauthor=S.+Marshallauthor=D.+Painauthor=K.+Wooldridge&title=Antiallergic+activity+of+8-azapurin-6-ones+with+heterocyclic+2-substituents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Antiallergic activity of 8-azapurin-6-ones with heterocyclic 2-substituents</span></div><div class="casAuthors">Holland, Anthony; Jackson, David; Chaplen, Peter; Lunt, Edward; Marshall, Stewart; Pain, David; Wooldridge, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">447-9</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    </div><div class="casAbstract">The synthesis and antiallergic activity in the rat passive cutaneous anaphylactic reaction of a series of 2-heterocyclyl-8-azapurin-6-ones (I) is described.  No significant correlation with partition factors was obsd. but there is some evidence to suggest that activity is enhanced when the 2-substituent contains a group which is capable of forming a hydrogen bond with the 1-position of the azapurinone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-8X5iRsmlJrVg90H21EOLACvtfcHk0lgH2Blrc65HGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhtlSitrc%253D&md5=0050a686a37e795b4ec7f38e13761557</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DA.%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DChaplen%26aufirst%3DP.%26aulast%3DLunt%26aufirst%3DE.%26aulast%3DMarshall%26aufirst%3DS.%26aulast%3DPain%26aufirst%3DD.%26aulast%3DWooldridge%26aufirst%3DK.%26atitle%3DAntiallergic%2520activity%2520of%25208-azapurin-6-ones%2520with%2520heterocyclic%25202-substituents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%2520-%2520Chim.%2520Ther.%26date%3D1975%26volume%3D10%26spage%3D447%26epage%3D449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P.</span></span> <span> </span><span class="NLM_article-title">Sildenafil (VIAGRA(TM)), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1824</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(96)00323-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2F0960-894X%2896%2900323-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK2sXjsVyrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=1819-1824&author=N.+K.+Terrettauthor=A.+S.+Bellauthor=D.+Brownauthor=P.+Ellis&title=Sildenafil+%28VIAGRA%28TM%29%29%2C+a+potent+and+selective+inhibitor+of+type+5+cGMP+phosphodiesterase+with+utility+for+the+treatment+of+male+erectile+dysfunction&doi=10.1016%2F0960-894X%2896%2900323-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction</span></div><div class="casAuthors">Terrett, Nicholas K.; Bell, Andrew S.; Brown, David; Ellis, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1819-1824</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">5-(2'-Alkoxyphenyl)pyrazolo[4,3-d]pyrimidin-7-ones, and in particular the authors' preferred compd., sildenafil (Viagra), discovered through a rational drug design program, are potent and selective inhibitors of the type 5 cGMP phosphodiesterase from both rabbit platelets and human corpus cavernosum.  Sildenafil is currently in the clinic for the oral treatment of male erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7W7FHK-wEJ7Vg90H21EOLACvtfcHk0lgH2Blrc65HGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsVyrtLw%253D&md5=2b2a31d0880dc0089a6253bcd7b182c9</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900323-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900323-X%26sid%3Dliteratum%253Aachs%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DEllis%26aufirst%3DP.%26atitle%3DSildenafil%2520%2528VIAGRA%2528TM%2529%2529%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520type%25205%2520cGMP%2520phosphodiesterase%2520with%2520utility%2520for%2520the%2520treatment%2520of%2520male%2520erectile%2520dysfunction%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D1819%26epage%3D1824%26doi%3D10.1016%2F0960-894X%2896%2900323-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sung, B.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeon Hwang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho Jeon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwan
Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min Yoon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyun, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin Eum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyu Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myung Cho, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>425</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1038/nature01914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnature01914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12955149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=98-102&author=B.-J.+Sungauthor=K.+Yeon+Hwangauthor=Y.+Ho+Jeonauthor=J.+I.+Leeauthor=Y.-S.+Heoauthor=J.+Hwan%0AKimauthor=J.+Moonauthor=J.+Min+Yoonauthor=Y.-L.+Hyunauthor=E.+Kimauthor=S.+Jin+Eumauthor=S.-Y.+Parkauthor=J.-O.+Leeauthor=T.+Gyu+Leeauthor=S.+Roauthor=J.+Myung+Cho&title=Structure+of+the+catalytic+domain+of+human+phosphodiesterase+5+with+bound+drug+molecules&doi=10.1038%2Fnature01914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules</span></div><div class="casAuthors">Sung, Byung-Je; Hwang, Kwang Yeon; Jeon, Young Ho; Lee, Jae Il; Heo, Yong-Seok; Kim, Jin Hwan; Moon, Jinho; Yoon, Jung Min; Hyun, Young-Lan; Kim, Eunmi; Eum, Sung Jin; Park, Sam-Yong; Lee, Jie-Oh; Lee, Tae Gyu; Ro, Seonggu; Cho, Joong Myung</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6953</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cAMP and cGMP.  As essential regulators of cyclic nucleotide signaling with diverse physiol. functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction.  Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolyzing activity in human corpus cavernosum tissue.  It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction.  Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available.  Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug mols. sildenafil, tadalafil (Cialis) and vardenafil (Levitra).  These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr5pTrMfa72rVg90H21EOLACvtfcHk0lgH2Blrc65HGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D&md5=8459333ee12ed3469f7b48d6e7f9fd5d</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature01914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01914%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DB.-J.%26aulast%3DYeon%2BHwang%26aufirst%3DK.%26aulast%3DHo%2BJeon%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DJ.%2BI.%26aulast%3DHeo%26aufirst%3DY.-S.%26aulast%3DHwan%2BKim%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DJ.%26aulast%3DMin%2BYoon%26aufirst%3DJ.%26aulast%3DHyun%26aufirst%3DY.-L.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DJin%2BEum%26aufirst%3DS.%26aulast%3DPark%26aufirst%3DS.-Y.%26aulast%3DLee%26aufirst%3DJ.-O.%26aulast%3DGyu%2BLee%26aufirst%3DT.%26aulast%3DRo%26aufirst%3DS.%26aulast%3DMyung%2BCho%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520catalytic%2520domain%2520of%2520human%2520phosphodiesterase%25205%2520with%2520bound%2520drug%2520molecules%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D98%26epage%3D102%26doi%3D10.1038%2Fnature01914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Structure-based discovery of PDEs inhibitors</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150825142134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F1568026615666150825142134" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=917-933&author=L.+Liauthor=W.+Chenauthor=T.+Chenauthor=J.+Renauthor=Y.+Xu&title=Structure-based+discovery+of+PDEs+inhibitors&doi=10.2174%2F1568026615666150825142134"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150825142134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150825142134%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DStructure-based%2520discovery%2520of%2520PDEs%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D16%26spage%3D917%26epage%3D933%26doi%3D10.2174%2F1568026615666150825142134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badesch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parpia, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzyna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Sildenafil citrate therapy for pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">2148</span>– <span class="NLM_lpage">2157</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa050010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa050010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16291984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1ajtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=2148-2157&author=N.+Galieauthor=H.+A.+Ghofraniauthor=A.+Torbickiauthor=R.+J.+Barstauthor=L.+J.+Rubinauthor=D.+Badeschauthor=T.+Flemingauthor=T.+Parpiaauthor=G.+Burgessauthor=A.+Branziauthor=F.+Grimmingerauthor=M.+Kurzynaauthor=G.+Simonneau&title=Sildenafil+citrate+therapy+for+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa050010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil citrate therapy for pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Ghofrani, Hossein A.; Torbicki, Adam; Barst, Robyn J.; Rubin, Lewis J.; Badesch, David; Fleming, Thomas; Parpia, Tamiza; Burgess, Gary; Branzi, Angelo; Grimminger, Friedrich; Kurzyna, Marcin; Simonneau, Gerald</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2148-2157</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cGMP, thereby enhancing the cGMP-mediated relaxation and growth inhibition of vascular smooth-muscle cells, including those in the lung.  METHODS: In this double-blind, placebo-controlled study, we randomly assigned 278 patients with symptomatic pulmonary arterial hypertension (either idiopathic or assocd. with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts) to placebo or sildenafil (20, 40, or 80 mg) orally three times daily for 12 wk.  The primary end point was the change from baseline to week 12 in the distance walked in six minutes.  The change in mean pulmonary-artery pressure and World Health Organization (WHO) functional class and the incidence of clin. worsening were also assessed, but the study was not powered to assess mortality.  Patients completing the 12-wk randomized study could enter a long-term extension study.  RESULTS: The distance walked in six minutes increased from baseline in all sildenafil groups; the mean placebo-cor. treatment effects were 45 m (+ 13.0 %), 46 m (+ 13.3 %), and 50 m (+ 14.7 %) for 20, 40, and 80 mg of sildenafil, resp. (P < 0.001 for all comparisons).  All sildenafil doses reduced the mean pulmonary-artery pressure (P = 0.04, P = 0.01, and P < 0.001, resp.), improved the WHO functional class (P = 0.003, P < 0.001, and P < 0.001, resp.), and were assocd. with side effects such as flushing, dyspepsia, and diarrhea.  The incidence of clin. worsening did not differ significantly between the patients treated with sildenafil and those treated with placebo.  Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m.  CONCLUSIONS: Sildenafil improves exercise capacity, WHO functional class, and hemodynamics in patients with symptomatic pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRmk6YHttM7Vg90H21EOLACvtfcHk0liQENJttv7XQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1ajtb%252FI&md5=98f9d612bdeb37178f0910263d9ca97f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050010%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26aulast%3DBadesch%26aufirst%3DD.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DParpia%26aufirst%3DT.%26aulast%3DBurgess%26aufirst%3DG.%26aulast%3DBranzi%26aufirst%3DA.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DKurzyna%26aufirst%3DM.%26aulast%3DSimonneau%26aufirst%3DG.%26atitle%3DSildenafil%2520citrate%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D2148%26epage%3D2157%26doi%3D10.1056%2FNEJMoa050010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayvergiya, R.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">851.e1</span>– <span class="NLM_lpage">851.e5</span>, <span class="refDoi"> DOI: 10.1016/j.ahj.2005.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ahj.2005.09.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2006&pages=851.e1-851.e5&author=T.+P.+Singhauthor=M.+Rohitauthor=A.+Groverauthor=D.+Malhotraauthor=R.+Vijayvergiya&title=A+randomized%2C+placebo-controlled%2C+double-blind%2C+crossover+study+to+evaluate+the+efficacy+of+oral+sildenafil+therapy+in+severe+pulmonary+artery+hypertension&doi=10.1016%2Fj.ahj.2005.09.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2005.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2005.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DT.%2BP.%26aulast%3DRohit%26aufirst%3DM.%26aulast%3DGrover%26aufirst%3DA.%26aulast%3DMalhotra%26aufirst%3DD.%26aulast%3DVijayvergiya%26aufirst%3DR.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520double-blind%252C%2520crossover%2520study%2520to%2520evaluate%2520the%2520efficacy%2520of%2520oral%2520sildenafil%2520therapy%2520in%2520severe%2520pulmonary%2520artery%2520hypertension%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2006%26volume%3D151%26spage%3D851.e1%26epage%3D851.e5%26doi%3D10.1016%2Fj.ahj.2005.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Monnier
de Gouville, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coste, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirilovsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyafil, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labaudinière, R.</span></span> <span> </span><span class="NLM_article-title">The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1H-imidazo[1‘,5‘:1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4525</span>– <span class="NLM_lpage">4532</span>, <span class="refDoi"> DOI: 10.1021/jm030056e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030056e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4525-4532&author=A.+Dauganauthor=P.+Grondinauthor=C.+Ruaultauthor=A.-C.+Le+Monnier%0Ade+Gouvilleauthor=H.+Costeauthor=J.+Kirilovskyauthor=F.+Hyafilauthor=R.+Labaudini%C3%A8re&title=The+discovery+of+tadalafil%3A+A+novel+and+highly+selective+PDE5+inhibitor.+1%3A5%2C6%2C11%2C11a-tetrahydro-1H-imidazo%5B1%E2%80%98%2C5%E2%80%98%3A1%2C6%5Dpyrido%5B3%2C4-b%5Dindole-1%2C3%282H%29-dione+analogues&doi=10.1021%2Fjm030056e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues</span></div><div class="casAuthors">Daugan, Alain; Grondin, Pascal; Ruault, Cecile; Le Monnier de Gouville, Anne-Charlotte; Coste, Herve; Kirilovsky, Jorge; Hyafil, Francois; Labaudiniere, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4525-4532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from Et β-carboline-3-carboxylate (β-CCE), 1, a modest inhibitor of type 5 phosphodiesterase (PDE5), a series of functionalized tetrahydro-β-carboline derivs. has been identified as a novel chem. class of potent and selective PDE5 inhibitors.  Optimization of the side chain on the hydantoin ring of initial lead compd. 2 and of the arom. ring on position 5 led to the identification of compd. 6e, a highly potent and selective PDE5 inhibitor, with greater selectivity for PDE5 vs. PDE1-4 than sildenafil.  Compd. 6e demonstrated a long lasting and significant blood pressure lowering effect after iv administration in the spontaneously hypertensive rat model but showed only moderate oral in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF0Ynxcj9_8rVg90H21EOLACvtfcHk0liQENJttv7XQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCju78%253D&md5=7c3b9aaf206cb18faaafc398c304357c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm030056e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030056e%26sid%3Dliteratum%253Aachs%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DGrondin%26aufirst%3DP.%26aulast%3DRuault%26aufirst%3DC.%26aulast%3DLe%2BMonnier%2Bde%2BGouville%26aufirst%3DA.-C.%26aulast%3DCoste%26aufirst%3DH.%26aulast%3DKirilovsky%26aufirst%3DJ.%26aulast%3DHyafil%26aufirst%3DF.%26aulast%3DLabaudini%25C3%25A8re%26aufirst%3DR.%26atitle%3DThe%2520discovery%2520of%2520tadalafil%253A%2520A%2520novel%2520and%2520highly%2520selective%2520PDE5%2520inhibitor.%25201%253A5%252C6%252C11%252C11a-tetrahydro-1H-imidazo%255B1%25E2%2580%2598%252C5%25E2%2580%2598%253A1%252C6%255Dpyrido%255B3%252C4-b%255Dindole-1%252C3%25282H%2529-dione%2520analogues%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4525%26epage%3D4532%26doi%3D10.1021%2Fjm030056e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brundage, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safdar, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beardsworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frumkin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Resp. Tadalafil therapy for pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2894</span>– <span class="NLM_lpage">2903</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.108.839274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.108.839274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19470885" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1alsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2009&pages=2894-2903&author=N.+Galieauthor=B.+H.+Brundageauthor=H.+A.+Ghofraniauthor=R.+J.+Oudizauthor=G.+Simonneauauthor=Z.+Safdarauthor=S.+Shapiroauthor=R.+J.+Whiteauthor=M.+Chanauthor=A.+Beardsworthauthor=L.+Frumkinauthor=R.+J.+Barst&title=Resp.+Tadalafil+therapy+for+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.108.839274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil Therapy for Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Galie, Nazzareno; Brundage, Bruce H.; Ghofrani, Hossein A.; Oudiz, Ronald J.; Simonneau, Gerald; Safdar, Zeenat; Shapiro, Shelley; White, R. James; Chan, Melanie; Beardsworth, Anthony; Frumkin, Lyn; Barst, Robyn J.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2894-2903</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Treatment options for pulmonary arterial hypertension target the prostacyclin, endothelin, or nitric oxide pathways.  Tadalafil, a phosphodiesterase type-5 inhibitor, increases cGMP, the final mediator in the nitric oxide pathway.  Methods and Results: In this 16-wk, double-blind, placebo-controlled study, 405 patients with pulmonary arterial hypertension (idiopathic or assocd.), either treatment-naive or on background therapy with the endothelin receptor antagonist bosentan, were randomized to placebo or tadalafil 2.5, 10, 20, or 40 mg orally once daily.  The primary end point was the change from baseline to week 16 in the distance walked in 6 min.  Changes in World Health Organization functional class, clin. worsening, and health-related quality of life were also assessed.  Patients completing the 16-wk study could enter a long-term extension study.  Tadalafil increased the distance walked in 6 min in a dose-dependent manner; only the 40-mg dose met the prespecified level of statistical significance (P<0.01).  Overall, the mean placebo-cor. treatment effect was 33 m (95% confidence interval, 15 to 50 m).  In the bosentan-naive group, the treatment effect was 44 m (95% confidence interval, 20 to 69 m) compared with 23 m (95% confidence interval, -2 to 48 m) in patients on background bosentan therapy.  Tadalafil 40 mg improved the time to clin. worsening (P=0.041), incidence of clin. worsening (68% relative risk redn.; P=0.038), and health-related quality of life.  The changes in World Health Organization functional class were not statistically significant.  The most common treatment-related adverse events reported with tadalafil were headache, myalgia, and flushing.  Conclusions: In patients with pulmonary arterial hypertension, tadalafil 40 mg was well tolerated and improved exercise capacity and quality of life measures and reduced clin. worsening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRgmNAQBkSLVg90H21EOLACvtfcHk0lhviiiYCcbqZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1alsb0%253D&md5=64556d999b15e8a5269c03c810518ccc</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.108.839274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.108.839274%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DBrundage%26aufirst%3DB.%2BH.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSafdar%26aufirst%3DZ.%26aulast%3DShapiro%26aufirst%3DS.%26aulast%3DWhite%26aufirst%3DR.%2BJ.%26aulast%3DChan%26aufirst%3DM.%26aulast%3DBeardsworth%26aufirst%3DA.%26aulast%3DFrumkin%26aufirst%3DL.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26atitle%3DResp.%2520Tadalafil%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2009%26volume%3D119%26spage%3D2894%26epage%3D2903%26doi%3D10.1161%2FCIRCULATIONAHA.108.839274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haning, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niewohner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Es-Sayed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bischoff, E.</span></span> <span> </span><span class="NLM_article-title">Imidazo 5,1-f 1,2,4 triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)00030-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0960-894X%2802%2900030-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11958981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslGkt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=865-868&author=H.+Haningauthor=U.+Niewohnerauthor=T.+Schenkeauthor=M.+Es-Sayedauthor=G.+Schmidtauthor=T.+Lampeauthor=E.+Bischoff&title=Imidazo+5%2C1-f+1%2C2%2C4+triazin-4%283H%29-ones%2C+a+new+class+of+potent+PDE+5+inhibitors&doi=10.1016%2FS0960-894X%2802%2900030-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors</span></div><div class="casAuthors">Haning, Helmut; Niewohner, Ulrich; Schenke, Thomas; Es-Sayed, Mazen; Schmidt, Gunter; Lampe, Thomas; Bischoff, Erwin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">865-868</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">2-Aryl-substituted imidazo[5,1-f][1,2,4]triazin-4(3H)-ones represent a new class of potent cGMP-PDE 5 inhibitors that prove to be superior to other purine-isosteric inhibitors.  Subnanomolar inhibitors of PDE 5 with activity in in-vivo models for erectile dysfunction have been identified.  BAY 38-9456 (Vardenafil-hydrochloride) has been selected for clin. studies in the indication of erectile dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpWwnsndy43rVg90H21EOLACvtfcHk0lhviiiYCcbqZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslGkt7c%253D&md5=cb00c9b2b1e68aa9ea254c4fe330b8a9</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2900030-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252900030-6%26sid%3Dliteratum%253Aachs%26aulast%3DHaning%26aufirst%3DH.%26aulast%3DNiewohner%26aufirst%3DU.%26aulast%3DSchenke%26aufirst%3DT.%26aulast%3DEs-Sayed%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DLampe%26aufirst%3DT.%26aulast%3DBischoff%26aufirst%3DE.%26atitle%3DImidazo%25205%252C1-f%25201%252C2%252C4%2520triazin-4%25283H%2529-ones%252C%2520a%2520new%2520class%2520of%2520potent%2520PDE%25205%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D865%26epage%3D868%26doi%3D10.1016%2FS0960-894X%2802%2900030-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ormrod, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easthope, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figgitt, D. P.</span></span> <span> </span><span class="NLM_article-title">Vardenafil</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.2165/00002512-200219030-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2165%2F00002512-200219030-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12027779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsF2mtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=217-227&author=D.+Ormrodauthor=S.+E.+Easthopeauthor=D.+P.+Figgitt&title=Vardenafil&doi=10.2165%2F00002512-200219030-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Vardenafil</span></div><div class="casAuthors">Ormrod, Douglas; Easthope, Stephanie E.; Figgitt, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), an enzyme which hydrolyzes cyclic guanosine monophosphate in the cavernosum tissue of the penis.  Inhibition of PDE5 results in increased arterial blood flow leading to enlargement of the corpus cavernosum.  Because of the increased tumescence, veins are compressed between the corpus cavernosum and the tunica albuginea, resulting in an erection.  Vardenafil has a high bioavailability and is rapidly absorbed.  An erection of >60% rigidity was maintained for approx. twice as long following visual stimulation in patients treated with vardenafil 10 or 20mg than in recipients of placebo.  In a large, placebo-controlled trial in patients with mild to severe erectile dysfunction (ED), vardenafil 5, 10 or 20mg taken as needed over a 12-wk period significantly improved the scores in questions 3 and 4 of the International Index of Erectile Function (IIEF).  The rate of successful attempts at intercourse with ejaculation was also significantly higher with vardenafil (71 to 75%) than in the placebo group (39.5%), and significantly more patients treated with vardenafil than placebo responded 'yes' to a Global Assessment Question (GAQ) asking if treatment had improved erections.  In a 26-wk trial in 736 men with ED of varied etiologies and severity patients receiving vardenafil 5, 10 or 20mg experienced significantly improved erections with 85% of vardenafil 20mg recipients reporting improved erectile function (assessed using the GAQ) compared with 28% of placebo recipients.  Treatment with vardenafil also significantly improved scores in response to questions 3 and 4 of the IIEF compared with placebo.  A 12-wk trial in 452 men with ED assocd. with diabetes mellitus demonstrated that treatment with vardenafil 20mg compared with placebo significantly improved IIEF erectile function domain scores and the rate of pos. responders to the erectile improvement GAQ.  Similar results were reported in a placebo-controlled trial of vardenafil 10 to 20mg involving 440 patients with ED after radical prostatectomy.  Adverse events assocd. with vardenafil were those commonly assocd. with PDE5 inhibitors: headache, flushing, dyspepsia and rhinitis.  These were mostly dose-dependent and mild to moderate in intensity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG-FWZ6nl6-bVg90H21EOLACvtfcHk0ljAagpij1QHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsF2mtLc%253D&md5=88a0159222b6ca6d2de7b48615243704</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.2165%2F00002512-200219030-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002512-200219030-00005%26sid%3Dliteratum%253Aachs%26aulast%3DOrmrod%26aufirst%3DD.%26aulast%3DEasthope%26aufirst%3DS.%2BE.%26aulast%3DFiggitt%26aufirst%3DD.%2BP.%26atitle%3DVardenafil%26jtitle%3DDrugs%2520Aging%26date%3D2002%26volume%3D19%26spage%3D217%26epage%3D227%26doi%3D10.2165%2F00002512-200219030-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Vardenafil in pulmonary arterial hypertension a randomized, double-blind, placebo-controlled study</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">1723</span>– <span class="NLM_lpage">1729</span>, <span class="refDoi"> DOI: 10.1164/rccm.201101-0093OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201101-0093OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21471085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsF2nsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=1723-1729&author=Z.+C.+Jingauthor=Z.+X.+Yuauthor=J.+Y.+Shenauthor=B.+X.+Wuauthor=K.+F.+Xuauthor=X.+Y.+Zhuauthor=L.+Panauthor=Z.+L.+Zhangauthor=X.+Q.+Liuauthor=Y.+S.+Zhangauthor=X.+Jiangauthor=N.+Galie&title=Vardenafil+in+pulmonary+arterial+hypertension+a+randomized%2C+double-blind%2C+placebo-controlled+study&doi=10.1164%2Frccm.201101-0093OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Vardenafil in pulmonary arterial hypertension</span></div><div class="casAuthors">Jing, Zhi-Cheng; Yu, Zai-Xin; Shen, Jie-Yan; Wu, Bing-Xiang; Xu, Kai-Feng; Zhu, Xian-Yang; Pan, Lei; Zhang, Zhuo-Li; Liu, Xue-Qin; Zhang, Yu-Shun; Jiang, Xin; Galie, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1723-1729</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Although the phosphodiesterase type 5 inhibitors sildenafil and tadalafil have demonstrated efficacy in patients with pulmonary arterial hypertension (PAH), monotherapy with these agents has not been conclusively shown to reduce clin. worsening events.  To evaluate the safety and efficacy of the phosphodiesterase type 5 inhibitor vardenafil in Chinese patients with PAH.  In a randomized, double-blind, placebo-controlled study, 66 patients with PAH were randomized 2:1 to vardenafil (5 mg once daily for 4 wk then 5 mg twice daily; n = 44) or placebo (n = 22) for 12 wk.  Patients completing this phase were then treated with open-label vardenafil (5 mg twice daily) for a further 12 wk.  At week 12, the mean placebo-cor. 6-min walking distance was increased with vardenafil (69 m; P < 0.001), and this improvement was maintained for at least 24 wk.  Vardenafil also increased the mean placebo-cor. cardiac index (0.39 L/min-1/m-2; P = 0.005) and decreased mean pulmonary arterial pressure and pulmonary vascular resistance (-5.3 mm Hg, P = 0.047; -4.7 Wood U, P = 0.003; resp.) at Week 12.  4 atients in the placebo group (20%) and one in the vardenafil group (2.3%) had clin. worsening events (hazard ratio 0.105; 95% confidence interval, 0.012-0.938; P = 0.044).  Vardenafil was assocd. with only mild and transient adverse events.  Vardenafil is effective and well tolerated in patients with PAH at a dose of 5 mg twice daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC4vbfiG3EM7Vg90H21EOLACvtfcHk0ljAagpij1QHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsF2nsLs%253D&md5=c19b3a9b0a98c6ea2e86e955777f363c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1164%2Frccm.201101-0093OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201101-0093OC%26sid%3Dliteratum%253Aachs%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DYu%26aufirst%3DZ.%2BX.%26aulast%3DShen%26aufirst%3DJ.%2BY.%26aulast%3DWu%26aufirst%3DB.%2BX.%26aulast%3DXu%26aufirst%3DK.%2BF.%26aulast%3DZhu%26aufirst%3DX.%2BY.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%2BL.%26aulast%3DLiu%26aufirst%3DX.%2BQ.%26aulast%3DZhang%26aufirst%3DY.%2BS.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DGalie%26aufirst%3DN.%26atitle%3DVardenafil%2520in%2520pulmonary%2520arterial%2520hypertension%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D1723%26epage%3D1729%26doi%3D10.1164%2Frccm.201101-0093OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noh, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghim, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, K. S.</span></span> <span> </span><span class="NLM_article-title">Effects of renal impairment on the pharmacokinetics and safety of udenafil</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1002/jcph.1095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fjcph.1095" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29537612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2murnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=905-912&author=Y.+S.+Choauthor=Y.+H.+Nohauthor=H.+S.+Limauthor=S.+H.+Choauthor=J.+L.+Ghimauthor=S.+Choeauthor=S.+B.+Kimauthor=J.+S.+Parkauthor=S.+K.+Leeauthor=W.+S.+Yangauthor=J.+W.+Changauthor=M.+Y.+Bahngauthor=K.+S.+Bae&title=Effects+of+renal+impairment+on+the+pharmacokinetics+and+safety+of+udenafil&doi=10.1002%2Fjcph.1095"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil</span></div><div class="casAuthors">Cho, Yong-Soon; Noh, Yook-Hwan; Lim, Hyeong-Seok; Cho, Sang-Heon; Ghim, Jong-Lyul; Choe, Sangmin; Kim, Soon-Bae; Park, Jung-Sik; Lee, Sang-Koo; Yang, Won-Seok; Chang, Jai-Won; Bahng, Mi-Young; Bae, Kyun-Seop</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">905-912</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Udenafil is a phosphodiesterase-5 inhibitor used to treat erectile dysfunction.  Although udenafil is not predominantly eliminated by the kidney, renal impairment can alter its secretion/transport pathways.  Drug pharmacokinetics and safety must therefore be assessed in subjects with a renal impairment.  We investigated the effects of impaired renal function on the pharmacokinetics and safety of a single 100-mg oral dose of udenafil in a single-dose, open-label, parallel-group study of 31 subjects.  Cockcroft-Gault creatinine clearance was used to stratify these subjects into healthy controls (>80 mL·min-1) and individuals with mild (50 to ≤80 mL·min-1), moderate (30 to ≤50 mL·min-1), and severe (<30 mL·min-1) renal impairment.  Pharmacokinetic measurements and safety assessments indicated that the geometric mean of the area under the concn.-time curve to the last measurement in mildly, moderately, and severely renally impaired subjects was 1.30- (90% CI 1.05-1.60), 1.62- (90% CI 1.28-2.06), and 1.60- (90% CI 1.28-2.01) fold higher, resp., than the healthy controls.  The geometric mean of the max. obsd. concn. was 1.41- (90% CI 1.05-1.88), 2.02- (90% CI 1.47-2.79), and 1.65- (90% CI: 1.21-2.24) fold higher, resp.  Significant correlations were obsd. among the creatinine clearance, oral clearance, and max. concn. of udenafil (P < .01).  All adverse events were mild, and no subject discontinued the study.  Udenafil administration was well tolerated in all groups.  In view of the clin. relevance of drug exposure, our findings indicate that a dose adjustment of udenafil is warranted in subjects with moderate or severe renal impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJzpmGAdfoOrVg90H21EOLACvtfcHk0ljAagpij1QHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2murnN&md5=aee92e306693a964d6235dd4a70e44f3</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1002%2Fjcph.1095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.1095%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DNoh%26aufirst%3DY.%2BH.%26aulast%3DLim%26aufirst%3DH.%2BS.%26aulast%3DCho%26aufirst%3DS.%2BH.%26aulast%3DGhim%26aufirst%3DJ.%2BL.%26aulast%3DChoe%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DPark%26aufirst%3DJ.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DYang%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DBahng%26aufirst%3DM.%2BY.%26aulast%3DBae%26aufirst%3DK.%2BS.%26atitle%3DEffects%2520of%2520renal%2520impairment%2520on%2520the%2520pharmacokinetics%2520and%2520safety%2520of%2520udenafil%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2018%26volume%3D58%26spage%3D905%26epage%3D912%26doi%3D10.1002%2Fjcph.1095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span> <span> </span><span class="NLM_article-title">Udenafil as a therapeutic option for pulmonary arterial hypertension</span>. <i>Korean Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.4070/kcj.2019.0023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.4070%2Fkcj.2019.0023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30808087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3cfnvVGjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2019&pages=361-362&author=H.+Y.+Kimauthor=K.+H.+Kim&title=Udenafil+as+a+therapeutic+option+for+pulmonary+arterial+hypertension&doi=10.4070%2Fkcj.2019.0023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Udenafil as a Therapeutic Option for Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Kim Hyung Yoon; Kim Kye Hun</div><div class="citationInfo"><span class="NLM_cas:title">Korean circulation journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">361-362</span>
        ISSN:<span class="NLM_cas:issn">1738-5520</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8lEcRsF401sAKB7Fa-xrUfW6udTcc2eZn04VeVDkjkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfnvVGjtg%253D%253D&md5=b3d8bcd3407eb75a3bbddbca6c8d700f</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.4070%2Fkcj.2019.0023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4070%252Fkcj.2019.0023%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DK.%2BH.%26atitle%3DUdenafil%2520as%2520a%2520therapeutic%2520option%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DKorean%2520Circ.%2520J.%26date%3D2019%26volume%3D49%26spage%3D361%26epage%3D362%26doi%3D10.4070%2Fkcj.2019.0023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, H.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-K.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of udenafil for the treatment of pulmonary arterial hypertension: a placebo-controlled, double-blind, phase IIb clinical trial</span>. <i>Clin. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1499</span>– <span class="NLM_lpage">1507</span>, <span class="refDoi"> DOI: 10.1016/j.clinthera.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.clinthera.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31202506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2019&pages=1499-1507&author=H.-J.+Changauthor=S.+Songauthor=S.-A.+Changauthor=H.-K.+Kimauthor=H.-O.+Jungauthor=J.-H.+Choiauthor=J.+S.+Leeauthor=K.-H.+Kimauthor=J.-O.+Jeongauthor=J.+H.+Leeauthor=D.-K.+Kim&title=Efficacy+and+safety+of+udenafil+for+the+treatment+of+pulmonary+arterial+hypertension%3A+a+placebo-controlled%2C+double-blind%2C+phase+IIb+clinical+trial&doi=10.1016%2Fj.clinthera.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial</span></div><div class="casAuthors">Chang, Hyuk-Jae; Song, Shinjeong; Chang, Sung-A.; Kim, Hyung-Kwan; Jung, Hae-Ok; Choi, Jung-Hyun; Lee, Jae Seung; Kim, Kye-Hun; Jeong, Jin-Ok; Lee, Ju Hee; Kim, Duk-Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1499-1507</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Udenafil is an oral phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction.  In a multicenter, placebo-controlled, randomized Phase IIa study, the redn. of pulmonary vascular resistance index was greater with a 50-mg baseline dose of udenafil than with the 100-mg dose, the cardiac index did not decrease at most points, and the safety was excellent, suggesting that 50-mg udenafil could be used in a Phase IIb trial.In this 16-wk, double-blind, placebo-controlled study, 63 patients with pulmonary arterial hypertension were randomized to receive 50-mg udenafil or a placebo BID.  The primary efficacy end point was the 6-min walking distance.  The secondary efficacy end points were the Borg dyspnea score and time to clin. worsening.  Patients who completed the 16-wk study could participate in a long-term extension study.: In terms of the difference between the baseline and 16-wk 6-min walking distance in both groups, the mean placebo-cor. treatment effect was 25 (58) m (P = 0.0873).  Among the patients with a history of endothelin receptor antagonist therapy, the treatment effect at week 16 between the udenafil and placebo groups was 34 (60) m (P = 0.0460).  However, there were no significant differences in the Borg dyspnea score and time to clin. worsening between groups.  The safety profile and adverse effects of udenafil were similar to those of typical phosphodiesterase-5 inhibitors seen in previous studies.Udenafil has a favorable safety profile and improves exercise capacity in patients with pulmonary arterial hypertension.  ClinicalTrials.gov identifier: NCT01553721.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmOGeG2uTI-rVg90H21EOLACvtfcHk0lh8khv41vZUSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKms7vJ&md5=84fa5486a1ed837c065de5f18801fd0b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.-J.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DH.-K.%26aulast%3DJung%26aufirst%3DH.-O.%26aulast%3DChoi%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DJeong%26aufirst%3DJ.-O.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DD.-K.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520udenafil%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%253A%2520a%2520placebo-controlled%252C%2520double-blind%252C%2520phase%2520IIb%2520clinical%2520trial%26jtitle%3DClin.%2520Ther.%26date%3D2019%26volume%3D41%26spage%3D1499%26epage%3D1507%26doi%3D10.1016%2Fj.clinthera.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Q. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. S.</span></span> <span> </span><span class="NLM_article-title">2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2777</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.03.125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.bmcl.2009.03.125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19375311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=2777-2779&author=H.+L.+Duanauthor=J.+Zhengauthor=Q.+L.+Laiauthor=Z.+Liuauthor=G.+H.+Tianauthor=Z.+Wangauthor=J.+F.+Liauthor=J.+S.+Shen&title=2-Phenylquinazolin-4%283H%29-one%2C+a+class+of+potent+PDE5+inhibitors+with+high+selectivity+versus+PDE6&doi=10.1016%2Fj.bmcl.2009.03.125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6</span></div><div class="casAuthors">Duan, Hongliang; Zheng, Jin; Lai, Qinglin; Liu, Zheng; Tian, Guanghui; Wang, Zhen; Li, Jianfeng; Shen, Jingshan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2777-2779</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In our efforts to minimize the side effects assocd. with low selectivity against the other PDE isoenzymes, a novel class of 2-phenylquinazolin-4(3H)-one derivs. I (R1 = H, Me, Et, F, Cl, Br, I, vinyl, n-Pr, n-Bu; R2 = H, Me), were designed and prepd. as potent PDE5 inhibitors with high selectivity against PDE6.  The syntheses and SAR studies of such mols. were reported.  Particularly, compd. I (R1 = Cl; R2 = Me) exhibited more than 100-fold selectivity vs. PDE6 than sildenafil.  Moreover, this compd. also showed comparable efficacy with sildenafil in rat erection model in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcve_9fB6it7Vg90H21EOLACvtfcHk0lh8khv41vZUSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltl2rsLk%253D&md5=37770ce876adebb1aad1b092f892275c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.03.125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.03.125%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DH.%2BL.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DQ.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DG.%2BH.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%2BF.%26aulast%3DShen%26aufirst%3DJ.%2BS.%26atitle%3D2-Phenylquinazolin-4%25283H%2529-one%252C%2520a%2520class%2520of%2520potent%2520PDE5%2520inhibitors%2520with%2520high%2520selectivity%2520versus%2520PDE6%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D2777%26epage%3D2779%26doi%3D10.1016%2Fj.bmcl.2009.03.125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrett, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10540</span>– <span class="NLM_lpage">10550</span>, <span class="refDoi"> DOI: 10.1021/jm301159y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301159y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10540-10550&author=G.+Wangauthor=Z.+Liuauthor=T.+T.+Chenauthor=Z.+Wangauthor=H.+Y.+Yangauthor=M.+Y.+Zhengauthor=J.+Renauthor=G.+H.+Tianauthor=X.+J.+Yangauthor=L.+Liauthor=J.+F.+Liauthor=J.+Suoauthor=R.+X.+Zhangauthor=X.+R.+Jiangauthor=N.+K.+Terrettauthor=J.+S.+Shenauthor=Y.+C.+Xuauthor=H.+L.+Jiang&title=Design%2C+synthesis%2C+and+pharmacological+evaluation+of+monocyclic+pyrimidinones+as+novel+inhibitors+of+PDE5&doi=10.1021%2Fjm301159y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5</span></div><div class="casAuthors">Wang, Guan; Liu, Zheng; Chen, Tiantian; Wang, Zhen; Yang, Huaiyu; Zheng, Mingyue; Ren, Jing; Tian, Guanghui; Yang, Xiaojun; Li, Li; Li, Jianfeng; Suo, Jin; Zhang, Rongxia; Jiang, Xiangrui; Terrett, Nicholas Kenneth; Shen, Jingshan; Xu, Yechun; Jiang, Hualiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10540-10550</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Piperazinylsulfonylphenyl pyrimidinones I [R = EtCH2, Bu, BuCH2CH2; R1 = H, MeCONH, F, Cl, Br, I, Me, Et, EtCH2; R2 = HO, H2N, MeCONH, Me, Et, EtCH2, Me2CH, Me2CHCH2, Ph, F3C; R1R2 = (CH2)3] were prepd. as inhibitors of phosphodiesterase 5 (PDE5) for potential use as drugs for the treatment of erectile dysfunction in men.  The inhibition of PDE5 by I was detd. in vitro.  I (R = EtCH2; R1 = R2 = Et) was the most potent compd. of those tested with an IC50 value of 1.6 nM against PDE5 and 25->5000 fold selectivity against ten other phosphodiesterases; the pharmacokinetics of I on i.v. and oral administration to rats and its activity in a rat model of erectile dysfunction were also detd.  The structures of I [R = EtCH2; R1R2 = (CH2)3] and of I (R = EtCH2; R1 = R2 = Et) bound to human PDE5 and including a water mol. responsible for important enzyme-substrate interactions were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjvKdEhRg2F7Vg90H21EOLACvtfcHk0liPYdLqS9nPnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Cksr%252FE&md5=55c3b0ef3e53d78c62a4833bcd13e69a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm301159y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301159y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%2BT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%2BY.%26aulast%3DZheng%26aufirst%3DM.%2BY.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DG.%2BH.%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DJ.%2BF.%26aulast%3DSuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DR.%2BX.%26aulast%3DJiang%26aufirst%3DX.%2BR.%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DShen%26aufirst%3DJ.%2BS.%26aulast%3DXu%26aufirst%3DY.%2BC.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520pharmacological%2520evaluation%2520of%2520monocyclic%2520pyrimidinones%2520as%2520novel%2520inhibitors%2520of%2520PDE5%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10540%26epage%3D10550%26doi%3D10.1021%2Fjm301159y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisa, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4979</span>– <span class="NLM_lpage">4990</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00123</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00123" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotl2nt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4979-4990&author=Z.+Wangauthor=X.+R.+Jiangauthor=X.+L.+Zhangauthor=G.+H.+Tianauthor=R.+L.+Yangauthor=J.+Z.+Wuauthor=X.+L.+Zouauthor=Z.+Liuauthor=X.+J.+Yangauthor=C.+H.+Wuauthor=J.+Shiauthor=J.+F.+Liauthor=J.+Suoauthor=Y.+Wangauthor=R.+X.+Zhangauthor=Z.+J.+Xuauthor=X.+D.+Gongauthor=Y.+Heauthor=W.+L.+Zhuauthor=H.+A.+Aisaauthor=H.+L.+Jiangauthor=Y.+C.+Xuauthor=J.+S.+Shen&title=Pharmacokinetics-driven+optimization+of+4%283H%29-pyrimidinones+as+phosphodiesterase+type+5+inhibitors+leading+to+TPN171%2C+a+clinical+candidate+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.9b00123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics-driven optimization of 4(3H)-pyrimidinones as phosphodiesterase type 5 inhibitors leading to TPN171, a clinical candidate for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Wang, Zhen; Jiang, Xiangrui; Zhang, Xianglei; Tian, Guanghui; Yang, Rulei; Wu, Jianzhong; Zou, Xiaoli; Liu, Zheng; Yang, Xiaojun; Wu, Chunhui; Shi, Jing; Li, Jianfeng; Suo, Jin; Wang, Yu; Zhang, Rongxia; Xu, Zhijian; Gong, Xudong; He, Yang; Zhu, Weiliang; Aisa, Haji Akber; Jiang, Hualiang; Xu, Yechun; Shen, Jingshan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4979-4990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase type 5 (PDE5) inhibitors are first-line therapy for pulmonary arterial hypertension (PAH) and erectile dysfunction.  As a continuing work to improve the terminal half-lives and oral bioavailabilities of our previously reported 4(3H)-pyrimidones, a pharmacokinetics-driven optimization focusing on the terminal substituent is described.  Two major congeneric series of 4(3H)-pyrimidones, the aminosulfonylphenylpyrimidones and acylaminophenylpyrimidones, were designed, synthesized, and pharmacol. assessed in vitro and in vivo.  Among them, compd. 15 (I) (CAS 1229018-87-4) (TPN171) with subnanomolar potency for PDE5 and good selectivity over PDE6 was finally recognized as a potential drug candidate, and its pharmacokinetic profiles in rats and dogs are significantly improved compared to the starting compd. (3).  Moreover, I was proven to exert a longer lasting effect than sildenafil in animal models, providing a foundation for a once-daily oral administration for its clin. use.  I Is currently being investigated in a phase II clin. trial for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSBJC7qO7NLVg90H21EOLACvtfcHk0liPYdLqS9nPnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotl2nt78%253D&md5=5d0d84757d86a641744630c0f7739376</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00123%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DX.%2BR.%26aulast%3DZhang%26aufirst%3DX.%2BL.%26aulast%3DTian%26aufirst%3DG.%2BH.%26aulast%3DYang%26aufirst%3DR.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DZou%26aufirst%3DX.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DWu%26aufirst%3DC.%2BH.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%2BF.%26aulast%3DSuo%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DR.%2BX.%26aulast%3DXu%26aufirst%3DZ.%2BJ.%26aulast%3DGong%26aufirst%3DX.%2BD.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DW.%2BL.%26aulast%3DAisa%26aufirst%3DH.%2BA.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DXu%26aufirst%3DY.%2BC.%26aulast%3DShen%26aufirst%3DJ.%2BS.%26atitle%3DPharmacokinetics-driven%2520optimization%2520of%25204%25283H%2529-pyrimidinones%2520as%2520phosphodiesterase%2520type%25205%2520inhibitors%2520leading%2520to%2520TPN171%252C%2520a%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4979%26epage%3D4990%26doi%3D10.1021%2Facs.jmedchem.9b00123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadowitz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikka, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokman, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom, W. J. G.</span></span> <span> </span><span class="NLM_article-title">Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.2174/138920013804870600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F138920013804870600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23140258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFagu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=265-269&author=S.+Gurauthor=P.+J.+Kadowitzauthor=A.+Gokceauthor=S.+C.+Sikkaauthor=U.+Lokmanauthor=W.+J.+G.+Hellstrom&title=Update+on+drug+interactions+with+phosphodiesterase-5+inhibitors+prescribed+as+first-line+therapy+for+patients+with+erectile+dysfunction+or+pulmonary+hypertension&doi=10.2174%2F138920013804870600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension</span></div><div class="casAuthors">Gur, Serap; Kadowitz, Philip J.; Gokce, Ahmet; Sikka, Suresh C.; Lokman, Utku; Hellstrom, Wayne J. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase-5 inhibitors (PDE5i, sildenafil, vardenafil, tadalafil and avanafil) are a first-line medical therapy for erectile dysfunction (ED).  In all likelihood, PDE5i usage will increase because sildenafil (Viagra and Revatio) and tadalafil (Cialis and Adcirca) have recently been recommended as first-line therapy for patients with pulmonary hypertension (PH).  PDE5i exhibit higher plasma concns. when co-administered with cytochrome P (CYP) 3A inhibitors, which influences their side-effect profile.  The higher PDE5i plasma concns., caused by CYP3A inhibitors, influence the severity and timing of PDE5i drug interactions and require dose adjustment.  PDE5i are safe when used with most antihypertensive agents, but co-administration with nitrates or α-blockers can cause severe hypotension and syncope.  Dose adjustment is also necessary when PDE5i are co-administered with CYP3A inducers.  The combination of oral tadalafil and bosentan (endothelin receptor antagonist) reduces tadalafil levels and requires dose adjustment.  Current literature reports a no. of interactions between PDE5i and other agents and further studies are needed to expand our knowledge base of these interactions.  This review discusses relevant PDE5i drug interactions, including those with CYP 450 inhibitors and inducers which are frequently used during the treatment of ED and PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraWOtrU04kSLVg90H21EOLACvtfcHk0liPYdLqS9nPnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFagu7c%253D&md5=01a26a94eb0b30d89eeaf01bb35c8508</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.2174%2F138920013804870600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920013804870600%26sid%3Dliteratum%253Aachs%26aulast%3DGur%26aufirst%3DS.%26aulast%3DKadowitz%26aufirst%3DP.%2BJ.%26aulast%3DGokce%26aufirst%3DA.%26aulast%3DSikka%26aufirst%3DS.%2BC.%26aulast%3DLokman%26aufirst%3DU.%26aulast%3DHellstrom%26aufirst%3DW.%2BJ.%2BG.%26atitle%3DUpdate%2520on%2520drug%2520interactions%2520with%2520phosphodiesterase-5%2520inhibitors%2520prescribed%2520as%2520first-line%2520therapy%2520for%2520patients%2520with%2520erectile%2520dysfunction%2520or%2520pulmonary%2520hypertension%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2013%26volume%3D14%26spage%3D265%26epage%3D269%26doi%3D10.2174%2F138920013804870600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Alija, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet-Buchholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feurer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furstner, C.</span></span> <span> </span><span class="NLM_article-title">NO-independent stimulators of soluble guanylate cyclase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00073-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0960-894X%2801%2900073-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11277519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=781-784&author=A.+Straubauthor=J.+P.+Staschauthor=C.+Alonso-Alijaauthor=J.+Benet-Buchholzauthor=B.+Duckeauthor=A.+Feurerauthor=C.+Furstner&title=NO-independent+stimulators+of+soluble+guanylate+cyclase&doi=10.1016%2FS0960-894X%2801%2900073-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">NO-Independent stimulators of soluble guanylate cyclase</span></div><div class="casAuthors">Straub, A.; Stasch, J.-P.; Alonso-Alija, C.; Benet-Buchholz, J.; Ducke, B.; Feurer, A.; Furstner, C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">781-784</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">SARs around a novel type of guanylate cyclase stimulator which act by a mechanism different from classical NO-donors are described.  Several pyrazolopyridinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application.  The SARs around a novel type of stimulators of sol. guanylate cyclase, their relaxing effects on preconstricted rabbit aortic rings (measured as IC50s) and their hypotensive properties are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog9vZU756NFbVg90H21EOLACvtfcHk0liOBV_OJmMKrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOjtLw%253D&md5=9abba586008935963c6124594b0fcb7a</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900073-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900073-7%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DBenet-Buchholz%26aufirst%3DJ.%26aulast%3DDucke%26aufirst%3DB.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DFurstner%26aufirst%3DC.%26atitle%3DNO-independent%2520stimulators%2520of%2520soluble%2520guanylate%2520cyclase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D781%26epage%3D784%26doi%3D10.1016%2FS0960-894X%2801%2900073-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Alija, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apeler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembowsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feurer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minuth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perzborn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleiss, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, M.</span></span> <span> </span><span class="NLM_article-title">NO-independent regulatory site on soluble guanylate cyclase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>410</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1038/35065611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F35065611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11242081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVyrur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=2001&pages=212-215&author=J.+P.+Staschauthor=E.+M.+Beckerauthor=C.+Alonso-Alijaauthor=H.+Apelerauthor=K.+Dembowskyauthor=A.+Feurerauthor=R.+Gerzerauthor=T.+Minuthauthor=E.+Perzbornauthor=U.+Pleissauthor=H.+Schroderauthor=W.+Schroederauthor=E.+Stahlauthor=W.+Steinkeauthor=A.+Straubauthor=M.+Schramm&title=NO-independent+regulatory+site+on+soluble+guanylate+cyclase&doi=10.1038%2F35065611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">NO-independent regulatory site on soluble guanylate cyclase</span></div><div class="casAuthors">Stasch, Johannes-Peter; Becker, Eva Maria; Alonso-Alija, Cristina; Apeler, Heiner; Dembowsky, Klaus; Feurer, Achim; Gerzer, Rupert; Minuth, Torsten; Perzborn, Elisabeth; Pleiss, Ulrich; Schroder, Henning; Schroeder, Werner; Stahl, Eike; Steinke, Wolfram; Straub, Alexander; Schramm, Mathias</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">410</span>
        (<span class="NLM_cas:issue">6825</span>),
    <span class="NLM_cas:pages">212-215</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Nitric oxide (NO) is a widespread, potent, biol. mediator that has many physiol. and pathophysiol. roles.  Research in the field of NO appears to have followed a straightforward path, and the findings have been progressive: NO and cGMP are involved in vasodilatation; glycerol trinitrate relaxes vascular smooth muscles by bioconversion to NO; mammalian cells synthesize NO; and last, NO mediates vasodilation by stimulating the sol. guanylate cyclase (sGC), a heterodimeric (α/β) heme protein that converts GTP to cGMP.  Here the authors report the discovery of a regulatory site on sGC.  Using photoaffinity labeling, the authors have identified the cysteine 238 and cysteine 243 region in the α1-subunit of sGC as the target for a new type of sGC stimulator.  Moreover, the authors present a pyrazolopyridine, BAY 41-2272, that potently stimulates sGC through this site by a mechanism that is independent of NO.  This results in antiplatelet activity, a strong decrease in blood pressure and an increase in survival in a low-NO rat model of hypertension, and as such may offer an approach for treating cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6lC7feiF4MLVg90H21EOLACvtfcHk0liOBV_OJmMKrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVyrur0%253D&md5=eb7d71bfc37767a0a371ba6fb0aec905</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1038%2F35065611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35065611%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DBecker%26aufirst%3DE.%2BM.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DApeler%26aufirst%3DH.%26aulast%3DDembowsky%26aufirst%3DK.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DGerzer%26aufirst%3DR.%26aulast%3DMinuth%26aufirst%3DT.%26aulast%3DPerzborn%26aufirst%3DE.%26aulast%3DPleiss%26aufirst%3DU.%26aulast%3DSchroder%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DW.%26aulast%3DStahl%26aufirst%3DE.%26aulast%3DSteinke%26aufirst%3DW.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DSchramm%26aufirst%3DM.%26atitle%3DNO-independent%2520regulatory%2520site%2520on%2520soluble%2520guanylate%2520cyclase%26jtitle%3DNature%26date%3D2001%26volume%3D410%26spage%3D212%26epage%3D215%26doi%3D10.1038%2F35065611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Alija, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apeler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dembowsky, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feurer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minuth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perzborn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41–8543: in vitro studies</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0704484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fsj.bjp.0704484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11815368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38Xht1KrsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=333-343&author=J.+P.+Staschauthor=C.+Alonso-Alijaauthor=H.+Apelerauthor=K.+Dembowskyauthor=A.+Feurerauthor=T.+Minuthauthor=E.+Perzbornauthor=M.+Schrammauthor=A.+Straub&title=Pharmacological+actions+of+a+novel+NO-independent+guanylyl+cyclase+stimulator%2C+BAY+41%E2%80%938543%3A+in+vitro+studies&doi=10.1038%2Fsj.bjp.0704484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies</span></div><div class="casAuthors">Stasch, Johannes-Peter; Alonso-Alija, Cristina; Apeler, Heiner; Dembowsky, Klaus; Feurer, Achim; Minuth, Torsten; Perzborn, Elisabeth; Schramm, Matthias; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">333-343</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BAY 41-8543 is a novel, highly specific and so far the most potent NO-independent stimulator of sGC.  Here we report the effects of BAY 41-8543 on the isolated enzyme, endothelial cells, platelets, isolated vessels and Langendorff heart prepn.  BAY 41-8543 stimulates the recombinant sGC concn.-dependently from 0.0001 μM to 100 μM up to 92-fold.  In combination, BAY 41-8543 and NO have synergistic effects over a wide range of concns.  Similar results are shown in implying that BAY 41-8543 stimulates the sGC directly and furthermore makes the enzyme more sensitive to its endogenous activator NO.  In vitro, BAY 41-8543 is a potent relaxing agent of aortas, saphenous arteries, coronary arteries and veins with IC50-values in the nM range.  In the rat heart Langendorff prepn., BAY 41-8543 potently reduces coronary perfusion pressure from 10-9 to 10-6 g ml-1 without any effect on left ventricular pressure and heart rate.  BAY 41-8543 is effective even under nitrate tolerance conditions proved by the same vasorelaxing effect on aortic rings taken either from normal or nitrate-tolerant rats.  BAY 41-8543 is a potent inhibitor of collagen-mediated aggregation in washed human platelets (IC50=0.09 μM).  In plasma, BAY 41-8543 inhibits collagen-mediated aggregation better than ADP-induced aggregation, but has no effect on the thrombin pathway.  BAY 41-8543 is also a potent direct stimulator of the cGMP/PKG/VASP pathway in platelets and synergizes with NO over a wide range of concns.  These results suggest that BAY 41-8543 is on the one hand an invaluable tool for studying sGC signaling in vitro and on the other hand its unique profile may offer a novel approach for treating cardiovascular diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqGtfBYQ5mtLVg90H21EOLACvtfcHk0liWTUOVeDXrmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xht1KrsLk%253D&md5=636596e7eb0ba2cf19b71b095a895e72</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704484%26sid%3Dliteratum%253Aachs%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26aulast%3DAlonso-Alija%26aufirst%3DC.%26aulast%3DApeler%26aufirst%3DH.%26aulast%3DDembowsky%26aufirst%3DK.%26aulast%3DFeurer%26aufirst%3DA.%26aulast%3DMinuth%26aufirst%3DT.%26aulast%3DPerzborn%26aufirst%3DE.%26aulast%3DSchramm%26aufirst%3DM.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DPharmacological%2520actions%2520of%2520a%2520novel%2520NO-independent%2520guanylyl%2520cyclase%2520stimulator%252C%2520BAY%252041%25E2%2580%25938543%253A%2520in%2520vitro%2520studies%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26spage%3D333%26epage%3D343%26doi%3D10.1038%2Fsj.bjp.0704484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet-Buckholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frode, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlsdorfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siefert, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1717</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00034-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0968-0896%2802%2900034-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11937330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XisFWhtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=1711-1717&author=A.+Straubauthor=J.+Benet-Buckholzauthor=R.+Frodeauthor=A.+Kernauthor=C.+Kohlsdorferauthor=P.+Schmittauthor=T.+Schwarzauthor=H.+M.+Siefertauthor=J.+P.+Stasch&title=Metabolites+of+orally+active+NO-independent+pyrazolopyridine+stimulators+of+soluble+guanylate+cyclase&doi=10.1016%2FS0968-0896%2802%2900034-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolites of Orally Active NO-Independent Pyrazolopyridine Stimulators of Soluble Guanylate Cyclase</span></div><div class="casAuthors">Straub, Alexander; Benet-Buckholz, Jordi; Frode, Rita; Kern, Armin; Kohlsdorfer, Christian; Schmitt, Peter; Schwarz, Thomas; Siefert, Hans-Martin; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1711-1717</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The pyrazolopyridine stimulators of sol. guanylate cyclase BAY 41-2272 and 41-8543 were oxidised in rats and dogs at their 5-pyrimidinyl-cyclopropyl and -morpholino residue.  These metabolites activate the sol. guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp41R8sAg7AVrVg90H21EOLACvtfcHk0liWTUOVeDXrmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisFWhtL4%253D&md5=dd0c98bd41b083b218b85be30daabd5e</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900034-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900034-2%26sid%3Dliteratum%253Aachs%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DBenet-Buckholz%26aufirst%3DJ.%26aulast%3DFrode%26aufirst%3DR.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DKohlsdorfer%26aufirst%3DC.%26aulast%3DSchmitt%26aufirst%3DP.%26aulast%3DSchwarz%26aufirst%3DT.%26aulast%3DSiefert%26aufirst%3DH.%2BM.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DMetabolites%2520of%2520orally%2520active%2520NO-independent%2520pyrazolopyridine%2520stimulators%2520of%2520soluble%2520guanylate%2520cyclase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D1711%26epage%3D1717%26doi%3D10.1016%2FS0968-0896%2802%2900034-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keogh, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langleben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilama, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuser, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span> <span> </span><span class="NLM_article-title">Riociguat for the treatment of pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1209655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1209655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23883378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=330-340&author=H.+A.+Ghofraniauthor=N.+Galieauthor=F.+Grimmingerauthor=E.+Grunigauthor=M.+Humbertauthor=Z.+C.+Jingauthor=A.+M.+Keoghauthor=D.+Langlebenauthor=M.+O.+Kilamaauthor=A.+Fritschauthor=D.+Neuserauthor=L.+J.+Rubin&title=Riociguat+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1209655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Riociguat for the treatment of pulmonary arterial hypertension</span></div><div class="casAuthors">Ghofrani, Hossein-Ardeschir; Galie, Nazzareno; Grimminger, Friedrich; Gruenig, Ekkehard; Humbert, Marc; Jing, Zhi-Cheng; Keogh, Anne M.; Langleben, David; Kilama, Michael Ochan; Fritsch, Arno; Neuser, Dieter; Rubin, Lewis J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">330-340</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Riociguat, a sol. guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension.  METHODS: In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-max. group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-max. group).  The 1.5 mg-max. group was included for exploratory purposes, and the data from that group were analyzed descriptively.  Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible.  The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 min.  Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clin. worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety.  RESULTS: By week 12, the 6-min walk distance had increased by a mean of 30 m in the 2.5 mg-max. group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P<0.001).  Prespecified subgroup analyses showed that riociguat improved the 6-min walk distance both in patients who were receiving no other treatment for the disease and in those who were receiving endothelin-receptor antagonists or prostanoids.  There were significant improvements in pulmonary vascular resistance (P<0.001), NT-proBNP levels (P<0.001), WHO functional class (P = 0.003), time to clin. worsening (P = 0.005), and Borg dyspnea score (P = 0.002).  The most common serious adverse event in the placebo group and the 2.5 mg-max. group was syncope (4% and 1%, resp.).  CONCLUSIONS: Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCUP-sJMAaXrVg90H21EOLACvtfcHk0liWTUOVeDXrmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2nur7K&md5=dc8f91183c5bfc8c1ec0d0f56b2ac0e2</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1209655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1209655%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DJing%26aufirst%3DZ.%2BC.%26aulast%3DKeogh%26aufirst%3DA.%2BM.%26aulast%3DLangleben%26aufirst%3DD.%26aulast%3DKilama%26aufirst%3DM.%2BO.%26aulast%3DFritsch%26aufirst%3DA.%26aulast%3DNeuser%26aufirst%3DD.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DRiociguat%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D330%26epage%3D340%26doi%3D10.1056%2FNEJMoa1209655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muck, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artmeier-Brandt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weimann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensing, G.</span></span> <span> </span><span class="NLM_article-title">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63–2521: An ascending-dose study in healthy male volunteers</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">926</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1177/0091270008319793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F0091270008319793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18519919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=926-934&author=R.+Freyauthor=W.+Muckauthor=S.+Ungerauthor=U.+Artmeier-Brandtauthor=G.+Weimannauthor=G.+Wensing&title=Single-dose+pharmacokinetics%2C+pharmacodynamics%2C+tolerability%2C+and+safety+of+the+soluble+guanylate+cyclase+stimulator+BAY+63%E2%80%932521%3A+An+ascending-dose+study+in+healthy+male+volunteers&doi=10.1177%2F0091270008319793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers</span></div><div class="casAuthors">Frey, Reiner; Mueck, Wolfgang; Unger, Sigrun; Artmeier-Brandt, Ulrike; Weimann, Gerrit; Wensing, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The aim of the study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BAY 63-2521, a new drug in development for pulmonary hypertension.  Fifty-eight healthy male volunteers received a single oral dose of BAY 63-2521 (0.25-5 mg) or placebo.  No serious adverse events were reported; there were no life-threatening events.  Heart rate over 1 min, an indicator of the effect of a vasodilating agent on the cardiovascular system in healthy subjects, was increased dose dependently vs. placebo at BAY 63-2521 doses of 1 to 5 mg (P < .01).  Mean arterial and diastolic pressures were decreased vs. placebo at doses of 1 mg (P < .05) and 5 mg (P < .01).  Systolic pressure was not significantly affected.  BAY 63-2521 was readily absorbed and exhibited dose-proportional pharmacokinetics.  The pharmacodynamic and pharmacokinetic properties of BAY 63-2521 suggest that it can offer a unique mode of action in the treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom6tfQEA1oN7Vg90H21EOLACvtfcHk0ljtx6yxcEnHmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWqur0%253D&md5=770d25ef69e46729dbf3a1bc2080d40f</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1177%2F0091270008319793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008319793%26sid%3Dliteratum%253Aachs%26aulast%3DFrey%26aufirst%3DR.%26aulast%3DMuck%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DS.%26aulast%3DArtmeier-Brandt%26aufirst%3DU.%26aulast%3DWeimann%26aufirst%3DG.%26aulast%3DWensing%26aufirst%3DG.%26atitle%3DSingle-dose%2520pharmacokinetics%252C%2520pharmacodynamics%252C%2520tolerability%252C%2520and%2520safety%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520BAY%252063%25E2%2580%25932521%253A%2520An%2520ascending-dose%2520study%2520in%2520healthy%2520male%2520volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D926%26epage%3D934%26doi%3D10.1177%2F0091270008319793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Follmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackerstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redlich, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunder, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebenow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroh, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker-Pelster, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretschmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiss, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jautelat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knorr, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondritzki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trubel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5146</span>– <span class="NLM_lpage">5161</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00449</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5146-5161&author=M.+Follmannauthor=J.+Ackerstaffauthor=G.+Redlichauthor=F.+Wunderauthor=D.+Langauthor=A.+Kernauthor=P.+Feyauthor=N.+Griebenowauthor=W.+Krohauthor=E.+M.+Becker-Pelsterauthor=A.+Kretschmerauthor=V.+Geissauthor=V.+Liauthor=A.+Straubauthor=J.+Mittendorfauthor=R.+Jautelatauthor=H.+Schirokauthor=K.+H.+Schlemmerauthor=K.+Lustigauthor=M.+Gerischauthor=A.+Knorrauthor=H.+Tinelauthor=T.+Mondritzkiauthor=H.+Trubelauthor=P.+Sandnerauthor=J.+P.+Stasch&title=Discovery+of+the+soluble+guanylate+cyclase+stimulator+vericiguat+%28BAY+1021189%29+for+the+treatment+of+chronic+heart+failure&doi=10.1021%2Facs.jmedchem.7b00449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure</span></div><div class="casAuthors">Follmann, Markus; Ackerstaff, Jens; Redlich, Gorden; Wunder, Frank; Lang, Dieter; Kern, Armin; Fey, Peter; Griebenow, Nils; Kroh, Walter; Becker-Pelster, Eva-Maria; Kretschmer, Axel; Geiss, Volker; Li, Volkhart; Straub, Alexander; Mittendorf, Joachim; Jautelat, Rolf; Schirok, Hartmut; Schlemmer, Karl-Heinz; Lustig, Klemens; Gerisch, Michael; Knorr, Andreas; Tinel, Hanna; Mondritzki, Thomas; Truebel, Hubert; Sandner, Peter; Stasch, Johannes-Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5146-5161</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first-in-class sol. guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension.  Despite its outstanding pharmacol. profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen.  In our efforts to further optimize the compd. class, we have uncovered interesting structure-activity relationships and were able to decrease oxidative metab. significantly.  These studies resulting in the discovery of once daily sGC stimulator vericiguat (compd. 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-r7F0gcVCrVg90H21EOLACvtfcHk0ljtx6yxcEnHmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgtb8%253D&md5=3b002cf2ab9fc92482fe08d6cac16302</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00449%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DAckerstaff%26aufirst%3DJ.%26aulast%3DRedlich%26aufirst%3DG.%26aulast%3DWunder%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DKern%26aufirst%3DA.%26aulast%3DFey%26aufirst%3DP.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DKroh%26aufirst%3DW.%26aulast%3DBecker-Pelster%26aufirst%3DE.%2BM.%26aulast%3DKretschmer%26aufirst%3DA.%26aulast%3DGeiss%26aufirst%3DV.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DStraub%26aufirst%3DA.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DJautelat%26aufirst%3DR.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DKnorr%26aufirst%3DA.%26aulast%3DTinel%26aufirst%3DH.%26aulast%3DMondritzki%26aufirst%3DT.%26aulast%3DTrubel%26aufirst%3DH.%26aulast%3DSandner%26aufirst%3DP.%26aulast%3DStasch%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520vericiguat%2520%2528BAY%25201021189%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520heart%2520failure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5146%26epage%3D5161%26doi%3D10.1021%2Facs.jmedchem.7b00449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roessig, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anstrom, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voors, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C. S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponikowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temple, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieske, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ezekowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koglin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, C. M.</span></span> <span> </span><span class="NLM_article-title">A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator the VICTORIA trial</span>. <i>JACC-Heart Fail.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/j.jchf.2017.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jchf.2017.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29032136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1M7gslSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=96-104&author=P.+W.+Armstrongauthor=L.+Roessigauthor=M.+J.+Patelauthor=K.+J.+Anstromauthor=J.+Butlerauthor=A.+A.+Voorsauthor=C.+S.+P.+Lamauthor=P.+Ponikowskiauthor=T.+Templeauthor=B.+Pieskeauthor=J.+Ezekowitzauthor=A.+F.+Hernandezauthor=J.+Koglinauthor=C.+M.+O%E2%80%99Connor&title=A+multicenter%2C+randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+efficacy+and+safety+of+the+oral+soluble+guanylate+cyclase+stimulator+the+VICTORIA+trial&doi=10.1016%2Fj.jchf.2017.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial</span></div><div class="casAuthors">Armstrong Paul W; Roessig Lothar; Patel Mahesh J; Koglin Joerg; Anstrom Kevin J; Hernandez Adrian F; Butler Javed; Voors Adriaan A; Lam Carolyn S P; Ponikowski Piotr; Temple Tracy; Ezekowitz Justin; Pieske Burkert; O'Connor Christopher M</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Heart failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">96-104</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This trial sought to evaluate whether vericiguat, a novel oral soluble guanylate cyclase (sGC) stimulator, was superior to placebo, on a background of standard of care, in increasing the time to the first occurrence of the composite endpoints of cardiovascular (CV) death and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction (HFrEF).  Deficiency in sGC-derived cyclic guanosine monophosphate (cGMP) causes both myocardial dysfunction and impaired endothelium-dependent vasomotor regulation that includes the myocardial microcirculation.  Experimental studies have suggested multiple potential benefits of sGC stimulators including prevention, or even reversal, of left ventricular hypertrophy and fibrosis, as well as reduction of ventricular afterload through both systemic and pulmonary vasodilation.  Hence, restoration of sufficient nitric oxide (NO)-sGC-cGMP signaling has been proposed as an important treatment target in HF.  Vericiguat has been shown to directly stimulate sGC and enhance sGC sensitivity to endogenous NO.  Available phase IIb data in HFrEF patients indicate vericiguat is safe and well-tolerated, and exploratory analyses indicate that it results in a dose-dependent, clinically significant reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) at the highest tested dose.  VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) is a randomized, placebo-controlled, parallel group, multicenter, double-blind, event-driven phase 3 trial of vericiguat in subjects with HFrEF.  Approximately 4,872 subjects will be randomized to evaluate the efficacy and safety of vericiguat compared with placebo on a background of standard of care.  After a screening phase of up to 30 days, eligible subjects will be treated until the required number of cardiovascular deaths is observed.  The estimated median follow-up duration is approximately 18 months.  All subjects will be followed until study completion to assess for the occurrence of endpoint events.  VICTORIA will establish the efficacy and safety of vericiguat on cardiovascular death and HF hospitalization in patients with HFrEF. (A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction [HFrEF]-VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction [VICTORIA]; NCT02861534).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSuusnxBwex6-9TkgmBqTqfW6udTcc2eYqMkwfeqsOLLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7gslSrsA%253D%253D&md5=c8e8bb390697ce18c89824cd9f758d44</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.jchf.2017.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchf.2017.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DP.%2BW.%26aulast%3DRoessig%26aufirst%3DL.%26aulast%3DPatel%26aufirst%3DM.%2BJ.%26aulast%3DAnstrom%26aufirst%3DK.%2BJ.%26aulast%3DButler%26aufirst%3DJ.%26aulast%3DVoors%26aufirst%3DA.%2BA.%26aulast%3DLam%26aufirst%3DC.%2BS.%2BP.%26aulast%3DPonikowski%26aufirst%3DP.%26aulast%3DTemple%26aufirst%3DT.%26aulast%3DPieske%26aufirst%3DB.%26aulast%3DEzekowitz%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DA.%2BF.%26aulast%3DKoglin%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DC.%2BM.%26atitle%3DA%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520the%2520oral%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520the%2520VICTORIA%2520trial%26jtitle%3DJACC-Heart%2520Fail.%26date%3D2018%26volume%3D6%26spage%3D96%26epage%3D104%26doi%3D10.1016%2Fj.jchf.2017.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Follmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griebenow, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mais, F.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirok, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stasch, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, A.</span></span> <span> </span><span class="NLM_article-title">The chemistry and biology of soluble guanylate cyclase stimulators and activators</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9462</span>, <span class="refDoi"> DOI: 10.1002/anie.201302588</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fanie.201302588" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=9442-9462&author=M.+Follmannauthor=N.+Griebenowauthor=M.+G.+Hahnauthor=I.+Hartungauthor=F.-J.+Maisauthor=J.+Mittendorfauthor=M.+Schaeferauthor=H.+Schirokauthor=J.-P.+Staschauthor=F.+Stollauthor=A.+Straub&title=The+chemistry+and+biology+of+soluble+guanylate+cyclase+stimulators+and+activators&doi=10.1002%2Fanie.201302588"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators</span></div><div class="casAuthors">Follmann, Markus; Griebenow, Nils; Hahn, Michael G.; Hartung, Ingo; Mais, Franz-Josef; Mittendorf, Joachim; Schaefer, Martina; Schirok, Hartmut; Stasch, Johannes-Peter; Stoll, Friederike; Straub, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">9442-9462</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for more than 130 years.  Still today, NO-donor drugs are important in the management of cardiovascular diseases.  However, inhaled NO or drugs releasing NO and org. nitrates are assocd. with noteworthy therapeutic shortcomings, including resistance to NO in some disease states, the development of tolerance during long-term treatment, and nonspecific effects, such as post-translational modification of proteins.  The beneficial actions of NO are mediated by stimulation of sol. guanylate cyclase (sGC), a heme-contg. enzyme which produces the intracellular signaling mol. cGMP.  Recently, two classes of compds. have been discovered that amplify the function of sGC in a NO-independent manner, the so-called sGC stimulators and sGC activators.  The most advanced drug, the sGC stimulator riociguat, has successfully undergone Phase III clin. trials for different forms of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1k3LI-HnJc7Vg90H21EOLACvtfcHk0lh7rhVDpJtXJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSiu77K&md5=d84536785fcea442b23179a6d7bf7246</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1002%2Fanie.201302588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201302588%26sid%3Dliteratum%253Aachs%26aulast%3DFollmann%26aufirst%3DM.%26aulast%3DGriebenow%26aufirst%3DN.%26aulast%3DHahn%26aufirst%3DM.%2BG.%26aulast%3DHartung%26aufirst%3DI.%26aulast%3DMais%26aufirst%3DF.-J.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DSchaefer%26aufirst%3DM.%26aulast%3DSchirok%26aufirst%3DH.%26aulast%3DStasch%26aufirst%3DJ.-P.%26aulast%3DStoll%26aufirst%3DF.%26aulast%3DStraub%26aufirst%3DA.%26atitle%3DThe%2520chemistry%2520and%2520biology%2520of%2520soluble%2520guanylate%2520cyclase%2520stimulators%2520and%2520activators%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D9442%26epage%3D9462%26doi%3D10.1002%2Fanie.201302588" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanrahan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakefield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chickering, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruff, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Profy, A. T.</span></span> <span> </span><span class="NLM_article-title">A randomized, placebo-controlled, multiple-ascending-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the soluble guanylate cyclase stimulator praliciguat in healthy subjects</span>. <i>Clin. Pharmacol. Drug Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1002/cpdd.627</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1002%2Fcpdd.627" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30422390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSju7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2019&pages=564-575&author=J.+P.+Hanrahanauthor=J.+D.+Wakefieldauthor=P.+J.+Wilsonauthor=M.+Mihovaauthor=J.+G.+Chickeringauthor=D.+Ruffauthor=M.+Hallauthor=G.+T.+Milneauthor=M.+G.+Currieauthor=A.+T.+Profy&title=A+randomized%2C+placebo-controlled%2C+multiple-ascending-dose+study+to+assess+the+safety%2C+tolerability%2C+pharmacokinetics%2C+and+pharmacodynamics+of+the+soluble+guanylate+cyclase+stimulator+praliciguat+in+healthy+subjects&doi=10.1002%2Fcpdd.627"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects</span></div><div class="casAuthors">Hanrahan, John P.; Wakefield, James D.; Wilson, Phebe J.; Mihova, Marina; Chickering, Jennifer G.; Ruff, Dennis; Hall, Michael; Milne, G. Todd; Currie, Mark G.; Profy, Albert T.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology in Drug Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">564-575</span>CODEN:
                <span class="NLM_cas:coden">CPDDAH</span>;
        ISSN:<span class="NLM_cas:issn">2160-7648</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Nitric oxide (NO)-sol. guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) signaling is central to the regulation of several physiol. processes, including blood flow and inflammation.  Deficient NO signaling is implicated in multiple diseases. sGC stimulators are small mols. that enhance sGC activity, particularly in combination with NO.  In a randomized, placebo-controlled phase 1 study, the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the sGC stimulator praliciguat were assessed in 44 healthy adults.  Four cohorts of 11 subjects (8 praliciguat, 3 placebo) received once-daily praliciguat for 14 days before up-titrating for 7 days (treatment sequences: 15/30 mg, 20/40 mg, 30/40 mg, and wt.-based).  All doses were tolerated.  No serious or severe adverse events (AEs) were reported.  The most common AEs in praliciguat recipients were headache and symptoms consistent with blood pressure (BP) lowering/vasodilation.  There were no lab., vital sign, electrocardiog., or platelet function findings indicative of a safety concern.  Pharmacokinetics were dose proportional, with an effective half-life of 24-37 h, supporting once-daily dosing.  Praliciguat produced dose-related increases in plasma cGMP consistent with stimulation of sGC.  Repeated once-daily dosing showed sustained decreases in BP.  Results support evaluation of praliciguat for the treatment of conditions assocd. with deficient NO signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbtRhsglmF7bVg90H21EOLACvtfcHk0lh7rhVDpJtXJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSju7nL&md5=5d984c96d74d4ceda4da9c310a229d5f</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fcpdd.627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpdd.627%26sid%3Dliteratum%253Aachs%26aulast%3DHanrahan%26aufirst%3DJ.%2BP.%26aulast%3DWakefield%26aufirst%3DJ.%2BD.%26aulast%3DWilson%26aufirst%3DP.%2BJ.%26aulast%3DMihova%26aufirst%3DM.%26aulast%3DChickering%26aufirst%3DJ.%2BG.%26aulast%3DRuff%26aufirst%3DD.%26aulast%3DHall%26aufirst%3DM.%26aulast%3DMilne%26aufirst%3DG.%2BT.%26aulast%3DCurrie%26aufirst%3DM.%2BG.%26aulast%3DProfy%26aufirst%3DA.%2BT.%26atitle%3DA%2520randomized%252C%2520placebo-controlled%252C%2520multiple-ascending-dose%2520study%2520to%2520assess%2520the%2520safety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520pharmacodynamics%2520of%2520the%2520soluble%2520guanylate%2520cyclase%2520stimulator%2520praliciguat%2520in%2520healthy%2520subjects%26jtitle%3DClin.%2520Pharmacol.%2520Drug%2520Dev.%26date%3D2019%26volume%3D8%26spage%3D564%26epage%3D575%26doi%3D10.1002%2Fcpdd.627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buys, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmer, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chickering, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Profy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadcock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masferrer, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milne, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential</span>. <i>Nitric Oxide</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.niox.2018.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.niox.2018.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29859918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVyqurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=72-80&author=E.+S.+Buysauthor=D.+P.+Zimmerauthor=J.+Chickeringauthor=R.+Graulauthor=Y.+T.+Chienauthor=A.+Profyauthor=J.+R.+Hadcockauthor=J.+L.+Masferrerauthor=T.+Milne&title=Discovery+and+development+of+next+generation+sGC+stimulators+with+diverse+multidimensional+pharmacology+and+broad+therapeutic+potential&doi=10.1016%2Fj.niox.2018.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential</span></div><div class="casAuthors">Buys, E. S.; Zimmer, D. P.; Chickering, J.; Graul, R.; Chien, Y. T.; Profy, A.; Hadcock, J. R.; Masferrer, J. L.; Milne, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">Nitric Oxide</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">72-80</span>CODEN:
                <span class="NLM_cas:coden">NIOXF5</span>;
        ISSN:<span class="NLM_cas:issn">1089-8603</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Nitric oxide (NO)-sensitive sol. guanylyl cyclase (sGC), an enzyme that catalyzes the conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophophate (cGMP), transduces many of the physiol. effects of the gasotransmitter NO.  Upon binding of NO to the prosthetic heme group of sGC, a conformational change occurs, resulting in enzymic activation and increased prodn. of cGMP. cGMP modulates several downstream cellular and physiol. responses, including but not limited to vasodilation.  Impairment of this signaling system and altered NO-cGMP homeostasis have been implicated in cardiovascular, pulmonary, renal, gastrointestinal, central nervous system, and hepatic pathologies. sGC stimulators, small mol. drugs that synergistically increase sGC enzyme activity with NO, have shown great potential to treat a variety of diseases via modulation of NO-sGC-cGMP signaling.  Here, we give an overview of novel, orally available sGC stimulators that Ironwood Pharmaceuticals is developing.  We outline the non-clin. and clin. studies, highlighting pharmacol. and pharmacokinetic (PK) profiles, including pharmacodynamic (PD) effects, and efficacy in a variety of disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjoqbbNZMdOLVg90H21EOLACvtfcHk0ljDv9Rlbs9vbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVyqurrF&md5=3eebb2810112cb030d53625d0f33ac42</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.niox.2018.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.niox.2018.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DBuys%26aufirst%3DE.%2BS.%26aulast%3DZimmer%26aufirst%3DD.%2BP.%26aulast%3DChickering%26aufirst%3DJ.%26aulast%3DGraul%26aufirst%3DR.%26aulast%3DChien%26aufirst%3DY.%2BT.%26aulast%3DProfy%26aufirst%3DA.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DMasferrer%26aufirst%3DJ.%2BL.%26aulast%3DMilne%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520development%2520of%2520next%2520generation%2520sGC%2520stimulators%2520with%2520diverse%2520multidimensional%2520pharmacology%2520and%2520broad%2520therapeutic%2520potential%26jtitle%3DNitric%2520Oxide%26date%3D2018%26volume%3D78%26spage%3D72%26epage%3D80%26doi%3D10.1016%2Fj.niox.2018.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00114-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2FS0092-8674%2800%2900114-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0ljDv9Rlbs9vbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225%26doi%3D10.1016%2FS0092-8674%2800%2900114-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fartoukh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rain, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galanaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duroux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emilie, D.</span></span> <span> </span><span class="NLM_article-title">Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">554</span>– <span class="NLM_lpage">559</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=9596101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADyaK1c3lsFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1998&pages=554-559&author=M.+Humbertauthor=G.+Montiauthor=M.+Fartoukhauthor=A.+Magnanauthor=F.+Brenotauthor=B.+Rainauthor=F.+Capronauthor=P.+Galanaudauthor=P.+Durouxauthor=G.+Simonneauauthor=D.+Emilie&title=Platelet-derived+growth+factor+expression+in+primary+pulmonary+hypertension%3A+comparison+of+HIV+seropositive+and+HIV+seronegative+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients</span></div><div class="casAuthors">Humbert M; Monti G; Fartoukh M; Magnan A; Brenot F; Rain B; Capron F; Galanaud P; Duroux P; Simonneau G; Emilie D</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">554-9</span>
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    </div><div class="casAbstract">Primary pulmonary hypertension (PPH) is characterized by intimal fibrosis and cell proliferation (including fibroblasts, smooth muscle and endothelial cells) in the distal pulmonary arterial tree.  Considerable interest has been generated by recent reports of PPH in human immunodeficiency virus (HIV)-1-infected individuals.  Although the lack of evidence for a pulmonary artery infection has suggested that in such cases HIV may act through mediator release rather than by direct endothelial infection, the mechanisms underlying HIV-associated PPH remain poorly defined.  Platelet-derived growth factor (PDGF) has the ability to induce smooth muscle cell and fibroblast proliferation and migration.  Given these considerations, we have attempted to document a possible role for PDGF in PPH occurring in HIV seropositive and seronegative patients.  Using semiquantitative polymerase chain reaction (PCR), PDGF A-chain messenger ribonucleic acid (mRNA) expression was analysed in surgical lung biopsies from 13 HIV seronegative patients and one HIV seropositive patient, all displaying severe PPH.  In parallel, lung samples from two patients with HIV-1-associated PPH were studied by immunohistochemistry and in situ hybridization.  Results were compared to those obtained in three HIV-1-infected individuals with no pulmonary complication (as demonstrated by clinical, radiological, bacteriological, and necropsy findings) and five control lung biopsies.  As compared to controls, PDGF A-chain mRNA expression is elevated in lung biopsies from patients displaying PPH (p=0.029).  In HIV-1-associated PPH, interstitial perivascular cells expressing PDGF A-chain mRNA and protein could be detected by in situ hybridization and immunohistochemistry, respectively.  Platelet-derived growth factor expression is elevated in lung biopsies of patients displaying primary pulmonary hypertension.  Growth factors such as platelet-derived growth factor may play a part in the initiation and/or progression of primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiQHPFYGCsehdUSIfHIn4FfW6udTcc2eaMdifisx9K4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c3lsFGnsg%253D%253D&md5=5ebf91f1c357b582fa71199365b90544</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DMonti%26aufirst%3DG.%26aulast%3DFartoukh%26aufirst%3DM.%26aulast%3DMagnan%26aufirst%3DA.%26aulast%3DBrenot%26aufirst%3DF.%26aulast%3DRain%26aufirst%3DB.%26aulast%3DCapron%26aufirst%3DF.%26aulast%3DGalanaud%26aufirst%3DP.%26aulast%3DDuroux%26aufirst%3DP.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DEmilie%26aufirst%3DD.%26atitle%3DPlatelet-derived%2520growth%2520factor%2520expression%2520in%2520primary%2520pulmonary%2520hypertension%253A%2520comparison%2520of%2520HIV%2520seropositive%2520and%2520HIV%2520seronegative%2520patients%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D1998%26volume%3D11%26spage%3D554%26epage%3D559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramaniam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cras, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grover, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsella, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abman, S. H.</span></span> <span> </span><span class="NLM_article-title">Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus</span>. <i>Am. J. Physiol.-Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">L826</span>– <span class="NLM_lpage">L833</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00199.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1152%2Fajplung.00199.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12533438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjvFKjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=L826-L833&author=V.+Balasubramaniamauthor=T.+D.+Le+Crasauthor=D.+D.+Ivyauthor=T.+R.+Groverauthor=J.+P.+Kinsellaauthor=S.+H.+Abman&title=Role+of+platelet-derived+growth+factor+in+vascular+remodeling+during+pulmonary+hypertension+in+the+ovine+fetus&doi=10.1152%2Fajplung.00199.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus</span></div><div class="casAuthors">Balasubramaniam, Vivek; Le Cras, Timothy D.; Ivy, D. Dunbar; Grover, Theresa R.; Kinsella, John P.; Abman, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">5, Pt. 1</span>),
    <span class="NLM_cas:pages">L826-L833</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Platelet-derived growth factor (PDGF) is a potent smooth muscle cell mitogen that may contribute to smooth muscle hyperplasia during the development of chronic pulmonary hypertension (PH).  The authors studied changes in PDGFα- and β-receptor and ligand expression in lambs with chronic intrauterine PH induced by partial ligation of the ductus arteriosus (DA) at gestational age 124-128 days (term = 147 days).  Western blot anal. performed on whole lung homogenates from PH animals after 8 days of DA ligation showed a twofold increase in PDGFα- and β-receptor proteins compared with age-matched controls.  Lung PDGF-A and -B mRNA expression did not differ between PH and control animals.  The authors treated PH animals with NX1975, an aptamer that selectively inhibits PDGF-B, by infusion into the left pulmonary artery for 7 days after DA ligation.  NX1975 reduced the development of muscular thickening of small pulmonary arteries by 47% and right ventricular hypertrophy (RVH) by 66%.  Lung PDGFα- and β-receptor expression is increased in perinatal PH, and NX1975 reduces the increase in wall thickness of small pulmonary arteries and RVH in this model.  The authors speculate that PDGF signaling contributes to structural vascular remodeling in perinatal PH and that selective PDGF inhibition may provide a novel therapeutic strategy for the treatment of chronic PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmHQJEH3HWebVg90H21EOLACvtfcHk0liw76ksdM_ezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjvFKjs7g%253D&md5=3c0c2ea001c5be85fe942c74d3245994</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00199.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00199.2002%26sid%3Dliteratum%253Aachs%26aulast%3DBalasubramaniam%26aufirst%3DV.%26aulast%3DLe%2BCras%26aufirst%3DT.%2BD.%26aulast%3DIvy%26aufirst%3DD.%2BD.%26aulast%3DGrover%26aufirst%3DT.%2BR.%26aulast%3DKinsella%26aufirst%3DJ.%2BP.%26aulast%3DAbman%26aufirst%3DS.%2BH.%26atitle%3DRole%2520of%2520platelet-derived%2520growth%2520factor%2520in%2520vascular%2520remodeling%2520during%2520pulmonary%2520hypertension%2520in%2520the%2520ovine%2520fetus%26jtitle%3DAm.%2520J.%2520Physiol.-Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2003%26volume%3D284%26spage%3DL826%26epage%3DL833%26doi%3D10.1152%2Fajplung.00199.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dony, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydykov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span> <span> </span><span class="NLM_article-title">Reversal of experimental pulmonary hypertension by PDGF inhibition</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">2811</span>– <span class="NLM_lpage">2821</span>, <span class="refDoi"> DOI: 10.1172/JCI24838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI24838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16200212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2811-2821&author=R.+T.+Schermulyauthor=E.+Donyauthor=H.+A.+Ghofraniauthor=S.+Pullamsettiauthor=R.+Savaiauthor=M.+Rothauthor=A.+Sydykovauthor=Y.+J.+Laiauthor=N.+Weissmannauthor=W.+Seegerauthor=F.+Grimminger&title=Reversal+of+experimental+pulmonary+hypertension+by+PDGF+inhibition&doi=10.1172%2FJCI24838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of experimental pulmonary hypertension by PDGF inhibition</span></div><div class="casAuthors">Schermuly, Ralph Theo; Dony, Eva; Ghofrani, Hossein Ardeschir; Pullamsetti, Soni; Savai, Rajkumar; Roth, Markus; Sydykov, Akylbek; Lai, Ying Ju; Weissmann, Norbert; Seeger, Werner; Grimminger, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2811-2821</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Progression of pulmonary hypertension is assocd. with increased proliferation and migration of pulmonary vascular smooth muscle cells.  PDGF is a potent mitogen and involved in this process.  We now report that the PDGF receptor antagonist STI571 (imatinib) reversed advanced pulmonary vascular disease in 2 animal models of pulmonary hypertension.  In rats with monocrotaline-induced pulmonary hypertension, therapy with daily administration of STI571 was started 28 days after induction of the disease.  A 2-wk treatment resulted in 100% survival, compared with only 50% in sham-treated rats.  The changes in RV pressure, measured continuously by telemetry, and right heart hypertrophy were reversed to near-normal levels.  STI571 prevented phosphorylation of the PDGF receptor and suppressed activation of downstream signaling pathways.  Similar results were obtained in chronically hypoxic mice, which were treated with STI571 after full establishment of pulmonary hypertension.  Moreover, expression of the PDGF receptor was significantly increased in lung tissue from pulmonary arterial hypertension patients compared with healthy donor lung tissue.  We conclude that STI571 reverses vascular remodeling and cor pulmonale in severe exptl. pulmonary hypertension regardless of the initiating stimulus.  This regimen offers a unique novel approach for antiremodeling therapy in progressed pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou65hFsYybr7Vg90H21EOLACvtfcHk0liw76ksdM_ezg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7bN&md5=467e940da906ab3fed2802b68e135c03</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1172%2FJCI24838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24838%26sid%3Dliteratum%253Aachs%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DDony%26aufirst%3DE.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DPullamsetti%26aufirst%3DS.%26aulast%3DSavai%26aufirst%3DR.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DSydykov%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BJ.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DReversal%2520of%2520experimental%2520pulmonary%2520hypertension%2520by%2520PDGF%2520inhibition%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2811%26epage%3D2821%26doi%3D10.1172%2FJCI24838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambaryan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huertas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambrecht, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Launay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Kaminsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span> <span> </span><span class="NLM_article-title">C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1164/rccm.201006-0905OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201006-0905OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21471108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3Mnmt1ymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2011&pages=116-123&author=D.+Montaniauthor=F.+Perrosauthor=N.+Gambaryanauthor=B.+Girerdauthor=P.+Dorfmullerauthor=L.+C.+Priceauthor=A.+Huertasauthor=H.+Hammadauthor=B.+N.+Lambrechtauthor=G.+Simonneauauthor=J.+M.+Launayauthor=S.+Cohen-Kaminskyauthor=M.+Humbert&title=C-kit-positive+cells+accumulate+in+remodeled+vessels+of+idiopathic+pulmonary+arterial+hypertension&doi=10.1164%2Frccm.201006-0905OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension</span></div><div class="casAuthors">Montani David; Perros Frederic; Gambaryan Natalia; Girerd Barbara; Dorfmuller Peter; Price Laura C; Huertas Alice; Hammad Hamida; Lambrecht Bart; Simonneau Gerald; Launay Jean-Marie; Cohen-Kaminsky Sylvia; Humbert Marc</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  C-kit(+) cells, including bone marrow (BM)-derived progenitors and mast cells, may participate in vascular remodelling.  Because recent studies suggest that c-kit may be a target for innovative therapies in experimental pulmonary hypertension, we investigated the contribution of c-kit(+) cells in human idiopathic pulmonary arterial hypertension (IPAH).  OBJECTIVES:  To investigate the contribution of c-kit(+) cells in human IPAH.  METHODS:  Single c-kit, CXCL12/SDF-1α, CXCR4, CD34, and multiple c-kit, α-smooth muscle actin (α-SMA) and tryptase immunostainings were performed in IPAH lungs.  C-kit mRNA expression was quantified by real-time polymerase chain reaction in microdissected pulmonary arteries from patients with IPAH and control subjects.  Phenotype and function of circulating progenitors were analyzed by flow cytometry.  Plasma levels of soluble c-kit and CXCL12/SDF-1α were measured by ELISA.  MEASUREMENTS AND MAIN RESULTS:  Infiltration of c-kit(+) cells in pulmonary arterial lesions was associated with an increase in c-kit mRNA expression (P < 0.01 compared with control subjects).  Both c-kit(+)/tryptase(+) mast cells and c-kit(+)/tryptase(-) BM-derived cells were increased in pulmonary arteries of patients with IPAH compared with control subjects (106.6 ± 54.5 vs. 28 ± 16.8/mm(2) and 143.8 ± 101.1 vs. 23.3 ± 11.9/mm(2); all P<0.01).  Plasma-soluble c-kit was increased in IPAH compared with control subjects (27.4 ± 12.4 vs. 19.5 ± 5.8 ng/ml; P<0.05).  Two populations of circulating BM-derived cells (lin-CD34(high)CD133(high) [c-kit(high)CXCR4(low)] and lin-CD34(low)CD133(-) [c-kit(low)CXCR4(high)]) were increased in IPAH compared with control subjects (P=0.01).  Pulmonary arterial lesions were associated with vasa vasorum expansion expressing CXL12/SDF-1α that may recruit c-kit(+) cells.  CONCLUSIONS:  In IPAH, c-kit(+) cells infiltrate pulmonary arterial lesions and may participate to vascular remodeling.  Therefore, c-kit may represent a potential target for innovative PAH therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT47ixLTvkYifIW7hznt0zpfW6udTcc2eb1psvyjc8PKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mnmt1ymtw%253D%253D&md5=dac39aaf375a4707395ba94b699e432c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1164%2Frccm.201006-0905OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201006-0905OC%26sid%3Dliteratum%253Aachs%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DGambaryan%26aufirst%3DN.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DPrice%26aufirst%3DL.%2BC.%26aulast%3DHuertas%26aufirst%3DA.%26aulast%3DHammad%26aufirst%3DH.%26aulast%3DLambrecht%26aufirst%3DB.%2BN.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DLaunay%26aufirst%3DJ.%2BM.%26aulast%3DCohen-Kaminsky%26aufirst%3DS.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DC-kit-positive%2520cells%2520accumulate%2520in%2520remodeled%2520vessels%2520of%2520idiopathic%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D184%26spage%3D116%26epage%3D123%26doi%3D10.1164%2Frccm.201006-0905OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourge, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Sanchez, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassoun, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span> <span> </span><span class="NLM_article-title">Imatinib mesylate as add-on therapy for pulmonary arterial hypertension results of the randomized IMPRES study</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1128</span>– <span class="NLM_lpage">1138</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.112.000765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.112.000765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23403476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFersbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2013&pages=1128-1138&author=M.+M.+Hoeperauthor=R.+J.+Barstauthor=R.+C.+Bourgeauthor=J.+Feldmanauthor=A.+E.+Frostauthor=N.+Galieauthor=M.+A.+Gomez-Sanchezauthor=F.+Grimmingerauthor=E.+Grunigauthor=P.+M.+Hassounauthor=N.+W.+Morrellauthor=A.+J.+Peacockauthor=T.+Satohauthor=G.+Simonneauauthor=V.+F.+Tapsonauthor=F.+Torresauthor=D.+Lawrenceauthor=D.+A.+Quinnauthor=H.+A.+Ghofrani&title=Imatinib+mesylate+as+add-on+therapy+for+pulmonary+arterial+hypertension+results+of+the+randomized+IMPRES+study&doi=10.1161%2FCIRCULATIONAHA.112.000765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study</span></div><div class="casAuthors">Hoeper, Marius M.; Barst, Robyn J.; Bourge, Robert C.; Feldman, Jeremy; Frost, Adaani E.; Galie, Nazzareno; Gomez-Sanchez, Miguel Angel; Grimminger, Friedrich; Gruenig, Ekkehard; Hassoun, Paul M.; Morrell, Nicholas W.; Peacock, Andrew J.; Satoh, Toru; Simonneau, Gerald; Tapson, Victor F.; Torres, Fernando; Lawrence, David; Quinn, Deborah A.; Ghofrani, Hossein-Ardeschir</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1128-1138</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: By its inhibitory effect on platelet-derived growth factor signaling, imatinib could be efficacious in treating patients with pulmonary arterial hypertension (PAH).  METHODS AND RESULTS: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES), a randomized, double-blind, placebo-controlled 24-wk trial, evaluated imatinib in patients with pulmonary vascular resistance ≥800 dyne·s·cm symptomatic on ≥2 PAH therapies.  The primary outcome was change in 6-min walk distance.  Secondary outcomes included changes in hemodynamics, functional class, serum levels of N-terminal brain natriuretic peptide, and time to clin. worsening.  After completion of the core study, patients could enter an open-label long-term extension study.  Of 202 patients enrolled, 41% patients received 3 PAH therapies, with the remainder on 2 therapies.  After 24 wk, the mean placebo-cor. treatment effect on 6-min walk distance was 32 m (95% confidence interval, 12-52; P=0.002), an effect maintained in the extension study in patients remaining on imatinib.  Pulmonary vascular resistance decreased by 379 dyne·s·cm (95% confidence interval, -502 to - 255; P<0.001, between-group difference).  Functional class, time to clin. worsening, and mortality did not differ between treatments.  Serious adverse events and discontinuations were more frequent with imatinib than placebo (44% vs. 30% and 33% vs. 18%, resp.).  Subdural hematoma occurred in 8 patients (2 in the core study, 6 in the extension) receiving imatinib and anticoagulation.  CONCLUSIONS: Imatinib improved exercise capacity and hemodynamics in patients with advanced PAH, but serious adverse events and study drug discontinuations were common.  Further studies are needed to investigate the long-term safety and efficacy of imatinib in patients with PAH.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov.  Unique identifier: NCT00902174 (core study); NCT01392495 (extension).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSK-dic_4oALVg90H21EOLACvtfcHk0liVYgkBAA3x9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFersbo%253D&md5=1e5af4253848beee8181e4489c1cc8c0</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.000765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.000765%26sid%3Dliteratum%253Aachs%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DBourge%26aufirst%3DR.%2BC.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DGomez-Sanchez%26aufirst%3DM.%2BA.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DHassoun%26aufirst%3DP.%2BM.%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DTapson%26aufirst%3DV.%2BF.%26aulast%3DTorres%26aufirst%3DF.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DQuinn%26aufirst%3DD.%2BA.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26atitle%3DImatinib%2520mesylate%2520as%2520add-on%2520therapy%2520for%2520pulmonary%2520arterial%2520hypertension%2520results%2520of%2520the%2520randomized%2520IMPRES%2520study%26jtitle%3DCirculation%26date%3D2013%26volume%3D127%26spage%3D1128%26epage%3D1138%26doi%3D10.1161%2FCIRCULATIONAHA.112.000765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juengel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriegsmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schett, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distler, J. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Distler, O.</span></span> <span> </span><span class="NLM_article-title">Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1382</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2011-200940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1136%2Fannrheumdis-2011-200940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22523431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Ont73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2012&pages=1382-1387&author=B.+Maurerauthor=N.+Reichauthor=A.+Juengelauthor=J.+Kriegsmannauthor=R.+E.+Gayauthor=G.+Schettauthor=B.+A.+Michelauthor=S.+Gayauthor=J.+H.+W.+Distlerauthor=O.+Distler&title=Fra-2+transgenic+mice+as+a+novel+model+of+pulmonary+hypertension+associated+with+systemic+sclerosis&doi=10.1136%2Fannrheumdis-2011-200940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis</span></div><div class="casAuthors">Maurer, Britta; Reich, Nicole; Juengel, Astrid; Kriegsmann, Joerg; Gay, Renate E.; Schett, Georg; Michel, Beat A.; Gay, Steffen; Distler, Joerg H. W.; Distler, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1382-1387</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objectives: Systemic sclerosis-assocd. pulmonary arterial hypertension differs from idiopathic pulmonary arterial hypertension with respect to histopathol., treatment responses and survival.  Medical progress on PAH is hampered by the lack of human biosamples and suitable animal models.  In this study, the authors evaluated fos-related antigen 2 (Fra-2) transgenic mice as a novel model for systemic sclerosis-assocd. pulmonary arterial hypertension.  Methods: Lung sections of Fra-2 transgenic (n=12) and wild-type mice (n=6) were analyzed at 16 wk by histol. using Dana Point criteria.  Cellular and mol. key players were assessed by immunohistochem.  To test the model's sensitivity to change over treatment, a subgroup of Fra-2 transgenic mice (n=6) was treated with the tyrosine kinase inhibitor nilotinib twice daily 37.5 mg orally from 8 wk of age.  Results: Fra-2 transgenic mice developed severe vascular remodelling of pulmonary arteries and nonspecific interstitial pneumonia-like interstitial lung disease resembling human systemic sclerosis-assocd. pulmonary hypertension.  Histol. features typical for systemic sclerosis-assocd. pulmonary arterial hypertension, such as intimal thickening with concentric laminar lesions, medial hypertrophy, perivascular inflammatory infiltrates, adventitial fibrosis, but not pulmonary occlusive venopathy were frequently detected.  Platelet-derived growth factor signalling pathways were activated in pulmonary vessels of Fra-2 transgenic compared with wild-type mice.  Since treatment with nilotinib strongly prevented the development of proliferative vasculopathy and lung fibrosis, the model proved to be sensitive to treatment.  Conclusions: This study suggests that Fra-2 transgenic mice as an animal model of systemic sclerosis-assocd. pulmonary arterial hypertension display main characteristic features of the human disease.  It therefore allows studying pathophysiol. aspects and might serve as a preclin. model for interventional proof-of-concept studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRM8WsXpuJW7Vg90H21EOLACvtfcHk0liVYgkBAA3x9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Ont73E&md5=667e8d8cb815eac000650182cb39174b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2011-200940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2011-200940%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DReich%26aufirst%3DN.%26aulast%3DJuengel%26aufirst%3DA.%26aulast%3DKriegsmann%26aufirst%3DJ.%26aulast%3DGay%26aufirst%3DR.%2BE.%26aulast%3DSchett%26aufirst%3DG.%26aulast%3DMichel%26aufirst%3DB.%2BA.%26aulast%3DGay%26aufirst%3DS.%26aulast%3DDistler%26aufirst%3DJ.%2BH.%2BW.%26aulast%3DDistler%26aufirst%3DO.%26atitle%3DFra-2%2520transgenic%2520mice%2520as%2520a%2520novel%2520model%2520of%2520pulmonary%2520hypertension%2520associated%2520with%2520systemic%2520sclerosis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2012%26volume%3D71%26spage%3D1382%26epage%3D1387%26doi%3D10.1136%2Fannrheumdis-2011-200940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomberg-Maitland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barst, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coslet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrino, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bond, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Couture, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M. J.</span></span> <span> </span><span class="NLM_article-title">A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">310</span>, <span class="refDoi"> DOI: 10.1038/clpt.2009.217</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fclpt.2009.217" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20010555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=303-310&author=M.+Gomberg-Maitlandauthor=M.+L.+Maitlandauthor=R.+J.+Barstauthor=L.+Sugengauthor=S.+Cosletauthor=T.+J.+Perrinoauthor=L.+Bondauthor=M.+E.+La+Coutureauthor=S.+L.+Archerauthor=M.+J.+Ratain&title=A+dosing%2Fcross-development+study+of+the+multikinase+inhibitor+sorafenib+in+patients+with+pulmonary+arterial+hypertension&doi=10.1038%2Fclpt.2009.217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Gomberg-Maitland, M.; Maitland, M. L.; Barst, R. J.; Sugeng, L.; Coslet, S.; Perrino, T. J.; Bond, L.; La Couture, M. E.; Archer, S. L.; Ratain, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-310</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) and cancer share elements of pathophysiol.  This provides an opportunity for the cross-development of anticancer agents that can be used in improving PAH care.  The adaptation of new drugs across these disease populations warrants a structured approach.  This study was a 16-wk, phase Ib, single-center, open-label trial of the multikinase/angiogenesis inhibitor sorafenib.  In order to assess the safety of sorafenib in PAH, patients with advanced but stable disease on parenteral prostanoids (with or without oral sildenafil) were initiated on treatment at the lowest active dosage administered to cancer patients: 200 mg daily.  Patients underwent weekly clin. evaluations and monthly functional testing and dose escalations to a final dosage of 400 mg twice daily.  Among 12 patients (10 of them women), sorafenib was well tolerated at 200 mg twice daily.  The most common adverse events were moderate skin reactions on the hands and feet and alopecia.  Our conclusion was therefore that this is a tolerable dosing regimen for testing the therapeutic activity of sorafenib in PAH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV_iCSRXr2hLVg90H21EOLACvtfcHk0liVYgkBAA3x9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVSqtbs%253D&md5=4640e523b547fd0502b0b16f8c1443ae</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.217%26sid%3Dliteratum%253Aachs%26aulast%3DGomberg-Maitland%26aufirst%3DM.%26aulast%3DMaitland%26aufirst%3DM.%2BL.%26aulast%3DBarst%26aufirst%3DR.%2BJ.%26aulast%3DSugeng%26aufirst%3DL.%26aulast%3DCoslet%26aufirst%3DS.%26aulast%3DPerrino%26aufirst%3DT.%2BJ.%26aulast%3DBond%26aufirst%3DL.%26aulast%3DLa%2BCouture%26aufirst%3DM.%2BE.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26atitle%3DA%2520dosing%252Fcross-development%2520study%2520of%2520the%2520multikinase%2520inhibitor%2520sorafenib%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2010%26volume%3D87%26spage%3D303%26epage%3D310%26doi%3D10.1038%2Fclpt.2009.217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kataoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshino, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span> <span> </span><span class="NLM_article-title">Sorafenib as a potential strategy for refractory pulmonary arterial hypertension</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.pupt.2017.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28315488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvVWnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2017&pages=46-49&author=G.+Kimuraauthor=M.+Kataokaauthor=T.+Inamiauthor=K.+Fukudaauthor=H.+Yoshinoauthor=T.+Satoh&title=Sorafenib+as+a+potential+strategy+for+refractory+pulmonary+arterial+hypertension&doi=10.1016%2Fj.pupt.2017.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib as a potential strategy for refractory pulmonary arterial hypertension</span></div><div class="casAuthors">Kimura, Gou; Kataoka, Masaharu; Inami, Takumi; Fukuda, Keiichi; Yoshino, Hideaki; Satoh, Toru</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">46-49</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases.  We investigated the efficacy and safety of sorafenib for the treatment of patients with refractory pulmonary arterial hypertension (PAH).  Sorafenib was started in 9 patients (7 with idiopathic PAH, 2 with pulmonary veno-occlusive disease) who had severe PAH and right heart failure, in spite of treatment with vasodilators specific for PAH.  Sorafenib was started as an add-on therapy at a dose of 50 or 100 mg/day, and increased to 100-400 mg/day.  New York Heart Assocn. functional class improved in 8 patients and did not change in 1.  Mean pulmonary arterial pressure improved in 6 patients (14-28% decrease) and did not apparently change in 2 (follow-up catheterization was not performed in 1 patient).  The main adverse effects of sorafenib were skin reactions on the hands and feet, which appeared in 5 patients.  They were tolerable in 4 patients, but discontinuation of sorafenib was needed in only 1 patient.  In conclusion, sorafenib had favorable effects to improve symptoms and objective variables in patients with refractory PAH, with tolerable adverse events.  Sorafenib is an alternative strategy for patients with refractory PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTx8ugetoGdbVg90H21EOLACvtfcHk0ljdk1EtwFRGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvVWnt7o%253D&md5=a1bad595da6f14ee2ec3cd096c2740da</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DKimura%26aufirst%3DG.%26aulast%3DKataoka%26aufirst%3DM.%26aulast%3DInami%26aufirst%3DT.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DYoshino%26aufirst%3DH.%26aulast%3DSatoh%26aufirst%3DT.%26atitle%3DSorafenib%2520as%2520a%2520potential%2520strategy%2520for%2520refractory%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D44%26spage%3D46%26epage%3D49%26doi%3D10.1016%2Fj.pupt.2017.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergot, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunther, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouvaist, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canuet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poubeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natali, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Callaghan, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jais, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tubert-Bitter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalcman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension in patients treated by dasatinib</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2128</span>– <span class="NLM_lpage">2137</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.079921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.111.079921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22451584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVegt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=2128-2137&author=D.+Montaniauthor=E.+Bergotauthor=S.+Guntherauthor=L.+Savaleauthor=A.+Bergeronauthor=A.+Bourdinauthor=H.+Bouvaistauthor=M.+Canuetauthor=C.+Pisonauthor=M.+Macroauthor=P.+Poubeauauthor=B.+Girerdauthor=D.+Nataliauthor=C.+Guignabertauthor=F.+Perrosauthor=D.+S.+O%E2%80%99Callaghanauthor=X.+Jaisauthor=P.+Tubert-Bitterauthor=G.+Zalcmanauthor=O.+Sitbonauthor=G.+Simonneauauthor=M.+Humbert&title=Pulmonary+arterial+hypertension+in+patients+treated+by+dasatinib&doi=10.1161%2FCIRCULATIONAHA.111.079921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Pulmonary Arterial Hypertension in Patients Treated by Dasatinib</span></div><div class="casAuthors">Montani, David; Bergot, Emmanuel; Guenther, Sven; Savale, Laurent; Bergeron, Anne; Bourdin, Arnaud; Bouvaist, Helene; Canuet, Matthieu; Pison, Christophe; Macro, Margareth; Poubeau, Patrice; Girerd, Barbara; Natali, Delphine; Guignabert, Christophe; Perros, Frederic; O'Callaghan, Dermot S.; Jais, Xavier; Tubert-Bitter, Pascale; Zalcman, Gerard; Sitbon, Olivier; Simonneau, Gerald; Humbert, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2128-2137</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: The French pulmonary hypertension (PH) registry allows the survey of epidemiol. trends.  Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib.  METHODS AND RESULTS-: This study was designed to describe incident cases of dasatinib-assocd. PH reported in the French PH registry.  From the approval of dasatinib (Nov. 2006) to Sept. 30, 2010, 9 incident cases treated by dasatinib at the time of PH diagnosis were identified.  At diagnosis, patients had moderate to severe precapillary PH with functional and hemodynamic impairment.  No other incident PH cases were exposed to other tyrosine kinase inhibitors at the time of PH diagnosis.  Clin., functional, or hemodynamic improvements were obsd. within 4 mo of dasatinib discontinuation in all but 1 patient.  Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1).  After a median follow-up of 9 mo (min-max 3-36), the majority of patients did not demonstrate complete clin. and hemodynamic recovery, and no patients reached a normal value of mean pulmonary artery pressure (≤20 mm Hg).  Two patients (22%) died at follow-up (1 of unexplained sudden death and 1 of cardiac failure in the context of septicemia, resp., 8 and 12 mo after dasatinib withdrawal).  The lowest est. of incident PH occurring in patients exposed to dasatinib in France was 0.45%.  CONCLUSIONS-: Dasatinib may induce severe precapillary PH fulfilling the criteria of pulmonary arterial hypertension, thus suggesting a direct and specific effect of dasatinib on pulmonary vessels.  Improvement is usually obsd. after withdrawal of dasatinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOqwHaw1Dx_bVg90H21EOLACvtfcHk0ljdk1EtwFRGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVegt7Y%253D&md5=057e7a4655f81f3ffea08b1bac332335</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.079921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.079921%26sid%3Dliteratum%253Aachs%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DBergot%26aufirst%3DE.%26aulast%3DGunther%26aufirst%3DS.%26aulast%3DSavale%26aufirst%3DL.%26aulast%3DBergeron%26aufirst%3DA.%26aulast%3DBourdin%26aufirst%3DA.%26aulast%3DBouvaist%26aufirst%3DH.%26aulast%3DCanuet%26aufirst%3DM.%26aulast%3DPison%26aufirst%3DC.%26aulast%3DMacro%26aufirst%3DM.%26aulast%3DPoubeau%26aufirst%3DP.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DNatali%26aufirst%3DD.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DO%25E2%2580%2599Callaghan%26aufirst%3DD.%2BS.%26aulast%3DJais%26aufirst%3DX.%26aulast%3DTubert-Bitter%26aufirst%3DP.%26aulast%3DZalcman%26aufirst%3DG.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHumbert%26aufirst%3DM.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520in%2520patients%2520treated%2520by%2520dasatinib%26jtitle%3DCirculation%26date%3D2012%26volume%3D125%26spage%3D2128%26epage%3D2137%26doi%3D10.1161%2FCIRCULATIONAHA.111.079921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Etienne-Manneville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A.</span></span> <span> </span><span class="NLM_article-title">Rho GTPases in cell biology</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>420</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1038/nature01148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnature01148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12478284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVSitbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=420&publication_year=2002&pages=629-635&author=S.+Etienne-Mannevilleauthor=A.+Hall&title=Rho+GTPases+in+cell+biology&doi=10.1038%2Fnature01148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Rho GTPases in cell biology</span></div><div class="casAuthors">Etienne-Manneville, Sandrine; Hall, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">420</span>
        (<span class="NLM_cas:issue">6916</span>),
    <span class="NLM_cas:pages">629-635</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Rho GTPases are mol. switches that control a wide variety of signal transduction pathways in all eukaryotic cells.  They are known principally for their pivotal role in regulating the actin cytoskeleton, but their ability to influence cell polarity, microtubule dynamics, membrane transport pathways, and transcription factor activity is probably just as significant.  Underlying this biol. complexity is a simple biochem. idea, namely that by switching on a single GTPase, several distinct signaling pathways can be coordinately activated.  With spatial and temporal activation of multiple switches factored in, it is not surprising to find Rho GTPases having such a prominent role in eukaryotic cell biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo36ZCRk0eAD7Vg90H21EOLACvtfcHk0ljdk1EtwFRGLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVSitbw%253D&md5=87bec1cb1868fd1c13682c8e94260ee1</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnature01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01148%26sid%3Dliteratum%253Aachs%26aulast%3DEtienne-Manneville%26aufirst%3DS.%26aulast%3DHall%26aufirst%3DA.%26atitle%3DRho%2520GTPases%2520in%2520cell%2520biology%26jtitle%3DNature%26date%3D2002%26volume%3D420%26spage%3D629%26epage%3D635%26doi%3D10.1038%2Fnature01148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Do E, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1731</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-09-0135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1253%2Fcircj.CJ-09-0135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19590140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1MrnslyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2009&pages=1731-1739&author=Z.+Do+Eauthor=Y.+Fukumotoauthor=A.+Takakiauthor=S.+Tawaraauthor=J.+Ohashiauthor=M.+Nakanoauthor=T.+Tadaauthor=K.+Sajiauthor=K.+Sugimuraauthor=H.+Fujitaauthor=Y.+Hoshikawaauthor=J.+Nawataauthor=T.+Kondoauthor=H.+Shimokawa&title=Evidence+for+Rho-kinase+activation+in+patients+with+pulmonary+arterial+hypertension&doi=10.1253%2Fcircj.CJ-09-0135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">Do e Zhulanqiqige; Fukumoto Yoshihiro; Takaki Aya; Tawara Shunsuke; Ohashi Junko; Nakano Makoto; Tada Tomohiro; Saji Kenya; Sugimura Kohichiro; Fujita Hiroshi; Hoshikawa Yasushi; Nawata Jun; Kondo Takashi; Shimokawa Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation journal : official journal of the Japanese Circulation Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1731-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Direct evidence for Rho-kinase activation in patients with pulmonary hypertension (PH) is still lacking.  METHODS AND RESULTS:  Rho-kinase activity in circulating neutrophils was examined by determining the ratio of phosphorylated/total forms of myosin-binding subunit, a substrate of Rho-kinase, in 40 consecutive PH patients and 40 healthy controls.  Next, Rho-kinase expression and activity was examined in isolated human lung tissues (5 patients with idiopathic pulmonary arterial hypertension [IPAH], 5 controls) and vascular reactivity of isolated small human pulmonary arteries in vitro (4 IPAH, 4 controls).  Rho-kinase activity in circulating neutrophils was significantly increased in the PH patients overall compared with controls (P<0.0001).  Significant correlations were noted between Rho-kinase activity and the severity and duration of PAH (all P<0.05).  Rho-kinase expression and activity in isolated lung tissues also were significantly increased in the IPAH patients compared with the controls (both P<0.0001).  Endothelium-dependent relaxation was markedly impaired and serotonin-induced contraction (in the absence of the endothelium) markedly enhanced in the PAH patients compared with the controls, and the hypercontraction to serotonin was abolished by hydroxyfasudil, a specific Rho-kinase inhibitor.  CONCLUSIONS:  These results provide the first direct evidence for Rho-kinase activation in patients with PAH, suggesting the therapeutic importance of Rho-kinase in the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4QU0u6YEfW8kU0YCbOU3EfW6udTcc2ebbHcaDzy15dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrnslyisQ%253D%253D&md5=cf309c992e0595588917041d836dfe2a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-09-0135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-09-0135%26sid%3Dliteratum%253Aachs%26aulast%3DDo%2BE%26aufirst%3DZ.%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DTakaki%26aufirst%3DA.%26aulast%3DTawara%26aufirst%3DS.%26aulast%3DOhashi%26aufirst%3DJ.%26aulast%3DNakano%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DT.%26aulast%3DSaji%26aufirst%3DK.%26aulast%3DSugimura%26aufirst%3DK.%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DHoshikawa%26aufirst%3DY.%26aulast%3DNawata%26aufirst%3DJ.%26aulast%3DKondo%26aufirst%3DT.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DEvidence%2520for%2520Rho-kinase%2520activation%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirc.%2520J.%26date%3D2009%26volume%3D73%26spage%3D1731%26epage%3D1739%26doi%3D10.1253%2Fcircj.CJ-09-0135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mouchaers, K. T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalij, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postmus, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hinsbergh, V. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nieuw Amerongen, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Laarse, W. J.</span></span> <span> </span><span class="NLM_article-title">Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1183/09031936.00130209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00130209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20351034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFSrtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=800-807&author=K.+T.+B.+Mouchaersauthor=I.+Schalijauthor=M.+A.+de+Boerauthor=P.+E.+Postmusauthor=V.+W.+M.+van+Hinsberghauthor=G.+P.+van+Nieuw+Amerongenauthor=A.+Vonk+Noordegraafauthor=W.+J.+van+der+Laarse&title=Fasudil+reduces+monocrotaline-induced+pulmonary+arterial+hypertension%3A+comparison+with+bosentan+and+sildenafil&doi=10.1183%2F09031936.00130209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil</span></div><div class="casAuthors">Mouchaers, K. T. B.; Schalij, I.; de Boer, M. A.; Postmus, P. E.; van Hinsbergh, V. W. M.; van Nieuw Amerongen, G. P.; Noordegraaf, A. Vonk; van der Laarse, W. J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">800-807</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) still cannot be cured, warranting the search for novel treatments.  Fasudil (a Rho kinase inhibitor) was compared with bosentan (an endothelin receptor blocker) and sildenafil (a phosphodiesterase 5 inhibitor), with emphasis on right ventricular (RV) function, in a reversal rat model of monocrotaline (MCT)-induced PAH.  In addn., the effects of combining bosentan or sildenafil with fasudil were studied.  MCT (40 mg/kg body wt.-1) induced clear PAH in male Wistar rats (n = 9).  After 28 days, echocardiog., RV catheterization and histochem. showed that cardiac frequency, stroke vol. and RV contractility had deteriorated, accompanied by RV dilatation and hypertrophy, and marked pulmonary arterial wall thickening.  Mean pulmonary arterial pressure and pulmonary vascular resistance increased significantly compared to healthy rats (n = 9).  After 14 days, MCT-treated rats received a 14-day oral treatment with bosentan, sildenfil, fasudil or a combination of fasudil with either bosentan or sildenfil (all n = 9).  All treatments preserved cardiac frequency, stroke vol. and RV contractility, and reduced pulmonary vascular resistance and RV dilatation.  Fasudil lowered RV systolic pressure and mean pulmonary arterial pressure significantly, by reducing pulmonary arterial remodelling, which reduced RV hypertrophy.  Combining bosentan or sildenafil with fasudil had no synergistic effect.  Fasudil significantly improved PAH, to a greater degree than did bosentan and sildenafil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSaD9G1pFEz7Vg90H21EOLACvtfcHk0liszbsxe5gKKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFSrtL7E&md5=ee112a35549c6f53fe46f157a02e85a4</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1183%2F09031936.00130209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00130209%26sid%3Dliteratum%253Aachs%26aulast%3DMouchaers%26aufirst%3DK.%2BT.%2BB.%26aulast%3DSchalij%26aufirst%3DI.%26aulast%3Dde%2BBoer%26aufirst%3DM.%2BA.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3Dvan%2BHinsbergh%26aufirst%3DV.%2BW.%2BM.%26aulast%3Dvan%2BNieuw%2BAmerongen%26aufirst%3DG.%2BP.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3Dvan%2Bder%2BLaarse%26aufirst%3DW.%2BJ.%26atitle%3DFasudil%2520reduces%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%253A%2520comparison%2520with%2520bosentan%2520and%2520sildenafil%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D36%26spage%3D800%26epage%3D807%26doi%3D10.1183%2F09031936.00130209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osanai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension - a pilot efficacy trial</span>. <i>Circ. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2619</span>– <span class="NLM_lpage">2625</span>, <span class="refDoi"> DOI: 10.1253/circj.CJ-13-0443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1253%2Fcircj.CJ-13-0443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23912836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2013&pages=2619-2625&author=Y.+Fukumotoauthor=N.+Yamadaauthor=H.+Matsubaraauthor=M.+Mizoguchiauthor=K.+Uchinoauthor=A.+Yaoauthor=Y.+Kiharaauthor=M.+Kawanoauthor=H.+Watanabeauthor=Y.+Takedaauthor=T.+Adachiauthor=S.+Osanaiauthor=N.+Tanabeauthor=T.+Inoueauthor=A.+Kuboauthor=Y.+Otaauthor=K.+Fukudaauthor=T.+Nakanoauthor=H.+Shimokawa&title=Double-blind%2C+placebo-controlled+clinical+trial+with+a+Rho-kinase+inhibitor+in+pulmonary+arterial+hypertension+-+a+pilot+efficacy+trial&doi=10.1253%2Fcircj.CJ-13-0443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension - a pilot efficacy trial -</span></div><div class="casAuthors">Fukumoto, Yoshihiro; Yamada, Norikazu; Matsubara, Hiromi; Mizoguchi, Minori; Uchino, Kazuaki; Yao, Atsushi; Kihara, Yasuki; Kawano, Mitsuhiro; Watanabe, Hiroshi; Takeda, Yutaka; Adachi, Takeshi; Osanai, Shinobu; Tanabe, Nobuhiro; Inoue, Teruo; Kubo, Akihiro; Ota, Yuri; Fukuda, Koichiro; Nakano, Takeshi; Shimokawa, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2619-2625</span>CODEN:
                <span class="NLM_cas:coden">CJIOBY</span>;
        ISSN:<span class="NLM_cas:issn">1346-9843</span>.
    
            (<span class="NLM_cas:orgname">Japanese Circulation Society</span>)
        </div><div class="casAbstract">Background: We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models.  In the present study, we examd. the clin. effects of mid-term oral treatment with an extended release formulation of AT-877 (fasudil hydrochloride), a specific Rho-kinase inhibitor (AT-877ER) on PAH.  Methods and Results: 23 PAH patients were treated with either placebo (10/2 females/males, 51±16 years, idiopathic PAH (IPAH) in 6, PAH assocd. with connective tissue disease (CTD-PAH) in 3, PAH with congenital heart disease (CHD-PAH) in 2, and portal PAH in 1) or AT-877ER (6/5 females/males, 47±14 years, IPAH in 2, CTD-PAH in 5, and CHD-PAH in 4); 3 patients were excluded.  We performed a 6-min walk test and right heart catheterization in the remaining 20 patients, before and 3 mo after the treatment (placebo n=11, AT-877ER n=9).  Although there were no significant differences between the 2 groups for the 6-min walk distance, pulmonary hemodynamics tended to be improved in the AT-877ER group, esp. the prevalence of improved cardiac index from baseline, which was significantly higher in the AT-877ER than in the placebo group.  In the AT-877ER group, serum levels of hydroxyfasudil, an active metabolite of AT-877ER tended to correlate with improvements in the cardiac index and mean pulmonary artery pressure.  Conclusions: Mid-term treatment with oral AT-877ER showed addnl. improvement in pulmonary hemodynamics in patients with PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof001r8Pp19rVg90H21EOLACvtfcHk0ljpkarumDUmDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSns77I&md5=1f9a29ee6f6b0a9d40c80c883811f109</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1253%2Fcircj.CJ-13-0443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1253%252Fcircj.CJ-13-0443%26sid%3Dliteratum%253Aachs%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DYamada%26aufirst%3DN.%26aulast%3DMatsubara%26aufirst%3DH.%26aulast%3DMizoguchi%26aufirst%3DM.%26aulast%3DUchino%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DA.%26aulast%3DKihara%26aufirst%3DY.%26aulast%3DKawano%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DAdachi%26aufirst%3DT.%26aulast%3DOsanai%26aufirst%3DS.%26aulast%3DTanabe%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DA.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DFukuda%26aufirst%3DK.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DDouble-blind%252C%2520placebo-controlled%2520clinical%2520trial%2520with%2520a%2520Rho-kinase%2520inhibitor%2520in%2520pulmonary%2520arterial%2520hypertension%2520-%2520a%2520pilot%2520efficacy%2520trial%26jtitle%3DCirc.%2520J.%26date%3D2013%26volume%3D77%26spage%3D2619%26epage%3D2625%26doi%3D10.1253%2Fcircj.CJ-13-0443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukumoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demachi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawata, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokawa, H.</span></span> <span> </span><span class="NLM_article-title">Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension</span>. <i>Heart Vessels</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1007/s00380-009-1176-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1007%2Fs00380-009-1176-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20339976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3c3hsVGkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2010&pages=144-149&author=H.+Fujitaauthor=Y.+Fukumotoauthor=K.+Sajiauthor=K.+Sugimuraauthor=J.+Demachiauthor=J.+Nawataauthor=H.+Shimokawa&title=Acute+vasodilator+effects+of+inhaled+fasudil%2C+a+specific+Rho-kinase+inhibitor%2C+in+patients+with+pulmonary+arterial+hypertension&doi=10.1007%2Fs00380-009-1176-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension</span></div><div class="casAuthors">Fujita Hiroshi; Fukumoto Yoshihiro; Saji Kenya; Sugimura Koichiro; Demachi Jun; Nawata Jun; Shimokawa Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Heart and vessels</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">144-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models.  In the present study, we examined acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, as a more feasible option to locally deliver the drug for PAH.  We examined 15 patients with PAH (13 women and 2 men, 45 +/- 4 years old), including idiopathic PAH (n = 5), PAH associated with connective tissue disease (n = 6), PAH with congenital heart disease (n = 3), and portal PAH (n = 1).  In those patients, we performed right heart catheterization with a Swan-Ganz catheter in the two protocols with inhalation of nitric oxide (NO) (40 ppm, 10 min) and fasudil (30 mg, 10 min) with a sufficient interval (>30 min).  Both NO and fasudil inhalation significantly reduced mean pulmonary arterial pressure (PAP) (NO: P < 0.01, fasudil: P < 0.05) and tended to decrease pulmonary vascular resistance (NO: P = 0.07, fasudil: P = 0.1), but did not affect cardiac index.  The ratio of pulmonary to systemic vascular resistance was significantly reduced both in NO and fasudil inhalation (NO: P < 0.01, fasudil: P < 0.05), indicating that both NO and fasudil inhalation selectively affect lung tissues.  Interestingly, there was no correlation in the vasodilator effects between NO and fasudil, and a positive correlation with serum levels of high-sensitivity C-reactive protein was noted for fasudil but not for NO.  These results suggest that inhalation of fasudil is as effective as NO in patients with PAH, possibly through different mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSOIq-UL4l5qkbxh97K6Vt6fW6udTcc2eZ_44EaTcSbx7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3hsVGkuw%253D%253D&md5=d915eaa82bda541ef775f2d3f3fb376b</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1007%2Fs00380-009-1176-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00380-009-1176-8%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DH.%26aulast%3DFukumoto%26aufirst%3DY.%26aulast%3DSaji%26aufirst%3DK.%26aulast%3DSugimura%26aufirst%3DK.%26aulast%3DDemachi%26aufirst%3DJ.%26aulast%3DNawata%26aufirst%3DJ.%26aulast%3DShimokawa%26aufirst%3DH.%26atitle%3DAcute%2520vasodilator%2520effects%2520of%2520inhaled%2520fasudil%252C%2520a%2520specific%2520Rho-kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DHeart%2520Vessels%26date%3D2010%26volume%3D25%26spage%3D144%26epage%3D149%26doi%3D10.1007%2Fs00380-009-1176-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morigi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leoni, A.</span></span> <span> </span><span class="NLM_article-title">Small-molecules targeting kinases involved in pulmonary hypertension: A patent review (2010–2015)</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3510</span>– <span class="NLM_lpage">3527</span>, <span class="refDoi"> DOI: 10.2174/0929867323666160809093451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F0929867323666160809093451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27516199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=3510-3527&author=R.+Morigiauthor=M.+Rambaldiauthor=A.+Locatelliauthor=A.+Leoni&title=Small-molecules+targeting+kinases+involved+in+pulmonary+hypertension%3A+A+patent+review+%282010%E2%80%932015%29&doi=10.2174%2F0929867323666160809093451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)</span></div><div class="casAuthors">Morigi, Rita; Rambaldi, Mirella; Locatelli, Alessandra; Leoni, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">3510-3527</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Despite the fact that in recent years, a substantial progress has been made in the treatment of pulmonary hypertension, it is still a severe disease characterized by poor prognosis, and the search for new drugs remains a priority.  Current remedies address mainly the vasoconstrictor/ vasodilator imbalance in the pulmonary circulation, while the causes of the disease are only moderately affected.  Recently, the role of receptor and non receptor kinases in pulmonary hypertension has emerged and these targets were extensively considered for the development of new therapeutic strategies.  This review discusses the patents on small-mols. targeting kinases involved in the proliferation/apoptosis imbalance, typically present in pulmonary hypertension.  Methods: Bibliog. research for the inventions was carried out using Espacenet and Sci-Finder databases, "pulmonary hypertension and kinases" as research query and the range from 2010 to 2015.  Only patents published in English were considered.  A qual. anal. of the contents of each patent was made to examine the reported compds., the studies performed and the resulting conclusions.  Results: The review includes about thirty applications.  Moreover, in order to illustrate the pathophisiol. of the disease and the mechanisms of the targets, about forty addnl. papers were reported.  Considering that imatinib, a PDGF receptor inhibitor, entered the clin. trials for the treatment of pulmonary hypertension, the first patents were devoted to inhibitors of tyrosine kinase receptors, such as PDGFR and c-Kit.  Subsequently, in addn. to kinase receptors, the role of other pathways involved in pulmonary hypertension has emerged, and some research groups have focused their attention also on non-receptor kinases.  Fifteen patents on this topic reported these new targets and new derivs.  However, in most of the inventions, although the pulmonary hypertension is among the treatable diseases, the compds. were subjected only to antiproliferative assays and not to specific tests on animal models.  Conclusion: The studies reported in this review confirm the continuous research efforts aimed to identify new targets and new drugs for the treatment of pulmonary hypertension.  Several inhibitors of kinase were described.  These compds. could inhibit mainly important branching processes and pathol. growth of blood vessels, thereby might increase the lifespan of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4XuriOHsVrLVg90H21EOLACvtfcHk0ljpkarumDUmDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksb%252FN&md5=1678d159e602c532561ddc57f0ebea9d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.2174%2F0929867323666160809093451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666160809093451%26sid%3Dliteratum%253Aachs%26aulast%3DMorigi%26aufirst%3DR.%26aulast%3DRambaldi%26aufirst%3DM.%26aulast%3DLocatelli%26aufirst%3DA.%26aulast%3DLeoni%26aufirst%3DA.%26atitle%3DSmall-molecules%2520targeting%2520kinases%2520involved%2520in%2520pulmonary%2520hypertension%253A%2520A%2520patent%2520review%2520%25282010%25E2%2580%25932015%2529%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26spage%3D3510%26epage%3D3527%26doi%3D10.2174%2F0929867323666160809093451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. R.</span></span> <span> </span><span class="NLM_article-title">Molecular, pharmacological and functional diversity of 5-HT receptors</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">554</span>, <span class="refDoi"> DOI: 10.1016/S0091-3057(01)00746-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0091-3057%2801%2900746-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11888546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvVChtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=533-554&author=D.+Hoyerauthor=J.+P.+Hannonauthor=G.+R.+Martin&title=Molecular%2C+pharmacological+and+functional+diversity+of+5-HT+receptors&doi=10.1016%2FS0091-3057%2801%2900746-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular, pharmacological and functional diversity of 5-HT receptors</span></div><div class="casAuthors">Hoyer, Daniel; Hannon, Jason P.; Martin, Graeme R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-554</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-hydroxytryptamine, 5-HT) is probably unique among the monoamines in that its effects are subserved by as many as 13 distinct heptahelical, G-protein-coupled receptors (GPCRs) and one (presumably a family of) ligand-gated ion channel(s).  These receptors are divided into seven distinct classes (5-HT1 to 5-HT7) largely on the basis of their structural and operational characteristics.  While this degree of phys. diversity clearly underscores the physiol. importance of serotonin, evidence for an even greater degree of operational diversity continues to emerge.  The challenge for modern 5-HT research has therefore been to define more precisely the properties of the systems that make this incredible diversity possible.  Much progress in this regard has been made during the last decade with the realization that serotonin is possibly the least conservative monoamine transmitter and the cloning of its many receptors.  Coupled with the actions of an extremely avid and efficient reuptake system, this array of receptor subtypes provides almost limitless signaling capabilities to the extent that one might even question the need for other transmitter systems.  However, the complexity of the system appears endless, since posttranslational modifications, such as alternate splicing and RNA editing, increase the no. of proteins, oligomerization and heteromerization increase the no. of complexes, and multiple G-protein suggest receptor trafficking, allowing phenotypic switching and crosstalk within and possibly between receptor families.  Whether all these possibilities are used in vivo under physiol. or pathol. conditions remains to be firmly established, but in essence, such variety will keep the 5-HT community busy for quite some time.  Those who may have predicted that mol. biol. would largely simplify the life of pharmacologists have missed the point for 5-HT research in particular and, most probably, for many other transmitters.  This chapter is an attempt to summarize very briefly 5-HT receptor diversity.  The reward for unraveling this complex array of serotonin receptor-effector systems may be substantial, the ultimate prize being the development of important new drugs in a range of disease areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Nndw8IzJXLVg90H21EOLACvtfcHk0li6w5_7WTJEzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvVChtb4%253D&md5=2fd7e3ea62256c616688b45794a7606a</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FS0091-3057%2801%2900746-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0091-3057%252801%252900746-8%26sid%3Dliteratum%253Aachs%26aulast%3DHoyer%26aufirst%3DD.%26aulast%3DHannon%26aufirst%3DJ.%2BP.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26atitle%3DMolecular%252C%2520pharmacological%2520and%2520functional%2520diversity%2520of%25205-HT%2520receptors%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D71%26spage%3D533%26epage%3D554%26doi%3D10.1016%2FS0091-3057%2801%2900746-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaumann, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, F. O.</span></span> <span> </span><span class="NLM_article-title">5-Hydroxytryptamine receptors in the human cardiovascular system</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2005.12.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.pharmthera.2005.12.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16960982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1Sks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2006&pages=674-706&author=A.+J.+Kaumannauthor=F.+O.+Levy&title=5-Hydroxytryptamine+receptors+in+the+human+cardiovascular+system&doi=10.1016%2Fj.pharmthera.2005.12.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">5-Hydroxytryptamine receptors in the human cardiovascular system</span></div><div class="casAuthors">Kaumann, Alberto J.; Levy, Finn Olav</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">674-706</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The human cardiovascular system is exposed to plasma 5-hydroxytryptamine (5-HT, serotonin), usually released from platelets. 5-HT can produce harmful acute and chronic effects.  The acute cardiac effects of 5-HT consist of tachycardia (preceded on occasion by a brief reflex bradycardia), increased atrial contractility and prodn. of atrial arrhythmias.  Acute inotropic, lusitropic and arrhythmic effects of 5-HT on human ventricle become conspicuous after inhibition of phosphodiesterase (PDE) activity.  Human cardiostimulation is mediated through 5-HT4 receptors.  Atrial and ventricular PDE3 activity exerts a protective role against potentially harmful cardiostimulation.  Chronic exposure to high levels of 5-HT (from metastatic carcinoid tumors), the anorectic drug fenfluramine and its metabolites, as well as the ecstasy drug 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA) are assocd. with proliferative disease and thickening of cardiac valves, mediated through 5-HT2B receptors.  5-HT2B receptors have an obligatory physiol. role in murine cardiac embryol. but whether this happens in humans requires research.  Congenital heart block (CHB) is, on occasion, assocd. with autoantibodies against 5-HT4 receptors.  Acute vascular constriction by 5-HT is usually shared by 5-HT1B and 5-HT2A receptors, except in intracranial arteries which constrict only through 5-HT1B receptors.  Both 5-HT1B and 5-HT2A receptors can mediate coronary artery spasm but only 5-HT1B receptors appear involved in coronary spasm of patients treated with triptans or with Prinzmetal angina.  5-HT2A receptors constrict the portal venous system including esophageal collaterals in cirrhosis.  Chronic exposure to 5-HT can contribute to pulmonary hypertension through activation of constrictor 5-HT1B receptors and proliferative 5-HT2B receptors, and possibly through direct intracellular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Baa4LbQgzrVg90H21EOLACvtfcHk0li6w5_7WTJEzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1Sks70%253D&md5=ab1b7eaba55907f7e88bba89257b0908</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2005.12.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2005.12.004%26sid%3Dliteratum%253Aachs%26aulast%3DKaumann%26aufirst%3DA.%2BJ.%26aulast%3DLevy%26aufirst%3DF.%2BO.%26atitle%3D5-Hydroxytryptamine%2520receptors%2520in%2520the%2520human%2520cardiovascular%2520system%26jtitle%3DPharmacol.%2520Ther.%26date%3D2006%26volume%3D111%26spage%3D674%26epage%3D706%26doi%3D10.1016%2Fj.pharmthera.2005.12.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clayton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillis, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, A. G. B.</span></span> <span> </span><span class="NLM_article-title">5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone</span>. <i>Pulm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1006/pulp.1994.1007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1006%2Fpulp.1994.1007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7516208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK2cXitlKrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1994&pages=65-72&author=M.+R.+MacLeanauthor=R.+A.+Claytonauthor=S.+W.+Hillisauthor=P.+D.+McIntyreauthor=A.+J.+Peacockauthor=A.+G.+B.+Templeton&title=5-HT1-receptor-mediated+vasoconstriction+in+bovine+isolated+pulmonary+arteries%3A+influences+of+vascular+endothelium+and+tone&doi=10.1006%2Fpulp.1994.1007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone</span></div><div class="casAuthors">MacLean, M. R.; Clayton, R. A.; Hillis, S. W.; McIntyre, P. D.; Peacock, A. J.; Templeton, A. G. B.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">PUPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0952-0600</span>.
    </div><div class="casAbstract">Vasoconstrictor responses to 5-hydroxytryptamine (5-HT) and the 5-HT1D receptor agonist sumatriptan were studied in isolated bovine pulmonary artery rings.  The effects of the antagonists, ketanserin (5-HT2A-receptors) and methiothepin (5-HT1- and 5-HT2A-receptors) on these responses were detd.  The influences of vascular tone and the effect of removal of the vascular endothelium and pretreatment with the inhibitor of nitric oxide synthase, Nω-nitro-L-arginine methylester, were also studied.  In the absence of tone, in majority of vessels, sumatriptan did not induce significant contractions.  5-HT-induced responses were concn.-dependent and ketanserin and methiothepin antagonized these in a competitive fashion.  Removal of the endothelium or inclusion of L-NAME potentiated responses to sumatriptan.  The sensitivity to sumatriptan was increased by L-NAME only in the presence of the endothelium while max. responses to sumatriptan were potentiated in both unrubbed and rubbed vessels.  Removal of the endothelium and/or inclusion of L-NAME had no significant effect on responses to 5-HT.  U46619-induced tone markedly increased sumatriptan-induced responses which were competitively antagonized by methiothepin but were relatively resistant to ketanserin, verifying activation of a 5-HT1D receptor.  Responses to 5-HT were also potentiated and competitively antagonized by ketanserin, and further antagonized by methiothepin.  With tone present, lower concns. of 5-HT were ketanserin-resistant and methiothepin-sensitive, indicating activation of a 5-HT1-like receptor.  The results indicate that, in bovine pulmonary arteries, in the absence of vascular tone, 5-HT mediates vasoconstriction via 5-HT2A receptors while with tone present, a 5-HT1D-like response to both 5-HT and sumatriptan is obsd.  The sumatriptan-induced response in potentiated by L-NAME and endothelium removal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWDuR9CUYeKLVg90H21EOLACvtfcHk0li6w5_7WTJEzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitlKrtbc%253D&md5=4acaaa8e9e401c48b4678c3b0914267f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1006%2Fpulp.1994.1007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fpulp.1994.1007%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DClayton%26aufirst%3DR.%2BA.%26aulast%3DHillis%26aufirst%3DS.%2BW.%26aulast%3DMcIntyre%26aufirst%3DP.%2BD.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DTempleton%26aufirst%3DA.%2BG.%2BB.%26atitle%3D5-HT1-receptor-mediated%2520vasoconstriction%2520in%2520bovine%2520isolated%2520pulmonary%2520arteries%253A%2520influences%2520of%2520vascular%2520endothelium%2520and%2520tone%26jtitle%3DPulm.%2520Pharmacol.%26date%3D1994%26volume%3D7%26spage%3D65%26epage%3D72%26doi%3D10.1006%2Fpulp.1994.1007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?</span>. <i>J. Lab. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1016/S0022-2143(99)90114-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0022-2143%2899%2990114-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10444023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXlsFegtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=1999&pages=105-114&author=M.+R.+MacLean&title=Endothelin-1+and+serotonin%3A+mediators+of+primary+and+secondary+pulmonary+hypertension%3F&doi=10.1016%2FS0022-2143%2899%2990114-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?</span></div><div class="casAuthors">MacLean, Margaret R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Laboratory and Clinical Medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-114</span>CODEN:
                <span class="NLM_cas:coden">JLCMAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2143</span>.
    
            (<span class="NLM_cas:orgname">Mosby, Inc.</span>)
        </div><div class="casAbstract">A review with 133 refs.  Pulmonary hypertension (PHT) is a disease involving vasoconstriction and proliferation of the vascular smooth muscle.  ET-1 and serotonin are potent vasoconstrictors of the pulmonary arterial circulation and mitogens of pulmonary vascular smooth muscle cells.  Plasma levels of both serotonin and ET-1 are elevated in both primary and secondary PHT.  Hence they may contribute both to pulmonary vascular remodeling and the increased pulmonary vascular tone evident in PHT.  The influence of both mediators on the pulmonary vasculature and their putative roles in PHT is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogEGGVluxdeLVg90H21EOLACvtfcHk0li6w5_7WTJEzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlsFegtL0%253D&md5=b544eaa565ad39e68c24ccb27617e7e2</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2FS0022-2143%2899%2990114-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2143%252899%252990114-2%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DEndothelin-1%2520and%2520serotonin%253A%2520mediators%2520of%2520primary%2520and%2520secondary%2520pulmonary%2520hypertension%253F%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1999%26volume%3D134%26spage%3D105%26epage%3D114%26doi%3D10.1016%2FS0022-2143%2899%2990114-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porvasnik, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Germain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gannon, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shacham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mousily, F.</span></span> <span> </span><span class="NLM_article-title">PRX-08066, a novel 5-hydroxytryptamine receptor 2b antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>334</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">372</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.165001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.109.165001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20430844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KisLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=334&publication_year=2010&pages=364-372&author=S.+L.+Porvasnikauthor=S.+Germainauthor=J.+Emburyauthor=K.+S.+Gannonauthor=V.+Jacquesauthor=J.+Murrayauthor=B.+J.+Byrneauthor=S.+Shachamauthor=F.+Al-Mousily&title=PRX-08066%2C+a+novel+5-hydroxytryptamine+receptor+2b+antagonist%2C+reduces+monocrotaline-induced+pulmonary+arterial+hypertension+and+right+ventricular+hypertrophy+in+rats&doi=10.1124%2Fjpet.109.165001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats</span></div><div class="casAuthors">Porvasnik, Stacy L.; Germain, Sean; Embury, Jennifer; Gannon, Kimberley S.; Jacques, Vincent; Murray, Justin; Byrne, Barry J.; Shacham, Sharon; Al-Mousily, Faris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">334</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">364-372</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a life-threatening disease that results in right ventricular failure.  5-((4-(6-Chlorothieno[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumarate (PRX-08066) is a selective 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist that causes selective vasodilation of pulmonary arteries.  In the current study, the effects of PRX-08066 were assessed by using the monocrotaline (MCT)-induced PAH rat model.  Male rats received 40 mg/kg MCT or phosphate-buffered saline and were treated orally twice a day with vehicle or 50 or 100 mg/kg PRX-08066 for 5 wk.  Pulmonary and cardiac functions were evaluated by hemodynamics, heart wt., magnetic resonance imaging (MRI), pulmonary artery (PA) morphol., and histol.  Cardiac MRI demonstrated that PRX-08066 (100 mg/kg) significantly (P < 0.05) improved right ventricular ejection fraction.  PRX-08066 significantly reduced peak PA pressure at 50 and 100 mg/kg (P < 0.05 and < 0.01, resp.) compared with MCT control animals.  PRX-08066 therapy also significantly reduced right ventricle (RV)/body wt. and RV/left ventricle + septum (P < 0.01 and < 0.001, resp.) compared with MCT-treated animals.  Morphometric assessment of pulmonary arterioles revealed a significant redn. in medial wall thickening and lumen occlusion assocd. with both doses of PRX-08066 (P < 0.01).  The 5-HT2BR antagonist PRX-08066 significantly attenuated the elevation in PA pressure and RV hypertrophy and maintained cardiac function.  Pulmonary vascular remodeling was also diminished compared with MCT control rats.  PRX-08066 prevents the severity of PAH in the MCT rat model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_CaIqQmpIS7Vg90H21EOLACvtfcHk0lgZHuHEyfjFwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KisLbJ&md5=c00235e9c830eb3a3937fa3696dac88b</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.165001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.165001%26sid%3Dliteratum%253Aachs%26aulast%3DPorvasnik%26aufirst%3DS.%2BL.%26aulast%3DGermain%26aufirst%3DS.%26aulast%3DEmbury%26aufirst%3DJ.%26aulast%3DGannon%26aufirst%3DK.%2BS.%26aulast%3DJacques%26aufirst%3DV.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DByrne%26aufirst%3DB.%2BJ.%26aulast%3DShacham%26aufirst%3DS.%26aulast%3DAl-Mousily%26aufirst%3DF.%26atitle%3DPRX-08066%252C%2520a%2520novel%25205-hydroxytryptamine%2520receptor%25202b%2520antagonist%252C%2520reduces%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520and%2520right%2520ventricular%2520hypertrophy%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D334%26spage%3D364%26epage%3D372%26doi%3D10.1124%2Fjpet.109.165001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumitrascu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulcke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konigshoff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickelberg, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S. S.</span></span> <span> </span><span class="NLM_article-title">Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1104</span>– <span class="NLM_lpage">1118</span>, <span class="refDoi"> DOI: 10.1183/09031936.00126010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F09031936.00126010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20947677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFyrsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2011&pages=1104-1118&author=R.+Dumitrascuauthor=C.+Kulckeauthor=M.+Konigshoffauthor=F.+Kouriauthor=X.+Yangauthor=N.+Morrellauthor=H.+A.+Ghofraniauthor=N.+Weissmannauthor=R.+Reiterauthor=W.+Seegerauthor=F.+Grimmingerauthor=O.+Eickelbergauthor=R.+T.+Schermulyauthor=S.+S.+Pullamsetti&title=Terguride+ameliorates+monocrotaline-induced+pulmonary+hypertension+in+rats&doi=10.1183%2F09031936.00126010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats</span></div><div class="casAuthors">Dumitrascu, R.; Kulcke, C.; Koenigshoff, M.; Kouri, F.; Yang, X.; Morrell, N.; Ghofrani, H. A.; Weissmann, N.; Reiter, R.; Seeger, W.; Grimminger, F.; Eickelberg, O.; Schermuly, R. T.; Pullamsetti, S. S.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1104-1118</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a life-threatening disease characterised by vasoconstriction and remodelling of the pulmonary vasculature.  The serotonin (5-hydroxytryptamine (5-HT)) pathway has been shown to play a major role in the pathogenesis of PAH, but pharmacol. modulation of this pathway for treatment of PAH is, to date, at a pre-clin. level.  Terguride is a 5-HT receptor (5-HTR) antagonist that is well tolerated and clin. approved for ovulation disorders.  Immunohistochem. against 5-HTR2A/B on human lungs revealed their localisation to the vascular smooth muscle layer and quant. RT-PCR showed 5-HTR2B upregulation in pulmonary artery smooth muscle cells (PASMC) isolated from PAH patients.  Proliferation and migration of cultured primary human PASMC were dose-dependently blocked by terguride.  Therapeutic 5-HT signalling inhibition was 1) demonstrated in isolated, ventilated and perfused rat lungs and 2) by chronic terguride treatment of rats with monocrotaline (MCT)-induced pulmonary hypertension in a preventive or curative approach.  Terguride inhibited proliferation of PASMCs and abolished 5-HT-induced pulmonary vasoconstriction.  Chronic terguride treatment prevented dose-dependently the development and progression of MCT-induced PAH in rats.  Thus, terguride represents a valuable novel therapeutic approach in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsGNpNHdRcQLVg90H21EOLACvtfcHk0lgZHuHEyfjFwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFyrsLw%253D&md5=ee0d0587c29d605847294b963e32e2ab</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1183%2F09031936.00126010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00126010%26sid%3Dliteratum%253Aachs%26aulast%3DDumitrascu%26aufirst%3DR.%26aulast%3DKulcke%26aufirst%3DC.%26aulast%3DKonigshoff%26aufirst%3DM.%26aulast%3DKouri%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMorrell%26aufirst%3DN.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DReiter%26aufirst%3DR.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DEickelberg%26aufirst%3DO.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26atitle%3DTerguride%2520ameliorates%2520monocrotaline-induced%2520pulmonary%2520hypertension%2520in%2520rats%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2011%26volume%3D37%26spage%3D1104%26epage%3D1118%26doi%3D10.1183%2F09031936.00126010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schymura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novoyatleva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojonazarov, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wietelmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luitel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krompiec, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretyn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pullamsetti, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span> <span> </span><span class="NLM_article-title">5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2015</i></span>,  <span class="NLM_fpage">438403</span>, <span class="refDoi"> DOI: 10.1155/2015/438403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1155%2F2015%2F438403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25667920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2MrktlChtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=438403&author=W.+Janssenauthor=Y.+Schymuraauthor=T.+Novoyatlevaauthor=B.+Kojonazarovauthor=M.+Boehmauthor=A.+Wietelmannauthor=H.+Luitelauthor=K.+Murmannauthor=D.+R.+Krompiecauthor=A.+Tretynauthor=S.+S.+Pullamsettiauthor=N.+Weissmannauthor=W.+Seegerauthor=H.+A.+Ghofraniauthor=R.+T.+Schermuly&title=5-HT2B+receptor+antagonists+inhibit+fibrosis+and+protect+from+RV+heart+failure&doi=10.1155%2F2015%2F438403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure</span></div><div class="casAuthors">Janssen Wiebke; Novoyatleva Tatyana; Kojonazarov Baktybek; Boehm Mario; Luitel Himal; Murmann Kirsten; Krompiec Damian Richard; Weissmann Norbert; Ghofrani Hossein Ardeschir; Schermuly Ralph Theo; Schymura Yves; Wietelmann Astrid; Tretyn Aleksandra; Pullamsetti Soni Savai; Seeger Werner</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2015</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">438403</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The serotonin (5-HT) pathway was shown to play a role in pulmonary hypertension (PH), but its functions in right ventricular failure (RVF) remain poorly understood.  The aim of the current study was to investigate the effects of Terguride (5-HT2A and 2B receptor antagonist) or SB204741 (5-HT2B receptor antagonist) on right heart function and structure upon pulmonary artery banding (PAB) in mice.  METHODS:  Seven days after PAB, mice were treated for 14 days with Terguride (0.2 mg/kg bid) or SB204741 (5 mg/kg day).  Right heart function and remodeling were assessed by right heart catheterization, magnetic resonance imaging (MRI), and histomorphometric methods.  Total secreted collagen content was determined in mouse cardiac fibroblasts isolated from RV tissues.  RESULTS:  Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB.  Moreover, 5-HT2B receptor antagonists diminished TGF-beta1 induced collagen synthesis of RV cardiac fibroblasts in vitro.  CONCLUSION:  5-HT2B receptor antagonists reduce collagen deposition, thereby inhibiting right ventricular fibrosis.  Chronic treatment prevented the development and progression of pressure overload-induced RVF in mice.  Thus, 5-HT2B receptor antagonists represent a valuable novel therapeutic approach for RVF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFnL20FdRuuBpyrDyM_m9cfW6udTcc2ebKKoxY5lvf9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MrktlChtg%253D%253D&md5=9bccc5e39722aa7085103a62031abaa1</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1155%2F2015%2F438403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F438403%26sid%3Dliteratum%253Aachs%26aulast%3DJanssen%26aufirst%3DW.%26aulast%3DSchymura%26aufirst%3DY.%26aulast%3DNovoyatleva%26aufirst%3DT.%26aulast%3DKojonazarov%26aufirst%3DB.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DWietelmann%26aufirst%3DA.%26aulast%3DLuitel%26aufirst%3DH.%26aulast%3DMurmann%26aufirst%3DK.%26aulast%3DKrompiec%26aufirst%3DD.%2BR.%26aulast%3DTretyn%26aufirst%3DA.%26aulast%3DPullamsetti%26aufirst%3DS.%2BS.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26atitle%3D5-HT2B%2520receptor%2520antagonists%2520inhibit%2520fibrosis%2520and%2520protect%2520from%2520RV%2520heart%2520failure%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D438403%26doi%3D10.1155%2F2015%2F438403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hiti, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neurohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halank, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaehler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olschewski, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filusch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenkranz, S.</span></span> <span> </span><span class="NLM_article-title">Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase iia study</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">A2496</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2012&pages=A2496&author=H.+A.+Ghofraniauthor=H.+Al-Hitiauthor=A.+Vonk-Noordegraafauthor=J.+Behrauthor=C.+Neurohrauthor=P.+Jansaauthor=H.+Wilkensauthor=M.+M.+Hoeperauthor=E.+Gruenigauthor=C.+Opitzauthor=R.+Speichauthor=R.+Ewertauthor=M.+Halankauthor=A.+Torbickiauthor=C.+Kaehlerauthor=H.+Olschewskiauthor=A.+Filuschauthor=R.+Reiterauthor=S.+Rosenkranz&title=Proof-of-concept+study+to+investigate+the+efficacy%2C+hemodynamics+and+tolerability+of+terguride+vs.+placebo+in+subjects+with+pulmonary+arterial+hypertension%3A+results+of+a+double+blind%2C+randomised%2C+prospective+phase+iia+study&doi=10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DAl-Hiti%26aufirst%3DH.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DNeurohr%26aufirst%3DC.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DWilkens%26aufirst%3DH.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DGruenig%26aufirst%3DE.%26aulast%3DOpitz%26aufirst%3DC.%26aulast%3DSpeich%26aufirst%3DR.%26aulast%3DEwert%26aufirst%3DR.%26aulast%3DHalank%26aufirst%3DM.%26aulast%3DTorbicki%26aufirst%3DA.%26aulast%3DKaehler%26aufirst%3DC.%26aulast%3DOlschewski%26aufirst%3DH.%26aulast%3DFilusch%26aufirst%3DA.%26aulast%3DReiter%26aufirst%3DR.%26aulast%3DRosenkranz%26aufirst%3DS.%26atitle%3DProof-of-concept%2520study%2520to%2520investigate%2520the%2520efficacy%252C%2520hemodynamics%2520and%2520tolerability%2520of%2520terguride%2520vs.%2520placebo%2520in%2520subjects%2520with%2520pulmonary%2520arterial%2520hypertension%253A%2520results%2520of%2520a%2520double%2520blind%252C%2520randomised%252C%2520prospective%2520phase%2520iia%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D187%26spage%3DA2496%26doi%3D10.1164%2Fajrccm-conference.2012.185.1_MeetingAbstracts.A2496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penner, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahnichen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latte, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schurad, B.</span></span> <span> </span><span class="NLM_article-title">Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: Absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis</span>. <i>Clin. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1097/00002826-200603000-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1097%2F00002826-200603000-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16614540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2006&pages=80-86&author=C.+Hofmannauthor=U.+Pennerauthor=R.+Dorowauthor=H.+H.+Pertzauthor=S.+Jahnichenauthor=R.+Horowskiauthor=K.+P.+Latteauthor=D.+Pallaauthor=B.+Schurad&title=Lisuride%2C+a+dopamine+receptor+agonist+with+5-HT2B+receptor+antagonist+properties%3A+Absence+of+cardiac+valvulopathy+adverse+drug+reaction+reports+supports+the+concept+of+a+crucial+role+for+5-HT2B+receptor+agonism+in+cardiac+valvular+fibrosis&doi=10.1097%2F00002826-200603000-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis</span></div><div class="casAuthors">Hofmann, C.; Penner, U.; Dorow, R.; Pertz, H. H.; Jaehnichen, S.; Horowski, R.; Latte, K. P.; Palla, D.; Schurad, B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neuropharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-86</span>CODEN:
                <span class="NLM_cas:coden">CLNEDB</span>;
        ISSN:<span class="NLM_cas:issn">0362-5664</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Objectives: The high incidence of fibrotic cardiac valvulopathies reported in assocn. with the 8β-ergoline dopamine (DA) agonist, pergolide, and also case reports for cabergoline and bromocriptine have made it necessary to review the theor. basis and actual findings in the case of another DA agonist, the 8α-ergoline lisuride (used since the 1970s for migraine prophylaxis as well as since the 1980s for its prolactin-lowering and anti-Parkinson activity).  Methods: We have reviewed the pharmacol. of lisuride in relation to other DA agonists, and we have performed a throughout literature search as well as a search of our own and other adverse drug reaction databases for a possible relationship of lisuride with cardiac valvulopathy or for any reports of fibrosis in other locations.  Results: Our review of the pharmacol. and the literature strongly suggests that drug-induced cardiac valvulopathies are always related to a stimulatory drug effect on trophic 5-HT2B receptors.  As lisuride is devoid of such an effect, but on the contrary is an extremely potent 5-HT2B antagonist, an assocn. of lisuride therapy with cardiac valvulopathies seems to be highly unlikely.  In agreement with this hypothesis, not a single report of a cardiac valvulopathy assocd. with lisuride therapy has been identified in any database so far.Furthermore, against a background of an estd. 360,000 patient years, we have found only a very small no. of cases of any other form of fibrosis (1× retroperitoneal, 2× pleural, 2× pulmonary, 1× interstitial pulmonary changes), in part combined with other risk factors and confounding variables.  This closely matches 4 reports available from WHO (1× retroperitoneal, 3× pleural fibrosis).  In addn., only 5 other possibly related conditions (3× pleural effusion, 1× pleuritis, 1× pericarditis) were identified in the lisuride adverse drug reaction database of Schering, Berlin.  Conclusions: No link has been found between lisuride use and fibrotic cardiac valvulopathy, in agreement with the 5-HT2B receptor antagonist effect of this drug.  The very low incidence of spontaneous reports of any other fibrosis could be even compatible with an assocn. by chance in the population exposed to lisuride.  Although close monitoring for this kind of side effects is still to be recommended in the therapy with lisuride, our data do not support the concept of a class effect suggesting that all ergot-derived drugs and esp. DA receptor agonists with some chem. similarity to the ergot structure will cause or facilitate cardiac valvulopathies as obsd. with pergolide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO6Rsrw9jtzLVg90H21EOLACvtfcHk0lj2_Wc0fSuoqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsVersr4%253D&md5=a12de38613de4f88bf099762849ef0df</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1097%2F00002826-200603000-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00002826-200603000-00005%26sid%3Dliteratum%253Aachs%26aulast%3DHofmann%26aufirst%3DC.%26aulast%3DPenner%26aufirst%3DU.%26aulast%3DDorow%26aufirst%3DR.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26aulast%3DJahnichen%26aufirst%3DS.%26aulast%3DHorowski%26aufirst%3DR.%26aulast%3DLatte%26aufirst%3DK.%2BP.%26aulast%3DPalla%26aufirst%3DD.%26aulast%3DSchurad%26aufirst%3DB.%26atitle%3DLisuride%252C%2520a%2520dopamine%2520receptor%2520agonist%2520with%25205-HT2B%2520receptor%2520antagonist%2520properties%253A%2520Absence%2520of%2520cardiac%2520valvulopathy%2520adverse%2520drug%2520reaction%2520reports%2520supports%2520the%2520concept%2520of%2520a%2520crucial%2520role%2520for%25205-HT2B%2520receptor%2520agonism%2520in%2520cardiac%2520valvular%2520fibrosis%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2006%26volume%3D29%26spage%3D80%26epage%3D86%26doi%3D10.1097%2F00002826-200603000-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herve, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span> <span> </span><span class="NLM_article-title">5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0703570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fsj.bjp.0703570" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10991906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlGktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2000&pages=161-168&author=M.+R.+MacLeanauthor=P.+Herveauthor=S.+Eddahibiauthor=S.+Adnot&title=5-hydroxytryptamine+and+the+pulmonary+circulation%3A+receptors%2C+transporters+and+relevance+to+pulmonary+arterial+hypertension&doi=10.1038%2Fsj.bjp.0703570"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">5-hydroxytryptamine and the pulmonary circulation: receptors, transporters, and relevance to pulmonary arterial hypertension</span></div><div class="casAuthors">MacLean, Margaret R.; Herve, Philippe; Eddahibi, Saadia; Adnot, Serge</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-168</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with few refs. is given on normal pulmonary circulation, the role of circulating 5-hydroxytryptamine (5-HT) in pulmonary arterial hypertension (PAH), 5-HT and pulmonary vascular remodeling, and 5-HT and pulmonary vasoconstriction.  Evidence suggests that there are crit. changes in platelet handling of 5-HT, and perhaps handling of platelets by the lung, combined with changes in the pulmonary vascular smooth muscle response to 5-HT, which can lead to PAH.  In primary PAH, 2ndary PAH, or after anorexigen intake, there may be deficiencies in 5-HT re-uptake into platelets which would lead to increased circulating or local 5-HT levels.  Where 5-HT release from platelets is stimulated or monoamine oxidase-B activity is compromised, this effect may be amplified.  Increased local levels of 5-HT, induced by platelet release or increased accumulation of platelets in the lung, would expose pulmonary vascular smooth muscle cells (SMCs) to elevated levels of 5-HT.  The effect of this would be to increase vascular pulmonary smooth muscle contraction and proliferation.  Contraction would result from increased stimulation of the 5-HT1B receptor, an effect which would be potentiated in PAH by increased vascular tone, increased Gq-/Gi-protein synergy, and decreased cyclic GMP levels.  Current evidence suggests that 5-HT-induced proliferation occurs primarily through 5-HT uptake by the 5-HT transporter (5-HTT).  In hypoxia, after anorexigen intake, and perhaps in genetically predisposed primary PAH patients and in 2ndary PAH, increased expression of 5-HTT may lead to further increases in the transport of 5-HT into the SMCs and increased proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzBoYsVVJ3xrVg90H21EOLACvtfcHk0ljQ1dzS0IPW4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlGktbo%253D&md5=d7e332a3868423f39714a405e021f2d1</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0703570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0703570%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DHerve%26aufirst%3DP.%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DAdnot%26aufirst%3DS.%26atitle%3D5-hydroxytryptamine%2520and%2520the%2520pulmonary%2520circulation%253A%2520receptors%252C%2520transporters%2520and%2520relevance%2520to%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2000%26volume%3D131%26spage%3D161%26epage%3D168%26doi%3D10.1038%2Fsj.bjp.0703570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martres, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffestin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span> <span> </span><span class="NLM_article-title">Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells - relationship with the mitogenic action of serotonin</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1161/01.RES.84.3.329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.RES.84.3.329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10024307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXhsVaksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1999&pages=329-336&author=S.+Eddahibiauthor=V.+Fabreauthor=C.+Boniauthor=M.+P.+Martresauthor=B.+Raffestinauthor=M.+Hamonauthor=S.+Adnot&title=Induction+of+serotonin+transporter+by+hypoxia+in+pulmonary+vascular+smooth+muscle+cells+-+relationship+with+the+mitogenic+action+of+serotonin&doi=10.1161%2F01.RES.84.3.329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells: Relationship with the mitogenic action of serotonin</span></div><div class="casAuthors">Eddahibi, S.; Fabre, V.; Boni, C.; Martres, M. P.; Raffestin, B.; Hamon, M.; Adnot, S.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The increased delivery of serotonin (5-hydroxytryptamine, 5-HT) to the lung aggravates the development of hypoxia-induced pulmonary hypertension in rats, possibly through stimulation of the proliferation of pulmonary artery smooth muscle cells (PA-SMCs).  In cultured rat PA-SMCs, 5-HT (10-8 to 10-6 M) induced DNA synthesis and potentiated the mitogenic effect of platelet-derived growth factor-BB (10 ng/mL).  This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10-6 M) and paroxetine (10-7 M), but it was unaltered by ketanserin (10-6 M), a 5-HT2A receptor antagonist.  In PA-SMCs exposed to hypoxia, the levels of 5-HTT mRNA (measured by competitive reverse transcriptase-polymerase chain reaction) increased by 240% within 2 h, followed by a 3-fold increase in the uptake of [3H]5-HT at 24 h.  Cotransfection of the cells with a construct of human 5-HTT promoter-luciferase gene reporter and of pCMV-β-galactosidase gene allowed the demonstration that exposure of cells to hypoxia produced a 5.5-fold increase in luciferase activity, with no change in β-galactosidase activity.  The increased expression of 5-HTT in hypoxic cells was assocd. with a greater mitogenic response to 5-HT (10-8 to 10-6 M) in the absence as well as in the presence of platelet-derived growth factor-BB.  5-HTT expression assessed by quant. reverse transcriptase-polymerase chain reaction and in situ hybridization in the lungs was found to predominate in the media of pulmonary artery, in which a marked increase was noted in rats that had been exposed to hypoxia for 15 days.  These data show that in vitro and in vivo exposure to hypoxia induces, via a transcriptional mechanism, 5-HTT expression in PA-SMCs, and that this effect contributes to the stimulatory action of 5-HT on PA-SMC proliferation.  In vivo expression of 5-HTT by PA-SMC may play a key role in serotonin-mediated pulmonary vascular remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpacqtF7lz_j7Vg90H21EOLACvtfcHk0ljQ1dzS0IPW4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsVaksb0%253D&md5=19a32c4f022c7bd14a8f9beeb2762934</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1161%2F01.RES.84.3.329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.84.3.329%26sid%3Dliteratum%253Aachs%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DFabre%26aufirst%3DV.%26aulast%3DBoni%26aufirst%3DC.%26aulast%3DMartres%26aufirst%3DM.%2BP.%26aulast%3DRaffestin%26aufirst%3DB.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdnot%26aufirst%3DS.%26atitle%3DInduction%2520of%2520serotonin%2520transporter%2520by%2520hypoxia%2520in%2520pulmonary%2520vascular%2520smooth%2520muscle%2520cells%2520-%2520relationship%2520with%2520the%2520mitogenic%2520action%2520of%2520serotonin%26jtitle%3DCirc.%2520Res.%26date%3D1999%26volume%3D84%26spage%3D329%26epage%3D336%26doi%3D10.1161%2F01.RES.84.3.329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuchar, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morecroft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheward, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colston, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmar, A.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the 5-hydroxytryptamine transporter gene - effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2150</span>– <span class="NLM_lpage">2155</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000127375.56172.92</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.CIR.0000127375.56172.92" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15078799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsVWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2004&pages=2150-2155&author=M.+R.+MacLeanauthor=G.+A.+Deucharauthor=M.+N.+Hicksauthor=I.+Morecroftauthor=S.+B.+Shenauthor=J.+Shewardauthor=J.+Colstonauthor=L.+Loughlinauthor=M.+Nilsenauthor=Y.+Dempsieauthor=A.+Harmar&title=Overexpression+of+the+5-hydroxytryptamine+transporter+gene+-+effect+on+pulmonary+hemodynamics+and+hypoxia-induced+pulmonary+hypertension&doi=10.1161%2F01.CIR.0000127375.56172.92"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the 5-hydroxytryptamine transporter gene. Effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension</span></div><div class="casAuthors">MacLean, Margaret R.; Deuchar, Graeme A.; Hicks, Martin N.; Morecroft, Ian; Shen, Sanbing; Sheward, John; Colston, Janet; Loughlin, Lynn; Nilsen, Margaret; Dempsie, Yvonne; Harmar, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2150-2155</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Increased serotonin (5-hydroxytryptamine, 5-HT) transporter activity has been obsd. in human familial pulmonary hypertension.  The authors investigated pulmonary hemodynamics and the development of hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in mice overexpressing the gene for the 5-HT transporter (5-HTT+ mice).  Right ventricular pressure was elevated 3-fold in normoxic 5-HTT+ mice compared with their wild-type controls.  Hypoxia-induced increases in right ventricular hypertrophy and pulmonary vascular remodeling were also potentiated in the 5-HTT+ mice.  5-HTT-like immunoreactivity, protein, and binding sites were markedly increased in the lungs from the 5-HTT+ mice.  Hypoxia, however, decreased 5-HT transporter immunoreactivity, mRNA transcription, protein, and binding sites in both wild-type and 5-HTT+ mice.  Thus, increased 5-HT transporter expression causes elevated right ventricular pressures, and this occurs before the onset of right ventricular hypertrophy or pulmonary arterial remodeling.  Hypoxia-induced remodeling is, however, increased in 5-HTT+ mice, whereas hypoxia inhibits 5-HTT expression.  This provides a unique model that demonstrates differential mechanisms for familial pulmonary arterial hypertension and pulmonary arterial hypertension with hypoxemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvHzyGg-PT_bVg90H21EOLACvtfcHk0ljQ1dzS0IPW4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsVWqsr8%253D&md5=3919397704835d78387c5b0dea8169df</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000127375.56172.92&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000127375.56172.92%26sid%3Dliteratum%253Aachs%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DDeuchar%26aufirst%3DG.%2BA.%26aulast%3DHicks%26aufirst%3DM.%2BN.%26aulast%3DMorecroft%26aufirst%3DI.%26aulast%3DShen%26aufirst%3DS.%2BB.%26aulast%3DSheward%26aufirst%3DJ.%26aulast%3DColston%26aufirst%3DJ.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DDempsie%26aufirst%3DY.%26aulast%3DHarmar%26aufirst%3DA.%26atitle%3DOverexpression%2520of%2520the%25205-hydroxytryptamine%2520transporter%2520gene%2520-%2520effect%2520on%2520pulmonary%2520hemodynamics%2520and%2520hypoxia-induced%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2004%26volume%3D109%26spage%3D2150%26epage%3D2155%26doi%3D10.1161%2F01.CIR.0000127375.56172.92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartevelle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span> <span> </span><span class="NLM_article-title">Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1263</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000126847.27660.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.RES.0000126847.27660.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15059929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjs1ylurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2004&pages=1263-1270&author=E.+Marcosauthor=E.+Fadelauthor=O.+Sanchezauthor=M.+Humbertauthor=P.+Dartevelleauthor=G.+Simonneauauthor=M.+Hamonauthor=S.+Adnotauthor=S.+Eddahibi&title=Serotonin-induced+smooth+muscle+hyperplasia+in+various+forms+of+human+pulmonary+hypertension&doi=10.1161%2F01.RES.0000126847.27660.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin-Induced Smooth Muscle Hyperplasia in Various Forms of Human Pulmonary Hypertension</span></div><div class="casAuthors">Marcos, Elisabeth; Fadel, Elie; Sanchez, Olivier; Humbert, Marc; Dartevelle, Philippe; Simonneau, Gerald; Hamon, Michel; Adnot, Serge; Eddahibi, Saadia</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1263-1270</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Hyperplasia of pulmonary artery smooth muscle cells (PA-SMCs) is a hallmark pathol. feature of pulmonary hypertension (PH).  Serotonin (5-HT) is involved in the hyperplasia through its interactions with specific receptors and internalization by a specific plasma membrane transporter.  We investigated the expression and role of the 5-HT transporter (5-HTT) and 5-HT1B, 5-HT2A, and 5-HT2B receptors in lungs and isolated PA-SMCs from patients with primary PH (n=14), pulmonary veno-occlusive disease (n=4), or secondary PH (SPH, n=8) and nonpulmonary hypertensive control subjects.  Whereas strong immunostaining for the three receptor types and 5-HTT was seen in remodeled pulmonary vessels from patients in all PH categories, only 5-HTT expression was increased in lungs and cultured PA-SMCs from patients vs. controls.  The increased growth response of PA-SMCs from patients with primary PH, pulmonary veno-occlusive disease, or SPH to 5-HT or serum was entirely attributable to 5-HTT overexpression, because 5-HTT inhibitors but not 5-HT receptor antagonists abolished 5-HT mitogenic activity and reduced the serum-induced growth response to similar levels in patients as in controls.  The L-allelic variant of the 5-HTT gene promoter, which is assocd. with 5-HTT overexpression, was present homozygously in 14 of 25 (56%) lung transplantation patients with SPH but in only 27% of controls.  Polymorphism of the 5-HTT gene promoter was only partly responsible for the increased 5-HTT expression in PH, because PA-SMCs from patients exhibited higher 5-HTT levels than same-genotype cells from controls and no addnl. promoter sequence alterations were found.  We conclude that 5-HTT overexpression is a common pathogenic mechanism in various forms of PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosAimQG2yqP7Vg90H21EOLACvtfcHk0lgjDm6eNThnGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjs1ylurg%253D&md5=cefd064d9977e3650aa02e34cc5fd548</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000126847.27660.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000126847.27660.69%26sid%3Dliteratum%253Aachs%26aulast%3DMarcos%26aufirst%3DE.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DSanchez%26aufirst%3DO.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DDartevelle%26aufirst%3DP.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DEddahibi%26aufirst%3DS.%26atitle%3DSerotonin-induced%2520smooth%2520muscle%2520hyperplasia%2520in%2520various%2520forms%2520of%2520human%2520pulmonary%2520hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2004%26volume%3D94%26spage%3D1263%26epage%3D1270%26doi%3D10.1161%2F01.RES.0000126847.27660.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walther, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span> <span> </span><span class="NLM_article-title">A unique central tryptophan hydroxylase isoform</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1673</span>– <span class="NLM_lpage">1680</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(03)00556-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0006-2952%2803%2900556-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=14563478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVyktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2003&pages=1673-1680&author=D.+J.+Waltherauthor=M.+Bader&title=A+unique+central+tryptophan+hydroxylase+isoform&doi=10.1016%2FS0006-2952%2803%2900556-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">A unique central tryptophan hydroxylase isoform</span></div><div class="casAuthors">Walther, Diego J.; Bader, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1673-1680</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-hydroxytryptophan, 5-HT) is a neurotransmitter synthesized in the raphe nuclei of the brain stem and involved in the central control of food intake, sleep, and mood.  Accordingly, dysfunction of the serotonin system has been implicated in the pathogenesis of psychiatric diseases.  At the same time, serotonin is a peripheral hormone produced mainly by enterochromaffin cells in the intestine and stored in platelets, where it is involved in vasoconstriction, hemostasis, and the control of immune responses.  Moreover, serotonin is a precursor for melatonin and is therefore synthesized in high amts. in the pineal gland.  Tryptophan hydroxylase (TPH) catalyzes the rate limiting step in 5-HT synthesis.  Until recently, only one gene encoding TPH was described for vertebrates.  By gene targeting, we functionally ablated this gene in mice.  To our surprise, the resulting animals, although being deficient for serotonin in the periphery and in the pineal gland, exhibited close to normal levels of 5-HT in the brain stem.  This led us to the detection of a second TPH gene in the genome of humans, mice, and rats, called TPH2.  This gene is predominantly expressed in the brain stem, while the classical TPH gene, now called TPH1, is expressed in the gut, pineal gland, spleen, and thymus.  These findings clarify puzzling data, which have been collected over the last decades about partially purified TPH proteins with different characteristics and justify a new concept of the serotonin system.  In fact, there are two serotonin systems in vertebrates, independently regulated and with distinct functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz12marm0a7bVg90H21EOLACvtfcHk0lgjDm6eNThnGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVyktr8%253D&md5=e936196cebd2fdf6a8fff9bd63bf3bc7</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2803%2900556-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252803%252900556-2%26sid%3Dliteratum%253Aachs%26aulast%3DWalther%26aufirst%3DD.%2BJ.%26aulast%3DBader%26aufirst%3DM.%26atitle%3DA%2520unique%2520central%2520tryptophan%2520hydroxylase%2520isoform%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2003%26volume%3D66%26spage%3D1673%26epage%3D1680%26doi%3D10.1016%2FS0006-2952%2803%2900556-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlier-Mur, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewachter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dartevelle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanoun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saurini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span> <span> </span><span class="NLM_article-title">Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - critical role for serotonin-induced smooth muscle hyperplasia</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1857</span>– <span class="NLM_lpage">1864</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.105.591321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.105.591321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16606791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlCjurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2006&pages=1857-1864&author=S.+Eddahibiauthor=C.+Guignabertauthor=A.+M.+Barlier-Murauthor=L.+Dewachterauthor=E.+Fadelauthor=P.+Dartevelleauthor=M.+Humbertauthor=G.+Simonneauauthor=N.+Hanounauthor=F.+Sauriniauthor=M.+Hamonauthor=S.+Adnot&title=Cross+talk+between+endothelial+and+smooth+muscle+cells+in+pulmonary+hypertension+-+critical+role+for+serotonin-induced+smooth+muscle+hyperplasia&doi=10.1161%2FCIRCULATIONAHA.105.591321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Cross Talk Between Endothelial and Smooth Muscle Cells in Pulmonary Hypertension</span></div><div class="casAuthors">Eddahibi, Saadia; Guignabert, Christophe; Barlier-Mur, Anne-Marie; Dewachter, Laurence; Fadel, Elie; Dartevelle, Philippe; Humbert, Marc; Simonneau, Gerald; Hanoun, Naima; Saurini, Francoise; Hamon, Michel; Adnot, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background- The mechanism of pulmonary artery smooth muscle cell (PA-SMC) hyperplasia in idiopathic pulmonary artery hypertension (iPH) may involve both an inherent characteristic of PA-SMCs and abnormal control by external stimuli.  We investigated the role of pulmonary microvascular endothelial cells (P-ECs) in controlling PA-SMC growth.  Methods and Results- Serum-free medium of quiescent P-ECs elicited marked PA-SMC proliferation, and this effect was greater with P-ECs from patients with iPH than from control subjects and greater with PA-SMCs from these patients than from control subjects.  Fluoxetine, which inhibits serotonin-induced mitogenesis by blocking the serotonin transporter, and p-chlorophenylalanine, which inhibits serotonin synthesis by blocking tryptophan hydroxylase (TPH), caused a similar 60% redn. in the growth-promoting effect of P-EC media, whereas endothelin receptor blockers had no effect.  Assays of TPH activity in P-EC medium based on p-chlorophenylalanine-sensitive 5-hydroxytryptophan accumulation or serotonin detn. indicated serotonin synthesis by P-ECs and an increase in this TPH-dependent process in iPH.  Expression of the tph1 gene encoding the peripheral form of the TPH enzyme was increased in lungs and P-ECs from patients with iPH.  Lung TPH1 immunostaining was confined to the pulmonary vessel intima.  Conclusions- P-ECs produce paracrine factors governing PA-SMC growth.  Serotonin, the main P-EC-derived growth factor, is overproduced in iPH and contributes to PA-SMC hyperplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFS3T_5SojibVg90H21EOLACvtfcHk0lgjDm6eNThnGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlCjurY%253D&md5=2e3804a104cd05f6b17f77da7c26b63b</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.105.591321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.105.591321%26sid%3Dliteratum%253Aachs%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DBarlier-Mur%26aufirst%3DA.%2BM.%26aulast%3DDewachter%26aufirst%3DL.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DDartevelle%26aufirst%3DP.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DHanoun%26aufirst%3DN.%26aulast%3DSaurini%26aufirst%3DF.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdnot%26aufirst%3DS.%26atitle%3DCross%2520talk%2520between%2520endothelial%2520and%2520smooth%2520muscle%2520cells%2520in%2520pulmonary%2520hypertension%2520-%2520critical%2520role%2520for%2520serotonin-induced%2520smooth%2520muscle%2520hyperplasia%26jtitle%3DCirculation%26date%3D2006%26volume%3D113%26spage%3D1857%26epage%3D1864%26doi%3D10.1161%2FCIRCULATIONAHA.105.591321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morecroft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempsie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotnik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1161/01.HYP.0000252210.58849.78</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.HYP.0000252210.58849.78" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17130306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD28jks1Okuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2007&pages=232-236&author=I.+Morecroftauthor=Y.+Dempsieauthor=M.+Baderauthor=D.+J.+Waltherauthor=K.+Kotnikauthor=L.+Loughlinauthor=M.+Nilsenauthor=M.+R.+MacLean&title=Effect+of+tryptophan+hydroxylase+1+deficiency+on+the+development+of+hypoxia-induced+pulmonary+hypertension&doi=10.1161%2F01.HYP.0000252210.58849.78"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension</span></div><div class="casAuthors">Morecroft Ian; Dempsie Yvonne; Bader Michael; Walther Diego J; Kotnik Katarina; Loughlin Lynn; Nilsen Margaret; MacLean Margaret R</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension (Dallas, Tex. : 1979)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">232-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tryptophan hydroxylase 1 catalyzes the rate-limiting step in the synthesis of serotonin in the periphery.  Recently, it has been shown that expression of the tryptophan hydroxylase 1 gene is increased in lungs and pulmonary endothelial cells from patients with idiopathic pulmonary arterial hypertension.  Here we investigated the effect of genetic deletion of tryptophan hydroxylase 1 on hypoxia-induced pulmonary arterial hypertension in mice by measuring pulmonary hemodynamics and pulmonary vascular remodeling before and after 2 weeks of hypoxia.  In wild-type mice, hypoxia increased right ventricular pressure and pulmonary vascular remodeling.  These effects of hypoxia were attenuated in the tryptophan hydroxylase 1-/-mice.  Hypoxia increased right ventricular hypertrophy in both wild-type and tryptophan hydroxylase 1-/-mice suggesting that in vivo peripheral serotonin has a differential effect on the pulmonary vasculature and right ventricular hypertrophy.  Contractile responses to serotonin were increased in pulmonary arteries from tryptophan hydroxylase 1-/-mice.  Hypoxia increased serotonin-mediated contraction in vessels from the wild-type mice, but this was not further increased by hypoxia in the tryptophan hydroxylase 1-/-mice.  In conclusion, these results indicate that tryptophan hydroxylase 1 and peripheral serotonin play an essential role in the development of hypoxia-induced elevations in pulmonary pressures and hypoxia-induced pulmonary vascular remodeling.  In addition, the results suggest that, in mice, serotonin has differential effects on the pulmonary vasculature and right ventricular hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpF0xWk9GDFP6AExegM5LLfW6udTcc2eZa9NGckN1K7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28jks1Okuw%253D%253D&md5=a8a3f072fa1b7d4cb051c01170f0a963</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1161%2F01.HYP.0000252210.58849.78&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.HYP.0000252210.58849.78%26sid%3Dliteratum%253Aachs%26aulast%3DMorecroft%26aufirst%3DI.%26aulast%3DDempsie%26aufirst%3DY.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DWalther%26aufirst%3DD.%2BJ.%26aulast%3DKotnik%26aufirst%3DK.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DEffect%2520of%2520tryptophan%2520hydroxylase%25201%2520deficiency%2520on%2520the%2520development%2520of%2520hypoxia-induced%2520pulmonary%2520hypertension%26jtitle%3DHypertension%26date%3D2007%26volume%3D49%26spage%3D232%26epage%3D236%26doi%3D10.1161%2F01.HYP.0000252210.58849.78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aiello, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourassa, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavasin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V.</span></span> <span> </span><span class="NLM_article-title">Tryptophan hydroxylase 1 inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">267</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.237933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1124%2Fjpet.116.237933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27927914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=267-279&author=R.+J.+Aielloauthor=P.+A.+Bourassaauthor=Q.+Zhangauthor=J.+Dubinsauthor=D.+R.+Goldbergauthor=S.+De+Lombaertauthor=M.+Humbertauthor=C.+Guignabertauthor=M.+A.+Cavasinauthor=T.+A.+McKinseyauthor=V.+Paralkar&title=Tryptophan+hydroxylase+1+inhibition+impacts+pulmonary+vascular+remodeling+in+two+rat+models+of+pulmonary+hypertension&doi=10.1124%2Fjpet.116.237933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Tryptophan hydroxylase 1 inhibition impacts pulmonary vascular remodeling in two rat models of pulmonary hypertension</span></div><div class="casAuthors">Aiello, Robert J.; Bourassa, Patricia-Ann; Zhang, Qing; Dubins, Jeffrey; Goldberg, Daniel R.; De Lombaert, Stephane; Humbert, Marc; Guignabert, Christophe; Cavasin, Maria A.; McKinsey, Timothy A.; Paralkar, Vishwas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">267-279</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a progressive disease defined by a chronic elevation in pulmonary arterial pressure with extensive pulmonary vascular remodeling and perivascular inflammation characterized by an accumulation of macrophages, lymphocytes, dendritic cells, and mast cells.  Although the exact etiol. of the disease is unknown, clin. as well as preclin. data strongly implicate a role for serotonin (5-HT) in the process.  Here, we investigated the chronic effects of pharmacol. inhibition of tryptophan hydroxylase 1 (TPH1), the rate-limiting enzyme in peripheral 5-HT biosynthesis, in two preclin. models of pulmonary hypertension (PH), the monocrotaline (MCT) rat and the semaxanib (SUGEN, Medinoah, Suzhou, China)-hypoxia rat.  In both PH models, Et (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate and Et (S)-8-(2-amino-6-((R)-1-(3',4'-dimethyl-3-(3-methyl-1 H-pyrazol-1-yl)-[1,1'-biphenyl]-4-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate, novel orally active TPH1 inhibitors with nanomolar in vitro potency, decreased serum, gut, and lung 5-HT levels in a dose-dependent manner and significantly reduced pulmonary arterial pressure, and pulmonary vessel wall thickness and occlusion in male rats.  In the MCT rat model, decreases in lung 5-HT significantly correlated with redns. in histamine levels and mast cell no. (P < 0.001, r2 = 0.88).  In contrast, neither ambrisentan nor tadalafil, which are vasodilators approved for the treatment of PAH, reduced mast cell no. or 5-HT levels, nor were they as effective in treating the vascular remodeling as were the TPH1 inhibitors.  When administered in combination with ambrisentan, the TPH1 inhibitors showed an additive effect on pulmonary vascular remodeling and pressures.  These data demonstrate that in addn. to reducing vascular remodeling, TPH1 inhibition has the added benefit of reducing the perivascular mast cell accumulation assocd. with PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoplnkLwVNX7bVg90H21EOLACvtfcHk0ljrxZ9rY9d_Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjsLs%253D&md5=b128f38244f6bb26557f43b115bf335d</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.237933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.237933%26sid%3Dliteratum%253Aachs%26aulast%3DAiello%26aufirst%3DR.%2BJ.%26aulast%3DBourassa%26aufirst%3DP.%2BA.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DDubins%26aufirst%3DJ.%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DCavasin%26aufirst%3DM.%2BA.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DParalkar%26aufirst%3DV.%26atitle%3DTryptophan%2520hydroxylase%25201%2520inhibition%2520impacts%2520pulmonary%2520vascular%2520remodeling%2520in%2520two%2520rat%2520models%2520of%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D267%26epage%3D279%26doi%3D10.1124%2Fjpet.116.237933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span> <span> </span><span class="NLM_article-title">Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.113.301141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCRESAHA.113.301141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24951765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2014&pages=165-175&author=M.+Rabinovitchauthor=C.+Guignabertauthor=M.+Humbertauthor=M.+R.+Nicolls&title=Inflammation+and+immunity+in+the+pathogenesis+of+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCRESAHA.113.301141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Rabinovitch, Marlene; Guignabert, Christophe; Humbert, Marc; Nicolls, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-175</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">This review summarizes an expanding body of knowledge indicating that failure to resolve inflammation and altered immune processes underlie the development of pulmonary arterial hypertension.  The chemokines and cytokines implicated in pulmonary arterial hypertension that could form a biomarker platform are discussed.  Pre-clin. studies that provide the basis for dysregulated immunity in animal models of the disease are reviewed.  In addn., we present therapies that target inflammatory/immune mechanisms that are currently enrolling patients, and discuss others in development.  We show how genetic and metabolic abnormalities are inextricably linked to dysregulated immunity and adverse remodeling in the pulmonary arteries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYuJ3RliFVC7Vg90H21EOLACvtfcHk0ljrxZ9rY9d_Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVahtr%252FL&md5=d3a2fe2798a44bdcdf4e5e0f8c71ab99</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.113.301141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.113.301141%26sid%3Dliteratum%253Aachs%26aulast%3DRabinovitch%26aufirst%3DM.%26aulast%3DGuignabert%26aufirst%3DC.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26atitle%3DInflammation%2520and%2520immunity%2520in%2520the%2520pathogenesis%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2014%26volume%3D115%26spage%3D165%26epage%3D175%26doi%3D10.1161%2FCIRCRESAHA.113.301141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syrkina, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolliputi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, A. B.</span></span> <span> </span><span class="NLM_article-title">Interleukin-6 overexpression induces pulmonary hypertension</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">244</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.108.182014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCRESAHA.108.182014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19074475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntFahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2009&pages=236-244&author=M.+K.+Steinerauthor=O.+L.+Syrkinaauthor=N.+Kolliputiauthor=E.+J.+Markauthor=C.+A.+Halesauthor=A.+B.+Waxman&title=Interleukin-6+overexpression+induces+pulmonary+hypertension&doi=10.1161%2FCIRCRESAHA.108.182014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-6 Overexpression Induces Pulmonary Hypertension</span></div><div class="casAuthors">Steiner, M. Kathryn; Syrkina, Olga L.; Kolliputi, Narasaish; Mark, Eugene J.; Hales, Charles A.; Waxman, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-244</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Inflammatory cytokine interleukin (IL)-6 is elevated in the serum and lungs of patients with pulmonary artery hypertension (PAH).  Several animal models of PAH cite the potential role of inflammatory mediators.  We investigated role of IL-6 in the pathogenesis of pulmonary vascular disease.  Indexes of pulmonary vascular remodeling were measured in lung-specific IL-6-overexpressing transgenic mice (Tg+) and compared to wild-type (Tg-) controls in both normoxic and chronic hypoxic conditions.  The Tg+ mice exhibited elevated right ventricular systolic pressures and right ventricular hypertrophy with corresponding pulmonary vasculopathic changes, all of which were exacerbated by chronic hypoxia.  IL-6 overexpression increased muscularization of the proximal arterial tree, and hypoxia enhanced this effect.  It also reproduced the muscularization and proliferative arteriopathy seen in the distal arteriolar vessels of PAH patients.  The latter was characterized by the formation of occlusive neointimal angioproliferative lesions that worsened with hypoxia and were composed of endothelial cells and T-lymphocytes.  IL-6-induced arteriopathic changes were accompanied by activation of proangiogenic factor, vascular endothelial growth factor, the proproliferative kinase extracellular signal-regulated kinase, proproliferative transcription factors c-MYC and MAX, and the antiapoptotic proteins survivin and Bcl-2 and downregulation of the growth inhibitor transforming growth factor-β and proapoptotic kinases JNK and p38.  These findings suggest that IL-6 promotes the development and progression of pulmonary vascular remodeling and PAH through proproliferative antiapoptotic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1C-jlJztGbVg90H21EOLACvtfcHk0ljrxZ9rY9d_Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntFahsQ%253D%253D&md5=4da16f129cada7855f50838de111ccd1</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.108.182014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.108.182014%26sid%3Dliteratum%253Aachs%26aulast%3DSteiner%26aufirst%3DM.%2BK.%26aulast%3DSyrkina%26aufirst%3DO.%2BL.%26aulast%3DKolliputi%26aufirst%3DN.%26aulast%3DMark%26aufirst%3DE.%2BJ.%26aulast%3DHales%26aufirst%3DC.%2BA.%26aulast%3DWaxman%26aufirst%3DA.%2BB.%26atitle%3DInterleukin-6%2520overexpression%2520induces%2520pulmonary%2520hypertension%26jtitle%3DCirc.%2520Res.%26date%3D2009%26volume%3D104%26spage%3D236%26epage%3D244%26doi%3D10.1161%2FCIRCRESAHA.108.182014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savale, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rideau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izziki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitre, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adnot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span> <span> </span><span class="NLM_article-title">Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-10-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-10-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19173740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1M7kvVyrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=6&author=L.+Savaleauthor=L.+Tuauthor=D.+Rideauauthor=M.+Izzikiauthor=B.+Maitreauthor=S.+Adnotauthor=S.+Eddahibi&title=Impact+of+interleukin-6+on+hypoxia-induced+pulmonary+hypertension+and+lung+inflammation+in+mice&doi=10.1186%2F1465-9921-10-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice</span></div><div class="casAuthors">Savale Laurent; Tu Ly; Rideau Dominique; Izziki Mohamed; Maitre Bernard; Adnot Serge; Eddahibi Saadia</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Inflammation may contribute to the pathogenesis of various forms of pulmonary hypertension (PH).  Recent studies in patients with idiopathic PH or PH associated with underlying diseases suggest a role for interleukin-6 (IL-6).  METHODS:  To determine whether endogenous IL-6 contributes to mediate hypoxic PH and lung inflammation, we studied IL-6-deficient (IL-6-/-) and wild-type (IL-6+/+) mice exposed to hypoxia for 2 weeks.  RESULTS:  Right ventricular systolic pressure, right ventricle hypertrophy, and the number and media thickness of muscular pulmonary vessels were decreased in IL-6-/- mice compared to wild-type controls after 2 weeks' hypoxia, although the pressure response to acute hypoxia was similar in IL-6+/+ and IL-6-/- mice.  Hypoxia exposure of IL-6+/+ mice led to marked increases in IL-6 mRNA and protein levels within the first week, with positive IL-6 immunostaining in the pulmonary vessel walls.  Lung IL-6 receptor and gp 130 (the IL-6 signal transducer) mRNA levels increased after 1 and 2 weeks' hypoxia.  In vitro studies of cultured human pulmonary-artery smooth-muscle-cells (PA-SMCs) and microvascular endothelial cells revealed prominent synthesis of IL-6 by PA-SMCs, with further stimulation by hypoxia.  IL-6 also markedly stimulated PA-SMC migration without affecting proliferation.  Hypoxic IL-6-/- mice showed less inflammatory cell recruitment in the lungs, compared to hypoxic wild-type mice, as assessed by lung protein levels and immunostaining for the specific macrophage marker F4/80, with no difference in lung expression of adhesion molecules or cytokines.  CONCLUSION:  These data suggest that IL-6 may be actively involved in hypoxia-induced lung inflammation and pulmonary vascular remodeling in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAwDSSNFgLuzAyhZbj3lKdfW6udTcc2eZ0UvjlEeo9Ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7kvVyrtg%253D%253D&md5=05e1362bd7c29392099ae91149a9e800</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-10-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-10-6%26sid%3Dliteratum%253Aachs%26aulast%3DSavale%26aufirst%3DL.%26aulast%3DTu%26aufirst%3DL.%26aulast%3DRideau%26aufirst%3DD.%26aulast%3DIzziki%26aufirst%3DM.%26aulast%3DMaitre%26aufirst%3DB.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DEddahibi%26aufirst%3DS.%26atitle%3DImpact%2520of%2520interleukin-6%2520on%2520hypoxia-induced%2520pulmonary%2520hypertension%2520and%2520lung%2520inflammation%2520in%2520mice%26jtitle%3DRespir.%2520Res.%26date%3D2009%26volume%3D10%26spage%3D6%26doi%3D10.1186%2F1465-9921-10-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Sanchez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaine, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knightbridge, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunclark, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corris, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toshner, M.</span></span> <span> </span><span class="NLM_article-title">Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterional hypertensi</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">204589321773582</span>, <span class="refDoi"> DOI: 10.1177/2045893217735820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F2045893217735820" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=204589321773582&author=J.+Hernandez-Sanchezauthor=L.+Harlowauthor=C.+Churchauthor=S.+Gaineauthor=E.+Knightbridgeauthor=K.+Bunclarkauthor=D.+Gorauthor=A.+Beddingauthor=N.+Morrellauthor=P.+Corrisauthor=M.+Toshner&title=Clinical+trial+protocol+for+TRANSFORM-UK%3A+A+therapeutic+open-label+study+of+tocilizumab+in+the+treatment+of+pulmonary+arterional+hypertensi&doi=10.1177%2F2045893217735820"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1177%2F2045893217735820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045893217735820%26sid%3Dliteratum%253Aachs%26aulast%3DHernandez-Sanchez%26aufirst%3DJ.%26aulast%3DHarlow%26aufirst%3DL.%26aulast%3DChurch%26aufirst%3DC.%26aulast%3DGaine%26aufirst%3DS.%26aulast%3DKnightbridge%26aufirst%3DE.%26aulast%3DBunclark%26aufirst%3DK.%26aulast%3DGor%26aufirst%3DD.%26aulast%3DBedding%26aufirst%3DA.%26aulast%3DMorrell%26aufirst%3DN.%26aulast%3DCorris%26aufirst%3DP.%26aulast%3DToshner%26aufirst%3DM.%26atitle%3DClinical%2520trial%2520protocol%2520for%2520TRANSFORM-UK%253A%2520A%2520therapeutic%2520open-label%2520study%2520of%2520tocilizumab%2520in%2520the%2520treatment%2520of%2520pulmonary%2520arterional%2520hypertensi%26jtitle%3DPulm.%2520Circ.%26date%3D2018%26volume%3D8%26spage%3D204589321773582%26doi%3D10.1177%2F2045893217735820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grzegorzewska, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czajka, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stawski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isenberg, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browning, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowska, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyl fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41605</span>, <span class="refDoi"> DOI: 10.1038/srep41605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fsrep41605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28150703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVygtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=41605&author=A.+P.+Grzegorzewskaauthor=F.+Setaauthor=R.+Hanauthor=C.+A.+Czajkaauthor=K.+Makinoauthor=L.+Stawskiauthor=J.+S.+Isenbergauthor=J.+L.+Browningauthor=M.+Trojanowska&title=Dimethyl+fumarate+ameliorates+pulmonary+arterial+hypertension+and+lung+fibrosis+by+targeting+multiple+pathways&doi=10.1038%2Fsrep41605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways</span></div><div class="casAuthors">Grzegorzewska, Agnieszka P.; Seta, Francesca; Han, Rong; Czajka, Caitlin A.; Makino, Katsunari; Stawski, Lukasz; Isenberg, Jeffrey S.; Browning, Jeffrey L.; Trojanowska, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41605</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a fatal condition for which there is no cure.  Di-Me Fumarate (DMF) is an FDA approved anti-oxidative and anti-inflammatory agent with a favorable safety record.  The goal of this study was to assess the effectiveness of DMF as a therapy for PAH using patient-derived cells and murine models.  We show that DMF treatment is effective in reversing hemodynamic changes, reducing inflammation, oxidative damage, and fibrosis in the exptl. models of PAH and lung fibrosis.  Our findings indicate that effects of DMF are facilitated by inhibiting pro-inflammatory NFκB, STAT3 and cJUN signaling, as well as βTRCP-dependent degrdn. of the pro-fibrogenic mediators Sp1, TAZ and β-catenin.  These results provide a novel insight into the mechanism of its action.  Collectively, preclin. results demonstrate beneficial effects of DMF on key mol. pathways contributing to PAH, and support its testing in PAH treatment in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZiXCweVxYPbVg90H21EOLACvtfcHk0lj0voOsR4n9_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVygtLw%253D&md5=632d10d6a023ec9484395e5281ff3699</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1038%2Fsrep41605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep41605%26sid%3Dliteratum%253Aachs%26aulast%3DGrzegorzewska%26aufirst%3DA.%2BP.%26aulast%3DSeta%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DR.%26aulast%3DCzajka%26aufirst%3DC.%2BA.%26aulast%3DMakino%26aufirst%3DK.%26aulast%3DStawski%26aufirst%3DL.%26aulast%3DIsenberg%26aufirst%3DJ.%2BS.%26aulast%3DBrowning%26aufirst%3DJ.%2BL.%26aulast%3DTrojanowska%26aufirst%3DM.%26atitle%3DDimethyl%2520fumarate%2520ameliorates%2520pulmonary%2520arterial%2520hypertension%2520and%2520lung%2520fibrosis%2520by%2520targeting%2520multiple%2520pathways%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D41605%26doi%3D10.1038%2Fsrep41605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terry, M.</span></span> Reata Pharma Updates Business Operations and Clinical Trials in Light of COVID-19 Pandemic. <a href="https://www.biospace.com/article/reata-pharma-pauses-or-modifies-some-clinical-trials-in-response-to-covid-19/" class="extLink">https://www.biospace.com/article/reata-pharma-pauses-or-modifies-some-clinical-trials-in-response-to-covid-19/</a> (accessed Mar 31, 2020).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Terry%2C+M.+Reata+Pharma+Updates+Business+Operations+and+Clinical+Trials+in+Light+of+COVID-19+Pandemic.+https%3A%2F%2Fwww.biospace.com%2Farticle%2Freata-pharma-pauses-or-modifies-some-clinical-trials-in-response-to-covid-19%2F+%28accessed+Mar+31%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DTerry%26aufirst%3DM." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chieffo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorkasky, D. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic effects of oral cxa-10, a nitro fatty acid, after single and multiple ascending doses in healthy and obese subjects</span>. <i>Clin. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">676</span>, <span class="refDoi"> DOI: 10.1111/cts.12672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fcts.12672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31343124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Oju7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=667-676&author=R.+M.+Garnerauthor=D.+R.+Mouldauthor=C.+Chieffoauthor=D.+K.+Jorkasky&title=Pharmacokinetic+and+pharmacodynamic+effects+of+oral+cxa-10%2C+a+nitro+fatty+acid%2C+after+single+and+multiple+ascending+doses+in+healthy+and+obese+subjects&doi=10.1111%2Fcts.12672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Pharmacodynamic Effects of Oral CXA-10, a Nitro Fatty Acid, After Single and Multiple Ascending Doses in Healthy and Obese Subjects</span></div><div class="casAuthors">Garner, Rachel M.; Mould, Diane R.; Chieffo, Carla; Jorkasky, Diane K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">667-676</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">10-nitro-9(E)-octadec-9-enoic acid (CXA-10), a novel nitro fatty acid compd., demonstrates potential as a therapeutic agent in multiple disease indications in which oxidative stress, inflammation, fibrosis, and/or direct tissue toxicity play significant roles.  Phase I studies were conducted in healthy and obese subjects to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of oral CXA-10 after single and multiple doses in the fed and fasted states that would confirm the mechanisms of action of CXA-10.  After single and multiple ascending doses, CXA-10 demonstrated dose-proportional increases in plasma exposure.  CXA-10 decreased levels of biomarkers assocd. with altered inflammation and metabolic stress obsd. from nonclin. studies.  In CXA-10-202, a consistent decrease from baseline was obsd. with CXA-10 150 mg dose, but not 25 or 450 mg doses, for biomarkers of altered inflammation and metabolic dysfunction, including leptin, triglycerides, cholesterol, MCP-1, and IL-6.  In CXA-10-203, after coadministration with CXA-10, geometric mean peak plasma concn. (Cmax) and area under the plasma concn.-time curve from time point 0 to the end of the dosing interval (AUC0-t) decreased 20% and 25% for pravastatin, increased 10% and 25% for simvastatin, and decreased 20% and 5% for ezetimibe.  These findings are consistent with the pharmacol. effects of CXA-10.  Adverse events (AEs) were dose-related, and the most frequently reported AEs (>10% of subjects) were diarrhea, abdominal pain, and nausea.  CXA-10 was safe and well-tolerated with no clin. significant abnormalities reported on phys. examn., vital signs, clin. lab. evaluations, or electrocardiog. evaluation.  Phase II studies are underway in patients with focal segmental glomerulosclerosis and pulmonary arterial hypertension to investigate the efficacy and tolerability of CXA-10 75-300 mg once daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohI0XxPv9aZLVg90H21EOLACvtfcHk0liFippXwbtv0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Oju7rJ&md5=186578beba0cf48cb9b0ff785c7c8510</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1111%2Fcts.12672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcts.12672%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DR.%2BM.%26aulast%3DMould%26aufirst%3DD.%2BR.%26aulast%3DChieffo%26aufirst%3DC.%26aulast%3DJorkasky%26aufirst%3DD.%2BK.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520effects%2520of%2520oral%2520cxa-10%252C%2520a%2520nitro%2520fatty%2520acid%252C%2520after%2520single%2520and%2520multiple%2520ascending%2520doses%2520in%2520healthy%2520and%2520obese%2520subjects%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D12%26spage%3D667%26epage%3D676%26doi%3D10.1111%2Fcts.12672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. K.</span></span> <span> </span><span class="NLM_article-title">Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-12-45</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-12-45" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21477377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltVWqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=45&author=D.+Wuauthor=D.+Leeauthor=Y.+K.+Sung&title=Prospect+of+vasoactive+intestinal+peptide+therapy+for+COPD%2FPAH+and+asthma%3A+a+review&doi=10.1186%2F1465-9921-12-45"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review</span></div><div class="casAuthors">Wu, Dongmei; Lee, Dongwon; Sung, Yong Kiel</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  There is mounting evidence that pulmonary arterial hypertension (PAH), asthma and chronic obstructive pulmonary disease (COPD) share important pathol. features, including inflammation, smooth muscle contraction and remodeling.  No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation.  Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biol. actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions.  VIP has emerged as a promising drug candidate for the treatment of cardiopulmonary disorders such as PAH, asthma, and COPD.  Clin. application of VIP has been limited in the past for a no. of reasons, including its short plasma half-life and difficulty in administration routes.  The development of long-acting VIP analogs, in combination with appropriate drug delivery systems, may provide clin. useful agents for the treatment of PAH, asthma, and COPD.  This article reviews the physiol. significance of VIP in cardiopulmonary system and the therapeutic potential of VIP-based agents in the treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5_QNsDz7NQLVg90H21EOLACvtfcHk0liFippXwbtv0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltVWqsLs%253D&md5=bac7eef73abdc56025e41b62edf37990</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-12-45&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-12-45%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DSung%26aufirst%3DY.%2BK.%26atitle%3DProspect%2520of%2520vasoactive%2520intestinal%2520peptide%2520therapy%2520for%2520COPD%252FPAH%2520and%2520asthma%253A%2520a%2520review%26jtitle%3DRespir.%2520Res.%26date%3D2011%26volume%3D12%26spage%3D45%26doi%3D10.1186%2F1465-9921-12-45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosgoeller, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziesche, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raderer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiebellehner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonbank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, L. H.</span></span> <span> </span><span class="NLM_article-title">Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">1339</span>– <span class="NLM_lpage">1346</span>, <span class="refDoi"> DOI: 10.1172/JCI17500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI17500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12727925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2003&pages=1339-1346&author=V.+Petkovauthor=W.+Mosgoellerauthor=R.+Ziescheauthor=M.+Radererauthor=L.+Stiebellehnerauthor=K.+Vonbankauthor=G.+C.+Funkauthor=G.+Hamiltonauthor=C.+Novotnyauthor=B.+Burianauthor=L.+H.+Block&title=Vasoactive+intestinal+peptide+as+a+new+drug+for+treatment+of+primary+pulmonary+hypertension&doi=10.1172%2FJCI17500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension</span></div><div class="casAuthors">Petkov, Ventzislav; Mosgoeller, Wilhelm; Ziesche, Rolf; Raderer, Markus; Stiebellehner, Leopold; Vonbank, Karin; Funk, Georg-Christian; Hamilton, Gerhard; Novotny, Clemens; Burian, Bernhard; Block, Lutz-Henning</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1339-1346</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension is a fatal disease causing progressive right heart failure within 3 yr after diagnosis.  The authors describe a new concept for treatment of the disease using vasoactive intestinal peptide, a neuropeptide primarily functioning as a neurotransmitter that acts as a potent systemic and pulmonary vasodilator.  The authors' rationale is based on the finding of a deficiency of the peptide in serum and lung tissue of patients with primary pulmonary hypertension, as evidenced by RIA and immunohistochem.  The relevance of this finding is underlined by an upregulation of corresponding receptor sites as shown by Northern blot anal., Western blot anal., and immunol. techniques.  Consequently, the substitution with the hormone results in substantial improvement of hemodynamic and prognostic parameters of the disease without side effects.  It decreased the mean pulmonary artery pressure in the eight study patients, increased cardiac output, and mixed venous oxygen satn.  The authors' data provide enough proof for further investigation of vasoactive intestinal peptide and its role in primary pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ZJeNEVtCgLVg90H21EOLACvtfcHk0liFippXwbtv0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFCrsrs%253D&md5=ce63b24000dd5a198351c9184f45ea95</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1172%2FJCI17500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI17500%26sid%3Dliteratum%253Aachs%26aulast%3DPetkov%26aufirst%3DV.%26aulast%3DMosgoeller%26aufirst%3DW.%26aulast%3DZiesche%26aufirst%3DR.%26aulast%3DRaderer%26aufirst%3DM.%26aulast%3DStiebellehner%26aufirst%3DL.%26aulast%3DVonbank%26aufirst%3DK.%26aulast%3DFunk%26aufirst%3DG.%2BC.%26aulast%3DHamilton%26aufirst%3DG.%26aulast%3DNovotny%26aufirst%3DC.%26aulast%3DBurian%26aufirst%3DB.%26aulast%3DBlock%26aufirst%3DL.%2BH.%26atitle%3DVasoactive%2520intestinal%2520peptide%2520as%2520a%2520new%2520drug%2520for%2520treatment%2520of%2520primary%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2003%26volume%3D111%26spage%3D1339%26epage%3D1346%26doi%3D10.1172%2FJCI17500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McBride, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuspiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasiak, S.</span></span> <span> </span><span class="NLM_article-title">Mitochondria: more than just a powerhouse</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">R551</span>– <span class="NLM_lpage">R560</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cub.2006.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16860735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XntlCrur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=R551-R560&author=H.+M.+McBrideauthor=M.+Neuspielauthor=S.+Wasiak&title=Mitochondria%3A+more+than+just+a+powerhouse&doi=10.1016%2Fj.cub.2006.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria: More Than Just a Powerhouse</span></div><div class="casAuthors">McBride, Heidi M.; Neuspiel, Margaret; Wasiak, Sylwia</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">R551-R560</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Pioneering biochem. studies have long forged the concept that the mitochondria are the 'energy powerhouse of the cell'.  These studies, combined with the unique evolutionary origin of the mitochondria, led the way to decades of research focusing on the organelle as an essential, yet independent, functional component of the cell.  Recently, however, this conceptual view of this isolated organelle has been profoundly altered with the discovery that mitochondria function within an integrated reticulum that is continually remodeled by both fusion and fission events.  The identification of a no. of proteins that regulate these activities is beginning to provide mechanistic details of mitochondrial membrane remodeling.  However, the broader question remains regarding the underlying purpose of mitochondrial dynamics and the translation of these morphol. transitions into altered functional output.  One hypothesis has been that mitochondrial respiration and metab. may be spatially and temporally regulated by the architecture and positioning of the organelle.  Recent evidence supports and expands this idea by demonstrating that mitochondria are an integral part of multiple cell signaling cascades.  Interestingly, proteins such as GTPases, kinases, and phosphatases are involved in bi-directional communication between the mitochondrial reticulum and the rest of the cell.  These proteins link mitochondrial function and dynamics to the regulation of metab., cell-cycle control, development, antiviral responses, and cell death.  Here, the authors highlight emerging evidence that provides mol. definition to mitochondria as a central platform in the execution of diverse cellular events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHwM5rKw3FfrVg90H21EOLACvtfcHk0lgECgzTmT4l6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntlCrur4%253D&md5=632f53eea50d01ed97079782f17a8aaa</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DMcBride%26aufirst%3DH.%2BM.%26aulast%3DNeuspiel%26aufirst%3DM.%26aulast%3DWasiak%26aufirst%3DS.%26atitle%3DMitochondria%253A%2520more%2520than%2520just%2520a%2520powerhouse%26jtitle%3DCurr.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3DR551%26epage%3DR560%26doi%3D10.1016%2Fj.cub.2006.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMurtry, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyck, J. R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haromy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelakis, E. D.</span></span> <span> </span><span class="NLM_article-title">Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">830</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1161/01.RES.0000145360.16770.9f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2F01.RES.0000145360.16770.9f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15375007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1aitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=830-840&author=M.+S.+McMurtryauthor=S.+Bonnetauthor=X.+C.+Wuauthor=J.+R.+B.+Dyckauthor=A.+Haromyauthor=K.+Hashimotoauthor=E.+D.+Michelakis&title=Dichloroacetate+prevents+and+reverses+pulmonary+hypertension+by+inducing+pulmonary+artery+smooth+muscle+cell+apoptosis&doi=10.1161%2F01.RES.0000145360.16770.9f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Dichloroacetate Prevents and Reverses Pulmonary Hypertension by Inducing Pulmonary Artery Smooth Muscle Cell Apoptosis</span></div><div class="casAuthors">McMurtry, M. Sean; Bonnet, Sebastien; Wu, Xichen; Dyck, Jason R. B.; Haromy, Alois; Hashimoto, Kyoko; Michelakis, Evangelos D.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">830-840</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The pulmonary arteries (PA) in pulmonary arterial hypertension (PAH) are constricted and remodeled.  They have suppressed apoptosis, partly attributable to suppression of the bone morphogenetic protein axis and selective downregulation of PA smooth muscle cell (PASMC) voltage-gated K+ channels, including Kv1.5.  The Kv downregulation-induced increase in [K+]i, tonically inhibits caspases, further suppressing apoptosis.  Mitochondria control apoptosis and produce activated oxygen species like H2O2, which regulate vascular tone by activating K+ channels, but their role in PAH is unknown.  We show that dichloroacetate (DCA), a metabolic modulator that increases mitochondrial oxidative phosphorylation, prevents and reverses established monocrotaline-induced PAH (MCT-PAH), significantly improving mortality.  Compared with MCT-PAH, DCA-treated rats (80 mg/kg per day in drinking water on day 14 after MCT, studied on day 21) have decreased pulmonary, but not systemic, vascular resistance (63% decrease, P<0.002), PA medial thickness (28% decrease, P<0.0001), and right ventricular hypertrophy (34% decrease, P<0.001).  DCA is similarly effective when given at day 1 or day 21 after MCT (studied day 28) but has no effect on normal rats.  DCA depolarizes MCT-PAH PASMC mitochondria and causes release of H2O2 and cytochrome c, inducing a 10-fold increase in apoptosis within the PA media (TUNEL and caspase 3 activity) and decreasing proliferation (proliferating-cell nuclear antigen and BrdU assays).  Immunoblots, immunohistochem., laser-captured microdissection-quant. reverse-transcription polymerase chain reaction and patch-clamping show that DCA reverses the Kv1.5 downregulation in resistance PAs.  In summary, DCA reverses PA remodeling by increasing the mitochondria-dependent apoptosis/proliferation ratio and upregulating Kv1.5 in the media.  We identify mitochondria-dependent apoptosis as a potential target for therapy and DCA as an effective and selective treatment for PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyP_V5-EJWBLVg90H21EOLACvtfcHk0lgECgzTmT4l6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1aitr8%253D&md5=82b4526a1abc7f5f881b7756877a7823</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1161%2F01.RES.0000145360.16770.9f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.RES.0000145360.16770.9f%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurtry%26aufirst%3DM.%2BS.%26aulast%3DBonnet%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%2BC.%26aulast%3DDyck%26aufirst%3DJ.%2BR.%2BB.%26aulast%3DHaromy%26aufirst%3DA.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26atitle%3DDichloroacetate%2520prevents%2520and%2520reverses%2520pulmonary%2520hypertension%2520by%2520inducing%2520pulmonary%2520artery%2520smooth%2520muscle%2520cell%2520apoptosis%26jtitle%3DCirc.%2520Res.%26date%3D2004%26volume%3D95%26spage%3D830%26epage%3D840%26doi%3D10.1161%2F01.RES.0000145360.16770.9f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michelakis, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurtu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cupitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Regan, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wharton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiely, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnaird, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boukouris, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagendran, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wort, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaao4583</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aao4583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1126%2Fscitranslmed.aao4583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29070699" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaao4583&author=E.+D.+Michelakisauthor=V.+Gurtuauthor=L.+Websterauthor=G.+Barnesauthor=G.+Watsonauthor=L.+Howardauthor=J.+Cupittauthor=I.+Patersonauthor=R.+B.+Thompsonauthor=K.+Chowauthor=D.+P.+O%E2%80%99Reganauthor=L.+Zhaoauthor=J.+Whartonauthor=D.+G.+Kielyauthor=A.+Kinnairdauthor=A.+E.+Boukourisauthor=C.+Whiteauthor=J.+Nagendranauthor=D.+H.+Freedauthor=S.+J.+Wortauthor=J.+S.+R.+Gibbsauthor=M.+R.+Wilkins&title=Inhibition+of+pyruvate+dehydrogenase+kinase+improves+pulmonary+arterial+hypertension+in+genetically+susceptible+patients&doi=10.1126%2Fscitranslmed.aao4583"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aao4583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aao4583%26sid%3Dliteratum%253Aachs%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26aulast%3DGurtu%26aufirst%3DV.%26aulast%3DWebster%26aufirst%3DL.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DWatson%26aufirst%3DG.%26aulast%3DHoward%26aufirst%3DL.%26aulast%3DCupitt%26aufirst%3DJ.%26aulast%3DPaterson%26aufirst%3DI.%26aulast%3DThompson%26aufirst%3DR.%2BB.%26aulast%3DChow%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DD.%2BP.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DWharton%26aufirst%3DJ.%26aulast%3DKiely%26aufirst%3DD.%2BG.%26aulast%3DKinnaird%26aufirst%3DA.%26aulast%3DBoukouris%26aufirst%3DA.%2BE.%26aulast%3DWhite%26aufirst%3DC.%26aulast%3DNagendran%26aufirst%3DJ.%26aulast%3DFreed%26aufirst%3DD.%2BH.%26aulast%3DWort%26aufirst%3DS.%2BJ.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%2BR.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DInhibition%2520of%2520pyruvate%2520dehydrogenase%2520kinase%2520improves%2520pulmonary%2520arterial%2520hypertension%2520in%2520genetically%2520susceptible%2520patients%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaao4583%26doi%3D10.1126%2Fscitranslmed.aao4583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orriols, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Puerto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span> <span> </span><span class="NLM_article-title">BMP type II receptor as a therapeutic target in pulmonary arterial hypertension</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">2979</span>– <span class="NLM_lpage">2995</span>, <span class="refDoi"> DOI: 10.1007/s00018-017-2510-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1007%2Fs00018-017-2510-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28447104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmslaqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2017&pages=2979-2995&author=M.+Orriolsauthor=M.+C.+Gomez-Puertoauthor=P.+ten+Dijke&title=BMP+type+II+receptor+as+a+therapeutic+target+in+pulmonary+arterial+hypertension&doi=10.1007%2Fs00018-017-2510-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">BMP type II receptor as a therapeutic target in pulmonary arterial hypertension</span></div><div class="casAuthors">Orriols, Mar; Gomez-Puerto, Maria Catalina; ten Dijke, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2979-2995</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a chronic disease characterized by a progressive elevation in mean pulmonary arterial pressure.  This occurs due to abnormal remodeling of small peripheral lung vasculature resulting in progressive occlusion of the artery lumen that eventually causes right heart failure and death.  The most common cause of PAH is inactivating mutations in the gene encoding a bone morphogenetic protein type II receptor (BMPRII).  Current therapeutic options for PAH are limited and focused mainly on reversal of pulmonary vasoconstriction and proliferation of vascular cells.  Although these treatments can relieve disease symptoms, PAH remains a progressive lethal disease.  Emerging data suggest that restoration of BMPRII signaling in PAH is a promising alternative that could prevent and reverse pulmonary vascular remodeling.  Here we will focus on recent advances in rescuing BMPRII expression, function or signaling to prevent and reverse pulmonary vascular remodeling in PAH and its feasibility for clin. translation.  Furthermore, we summarize the role of described miRNAs that directly target the BMPR2 gene in blood vessels.  We discuss the therapeutic potential and the limitations of promising new approaches to restore BMPRII signaling in PAH patients.  Different mutations in BMPR2 and environmental/genetic factors make PAH a heterogeneous disease and it is thus likely that the best approach will be patient-tailored therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqmQOKKlgN-rVg90H21EOLACvtfcHk0lhTlWX4OAoSGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmslaqtro%253D&md5=5ecd1c04726b31366f8f33e5260a5c53</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1007%2Fs00018-017-2510-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-017-2510-4%26sid%3Dliteratum%253Aachs%26aulast%3DOrriols%26aufirst%3DM.%26aulast%3DGomez-Puerto%26aufirst%3DM.%2BC.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26atitle%3DBMP%2520type%2520II%2520receptor%2520as%2520a%2520therapeutic%2520target%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2017%26volume%3D74%26spage%3D2979%26epage%3D2995%26doi%3D10.1007%2Fs00018-017-2510-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beppu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloch, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, S. P.</span></span> <span> </span><span class="NLM_article-title">Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.107.736801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.107.736801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=18663089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVChsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2008&pages=722-730&author=K.-H.+Hongauthor=Y.+J.+Leeauthor=E.+Leeauthor=S.+O.+Parkauthor=C.+Hanauthor=H.+Beppuauthor=E.+Liauthor=M.+K.+Raizadaauthor=K.+D.+Blochauthor=S.+P.+Oh&title=Genetic+ablation+of+the+Bmpr2+gene+in+pulmonary+endothelium+is+sufficient+to+predispose+to+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.107.736801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic Ablation of the Bmpr2 Gene in Pulmonary Endothelium Is Sufficient to Predispose to Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Hong, Kwon-Ho; Lee, Young Jae; Lee, Eunji; Park, Sung Ok; Han, Chul; Beppu, Hideyuki; Li, En; Raizada, Mohan K.; Bloch, Kenneth D.; Oh, S. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">722-730</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a rare but fatal lung disease of diverse origins.  PAH is now further subclassified as idiopathic PAH, familial PAH, and assocd. PAH varieties.  Heterozygous mutations in BMPR2 can be detected in 50% to 70% of patients with familial PAH and 10% to 40% of patients with idiopathic PAH.  Although endothelial cells have been suspected as the cellular origin of PAH pathogenesis, no direct in vivo evidence has been clearly presented.  The present study was designed to investigate whether endothelial Bmpr2 deletion can predispose to PAH.  The Bmpr2 gene was deleted in pulmonary endothelial cells using Bmpr2 conditional knockout mice and a novel endothelial Cre transgenic mouse line.  Wide ranges of right ventricular systolic pressure were obsd. in mice with heterozygous (21.7 to 44.1 mm Hg; median, 23.7 mm Hg) and homozygous (20.7 to 56.3 mm Hg; median, 27 mm Hg) conditional deletion of Bmpr2 in pulmonary endothelial cells compared with control mice (19.9 to 26.7 mm Hg; median, 23 mm Hg) at 2 to 7 mo of age.  A subset of mice with right ventricular systolic pressure >30 mm Hg exhibited right ventricular hypertrophy and an increase in the no. and wall thickness of muscularized distal pulmonary arteries.  In the lungs of these mice with high right ventricular systolic pressure, the expression of proteins involved in the pathogenesis of PAH such as serotonin transporter and tenascin-C was elevated in distal arteries and had a high incidence of perivascular leukocyte infiltration and in situ thrombosis.  Conditional heterozygous or homozygous Bmpr2 deletion in pulmonary endothelial cells predisposes mice to develop PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCVtZPvLz7bVg90H21EOLACvtfcHk0lhTlWX4OAoSGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVChsrc%253D&md5=65f0aafb8d74e90f3118ea5107544d2d</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.107.736801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.107.736801%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DK.-H.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DS.%2BO.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DBeppu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26aulast%3DBloch%26aufirst%3DK.%2BD.%26aulast%3DOh%26aufirst%3DS.%2BP.%26atitle%3DGenetic%2520ablation%2520of%2520the%2520Bmpr2%2520gene%2520in%2520pulmonary%2520endothelium%2520is%2520sufficient%2520to%2520predispose%2520to%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2008%26volume%3D118%26spage%3D722%26epage%3D730%26doi%3D10.1161%2FCIRCULATIONAHA.107.736801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauciulo, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yacoub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhail, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higenbottam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J. S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crozier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allcock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corris, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trembath, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, W. C.</span></span> <span> </span><span class="NLM_article-title">Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family</span>. <i>J. Med. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">745</span>, <span class="refDoi"> DOI: 10.1136/jmg.37.10.741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1136%2Fjmg.37.10.741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11015450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVOisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2000&pages=741-745&author=J.+R.+Thomsonauthor=R.+D.+Machadoauthor=M.+W.+Pauciuloauthor=N.+V.+Morganauthor=M.+Humbertauthor=G.+C.+Elliottauthor=K.+Wardauthor=M.+Yacoubauthor=G.+Mikhailauthor=P.+Rogersauthor=J.+Newmanauthor=L.+Wheelerauthor=T.+Higenbottamauthor=J.+S.+R.+Gibbsauthor=J.+Eganauthor=A.+Crozierauthor=A.+Peacockauthor=R.+Allcockauthor=P.+Corrisauthor=J.+E.+Loydauthor=R.+C.+Trembathauthor=W.+C.+Nichols&title=Sporadic+primary+pulmonary+hypertension+is+associated+with+germline+mutations+of+the+gene+encoding+BMPR-II%2C+a+receptor+member+of+the+TGF-beta+family&doi=10.1136%2Fjmg.37.10.741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family</span></div><div class="casAuthors">Thomson, Jennifer R.; Machado, Rajiv D.; Pauciulo, Michael W.; Morgan, Neil V.; Humbert, Marc; Elliott, Greg C.; Ward, Ken; Yacoub, Magdi; Mikhail, Ghada; Rogers, Paula; Newman, John; Wheeler, Lisa; Higenbottam, Timothy; Gibbs, J. Simon R.; Egan, Jim; Crozier, Agnes; Peacock, Andrew; Allcock, Robert; Corris, Paul; Loyd, James E.; Trembath, Richard C.; Nichols, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medical Genetics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">741-745</span>CODEN:
                <span class="NLM_cas:coden">JMDGAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-2593</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Primary pulmonary hypertension (PPH), resulting from occlusion of small pulmonary arteries, is a devastating condition.  Mutations of the bone morphogenetic protein receptor type II gene (BMPR2), a component of the transforming growth factor beta (TGF-β) family which plays a key role in cell growth, have recently been identified as causing familial PPH.  The authors have searched for BMPR2 gene mutations in sporadic PPH patients to det. whether the same genetic defect underlies the more common form of the disorder.  The authors investigated 50 unrelated patients, with a clin. diagnosis of PPH and no identifiable family history of pulmonary hypertension, by direct sequencing of the entire coding region and intron/exon boundaries of the BMPR2 gene.  DNA from available parent pairs was used to assess the occurrence of spontaneous (de novo) mutations contributing to sporadic PPH.  The authors found a total of 11 different heterozygous germline mutations of the BMPR2 gene in 13 of the 50 PPH patients studied, including missense, nonsense, and frameshift mutations each predicted to alter the cell signaling response to specific ligands.  Parental anal. showed three occurrences of paternal transmission and two of de novo mutation of the BMPR2 gene in sporadic PPH.  The sporadic form of PPH is assocd. with germline mutations of the gene encoding the receptor protein BMPR-II in at least 26% of cases.  A mol. classification of PPH, based upon the presence or absence of BMPR2 mutations, has important implications for patient management and screening of relatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-vtoLoka2dbVg90H21EOLACvtfcHk0lhTlWX4OAoSGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVOisrs%253D&md5=4bf7123d773053fc55eff0b65078c06d</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1136%2Fjmg.37.10.741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjmg.37.10.741%26sid%3Dliteratum%253Aachs%26aulast%3DThomson%26aufirst%3DJ.%2BR.%26aulast%3DMachado%26aufirst%3DR.%2BD.%26aulast%3DPauciulo%26aufirst%3DM.%2BW.%26aulast%3DMorgan%26aufirst%3DN.%2BV.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DElliott%26aufirst%3DG.%2BC.%26aulast%3DWard%26aufirst%3DK.%26aulast%3DYacoub%26aufirst%3DM.%26aulast%3DMikhail%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DP.%26aulast%3DNewman%26aufirst%3DJ.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DHigenbottam%26aufirst%3DT.%26aulast%3DGibbs%26aufirst%3DJ.%2BS.%2BR.%26aulast%3DEgan%26aufirst%3DJ.%26aulast%3DCrozier%26aufirst%3DA.%26aulast%3DPeacock%26aufirst%3DA.%26aulast%3DAllcock%26aufirst%3DR.%26aulast%3DCorris%26aufirst%3DP.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DTrembath%26aufirst%3DR.%2BC.%26aulast%3DNichols%26aufirst%3DW.%2BC.%26atitle%3DSporadic%2520primary%2520pulmonary%2520hypertension%2520is%2520associated%2520with%2520germline%2520mutations%2520of%2520the%2520gene%2520encoding%2520BMPR-II%252C%2520a%2520receptor%2520member%2520of%2520the%2520TGF-beta%2520family%26jtitle%3DJ.%2520Med.%2520Genet.%26date%3D2000%26volume%3D37%26spage%3D741%26epage%3D745%26doi%3D10.1136%2Fjmg.37.10.741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girerd, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palazzini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichstaedt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinderhofer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenzweig, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptoge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Angelantonio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, N. W.</span></span> <span> </span><span class="NLM_article-title">BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(15)00544-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS2213-2600%2815%2900544-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26795434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=129-137&author=J.+D.+W.+Evansauthor=B.+Girerdauthor=D.+Montaniauthor=X.-J.+Wangauthor=N.+Galieauthor=E.+D.+Austinauthor=G.+Elliottauthor=K.+Asanoauthor=E.+Grunigauthor=Y.+Yanauthor=Z.-C.+Jingauthor=A.+Manesauthor=M.+Palazziniauthor=L.+A.+Wheelerauthor=I.+Nakayamaauthor=T.+Satohauthor=C.+Eichstaedtauthor=K.+Hinderhoferauthor=M.+Wolfauthor=E.+B.+Rosenzweigauthor=W.+K.+Chungauthor=F.+Soubrierauthor=G.+Simonneauauthor=O.+Sitbonauthor=S.+Grafauthor=S.+Kaptogeauthor=E.+Di+Angelantonioauthor=M.+Humbertauthor=N.+W.+Morrell&title=BMPR2+mutations+and+survival+in+pulmonary+arterial+hypertension%3A+an+individual+participant+data+meta-analysis&doi=10.1016%2FS2213-2600%2815%2900544-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis</span></div><div class="casAuthors">Evans, Jonathan D. W.; Girerd, Barbara; Montani, David; Wang, Xiao-Jian; Galie, Nazzareno; Austin, Eric D.; Elliott, Greg; Asano, Koichiro; Grunig, Ekkehard; Yan, Yi; Jing, Zhi-Cheng; Manes, Alessandra; Palazzini, Massimiliano; Wheeler, Lisa A.; Nakayama, Ikue; Satoh, Toru; Eichstaedt, Christina; Hinderhofer, Katrin; Wolf, Matthias; Rosenzweig, Erika B.; Chung, Wendy K.; Soubrier, Florent; Simonneau, Gerald; Sitbon, Olivier; Graf, Stefan; Kaptoge, Stephen; Di Angelantonio, Emanuele; Humbert, Marc; Morrell, Nicholas W.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-137</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH).  However, the effect of BMPR2 mutations on clin. phenotype and outcomes remains uncertain.  We analyzed individual participant data of 1550 patients with idiopathic, heritable, and anorexigen-assocd. PAH from eight cohorts that had been systematically tested for BMPR2 mutations.  The primary outcome was the composite of death or lung transplantation.  All-cause mortality was the secondary outcome.  Hazard ratios (HRs) for death or transplantation and all-cause mortality assocd. with the presence of BMPR2 mutation were calcd. using Cox proportional hazards models stratified by cohort.  Overall, 448 (29%) of 1550 patients had a BMPR2 mutation.  Mutation carriers were younger at diagnosis (mean age 35·4 [SD 14·8] vs 42·0 [17·8] years), had a higher mean pulmonary artery pressure (60·5 [13·8] vs 56·4 [15·3] mm Hg) and pulmonary vascular resistance (16·6 [8·3] vs 12·9 [8·3] Wood units), and lower cardiac index (2·11 [0·69] vs 2·51 [0·92] L/min per m2; all p<0·0001).  Patients with BMPR2 mutations were less likely to respond to acute vasodilator testing (3% [10 of 380] vs 16% [147 of 907]; p<0·0001).  Among the 1164 individuals with available survival data, age-adjusted and sex-adjusted HRs comparing BMPR2 mutation carriers with non-carriers were 1·42 (95% CI 1·15-1·75; p=0·0011) for the composite of death or lung transplantation and 1·27 (1·00-1·60; p=0·046) for all-cause mortality.  These HRs were attenuated after adjustment for potential mediators including pulmonary vascular resistance, cardiac index, and vasoreactivity.  HRs for death or transplantation and all-cause mortality assocd. with BMPR2 mutation were similar in men and women, but higher in patients with a younger age at diagnosis (p=0·0030 for death or transplantation, p=0·011 for all-cause mortality).  Patients with PAH and BMPR2 mutations present at a younger age with more severe disease, and are at increased risk of death, and death or transplantation, compared with those without BMPR2 mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpil4DxmJ39dLVg90H21EOLACvtfcHk0lhe1emqK_L0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSrtbs%253D&md5=eaa90344770804008e9dee30b777d5a1</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2815%2900544-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252815%252900544-5%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%2BD.%2BW.%26aulast%3DGirerd%26aufirst%3DB.%26aulast%3DMontani%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.-J.%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DElliott%26aufirst%3DG.%26aulast%3DAsano%26aufirst%3DK.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DJing%26aufirst%3DZ.-C.%26aulast%3DManes%26aufirst%3DA.%26aulast%3DPalazzini%26aufirst%3DM.%26aulast%3DWheeler%26aufirst%3DL.%2BA.%26aulast%3DNakayama%26aufirst%3DI.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DEichstaedt%26aufirst%3DC.%26aulast%3DHinderhofer%26aufirst%3DK.%26aulast%3DWolf%26aufirst%3DM.%26aulast%3DRosenzweig%26aufirst%3DE.%2BB.%26aulast%3DChung%26aufirst%3DW.%2BK.%26aulast%3DSoubrier%26aufirst%3DF.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DGraf%26aufirst%3DS.%26aulast%3DKaptoge%26aufirst%3DS.%26aulast%3DDi%2BAngelantonio%26aufirst%3DE.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DMorrell%26aufirst%3DN.%2BW.%26atitle%3DBMPR2%2520mutations%2520and%2520survival%2520in%2520pulmonary%2520arterial%2520hypertension%253A%2520an%2520individual%2520participant%2520data%2520meta-analysis%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2016%26volume%3D4%26spage%3D129%26epage%3D137%26doi%3D10.1016%2FS2213-2600%2815%2900544-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiekerkoetter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudheendra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Bizri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haghighat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haghighat, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Perez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solow-Cordero, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beachy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wandless, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Dijke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">FK506 activates BMPR2 rescues endothelial dysfunction, and reverses pulmonary hypertension</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">3600</span>– <span class="NLM_lpage">3613</span>, <span class="refDoi"> DOI: 10.1172/JCI65592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI65592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23867624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3600-3613&author=E.+Spiekerkoetterauthor=X.+Tianauthor=J.+Caiauthor=R.+K.+Hopperauthor=D.+Sudheendraauthor=C.+G.+Liauthor=N.+El-Bizriauthor=H.+Sawadaauthor=R.+Haghighatauthor=R.+Chanauthor=L.+Haghighatauthor=V.+de+Jesus+Perezauthor=L.+Wangauthor=S.+Reddyauthor=M.+Zhaoauthor=D.+Bernsteinauthor=D.+E.+Solow-Corderoauthor=P.+A.+Beachyauthor=T.+J.+Wandlessauthor=P.+ten+Dijkeauthor=M.+Rabinovitch&title=FK506+activates+BMPR2+rescues+endothelial+dysfunction%2C+and+reverses+pulmonary+hypertension&doi=10.1172%2FJCI65592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension</span></div><div class="casAuthors">Spiekerkoetter, Edda; Tian, Xuefei; Cai, Jie; Hopper, Rachel K.; Sudheendra, Deepti; Li, Caiyun G.; El-Bizri, Nesrine; Sawada, Hirofumi; Haghighat, Roxanna; Chan, Roshelle; Haghighat, Leila; Perez, Vinicio de Jesus; Wang, Lingli; Reddy, Sushma; Zhao, Mingming; Bernstein, Daniel; Solow-Cordero, David E.; Beachy, Philip A.; Wandless, Thomas J.; ten Dijke, Peter; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3600-3613</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Dysfunctional bone morphogenetic protein receptor-2 (BMPR2) signaling is implicated in the pathogenesis of pulmonary arterial hypertension (PAH).  We used a transcriptional high-throughput luciferase reporter assay to screen 3,756 FDA-approved drugs and bioactive compds. for induction of BMPR2 signaling.  The best response was achieved with FK506 (tacrolimus), via a dual mechanism of action as a calcineurin inhibitor that also binds FK-binding protein-12 (FKBP12), a repressor of BMP signaling.  FK506 released FKBP12 from type I receptors activin receptor-like kinase 1 (ALK1), ALK2, and ALK3 and activated downstream SMAD1/5 and MAPK signaling and ID1 gene regulation in a manner superior to the calcineurin inhibitor cyclosporine and the FKBP12 ligand rapamycin.  In pulmonary artery endothelial cells (ECs) from patients with idiopathic PAH, low-dose FK506 reversed dysfunctional BMPR2 signaling.  In mice with conditional Bmpr2 deletion in ECs, low-dose FK506 prevented exaggerated chronic hypoxic PAH assocd. with induction of EC targets of BMP signaling, such as apelin.  Low-dose FK506 also reversed severe PAH in rats with medial hypertrophy following monocrotaline and in rats with neointima formation following VEGF receptor blockade and chronic hypoxia.  Our studies indicate that low-dose FK506 could be useful in the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw2XivYtxF8bVg90H21EOLACvtfcHk0lhe1emqK_L0ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtbbJ&md5=5ad349b62d39390a7bfcee1458bd8e12</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1172%2FJCI65592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65592%26sid%3Dliteratum%253Aachs%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DHopper%26aufirst%3DR.%2BK.%26aulast%3DSudheendra%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%2BG.%26aulast%3DEl-Bizri%26aufirst%3DN.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DHaghighat%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DR.%26aulast%3DHaghighat%26aufirst%3DL.%26aulast%3Dde%2BJesus%2BPerez%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DReddy%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DBernstein%26aufirst%3DD.%26aulast%3DSolow-Cordero%26aufirst%3DD.%2BE.%26aulast%3DBeachy%26aufirst%3DP.%2BA.%26aulast%3DWandless%26aufirst%3DT.%2BJ.%26aulast%3Dten%2BDijke%26aufirst%3DP.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DFK506%2520activates%2520BMPR2%2520rescues%2520endothelial%2520dysfunction%252C%2520and%2520reverses%2520pulmonary%2520hypertension%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D3600%26epage%3D3613%26doi%3D10.1172%2FJCI65592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spiekerkoetter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudheendra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosario, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long-Boyle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedlin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanian, R. T.</span></span> <span> </span><span class="NLM_article-title">Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1602449</span>, <span class="refDoi"> DOI: 10.1183/13993003.02449-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.02449-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28893866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOqs7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1602449&author=E.+Spiekerkoetterauthor=Y.+K.+Sungauthor=D.+Sudheendraauthor=V.+Scottauthor=P.+Del+Rosarioauthor=M.+Billauthor=F.+Haddadauthor=J.+Long-Boyleauthor=H.+Hedlinauthor=R.+T.+Zamanian&title=Randomised+placebo-controlled+safety+and+tolerability+trial+of+FK506+%28tacrolimus%29+for+pulmonary+arterial+hypertension&doi=10.1183%2F13993003.02449-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension</span></div><div class="casAuthors">Spiekerkoetter, Edda; YSung, on K.; Sudheendra, Deepti; Scott, Valerie; Del Rosario, Patricia; Bill, Matthew; Haddad, Francois; Long-Boyle, Janel; Hedlin, Haley; Zamanian, Roham T.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1602449/1-1602449/12</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a devastating disease characterized by occlusive pulmonary vasculopathy.  Activation of bone morphogenetic protein receptor 2 (BMPR2) signalling by FK506 (tacrolimus) reverses occlusive vasculopathy in rodent PAH models.  Here, we detd. the safety and tolerability of low-level FK506 therapy in stable PAH patients.  We performed a randomized, double-blind, placebo-controlled, 16-wk, single-center, phase IIa trial in PAH patients with New York Heart Assocn. functional class II/III symptoms using three FK506 target levels (<2, 2-3 and 3-5 ng mL-1). 23 patients were randomized and 20 patients completed the trial.  FK506 was generally well tolerated, with nausea/diarrhoea being the most commonly reported adverse event and no observation of line infections in patients on i.v. prostacyclin therapy.  PAH patients had significantly lower BMPR2 expression in peripheral blood mononuclear cells vs. healthy controls (n=13; p=0.005), which improved after FK506 treatment.  While we obsd. that some patients responded with a pronounced increase in BMPR2 expression as well as improvement in 6-min walk distance, and serol. and echocardiog. parameters of heart failure, these changes were not significant.  Low-level FK506 is well tolerated and increases BMPR2 in subsets of PAH patients.  These results support the study of FK506 in a phase IIb efficacy trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIOKtxNjTCtLVg90H21EOLACvtfcHk0lj-W8ntkT004A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOqs7%252FJ&md5=dd30eb06b5d86c95394d97c4be875ec8</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1183%2F13993003.02449-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02449-2016%26sid%3Dliteratum%253Aachs%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DSung%26aufirst%3DY.%2BK.%26aulast%3DSudheendra%26aufirst%3DD.%26aulast%3DScott%26aufirst%3DV.%26aulast%3DDel%2BRosario%26aufirst%3DP.%26aulast%3DBill%26aufirst%3DM.%26aulast%3DHaddad%26aufirst%3DF.%26aulast%3DLong-Boyle%26aufirst%3DJ.%26aulast%3DHedlin%26aufirst%3DH.%26aulast%3DZamanian%26aufirst%3DR.%2BT.%26atitle%3DRandomised%2520placebo-controlled%2520safety%2520and%2520tolerability%2520trial%2520of%2520FK506%2520%2528tacrolimus%2529%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2017%26volume%3D50%26spage%3D1602449%26doi%3D10.1183%2F13993003.02449-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, S. Y.</span></span> <span> </span><span class="NLM_article-title">Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">544</span>, <span class="refDoi"> DOI: 10.1177/153537020623100507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F153537020623100507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XktlCqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2006&pages=534-544&author=Y.+G.+Chenauthor=Q.+Wangauthor=S.+L.+Linauthor=C.+D.+Changauthor=J.+Chungauthor=S.+Y.+Ying&title=Activin+signaling+and+its+role+in+regulation+of+cell+proliferation%2C+apoptosis%2C+and+carcinogenesis&doi=10.1177%2F153537020623100507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Activin signaling and its role in regulation of cell proliferation, apoptosis, and carcinogenesis</span></div><div class="casAuthors">Chen, Ye-Guang; Wang, Qiang; Lin, Shi-Lung; Chang, C. Donald; Chung, Jody; Ying, Shao-Yao</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (Maywood, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-544</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3702</span>.
    
            (<span class="NLM_cas:orgname">Society for Experimental Biology and Medicine</span>)
        </div><div class="casAbstract">A review.  Activins, cytokine members of the transforming growth factor-β superfamily, have various effects on many physiol. processes, including cell proliferation, cell death, metab., homeostasis, differentiation, immune responses endocrine function, etc.  Activins interact with two structurally related serine/threonine kinase receptors, type I and type II, and initiate downstream signaling via Smads to regulate gene expression.  Understanding how activin signaling is controlled extracellularly and intracellularly would not only lead to more complete understanding of cell growth and apoptosis, but would also provide the basis for therapeutic strategies to treat cancer and other related diseases.  This review focuses on the recent progress on activin-receptor interactions, regulations of activin signaling by ligand-binding proteins, receptor-binding proteins, and nucleocytoplasmic shuttling of Smad proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosDb2ITvjIZbVg90H21EOLACvtfcHk0lj-W8ntkT004A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktlCqs7g%253D&md5=2c97f63e0e704d808b22acfc1e73c82c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1177%2F153537020623100507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F153537020623100507%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%2BG.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DS.%2BL.%26aulast%3DChang%26aufirst%3DC.%2BD.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DYing%26aufirst%3DS.%2BY.%26atitle%3DActivin%2520signaling%2520and%2520its%2520role%2520in%2520regulation%2520of%2520cell%2520proliferation%252C%2520apoptosis%252C%2520and%2520carcinogenesis%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2006%26volume%3D231%26spage%3D534%26epage%3D544%26doi%3D10.1177%2F153537020623100507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchida, K.</span></span> <span> </span><span class="NLM_article-title">Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders</span>. <i>Curr. Drug Targets: Immune, Endocr. Metab. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.2174/1568008043339901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.2174%2F1568008043339901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15180456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslCmsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=157-166&author=K.+Tsuchida&title=Activins%2C+myostatin+and+related+TGF-%CE%B2+family+members+as+novel+therapeutic+targets+for+endocrine%2C+metabolic+and+immune+disorders&doi=10.2174%2F1568008043339901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders</span></div><div class="casAuthors">Tsuchida, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Immune, Endocrine and Metabolic Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">157-166</span>CODEN:
                <span class="NLM_cas:coden">CDTIBT</span>;
        ISSN:<span class="NLM_cas:issn">1568-0088</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Activins and inhibins were first identified by virtue of their ability to regulate FSH secretion from the anterior pituitary.  Activins are also powerful regulators of gonadal functions.  However, the physiol. functions of activins are not restricted to reproductive tissues.  Activins are involved in apoptosis of hepatocytes and B cells, fibrosis, inflammation and neurogenesis.  Activins are regarded as novel drug targets since blocking activins would provide benefits by preventing apoptosis, fibrosis, inflammation and growth of several cancers.  Activins are members of the transforming growth factor-β (TGF-β) family, which has numerous peptide growth and differentiation factors including activins, bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and TGF-βs.  Among them, GDF8 is also known as myostatin and is structurally related to activins.  Myostatin is specifically expressed in the skeletal muscle lineage and is a candidate for muscle chalone neg. regulating the growth of myoblasts.  Myostatin is regarded as a good drug target since therapeutics that modulate skeletal muscle growth would be useful for disease conditions such as muscular dystrophy, sarcopenia, cachexia and even diabetes.  Recent studies have revealed that activins and myostatin signal through activin type II receptors (ActRIIA and ActRIIB) and their activities are regulated by extracellular binding proteins, follistatins and follistatin-related gene (FLRG).  Furthermore, signaling of activins, myostatin and related ligands is also controlled by intracellular receptor-interacting proteins by novel mechanisms.  In this review, I would like to show the current progress in the field emphasizing the importance of activins and myostatin as novel drug targets for immune, endocrine and metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2xmKCp92gFLVg90H21EOLACvtfcHk0lj-W8ntkT004A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslCmsLg%253D&md5=0db8183320abb3a098713416bfe35597</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.2174%2F1568008043339901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568008043339901%26sid%3Dliteratum%253Aachs%26aulast%3DTsuchida%26aufirst%3DK.%26atitle%3DActivins%252C%2520myostatin%2520and%2520related%2520TGF-%25CE%25B2%2520family%2520members%2520as%2520novel%2520therapeutic%2520targets%2520for%2520endocrine%252C%2520metabolic%2520and%2520immune%2520disorders%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Immune%252C%2520Endocr.%2520Metab.%2520Disord.%26date%3D2004%26volume%3D4%26spage%3D157%26epage%3D166%26doi%3D10.2174%2F1568008043339901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yung, L.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augur, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocobo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli de Frias, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosas, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sako, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearsall, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quisel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. B.</span></span> <span> </span><span class="NLM_article-title">ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">eaaz5660</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aaz5660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1126%2Fscitranslmed.aaz5660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=32404506" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eaaz5660&author=L.-M.+Yungauthor=P.+Yangauthor=S.+Joshiauthor=Z.+M.+Augurauthor=S.+S.+J.+Kimauthor=G.+A.+Bocoboauthor=T.+Dinterauthor=L.+Tronconeauthor=P.-S.+Chenauthor=M.+E.+McNeilauthor=M.+Southwoodauthor=S.+Poli+de+Friasauthor=J.+Knopfauthor=I.+O.+Rosasauthor=D.+Sakoauthor=R.+S.+Pearsallauthor=J.+D.+Quiselauthor=G.+Liauthor=R.+Kumarauthor=P.+B.+Yu&title=ACTRIIA-Fc+rebalances+activin%2FGDF+versus+BMP+signaling+in+pulmonary+hypertension&doi=10.1126%2Fscitranslmed.aaz5660"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaz5660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaz5660%26sid%3Dliteratum%253Aachs%26aulast%3DYung%26aufirst%3DL.-M.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DJoshi%26aufirst%3DS.%26aulast%3DAugur%26aufirst%3DZ.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BS.%2BJ.%26aulast%3DBocobo%26aufirst%3DG.%2BA.%26aulast%3DDinter%26aufirst%3DT.%26aulast%3DTroncone%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DP.-S.%26aulast%3DMcNeil%26aufirst%3DM.%2BE.%26aulast%3DSouthwood%26aufirst%3DM.%26aulast%3DPoli%2Bde%2BFrias%26aufirst%3DS.%26aulast%3DKnopf%26aufirst%3DJ.%26aulast%3DRosas%26aufirst%3DI.%2BO.%26aulast%3DSako%26aufirst%3DD.%26aulast%3DPearsall%26aufirst%3DR.%2BS.%26aulast%3DQuisel%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DP.%2BB.%26atitle%3DACTRIIA-Fc%2520rebalances%2520activin%252FGDF%2520versus%2520BMP%2520signaling%2520in%2520pulmonary%2520hypertension%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26spage%3Deaaz5660%26doi%3D10.1126%2Fscitranslmed.aaz5660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tofovic, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzoubi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span> <span> </span><span class="NLM_article-title">Gender, sex hormones and pulmonary hypertension</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">294</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.4103/2045-8932.114756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.4103%2F2045-8932.114756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24015330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2cflt1Grsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=294-314&author=E.+D.+Austinauthor=T.+Lahmauthor=J.+Westauthor=S.+P.+Tofovicauthor=A.+K.+Johansenauthor=M.+R.+MacLeanauthor=A.+Alzoubiauthor=M.+Oka&title=Gender%2C+sex+hormones+and+pulmonary+hypertension&doi=10.4103%2F2045-8932.114756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Gender, sex hormones and pulmonary hypertension</span></div><div class="casAuthors">Austin Eric D; Lahm Tim; West James; Tofovic Stevan P; Johansen Anne Katrine; Maclean Margaret R; Alzoubi Abdallah; Oka Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary circulation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">294-314</span>
        ISSN:<span class="NLM_cas:issn">2045-8932</span>.
    </div><div class="casAbstract">Most subtypes of pulmonary arterial hypertension (PAH) are characterized by a greater susceptibility to disease among females, although females with PAH appear to live longer after diagnosis.  While this "estrogen paradox  of enhanced female survival despite increased female susceptibility remains a mystery, recent progress has begun to shed light upon the interplay of sex hormones, the pathogenesis of pulmonary hypertension, and the right ventricular response to stress.  For example, emerging data in humans and experimental models suggest that estrogens or differential sex hormone metabolism may modify disease risk among susceptible subjects, and that estrogens may interact with additional local factors such as serotonin to enhance the potentially damaging chronic effects of estrogens on the pulmonary vasculature.  Regardless, it remains unclear why not all estrogenic compounds behave equally, nor why estrogens appear to be protective in certain settings but detrimental in others.  The contribution of androgens and other compounds, such as dehydroepiandrosterone, to pathogenesis and possibly treatment must be considered as well.  In this review, we will discuss the recent understandings on how estrogens, estrogen metabolism, dehydroepiandrosterone, and additional susceptibility factors may all contribute to the pathogenesis or potentially to the treatment of pulmonary hypertension, by evaluating current human, cell-based, and experimental model data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcUy7J5i-R9rGbPKh4T9eAfW6udTcc2eZc9gO4AQqrcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflt1Grsg%253D%253D&md5=0516422de82cbf12a27578d2d9487c09</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.4103%2F2045-8932.114756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2045-8932.114756%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DLahm%26aufirst%3DT.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DTofovic%26aufirst%3DS.%2BP.%26aulast%3DJohansen%26aufirst%3DA.%2BK.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26aulast%3DAlzoubi%26aufirst%3DA.%26aulast%3DOka%26aufirst%3DM.%26atitle%3DGender%252C%2520sex%2520hormones%2520and%2520pulmonary%2520hypertension%26jtitle%3DPulm.%2520Circ.%26date%3D2013%26volume%3D3%26spage%3D294%26epage%3D314%26doi%3D10.4103%2F2045-8932.114756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciuclan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morecroft, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mair, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1087</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.111.062927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.111.062927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22859684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kit73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=1087-1098&author=K.+Whiteauthor=A.+K.+Johansenauthor=M.+Nilsenauthor=L.+Ciuclanauthor=E.+Wallaceauthor=L.+Patonauthor=A.+Campbellauthor=I.+Morecroftauthor=L.+Loughlinauthor=J.+D.+McClureauthor=M.+Thomasauthor=K.+M.+Mairauthor=M.+R.+MacLean&title=Activity+of+the+estrogen-metabolizing+enzyme+cytochrome+P450+1B1+influences+the+development+of+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.111.062927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Estrogen-Metabolizing Enzyme Cytochrome P450 1B1 Influences the Development of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">White, Kevin; Johansen, Anne Katrine; Nilsen, Margaret; Ciuclan, Loredana; Wallace, Emma; Paton, Leigh; Campbell, Annabel; Morecroft, Ian; Loughlin, Lynn; McClure, John D.; Thomas, Matthew; Mair, Kirsty M.; MacLean, Margaret R.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1087-1098</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Pulmonary arterial hypertension (PAH) is a hyperproliferative vascular disorder obsd. predominantly in women.  Estrogen is a potent mitogen in human pulmonary artery smooth muscle cells and contributes to PAH in vivo; however, the mechanisms attributed to this causation remain obscure.  Curiously, heightened expression of the estrogen-metabolizing enzyme cytochrome P 450 1B1 (CYP1B1) is reported in idiopathic PAH and murine models of PAH.  Methods and results: Here, we investigated the putative pathogenic role of CYP1B1 in PAH.  Quant. reverse transcription-polymerase chain reaction, immunoblotting, and in situ anal. revealed that pulmonary CYP1B1 is increased in hypoxic PAH, hypoxic+SU5416 PAH, and human PAH and is highly expressed within the pulmonary vascular wall.  PAH was assessed in mice via measurement of right ventricular hypertrophy, pulmonary vascular remodeling, and right ventricular systolic pressure.  Hypoxic PAH was attenuated in CYP1B1 mice, and the potent CYP1B1 inhibitor 2,3',4,5'-tetramethoxystilbene (TMS; 3 mg · kg · d IP) significantly attenuated hypoxic PAH and hypoxic+SU5416 PAH in vivo.  TMS also abolished estrogen-induced proliferation in human pulmonary artery smooth muscle cells and PAH-pulmonary artery smooth muscle cells.  The estrogen metabolite 16α-hydroxyestrone provoked human pulmonary artery smooth muscle cell proliferation, and this mitogenic effect was greatly pronounced in PAH-pulmonary artery smooth muscle cells.  ELISA anal. revealed that 16α-hydroxyestrone concn. was elevated in PAH, consistent with CYP1B1 overexpression and activity.  Finally, administration of the CYP1B1 metabolite 16α-hydroxyestrone (1.5 mg · kg · d IP) caused the development of PAH in mice.  Concusions: Increased CYP1B1-mediated estrogen metab. promotes the development of PAH, likely via the formation of mitogens, including 16α-hydroxyestrone.  Collectively, this study reveals a possible novel therapeutic target in clin. PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGTU4PCypUPrVg90H21EOLACvtfcHk0lhcrd2u-heR6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kit73F&md5=ade99961b423dec036e0f0de164ec619</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.111.062927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.111.062927%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DJohansen%26aufirst%3DA.%2BK.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DCiuclan%26aufirst%3DL.%26aulast%3DWallace%26aufirst%3DE.%26aulast%3DPaton%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DMorecroft%26aufirst%3DI.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DMcClure%26aufirst%3DJ.%2BD.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMair%26aufirst%3DK.%2BM.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DActivity%2520of%2520the%2520estrogen-metabolizing%2520enzyme%2520cytochrome%2520P450%25201B1%2520influences%2520the%2520development%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D1087%26epage%3D1098%26doi%3D10.1161%2FCIRCULATIONAHA.111.062927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackwell, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaddipati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gladson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, K. B.</span></span> <span> </span><span class="NLM_article-title">BMPR2 expression is suppressed by signaling through the estrogen receptor</span>. <i>Biol. Sex Differ.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi"> DOI: 10.1186/2042-6410-3-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F2042-6410-3-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22348410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvVKqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=6&author=E.+D.+Austinauthor=R.+Hamidauthor=A.+R.+Hemnesauthor=J.+E.+Loydauthor=T.+Blackwellauthor=C.+Yuauthor=J.+A.+Phillipsauthor=R.+Gaddipatiauthor=S.+Gladsonauthor=E.+Guauthor=J.+Westauthor=K.+B.+Lane&title=BMPR2+expression+is+suppressed+by+signaling+through+the+estrogen+receptor&doi=10.1186%2F2042-6410-3-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">BMPR2 expression is suppressed by signaling through the estrogen receptor</span></div><div class="casAuthors">Austin, Eric D.; Hamid, Rizwan; Hemnes, Anna R.; Loyd, James E.; Blackwell, Tom; Yu, Chang; Phillips, John A., III; Gaddipati, Radhika; Gladson, Santhi; Gu, Everett; West, James; Lane, Kirk B.</div><div class="citationInfo"><span class="NLM_cas:title">Biology of Sex Differences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6</span>CODEN:
                <span class="NLM_cas:coden">BSDIB9</span>;
        ISSN:<span class="NLM_cas:issn">2042-6410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Studies in multiple organ systems have shown cross-talk between signaling through the bone morphogenetic protein receptor type 2 (BMPR2) and estrogen pathways.  In humans, pulmonary arterial hypertension (PAH) has a female predominance, and is assocd. with decreased BMPR2 expression.  The goal of this study was to det. if estrogens suppress BMPR2 expression.  Methods: A variety of techniques were utilized across several model platforms to evaluate the relationship between estrogens and BMPR2 gene expression.  We used quant. RT-PCR, gel mobility shift, and luciferase activity assays in human samples, live mice, and cell culture.  Results: BMPR2 expression is reduced in lymphocytes from female patients compared with male patients, and in whole lungs from female mice compared with male mice.  There is an evolutionarily conserved estrogen receptor binding site in the BMPR2 promoter, which binds estrogen receptor by gel-shift assay.  Increased exogenous estrogen decreases BMPR2 expression in cell culture, particularly when induced to proliferate.  Transfection of increasing quantities of estrogen receptor alpha correlates strongly with decreasing expression of BMPR2.  Conclusions: BMPR2 gene expression is reduced in females compared to males in live humans and in mice, likely through direct estrogen receptor alpha binding to the BMPR2 promoter.  This reduced BMPR2 expression may contribute to the increased prevalence of PAH in females.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDjUDPfj-fN7Vg90H21EOLACvtfcHk0lhcrd2u-heR6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvVKqsb4%253D&md5=b6110ad4045f57748aa935c619d5adcc</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1186%2F2042-6410-3-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2042-6410-3-6%26sid%3Dliteratum%253Aachs%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DHamid%26aufirst%3DR.%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DBlackwell%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DPhillips%26aufirst%3DJ.%2BA.%26aulast%3DGaddipati%26aufirst%3DR.%26aulast%3DGladson%26aufirst%3DS.%26aulast%3DGu%26aufirst%3DE.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DK.%2BB.%26atitle%3DBMPR2%2520expression%2520is%2520suppressed%2520by%2520signaling%2520through%2520the%2520estrogen%2520receptor%26jtitle%3DBiol.%2520Sex%2520Differ.%26date%3D2012%26volume%3D3%26spage%3D6%26doi%3D10.1186%2F2042-6410-3-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farber-Eger, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span> <span> </span><span class="NLM_article-title">Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1602337</span>, <span class="refDoi"> DOI: 10.1183/13993003.02337-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.02337-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28775043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGisbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1602337&author=X.+P.+Chenauthor=E.+D.+Austinauthor=M.+Talatiauthor=J.+P.+Fesselauthor=E.+H.+Farber-Egerauthor=E.+L.+Brittainauthor=A.+R.+Hemnesauthor=J.+E.+Loydauthor=J.+West&title=Oestrogen+inhibition+reverses+pulmonary+arterial+hypertension+and+associated+metabolic+defects&doi=10.1183%2F13993003.02337-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects</span></div><div class="casAuthors">Chen, Xinping; Austin, Eric D.; Talati, Megha; Fessel, Joshua P.; Farber-Eger, Eric H.; Brittain, Evan L.; Hemnes, Anna R.; Loyd, James E.; West, James</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1602337/1-1602337/14</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Increased estrogen is a strong epidemiol. risk factor for development of pulmonary arterial hypertension (PAH) in patients, assocd. with metabolic defects.  In addn., estrogens drive penetrance in mice carrying mutations in bone morphogenetic protein receptor type II (BMPR2), the cause of most heritable PAH.  The goal of the present study was to det. whether inhibition of estrogens was effective in the treatment of PAH in these mice.  The estrogen inhibitors fulvestrant and anastrozole were used in a prevention and treatment paradigm in BMPR2 mutant mice, and tamoxifen was used for treatment.  In addn., BMPR2 mutant mice were crossed onto estrogen receptor (ESR)1 and ESR2 knockout backgrounds to assess receptor specificity.  Haemodynamic and metabolic outcomes were measured.  Estrogen inhibition both prevented and treated PAH in BMPR2 mutant mice.  This was assocd. with redn. in metabolic defects including oxidised lipid formation, insulin resistance and rescue of peroxisome proliferator-activated receptor-γ and CD36.  The effect was mediated primarily through ESR2, but partially through ESR1.  Our data suggest that trials of estrogen inhibition in human PAH are warranted, and may improve pulmonary vascular disease through amelioration of metabolic defects.  Although fulvestrant and anastrozole were more effective than tamoxifen, tamoxifen may be useful in premenopausal females, because of a reduced risk of induction of menopause.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI-goSKEPWGLVg90H21EOLACvtfcHk0licRbFEkdEwrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGisbjO&md5=aab0f0b57fe92c0dc5a45bf1b19e70e1</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1183%2F13993003.02337-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02337-2016%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BP.%26aulast%3DAustin%26aufirst%3DE.%2BD.%26aulast%3DTalati%26aufirst%3DM.%26aulast%3DFessel%26aufirst%3DJ.%2BP.%26aulast%3DFarber-Eger%26aufirst%3DE.%2BH.%26aulast%3DBrittain%26aufirst%3DE.%2BL.%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DWest%26aufirst%3DJ.%26atitle%3DOestrogen%2520inhibition%2520reverses%2520pulmonary%2520arterial%2520hypertension%2520and%2520associated%2520metabolic%2520defects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2017%26volume%3D50%26spage%3D1602337%26doi%3D10.1183%2F13993003.02337-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maynard, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champion, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleaves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. H.</span></span> <span> </span><span class="NLM_article-title">Testosterone negatively regulates right ventricular load stress responses in mice</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">352</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.4103/2045-8932.101647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.4103%2F2045-8932.101647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23130103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOrs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=352-358&author=A.+R.+Hemnesauthor=K.+B.+Maynardauthor=H.+C.+Championauthor=L.+Gleavesauthor=N.+Pennerauthor=J.+Westauthor=J.+H.+Newman&title=Testosterone+negatively+regulates+right+ventricular+load+stress+responses+in+mice&doi=10.4103%2F2045-8932.101647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Testosterone negatively regulates right ventricular load stress responses in mice</span></div><div class="casAuthors">Hemnes, Anna R.; Maynard, Karen B.; Champion, Hunter C.; Gleaves, Linda; Penner, Niki; West, James; Newman, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">352-358</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">Medknow Publications and Media Pvt. Ltd.</span>)
        </div><div class="casAbstract">Right ventricular (RV) function is the major determinant of mortality in pulmonary arterial hypertension and male sex is a strong predictor of mortality in this disease.  The effects of testosterone on RV structure and function in load stress are presently unknown.  We tested whether testosterone levels affect RV hypertrophic responses, fibrosis and function.  Male C57BL/6 mice underwent castration or sham followed by pulmonary artery banding (PAB) or sham.  After recovery, testosterone pellets were placed in a subset of the castrated mice and mice were maintained for at least two weeks, when they underwent hemodynamic measurements and tissues were harvested.  Plasma levels of testosterone were reduced by castration and repleted by testosterone administration.  In PAB, castration resulted in lower right ventricle/left ventricle + septum (RV/LV + S) and myocyte diam. (P < 0.05).  Replacement of testosterone normalized these parameters and increased RV fibrosis (P < 0.05).  Two weeks of PAB resulted in increased RV systolic pressure in all groups with decreased markers of RV systolic and diastolic function, specifically reduced ejection fraction and increased time const. and dPdt min. (P < 0.05), though there was minimal effect of testosterone on hemodynamic parameters.  Survival was improved in mice that underwent castration with PAB compared with PAB alone (P < 0.05).  Testosterone affects RV hypertrophic response to load stress through increased myocyte size and increased fibrosis in mice.  Castration and testosterone replacement are not accompanied by significant alterations in RV in vivo hemodynamics, but testosterone deprivation appears to improve survival in PAB.  Further study of the role of testosterone in RV dysfunction is warranted to better understand these findings in the context of human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSnxnznj6vwrVg90H21EOLACvtfcHk0licRbFEkdEwrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOrs7vK&md5=35798590ccecab369d1bea43deda0c80</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.4103%2F2045-8932.101647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2045-8932.101647%26sid%3Dliteratum%253Aachs%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DMaynard%26aufirst%3DK.%2BB.%26aulast%3DChampion%26aufirst%3DH.%2BC.%26aulast%3DGleaves%26aufirst%3DL.%26aulast%3DPenner%26aufirst%3DN.%26aulast%3DWest%26aufirst%3DJ.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26atitle%3DTestosterone%2520negatively%2520regulates%2520right%2520ventricular%2520load%2520stress%2520responses%2520in%2520mice%26jtitle%3DPulm.%2520Circ.%26date%3D2012%26volume%3D2%26spage%3D352%26epage%3D358%26doi%3D10.4103%2F2045-8932.101647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer-Chicko, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ky, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palevsky, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisciano, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Propert, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanczyk, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittenhall, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventetuolo, C. E.</span></span> <span> </span><span class="NLM_article-title">Anastrozole in pulmonary arterial hypertension a randomized, double-blind, placebo-controlled trial</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>195</i></span>,  <span class="NLM_fpage">360</span>– <span class="NLM_lpage">368</span>, <span class="refDoi"> DOI: 10.1164/rccm.201605-1024OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201605-1024OC" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2016&pages=360-368&author=S.+M.+Kawutauthor=C.+L.+Archer-Chickoauthor=A.+DiMicheleauthor=J.+S.+Fritzauthor=J.+R.+Klingerauthor=B.+Kyauthor=H.+I.+Palevskyauthor=A.+J.+Palmiscianoauthor=M.+Patelauthor=D.+Pinderauthor=K.+J.+Propertauthor=K.+A.+Smithauthor=F.+Stanczykauthor=R.+Tracyauthor=A.+Vaidyaauthor=M.+E.+Whittenhallauthor=C.+E.+Ventetuolo&title=Anastrozole+in+pulmonary+arterial+hypertension+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1164%2Frccm.201605-1024OC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1164%2Frccm.201605-1024OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201605-1024OC%26sid%3Dliteratum%253Aachs%26aulast%3DKawut%26aufirst%3DS.%2BM.%26aulast%3DArcher-Chicko%26aufirst%3DC.%2BL.%26aulast%3DDiMichele%26aufirst%3DA.%26aulast%3DFritz%26aufirst%3DJ.%2BS.%26aulast%3DKlinger%26aufirst%3DJ.%2BR.%26aulast%3DKy%26aufirst%3DB.%26aulast%3DPalevsky%26aufirst%3DH.%2BI.%26aulast%3DPalmisciano%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPinder%26aufirst%3DD.%26aulast%3DPropert%26aufirst%3DK.%2BJ.%26aulast%3DSmith%26aufirst%3DK.%2BA.%26aulast%3DStanczyk%26aufirst%3DF.%26aulast%3DTracy%26aufirst%3DR.%26aulast%3DVaidya%26aufirst%3DA.%26aulast%3DWhittenhall%26aufirst%3DM.%2BE.%26aulast%3DVentetuolo%26aufirst%3DC.%2BE.%26atitle%3DAnastrozole%2520in%2520pulmonary%2520arterial%2520hypertension%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2016%26volume%3D195%26spage%3D360%26epage%3D368%26doi%3D10.1164%2Frccm.201605-1024OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Naamani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palevsky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankoff, D.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant for the treatment of pulmonary arterial hypertension</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1456</span>– <span class="NLM_lpage">1459</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201904-328RL</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1513%2FAnnalsATS.201904-328RL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31314997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3Mzot1Kqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=1456-1459&author=S.+Kawutauthor=D.+Pinderauthor=N.+Al-Naamaniauthor=A.+McCormickauthor=H.+Palevskyauthor=J.+Fritzauthor=K.+Smithauthor=J.+Mazurekauthor=M.+Doyleauthor=M.+MacLeanauthor=A.+DeMicheleauthor=D.+Mankoff&title=Fulvestrant+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1513%2FAnnalsATS.201904-328RL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Kawut Steven M; Pinder Diane; Al-Naamani Nadine; McCormick Amber; Palevsky Harold I; Fritz Jason; Smith K Akaya; Mazurek Jeremy A; DeMichele Angela; Mankoff David A; Doyle Margaret F; MacLean Margaret R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1456-1459</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWZiQOqYuLoMzK395ZObgVfW6udTcc2eaXEQpfXObpxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mzot1Kqsg%253D%253D&md5=46e90f24e4dbe259b2da7150b4ab9ddf</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201904-328RL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201904-328RL%26sid%3Dliteratum%253Aachs%26aulast%3DKawut%26aufirst%3DS.%26aulast%3DPinder%26aufirst%3DD.%26aulast%3DAl-Naamani%26aufirst%3DN.%26aulast%3DMcCormick%26aufirst%3DA.%26aulast%3DPalevsky%26aufirst%3DH.%26aulast%3DFritz%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DMazurek%26aufirst%3DJ.%26aulast%3DDoyle%26aufirst%3DM.%26aulast%3DMacLean%26aufirst%3DM.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DMankoff%26aufirst%3DD.%26atitle%3DFulvestrant%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2019%26volume%3D16%26spage%3D1456%26epage%3D1459%26doi%3D10.1513%2FAnnalsATS.201904-328RL" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maron, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, J. A.</span></span> <span> </span><span class="NLM_article-title">Emerging concepts in the molecular basis of pulmonary arterial hypertension part II: neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">2079</span>– <span class="NLM_lpage">2091</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.114.006980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.114.006980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26056345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2MbhvVyntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2015&pages=2079-2091&author=B.+A.+Maronauthor=J.+A.+Leopold&title=Emerging+concepts+in+the+molecular+basis+of+pulmonary+arterial+hypertension+part+II%3A+neurohormonal+signaling+contributes+to+the+pulmonary+vascular+and+right+ventricular+pathophenotype+of+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.114.006980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Maron Bradley A; Leopold Jane A</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2079-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSG1EvMG3_C9bHMBt0mMIXfW6udTcc2eaXEQpfXObpxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbhvVyntQ%253D%253D&md5=90439325950a5f24f31599ccf04a9221</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.114.006980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.114.006980%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DB.%2BA.%26aulast%3DLeopold%26aufirst%3DJ.%2BA.%26atitle%3DEmerging%2520concepts%2520in%2520the%2520molecular%2520basis%2520of%2520pulmonary%2520arterial%2520hypertension%2520part%2520II%253A%2520neurohormonal%2520signaling%2520contributes%2520to%2520the%2520pulmonary%2520vascular%2520and%2520right%2520ventricular%2520pathophenotype%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2015%26volume%3D131%26spage%3D2079%26epage%3D2091%26doi%3D10.1161%2FCIRCULATIONAHA.114.006980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Souza, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theccanat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toth, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogoriler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaxall, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhter, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, S. L.</span></span> <span> </span><span class="NLM_article-title">GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy therapeutic implications in pulmonary hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">2859</span>– <span class="NLM_lpage">2869</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.112.109868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.112.109868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23124027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVeksr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=2859-2869&author=L.+Piaoauthor=Y.+H.+Fangauthor=K.+S.+Parikhauthor=J.+J.+Ryanauthor=K.+M.+D%E2%80%99Souzaauthor=T.+Theccanatauthor=P.+T.+Tothauthor=J.+Pogorilerauthor=J.+Paulauthor=B.+C.+Blaxallauthor=S.+A.+Akhterauthor=S.+L.+Archer&title=GRK2-mediated+inhibition+of+adrenergic+and+dopaminergic+signaling+in+right+ventricular+hypertrophy+therapeutic+implications+in+pulmonary+hypertension&doi=10.1161%2FCIRCULATIONAHA.112.109868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">GRK2-Mediated Inhibition of Adrenergic and Dopaminergic Signaling in Right Ventricular Hypertrophy: Therapeutic Implications in Pulmonary Hypertension</span></div><div class="casAuthors">Piao, Lin; Fang, Yong-Hu; Parikh, Kishan S.; Ryan, John J.; D'Souza, Karen M.; Theccanat, Tiju; Toth, Peter T.; Pogoriler, Jennifer; Paul, Jonathan; Blaxall, Burns C.; Akhter, Shahab A.; Archer, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2859-2869</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: The cause and consequences of impaired adrenergic signaling in right ventricular failure/hypertrophy (RVH) are poorly understood.  We hypothesized that G protein-coupled receptor kinase-2 (GRK2)-mediated uncoupling of β-adrenergic receptor signaling impairs inotropic reserve.  The implications of right ventricular (RV) adrenergic remodeling for inotrope selection and the therapeutic benefit of interrupting Gβγ-GRK2 interaction, using gallein, were tested.  METHODS AND RESULTS: Chamber-specificity and cellular localization of adrenergic remodeling were compared in rodent RVH assocd. with pulmonary arterial hypertension (PAH-RVH; SU5416+chronic-hypoxia or Monocrotaline) vs. pulmonary artery banding-induced RVH (PAB-RVH).  Results were corroborated in RV arrays from 10 PAH patients vs. controls.  Inotropic reserve was assessed in RV- and left ventricular-Langendorff models and in vivo.  Gallein therapy (1.8 mg/kg/day ×2-wk) was assessed.  Despite similar RVH, cardiac output (58.3±4.9 vs. 82.9±4.8 mL/min; P<0.001) and treadmill distance (41.5±11.6 vs. 244.1±12.4 m; P<0.001) were lower in PAH-RVH vs. PAB-RVH.  In PAH-RVH vs. PAB-RVH there was greater downregulation of β1-, α1- and dopamine-1 receptors, more left ventricular involvement, and greater impairment of RV contractile reserve.  RV GRK2 activity increased in parallel with a redn. in both adrenergic receptor expression and inotrope-stimulated cAMP levels (P<0.01). β1-receptor downregulation also occurred in human PAH-RVH.  Dobutamine was superior to dopamine as an RV inotrope, both ex vivo and in vivo.  CONCLUSIONS: GRK2-mediated desensitization-downregulation of adrenergic and dopaminergic receptors impairs inotropic reserve in PAH-RVH.  Acute inotropic support in RVH is best accomplished by dobutamine, reflecting its better coupling to adenylyl cyclase and the reliance of dopamine on dopamine-1-receptor signaling, which is impaired in RVH.  Inhibiting Gβγ-GRK2 interactions has therapeutic benefit in RVH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfnSYQaT00wrVg90H21EOLACvtfcHk0ljRglVldDLJuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVeksr%252FP&md5=768b029e33781eb8edd14e03ee1f0911</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.109868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.109868%26sid%3Dliteratum%253Aachs%26aulast%3DPiao%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DY.%2BH.%26aulast%3DParikh%26aufirst%3DK.%2BS.%26aulast%3DRyan%26aufirst%3DJ.%2BJ.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DK.%2BM.%26aulast%3DTheccanat%26aufirst%3DT.%26aulast%3DToth%26aufirst%3DP.%2BT.%26aulast%3DPogoriler%26aufirst%3DJ.%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DBlaxall%26aufirst%3DB.%2BC.%26aulast%3DAkhter%26aufirst%3DS.%2BA.%26aulast%3DArcher%26aufirst%3DS.%2BL.%26atitle%3DGRK2-mediated%2520inhibition%2520of%2520adrenergic%2520and%2520dopaminergic%2520signaling%2520in%2520right%2520ventricular%2520hypertrophy%2520therapeutic%2520implications%2520in%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D2859%26epage%3D2869%26doi%3D10.1161%2FCIRCULATIONAHA.112.109868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogaard, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chau, V. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoke, N. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskauskas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasper, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloum, F. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voelkel, N. F.</span></span> <span> </span><span class="NLM_article-title">Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">652</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1164/rccm.201003-0335OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201003-0335OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=20508210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yhtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2010&pages=652-660&author=H.+J.+Bogaardauthor=R.+Natarajanauthor=S.+Mizunoauthor=A.+Abbateauthor=P.+J.+Changauthor=V.+Q.+Chauauthor=N.+N.+Hokeauthor=D.+Kraskauskasauthor=M.+Kasperauthor=F.+N.+Salloumauthor=N.+F.+Voelkel&title=Adrenergic+receptor+blockade+reverses+right+heart+remodeling+and+dysfunction+in+pulmonary+hypertensive+rats&doi=10.1164%2Frccm.201003-0335OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats</span></div><div class="casAuthors">Bogaard, Harm J.; Natarajan, Ramesh; Mizuno, Shiro; Abbate, Antonio; Chang, Philip J.; Chau, Vinh Q.; Hoke, Nicholas N.; Kraskauskas, Donatas; Kasper, Michael; Salloum, Fadi N.; Voelkel, Norbert F.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">652-660</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Most patients with pulmonary arterial hypertension (PAH) die from right heart failure.  β-Adrenergic receptor blockade reduces mortality by about 30% in patients with left-sided systolic heart failure, but is not used in PAH.  Objectives: To assess the effect of the adrenergic receptor blocker carvedilol on the pulmonary circulation and right heart in exptl. pulmonary hypertension in rats.  Methods: Angioproliferative pulmonary hypertension was induced in rats by combined exposure to the vascular endothelial growth factor-receptor antagonist SU5416 and hypoxia.  Carvedilol treatment was started after establishment of pulmonary hypertension and right heart dysfunction.  Measurements and Main Results: Compared with vehicle-treated animals, treatment with carvedilol resulted in increased exercise endurance; improved right ventricular (RV) function (increased tricuspid annular plane systolic excursion and decreased RV dilatation); and an increased cardiac output.  The morphol. of the pulmonary vessels and the RV afterload were not affected by carvedilol.  Carvedilol treatment was assocd. with enhancement of RV fetal gene reactivation, increased protein kinase G (PKG) activity, and a redn. in capillary rarefaction and fibrosis.  Metoprolol had similar but less pronounced effects in the SU5416 and hypoxia model.  Cardioprotective effects were noted of both carvedilol and metoprolol in the monocrotaline model.  In the case of carvedilol, but not metoprolol, part of these effects resulted from a prevention of monocrotaline-induced lung remodeling.  Conclusions: Adrenergic receptor blockade reverses RV remodeling and improves RV function in exptl. pulmonary hypertension.  β-Adrenergic receptor blockers are not recommended in humans with PAH before their safety and efficacy are assessed in well-designed clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6wJ8_tfYGxLVg90H21EOLACvtfcHk0lg-PfP_KSZc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yhtrzJ&md5=cfc04844eb9ca5b533d9f7bbabcda90d</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1164%2Frccm.201003-0335OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201003-0335OC%26sid%3Dliteratum%253Aachs%26aulast%3DBogaard%26aufirst%3DH.%2BJ.%26aulast%3DNatarajan%26aufirst%3DR.%26aulast%3DMizuno%26aufirst%3DS.%26aulast%3DAbbate%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DP.%2BJ.%26aulast%3DChau%26aufirst%3DV.%2BQ.%26aulast%3DHoke%26aufirst%3DN.%2BN.%26aulast%3DKraskauskas%26aufirst%3DD.%26aulast%3DKasper%26aufirst%3DM.%26aulast%3DSalloum%26aufirst%3DF.%2BN.%26aulast%3DVoelkel%26aufirst%3DN.%2BF.%26atitle%3DAdrenergic%2520receptor%2520blockade%2520reverses%2520right%2520heart%2520remodeling%2520and%2520dysfunction%2520in%2520pulmonary%2520hypertensive%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D182%26spage%3D652%26epage%3D660%26doi%3D10.1164%2Frccm.201003-0335OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Man, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handoko, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Ballegoij, J. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalij, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaards, S. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postmus, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Velden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerhof, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulus, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span> <span> </span><span class="NLM_article-title">Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension</span>. <i>Circ.: Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1161/CIRCHEARTFAILURE.111.964494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCHEARTFAILURE.111.964494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22157723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=97-105&author=F.+S.+de+Manauthor=M.+L.+Handokoauthor=J.+J.+M.+van+Ballegoijauthor=I.+Schalijauthor=S.+J.+P.+Bogaardsauthor=P.+E.+Postmusauthor=J.+van+der%0AVeldenauthor=N.+Westerhofauthor=W.+J.+Paulusauthor=A.+Vonk-Noordegraaf&title=Bisoprolol+delays+progression+towards+right+heart+failure+in+experimental+pulmonary+hypertension&doi=10.1161%2FCIRCHEARTFAILURE.111.964494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension</span></div><div class="casAuthors">de Man, Frances S.; Handoko, M. Louis; van Ballegoij, Joris J. M.; Schalij, Ingrid; Bogaards, Sylvia J. P.; Postmus, Pieter E.; van der Velden, Jolanda; Westerhof, Nico; Paulus, Walter J.; Vonk-Noordegraaf, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Circulation: Heart Failure</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-105</span>CODEN:
                <span class="NLM_cas:coden">CHFICM</span>;
        ISSN:<span class="NLM_cas:issn">1941-3289</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: In pulmonary arterial hypertension (PH), sympathetic adrenergic activity is highly elevated.  Sympathetic overactivity is a compensatory mechanism at first, but might be detrimental for cardiac function in the long run.  We therefore investigated whether chronic low-dose treatment with bisoprolol (a cardioselective β-blocker) has beneficial effects on cardiac function in exptl. PH.  Methods and Results: PH was induced in rats by a single injection of monocrotaline (60 mg/kg).  Pressure telemetry in PH rats revealed that 10 mg/kg bisoprolol was the lowest dose that blunted heart rate response during daily activity.  Ten days after monocrotaline injection, echocardiog. was performed and PH rats were randomized for bisoprolol treatment (oral gavage) or vehicle (n=7/group).  At end of study (body mass loss >5%), echocardiog. was repeated, with addnl. pressure-vol. measurements and histomol. analyses.  Compared with control, right ventricular (RV) systolic pressure and arterial elastance (measure of vascular resistance) more than tripled in PH.  Bisoprolol delayed time to right heart failure (P<0.05).  RV afterload was unaffected, however, bisoprolol treatment increased RV contractility and filling (both P<0.01), and partially restored right ventriculo-arterial coupling and cardiac output (both P<0.05).  Bisoprolol restored RV β-adrenergic receptor signaling.  Histol. revealed significantly less RV fibrosis and myocardial inflammation in bisoprolol treated PH rats.  Conclusions: In exptl. PH, treatment with bisoprolol delays progression toward right heart failure, and partially preserves RV systolic and diastolic function.  These promising results suggest a therapeutic role for β-blockers in PH that warrants further clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ4g99I61kR7Vg90H21EOLACvtfcHk0lg-PfP_KSZc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVCrt70%253D&md5=0c7bf27bad4692d06dc27cd4f9935653</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1161%2FCIRCHEARTFAILURE.111.964494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCHEARTFAILURE.111.964494%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMan%26aufirst%3DF.%2BS.%26aulast%3DHandoko%26aufirst%3DM.%2BL.%26aulast%3Dvan%2BBallegoij%26aufirst%3DJ.%2BJ.%2BM.%26aulast%3DSchalij%26aufirst%3DI.%26aulast%3DBogaards%26aufirst%3DS.%2BJ.%2BP.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DJ.%26aulast%3DWesterhof%26aufirst%3DN.%26aulast%3DPaulus%26aufirst%3DW.%2BJ.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26atitle%3DBisoprolol%2520delays%2520progression%2520towards%2520right%2520heart%2520failure%2520in%2520experimental%2520pulmonary%2520hypertension%26jtitle%3DCirc.%253A%2520Heart%2520Failure%26date%3D2012%26volume%3D5%26spage%3D97%26epage%3D105%26doi%3D10.1161%2FCIRCHEARTFAILURE.111.964494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saygin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asosingh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comhair, S. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highland, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W. H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erzurum, S. C.</span></span> <span> </span><span class="NLM_article-title">Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">95240</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.95240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2Fjci.insight.95240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28814664" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=95240&author=S.+Farhaauthor=D.+Sayginauthor=M.+M.+Parkauthor=H.+I.+Cheongauthor=K.+Asosinghauthor=S.+A.+A.+Comhairauthor=O.+R.+Stephensauthor=E.+C.+Roachauthor=J.+Sharpauthor=K.+B.+Highlandauthor=F.+P.+DiFilippoauthor=D.+R.+Neumannauthor=W.+H.+W.+Tangauthor=S.+C.+Erzurum&title=Pulmonary+arterial+hypertension+treatment+with+carvedilol+for+heart+failure%3A+a+randomized+controlled+trial&doi=10.1172%2Fjci.insight.95240"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.95240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.95240%26sid%3Dliteratum%253Aachs%26aulast%3DFarha%26aufirst%3DS.%26aulast%3DSaygin%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DM.%2BM.%26aulast%3DCheong%26aufirst%3DH.%2BI.%26aulast%3DAsosingh%26aufirst%3DK.%26aulast%3DComhair%26aufirst%3DS.%2BA.%2BA.%26aulast%3DStephens%26aufirst%3DO.%2BR.%26aulast%3DRoach%26aufirst%3DE.%2BC.%26aulast%3DSharp%26aufirst%3DJ.%26aulast%3DHighland%26aufirst%3DK.%2BB.%26aulast%3DDiFilippo%26aufirst%3DF.%2BP.%26aulast%3DNeumann%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DW.%2BH.%2BW.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26atitle%3DPulmonary%2520arterial%2520hypertension%2520treatment%2520with%2520carvedilol%2520for%2520heart%2520failure%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26spage%3D95240%26doi%3D10.1172%2Fjci.insight.95240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van Campen, J. S.J.A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Boer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Veerdonk, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Bruggen, C. E.E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allaart, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raijmakers, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymans, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handoko, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Man, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaard, H.-J.</span></span> <span> </span><span class="NLM_article-title">Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1183/13993003.00090-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.00090-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27390285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2s7nvFOquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2016&pages=787-796&author=J.+S.J.A.+van+Campenauthor=K.+de+Boerauthor=M.+C.+van+de+Veerdonkauthor=C.+E.E.+van+der+Bruggenauthor=C.+P.+Allaartauthor=P.+G.+Raijmakersauthor=M.+W.+Heymansauthor=J.+T.+Marcusauthor=H.+J.+Harmsauthor=M.+L.+Handokoauthor=F.+S.+de+Manauthor=A.+Vonk+Noordegraafauthor=H.-J.+Bogaard&title=Bisoprolol+in+idiopathic+pulmonary+arterial+hypertension%3A+an+explorative+study&doi=10.1183%2F13993003.00090-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study</span></div><div class="casAuthors">van Campen Jasmijn S J A; de Boer Karin; van de Veerdonk Marielle C; van der Bruggen Cathelijne E E; Vonk Noordegraaf Anton; Allaart Cor P; Handoko M Louis; Raijmakers Pieter G; Heymans Martijn W; Marcus J Tim; Harms Hendrik J; de Man Frances S; Bogaard Harm-Jan</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">787-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">While beta-blockers are considered contraindicated in pulmonary arterial hypertension (PAH), the prognostic significance of sympathetic nervous system over-activity suggests a potential benefit of beta-blocker therapy.  The aim of this randomised, placebo-controlled, crossover, single centre study was to determine the effects of bisoprolol on right ventricular ejection fraction (RVEF) in idiopathic PAH (iPAH) patients.  Additional efficacy and safety parameters were explored.Patients with optimally treated, stable iPAH (New York Heart Association functional class II/III) were randomised to placebo or bisoprolol.  Imaging and functional measurements were performed at baseline, crossover and end of study.18 iPAH patients were included, because inclusion faltered before enrolment of the targeted 25 patients. 17 patients completed 6 months of bisoprolol, 15 tolerated bisoprolol, one patient required intravenous diuretics.  Bisoprolol was associated with a lower heart rate (17 beats per minute, p=0.0001) but RVEF remained unchanged.  A drop in cardiac index (0.5 L·min(-1)·m(-2), p=0.015) was observed, along with a trend towards a decreased 6-min walking distance (6MWD).Although careful up-titration of bisoprolol was tolerated by most patients and resulted in a decreased heart rate, no benefit of bisoprolol in iPAH was demonstrated.  Decreases in cardiac index and 6MWD suggest a deteriorated cardiac function.  The results do not favour the use of bisoprolol in iPAH patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_zHE52IrdNNTrvPZP1IpfW6udTcc2eYxcqZ_2vjrYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7nvFOquw%253D%253D&md5=917e7c1c05dda5ab5848185833efe972</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1183%2F13993003.00090-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.00090-2016%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BCampen%26aufirst%3DJ.%2BS.J.A.%26aulast%3Dde%2BBoer%26aufirst%3DK.%26aulast%3Dvan%2Bde%2BVeerdonk%26aufirst%3DM.%2BC.%26aulast%3Dvan%2Bder%2BBruggen%26aufirst%3DC.%2BE.E.%26aulast%3DAllaart%26aufirst%3DC.%2BP.%26aulast%3DRaijmakers%26aufirst%3DP.%2BG.%26aulast%3DHeymans%26aufirst%3DM.%2BW.%26aulast%3DMarcus%26aufirst%3DJ.%2BT.%26aulast%3DHarms%26aufirst%3DH.%2BJ.%26aulast%3DHandoko%26aufirst%3DM.%2BL.%26aulast%3Dde%2BMan%26aufirst%3DF.%2BS.%26aulast%3DVonk%2BNoordegraaf%26aufirst%3DA.%26aulast%3DBogaard%26aufirst%3DH.-J.%26atitle%3DBisoprolol%2520in%2520idiopathic%2520pulmonary%2520arterial%2520hypertension%253A%2520an%2520explorative%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2016%26volume%3D48%26spage%3D787%26epage%3D796%26doi%3D10.1183%2F13993003.00090-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrario, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strawn, W. B.</span></span> <span> </span><span class="NLM_article-title">Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2006.01.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.amjcard.2006.01.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=16784934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVOju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2006&pages=121-128&author=C.+M.+Ferrarioauthor=W.+B.+Strawn&title=Role+of+the+renin-angiotensin-aldosterone+system+and+proinflammatory+mediators+in+cardiovascular+disease&doi=10.1016%2Fj.amjcard.2006.01.059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the Renin-Angiotensin-Aldosterone System and Proinflammatory Mediators in Cardiovascular Disease</span></div><div class="casAuthors">Ferrario, Carlos M.; Strawn, William B.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Inflammation is a key mechanism in the initiation, progression, and clin. sequelae of cardiovascular diseases (CVDs), including atherosclerosis, nephropathy, and cardiomyopathy.  Angiotensin II, the major effector peptide of the renin-angiotensin-aldosterone system (RAAS), plays a significant role in the advent and perpetuation of these inflammatory diseases, most notably in atherogenesis.  Consequently, suppression of the influence of angiotensin II by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce or potentially reverse atherosclerosis and other inflammation-assocd. CVDs.  Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors exert anti-inflammatory actions and prevent or reduce the development of atherosclerosis in animal models.  Clin., RAAS suppression reduces common carotid and femoral artery intima-media thickness, thus indicating moderation of the vascular disease process.  These clin. benefits likely involve restraint of the deleterious effects of angiotensin II in addn. to, or independent of, lowering blood pressure.  Increasing evidence that the detection and monitoring of vascular inflammation are important tools in the management of atherosclerosis also implicates the RAAS in this pathogenic process.  Inflammatory mols. such as intercellular adhesion mol.-1, vascular cell adhesion mol.-1, monocyte chemoattractant protein-1, tumor necrosis factor-α, and C-reactive protein have potential diagnostic and prognostic values in CVD and are modified by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers.  Monitoring these markers may be crucial for detg. which agents, or combinations of agents, will result in the most clin. beneficial outcomes for patients.  Large-scale trials are still required to det. the effects of the long-term suppression of inflammation on CVDs through the use of RAAS modulating agents, as well as to det. how closely markers of inflammatory activity may correlate with CVD outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosh0yQAEuVR7Vg90H21EOLACvtfcHk0lgrYkT_cR7cfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVOju7w%253D&md5=b9843797edf7a0e38d78e690d720efa7</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2006.01.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2006.01.059%26sid%3Dliteratum%253Aachs%26aulast%3DFerrario%26aufirst%3DC.%2BM.%26aulast%3DStrawn%26aufirst%3DW.%2BB.%26atitle%3DRole%2520of%2520the%2520renin-angiotensin-aldosterone%2520system%2520and%2520proinflammatory%2520mediators%2520in%2520cardiovascular%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2006%26volume%3D98%26spage%3D121%26epage%3D128%26doi%3D10.1016%2Fj.amjcard.2006.01.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Man, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handoko, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schalij, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boonstra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postmus, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Velden, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eddahibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guignabert, C.</span></span> <span> </span><span class="NLM_article-title">Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">780</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1164/rccm.201203-0411OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201203-0411OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22859525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslynsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2012&pages=780-789&author=F.+S.+de+Manauthor=L.+Tuauthor=M.+L.+Handokoauthor=S.+Rainauthor=G.+Ruiterauthor=C.+Francoisauthor=I.+Schalijauthor=P.+Dorfmullerauthor=G.+Simonneauauthor=E.+Fadelauthor=F.+Perrosauthor=A.+Boonstraauthor=P.+E.+Postmusauthor=I.+van+der+Veldenauthor=A.+Vonk-Noordegraafauthor=M.+Humbertauthor=S.+Eddahibiauthor=C.+Guignabert&title=Dysregulated+renin-angiotensin-aldosterone+system+contributes+to+pulmonary+arterial+hypertension&doi=10.1164%2Frccm.201203-0411OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension</span></div><div class="casAuthors">de Man, Frances S.; Tu, Ly; Handoko, M. Louis; Rain, Silvia; Ruiter, Gerrina; Francois, Charlene; Schalij, Ingrid; Dorfmuller, Peter; Simonneau, Gerald; Fadel, Elie; Perros, Frederic; Boonstra, Anco; Postmus, Piet E.; van der Velden, Jolanda; Vonk-Noordegraaf, Anton; Humbert, Marc; Eddahibi, Saadia; Guignabert, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">780-789</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Patients with idiopathic pulmonary arterial hypertension (iPAH) often have a low cardiac output.  To compensate, neurohormonal systems such as the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system are up-regulated, but this may have long-term neg. effects on the progression of iPAH.  Objectives: Assess systemic and pulmonary RAAS activity in patients with iPAH and det. the efficacy of chronic RAAS inhibition in exptl. PAH.  Methods: We collected 79 blood samples from 58 patients with iPAH in the VU University Medical Center Amsterdam (between 2004 and 2010) to det. systemic RAAS activity.  Measurements and Main Results: We obsd. increased levels of renin, angiotensin (Ang)I, and AngII, which were assocd. with disease progression (P < 0.05) and mortality (P < 0.05).  To det. pulmonary RAAS activity, lung specimens were obtained from patients with iPAH (during lung transplantation, n = 13) and control subjects (during lobectomy or pneumonectomy for cancer, n = 14).  Local RAAS activity in pulmonary arteries of patients with iPAH was increased, demonstrated by elevated angiotensin-converting enzyme activity in pulmonary endothelial cells and increased AngII type 1 (AT1) receptor expression and signaling.  In addn., local RAAS up-regulation was assocd. with increased pulmonary artery smooth muscle cell proliferation via enhanced AT1 receptor signaling in patients with iPAH compared with control subjects.  Finally, to det. the therapeutic potential of RAAS activity, we assessed the chronic effects of an AT1 receptor antagonist (losartan) in the monocrotaline PAH rat model (60 mg/kg).  Losartan delayed disease progression, decreased right ventricular afterload and pulmonary vascular remodeling, and restored right ventricular-arterial coupling in rats with PAH.  Conclusions: Systemic and pulmonary RAAS activities are increased in patients with iPAH and are assocd. with increased pulmonary vascular remodeling.  Chronic inhibition of RAAS by losartan is beneficial in exptl. PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraIen40FBoKbVg90H21EOLACvtfcHk0ljwmqaHwGbfRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslynsrfJ&md5=a4a0689ac69e3f81289e0ecbba1a3e0a</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1164%2Frccm.201203-0411OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201203-0411OC%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BMan%26aufirst%3DF.%2BS.%26aulast%3DTu%26aufirst%3DL.%26aulast%3DHandoko%26aufirst%3DM.%2BL.%26aulast%3DRain%26aufirst%3DS.%26aulast%3DRuiter%26aufirst%3DG.%26aulast%3DFrancois%26aufirst%3DC.%26aulast%3DSchalij%26aufirst%3DI.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DBoonstra%26aufirst%3DA.%26aulast%3DPostmus%26aufirst%3DP.%2BE.%26aulast%3Dvan%2Bder%2BVelden%26aufirst%3DI.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DEddahibi%26aufirst%3DS.%26aulast%3DGuignabert%26aufirst%3DC.%26atitle%3DDysregulated%2520renin-angiotensin-aldosterone%2520system%2520contributes%2520to%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D186%26spage%3D780%26epage%3D789%26doi%3D10.1164%2Frccm.201203-0411OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maron, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opotowsky, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landzberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waxman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, J. A.</span></span> <span> </span><span class="NLM_article-title">Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study</span>. <i>Eur. J. Heart Failure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1093/eurjhf/hfs173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1093%2Feurjhf%2Fhfs173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23111998" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=277-283&author=B.+A.+Maronauthor=A.+R.+Opotowskyauthor=M.+J.+Landzbergauthor=J.+Loscalzoauthor=A.+B.+Waxmanauthor=J.+A.+Leopold&title=Plasma+aldosterone+levels+are+elevated+in+patients+with+pulmonary+arterial+hypertension+in+the+absence+of+left+ventricular+heart+failure%3A+a+pilot+study&doi=10.1093%2Feurjhf%2Fhfs173"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study</span></div><div class="casAuthors">Maron, Bradley A.; Opotowsky, Alexander R.; Landzberg, Michael J.; Loscalzo, Joseph; Waxman, Aaron B.; Leopold, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Heart Failure</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-283</span>CODEN:
                <span class="NLM_cas:coden">EJHFFS</span>;
        ISSN:<span class="NLM_cas:issn">1388-9842</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Aims: Elevated levels of the mineralocorticoid hormone aldosterone are recognized as a modifiable contributor to the pathophysiol. of select cardiovascular diseases due to left heart failure.  In pulmonary arterial hypertension (PAH), pulmonary vascular remodelling induces right ventricular dysfunction and heart failure in the absence of left ventricular (LV) dysfunction.  Hyperaldosteronism has emerged as a promoter of pulmonary vascular disease in exptl. animal models of PAH; however, the extent to which hyperaldosteronism is assocd. with PAH in patients is unknown.  Thus, the central aim of the current study is to det. if hyperaldosteronism is an unrecognized component of the PAH clin. syndrome.  Methods and results: Plasma aldosterone levels and invasive cardiopulmonary haemodynamic measurements were obtained for 25 patients referred for evaluation of unexplained dyspnoea or pulmonary hypertension.  Compared with controls (n = 5), patients with PAH (n = 18) demonstrated significantly increased plasma aldosterone levels (1200.4 ± 423.9 vs. 5959.1 ± 2817.9 pg/mL, P < 0.02), mean pulmonary artery pressure (21.4 ± 5.0 vs. 45.5 ± 10.4 mmHg, P < 0.002), and pulmonary vascular resistance (PVR) (1.41 ± 0.6 vs. 7.3 ± 3.8 Wood units, P < 0.003) without differences in LV ejection fraction or pulmonary capillary wedge pressure between groups.  Among patients not prescribed PAH-specific pharmacotherapy prior to cardiac catheterization, a subgroup of the cohort with severe pulmonary hypertension, aldosterone levels correlated pos. with PVR (r = 0.72, P < 0.02) and transpulmonary gradient (r = 0.69, P < 0.02), but correlated inversely with cardiac output (r = -0.79, P < 0.005).  Conclusions: These data demonstrate a novel cardiopulmonary haemodynamic profile assocd. with hyperaldosteronism in patients: diminished cardiac output due to pulmonary vascular disease in the absence of LV heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7mixfV2NH8LVg90H21EOLACvtfcHk0ljwmqaHwGbfRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFGhtrc%253D&md5=bbcd872a845014dee58962200cb6cda8</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1093%2Feurjhf%2Fhfs173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurjhf%252Fhfs173%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DB.%2BA.%26aulast%3DOpotowsky%26aufirst%3DA.%2BR.%26aulast%3DLandzberg%26aufirst%3DM.%2BJ.%26aulast%3DLoscalzo%26aufirst%3DJ.%26aulast%3DWaxman%26aufirst%3DA.%2BB.%26aulast%3DLeopold%26aufirst%3DJ.%2BA.%26atitle%3DPlasma%2520aldosterone%2520levels%2520are%2520elevated%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520in%2520the%2520absence%2520of%2520left%2520ventricular%2520heart%2520failure%253A%2520a%2520pilot%2520study%26jtitle%3DEur.%2520J.%2520Heart%2520Failure%26date%3D2013%26volume%3D15%26spage%3D277%26epage%3D283%26doi%3D10.1093%2Feurjhf%2Fhfs173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maron, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loscalzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, J. A.</span></span> <span> </span><span class="NLM_article-title">Aldosterone inactivates the endothelin-B Receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">963</span>– <span class="NLM_lpage">974</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.112.094722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.112.094722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22787113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=963-974&author=B.+A.+Maronauthor=Y.+Y.+Zhangauthor=K.+Whiteauthor=S.+Y.+Chanauthor=D.+E.+Handyauthor=C.+E.+Mahoneyauthor=J.+Loscalzoauthor=J.+A.+Leopold&title=Aldosterone+inactivates+the+endothelin-B+Receptor+via+a+cysteinyl+thiol+redox+switch+to+decrease+pulmonary+endothelial+nitric+oxide+levels+and+modulate+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.112.094722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Aldosterone Inactivates the Endothelin-B Receptor via a Cysteinyl Thiol Redox Switch to Decrease Pulmonary Endothelial Nitric Oxide Levels and Modulate Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Maron, Bradley A.; Zhang, Ying-Yi; White, Kevin; Chan, Stephen Y.; Handy, Diane E.; Mahoney, Christopher E.; Loscalzo, Joseph; Leopold, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">963-974</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND-: Pulmonary arterial hypertension (PAH) is characterized, in part, by decreased endothelial nitric oxide (NO) prodn. and elevated levels of endothelin-1.  Endothelin-1 is known to stimulate endothelial nitric oxide synthase (eNOS) via the endothelin-B receptor (ETB), suggesting that this signaling pathway is perturbed in PAH.  Endothelin-1 also stimulates adrenal aldosterone synthesis; in systemic blood vessels, hyperaldosteronism induces vascular dysfunction by increasing endothelial reactive oxygen species generation and decreasing NO levels.  We hypothesized that aldosterone modulates PAH by disrupting ETB-eNOS signaling through a mechanism involving increased pulmonary endothelial oxidant stress.  METHODS AND RESULTS-: In rats with PAH, elevated endothelin-1 levels were assocd. with elevated aldosterone levels in plasma and lung tissue and decreased lung NO metabolites in the absence of left-sided heart failure.  In human pulmonary artery endothelial cells, endothelin-1 increased aldosterone levels via peroxisome proliferator-activated receptor gamma coactivator-1α/steroidogenesis factor-1-dependent upregulation of aldosterone synthase.  Aldosterone also increased reactive oxygen species prodn., which oxidatively modified cysteinyl thiols in the eNOS-activating region of ETB to decrease endothelin-1-stimulated eNOS activity.  Substitution of ETB-Cys405 with alanine improved ETB-dependent NO synthesis under conditions of oxidant stress, confirming that Cys405 is a redox-sensitive thiol that is necessary for ETB-eNOS signaling.  In human pulmonary artery endothelial cells, mineralocorticoid receptor antagonism with spironolactone decreased aldosterone-mediated reactive oxygen species generation and restored ETB-dependent NO prodn.  Spironolactone or eplerenone prevented or reversed pulmonary vascular remodeling and improved cardiopulmonary hemodynamics in 2 animal models of PAH in vivo.  CONCLUSIONS-: Our findings demonstrate that aldosterone modulates an ETB cysteinyl thiol redox switch to decrease pulmonary endothelium-derived NO and promote PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4lo1WeB8Nm7Vg90H21EOLACvtfcHk0ljwmqaHwGbfRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjP&md5=673b9f1c4b352ba3acfb2a0991c35f5e</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.112.094722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.112.094722%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DB.%2BA.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DWhite%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DS.%2BY.%26aulast%3DHandy%26aufirst%3DD.%2BE.%26aulast%3DMahoney%26aufirst%3DC.%2BE.%26aulast%3DLoscalzo%26aufirst%3DJ.%26aulast%3DLeopold%26aufirst%3DJ.%2BA.%26atitle%3DAldosterone%2520inactivates%2520the%2520endothelin-B%2520Receptor%2520via%2520a%2520cysteinyl%2520thiol%2520redox%2520switch%2520to%2520decrease%2520pulmonary%2520endothelial%2520nitric%2520oxide%2520levels%2520and%2520modulate%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2012%26volume%3D126%26spage%3D963%26epage%3D974%26doi%3D10.1161%2FCIRCULATIONAHA.112.094722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X. L.</span></span> <span> </span><span class="NLM_article-title">The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease</span>. <i>Cardiology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1159/000346884</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1159%2F000346884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23548773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmslartbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2013&pages=208-212&author=H.+L.+Daiauthor=Y.+Guoauthor=X.+F.+Guangauthor=Z.+C.+Xiaoauthor=M.+Zhangauthor=X.+L.+Yin&title=The+changes+of+serum+angiotensin-converting+enzyme+2+in+patients+with+pulmonary+arterial+hypertension+due+to+congenital+heart+disease&doi=10.1159%2F000346884"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">The Changes of Serum Angiotensin-Converting Enzyme 2 in Patients with Pulmonary Arterial Hypertension due to Congenital Heart Disease</span></div><div class="casAuthors">Dai, Hai-long; Guo, Yue; Guang, Xue-feng; Xiao, Zhi-cheng; Zhang, Ming; Yin, Xiao-long</div><div class="citationInfo"><span class="NLM_cas:title">Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">208-212</span>CODEN:
                <span class="NLM_cas:coden">CAGYAO</span>;
        ISSN:<span class="NLM_cas:issn">0008-6312</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Angiotensin-converting enzyme 2 (ACE2), a primary component of the vasoprotective axis in the renin-angiotensin system (RAS), has recently been found to have regulatory actions in hypoxic pulmonary hypertension and monocrotaline-induced pulmonary hypertension.  We explored the hypothesis that the level of ACE2 protein contents may be decreased in patients with pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD).  Objective: We obsd. the serum ACE2 protein contents in patients with PAH due to CHD (CHD-PAH), and investigated their correlation with mean pulmonary arterial pressure (mPAP).  Methods: One hundred and four patients with CHD and 33 normal control patients (group A) were involved in the research.  The patients with CHD were divided into 55 cases of nonpulmonary hypertension (group B), 25 cases of mild to moderate pulmonary hypertension (group C) and 24 cases of severe pulmonary hypertension (group D).  The serum level of ACE2 protein contents were detected by ELISA (ELISA), and the relationship between these contents and mPAP were analyzed.  Results: ACE2 protein contents significantly declined as mPAP increased.  The mPAP was neg. correlated with the level of ACE2 protein contents.  Conclusions: These results demonstrated that ACE2 may play an important regulatory role in CHD-PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpycMoNtADxrbVg90H21EOLACvtfcHk0liOJY3nu2V8vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmslartbs%253D&md5=614d9b8abbc835d937b593fc52e5553f</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1159%2F000346884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000346884%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DH.%2BL.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DGuang%26aufirst%3DX.%2BF.%26aulast%3DXiao%26aufirst%3DZ.%2BC.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DYin%26aufirst%3DX.%2BL.%26atitle%3DThe%2520changes%2520of%2520serum%2520angiotensin-converting%2520enzyme%25202%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%2520due%2520to%2520congenital%2520heart%2520disease%26jtitle%3DCardiology%26date%3D2013%26volume%3D124%26spage%3D208%26epage%3D212%26doi%3D10.1159%2F000346884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R. A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maric, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, D. M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Buhr, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heringer-Walther, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, S. V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendes, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemos, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnole-Santos, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheiss, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speth, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, T.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">8258</span>– <span class="NLM_lpage">8263</span>, <span class="refDoi"> DOI: 10.1073/pnas.1432869100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1073%2Fpnas.1432869100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=12829792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlsFGnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2003&pages=8258-8263&author=R.+A.+S.+Santosauthor=A.+Silvaauthor=C.+Maricauthor=D.+M.+R.+Silvaauthor=R.+P.+Machadoauthor=I.+de+Buhrauthor=S.+Heringer-Waltherauthor=S.+V.+B.+Pinheiroauthor=M.+T.+Lopesauthor=M.+Baderauthor=E.+P.+Mendesauthor=V.+S.+Lemosauthor=M.+J.+Campagnole-Santosauthor=H.+P.+Schultheissauthor=R.+Spethauthor=T.+Walther&title=Angiotensin-%281%E2%80%937%29+is+an+endogenous+ligand+for+the+G+protein-coupled+receptor+Mas&doi=10.1073%2Fpnas.1432869100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas</span></div><div class="casAuthors">Santos, Robson A. S.; Simoes e Silva, Ana C.; Maric, Christine; Silva, Denise M. R.; Machado, Raquel Pillar; de Buhr, Insa; Heringer-Walther, Silvia; Pinheiro, Sergio Veloso B.; Lopes, Myriam Teresa; Bader, Michael; Mendes, Elizabeth P.; Lemos, Virgina Soares; Campagnole-Santos, Maria Jose; Schultheiss, Heinz-Peter; Speth, Robert; Walther, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">8258-8263</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The renin-angiotensin system plays a crit. role in blood pressure control and body fluid and electrolyte homeostasis.  Besides angiotensin (Ang) II, other Ang peptides, such as Ang III [Ang-(2-8)], Ang IV [Ang-(3-8)], and Ang-(1-7) may also have important biol. activities.  Ang-(1-7) has become an angiotensin of interest in the past few years, because its cardiovascular and baroreflex actions counteract those of Ang II.  Unique angiotensin-binding sites specific for this heptapeptide and studies with a selective Ang-(1-7) antagonist indicated the existence of a distinct Ang-(1-7) receptor.  The authors demonstrate that genetic deletion of the G protein coupled receptor encoded by the Mas protooncogene abolishes the binding of Ang-(1-7) to mouse kidneys.  Accordingly, Mas-deficient mice completely lack the antidiuretic action of Ang-(1-7) after an acute water load.  Ang-(1-7) binds to Mas-transfected cells and elicits arachidonic acid release.  Furthermore, Mas-deficient aortas lose their Ang-(1-7)-induced relaxation response.  Collectively, these findings identify Mas as a functional receptor for Ang-(1-7) and provide a clear mol. basis for the physiol. actions of this biol. active peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEGDVMsUC2rVg90H21EOLACvtfcHk0liOJY3nu2V8vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlsFGnsbc%253D&md5=cf5e4154ac09053f2c2633ba398186ab</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1432869100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1432869100%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%2BA.%2BS.%26aulast%3DSilva%26aufirst%3DA.%26aulast%3DMaric%26aufirst%3DC.%26aulast%3DSilva%26aufirst%3DD.%2BM.%2BR.%26aulast%3DMachado%26aufirst%3DR.%2BP.%26aulast%3Dde%2BBuhr%26aufirst%3DI.%26aulast%3DHeringer-Walther%26aufirst%3DS.%26aulast%3DPinheiro%26aufirst%3DS.%2BV.%2BB.%26aulast%3DLopes%26aufirst%3DM.%2BT.%26aulast%3DBader%26aufirst%3DM.%26aulast%3DMendes%26aufirst%3DE.%2BP.%26aulast%3DLemos%26aufirst%3DV.%2BS.%26aulast%3DCampagnole-Santos%26aufirst%3DM.%2BJ.%26aulast%3DSchultheiss%26aufirst%3DH.%2BP.%26aulast%3DSpeth%26aufirst%3DR.%26aulast%3DWalther%26aufirst%3DT.%26atitle%3DAngiotensin-%25281%25E2%2580%25937%2529%2520is%2520an%2520endogenous%2520ligand%2520for%2520the%2520G%2520protein-coupled%2520receptor%2520Mas%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2003%26volume%3D100%26spage%3D8258%26epage%3D8263%26doi%3D10.1073%2Fpnas.1432869100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinasabapathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katovich, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raizada, M. K.</span></span> <span> </span><span class="NLM_article-title">Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1–7) bioencapsulated in plant cells attenuates pulmonary hypertension</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1259</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.114.03871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FHYPERTENSIONAHA.114.03871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25225206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=1248-1259&author=V.+Shenoyauthor=K.+C.+Kwonauthor=A.+Rathinasabapathyauthor=S.+N.+Linauthor=G.+Y.+Jinauthor=C.+J.+Songauthor=P.+Shilauthor=A.+Nairauthor=Y.+F.+Qiauthor=Q.+H.+Liauthor=J.+Francisauthor=M.+J.+Katovichauthor=H.+Daniellauthor=M.+K.+Raizada&title=Oral+delivery+of+angiotensin-converting+enzyme+2+and+angiotensin-%281%E2%80%937%29+bioencapsulated+in+plant+cells+attenuates+pulmonary+hypertension&doi=10.1161%2FHYPERTENSIONAHA.114.03871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension</span></div><div class="casAuthors">Shenoy, Vinayak; Kwon, Kwang-Chul; Rathinasabapathy, Anandharajan; Lin, Shina; Jin, Guiying; Song, Chunjuan; Shil, Pollob; Nair, Anand; Qi, Yanfei; Li, Qiuhong; Francis, Joseph; Katovich, Michael J.; Daniell, Henry; Raizada, Mohan K.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1248-1259</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Emerging evidences indicate that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin-converting enzyme 2 (ACE2) and its enzymic product, angiotensin-(1-7) [Ang-(1-7)] contribute to the pathogenesis of pulmonary hypertension (PH).  However, long-term repetitive delivery of ACE2 or Ang-(1-7) would require enhanced protein stability and ease of administration to improve patient compliance.  Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect against gastric enzymic degrdn. and facilitates long-term storage at room temp.  Besides, fusion to a transmucosal carrier helps effective systemic absorption from the intestine on oral delivery.  We hypothesized that bioencapsulating ACE2 or Ang-(1-7) fused to the cholera nontoxin B subunit would enable development of an oral delivery system that is effective in treating PH.  PH was induced in male Sprague Dawley rats by monocrotaline administration.  Subset of animals was simultaneously treated with bioencapsulaed ACE2 or Ang-(1-7) (prevention protocol).  In a sep. set of expts., drug treatment was initiated after 2 wk of PH induction (reversal protocol).  Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) prevented the development of monocrotaline-induced PH and improved assocd. cardiopulmonary pathophysiol.  Furthermore, in the reversal protocol, oral ACE2 or Ang-(1-7) treatment significantly arrested disease progression, along with improvement in right heart function, and decrease in pulmonary vessel wall thickness.  In addn., a combination therapy with ACE2 and Ang-(1-7) augmented the beneficial effects against monocrotaline-induced lung injury.  Our study provides proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technol. for pulmonary disease therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCzZ3vAloHfbVg90H21EOLACvtfcHk0ljOUZyztDi4QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2ntLrE&md5=9369d6b29a8334de869b428938a128bc</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.114.03871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.114.03871%26sid%3Dliteratum%253Aachs%26aulast%3DShenoy%26aufirst%3DV.%26aulast%3DKwon%26aufirst%3DK.%2BC.%26aulast%3DRathinasabapathy%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DS.%2BN.%26aulast%3DJin%26aufirst%3DG.%2BY.%26aulast%3DSong%26aufirst%3DC.%2BJ.%26aulast%3DShil%26aufirst%3DP.%26aulast%3DNair%26aufirst%3DA.%26aulast%3DQi%26aufirst%3DY.%2BF.%26aulast%3DLi%26aufirst%3DQ.%2BH.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DKatovich%26aufirst%3DM.%2BJ.%26aulast%3DDaniell%26aufirst%3DH.%26aulast%3DRaizada%26aufirst%3DM.%2BK.%26atitle%3DOral%2520delivery%2520of%2520angiotensin-converting%2520enzyme%25202%2520and%2520angiotensin-%25281%25E2%2580%25937%2529%2520bioencapsulated%2520in%2520plant%2520cells%2520attenuates%2520pulmonary%2520hypertension%26jtitle%3DHypertension%26date%3D2014%26volume%3D64%26spage%3D1248%26epage%3D1259%26doi%3D10.1161%2FHYPERTENSIONAHA.114.03871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemnes, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathinasabapathy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessel, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fike, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortune, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerszten, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbins, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loyd, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, J.</span></span> <span> </span><span class="NLM_article-title">A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1702638</span>, <span class="refDoi"> DOI: 10.1183/13993003.02638-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F13993003.02638-2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29903860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1eqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2018&pages=1702638&author=A.+R.+Hemnesauthor=A.+Rathinasabapathyauthor=E.+A.+Austinauthor=E.+L.+Brittainauthor=E.+J.+Carrierauthor=X.+P.+Chenauthor=J.+P.+Fesselauthor=C.+D.+Fikeauthor=P.+Fongauthor=N.+Fortuneauthor=R.+E.+Gersztenauthor=J.+A.+Johnsonauthor=M.+Kaplowitzauthor=J.+H.+Newmanauthor=R.+Pianaauthor=M.+E.+Pughauthor=T.+W.+Riceauthor=I.+M.+Robbinsauthor=L.+Wheelerauthor=C.+Yuauthor=J.+E.+Loydauthor=J.+West&title=A+potential+therapeutic+role+for+angiotensin-converting+enzyme+2+in+human+pulmonary+arterial+hypertension&doi=10.1183%2F13993003.02638-2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension</span></div><div class="casAuthors">Hemnes, Anna R.; Rathinasabapathy, Anandharajan; Austin, Eric A.; Brittain, Evan L.; Carrier, Erica J.; Chen, Xinping; Fessel, Joshua P.; Fike, Candice D.; Fong, Peter; Fortune, Niki; Gerszten, Robert E.; Johnson, Jennifer A.; Kaplowitz, Mark; Newman, John H.; Piana, Robert; Pugh, Meredith E.; Rice, Todd W.; Robbins, Ivan M.; Wheeler, Lisa; Yu, Chang; Loyd, James E.; West, James</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1702638/1-1702638/12</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is a deadly disease with no cure.  Alternate conversion of angiotensin II (AngII) to angiotensin-(1-7) (Ang-(1-7)) by angiotensin-converting enzyme 2 (ACE2) resulting in Mas receptor (Mas1) activation improves rodent models of PAH.  Effects of recombinant human (rh) ACE2 in human PAH are unknown.  Our objective was to det. the effects of rhACE2 in PAH.  We defined the mol. effects of Mas1 activation using porcine pulmonary arteries, measured AngII/Ang-(1-7) levels in human PAH and conducted a phase IIa, open-label pilot study of a single infusion of rhACE2 (GSK2586881, 0.2 or 0.4 mg·kg-1 i.v.).  Superoxide dismutase 2 (SOD2) and inflammatory gene expression were identified as markers of Mas1 activation.  After confirming reduced plasma ACE2 activity in human PAH, five patients were enrolled in the trial.  GSK2586881 was well tolerated with significant improvement in cardiac output and pulmonary vascular resistance.  GSK2586881 infusion was assocd. with reduced plasma markers of inflammation within 2-4 h and increased SOD2 plasma protein at 2 wk.  PAH is characterised by reduced ACE2 activity.  Augmentation of ACE2 in a pilot study was well tolerated, assocd. with improved pulmonary haemodynamics and reduced markers of oxidant and inflammatory mediators.  Targeting this pathway may be beneficial in human PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxLA3NjqcCf7Vg90H21EOLACvtfcHk0ljOUZyztDi4QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1eqtL4%253D&md5=ff85f764b3a641f60fc7f2d9de088bea</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1183%2F13993003.02638-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.02638-2017%26sid%3Dliteratum%253Aachs%26aulast%3DHemnes%26aufirst%3DA.%2BR.%26aulast%3DRathinasabapathy%26aufirst%3DA.%26aulast%3DAustin%26aufirst%3DE.%2BA.%26aulast%3DBrittain%26aufirst%3DE.%2BL.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26aulast%3DChen%26aufirst%3DX.%2BP.%26aulast%3DFessel%26aufirst%3DJ.%2BP.%26aulast%3DFike%26aufirst%3DC.%2BD.%26aulast%3DFong%26aufirst%3DP.%26aulast%3DFortune%26aufirst%3DN.%26aulast%3DGerszten%26aufirst%3DR.%2BE.%26aulast%3DJohnson%26aufirst%3DJ.%2BA.%26aulast%3DKaplowitz%26aufirst%3DM.%26aulast%3DNewman%26aufirst%3DJ.%2BH.%26aulast%3DPiana%26aufirst%3DR.%26aulast%3DPugh%26aufirst%3DM.%2BE.%26aulast%3DRice%26aufirst%3DT.%2BW.%26aulast%3DRobbins%26aufirst%3DI.%2BM.%26aulast%3DWheeler%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DLoyd%26aufirst%3DJ.%2BE.%26aulast%3DWest%26aufirst%3DJ.%26atitle%3DA%2520potential%2520therapeutic%2520role%2520for%2520angiotensin-converting%2520enzyme%25202%2520in%2520human%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2018%26volume%3D51%26spage%3D1702638%26doi%3D10.1183%2F13993003.02638-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carrell, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeppsson, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurell, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaughan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boswell, D. R.</span></span> <span> </span><span class="NLM_article-title">Structure and variation of human alpha-1-antitrypsin</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1038/298329a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F298329a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=7045697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaL3sXhs12k" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=1982&pages=329-334&author=R.+W.+Carrellauthor=J.+O.+Jeppssonauthor=C.+B.+Laurellauthor=S.+O.+Brennanauthor=M.+C.+Owenauthor=L.+Vaughanauthor=D.+R.+Boswell&title=Structure+and+variation+of+human+alpha-1-antitrypsin&doi=10.1038%2F298329a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and variation of human α1-antitrypsin</span></div><div class="casAuthors">Carrell, Robin W.; Jeppsson, Jan-Olof; Laurell, Carl Bertil; Brennan, Stephen O.; Owen, Maurice C.; Vaughan, Lloyd; Boswell, D. Ross</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5872</span>),
    <span class="NLM_cas:pages">329-34</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">A review with 71 refs., discussing the sequence of α1-antitrypsin in relation to its role as a tissue scavenger of leukocyte elastase and how 2 abnormal variants commonly present in Europeans cause a deficiency that predisposes them to a progressive loss of lung elasticity.  The nature of the reactive center helps explain why cigarette smoking greatly accelerates the onset and severity of this degenerative process to give the disease emphysema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZGzYirKtcyrVg90H21EOLACvtfcHk0lgOIamrPsiMPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhs12k&md5=d44c54f9c44ee8da29cef9b7c22f1403</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1038%2F298329a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F298329a0%26sid%3Dliteratum%253Aachs%26aulast%3DCarrell%26aufirst%3DR.%2BW.%26aulast%3DJeppsson%26aufirst%3DJ.%2BO.%26aulast%3DLaurell%26aufirst%3DC.%2BB.%26aulast%3DBrennan%26aufirst%3DS.%2BO.%26aulast%3DOwen%26aufirst%3DM.%2BC.%26aulast%3DVaughan%26aufirst%3DL.%26aulast%3DBoswell%26aufirst%3DD.%2BR.%26atitle%3DStructure%2520and%2520variation%2520of%2520human%2520alpha-1-antitrypsin%26jtitle%3DNature%26date%3D1982%26volume%3D298%26spage%3D329%26epage%3D334%26doi%3D10.1038%2F298329a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldabbous, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul-Salam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duluc, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepke-Zaba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southwood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ainscough, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadinnapola, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toshner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciak-Stothard, B.</span></span> <span> </span><span class="NLM_article-title">Neutrophil extracellular traps promote angiogenesis: evidence from vascular pathology in pulmonary hypertension</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2078</span>– <span class="NLM_lpage">2087</span>, <span class="refDoi"> DOI: 10.1161/ATVBAHA.116.307634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FATVBAHA.116.307634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27470511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFensrnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=2078-2087&author=L.+Aldabbousauthor=V.+Abdul-Salamauthor=T.+McKinnonauthor=L.+Dulucauthor=J.+Pepke-Zabaauthor=M.+Southwoodauthor=A.+J.+Ainscoughauthor=C.+Hadinnapolaauthor=M.+R.+Wilkinsauthor=M.+Toshnerauthor=B.+Wojciak-Stothard&title=Neutrophil+extracellular+traps+promote+angiogenesis%3A+evidence+from+vascular+pathology+in+pulmonary+hypertension&doi=10.1161%2FATVBAHA.116.307634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension</span></div><div class="casAuthors">Aldabbous, Lulwah; Abdul-Salam, Vahitha; McKinnon, Tom; Duluc, Lucie; Pepke-Zaba, Joanna; Southwood, Mark; Ainscough, Alexander J.; Hadinnapola, Charaka; Wilkins, Martin R.; Toshner, Mark; Wojciak-Stothard, Beata</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2078-2087</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: Inflammation and dysregulated angiogenesis are features of endothelial dysfunction in pulmonary hypertension.  Neutrophil extracellular traps (NETs), produced by dying neutrophils, contribute to pathogenesis of numerous vascular disorders but their role in pulmonary hypertension has not been studied.  We sought evidence of (NETs) formation in pulmonary hypertension and investigated the effect of NETs on endothelial function.  APPROACH AND RESULTS-: Plasma and lung tissues of patients with pulmonary hypertension were analyzed for NET markers.  The effects of NETs on endothelial function were studied in vitro and in vivo.  Patients with chronic thromboembolic pulmonary hypertension and idiopathic pulmonary hypertension showed elevated plasma levels of DNA, neutrophil elastase, and myeloperoxidase.  NET-forming neutrophils and extensive areas of NETosis were found in the occlusive plexiform lesions and vascularized intrapulmonary thrombi.  NETs induced nuclear factor κB-dependent endothelial angiogenesis in vitro and increased vascularization of matrigel plugs in vivo.  Angiogenic responses were assocd. with increased release of matrix metalloproteinase-9, heparin-binding epidermal growth factor-like growth factor, latency-assocd. peptide of the transforming growth factor β1, and urokinase-type plasminogen activator, accompanied by increased endothelial permeability and cell motility.  NETs-induced responses depended on myeloperoxidase/H2O2-dependent activation of Toll-like receptor 4/nuclear factor κB signaling.  NETs stimulated the release of endothelin-1 in HPAECs (human pulmonary artery endothelial cells) and stimulated pulmonary smooth muscle cell proliferation in vitro.  CONCLUSIONS-: We are the first to implicate NETs in angiogenesis and provide a functional link between NETs and inflammatory angiogenesis in vitro and in vivo.  We demonstrate the potential pathol. relevance of this in 2 diseases of disordered vascular homeostasis, pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd9VtkXZ7XFbVg90H21EOLACvtfcHk0lgOIamrPsiMPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFensrnL&md5=b6c7506cfe5b41d4af6d434745c306de</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.116.307634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.116.307634%26sid%3Dliteratum%253Aachs%26aulast%3DAldabbous%26aufirst%3DL.%26aulast%3DAbdul-Salam%26aufirst%3DV.%26aulast%3DMcKinnon%26aufirst%3DT.%26aulast%3DDuluc%26aufirst%3DL.%26aulast%3DPepke-Zaba%26aufirst%3DJ.%26aulast%3DSouthwood%26aufirst%3DM.%26aulast%3DAinscough%26aufirst%3DA.%2BJ.%26aulast%3DHadinnapola%26aufirst%3DC.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DToshner%26aufirst%3DM.%26aulast%3DWojciak-Stothard%26aufirst%3DB.%26atitle%3DNeutrophil%2520extracellular%2520traps%2520promote%2520angiogenesis%253A%2520evidence%2520from%2520vascular%2520pathology%2520in%2520pulmonary%2520hypertension%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2016%26volume%3D36%26spage%3D2078%26epage%3D2087%26doi%3D10.1161%2FATVBAHA.116.307634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilbut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humpl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1038/76282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2F76282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10835689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkt12isbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=698-702&author=K.+N.+Cowanauthor=A.+Heilbutauthor=T.+Humplauthor=C.+Lamauthor=S.+Itoauthor=M.+Rabinovitch&title=Complete+reversal+of+fatal+pulmonary+hypertension+in+rats+by+a+serine+elastase+inhibitor&doi=10.1038%2F76282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor</span></div><div class="casAuthors">Cowan, Kyle Northcote; Heilbut, Adrian; Humpl, Tilman; Lam, Catherine; Ito, Shinya; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">698-702</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Progression of pulmonary hypertension is assocd. with increased serine elastase activity and the proteinase-dependent deposition of the extracellular matrix smooth muscle cell survival factor tenascin-C.  Tenascin-C amplifies the response of smooth muscle cells to growth factors, which are also liberated through matrix proteolysis.  Recent organ culture studies using hypertrophied rat pulmonary arteries have shown that elastase inhibitors suppress tenascin-C and induce smooth muscle cell apoptosis.  This initiates complete regression of the hypertrophied vessel wall by a coordinated loss of cellularity and extracellular matrix.  We now report that elastase inhibitors can reverse advanced pulmonary vascular disease produced in rats by injecting monocrotaline, an endothelial toxin.  We began oral administration of the peptidyl trifluoromethylketone serine elastase inhibitors M249314 or ZD0892 21 days after injection of monocrotaline.  A 1-wk treatment resulted in 92% survival, compared with 39% survival in untreated or vehicle-treated rats.  Pulmonary artery pressure and muscularization were reduced by myocyte apoptosis and loss of extracellular matrix, specifically elastin and tenascin-C.  After 2 wk, pulmonary artery pressure and structure normalized, and survival was 86%, compared with 0% in untreated or vehicle-treated rats.  Although concomitant treatment with various agents can reduce pulmonary hypertension, we have documented complete regression after establishment of malignant monocrotaline-induced disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJEvNkrAhGLVg90H21EOLACvtfcHk0lgOIamrPsiMPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkt12isbc%253D&md5=09b5ecab8278b8439ff21cc1c9d47cfd</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2F76282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F76282%26sid%3Dliteratum%253Aachs%26aulast%3DCowan%26aufirst%3DK.%2BN.%26aulast%3DHeilbut%26aufirst%3DA.%26aulast%3DHumpl%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DC.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DComplete%2520reversal%2520of%2520fatal%2520pulmonary%2520hypertension%2520in%2520rats%2520by%2520a%2520serine%2520elastase%2520inhibitor%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D698%26epage%3D702%26doi%3D10.1038%2F76282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zaidi, S. H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1161/hc0402.102866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2Fhc0402.102866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11815437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVGmurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2002&pages=516-521&author=S.+H.+E.+Zaidiauthor=X.+M.+Youauthor=S.+Ciuraauthor=M.+Husainauthor=M.+Rabinovitch&title=Overexpression+of+the+serine+elastase+inhibitor+elafin+protects+transgenic+mice+from+hypoxic+pulmonary+hypertension&doi=10.1161%2Fhc0402.102866"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension</span></div><div class="casAuthors">Zaidi, Syed H. E.; You, Xiao-Mang; Ciura, Sorana; Husain, Mansoor; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-521</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Increased serine elastase activity has been implicated in the vascular remodeling assocd. with chronic hypoxia-related pulmonary hypertension in rats.  In this study we detd. the time course of hypoxia-induced serine elastase activity in the murine lung and related this to initiation of a proteolytic cascade characterized by an increase in matrix metalloproteinases (MMPs).  We then used transgenic mice in which overexpression of the selective serine elastase inhibitor elafin was targeted to the cardiovascular system to det. whether upregulation of a naturally occurring serine elastase inhibitor suppresses MMPs and the hemodynamic and structural response to chronic hypoxia (air at 380 mm Hg).  In nontransgenic but not in elafin-transgenic mice, we documented a transient increase in serine elastase activity after 12 h of hypoxic exposure attributed to a 30-kDa protein as detd. by elastin zymog. and fluorophosphonate/fluorophosphate-biotin labeling.  Two days after hypoxia, the pro-forms of MMP-2 and MMP-9 were induced in the nontransgenic mice, but MMP-9 was suppressed in elafin-transgenic mice.  Acute hypoxic vasoconstriction was similar in nontransgenic and elafin-transgenic littermates.  Chronic hypoxia for 26 days resulted in > 1-fold increase in right ventricular pressure (P<0.004) in nontransgenic compared with control or elafin-transgenic littermates.  In the latter mice, normalization of the right ventricular pressure was assocd. with reduced muscularization and preservation of the no. of distal vessels (P<0.04 for both comparisons).  Modulation of the severity of chronic hypoxia-induced pulmonary vascular disease could be a function of endogenously expressed serine elastase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4gZPiZXntQrVg90H21EOLACvtfcHk0li8nMKYPxh2Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVGmurw%253D&md5=78af2fdea41a6490063abb1dd67da8c7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1161%2Fhc0402.102866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhc0402.102866%26sid%3Dliteratum%253Aachs%26aulast%3DZaidi%26aufirst%3DS.%2BH.%2BE.%26aulast%3DYou%26aufirst%3DX.%2BM.%26aulast%3DCiura%26aufirst%3DS.%26aulast%3DHusain%26aufirst%3DM.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DOverexpression%2520of%2520the%2520serine%2520elastase%2520inhibitor%2520elafin%2520protects%2520transgenic%2520mice%2520from%2520hypoxic%2520pulmonary%2520hypertension%26jtitle%3DCirculation%26date%3D2002%26volume%3D105%26spage%3D516%26epage%3D521%26doi%3D10.1161%2Fhc0402.102866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nickel, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekerkoetter, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaschwich, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diebold, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennigs, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sa, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockstill, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolls, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamanian, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bland, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1286</span>, <span class="refDoi"> DOI: 10.1164/rccm.201412-2291OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201412-2291OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25853696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=1273-1286&author=N.+P.+Nickelauthor=E.+Spiekerkoetterauthor=M.+X.+Guauthor=C.+Y.+G.+Liauthor=H.+Liauthor=M.+Kaschwichauthor=I.+Dieboldauthor=J.+K.+Hennigsauthor=K.+Y.+Kimauthor=K.+Miyagawaauthor=L.+L.+Wangauthor=A.+Q.+Caoauthor=S.+L.+Saauthor=X.+G.+Jiangauthor=R.+W.+Stockstillauthor=M.+R.+Nicollsauthor=R.+T.+Zamanianauthor=R.+D.+Blandauthor=M.+Rabinovitch&title=Elafin+reverses+pulmonary+hypertension+via+caveolin-1-dependent+bone+morphogenetic+protein+signaling&doi=10.1164%2Frccm.201412-2291OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling</span></div><div class="casAuthors">Nickel, Nils P.; Spiekerkoetter, Edda; Gu, Mingxia; Li, Caiyun G.; Li, Hai; Kaschwich, Mark; Diebold, Isabel; Hennigs, Jan K.; Kim, Ki-Yoon; Miyagawa, Kazuya; Wang, Lingli; Cao, Aiqin; Sa, Silin; Jiang, Xinguo; Stockstill, Raymond W.; Nicolls, Mark R.; Zamanian, Roham T.; Bland, Richard D.; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1273-1286</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Pulmonary arterial hypertension is characterized by endothelial dysfunction, impaired bone morphogenetic protein receptor 2 (BMPR2) signaling, and increased elastase activity.  Synthetic elastase inhibitors reverse exptl. pulmonary hypertension but cause hepatotoxicity in clin. studies.  The endogenous elastase inhibitor elafin attenuates hypoxic pulmonary hypertension in mice, but its potential to improve endothelial function and BMPR2 signaling, and to reverse severe exptl. pulmonary hypertension or vascular pathol. in the human disease was unknown.  Objectives: To assess elafin-mediated regression of pulmonary vascular pathol. in rats and in lung explants from patients with pulmonary hypertension.  To det. if elafin amplifies BMPR2 signaling in pulmonary artery endothelial cells and to elucidate the underlying mechanism.  Methods: Rats with pulmonary hypertension induced by vascular endothelial growth factor receptor blockade and hypoxia (Sugen/hypoxia) as well as lung organ cultures from patients with pulmonary hypertension were used to assess elafin-mediated reversibility of pulmonary vascular disease.  Pulmonary arterial endothelial cells from patients and control subjects were used to det. the efficacy and mechanism of elafin-mediated BMPR2 signaling.  Measurements and Main Results: In Sugen/hypoxia rats, elafin reduced elastase activity and reversed pulmonary hypertension, judged by regression of right ventricular systolic pressure and hypertrophy and pulmonary artery occlusive changes.  Elafin improved endothelial function by increasing apelin, a BMPR2 target.  Elafin induced apoptosis in human pulmonary arterial smooth muscle cells and decreased neointimal lesions in lung organ culture.  In normal and patient pulmonary artery endothelial cells, elafin promoted angiogenesis by increasing pSMAD-dependent and -independent BMPR2 signaling.  This was linked mechanistically to augmented interaction of BMPR2 with caveolin-1 via elafin-mediated stabilization of endothelial surface caveolin-1.  Conclusions: Elafin reverses obliterative changes in pulmonary arteries via elastase inhibition and caveolin-1-dependent amplification of BMPR2 signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_aA0F6wxMv7Vg90H21EOLACvtfcHk0li8nMKYPxh2Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVCmtb7M&md5=f03a10eb726fec9372a3a01f13eddb2c</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1164%2Frccm.201412-2291OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201412-2291OC%26sid%3Dliteratum%253Aachs%26aulast%3DNickel%26aufirst%3DN.%2BP.%26aulast%3DSpiekerkoetter%26aufirst%3DE.%26aulast%3DGu%26aufirst%3DM.%2BX.%26aulast%3DLi%26aufirst%3DC.%2BY.%2BG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DKaschwich%26aufirst%3DM.%26aulast%3DDiebold%26aufirst%3DI.%26aulast%3DHennigs%26aufirst%3DJ.%2BK.%26aulast%3DKim%26aufirst%3DK.%2BY.%26aulast%3DMiyagawa%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DL.%2BL.%26aulast%3DCao%26aufirst%3DA.%2BQ.%26aulast%3DSa%26aufirst%3DS.%2BL.%26aulast%3DJiang%26aufirst%3DX.%2BG.%26aulast%3DStockstill%26aufirst%3DR.%2BW.%26aulast%3DNicolls%26aufirst%3DM.%2BR.%26aulast%3DZamanian%26aufirst%3DR.%2BT.%26aulast%3DBland%26aufirst%3DR.%2BD.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DElafin%2520reverses%2520pulmonary%2520hypertension%2520via%2520caveolin-1-dependent%2520bone%2520morphogenetic%2520protein%2520signaling%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26spage%3D1273%26epage%3D1286%26doi%3D10.1164%2Frccm.201412-2291OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Federici, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigelsky, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNelly, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comhair, S. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erzurum, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldred, M. A.</span></span> <span> </span><span class="NLM_article-title">Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1164/rccm.201411-2128OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Frccm.201411-2128OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25918951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVynu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2015&pages=219-228&author=C.+Federiciauthor=K.+M.+Drakeauthor=C.+M.+Rigelskyauthor=L.+N.+McNellyauthor=S.+L.+Meadeauthor=S.+A.+A.+Comhairauthor=S.+C.+Erzurumauthor=M.+A.+Aldred&title=Increased+mutagen+sensitivity+and+DNA+damage+in+pulmonary+arterial+hypertension&doi=10.1164%2Frccm.201411-2128OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension</span></div><div class="casAuthors">Federici, Chiara; Drake, Kylie M.; Rigelsky, Christina M.; McNellyl, Lauren N.; Meade, Sirena L.; Comhair, Suzy A. A.; Erzurum, Serpil C.; Aldred, Micheala A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Pulmonary arterial hypertension (PAH) is a serious lung condition characterized by vascular remodeling in the precapillary pulmonary arterioles.  We and others have demonstrated chromosomal abnormalities and increased DNA damage in PAH lung vascular cells, but their timing and role in disease pathogenesis is unknown.  Objectives: We hypothesized that if DNA damage predates PAH, it might he an intrinsic cell property that is present outside the diseased lung.  Methods: We measured DNA damage, mutagen sensitivity, and reactive oxygen species (ROS) in lung and blood cells from patients with Group 1 PAH, their relatives, and unrelated control subjects.  Measurements and Main Results: Baseline DNA damage was significantly elevated in PAH, both in pulmonary artery endothelial cells (P < 0.05) and peripheral blood mononuclear cells (PBMC) (P < 0.001).  Remarkably, PBMC from unaffected relatives showed similar increases, indicating this is not related to PAH treatments.  ROS levels were also higher (P < 0.01).  DNA damage correlated with ROS prodn. and was suppressed by antioxidants (P < 0.001).  PBMC from patients and relatives also showed markedly increased sensitivity to two chemotherapeutic drugs, bleomycin and etoposide (P < 0.001).  Results were consistent across idiopathic, heritable, and assocd. PAH groups.  Conclusions: Levels of baseline and mutagen-induced DNA damage are intrinsically higher in PAH cells.  Similar results in PBMC from unaffected relatives suggest this may he a genetically detd. trait that predates disease onset and may act as a risk factor contributing to lung vascular remodeling following endothelial cell injury.  Further studies are required to fully characterize mutagen sensitivity, which could have important implications for clin. management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8qjI4maJxebVg90H21EOLACvtfcHk0li8nMKYPxh2Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVynu77N&md5=8054e5749fbec03e90a8f76b2b30f004</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1164%2Frccm.201411-2128OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201411-2128OC%26sid%3Dliteratum%253Aachs%26aulast%3DFederici%26aufirst%3DC.%26aulast%3DDrake%26aufirst%3DK.%2BM.%26aulast%3DRigelsky%26aufirst%3DC.%2BM.%26aulast%3DMcNelly%26aufirst%3DL.%2BN.%26aulast%3DMeade%26aufirst%3DS.%2BL.%26aulast%3DComhair%26aufirst%3DS.%2BA.%2BA.%26aulast%3DErzurum%26aufirst%3DS.%2BC.%26aulast%3DAldred%26aufirst%3DM.%2BA.%26atitle%3DIncreased%2520mutagen%2520sensitivity%2520and%2520DNA%2520damage%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D192%26spage%3D219%26epage%3D228%26doi%3D10.1164%2Frccm.201411-2128OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ranchoux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucherat, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span> <span> </span><span class="NLM_article-title">Review DNA damage and pulmonary hypertension</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">990</span>, <span class="refDoi"> DOI: 10.3390/ijms17060990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fijms17060990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=990&author=B.+Ranchouxauthor=J.+Melocheauthor=R.+Paulinauthor=O.+Boucheratauthor=S.+Provencherauthor=S.+Bonnet&title=Review+DNA+damage+and+pulmonary+hypertension&doi=10.3390%2Fijms17060990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">DNA damage and pulmonary hypertension</span></div><div class="casAuthors">Ranchoux, Benoit; Meloche, Jolyane; Paulin, Roxane; Boucherat, Olivier; Provencher, Steeve; Bonnet, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">990/1-990/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pulmonary hypertension (PH) is defined by a mean pulmonary arterial pressure over 25 mmHg at rest and is diagnosed by right heart catheterization.  Among the different groups of PH, pulmonary arterial hypertension (PAH) is characterized by a progressive obstruction of distal pulmonary arteries, related to endothelial cell dysfunction and vascular cell proliferation, which leads to an increased pulmonary vascular resistance, right ventricular hypertrophy, and right heart failure.  Although the primary trigger of PAH remains unknown, oxidative stress and inflammation have been shown to play a key role in the development and progression of vascular remodeling.  These factors are known to increase DNA damage that might favor the emergence of the proliferative and apoptosis-resistant phenotype obsd. in PAH vascular cells.  High levels of DNA damage were reported to occur in PAH lungs and remodeled arteries as well as in animal models of PH.  Moreover, recent studies have demonstrated that impaired DNA-response mechanisms may lead to an increased mutagen sensitivity in PAH patients.  Finally, PAH was linked with decreased breast cancer 1 protein (BRCA1) and DNA topoisomerase 2-binding protein 1 (TopBP1) expression, both involved in maintaining genome integrity.  This review aims to provide an overview of recent evidence of DNA damage and DNA repair deficiency and their implication in PAH pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtqqa2DNyVprVg90H21EOLACvtfcHk0lhF4QsfixUBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGqtbvK&md5=27ff03edee07462cba41c03c4d98142b</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.3390%2Fijms17060990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms17060990%26sid%3Dliteratum%253Aachs%26aulast%3DRanchoux%26aufirst%3DB.%26aulast%3DMeloche%26aufirst%3DJ.%26aulast%3DPaulin%26aufirst%3DR.%26aulast%3DBoucherat%26aufirst%3DO.%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DS.%26atitle%3DReview%2520DNA%2520damage%2520and%2520pulmonary%2520hypertension%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2016%26volume%3D17%26spage%3D990%26doi%3D10.3390%2Fijms17060990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meloche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflieger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaillancourt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potus, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zervopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graydon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courboulin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuils-Bonnet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couture, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelakis, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span> <span> </span><span class="NLM_article-title">Role for DNA damage signaling in pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">797</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.113.006167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.113.006167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24270264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlSnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=786-797&author=J.+Melocheauthor=A.+Pfliegerauthor=M.+Vaillancourtauthor=R.+Paulinauthor=F.+Potusauthor=S.+Zervopoulosauthor=C.+Graydonauthor=A.+Courboulinauthor=S.+Breuils-Bonnetauthor=E.+Tremblayauthor=C.+Coutureauthor=E.+D.+Michelakisauthor=S.+Provencherauthor=S.+Bonnet&title=Role+for+DNA+damage+signaling+in+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.113.006167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Role for DNA Damage Signaling in Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Meloche, Jolyane; Pflieger, Aude; Vaillancourt, Mylene; Paulin, Roxane; Potus, Francois; Zervopoulos, Sotirios; Graydon, Colin; Courboulin, Audrey; Breuils-Bonnet, Sandra; Tremblay, Eve; Couture, Christian; Michelakis, Evangelos D.; Provencher, Steeve; Bonnet, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">786-797</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: Pulmonary arterial hypertension (PAH) is assocd. with sustained inflammation known to promote DNA damage.  Despite these unfavorable environmental conditions, PAH pulmonary arterial smooth muscle cells (PASMCs) exhibit, in contrast to healthy PASMCs, a pro-proliferative and anti-apoptotic phenotype, sustained in time by the activation of miR-204, nuclear factor of activated T cells, and hypoxia-inducible factor 1-α.  We hypothesized that PAH-PASMCs have increased the activation of poly(ADP-ribose) polymerase-1 (PARP-1), a crit. enzyme implicated in DNA repair, allowing proliferation despite the presence of DNA-damaging insults, eventually leading to PAH.  METHODS AND RESULTS: Human PAH distal pulmonary arteries and cultured PAH-PASMCs exhibit increased DNA damage markers (53BP1 and γ-H2AX) and an overexpression of PARP-1 (immunoblot and activity assay), in comparison with healthy tissues/cells.  Healthy PASMCs treated with a clin. relevant dose of tumor necrosis factor-α harbored a similar phenotype, suggesting that inflammation induces DNA damage and PARP-1 activation in PAH.  We also showed that PARP-1 activation accounts for miR-204 downregulation (quant. reverse transcription polymerase chain reaction) and the subsequent activation of the transcription factors nuclear factor of activated T cells and hypoxia-inducible factor 1-α in PAH-PASMCs, previously shown to be crit. for PAH in several models.  These effects resulted in PASMC proliferation (Ki67, proliferating cell nuclear antigen, and WST1 assays) and resistance to apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling and Annexin V assays).  In vivo, the clin. available PARP inhibitor ABT-888 reversed PAH in 2 exptl. rat models (Sugen/hypoxia and monocrotaline).  CONCLUSIONS: These results show for the first time that the DNA damage/PARP-1 signaling pathway is important for PAH development and provide a new therapeutic target for this deadly disease with high translational potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktJ97sIdRjLVg90H21EOLACvtfcHk0lhF4QsfixUBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlSnsrY%253D&md5=f5cef653a9c6286f494685ac2d32f9c6</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.113.006167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.113.006167%26sid%3Dliteratum%253Aachs%26aulast%3DMeloche%26aufirst%3DJ.%26aulast%3DPflieger%26aufirst%3DA.%26aulast%3DVaillancourt%26aufirst%3DM.%26aulast%3DPaulin%26aufirst%3DR.%26aulast%3DPotus%26aufirst%3DF.%26aulast%3DZervopoulos%26aufirst%3DS.%26aulast%3DGraydon%26aufirst%3DC.%26aulast%3DCourboulin%26aufirst%3DA.%26aulast%3DBreuils-Bonnet%26aufirst%3DS.%26aulast%3DTremblay%26aufirst%3DE.%26aulast%3DCouture%26aufirst%3DC.%26aulast%3DMichelakis%26aufirst%3DE.%2BD.%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DS.%26atitle%3DRole%2520for%2520DNA%2520damage%2520signaling%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2014%26volume%3D129%26spage%3D786%26epage%3D797%26doi%3D10.1161%2FCIRCULATIONAHA.113.006167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span> <span> </span><span class="NLM_article-title">Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension</span>. <i>Mol. Cells</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.14348/molcells.2014.2308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.14348%2Fmolcells.2014.2308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24608803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1GgtL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=196-201&author=J.+Kim&title=Apelin-APJ+signaling%3A+a+potential+therapeutic+target+for+pulmonary+arterial+hypertension&doi=10.14348%2Fmolcells.2014.2308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension</span></div><div class="casAuthors">Kim, Jongmin</div><div class="citationInfo"><span class="NLM_cas:title">Molecules and Cells</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">196-201, 6 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOCEEK</span>;
        ISSN:<span class="NLM_cas:issn">1016-8478</span>.
    
            (<span class="NLM_cas:orgname">Korean Society for Molecular and Cellular Biology</span>)
        </div><div class="casAbstract">A review.  Pulmonary arterial hypertension (PAH) is a progressive disease characterized by the vascular remodeling of the pulmonary arterioles, including formation of plexiform and concentric lesions comprised of proliferative vascular cells.  Clin., PAH leads to increased pulmonary arterial pressure and subsequent right ventricular failure.  Existing therapies have improved the outcome but mortality still remains exceedingly high.  There is emerging evidence that the seven-transmembrane G-protein coupled receptor APJ and its cognate endogenous ligand apelin are important in the maintenance of pulmonary vascular homeostasis through the targeting of crit. mediators, such as Kruppel-like factor 2 (KLF2), endothelial nitric oxide synthase (eNOS), and microRNAs (miRNAs).  Disruption of this pathway plays a major part in the pathogenesis of PAH.  Given its role in the maintenance of pulmonary vascular homeostasis, the apelin-APJ pathway is a potential target for PAH therapy.  This review highlights the current state in the understanding of the apelin-APJ axis related to PAH and discusses the therapeutic potential of this signaling pathway as a novel paradigm of PAH therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNqPZpqOXMXLVg90H21EOLACvtfcHk0lhF4QsfixUBWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1GgtL7P&md5=65161f80f7231d8cf13d501a70d7318c</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.14348%2Fmolcells.2014.2308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14348%252Fmolcells.2014.2308%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DApelin-APJ%2520signaling%253A%2520a%2520potential%2520therapeutic%2520target%2520for%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DMol.%2520Cells%26date%3D2014%26volume%3D37%26spage%3D196%26epage%3D201%26doi%3D10.14348%2Fmolcells.2014.2308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatemoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaki, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimiya, M.</span></span> <span> </span><span class="NLM_article-title">The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism</span>. <i>Regul. Pept.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1016/S0167-0115(01)00236-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2FS0167-0115%2801%2900236-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11384769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjvV2rtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2001&pages=87-92&author=K.+Tatemotoauthor=K.+Takayamaauthor=M.+X.+Zouauthor=I.+Kumakiauthor=W.+Zhangauthor=K.+Kumanoauthor=M.+Fujimiya&title=The+novel+peptide+apelin+lowers+blood+pressure+via+a+nitric+oxide-dependent+mechanism&doi=10.1016%2FS0167-0115%2801%2900236-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism</span></div><div class="casAuthors">Tatemoto, K.; Takayama, K.; Zou, M.-X.; Kumaki, I.; Zhang, W.; Kumano, K.; Fujimiya, M.</div><div class="citationInfo"><span class="NLM_cas:title">Regulatory Peptides</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">REPPDY</span>;
        ISSN:<span class="NLM_cas:issn">0167-0115</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Apelin is an endogenous ligand of the human orphan receptor APJ.  The authors detected apelin-like immunoreactivity in the adipocytes, gastric mucosa, and Kupffer cells in the liver.  The authors also detected apelin-like immunoreactivity localized within the endothelia of small arteries in various organs.  Further, it was found that mean arterial pressure after the administration of apelin-12, apelin-13, and apelin-36 at a dose of 10 nmol/kg in anesthetized rats was reduced by 26, 11, and 5 mm Hg, resp.  In the presence of a nitric oxide (NO) synthase inhibitor, the effect of apelin-12 on blood pressure was abolished.  Furthermore, the administration of apelin-12 (10 nmol/kg) in rats produced a transitory elevation of the plasma nitrite/nitrate concn. from a basal level of 21.4 to 27.0 μM.  Thus, apelin may lower blood pressure via a nitric oxide-dependent mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr13vFqdwNahbVg90H21EOLACvtfcHk0liL1hNfSvIMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjvV2rtrY%253D&md5=af0d7ea0f8481a76a57d5207730a39e1</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1016%2FS0167-0115%2801%2900236-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-0115%252801%252900236-1%26sid%3Dliteratum%253Aachs%26aulast%3DTatemoto%26aufirst%3DK.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DZou%26aufirst%3DM.%2BX.%26aulast%3DKumaki%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DKumano%26aufirst%3DK.%26aulast%3DFujimiya%26aufirst%3DM.%26atitle%3DThe%2520novel%2520peptide%2520apelin%2520lowers%2520blood%2520pressure%2520via%2520a%2520nitric%2520oxide-dependent%2520mechanism%26jtitle%3DRegul.%2520Pept.%26date%3D2001%26volume%3D99%26spage%3D87%26epage%3D92%26doi%3D10.1016%2FS0167-0115%2801%2900236-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alastalo, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jesus Perez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskenvuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinovitch, M.</span></span> <span> </span><span class="NLM_article-title">Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">3735</span>– <span class="NLM_lpage">3746</span>, <span class="refDoi"> DOI: 10.1172/JCI43382</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1172%2FJCI43382" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=21821917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOhtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=3735-3746&author=T.-P.+Alastaloauthor=M.+Liauthor=V.+de+Jesus+Perezauthor=D.+Phamauthor=H.+Sawadaauthor=J.+K.+Wangauthor=M.+Koskenvuoauthor=L.+Wangauthor=B.+A.+Freemanauthor=H.+Y.+Changauthor=M.+Rabinovitch&title=Disruption+of+PPAR%CE%B3%2F%CE%B2-catenin-mediated+regulation+of+apelin+impairs+BMP-induced+mouse+and+human+pulmonary+arterial+EC+survival&doi=10.1172%2FJCI43382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival</span></div><div class="casAuthors">Alastalo, Tero-Pekka; Li, Molong; de Jesus Perez, Vinicio; Pham, David; Sawada, Hirofumi; Wang, Jordon K.; Koskenvuo, Minna; Wang, Lingli; Freeman, Bruce A.; Chang, Howard Y.; Rabinovitch, Marlene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3735-3746</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Reduced bone morphogenetic protein receptor 2 (BMPR2) expression in patients with pulmonary arterial hypertension (PAH) can impair pulmonary arterial EC (PAEC) function.  This can adversely affect EC survival and promote SMC proliferation.  We hypothesized that interventions to normalize expression of genes that are targets of BMPR2 signaling could restore PAEC function and prevent or reverse PAH.  Here we have characterized, in human PAECs, a BMPR2-mediated transcriptional complex between PPARγ and β-catenin and shown that disruption of this complex impaired BMP-mediated PAEC survival.  Using whole genome-wide ChIP-Chip promoter anal. and gene expression microarrays, we delineated PPARγ/β-catenin-dependent transcription of target genes including APLN, which encodes apelin.  We documented reduced PAEC expression of apelin in PAH patients vs. controls.  In cell culture expts., we showed that apelin-deficient PAECs were prone to apoptosis and promoted pulmonary arterial SMC (PASMC) proliferation.  Conversely, we established that apelin, like BMPR2 ligands, suppressed proliferation and induced apoptosis of PASMCs.  Consistent with these functions, administration of apelin reversed PAH in mice with reduced prodn. of apelin resulting from deletion of PPARγ in ECs.  Taken together, our findings suggest that apelin could be effective in treating PAH by rescuing BMPR2 and PAEC dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZixAy3nCZDrVg90H21EOLACvtfcHk0liL1hNfSvIMug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOhtr7P&md5=cb1311168b02baf1eb1173ade2739aec</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1172%2FJCI43382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI43382%26sid%3Dliteratum%253Aachs%26aulast%3DAlastalo%26aufirst%3DT.-P.%26aulast%3DLi%26aufirst%3DM.%26aulast%3Dde%2BJesus%2BPerez%26aufirst%3DV.%26aulast%3DPham%26aufirst%3DD.%26aulast%3DSawada%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%2BK.%26aulast%3DKoskenvuo%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFreeman%26aufirst%3DB.%2BA.%26aulast%3DChang%26aufirst%3DH.%2BY.%26aulast%3DRabinovitch%26aufirst%3DM.%26atitle%3DDisruption%2520of%2520PPAR%25CE%25B3%252F%25CE%25B2-catenin-mediated%2520regulation%2520of%2520apelin%2520impairs%2520BMP-induced%2520mouse%2520and%2520human%2520pulmonary%2520arterial%2520EC%2520survival%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D3735%26epage%3D3746%26doi%3D10.1172%2FJCI43382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Church, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayasekera, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welsh, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, L. S. G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onorato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stirrat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newby, D. E.</span></span> <span> </span><span class="NLM_article-title">Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension</span>. <i>JACC Basic Transl Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.jacbts.2018.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jacbts.2018.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29876530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1Mbkslelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2018&pages=176-186&author=L.+Brashauthor=M.+J.+Brewisauthor=A.+C.+Churchauthor=G.+Jayasekeraauthor=M.+K.+Johnsonauthor=N.+McGlincheyauthor=J.+Simpsonauthor=S.+Thomsonauthor=D.+J.+Welshauthor=A.+J.+Peacockauthor=G.+D.+Barnesauthor=S.+J.+Gibbsauthor=L.+S.+G.+E.+Howardauthor=G.+Watsonauthor=M.+R.+Wilkinsauthor=J.+Onoratoauthor=C.+Xuauthor=C.+Stirratauthor=D.+E.+Newby&title=Short-term+hemodynamic+effects+of+apelin+in+patients+with+pulmonary+arterial+hypertension&doi=10.1016%2Fj.jacbts.2018.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Brash Lauren; Brewis Melanie J; Church A Colin; Jayasekera Geeshath; Johnson Martin K; McGlinchey Neil; Simpson Joanne; Thomson Stephen; Welsh David J; Peacock Andrew J; Barnes Gareth D; Gibbs Simon J; Howard Luke S G E; Watson Geoffrey; Wilkins Martin R; Onorato Joelle; Xu Carrie; Stirrat Colin; Newby David E</div><div class="citationInfo"><span class="NLM_cas:title">JACC. Basic to translational science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-186</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models.  Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH.  In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr(1))apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr(1))apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output.  This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition.  Apelin agonism is a novel potential therapeutic target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNTM0d67PiEN-cVm4E2RlLfW6udTcc2eYq3MFHJZ5P6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mbkslelsg%253D%253D&md5=617243dd6dff4a6f05bb555b7c10deb5</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.jacbts.2018.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacbts.2018.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DBrash%26aufirst%3DL.%26aulast%3DBrewis%26aufirst%3DM.%2BJ.%26aulast%3DChurch%26aufirst%3DA.%2BC.%26aulast%3DJayasekera%26aufirst%3DG.%26aulast%3DJohnson%26aufirst%3DM.%2BK.%26aulast%3DMcGlinchey%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DS.%26aulast%3DWelsh%26aufirst%3DD.%2BJ.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DBarnes%26aufirst%3DG.%2BD.%26aulast%3DGibbs%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DL.%2BS.%2BG.%2BE.%26aulast%3DWatson%26aufirst%3DG.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26aulast%3DOnorato%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DStirrat%26aufirst%3DC.%26aulast%3DNewby%26aufirst%3DD.%2BE.%26atitle%3DShort-term%2520hemodynamic%2520effects%2520of%2520apelin%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJACC%2520Basic%2520Transl%2520Sci.%26date%3D2018%26volume%3D3%26spage%3D176%26epage%3D186%26doi%3D10.1016%2Fj.jacbts.2018.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walther, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengers, R. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laghmani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Folkerts, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pera, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenaar, G. T. M.</span></span> <span> </span><span class="NLM_article-title">Metformin attenuates hyperoxia-induced lung injury in neonatal rats by reducing the inflammatory response</span>. <i>Am. J. Physiol.: Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>309</i></span>,  <span class="NLM_fpage">L262</span>– <span class="NLM_lpage">L270</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00389.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1152%2Fajplung.00389.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26047641" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=L262-L270&author=X.+Y.+Chenauthor=F.+J.+Waltherauthor=R.+M.+A.+Sengersauthor=E.+Laghmaniauthor=A.+Salamauthor=G.+Folkertsauthor=T.+Peraauthor=G.+T.+M.+Wagenaar&title=Metformin+attenuates+hyperoxia-induced+lung+injury+in+neonatal+rats+by+reducing+the+inflammatory+response&doi=10.1152%2Fajplung.00389.2014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00389.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00389.2014%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BY.%26aulast%3DWalther%26aufirst%3DF.%2BJ.%26aulast%3DSengers%26aufirst%3DR.%2BM.%2BA.%26aulast%3DLaghmani%26aufirst%3DE.%26aulast%3DSalam%26aufirst%3DA.%26aulast%3DFolkerts%26aufirst%3DG.%26aulast%3DPera%26aufirst%3DT.%26aulast%3DWagenaar%26aufirst%3DG.%2BT.%2BM.%26atitle%3DMetformin%2520attenuates%2520hyperoxia-induced%2520lung%2520injury%2520in%2520neonatal%2520rats%2520by%2520reducing%2520the%2520inflammatory%2520response%26jtitle%3DAm.%2520J.%2520Physiol.%253A%2520Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2015%26volume%3D309%26spage%3DL262%26epage%3DL270%26doi%3D10.1152%2Fajplung.00389.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sartoretto, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melo, G. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, M. H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passaglia, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scavone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuman, R. K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortes, Z. B.</span></span> <span> </span><span class="NLM_article-title">Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2676</span>– <span class="NLM_lpage">2689</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2005.05.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.lfs.2005.05.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=15964597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpvFersrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=2676-2689&author=J.+L.+Sartorettoauthor=G.+A.+N.+Meloauthor=M.+H.+C.+Carvalhoauthor=D.+Nigroauthor=R.+T.+Passagliaauthor=C.+Scavoneauthor=R.+K.+N.+Cumanauthor=Z.+B.+Fortes&title=Metformin+treatment+restores+the+altered+microvascular+reactivity+in+neonatal+streptozotocin-induced+diabetic+rats+increasing+NOS+activity%2C+but+not+NOS+expression&doi=10.1016%2Fj.lfs.2005.05.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression</span></div><div class="casAuthors">Sartoretto, Juliano Luiz; Melo, Gessilda A. N.; Carvalho, Maria H. C.; Nigro, Dorothy; Passaglia, Rita T.; Scavone, Cristoforo; Cuman, Roberto K. N.; Fortes, Zuleica B.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2676-2689</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Abnormalities in vascular function are well recognized in diabetes.  Hyperglycemia may be central to the pathogenesis of vascular dysfunction but is not certain whether improvements in glycemic control will improve vascular function.  The effects of metformin, an antidiabetic agent that improves insulin sensitivity and glycemic control, on the microvascular reactivity have not been reported in neonatal streptozotocin-induced (n-STZ) diabetes.  Diabetes was induced by STZ injection (160 mg/kg, i.p.) in neonates (2-day-old) Wistar rats.  N-STZ diabetic rats were treated with metformin (300 mg/kg, 15 d, by gavage).  Using intravital microscopy the changes in mesenteric arteriolar and venular diams. were detd. in anesthetized control and n-STZ diabetic rats, before and after topical application of endothelium-dependent vasodilator agents, mediators or not of the inflammatory response, and endothelium-independent vasodilator agent.  We also detd. the total nitric oxide synthase (NOS) activity (conversion of -arginine to citrulline) and endothelial(e), inducible(i), and neuronal(n) NOS expression (using polymerase chain reaction after reverse transcription of the mRNAs into cDNAs) in the mesentery of metformin-treated n-STZ diabetic and vehicle-treated n-STZ diabetic and control rats.  Although metformin treatment did not correct the high glycemic levels and the impaired glucose tolerance, the reduced vasodilator responses and total NOS activity in n-STZ diabetic rats were cor. by the treatment.  Neither diabetes nor metformin treatment altered the expression of the three NOS isoforms.  We concluded that metformin restores the reduced response to vasodilator agents, independently of the correction of the metabolic alterations.  Improvement of total NOS activity might be in part responsible for the correction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBpo7orSU5Y7Vg90H21EOLACvtfcHk0liX3510AEEj_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpvFersrc%253D&md5=b4d0f631cfd2a3426fec47526955a052</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2005.05.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2005.05.022%26sid%3Dliteratum%253Aachs%26aulast%3DSartoretto%26aufirst%3DJ.%2BL.%26aulast%3DMelo%26aufirst%3DG.%2BA.%2BN.%26aulast%3DCarvalho%26aufirst%3DM.%2BH.%2BC.%26aulast%3DNigro%26aufirst%3DD.%26aulast%3DPassaglia%26aufirst%3DR.%2BT.%26aulast%3DScavone%26aufirst%3DC.%26aulast%3DCuman%26aufirst%3DR.%2BK.%2BN.%26aulast%3DFortes%26aufirst%3DZ.%2BB.%26atitle%3DMetformin%2520treatment%2520restores%2520the%2520altered%2520microvascular%2520reactivity%2520in%2520neonatal%2520streptozotocin-induced%2520diabetic%2520rats%2520increasing%2520NOS%2520activity%252C%2520but%2520not%2520NOS%2520expression%26jtitle%3DLife%2520Sci.%26date%3D2005%26volume%3D77%26spage%3D2676%26epage%3D2689%26doi%3D10.1016%2Fj.lfs.2005.05.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loughlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salt, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, M. R.</span></span> <span> </span><span class="NLM_article-title">Metformin reverses development of pulmonary hypertension via aromatase inhibition</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.116.07353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FHYPERTENSIONAHA.116.07353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27296990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=446-454&author=A.+Deanauthor=M.+Nilsenauthor=L.+Loughlinauthor=I.+P.+Saltauthor=M.+R.+MacLean&title=Metformin+reverses+development+of+pulmonary+hypertension+via+aromatase+inhibition&doi=10.1161%2FHYPERTENSIONAHA.116.07353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin Reverses Development of Pulmonary Hypertension via Aromatase Inhibition</span></div><div class="casAuthors">Dean, Afshan; Nilsen, Margaret; Loughlin, Lynn; Salt, Ian P.; MacLean, Margaret R.</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">446-454</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Females are more susceptible to pulmonary arterial hypertension than males, although the reasons remain unclear.  The hypoglycemic drug, metformin, is reported to have multiple actions, including the inhibition of aromatase and stimulation of AMP-activated protein kinase.  Inhibition of aromatase using anastrazole is protective in exptl. pulmonary hypertension but whether metformin attenuates pulmonary hypertension through this mechanism remains unknown.  We investigated whether metformin affected aromatase activity and if it could reduce the development of pulmonary hypertension in the sugen 5416/hypoxic rat model.  We also investigated its influence on proliferation in human pulmonary arterial smooth muscle cells.  Metformin reversed right ventricular systolic pressure, right ventricular hypertrophy, and decreased pulmonary vascular remodeling in the rat.  Furthermore, metformin increased rat lung AMP-activated protein kinase signaling, decreased lung and circulating estrogen levels, levels of aromatase, the estrogen metabolizing enzyme; cytochrome P 450 1B1 and its transcription factor; the aryl hydrocarbon receptor.  In human pulmonary arterial smooth muscle cells, metformin decreased proliferation and decreased estrogen synthesis by decreasing aromatase activity through the PII promoter site of Cyp19a1.  Thus, we report for the first time that metformin can reverse pulmonary hypertension through inhibition of aromatase and estrogen synthesis in a manner likely to be mediated by AMP-activated protein kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_x4Ml4x6vHLVg90H21EOLACvtfcHk0liX3510AEEj_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmsrfJ&md5=218ae77676c664641b751d24823082d5</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.116.07353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.116.07353%26sid%3Dliteratum%253Aachs%26aulast%3DDean%26aufirst%3DA.%26aulast%3DNilsen%26aufirst%3DM.%26aulast%3DLoughlin%26aufirst%3DL.%26aulast%3DSalt%26aufirst%3DI.%2BP.%26aulast%3DMacLean%26aufirst%3DM.%2BR.%26atitle%3DMetformin%2520reverses%2520development%2520of%2520pulmonary%2520hypertension%2520via%2520aromatase%2520inhibition%26jtitle%3DHypertension%26date%3D2016%26volume%3D68%26spage%3D446%26epage%3D454%26doi%3D10.1161%2FHYPERTENSIONAHA.116.07353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolli-Derkinderen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumas-de-La-Roque, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savineau, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loirand, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacaud, P.</span></span> <span> </span><span class="NLM_article-title">Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">1285</span>– <span class="NLM_lpage">1294</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2009.00445.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1111%2Fj.1476-5381.2009.00445.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=19814724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSksL7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2009&pages=1285-1294&author=C.+Agardauthor=M.+Rolli-Derkinderenauthor=E.+Dumas-de-La-Roqueauthor=M.+Rioauthor=C.+Saganauthor=J.+P.+Savineauauthor=G.+Loirandauthor=P.+Pacaud&title=Protective+role+of+the+antidiabetic+drug+metformin+against+chronic+experimental+pulmonary+hypertension&doi=10.1111%2Fj.1476-5381.2009.00445.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Protective role of the antidiabetic drug metformin against chronic experimental pulmonary hypertension</span></div><div class="casAuthors">Agard, C.; Rolli-Derkinderen, M.; Dumas-de-La-Roque, E.; Rio, M.; Sagan, C.; Savineau, J. P.; Loirand, G.; Pacaud, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1285-1294</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is assocd. with increased contraction and proliferation of pulmonary vascular smooth muscle cells.  The anti-diabetic drug metformin has been shown to have relaxant and anti-proliferation properties.  We thus examd. the effect of metformin in PAH.  Metformin effects were analyzed in hypoxia- and monocrotaline-induced PAH in rats.  Ex vivo and in vitro analyses were performed in lungs, pulmonary artery rings and cells.  In hypoxia- and monocrotaline-induced PAH, the changes in mean pulmonary arterial pressure and right heart hypertrophy were nearly normalized by metformin treatment (100 mg/kg-1/day-1).  Pulmonary arterial remodelling occurring in both exptl. models of PAH was also inhibited by metformin treatment.  In rats with monocrotaline-induced PAH, treatment with metformin significantly increased survival.  Metformin increased endothelial nitric oxide synthase phosphorylation and decreased Rho kinase activity in pulmonary artery from rats with PAH.  These effects are assocd. with an improvement of carbachol-induced relaxation and redn. of phenylephrine-induced contraction of pulmonary artery.  In addn., metformin inhibited mitogen-activated protein kinase activation and strongly reduced pulmonary arterial cell proliferation during PAH.  In vitro, metformin directly inhibited pulmonary artery smooth muscle cell growth.  Metformin protected against PAH, regardless of the initiating stimulus.  This protective effect may be related to its anti-remodelling property involving improvement of endothelial function, vasodilatory and anti-proliferative actions.  As metformin is currently prescribed to treat diabetic patients, assessment of its use as a therapy against PAH in humans should be easier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwTjiKlQR3ObVg90H21EOLACvtfcHk0liEu2MMuOKGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSksL7N&md5=efa7ad4365379282cfcc38e4a76dd9da</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2009.00445.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2009.00445.x%26sid%3Dliteratum%253Aachs%26aulast%3DAgard%26aufirst%3DC.%26aulast%3DRolli-Derkinderen%26aufirst%3DM.%26aulast%3DDumas-de-La-Roque%26aufirst%3DE.%26aulast%3DRio%26aufirst%3DM.%26aulast%3DSagan%26aufirst%3DC.%26aulast%3DSavineau%26aufirst%3DJ.%2BP.%26aulast%3DLoirand%26aufirst%3DG.%26aulast%3DPacaud%26aufirst%3DP.%26atitle%3DProtective%2520role%2520of%2520the%2520antidiabetic%2520drug%2520metformin%2520against%2520chronic%2520experimental%2520pulmonary%2520hypertension%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2009%26volume%3D158%26spage%3D1285%26epage%3D1294%26doi%3D10.1111%2Fj.1476-5381.2009.00445.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0liEu2MMuOKGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncharov, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudryashova, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihida-Stansbury, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLisser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krymskaya, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuder, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawut, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncharova, E. A.</span></span> <span> </span><span class="NLM_article-title">Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">864</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.113.004581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.113.004581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24270265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlShsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2014&pages=864-874&author=D.+A.+Goncharovauthor=T.+V.+Kudryashovaauthor=H.+Ziaiauthor=K.+Ihida-Stansburyauthor=H.+DeLisserauthor=V.+P.+Krymskayaauthor=R.+M.+Tuderauthor=S.+M.+Kawutauthor=E.+A.+Goncharova&title=Mammalian+target+of+rapamycin+complex+2+%28mTORC2%29+coordinates+pulmonary+artery+smooth+muscle+cell+metabolism%2C+proliferation%2C+and+survival+in+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.113.004581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian Target of Rapamycin Complex 2 (mTORC2) Coordinates Pulmonary Artery Smooth Muscle Cell Metabolism, Proliferation, and Survival in Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Goncharov, Dmitry A.; Kudryashova, Tatiana V.; Ziai, Houman; Ihida-Stansbury, Kaori; De Lisser, Horace; Krymskaya, Vera P.; Tuder, Rubin M.; Kawut, Steven M.; Goncharova, Elena A.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">864-874</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND: Enhanced proliferation, resistance to apoptosis, and metabolic shift to glycolysis of pulmonary arterial vascular smooth muscle cells (PAVSMCs) are key pathophysiol. components of pulmonary vascular remodeling in idiopathic pulmonary arterial hypertension (PAH).  The role of the distinct mammalian target of rapamycin (mTOR) complexes mTORC1 (mTOR-Raptor) and mTORC2 (mTOR-Rictor) in PAVSMC proliferation and survival in PAH and their therapeutic relevance are unknown.  METHODS AND RESULTS: Immunohistochem. and immunoblot analyses revealed that mTORC1 and mTORC2 pathways are markedly upregulated in small remodeled pulmonary arteries and isolated distal PAVSMCs from subjects with idiopathic PAH that have increased ATP levels, proliferation, and survival that depend on glycolytic metab.  Small interfering RNA- and pharmacol.-based anal. showed that although both mTORC1 and mTORC2 contribute to proliferation, only mTORC2 is required for ATP generation and survival of idiopathic PAH PAVSMCs.  MTORC2 downregulated the energy sensor AMP-activated protein kinase, which led to activation of mTORC1-S6 and increased proliferation, as well as a deficiency of the proapoptotic protein Bim and idiopathic PAH PAVSMC survival.  NADPH oxidase 4 (Nox4) protein levels were increased in idiopathic PAH PAVSMCs, which was necessary for mTORC2 activation, proliferation, and survival.  Nox4 levels and mTORC2 signaling were significantly upregulated in small pulmonary arteries from hypoxia-exposed rats at days 2 to 28 of hypoxia.  Treatment with the mTOR kinase inhibitor PP242 at days 15 to 28 suppressed mTORC2 but not Nox4, induced smooth muscle-specific apoptosis in small pulmonary arteries, and reversed hypoxia-induced pulmonary vascular remodeling in rats.  CONCLUSIONS: These data provide a novel mechanistic link of Nox4-dependent activation of mTORC2 via the energy sensor AMP-activated protein kinase to increased proliferation and survival of PAVSMCs in PAH, which suggests a new potential pathway for therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruk0h6H0v-47Vg90H21EOLACvtfcHk0liEu2MMuOKGww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlShsLY%253D&md5=7f796541aa267234775122dc776e5340</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.113.004581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.113.004581%26sid%3Dliteratum%253Aachs%26aulast%3DGoncharov%26aufirst%3DD.%2BA.%26aulast%3DKudryashova%26aufirst%3DT.%2BV.%26aulast%3DZiai%26aufirst%3DH.%26aulast%3DIhida-Stansbury%26aufirst%3DK.%26aulast%3DDeLisser%26aufirst%3DH.%26aulast%3DKrymskaya%26aufirst%3DV.%2BP.%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DKawut%26aufirst%3DS.%2BM.%26aulast%3DGoncharova%26aufirst%3DE.%2BA.%26atitle%3DMammalian%2520target%2520of%2520rapamycin%2520complex%25202%2520%2528mTORC2%2529%2520coordinates%2520pulmonary%2520artery%2520smooth%2520muscle%2520cell%2520metabolism%252C%2520proliferation%252C%2520and%2520survival%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2014%26volume%3D129%26spage%3D864%26epage%3D874%26doi%3D10.1161%2FCIRCULATIONAHA.113.004581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paddenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Lilien, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faulhammer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillmanns, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun-Dullaeus, R. C.</span></span> <span> </span><span class="NLM_article-title">Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-8-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2F1465-9921-8-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=17319968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD2s7lslChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=15&author=R.+Paddenbergauthor=P.+Stiegerauthor=A.+L.+von+Lilienauthor=P.+Faulhammerauthor=A.+Goldenbergauthor=H.+H.+Tillmannsauthor=W.+Kummerauthor=R.+C.+Braun-Dullaeus&title=Rapamycin+attenuates+hypoxia-induced+pulmonary+vascular+remodeling+and+right+ventricular+hypertrophy+in+mice&doi=10.1186%2F1465-9921-8-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice</span></div><div class="casAuthors">Paddenberg Renate; Stieger Philipp; von Lilien Anna-Laura; Faulhammer Petra; Goldenberg Anna; Tillmanns Harald H; Kummer Wolfgang; Braun-Dullaeus Ruediger C</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic hypoxia induces pulmonary arterial hypertension (PAH).  Smooth muscle cell (SMC) proliferation and hypertrophy are important contributors to the remodeling that occurs in chronic hypoxic pulmonary vasculature.  We hypothesized that rapamycin (RAPA), a potent cell cycle inhibitor, prevents pulmonary hypertension in chronic hypoxic mice.  METHODS:  Mice were held either at normoxia (N; 21% O2) or at hypobaric hypoxia (H; 0.5 atm; ~10% O2).  RAPA-treated animals (3 mg/kg*d, i.p.) were compared to animals injected with vehicle alone.  Proliferative activity within the pulmonary arteries was quantified by staining for Ki67 (positive nuclei/vessel) and media area was quantified by computer-aided planimetry after immune-labeling for alpha-smooth muscle actin (pixel/vessel).  The ratio of right ventricle to left ventricle plus septum (RV/[LV+S]) was used to determine right ventricular hypertrophy.  RESULTS:  Proliferative activity increased by 34% at day 4 in mice held under H (median: 0.38) compared to N (median: 0.28, p = 0.028) which was completely blocked by RAPA (median HO+RAPA: 0.23, p = 0.003).  H-induced proliferation had leveled off within 3 weeks.  At this time point media area had, however, increased by 53% from 91 (N) to 139 (H, p < 0.001) which was prevented by RAPA (H+RAPA: 102; p < 0.001).  RV/[LV+S] ratio which had risen from 0.17 (N) to 0.26 (H, p < 0.001) was attenuated in the H+RAPA group (0.22, p = 0.041).  For a therapeutic approach animals were exposed to H for 21 days followed by 21 days in H +/- RAPA.  Forty two days of H resulted in a media area of 129 (N: 83) which was significantly attenuated in RAPA-treated mice (H+RAPA: 92).  RV/[LV+S] ratios supported prevention of PH (N 0.13; H 0.27; H+RAPA 0.17).  RAPA treatment of N mice did not influence any parameter examined.  CONCLUSION:  Therapy with rapamycin may represent a new strategy for the treatment of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGyRcywODD80PI-fCgwosgfW6udTcc2eZk--Hi9Q2jXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s7lslChsQ%253D%253D&md5=4e2cdad1e0fccddfa68f40661b08a7cd</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-8-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-8-15%26sid%3Dliteratum%253Aachs%26aulast%3DPaddenberg%26aufirst%3DR.%26aulast%3DStieger%26aufirst%3DP.%26aulast%3Dvon%2BLilien%26aufirst%3DA.%2BL.%26aulast%3DFaulhammer%26aufirst%3DP.%26aulast%3DGoldenberg%26aufirst%3DA.%26aulast%3DTillmanns%26aufirst%3DH.%2BH.%26aulast%3DKummer%26aufirst%3DW.%26aulast%3DBraun-Dullaeus%26aufirst%3DR.%2BC.%26atitle%3DRapamycin%2520attenuates%2520hypoxia-induced%2520pulmonary%2520vascular%2520remodeling%2520and%2520right%2520ventricular%2520hypertrophy%2520in%2520mice%26jtitle%3DRespir.%2520Res.%26date%3D2007%26volume%3D8%26spage%3D15%26doi%3D10.1186%2F1465-9921-8-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bru-Mercier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courboulin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quatredeniers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucker-Martin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antigny, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakhleh, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranchoux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouadon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinhas, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vocelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fadel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen-Kaminsky, S.</span></span> <span> </span><span class="NLM_article-title">NMDA-type glutamate receptor activation promotes vascular remodeling and pulmonary arterial hypertension</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">2371</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1161/CIRCULATIONAHA.117.029930</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1161%2FCIRCULATIONAHA.117.029930" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29444988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVagsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2018&pages=2371-2389&author=S.+J.+Dumasauthor=G.+Bru-Mercierauthor=A.+Courboulinauthor=M.+Quatredeniersauthor=C.+Rucker-Martinauthor=F.+Antignyauthor=M.+K.+Nakhlehauthor=B.+Ranchouxauthor=E.+Gouadonauthor=M.+C.+Vinhasauthor=M.+Vocelleauthor=N.+Raymondauthor=P.+Dorfmullerauthor=E.+Fadelauthor=F.+Perrosauthor=M.+Humbertauthor=S.+Cohen-Kaminsky&title=NMDA-type+glutamate+receptor+activation+promotes+vascular+remodeling+and+pulmonary+arterial+hypertension&doi=10.1161%2FCIRCULATIONAHA.117.029930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Dumas, Sebastien J.; Bru-Mercier, Gilles; Courboulin, Audrey; Quatredeniers, Marceau; Ruecker-Martin, Catherine; Antigny, Fabrice; Nakhleh, Morad K.; Ranchoux, Benoit; Gouadon, Elodie; Vinhas, Maria-Candida; Vocelle, Matthieu; Raymond, Nicolas; Dorfmueller, Peter; Fadel, Elie; Perros, Frederic; Humbert, Marc; Cohen-Kaminsky, Sylvia</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2371-2389</span>CODEN:
                <span class="NLM_cas:coden">CIRCAZ</span>;
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Excessive proliferation and apoptosis resistance in pulmonary vascular cells underlie vascular remodeling in pulmonary arterial hypertension (PAH).  Specific treatments for PAH exist, mostly targeting endothelial dysfunction, but high pulmonary arterial pressure still causes heart failure and death.  Pulmonary vascular remodeling may be driven by metabolic reprogramming of vascular cells to increase glutaminolysis and glutamate prodn.  The N-methyl-D-aspartate receptor (NMDAR), a major neuronal glutamate receptor, is also expressed on vascular cells, but its role in PAH is unknown.  Methods: We assessed the status of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and controls through mass spectrometry imaging, Western blotting, and immunohistochem.  We measured the glutamate release from cultured pulmonary vascular cells using enzymic assays and analyzed NMDAR regulation/phosphorylation through Western blot expts.  The effect of NMDAR blockade on human pulmonary arterial smooth muscle cell proliferation was detd. using a BrdU incorporation assay.  We assessed the role of NMDARs in vascular remodeling assocd. to pulmonary hypertension, in both smooth muscle-specific NMDAR knockout mice exposed to chronic hypoxia and the monocrotaline rat model of pulmonary hypertension using NMDAR blockers.  Results: We report glutamate accumulation, upregulation of the NMDAR, and NMDAR engagement reflected by increases in GluN1-subunit phosphorylation in the pulmonary arteries of human patients with PAH.  Kv channel inhibition and type A-selective endothelin receptor activation amplified calcium-dependent glutamate release from human pulmonary arterial smooth muscle cell, and type A-selective endothelin receptor and platelet-derived growth factor receptor activation led to NMDAR engagement, highlighting crosstalk between the glutamate-NMDAR axis and major PAH-assocd. pathways.  The platelet-derived growth factor-BB-induced proliferation of human pulmonary arterial smooth muscle cells involved NMDAR activation and phosphorylated GluN1 subunit localization to cell-cell contacts, consistent with glutamatergic communication between proliferating human pulmonary arterial smooth muscle cells via NMDARs.  Smooth-muscle NMDAR deficiency in mice attenuated the vascular remodeling triggered by chronic hypoxia, highlighting the role of vascular NMDARs in pulmonary hypertension.  Pharmacol. NMDAR blockade in the monocrotaline rat model of pulmonary hypertension had beneficial effects on cardiac and vascular remodeling, decreasing endothelial dysfunction, cell proliferation, and apoptosis resistance while disrupting the glutamate-NMDAR pathway in pulmonary arteries.  Conclusions: These results reveal a dysregulation of the glutamate-NMDAR axis in the pulmonary arteries of patients with PAH and identify vascular NMDARs as targets for antiremodeling treatments in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTWbl26iE6Q7Vg90H21EOLACvtfcHk0lhQs18_g_xG3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVagsrbJ&md5=a515464a510fe449334c29bc5b8330ae</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1161%2FCIRCULATIONAHA.117.029930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCULATIONAHA.117.029930%26sid%3Dliteratum%253Aachs%26aulast%3DDumas%26aufirst%3DS.%2BJ.%26aulast%3DBru-Mercier%26aufirst%3DG.%26aulast%3DCourboulin%26aufirst%3DA.%26aulast%3DQuatredeniers%26aufirst%3DM.%26aulast%3DRucker-Martin%26aufirst%3DC.%26aulast%3DAntigny%26aufirst%3DF.%26aulast%3DNakhleh%26aufirst%3DM.%2BK.%26aulast%3DRanchoux%26aufirst%3DB.%26aulast%3DGouadon%26aufirst%3DE.%26aulast%3DVinhas%26aufirst%3DM.%2BC.%26aulast%3DVocelle%26aufirst%3DM.%26aulast%3DRaymond%26aufirst%3DN.%26aulast%3DDorfmuller%26aufirst%3DP.%26aulast%3DFadel%26aufirst%3DE.%26aulast%3DPerros%26aufirst%3DF.%26aulast%3DHumbert%26aufirst%3DM.%26aulast%3DCohen-Kaminsky%26aufirst%3DS.%26atitle%3DNMDA-type%2520glutamate%2520receptor%2520activation%2520promotes%2520vascular%2520remodeling%2520and%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DCirculation%26date%3D2018%26volume%3D137%26spage%3D2371%26epage%3D2389%26doi%3D10.1161%2FCIRCULATIONAHA.117.029930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel hybridization from isosorbide 5-mononitrate and bardoxolone methyl with dual activities of pulmonary vasodilation and vascular remodeling inhibition on pulmonary arterial hypertension rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1474</span>– <span class="NLM_lpage">1482</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVGls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1474-1482&author=Y.+Chengauthor=Y.+Gongauthor=S.+Qianauthor=Y.+Mouauthor=H.+Liauthor=X.+Chenauthor=H.+Kongauthor=W.+Xieauthor=H.+Wangauthor=Y.+Zhangauthor=Z.+Huang&title=Identification+of+a+novel+hybridization+from+isosorbide+5-mononitrate+and+bardoxolone+methyl+with+dual+activities+of+pulmonary+vasodilation+and+vascular+remodeling+inhibition+on+pulmonary+arterial+hypertension+rats&doi=10.1021%2Facs.jmedchem.7b01153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats</span></div><div class="casAuthors">Cheng, Yusheng; Gong, Yan; Qian, Shuai; Mou, Yi; Li, Hanrui; Chen, Xijing; Kong, Hui; Xie, Weiping; Wang, Hong; Zhang, Yihua; Huang, Zhangjian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1474-1482</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Given the clin. therapeutic efficacy of oral-dosed bardoxolone Me (1) and the selective vasodilatory effect caused by inhalation of nitric oxide (NO) on pulmonary arterial hypertension (PAH) patients, a new hybrid (CDDO-NO, 2) from 1 and NO donor isosorbide 5-mononitrate (3) was designed and synthesized.  This hybrid could liberate 1 and NO in the lungs of rats after trachea injection.  Significantly, 2 lowered mean pulmonary artery pressure (mPAP) and right ventricular systolic pressure (RVSP), decreased right ventricular hypertrophy (RVH), and attenuated pulmonary artery medial thickness (PAMT) and vascular muscularization in monocrotaline (MCT)-induced PAH rats.  Meanwhile, 2 inhibited overproliferation of perivascular cells and diminished macrophage infiltration and oxidative stress by inactivation of NOX4.  In addn., 2 markedly reduced cardiac hypertrophy and fibrosis in the PAH rats.  Overall, 2 exhibited potent dual activities of pulmonary vasodilation and vascular remodeling inhibition, suggesting that it may be a promising agent for PAH intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokAmpHGp1f87Vg90H21EOLACvtfcHk0lhsSp_G0LjTvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVGls70%253D&md5=1c6572d25d398bfbdc35173e9b59a377</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01153%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DS.%26aulast%3DMou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKong%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DIdentification%2520of%2520a%2520novel%2520hybridization%2520from%2520isosorbide%25205-mononitrate%2520and%2520bardoxolone%2520methyl%2520with%2520dual%2520activities%2520of%2520pulmonary%2520vasodilation%2520and%2520vascular%2520remodeling%2520inhibition%2520on%2520pulmonary%2520arterial%2520hypertension%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1474%26epage%3D1482%26doi%3D10.1021%2Facs.jmedchem.7b01153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pyrazolo[3,4-b] pyridine derivatives with dual activities of vascular remodeling inhibition and vasodilation for the treatment of pulmonary arterial hypertension</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">11215</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVWhtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=11215&author=L.+Huauthor=L.+Liauthor=Q.+Changauthor=S.+Fuauthor=J.+Qinauthor=Z.+Chenauthor=X.+Liauthor=Q.+Liuauthor=G.+Huauthor=Q.+Li&title=Discovery+of+novel+pyrazolo%5B3%2C4-b%5D+pyridine+derivatives+with+dual+activities+of+vascular+remodeling+inhibition+and+vasodilation+for+the+treatment+of+pulmonary+arterial+hypertension&doi=10.1021%2Facs.jmedchem.0c01132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Pyrazolo[3,4-b]Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension</span></div><div class="casAuthors">Hu, Liqing; Li, Lijun; Chang, Qi; Fu, Songsen; Qin, Jia; Chen, Zhuo; Li, Xiaohui; Liu, Qinglian; Hu, Gaoyun; Li, Qianbin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">11215-11234</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Current pulmonary arterial hypertension (PAH) therapeutic strategies mainly focus on vascular relaxation with less emphasis on vascular remodeling, which results in poor prognosis.  Hence, dual pathway regulators with vasodilation effect via sol. guanylate cyclase (sGC) stimulation and vascular remodeling regulation effect by AMP-activated protein kinase (AMPK) inhibition provide more advantages and potentialities.  Herein, we designed and synthesized a series of novel pyrazolo[3,4-b]pyridine derivs. based on sGC stimulator and AMPK inhibitor scaffolds.  In vitro, 2 exhibited moderate vasodilation activity and higher proliferation and migration suppressive effects compared to riociguat.  In vivo, 2 significantly decreased right ventricular systolic pressure (RVSP), attenuated pulmonary artery medial thickness (PAMT), and right ventricular hypertrophy (RVH) in hypoxia-induced PAH rat models (i.g.).  Given the unique advantages of significant vascular remodeling inhibition and moderate vascular relaxation based on the dual pathway regulation, we proposed 2 as a promising lead for anti-PAH drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxCtw-vcP3wrVg90H21EOLACvtfcHk0lhsSp_G0LjTvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVWhtr%252FJ&md5=1d1fa972aeb8b6e08b0ac40c8e4d0f57</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01132%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DQin%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520novel%2520pyrazolo%255B3%252C4-b%255D%2520pyridine%2520derivatives%2520with%2520dual%2520activities%2520of%2520vascular%2520remodeling%2520inhibition%2520and%2520vasodilation%2520for%2520the%2520treatment%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D11215%26doi%3D10.1021%2Facs.jmedchem.0c01132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. J.</span></span> <span> </span><span class="NLM_article-title">Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2012-0071OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1165%2Frcmb.2012-0071OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23065131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Kntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=125-134&author=J.+Wangauthor=Q.+Jiangauthor=L.+M.+Wanauthor=K.+Yangauthor=Y.+Zhangauthor=Y.+Q.+Chenauthor=E.+Wangauthor=N.+Laiauthor=L.+Zhaoauthor=H.+Jiangauthor=Y.+Q.+Sunauthor=N.+S.+Zhongauthor=P.+X.+Ranauthor=W.+J.+Lu&title=Sodium+tanshinone+IIA+sulfonate+inhibits+canonical+transient+receptor+potential+expression+in+pulmonary+arterial+smooth+muscle+from+pulmonary+hypertensive+rats&doi=10.1165%2Frcmb.2012-0071OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats</span></div><div class="casAuthors">Wang, Jian; Jiang, Qian; Wan, Limei; Yang, Kai; Zhang, Yi; Chen, Yuqin; Wang, Elizabeth; Lai, Ning; Zhao, Lei; Jiang, Hua; Sun, Yueqian; Zhong, Nanshan; Ran, Pixin; Lu, Wenju</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Danshen, the dried root of Salvia miltiorrhiza, is widely used in clinics in China for treating various diseases, including cardiovascular diseases.  Sodium tanshinone IIA sulfonate (STS), a water-sol. deriv. of tanshinone IIA isolated as the major active component from Danshen, was recently reported to be effective in attenuating the characteristic pulmonary vascular changes assocd. with chronically hypoxic pulmonary hypertension (CHPH); however, the underlying detailed mechanisms are poorly understood.  In this study, we investigated the effects of STS on basal intracellular Ca2+ concn. ([Ca2+]i) and store-operated Ca2+ entry (SOCE) in distal pulmonary arterial smooth muscle cells (PASMCs) exposed to prolonged hypoxia or isolated from CHPH rats.  SOCE measured by Mn2+ quenching of Fura-2 fluorescence in PASMCs from rats exposed to chronic hypoxia (10% O2, 21 d) was increased by 59%, and basal [Ca2+]i was increased by 119%; this effect was inhibited by i.p. injection of STS.  These inhibitory effects of STS on hypoxic increases of SOCE and basal [Ca2+]i were assocd. with reduced expression of canonical transient receptor potential (TRPC)1 and TRPC6 in distal pulmonary arterial smooth muscle and decreases on right ventricular pressure, right ventricular hypertrophy, and peripheral pulmonary vessel thickening.  In ex vivo cultured distal PASMCs from normoxic rats, STS (0-25 μM) dose-dependently inhibited hypoxia-induced cell proliferation and migration, paralleled with attenuation in increases of basal [Ca2+]i, SOCE, mRNA, and protein expression of TRPC1 and TRPC6.  STS also relieved right ventricular systolic pressure, right ventricular hypertrophy, and TRPC1 and TRPC6 protein expression in distal pulmonary arteries in a monocrotaline-induced rat model of pulmonary arterial hypertension.  These results indicate that STS prevents pulmonary arterial hypertension development likely by inhibiting TRPC1 and TRPC6 expression, resulting in normalized basal [Ca2+]i and attenuated proliferation and migration of PASMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocO4lRhKI0AbVg90H21EOLACvtfcHk0lhsSp_G0LjTvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Kntw%253D%253D&md5=ade066de6af0e4531fb20fa28c74705d</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2012-0071OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2012-0071OC%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWan%26aufirst%3DL.%2BM.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DWang%26aufirst%3DE.%26aulast%3DLai%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DY.%2BQ.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26aulast%3DRan%26aufirst%3DP.%2BX.%26aulast%3DLu%26aufirst%3DW.%2BJ.%26atitle%3DSodium%2520tanshinone%2520IIA%2520sulfonate%2520inhibits%2520canonical%2520transient%2520receptor%2520potential%2520expression%2520in%2520pulmonary%2520arterial%2520smooth%2520muscle%2520from%2520pulmonary%2520hypertensive%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2013%26volume%3D48%26spage%3D125%26epage%3D134%26doi%3D10.1165%2Frcmb.2012-0071OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span> <span> </span><span class="NLM_article-title">Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients</span>. <i>J. Thorac. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">172</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=23585945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC3srlt1CisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=169-172&author=J.+Wangauthor=W.+J.+Luauthor=W.+Wangauthor=N.+F.+Zhangauthor=H.+Wuauthor=C.+L.+Liuauthor=X.+Q.+Chenauthor=Y.+H.+Chenauthor=Y.+Q.+Chenauthor=Q.+Jiangauthor=L.+Xuauthor=L.+C.+Tianauthor=P.+X.+Ranauthor=N.+S.+Zhong&title=Promising+therapeutic+effects+of+sodium+tanshinone+IIA+sulfonate+towards+pulmonary+arterial+hypertension+in+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Promising therapeutic effects of sodium tanshinone IIA sulfonate towards pulmonary arterial hypertension in patients</span></div><div class="casAuthors">Wang Jian; Lu Wenju; Wang Wei; Zhang Nuofu; Wu Hua; Liu Chunli; Chen Xiuqing; Chen Yonghua; Chen Yuqin; Jiang Qian; Xu Lei; Tian Lichun; Ran Pixin; Zhong Nanshan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of thoracic disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-72</span>
        ISSN:<span class="NLM_cas:issn">2072-1439</span>.
    </div><div class="casAbstract">BACKGROUND:  Pulmonary hypertension (PH) is a lethal disease with no cure currently available.  Sodium Tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the major active component from salvia miltiorrhiza, a kind of Chinese herbal medicine.  We investigate the efficacy of STS towards treatment of PH patients.  METHODS AND RESULTS:  Five hospitalized patients were randomly enrolled for this study.  These patients were suffering from various types of serious PH without getting sufficient benefits from sildenafil treatment (20 mg tid) for at least three months.  The efficacy of STS on PH was evaluated by measuring the pulmonary arterial systolic pressure (PASP), RV size by echocardiography, 6-minute walking distance (6MWD), Borg dyspnea score, and WHO functional class of PH.  Patients aged from 17 to 46 (average 33±11) years old, pulmonary arterial systolic pressure (PASP) ranged from 60 to 140 mmHg, RV size ranged from 25 to 39 mm were included in study.  At the endpoint of observation for 8 weeks of STS infusion, they obtained reduction of PASP in the range of 14-45 (average 28.6±12.5) mmHg, RV size in the range of 0-10 (average 4.2±1.6).  All patients exhibited improved exercise capacity with an increase of 6MWD from 63 to 268 (average 138.4±40.7) meters, significantly reduced Borg dyspnea score from maximum 9 down to 1 or 0, and reduced WHO functional class of PH from III or IV down to II.  CONCLUSIONS:  These results indicate that STS exhibits remarkable beneficiary effects on treating PH patients either alone or in concert with sildenafil.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTmAHSB1C2JF3WEEzDrymxmfW6udTcc2eZmouZdY2qjjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srlt1CisQ%253D%253D&md5=2ac29f6ae8197f3a5aa510174cdb8716</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DN.%2BF.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DC.%2BL.%26aulast%3DChen%26aufirst%3DX.%2BQ.%26aulast%3DChen%26aufirst%3DY.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DL.%2BC.%26aulast%3DRan%26aufirst%3DP.%2BX.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26atitle%3DPromising%2520therapeutic%2520effects%2520of%2520sodium%2520tanshinone%2520IIA%2520sulfonate%2520towards%2520pulmonary%2520arterial%2520hypertension%2520in%2520patients%26jtitle%3DJ.%2520Thorac.%2520Dis.%26date%3D2013%26volume%3D5%26spage%3D169%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and clinical application of tetramethylpyrazine (an interesting natural compound isolated from ligusticum wallichii): Current status and perspective</span>. <i>Oxid. Med. Cell. Longevity</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">2124638</span>, <span class="refDoi"> DOI: 10.1155/2016/2124638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1155%2F2016%2F2124638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27668034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FitFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=2124638&author=Y.+K.+Zhaoauthor=Y.+Liuauthor=K.+J.+Chen&title=Mechanisms+and+clinical+application+of+tetramethylpyrazine+%28an+interesting+natural+compound+isolated+from+ligusticum+wallichii%29%3A+Current+status+and+perspective&doi=10.1155%2F2016%2F2124638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective</span></div><div class="casAuthors">Zhao Yingke; Liu Yue; Chen Keji</div><div class="citationInfo"><span class="NLM_cas:title">Oxidative medicine and cellular longevity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2124638</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Tetramethylpyrazine, a natural compound from Ligusticum wallichii (Chuan Xiong), has been extensively used in China for cardiovascular and cerebrovascular diseases for about 40 years.  Because of its effectiveness in multisystems, especially in cardiovascular, its pharmacological action, clinical application, and the structural modification have attracted broad attention.  In this paper its mechanisms of action, the clinical status, and synthetic derivatives will be reviewed briefly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnh5xfR2y40kGy1nwu7K2mfW6udTcc2eZmouZdY2qjjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FitFersw%253D%253D&md5=d75cf8fdc81fde0aa8e0ed3da7504af2</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1155%2F2016%2F2124638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F2124638%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%2BK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DK.%2BJ.%26atitle%3DMechanisms%2520and%2520clinical%2520application%2520of%2520tetramethylpyrazine%2520%2528an%2520interesting%2520natural%2520compound%2520isolated%2520from%2520ligusticum%2520wallichii%2529%253A%2520Current%2520status%2520and%2520perspective%26jtitle%3DOxid.%2520Med.%2520Cell.%2520Longevity%26date%3D2016%26volume%3D2016%26spage%3D2124638%26doi%3D10.1155%2F2016%2F2124638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naruse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y. F.</span></span> <span> </span><span class="NLM_article-title">Effects of tetramethylpyrazine, a Chinese medicine, on plasma endothelin-1 levels during acute pulmonary hypoxia in anesthetized dogs</span>. <i>J. Cardiovasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">S456</span>– <span class="NLM_lpage">S459</span>, <span class="refDoi"> DOI: 10.1097/00005344-199800001-00130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1097%2F00005344-199800001-00130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=9595511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1cXjtFartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1998&pages=S456-S459&author=W.+B.+Caoauthor=Z.+P.+Zengauthor=Y.+J.+Zhuauthor=W.+C.+Luoauthor=H.+Demuraauthor=M.+Naruseauthor=Y.+F.+Shi&title=Effects+of+tetramethylpyrazine%2C+a+Chinese+medicine%2C+on+plasma+endothelin-1+levels+during+acute+pulmonary+hypoxia+in+anesthetized+dogs&doi=10.1097%2F00005344-199800001-00130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of tetramethylpyrazine, a Chinese medicine, on plasma endothelin-1 levels during acute pulmonary hypoxia in anesthetized dogs</span></div><div class="casAuthors">Cao, Wei-Biao; Zeng, Zheng-Pei; Zhu, Yuan-Jue; Luo, Wei-Ci; Demura, Hiroshi; Naruse, Mitsuhide; Shi, Yi-Fan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">Suppl. 1, Endothelin V</span>),
    <span class="NLM_cas:pages">S456-S459</span>CODEN:
                <span class="NLM_cas:coden">JCPCDT</span>;
        ISSN:<span class="NLM_cas:issn">0160-2446</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Our study was designed to elucidate the effects of tetramethylpyrazine (TMP), a Chinese medicine, on plasma endothelin-1 (ET-1) levels in dogs with acute pulmonary alveolar hypoxia.  Anesthetized dogs were used under artificial ventilation with room air or a hypoxic gas mixt. (10% O2 and 90% N2) (n = 10) for 60 min.  Effects of TMP (80 mg/kg) were studied by i.v. injection of TMP before exposure to hypoxia (n = 8).  Mean pulmonary arterial pressure (PAPm), systemic arterial pressure (SAPm), right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and heart rate (HR) were measured.  The pulmonary vascular resistance (PVR) was calcd. by the equation of (PAPm-PCWP) × 8/CO.  Plasma ET-1 levels were detd. in the abdominal aorta and pulmonary artery by RIA.  The effects of TMP on PAP and plasma ET-1 level were evaluated by using percent increase in PAPm and the change of Da-pET (ΔET) before and after hypoxia.  Both PAPm and PVR were significantly elevated 5 min after acute hypoxia over a period of 60 min, whereas CO and PCWP did not change.  Plasma ET-1 levels in the abdominal aorta and Da-pET showed a significant increase.  Administration of TMP significantly decreased the hypoxia-induced increase in the PAPm, PVR, and ΔET.  These results suggest that TMP could be a useful therapeutic agent in the treatment of pulmonary hypertension induced by acute hypoxia through decrease of plasma ET-1 levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzZaZTgEs_7Vg90H21EOLACvtfcHk0lgCLeT_FQ9_eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtFartbc%253D&md5=c095548f63818356e292c59437c485ca</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1097%2F00005344-199800001-00130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005344-199800001-00130%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DW.%2BB.%26aulast%3DZeng%26aufirst%3DZ.%2BP.%26aulast%3DZhu%26aufirst%3DY.%2BJ.%26aulast%3DLuo%26aufirst%3DW.%2BC.%26aulast%3DDemura%26aufirst%3DH.%26aulast%3DNaruse%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%2BF.%26atitle%3DEffects%2520of%2520tetramethylpyrazine%252C%2520a%2520Chinese%2520medicine%252C%2520on%2520plasma%2520endothelin-1%2520levels%2520during%2520acute%2520pulmonary%2520hypoxia%2520in%2520anesthetized%2520dogs%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%26date%3D1998%26volume%3D31%26spage%3DS456%26epage%3DS459%26doi%3D10.1097%2F00005344-199800001-00130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, N. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Z. X.</span></span> <span> </span><span class="NLM_article-title">Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation</span>. <i>Chin. J. Appl. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">537</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2MfotVyisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2014&pages=532-537&author=E.+Z.+Fengauthor=S.+Y.+Yangauthor=N.+X.+Huangauthor=H.+Yinauthor=Y.+Zhangauthor=Z.+X.+Tian&title=Plasma+endothelin-1+and+nitric+oxide+correlate+with+ligustrazine+alleviation+of+pulmonary+artery+hypertension+in+patients+of+chronic+cor+pulmonale+from+high+altitude+plateau+during+acute+exacerbation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation</span></div><div class="casAuthors">Feng En-Zhi; Yang Sheng-Yue; Huang Ning-Xia; Yin He; Zhang Ying; Tian Zhong-Xin</div><div class="citationInfo"><span class="NLM_cas:title">Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">532-7</span>
        ISSN:<span class="NLM_cas:issn">1000-6834</span>.
    </div><div class="casAbstract">OBJECTIVE:  To explore the mechanisms involved in the ligustrazine alleviation of the pulmonary artery hypertension (PAH) in patients of chronic obstructive pulmonary disease (COPD) associated with chronic cor pulmonale (CCP) during exacerbation.  METHODS:  Seventy patients of COPD and CCP with acute exacerbation were randomly and equally divided into control group and treatment group.  The control group received standard treatment with antibiotics, antiasthmatic and expectorant medications, and oxygenation; and the ligustrazine treatment group received ligustrazine treatment (80 mg/d; i.v.; for 2 weeks) in addition to the standard treatment.  Before and at the end of 2 week treatment, the clinic responses of the two regimens were evaluated, plasma levels of endothelin-1 (ET-1) and nitric oxide (NO) were determined; arterial oxygen partial pressure (PaO2, mean pulmonary arterial pressure (mPAP), outflow tract of right ventricle (RVOT), and internal diameter of right ventricle (RV) were measured.  RESULTS:  Good clinic benefits were achieved in both the standard and ligustrazine regimens, plasma level of ET-1, values of mPAP, RV and RVOT decreased significantly, plasma level of NO and PaO2 values decreased (all P < 0.01 vs pre-treatment to all parameters).  Compared with the control group, ligustrazine greatly enhanced the clinic efficacy from 77.1% to 97.1% (P < 0.05), and also resulted in more significant changes of all these parameters (P < 0.01 vs control group for all parameters).  For both groups, the levels of plasma ET-1 were positively correlated with values of mPAP, RVOT, and RV (r = 0.710, 0.853, and 0.766, respectively, all P = 0.000), and negatively correlated with plasma NO and PaO2 (r = - 0.823, and - 0.752, respectively, all P = 0.000).  CONCLUSION:  Ligustrazine is effective in treating pulmonary artery hypertension during acute exacerbation of COPD and CCP in patients from the plateau area.  The observed changes in the plasma levels of NO and ET-1 in response to ligustrazine treatment suggest that ligustrazine may act through the selective effect on pulmonary blood vessels to enhance the synthesis and release of NO and suppress those of ET-1 from lung vascular endothelial cells, thus reducing pulmonary artery pressure and decreasing pulmonary arterial hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYL82f4RkqVjToTC3aBaesfW6udTcc2eZ2BMrpAjvvH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfotVyisA%253D%253D&md5=366a254a5f0286e5300c2717a56545c6</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DE.%2BZ.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DHuang%26aufirst%3DN.%2BX.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DZ.%2BX.%26atitle%3DPlasma%2520endothelin-1%2520and%2520nitric%2520oxide%2520correlate%2520with%2520ligustrazine%2520alleviation%2520of%2520pulmonary%2520artery%2520hypertension%2520in%2520patients%2520of%2520chronic%2520cor%2520pulmonale%2520from%2520high%2520altitude%2520plateau%2520during%2520acute%2520exacerbation%26jtitle%3DChin.%2520J.%2520Appl.%2520Physiol.%26date%3D2014%26volume%3D30%26spage%3D532%26epage%3D537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clifford, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howatson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, E. J.</span></span> <span> </span><span class="NLM_article-title">The potential benefits of red beetroot supplementation in health and disease</span>. <i>Nutrients</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2801</span>– <span class="NLM_lpage">2822</span>, <span class="refDoi"> DOI: 10.3390/nu7042801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fnu7042801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=25875121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotFKhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=2801-2822&author=T.+Cliffordauthor=G.+Howatsonauthor=D.+J.+Westauthor=E.+J.+Stevenson&title=The+potential+benefits+of+red+beetroot+supplementation+in+health+and+disease&doi=10.3390%2Fnu7042801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">The potential benefits of red beetroot supplementation in health and disease</span></div><div class="casAuthors">Clifford, Tom; Howatson, Glyn; West, Daniel J.; Stevenson, Emma J.</div><div class="citationInfo"><span class="NLM_cas:title">Nutrients</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2801-2822</span>CODEN:
                <span class="NLM_cas:coden">NUTRHU</span>;
        ISSN:<span class="NLM_cas:issn">2072-6643</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In recent years there has been a growing interest in the biol. activity of red beetroot (Beta vulgaris rubra) and its potential utility as a health promoting and disease preventing functional food.  As a source of nitrate, beetroot ingestion provides a natural means of increasing in vivo nitric oxide (NO) availability and has emerged as a potential strategy to prevent and manage pathologies assocd. with diminished NO bioavailability, notably hypertension and endothelial function.  Beetroot is also being considered as a promising therapeutic treatment in a range of clin. pathologies assocd. with oxidative stress and inflammation.  Its constituents, most notably the betalain pigments, display potent antioxidant, anti-inflammatory and chemo-preventive activity in vitro and in vivo.  The purpose of this review is to discuss beetroot's biol. activity and to evaluate evidence from studies that specifically investigated the effect of beetroot supplementation on inflammation, oxidative stress, cognition and endothelial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMfhI0Tw0fPrVg90H21EOLACvtfcHk0lg3_PghYITODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotFKhtLw%253D&md5=6f3d3b75aa8e2ee00520780249ed8e3d</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.3390%2Fnu7042801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnu7042801%26sid%3Dliteratum%253Aachs%26aulast%3DClifford%26aufirst%3DT.%26aulast%3DHowatson%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DD.%2BJ.%26aulast%3DStevenson%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520potential%2520benefits%2520of%2520red%2520beetroot%2520supplementation%2520in%2520health%2520and%2520disease%26jtitle%3DNutrients%26date%3D2015%26volume%3D7%26spage%3D2801%26epage%3D2822%26doi%3D10.3390%2Fnu7042801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Henrohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkstrand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundberg, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granstam, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingimarsdottir, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedenstrom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinovschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernroth, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedeland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wikstrom, G.</span></span> <span> </span><span class="NLM_article-title">Effects of oral supplementation with nitrate-rich beetroot juice in patients with pulmonary arterial hypertension- results from BEET-PAH, an exploratory randomized, double-blind, placebo-controlled, crossover study</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">653</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2018.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cardfail.2018.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30244181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=640-653&author=D.+Henrohnauthor=K.+Bjorkstrandauthor=J.+O.+Lundbergauthor=S.-O.+Granstamauthor=T.+Baronauthor=I.+J.+Ingimarsdottirauthor=H.+Hedenstromauthor=A.+Malinovschiauthor=M.-L.+Wernrothauthor=M.+Janssonauthor=M.+Hedelandauthor=G.+Wikstrom&title=Effects+of+oral+supplementation+with+nitrate-rich+beetroot+juice+in+patients+with+pulmonary+arterial+hypertension-+results+from+BEET-PAH%2C+an+exploratory+randomized%2C+double-blind%2C+placebo-controlled%2C+crossover+study&doi=10.1016%2Fj.cardfail.2018.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Oral Supplementation With Nitrate-Rich Beetroot Juice in Patients With Pulmonary Arterial Hypertension-Results From BEET-PAH, an Exploratory Randomized, Double-Blind, Placebo-Controlled, Crossover Study</span></div><div class="casAuthors">Henrohn, Dan; Bjoerkstrand, Kristoffer; Lundberg, Jon O.; Granstam, Sven-Olof; Baron, Tomasz; Ingimarsdottir, Inga J.; Hedenstroem, Hans; Malinovschi, Andrei; Wernroth, Mona-Lisa; Jansson, Martin; Hedeland, Mikael; Wikstroem, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiac Failure</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">640-653</span>CODEN:
                <span class="NLM_cas:coden">JCFAF9</span>;
        ISSN:<span class="NLM_cas:issn">1071-9164</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The nitrate-nitrite-nitric oxide (NO) pathway may represent a potential therapeutic target in patients with pulmonary arterial hypertension (PAH).  We explored the effects of dietary nitrate supplementation, with the use of nitrate-rich beetroot juice (BRJ), in patients with PAH.  We prospectively studied 15 patients with PAH in an exploratory randomized, double-blind, placebo-controlled, crossover trial.  The patients received nitrate-rich beetroot juice and placebo in 2 treatment periods of 7 days each.  Compared with placebo ingestion of BRJ resulted in increases in; fractional exhaled NO at all flow-rates, alveolar NO concns. and bronchial NO flux, and plasma and salivary levels of nitrate and nitrite.  Plasma ornithine levels decreased and indexes of relative arginine availability increased after BRJ compared to placebo.  A decrease in breathing frequency was obsd. during ergospirometry after BRJ.  A tendency for an improvement in right ventricular function was obsd. after ingestion of BRJ.  In addn. a tendency for an increase in the peak power output to peak oxygen consumption ratio was obsd., which became significant in patients reaching an increase of plasma nitrite >30% (responders).  An increase in the W peak/VO2 peak ratio was obsd. after BRJ ingestion in plasma nitrite responders.  These findings indicate that supplementation with inorg. nitrate increase NO synthase-independent NO prodn. from the nitrate-nitrite-NO pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok5_Ul2yZS-7Vg90H21EOLACvtfcHk0lg3_PghYITODw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOqsrzM&md5=0a5dc6c576884dd5c065d993c4867497</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2018.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2018.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DHenrohn%26aufirst%3DD.%26aulast%3DBjorkstrand%26aufirst%3DK.%26aulast%3DLundberg%26aufirst%3DJ.%2BO.%26aulast%3DGranstam%26aufirst%3DS.-O.%26aulast%3DBaron%26aufirst%3DT.%26aulast%3DIngimarsdottir%26aufirst%3DI.%2BJ.%26aulast%3DHedenstrom%26aufirst%3DH.%26aulast%3DMalinovschi%26aufirst%3DA.%26aulast%3DWernroth%26aufirst%3DM.-L.%26aulast%3DJansson%26aufirst%3DM.%26aulast%3DHedeland%26aufirst%3DM.%26aulast%3DWikstrom%26aufirst%3DG.%26atitle%3DEffects%2520of%2520oral%2520supplementation%2520with%2520nitrate-rich%2520beetroot%2520juice%2520in%2520patients%2520with%2520pulmonary%2520arterial%2520hypertension-%2520results%2520from%2520BEET-PAH%252C%2520an%2520exploratory%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520crossover%2520study%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2018%26volume%3D24%26spage%3D640%26epage%3D653%26doi%3D10.1016%2Fj.cardfail.2018.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nan, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhaxi, D. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D. X.</span></span> <span> </span><span class="NLM_article-title">Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1016/j.jep.2018.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jep.2018.01.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29325918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFels7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2018&pages=175-183&author=X.+M.+Nanauthor=S.+S.+Suauthor=K.+Maauthor=X.+D.+Maauthor=X.+M.+Wangauthor=D.+Z.+Zhaxiauthor=R.+L.+Geauthor=Z.+Q.+Liauthor=D.+X.+Lu&title=Bioactive+fraction+of+Rhodiola+algida+against+chronic+hypoxia-induced+pulmonary+arterial+hypertension+and+its+anti-proliferation+mechanism+in+rats&doi=10.1016%2Fj.jep.2018.01.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats</span></div><div class="casAuthors">Nan, Xingmei; Su, Shanshan; Ma, Ke; Ma, Xiaodong; Wang, Ximeng; Zhaxi, Dongzhu; Ge, Rili; Li, Zhanqiang; Lu, Dianxiang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-183</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Rhodiola algida var. tangutica (Maxim.) S. H. Fu is a perennial plant of the Crassulaceae family that grows in the mountainous regions of Asia.  The rhizome and roots of this plant have been long used as Tibetan folk medicine for preventing high altitude sickness.  The aim of this study was to det. the effect of bioactive fraction from R. algida (ACRT) on chronic hypoxia-induced pulmonary arterial hypertension (HPAH) and to understand the possible mechanism of its pharmacodynamic actions.  Male Sprague-Dawley rats were sepd. into five groups: control group, hypoxia group, and hypoxia+ACRT groups (62.5, 125, and 250 mg/kg/day of ACRT).  The chronic hypoxic environment was created in a hypobaric chamber by adjusting the inner pressure and oxygen content for 4 wk.  After 4 wk, major physiol. parameters of pulmonary arterial hypertension such as mPAP, right ventricle index (RV/LV+S, RVHI), hematocrit (Hct) levels and the medial vessel thickness (wt%) were measured.  Protein and mRNA expression levels of proliferating cell nuclear antigen (PCNA), cyclin D1, p27Kip1 and cyclin-dependent kinase 4 (CDK4) were detected by western blotting and real time PCR resp.  Chem. profile of ACRT was revealed by ultra performance liq. chromatog. coupled with quadrupole time of flight mass spectrometry (UHPLC-Q-TOF-MS/MS).  The results showed that a successful HPAH rat model was established in a hypobaric chamber for 4 wk, as indicated by the significant increase in mPAP, RV/LV+S, RV/BW and wt%.  Compared with the normal group, administration of ACRT reduced mPAP, right ventricular hypertrophy, pulmonary small artery wall thickness, and damage in ultrastructure induced by hypoxia in rats.  PCNA, cyclin D1, and CDK4 expression was reduced (p<0.05), and p27Kip1 expression increased (p<0.05) in hypoxia+ACRT groups compared to hypoxia. 38 constituents in bioactive fraction were identified by UHPLC-Q-TOF-MS/MS.  Our results suggest that ACRT could alleviate chronic hypoxia-induced pulmonary arterial hypertension.  And its anti-proliferation mechanism in rats based on decreasing PCNA, cyclin D1, CDK4 expression level and inhibiting p27Kip1 degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKTDWnOZiR_rVg90H21EOLACvtfcHk0liJAk8qPdZfIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFels7s%253D&md5=e9653dcef57fc9a19b6514bf38565901</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2018.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2018.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DNan%26aufirst%3DX.%2BM.%26aulast%3DSu%26aufirst%3DS.%2BS.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DX.%2BD.%26aulast%3DWang%26aufirst%3DX.%2BM.%26aulast%3DZhaxi%26aufirst%3DD.%2BZ.%26aulast%3DGe%26aufirst%3DR.%2BL.%26aulast%3DLi%26aufirst%3DZ.%2BQ.%26aulast%3DLu%26aufirst%3DD.%2BX.%26atitle%3DBioactive%2520fraction%2520of%2520Rhodiola%2520algida%2520against%2520chronic%2520hypoxia-induced%2520pulmonary%2520arterial%2520hypertension%2520and%2520its%2520anti-proliferation%2520mechanism%2520in%2520rats%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2018%26volume%3D216%26spage%3D175%26epage%3D183%26doi%3D10.1016%2Fj.jep.2018.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosanovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pak, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seimetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahal, B. K.</span></span> <span> </span><span class="NLM_article-title">Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1086/674303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1086%2F674303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=24618536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2crhvFaitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=499-506&author=D.+Kosanovicauthor=X.+Tianauthor=O.+Pakauthor=Y.+J.+Laiauthor=Y.+L.+Hsiehauthor=M.+Seimetzauthor=N.+Weissmannauthor=R.+T.+Schermulyauthor=B.+K.+Dahal&title=Rhodiola%3A+an+ordinary+plant+or+a+promising+future+therapy+for+pulmonary+hypertension%3F+a+brief+review&doi=10.1086%2F674303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review</span></div><div class="casAuthors">Kosanovic Djuro; Tian Xia; Pak Oleg; Lai Ying-Ju; Hsieh Yi-Ling; Seimetz Michael; Weissmann Norbert; Schermuly Ralph Theo; Dahal Bhola Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary circulation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-506</span>
        ISSN:<span class="NLM_cas:issn">2045-8932</span>.
    </div><div class="casAbstract">Abstract Pulmonary hypertension (PH) is a chronic, complex, and progressive disease that eventuates in fatality.  Research efforts over the past decades have resulted in therapeutic options that improve quality of life and prolong survival of patients, but they do not offer a cure.  We propose a philosophical model that a disturbed balance of yin and yang results in pulmonary vascular remodeling, the hallmark of PH pathology.  The model may be useful in exploring the wisdom of traditional Chinese medicine and incorporating it into mainstream PH research.  In this context, the medicinal plant Rhodiola can be of profound interest owing to its variety of health-friendly attributes.  Rhodiola has been shown to be beneficial in high-altitude-related symptoms and acute exacerbation of PH; moreover, improvement of PH has been demonstrated experimentally in chronically hypoxic rats.  The beneficial effects of Rhodiola in PH may be attributable to its potential targeting of the signaling pathways, such as endothelin-1, nitric oxide, vascular endothelial growth factor, angiotensin-converting enzyme, nuclear factor κ-B, tumor necrosis factor α, and interleukin-6.  Alterations in these mediators are implicated in PH pathogenesis, the characteristics of which include chronic pulmonary vasoconstriction, vasoproliferation, and vascular inflammation.  Salidroside, one of the compounds extracted from Rhodiola, has been found to provide therapeutic benefits in experimental PH.  As the data are limited and the field is in its infancy, further studies including in-depth analysis of the therapeutic effects on various animal models of PH are desirable.  We believe that future PH research should place an adequate and special emphasis on exploring and promoting the potential of traditional Chinese medicine, and to this end, the medicinal plant Rhodiola offers a promising field on which to embark.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzT7ePq8oZyzEwO064Z95rfW6udTcc2eapLp3Ap5SHqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crhvFaitQ%253D%253D&md5=3286794ff26fa50e4b4b3e7911366907</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1086%2F674303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F674303%26sid%3Dliteratum%253Aachs%26aulast%3DKosanovic%26aufirst%3DD.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DPak%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DY.%2BJ.%26aulast%3DHsieh%26aufirst%3DY.%2BL.%26aulast%3DSeimetz%26aufirst%3DM.%26aulast%3DWeissmann%26aufirst%3DN.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DDahal%26aufirst%3DB.%2BK.%26atitle%3DRhodiola%253A%2520an%2520ordinary%2520plant%2520or%2520a%2520promising%2520future%2520therapy%2520for%2520pulmonary%2520hypertension%253F%2520a%2520brief%2520review%26jtitle%3DPulm.%2520Circ.%26date%3D2013%26volume%3D3%26spage%3D499%26epage%3D506%26doi%3D10.1086%2F674303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gui, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span> <span> </span><span class="NLM_article-title">Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway</span>. <i>BMC Pulm. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">191</span>, <span class="refDoi"> DOI: 10.1186/s12890-017-0477-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2Fs12890-017-0477-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29233105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFyhsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=191&author=D.+Guiauthor=Z.+Cuiauthor=L.+Zhangauthor=C.+Yuauthor=D.+Yaoauthor=M.+Xuauthor=M.+Chenauthor=P.+Wuauthor=G.+Liauthor=L.+Wangauthor=X.+Huang&title=Salidroside+attenuates+hypoxia-induced+pulmonary+arterial+smooth+muscle+cell+proliferation+and+apoptosis+resistance+by+upregulating+autophagy+through+the+AMPK-mTOR-ULK1+pathway&doi=10.1186%2Fs12890-017-0477-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">Salidroside attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation and apoptosis resistance by upregulating autophagy through the AMPK-mTOR-ULK1 pathway</span></div><div class="casAuthors">Gui, Di; Cui, Zhimin; Zhang, Lin; Yu, Chang; Yao, Dan; Xu, Min; Chen, Mayun; Wu, Peiliang; Li, Guoping; Wang, Liangxing; Huang, Xiaoying</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">191/1-191/12</span>CODEN:
                <span class="NLM_cas:coden">BPMMBB</span>;
        ISSN:<span class="NLM_cas:issn">1471-2466</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Recent studies have shown that both adenosine monophosphate activated protein kinase (AMPK) and the mammalian target of rapamycin (mTOR) are energy sensors and are related to autophagy.  Our recent reports have shown that salidroside can exert protective effects against hypoxia-induced pulmonary arterial smooth muscle cell (PASMC) proliferation and apoptosis resistance through the AMPK pathway.  This study aims to explore the relationship among AMPK, mTOR and ULK1 in PASMCs under hypoxic conditions and to investigate whether the protective effects of salidroside are related to the autophagic cell death pathway.  Rat PASMCs were cultured and divided into five groups: the normoxia, hypoxia, hypoxia + MHY1485 (mTOR agonist), hypoxia + rapamycin (mTOR inhibitor) and hypoxia + salidroside groups.  Hypoxic cells were treated as indicated for 24 h.  Cell viability was evaluated by the CCK-8 assay.  Cell apoptosis was measured by the TUNEL assay.  The autophagy flux of PASMCs was evaluated with tandem mRFP-GFP fluorescence microscopy.  Autophagosomes were detected by electron microscopy.  Protein expression of LC3, p62, AMPK, P-AMPK (Thr 172), P-ULK1 (Ser 555 and Ser 317), mTOR, P-mTOR (Ser 2448), ULK1 and P-ULK1 (Ser 757) was detected by western blot assay.  PASMC proliferation and apoptosis resistance were obsd. under hypoxic conditions.  Autophagy flux, the no. of autophagosomes and the LC3II/LC3I ratio were increased in the hypoxia group compared with the normoxia group, whereas p62 expression was decreased.  Treatment with rapamycin or salidroside reversed hypoxia-induced PASMC proliferation and apoptosis resistance and further increased autophagy flux, autophagosome levels and the LC3II/LC3I ratio but decreased p62 expression.  Treatment with MHY1485 reversed hypoxia-induced PASMC apoptosis resistance and decreased autophagy flux as well as increased autophagosome levels, the LC3II/LC3I ratio and p62 expression.  P-AMPK (Thr 172) and P-ULK1 (Ser 555) of the AMPK-ULK1 pathway were increased in the hypoxia group and were further increased in the salidroside group.  Rapamycin and MHY1485 had no effect on either P-AMPK (Thr 172) or P-ULK1 (Ser 555).  Phosphorylation of ULK1 at serine 317 did not significantly affect the five groups.  Furthermore, P-mTOR (Ser 2448) and P-ULK1 (Ser 757) of the AMPK-mTOR-ULK1 pathway were decreased in the hypoxia group and were further decreased in the salidroside group.  MHY1485 increased the expression of both P-mTOR(Ser 2448) and P-ULK1(Ser 757), whereas rapamycin had the opposite effect.  Salidroside might inhibit hypoxia-induced PASMC proliferation and reverse apoptosis resistance via the upregulation of autophagy through both the AMPKa1-ULK1 and AMPKa1-mTOR-ULK1 pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPnYD3yg58kLVg90H21EOLACvtfcHk0liw9nKel2iXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFyhsr4%253D&md5=e6fe05dcb9370c330979018413a3f91e</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1186%2Fs12890-017-0477-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12890-017-0477-4%26sid%3Dliteratum%253Aachs%26aulast%3DGui%26aufirst%3DD.%26aulast%3DCui%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DX.%26atitle%3DSalidroside%2520attenuates%2520hypoxia-induced%2520pulmonary%2520arterial%2520smooth%2520muscle%2520cell%2520proliferation%2520and%2520apoptosis%2520resistance%2520by%2520upregulating%2520autophagy%2520through%2520the%2520AMPK-mTOR-ULK1%2520pathway%26jtitle%3DBMC%2520Pulm.%2520Med.%26date%3D2017%26volume%3D17%26spage%3D191%26doi%3D10.1186%2Fs12890-017-0477-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilfeather, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Effects of tetrandrine on growth factor-induced DNA synthesis and proliferative response of rat pulmonary artery smooth muscle cells</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1006/pupt.2000.0230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1006%2Fpupt.2000.0230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10799282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivFentr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=53-60&author=H.+L.+Wangauthor=S.+A.+Kilfeatherauthor=G.+R.+Martinauthor=C.+P.+Page&title=Effects+of+tetrandrine+on+growth+factor-induced+DNA+synthesis+and+proliferative+response+of+rat+pulmonary+artery+smooth+muscle+cells&doi=10.1006%2Fpupt.2000.0230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Tetrandrine on Growth Factor-induced DNA Synthesis and Proliferative Response of Rat Pulmonary Artery Smooth Muscle Cells</span></div><div class="casAuthors">Wang, H. L.; Kilfeather, S. A.; Martin, G. R.; Page, C. P.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">53-60</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The objective of the present study was to investigate the effect of tetrandrine (a plant alkaloid isolated from Stephenia tetrandra) on growth factor-induced DNA synthesis and proliferative responses of rat pulmonary artery smooth muscle cells.  Male rat and bovine pulmonary artery smooth muscle cells (PASMC) were cultured in Medium 199 contg. FBS (10%).  DNA synthesis was monitored from [3H]-thymidine uptake and cell proliferation by direct cell counting.  In the present study FBS (1% vol./vol.) caused a small increase in DNA synthesis above basal levels in rat and bovine PASMC (6% and 11% resp.).  Platelet-derived growth factor (PDGF, 50 ng/mL), fibroblast growth factor (FGF, 50 ng/mL) or interleukin-1α (IL-1α, 100 pg/mL) alone increased rat PASMC proliferation (69-85%) and DNA synthesis above basal levels (76-92%).  The addn. of these growth factors in combination with FBS (1%) resulted in higher increases in DNA synthesis above basal levels (rat PASMC:PDGF, 465%; FGF, 421%; IL-1α, 406%; bovine PASMC:PDGF, 279%).  Tetrandrine (10-5 M) inhibited FBS (10%)-induced rat PASMC proliferation (90.5%) and DNA synthesis (89.0%).  Tetrandrine significantly inhibited cell proliferation (86.5-98.5%) and DNA synthesis (79.9-89.0%) induced by FBS (1%) in combination with one of the following mitogens; PDGF (50 ng/mL), FGF (50 ng/mL), IL-1α (100 pg/mL).  The inhibitory effects of tetrandrine were obsd. between 10-6 and 10-5 M and PASMC viability was not affected by tetrandrine below 3×10-5 m.  In summary, these results suggest that tetrandrine can exert anti-proliferative effects against a range of mitogenic stimuli for vascular smooth muscle cells in vitro.  Such effects may contribute to the inhibitory effect of tetrandrine on pulmonary vascular remodeling assocd. with pulmonary hypertension.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSl6HIAaGyhrVg90H21EOLACvtfcHk0liw9nKel2iXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivFentr8%253D&md5=15410c8ee04fa9c3ec61f2792964ab12</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1006%2Fpupt.2000.0230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fpupt.2000.0230%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DKilfeather%26aufirst%3DS.%2BA.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DEffects%2520of%2520tetrandrine%2520on%2520growth%2520factor-induced%2520DNA%2520synthesis%2520and%2520proliferative%2520response%2520of%2520rat%2520pulmonary%2520artery%2520smooth%2520muscle%2520cells%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2000%26volume%3D13%26spage%3D53%26epage%3D60%26doi%3D10.1006%2Fpupt.2000.0230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W. P.</span></span> <span> </span><span class="NLM_article-title">Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1</span>. <i>J. Vasc. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1468</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1016/j.jvs.2015.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.jvs.2015.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26527422" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC28znvFKrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=1468-1477&author=X.+W.+Wangauthor=Y.+C.+Yangauthor=D.+P.+Yangauthor=G.+Tongauthor=S.+S.+Lvauthor=X.+Linauthor=C.+F.+Chenauthor=W.+P.+Dong&title=Tetrandrine+prevents+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats+through+regulation+of+the+protein+expression+of+inducible+nitric+oxide+synthase+and+cyclic+guanosine+monophosphate-dependent+protein+kinase+type+1&doi=10.1016%2Fj.jvs.2015.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1</span></div><div class="casAuthors">Wang Xiaowu; Yang Dongpeng; Tong Guang; Lv Shanshan; Lin Xi; Chen Changfu; Yang Yongchao; Dong Wenpeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of vascular surgery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1468-1477</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Pulmonary arterial hypertension (PAH) is a fatal disease characterized by a persistent elevation of pulmonary artery pressure and ventricular hypertrophy.  Tetrandrine is a bisbenzylisoquinoline alkaloid that can decrease blood pressure, inhibit the proliferation of vascular smooth muscle cells, and block cardiac hypertrophy, but whether it has a therapeutic effect on PAH remains poorly defined.  This study was undertaken to investigate the efficacy of tetrandrine on PAH.  METHODS:  Forty-eight male Sprague-Dawley rats were randomly and equally divided into four groups.  The control group was injected with normal saline; the others were injected with monocrotaline (MCT) to induce PAH, then treated with saline, tetrandrine, and vardenafil, respectively, from day 21 to day 42.  On day 43, we measured the mean pulmonary artery pressure under general anesthesia, dissected the rat, and calculated the right ventricular hypertrophy index [right ventricle/(left ventricle plus septum)].  Later we observed the changes in the pulmonary vascular wall; measured the expression of cyclic guanosine monophosphate-dependent protein kinase type 1 and inducible nitric oxide synthase; measured the levels of superoxide dismutase, glutathione, malondialdehyde, and catalase; and then compared the results among groups.  RESULTS:  Compared with the MCT group, rats treated with tetrandrine had attenuated mean pulmonary artery pressure (20.48 ± 1.49 vs 30.07 ± 1.51; P < .01) and right ventricular hypertrophy index (49.19 ± 2.45 vs 68.50 ± 1.95; P < .01), inhibited proliferation of pulmonary artery smooth muscle cells, and improved endothelial function.  Tetrandrine also upregulated the expression of protein kinase type 1 (90.86 ± 1.95 vs 67.34 ± 1.50; P < .01); downregulated the expression of inducible nitric oxide synthase (74.76 ± 1.48 vs 80.19 ± 0.28; P < .01); increased levels of superoxide dismutase (245.54 ± 12.98 vs 166.16 ± 21.42; P < .01), glutathione (0.699 ± 0.032 vs 0.514 ± 0.056; P < .01), and catalase (32.13 ± 2.33 vs 27.19 ± 2.72; P < .01); and decreased malondialdehyde (1.027 ± 0.039 vs 1.462 ± 0.055; P < .01).  CONCLUSIONS:  Tetrandrine alleviated MCT-induced PAH through regulation of nitric oxide signaling pathway and antioxidant and antiproliferation effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9xHanSufiLq69lAbTj9rGfW6udTcc2eb7dHxH4DNKYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28znvFKrsw%253D%253D&md5=5cc9af001cb0b115da465e74838296e8</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1016%2Fj.jvs.2015.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jvs.2015.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BW.%26aulast%3DYang%26aufirst%3DY.%2BC.%26aulast%3DYang%26aufirst%3DD.%2BP.%26aulast%3DTong%26aufirst%3DG.%26aulast%3DLv%26aufirst%3DS.%2BS.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%2BF.%26aulast%3DDong%26aufirst%3DW.%2BP.%26atitle%3DTetrandrine%2520prevents%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%2520through%2520regulation%2520of%2520the%2520protein%2520expression%2520of%2520inducible%2520nitric%2520oxide%2520synthase%2520and%2520cyclic%2520guanosine%2520monophosphate-dependent%2520protein%2520kinase%2520type%25201%26jtitle%3DJ.%2520Vasc.%2520Surg.%26date%3D2016%26volume%3D64%26spage%3D1468%26epage%3D1477%26doi%3D10.1016%2Fj.jvs.2015.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faul, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearl, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, P. N.</span></span> <span> </span><span class="NLM_article-title">Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">2252</span>– <span class="NLM_lpage">2258</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.162.6.2002018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1164%2Fajrccm.162.6.2002018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=11112148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD3M7gt1yqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2000&pages=2252-2258&author=J.+L.+Faulauthor=T.+Nishimuraauthor=G.+J.+Berryauthor=G.+V.+Bensonauthor=R.+G.+Pearlauthor=P.+N.+Kao&title=Triptolide+attenuates+pulmonary+arterial+hypertension+and+neointimal+formation+in+rats&doi=10.1164%2Fajrccm.162.6.2002018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats</span></div><div class="casAuthors">Faul J L; Nishimura T; Berry G J; Benson G V; Pearl R G; Kao P N</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2252-8</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">This paper reports the effect of triptolide (a diterpenoid triepoxide) on the development of monocrotaline (MCT)-induced pulmonary hypertension in pneumonectomized rats.  Male Sprague- Dawley rats were injected with MCT (60 mg/kg) on Day 7 after left pneumonectomy.  Rats received therapy from Day 5 to 35 with triptolide (0.25 mg/kg intraperitoneally, every other day, n = 10), or vehicle (0.1 ml of ethanol/cremophor intraperitoneally, every other day, n = 10).  By Day 35, triptolide-treated rats demonstrated lower mean pulmonary arterial pressure (mPAP) than vehicle-treated rats (mPAP 21 +/- 3 versus 42 +/- 5 mm Hg, p < 0.001).  Triptolide-treated rats also had significantly less right ventricular hypertrophy (RVH) and pulmonary arterial neointimal formation.  In a rescue experiment, rats initiated therapy on Day 21.  At Day 35, vehicle-treated rats (n = 4) had higher mPAP (40 +/- 9 mm Hg), greater RVH, and more severe pulmonary arterial neointimal formation than rats that received triptolide (0.25 mg/kg every other day, n = 7, mPAP 30 +/- 4 mm Hg) and rats that received triptolide (0.2 mg/kg daily, n = 7, mPAP 25 +/- 5 mm Hg, p < 0.01).  In pneumonectomized rats that receive MCT, triptolide attenuates the development of pulmonary hypertension and RVH, and promotes regression of pulmonary arterial neointimal formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLXhP7c5JA32x8TEN9K18QfW6udTcc2eaxOCS8k83zerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7gt1yqtA%253D%253D&md5=6e7c00f7c5b810fa40126a7deca304d8</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.162.6.2002018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.162.6.2002018%26sid%3Dliteratum%253Aachs%26aulast%3DFaul%26aufirst%3DJ.%2BL.%26aulast%3DNishimura%26aufirst%3DT.%26aulast%3DBerry%26aufirst%3DG.%2BJ.%26aulast%3DBenson%26aufirst%3DG.%2BV.%26aulast%3DPearl%26aufirst%3DR.%2BG.%26aulast%3DKao%26aufirst%3DP.%2BN.%26atitle%3DTriptolide%2520attenuates%2520pulmonary%2520arterial%2520hypertension%2520and%2520neointimal%2520formation%2520in%2520rats%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2000%26volume%3D162%26spage%3D2252%26epage%3D2258%26doi%3D10.1164%2Fajrccm.162.6.2002018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-B.</span></span> <span> </span><span class="NLM_article-title">The effect of breviscapine on the pulmonary arterial pressure and the expression of Rho-kinase in pulmonary arterioles of hypoxic rats</span>. <i>Chin. J. Tuberc. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">826</span>– <span class="NLM_lpage">830</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BD1M%252FjtFKgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=826-830&author=L.+Yangauthor=B.-X.+Zhengauthor=D.-Y.+Chengauthor=Q.-L.+Suauthor=L.-L.+Fanauthor=Y.-J.+Yangauthor=M.+Muauthor=W.-B.+Chen&title=The+effect+of+breviscapine+on+the+pulmonary+arterial+pressure+and+the+expression+of+Rho-kinase+in+pulmonary+arterioles+of+hypoxic+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of breviscapine on the pulmonary arterial pressure and the expression of Rho-kinase in pulmonary arterioles of hypoxic rats</span></div><div class="casAuthors">Yang Li; Zheng Bi-Xia; Cheng De-Yun; Su Qiao-Li; Fan Li-Li; Yang Yan-Juan; Mu Mao; Chen Wen-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">826-30</span>
        ISSN:<span class="NLM_cas:issn">1001-0939</span>.
    </div><div class="casAbstract">OBJECTIVE:  To observe the effect of breviscapine on the pulmonary artery pressure and the Rho-kinase and Rho-kinase mRNA in pulmonary arterioles of rats treated with hypoxia, and therefore to explore the mechanisms of breviscapine on hypoxic pulmonary hypertension.  METHODS:  Eighteen adult male SD rats were randomly divided into 3 groups.  One group was exposed to air (normal group), the second group was exposed to isobaric hypoxia for 3 weeks (hypoxic group), and the third group was exposed to hypoxia for 3 weeks and treated with breviscapine (preventive group).  Cardiac catheterization was used to measure the mean pulmonary arterial pressure (mPAP).  The heart was isolated, and the right ventricle (RV), left ventricle plus ventricular septum (LV + S) were weighed to calculate the ratio RV/(LV + S).  The ratio of vascular wall thickness/vascular external diameter (WT%) and the ratio of vascular wall area/total vascular area (WA%) were measured by image analysis.  The quantity of Rho-kinase and Rho-kinase mRNA in rat pulmonary arterioles were determined by immunohistochemistry and in situ hybridization respectively.  RESULTS:  The mPAP in the preventive group [(19.83 +/- 1.47) mm Hg, 1 mm Hg = 0.133 kPa] was significantly lower than that of the hypoxic group [(27.3 +/- 5.0) mm Hg], t = 4.28, P < 0.05.  The RV/(LV + S) in the preventive group (0.29 +/- 0.03) was significantly lower than that in the hypoxic group (0.34 +/- 0.05, t = 2.39, P < 0.05).  The WT% and WA% in the preventive group (25 +/- 5 and 45 +/- 5, respectively) were significantly lower than those in the hypoxic group (36 +/- 12 and 59 +/- 13, respectively, t = 4.89, 5.89, P < 0.05).  The positive staining of ROCKI and ROCKII on pulmonary arterioles in the preventive group (1.18 +/- 0.10 and 1.30 +/- 0.12, respectively) were significantly lower than those in the hypoxic group (1.29 +/- 0.08 and 1.63 +/- 0.24, respectively, t = 3.90, 5.82, P < 0.05).  The positive staining of ROCKI mRNA and ROCKII mRNA in the preventive group (1.23 +/- 0.13 and 1.22 +/- 0.06, respectively) were significantly lower than those in the hypoxic group (1.37 +/- 0.13 and 1.59 +/- 0.31, respectively, t = 3.94, 5.83, P < 0.05).  CONCLUSION:  Breviscapine was shown to prevent hypoxic pulmonary hypertension and decrease Rho-kinase and Rho-kinase mRNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTf9N__5pX2OEH3Rlp_k91zfW6udTcc2eaxOCS8k83zerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M%252FjtFKgtg%253D%253D&md5=e9b20bd925e0e4c775058ad883bdfb56</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DB.-X.%26aulast%3DCheng%26aufirst%3DD.-Y.%26aulast%3DSu%26aufirst%3DQ.-L.%26aulast%3DFan%26aufirst%3DL.-L.%26aulast%3DYang%26aufirst%3DY.-J.%26aulast%3DMu%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DW.-B.%26atitle%3DThe%2520effect%2520of%2520breviscapine%2520on%2520the%2520pulmonary%2520arterial%2520pressure%2520and%2520the%2520expression%2520of%2520Rho-kinase%2520in%2520pulmonary%2520arterioles%2520of%2520hypoxic%2520rats%26jtitle%3DChin.%2520J.%2520Tuberc.%2520Respir.%2520Dis.%26date%3D2008%26volume%3D31%26spage%3D826%26epage%3D830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. J.</span></span> <span> </span><span class="NLM_article-title">Effect of erigeron breviscapini on chronic hypoxic pulmonary hypertension and serumnitric oxide and endothel in-1 in rats</span>. <i>J. Huazhong Acta Med. Univ. Sci. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2001&pages=224-226&author=Y.+P.+Dingauthor=Y.+J.+Xu&title=Effect+of+erigeron+breviscapini+on+chronic+hypoxic+pulmonary+hypertension+and+serumnitric+oxide+and+endothel+in-1+in+rats"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DY.%2BP.%26aulast%3DXu%26aufirst%3DY.%2BJ.%26atitle%3DEffect%2520of%2520erigeron%2520breviscapini%2520on%2520chronic%2520hypoxic%2520pulmonary%2520hypertension%2520and%2520serumnitric%2520oxide%2520and%2520endothel%2520in-1%2520in%2520rats%26jtitle%3DJ.%2520Huazhong%2520Acta%2520Med.%2520Univ.%2520Sci.%2520Technol.%26date%3D2001%26volume%3D30%26spage%3D224%26epage%3D226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadipour, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalantar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosseini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehman, Z. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farmanullah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalantar, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. G.</span></span> <span> </span><span class="NLM_article-title">Hawthorn (crataegus oxyacantha) flavonoid extract as an effective medicinal plant derivative to prevent pulmonary hypertension and heart failure in broiler chickens</span>. <i>Open Access J. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">328</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=321-328&author=B.+Ahmadipourauthor=M.+Kalantarauthor=S.+M.+Hosseiniauthor=Z.+U.+Rehmanauthor=F.+Farmanullahauthor=M.+H.+Kalantarauthor=L.+G.+Yang&title=Hawthorn+%28crataegus+oxyacantha%29+flavonoid+extract+as+an+effective+medicinal+plant+derivative+to+prevent+pulmonary+hypertension+and+heart+failure+in+broiler+chickens"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAhmadipour%26aufirst%3DB.%26aulast%3DKalantar%26aufirst%3DM.%26aulast%3DHosseini%26aufirst%3DS.%2BM.%26aulast%3DRehman%26aufirst%3DZ.%2BU.%26aulast%3DFarmanullah%26aufirst%3DF.%26aulast%3DKalantar%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DL.%2BG.%26atitle%3DHawthorn%2520%2528crataegus%2520oxyacantha%2529%2520flavonoid%2520extract%2520as%2520an%2520effective%2520medicinal%2520plant%2520derivative%2520to%2520prevent%2520pulmonary%2520hypertension%2520and%2520heart%2520failure%2520in%2520broiler%2520chickens%26jtitle%3DOpen%2520Access%2520J.%2520Sci.%26date%3D2019%26volume%3D25%26spage%3D321%26epage%3D328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, M. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. C.</span></span> <span> </span><span class="NLM_article-title">Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats</span>. <i>Int. J. Med. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">942</span>– <span class="NLM_lpage">954</span>, <span class="refDoi"> DOI: 10.7150/ijms.16810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.7150%2Fijms.16810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27994500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1c%252FmsVGlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=942-954&author=D.+Q.+Xuauthor=Y.+Liauthor=B.+Zhangauthor=Y.+X.+Wangauthor=Y.+Liuauthor=Y.+Luoauthor=W.+Niuauthor=M.+Q.+Dongauthor=M.+L.+Liuauthor=H.+Y.+Dongauthor=P.+T.+Zhaoauthor=Z.+C.+Li&title=Resveratrol+alleviate+hypoxic+pulmonary+hypertension+via+anti-inflammation+and+anti-oxidant+pathways+in+rats&doi=10.7150%2Fijms.16810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats</span></div><div class="casAuthors">Xu Dunquan; Li Yan; Zhang Bo; Wang Yanxia; Liu Yi; Luo Ying; Niu Wen; Dong Mingqing; Liu Manling; Dong Haiying; Zhao Pengtao; Li Zhichao</div><div class="citationInfo"><span class="NLM_cas:title">International journal of medical sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">942-954</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Resveratrol, a plant-derived polyphenolic compound and a phytoestrogen, was shown to possess multiple protective effects including anti-inflammatory response and anti-oxidative stress.  Hypoxic pulmonary hypertension (HPH) is a progressive disease characterized by sustained vascular resistance and marked pulmonary vascular remodeling.  The exact mechanisms of HPH are still unclear, but inflammatory response and oxidative stress was demonstrated to participate in the progression of HPH.  The present study was designed to investigate the effects of resveratrol on HPH development.  Sprague-Dawley rats were challenged by hypoxia exposure for 28 days to mimic hypoxic pulmonary hypertension along with treating resveratrol (40 mg/kg/day).  Hemodynamic and pulmonary pathomorphology data were then obtained, and the anti-proliferation effect of resveratrol was determined by in vitro assays.  The anti-inflammation and anti-oxidative effects of resveratrol were investigated in vivo and in vitro.  The present study showed that resveratrol treatment alleviated right ventricular systolic pressure and pulmonary arterial remodeling induced by hypoxia.  In vitro experiments showed that resveratrol notably inhibited proliferation of pulmonary arterial smooth muscle cells in an ER-independent manner.  Data showed that resveratrol administration inhibited HIF-1 α expression in vivo and in vitro, suppressed inflammatory cells infiltration around the pulmonary arteries, and decreased ROS production induced by hypoxia in PAMSCs.  The inflammatory cytokines' mRNA levels of tumor necrosis factor α, interleukin 6, and interleukin 1β were all suppressed by resveratrol treatment.  The in vitro assays showed that resveratrol inhibited the expression of HIF-1 α via suppressing the MAPK/ERK1 and PI3K/AKT pathways.  The antioxidant axis of Nuclear factor erythroid-2 related factor 2/ Thioredoxin 1 (Nrf-2/Trx-1) was up-regulated both in lung tissues and in cultured PASMCs.  In general, the current study demonstrated that resveratrol may prevent pulmonary hypertension through its anti-proliferation, anti-inflammation and antioxidant effects.  Hence, the present data may offer novel targets and promising pharmacological perspective for treating hypoxic pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQEn6Xj-1_1wpHZzFRCXxVKfW6udTcc2eYUy69KSnbTQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c%252FmsVGlug%253D%253D&md5=8019e9e2f7172112a3c28590b599c8cf</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.7150%2Fijms.16810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fijms.16810%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%2BQ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%2BX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DM.%2BQ.%26aulast%3DLiu%26aufirst%3DM.%2BL.%26aulast%3DDong%26aufirst%3DH.%2BY.%26aulast%3DZhao%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DZ.%2BC.%26atitle%3DResveratrol%2520alleviate%2520hypoxic%2520pulmonary%2520hypertension%2520via%2520anti-inflammation%2520and%2520anti-oxidant%2520pathways%2520in%2520rats%26jtitle%3DInt.%2520J.%2520Med.%2520Sci.%26date%3D2016%26volume%3D13%26spage%3D942%26epage%3D954%26doi%3D10.7150%2Fijms.16810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Polydatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein kinase C mechanisms</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">7776</span>– <span class="NLM_lpage">7787</span>, <span class="refDoi"> DOI: 10.3390/ijms13067776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fijms13067776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=22837726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFSksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=7776-7787&author=Q.+Miaoauthor=X.+P.+Shiauthor=M.+X.+Yeauthor=J.+Zhangauthor=S.+Miaoauthor=S.+W.+Wangauthor=B.+Liauthor=X.+X.+Jiangauthor=S.+Zhangauthor=N.+Huauthor=J.+Liauthor=J.+Zhang&title=Polydatin+attenuates+hypoxic+pulmonary+hypertension+and+reverses+remodeling+through+protein+kinase+C+mechanisms&doi=10.3390%2Fijms13067776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Polydatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein kinase C mechanisms</span></div><div class="casAuthors">Miao, Qing; Shi, Xiao-Peng; Ye, Ming-Xiang; Zhang, Jin; Miao, Shan; Wang, Si-Wang; Li, Bo; Jiang, Xiu-Xiu; Zhang, Song; Hu, Nan; Li, Juan; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">7776-7787</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Hypoxic pulmonary hypertension is a life-threatening emergency if untreated.  Consistent pulmonary hypertension also leads to arteries and ventricular remodeling.  The clin. therapeutic strategy for pulmonary hypertension and the corresponding remodeling mainly interacts with NO, angiotensin II (Ang II) and elevated endothelin (ET) targets.  In the present study, we evaluated the effects of polydatin on hypoxia-induced pulmonary hypertension.  It was obsd. that polydatin attenuated hypoxic pulmonary hypertension, reversed remodeling, and regulated NO, Ang II, ET contents in the serum and lung samples.  However, forced activation of PKC signaling by its selective activator thymeleatoxin (THX) could abate the effects of polydatain.  These results suggest that polydatin might be a promising candidate for hypoxic pulmonary treatment through interaction with PKC mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv9UQgVkjAObVg90H21EOLACvtfcHk0lhSakBWDBKsCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFSksrc%253D&md5=cb2809f7c22f094ea1ca142287d1ad43</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.3390%2Fijms13067776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms13067776%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DX.%2BP.%26aulast%3DYe%26aufirst%3DM.%2BX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMiao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DX.%2BX.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DPolydatin%2520attenuates%2520hypoxic%2520pulmonary%2520hypertension%2520and%2520reverses%2520remodeling%2520through%2520protein%2520kinase%2520C%2520mechanisms%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2012%26volume%3D13%26spage%3D7776%26epage%3D7787%26doi%3D10.3390%2Fijms13067776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. L.</span></span> <span> </span><span class="NLM_article-title">Icariin Inhibits pulmonary hypertension induced by monocrotaline through enhancement of NO/cGMP signaling pathway in rats</span>. <i>Evid.-based Complement Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1155/2016/7915415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1155%2F2016%2F7915415" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&pages=1-10&author=L.+S.+Liauthor=Y.+M.+Luoauthor=J.+Liuauthor=Y.+Zhangauthor=X.+X.+Fuauthor=D.+L.+Yang&title=Icariin+Inhibits+pulmonary+hypertension+induced+by+monocrotaline+through+enhancement+of+NO%2FcGMP+signaling+pathway+in+rats&doi=10.1155%2F2016%2F7915415"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1155%2F2016%2F7915415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F7915415%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%2BS.%26aulast%3DLuo%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%2BX.%26aulast%3DYang%26aufirst%3DD.%2BL.%26atitle%3DIcariin%2520Inhibits%2520pulmonary%2520hypertension%2520induced%2520by%2520monocrotaline%2520through%2520enhancement%2520of%2520NO%252FcGMP%2520signaling%2520pathway%2520in%2520rats%26jtitle%3DEvid.-based%2520Complement%2520Altern.%2520Med.%26date%3D2016%26volume%3D2016%26spage%3D1%26epage%3D10%26doi%3D10.1155%2F2016%2F7915415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama, T.</span></span> <span> </span><span class="NLM_article-title">Relaxant effects of pyranocoumarin compounds isolated from a Chinese medical plant, Bai-Hua Qian-Hu, on isolated rabbit tracheas and pulmonary arteries</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1248/bpb.22.984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1248%2Fbpb.22.984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10513627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADyaK1MXmtFCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1999&pages=984-987&author=N.+C.+Zhaoauthor=W.+B.+Jinauthor=X.+H.+Zhangauthor=F.+L.+Guanauthor=Y.+B.+Sunauthor=H.+Adachiauthor=T.+Okuyama&title=Relaxant+effects+of+pyranocoumarin+compounds+isolated+from+a+Chinese+medical+plant%2C+Bai-Hua+Qian-Hu%2C+on+isolated+rabbit+tracheas+and+pulmonary+arteries&doi=10.1248%2Fbpb.22.984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Relaxant effects of pyranocoumarin compounds isolated from a chinese medical plant, Bai-Hua Qian-Hu, on isolated rabbit tracheas and pulmonary arteries</span></div><div class="casAuthors">Zhao, Nai-Cai; Jin, Wan-Bao; Zhang, Xin-Hua; Guan, Fu-Lan; Sun, Yu-Bin; Adachi, Hideyuki; Okuyama, Toru</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">984-987</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Qian-Hu is a well-known traditional Chinese medicine used for the treatment of respiratory diseases and pulmonary hypertension.  We compared the relaxant effects of pyranocoumarin compds., including (+)-praeruptorin A (Pra-C), Pd-Ia (=(±)-praeruptorin A), pteryxin, peucedanocoumarin II (P-II) and 8-methoxypsoralen (8-MOP) purified from Bai-Hua Qian-Hu (BQ) in isolated rabbit tracheas and pulmonary arteries.  Pra-C, pteryxin and Pd-Ia produced significant relaxant effects in tracheal prepns. constricted with 40 mM KCl or 10 μM acetylcholine.  The relaxant response to Pra-C, pteryxin or Pd-Ia in prepns. constricted with KCl was significantly more potent than that in prepns. constricted with acetylcholine.  Pra-C, pteryxin or Pd-Ia at a concn. of 30 μM completely relaxed tracheas constricted with 40 mM KCl, whereas P-II at the same concn. showed only partial relaxation.  In pulmonary arterial prepns., 8-MOP produced a significant relaxant effect on contractions by 10 μM phenylephrine, without any effect on the contraction by 40 mM KCl.  These results suggest that Pd-Ia, pteryxin and Pra-C for their calcium antagonistic action, and 8-MOP for its inhibitory effect on contraction induced by phenylephrine, may be the active principles of BQ for relaxing the smooth muscle of tracheas and pulmonary arteries, and the principle may produce a synergistic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN1-CMHpK-HLVg90H21EOLACvtfcHk0ljPCWJ2CrL-mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtFCmt70%253D&md5=14296394de549cd03e6a17f4a128d969</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1248%2Fbpb.22.984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.22.984%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DN.%2BC.%26aulast%3DJin%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DX.%2BH.%26aulast%3DGuan%26aufirst%3DF.%2BL.%26aulast%3DSun%26aufirst%3DY.%2BB.%26aulast%3DAdachi%26aufirst%3DH.%26aulast%3DOkuyama%26aufirst%3DT.%26atitle%3DRelaxant%2520effects%2520of%2520pyranocoumarin%2520compounds%2520isolated%2520from%2520a%2520Chinese%2520medical%2520plant%252C%2520Bai-Hua%2520Qian-Hu%252C%2520on%2520isolated%2520rabbit%2520tracheas%2520and%2520pulmonary%2520arteries%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D1999%26volume%3D22%26spage%3D984%26epage%3D987%26doi%3D10.1248%2Fbpb.22.984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. L.</span></span> <span> </span><span class="NLM_article-title">Osthole attenuates pulmonary arterial hypertension in monocrotaline-treated rats</span>. <i>Mol. Med. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2823</span>– <span class="NLM_lpage">2829</span>, <span class="refDoi"> DOI: 10.3892/mmr.2017.6876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3892%2Fmmr.2017.6876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28677726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2htr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=2823-2829&author=Y.+L.+Liauthor=Y.+W.+Wangauthor=Y.+Q.+Liauthor=Z.+Q.+Qianauthor=L.+Zhuauthor=D.+L.+Yang&title=Osthole+attenuates+pulmonary+arterial+hypertension+in+monocrotaline-treated+rats&doi=10.3892%2Fmmr.2017.6876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Osthole attenuates pulmonary arterial hypertension in monocrotaline-treated rats</span></div><div class="casAuthors">Li, Yeli; Wang, Yingwan; Li, Yiqi; Qian, Zhiqiang; Zhu, Ling; Yang, Danli</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2823-2829</span>CODEN:
                <span class="NLM_cas:coden">MMROA5</span>;
        ISSN:<span class="NLM_cas:issn">1791-3004</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is an insidious and progressive disease that is triggered by various cardiopulmonary diseases.  Inflammation has an important role in the progression of PAH.  Osthole (Ost) is a coumarin that has clear anti-inflammatory properties.  The present study aimed to investigate the effects of Ost on PAH, and to explore the mechanism underlying this effect.  Using the monocrota- line (MCT)-induced PAH rat model, the effects of Ost on PAH were investigated.  Rats were s.c. administered a single dose of MCT (50 mg/kg) to establish the PAH model, followed by daily treatment with Ost (10 or 20 mg/kg) by gavage for 28 days.  The mean pulmonary arterial pressure (mPAP) was measured and histol. anal. was performed.  The results demonstrated that Ost significantly decreased mPAP, and reduced thickening of the pulmonary artery, compared with in rats in the MCT group.  To further det. whether the effects of Ost on MCT-induced PAH were assocd. with inflammatory responses, the nuclear factor-κB (NF-κB) p65 signaling pathway was investigated by western blot anal.  The results demonstrated that Ost increased inhibition of the NF-κB p65 signaling pathway.  In conclusion, the results of the present study demonstrate that Ost may suppress the progression of MCT-induced PAH in rats, which may be, at least partially, mediated through modulation of the NF-κB p65 signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ftR9Qn-cjrVg90H21EOLACvtfcHk0ljPCWJ2CrL-mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2htr0%253D&md5=44d2028ab7d42898c6fde006dcd14881</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.3892%2Fmmr.2017.6876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fmmr.2017.6876%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BL.%26aulast%3DWang%26aufirst%3DY.%2BW.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DQian%26aufirst%3DZ.%2BQ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DD.%2BL.%26atitle%3DOsthole%2520attenuates%2520pulmonary%2520arterial%2520hypertension%2520in%2520monocrotaline-treated%2520rats%26jtitle%3DMol.%2520Med.%2520Rep.%26date%3D2017%26volume%3D16%26spage%3D2823%26epage%3D2829%26doi%3D10.3892%2Fmmr.2017.6876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-L.</span></span> <span> </span><span class="NLM_article-title">Osthole inhibits cell proliferation by regulating the TGF-β1/Smad/p38 signaling pathways in pulmonary arterial smooth muscle cells</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">109640</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2019.109640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.biopha.2019.109640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31810114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Ois7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2020&pages=109640&author=Y.+Yueauthor=Y.-Q.+Liauthor=S.+Fuauthor=Y.-T.+Wuauthor=L.+Zhuauthor=L.+Huaauthor=J.-Y.+Lvauthor=Y.-L.+Liauthor=D.-L.+Yang&title=Osthole+inhibits+cell+proliferation+by+regulating+the+TGF-%CE%B21%2FSmad%2Fp38+signaling+pathways+in+pulmonary+arterial+smooth+muscle+cells&doi=10.1016%2Fj.biopha.2019.109640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Osthole inhibits cell proliferation by regulating the TGF-β1/Smad/p38 signaling pathways in pulmonary arterial smooth muscle cells</span></div><div class="casAuthors">Yue, Yun; Li, Yi-qi; Fu, Shu; Wu, Yu-Ting; Zhu, Ling; Hua, Liang; Lv, Jun-Yuan; Li, Ye-Li; Yang, Dan-Li</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109640</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Pulmonary artery smooth muscle cell (PASMC) proliferation contributes to pulmonary vascular remodeling, which ultimately leads to pulmonary arterial hypertension (PAH).  Osthole has been previously shown to inhibit tumor cell growth.  Our previous expts. demonstrated that osthole could prevent monocrotaline-induced PAH and pulmonary artery remodeling in rats and that its effects might be assocd. with inhibiting PASMC proliferation.  However, the exact mechanism remains unclear.  In this study, we obsd. the inhibitory effect of osthole on platelet-derived growth factor (PDGF)-BB-induced rat PASMC growth, cell cycle progression and proliferating cell nuclear antigen (PCNA) expression, as measured by CCK-8 assay, flow cytometric anal. and western blotting, resp.  We also detected the expression and activities of the cell cycle regulators cyclin D1/CDK4, cyclin E1/CDK2, p53, p27 and p21 and the TGF-β1/Smad/p38 signaling pathways in rat PASMCs by western blotting.  Our results show that osthole effectively suppressed PDGF-BB-stimulated proliferation, PCNA protein expression, and cell cycle progression in rat PASMCs in vitro.  We further demonstrated that treatment with osthole significantly induced cell cycle arrest at the G0/G1 phase in PASMCs, which was supported by the finding that osthole significantly decreased cyclin D1/CDK4 and cyclin E1/CDK2 protein levels and increased p53, p27 and p21 protein levels.  These effects may partly be attributed to the downregulation of TGF-β1/Smad/p38 signaling pathway activation.  Our findings suggest that osthole is a potential therapeutic candidate that warrants further investigation regarding its potential use for the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZCwyfqz5MirVg90H21EOLACvtfcHk0ljPCWJ2CrL-mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Ois7jK&md5=5a039a640a6fdf4a8ae57f5763c61256</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.109640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.109640%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.-Q.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.-T.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DHua%26aufirst%3DL.%26aulast%3DLv%26aufirst%3DJ.-Y.%26aulast%3DLi%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DD.-L.%26atitle%3DOsthole%2520inhibits%2520cell%2520proliferation%2520by%2520regulating%2520the%2520TGF-%25CE%25B21%252FSmad%252Fp38%2520signaling%2520pathways%2520in%2520pulmonary%2520arterial%2520smooth%2520muscle%2520cells%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2020%26volume%3D121%26spage%3D109640%26doi%3D10.1016%2Fj.biopha.2019.109640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Q. H.</span></span> <span> </span><span class="NLM_article-title">Astragalus polysaccharides attenuate monocrotaline-induced pulmonary arterial hypertension in rats</span>. <i>Am. J. Chin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">789</span>, <span class="refDoi"> DOI: 10.1142/S0192415X17500410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1142%2FS0192415X17500410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28521513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsVGmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=773-789&author=L.+B.+Yuanauthor=C.+Y.+Huaauthor=S.+Gaoauthor=Y.+L.+Yinauthor=M.+Daiauthor=H.+Y.+Mengauthor=P.+P.+Liauthor=Z.+X.+Yangauthor=Q.+H.+Hu&title=Astragalus+polysaccharides+attenuate+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats&doi=10.1142%2FS0192415X17500410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Astragalus Polysaccharides Attenuate Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats</span></div><div class="casAuthors">Yuan, Lin-Bo; Hua, Chun-Yan; Gao, Sheng; Yin, Ya-Ling; Dai, Mao; Meng, Han-Yan; Li, Piao-Piao; Yang, Zhong-Xin; Hu, Qing-Hua</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Chinese Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">773-789</span>CODEN:
                <span class="NLM_cas:coden">AJCMBA</span>;
        ISSN:<span class="NLM_cas:issn">0192-415X</span>.
    
            (<span class="NLM_cas:orgname">World Scientific Publishing Co. Pte. Ltd.</span>)
        </div><div class="casAbstract">Astragalus polysaccharides (APS) have been shown to possess a variety of biol. activities including anti-oxidant and anti-inflammation functions in a no. of diseases.  However, their function in pulmonary arterial hypertension (PAH) is still unknown.  Rats received APS (200mg/kg once two days) for 2 wk after being injected with monocrotaline (MCT; 60mg/kg).  The pulmonary hemodynamic index, right ventricular hypertrophy, and lung morphol. features of the rat models were examd., as well as the NO/eNOS ratio of wet lung and dry lung wt. and MPO.  A qRT-PCR and p-IκB was used to assess IL-1β, IL-6 and TNF-α and WB was used to detect the total IκB.  Based on these measurements, it was found that APS reversed the MCT-induced increase in mean pulmonary arterial pressure (mPAP) (from 32.731mmHg to 26.707mmHg), decreased pulmonary vascular resistance (PVR) (from 289.021mmHg× min/L to 246.351mmHg×min/L), and reduced right ventricular hypertrophy (from 289.021mmHg×min/L to 246.351 mmHg×min/L) (p<0.05).  In terms of pulmonary artery remodeling, the WT% and WA% decreased with the addn. of APS.  In addn., it was found that APS promoted the synthesis of eNOS and the secretion of NO, promoting vasodilation and APS decreased the MCT-induced elevation of MPO, IL-1β, IL-6 and TNF-α, reducing inflammation.  Furthermore, APS was able to inhibit the activation of pho-IκBα.  In couclusion, APS ameliorates MCT-induced pulmonary artery hypertension by inhibiting pulmonary arterial remodeling partially via eNOS/NO and NF-κB signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0FFEQOpEK1LVg90H21EOLACvtfcHk0liR-h5RsanhQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsVGmt7o%253D&md5=636be119a4d7ac7e01128ed82c993f4b</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1142%2FS0192415X17500410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1142%252FS0192415X17500410%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%2BB.%26aulast%3DHua%26aufirst%3DC.%2BY.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DYin%26aufirst%3DY.%2BL.%26aulast%3DDai%26aufirst%3DM.%26aulast%3DMeng%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DP.%2BP.%26aulast%3DYang%26aufirst%3DZ.%2BX.%26aulast%3DHu%26aufirst%3DQ.%2BH.%26atitle%3DAstragalus%2520polysaccharides%2520attenuate%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%26jtitle%3DAm.%2520J.%2520Chin.%2520Med.%26date%3D2017%26volume%3D45%26spage%3D773%26epage%3D789%26doi%3D10.1142%2FS0192415X17500410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furutani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, T.</span></span> <span> </span><span class="NLM_article-title">Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">79</span>, <span class="refDoi"> DOI: 10.1186/s12931-019-1041-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1186%2Fs12931-019-1041-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31023308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252Fpt1CrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=79&author=T.+Zhangauthor=N.+Kawaguchiauthor=K.+Yoshiharaauthor=E.+Hayamaauthor=Y.+Furutaniauthor=K.+Kawaguchiauthor=T.+Tanakaauthor=T.+Nakanishi&title=Silibinin+efficacy+in+a+rat+model+of+pulmonary+arterial+hypertension+using+monocrotaline+and+chronic+hypoxia&doi=10.1186%2Fs12931-019-1041-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia</span></div><div class="casAuthors">Zhang Tingting; Kawaguchi Nanako; Yoshihara Kenji; Hayama Emiko; Furutani Yoshiyuki; Kawaguchi Kayoko; Tanaka Takeshi; Nakanishi Toshio; Zhang Tingting</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  C-X-C chemokine receptor type 4 (CXCR4) may be involved in the development of pulmonary arterial hypertension (PAH).  CXCR4 inhibitor AMD3100 was described to have a positive effect on the prevention of pulmonary arterial muscularization in PAH models.  Silibinin is a traditional medicine that has an antagonistic effect on CXCR4.  We investigated the effect of silibinin using rat models of PAH.  METHODS:  PAH was induced by a single subcutaneous injection of monocrotaline.  The rats were maintained in a chronic hypoxic condition (10% O2) with or without silibinin.  To evaluate the efficacy of silibinin on PAH, right ventricular systolic pressure (RVSP), Fulton index (weight ratio of right ventricle to the left ventricle and septum), percent medial wall thickness (% MT), and vascular occlusion score (VOS) were measured and calculated.  Immunohistochemical analysis was performed targeting CXCR4 and c-Kit.  Reverse transcription-quantitative polymerase chain reaction was performed for the stem cell markers CXCR4, stromal cell derived factor-1 (SDF-1), c-Kit, and stem cell factor (SCF), and the inflammatory markers monocyte chemoattractant protein 1 (MCP1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNFα).  Statistical analyses were performed using t-test and one-way analysis of variance with Bonferroni's post hoc test.  RESULTS:  Silibinin treatment for 1 week reduced RVSP and Fulton index.  Treatment for 2 weeks reduced RVSP, Fulton index, % MT, and VOS, as well as downregulating the expression of CXCR4, SDF-1, and TNFα in pulmonary arteries.  In contrast, treatment for 3 weeks failed to ameliorate PAH.  The time-course study demonstrated that RVSP, Fulton index, % MT, and VOS gradually increased over time, with a decrease in the expression of CXCR4 and TNFα occurring after 2 weeks of PAH development.  After 3 weeks, SDF-1, c-Kit, and SCF began to decrease and, after 5 weeks, MCP1 and IL-6 gradually accumulated.  CONCLUSIONS:  The CXCR4 inhibitor silibinin can ameliorate PAH, possibly through the suppression of the CXCR4/SDF-1 axis, until the point where PAH becomes a severe and irreversible condition.  Silibinin results in reduced pulmonary arterial pressure and delays pulmonary arteriolar occlusion and pulmonary vascular remodeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVkeWJ1Fp8_srRqEXsZufAfW6udTcc2eb1Z9PtzX5IELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252Fpt1CrtQ%253D%253D&md5=beeebd17b13886f3b88f65092d65e120</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1186%2Fs12931-019-1041-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-019-1041-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKawaguchi%26aufirst%3DN.%26aulast%3DYoshihara%26aufirst%3DK.%26aulast%3DHayama%26aufirst%3DE.%26aulast%3DFurutani%26aufirst%3DY.%26aulast%3DKawaguchi%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DNakanishi%26aufirst%3DT.%26atitle%3DSilibinin%2520efficacy%2520in%2520a%2520rat%2520model%2520of%2520pulmonary%2520arterial%2520hypertension%2520using%2520monocrotaline%2520and%2520chronic%2520hypoxia%26jtitle%3DRespir.%2520Res.%26date%3D2019%26volume%3D20%26spage%3D79%26doi%3D10.1186%2Fs12931-019-1041-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span> <span> </span><span class="NLM_article-title">Protective effects of 18β-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">108749</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2019.108749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.cbi.2019.108749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31325423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSrsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2019&pages=108749&author=M.+Zhangauthor=Z.+Changauthor=P.+Zhangauthor=Z.+Jingauthor=L.+Yanauthor=J.+Fengauthor=Z.+Huauthor=Q.+Xuauthor=W.+Zhouauthor=P.+Maauthor=Y.+Haoauthor=R.+Zhou&title=Protective+effects+of+18%CE%B2-glycyrrhetinic+acid+on+pulmonary+arterial+hypertension+via+regulation+of+Rho+A%2FRho+kinsase+pathway&doi=10.1016%2Fj.cbi.2019.108749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Protective effects of 18beta-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway</span></div><div class="casAuthors">Zhang, Min; Chang, Zhi; Zhang, Peng; Jing, Zhicheng; Yan, Lin; Feng, Jun; Hu, Zhiqiang; Xu, Qingbin; Zhou, Wei; Ma, Ping; Hao, Yinju; Zhou, Ru</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108749</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Excessive proliferation, migration and anti-apoptosis of pulmonary artery smooth muscle cells (PASMCs) are the basis for the development of pulmonary vascular remodeling, and it is the driving force for pulmonary arterial hypertension (PAH). 18beta-glycyrrhetinic acid is the main active substance extd. from Chinese herbal medicine licorice, with outstanding anti-inflammatory, anti-oxidn. and anti-proliferative effects.  Our team found in previous studies that 18beta-GA has protective effects on monocrotaline-induced PAH in rats.  However, the anti-angiogenic effect of 18beta-GA on PAH remains unclear.  Therefore, in order to further investigate whether the beneficial effects of 18beta-GA on PAH are related to its antiproliferative effect, we conducted expts. in vivo and in vitro.  In vivo, 18beta-GA relieved mean pulmonary arterial pressure, right ventricular systolic pressure, and right ventricular hypertrophy index, improving pulmonary remodeling.  Furthermore, after treatment with 18beta-GA, the expression of Rho A, ROCK1, ROCK2 was decreased and ROCK activity was inhibited in HPASMC.  In addn., 18beta-GA also attenuated PDGF-induced changes in p27kip1, Bax and Bcl-2.  In summary, these results indicate that 18beta-GA regulates the activity of RhoA-ROCK signaling pathway, inhibits the proliferation of HPASMCs, and has potential value in the treatment of PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiCEft5wUvrVg90H21EOLACvtfcHk0liR-h5RsanhQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSrsLnJ&md5=27b8ac4fdccf1e535417048b1d3c9901</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2019.108749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2019.108749%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DP.%26aulast%3DHao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DR.%26atitle%3DProtective%2520effects%2520of%252018%25CE%25B2-glycyrrhetinic%2520acid%2520on%2520pulmonary%2520arterial%2520hypertension%2520via%2520regulation%2520of%2520Rho%2520A%252FRho%2520kinsase%2520pathway%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2019%26volume%3D311%26spage%3D108749%26doi%3D10.1016%2Fj.cbi.2019.108749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, Y.</span></span> <span> </span><span class="NLM_article-title">Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">63430</span>– <span class="NLM_lpage">63441</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.18825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.18632%2Foncotarget.18825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28969002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FksVSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=63430-63441&author=Z.+Zhangauthor=L.+Zhangauthor=C.+Sunauthor=F.+Kongauthor=J.+Wangauthor=Q.+Xinauthor=W.+Jiangauthor=K.+Liauthor=O.+Chenauthor=Y.+Luan&title=Baicalin+attenuates+monocrotaline-induced+pulmonary+hypertension+through+bone+morphogenetic+protein+signaling+pathway&doi=10.18632%2Foncotarget.18825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Baicalin attenuates monocrotaline-induced pulmonary hypertension through bone morphogenetic protein signaling pathway</span></div><div class="casAuthors">Zhang Zhaohua; Zhang Luan; Sun Chao; Kong Feng; Wang Jue; Xin Qian; Jiang Wen; Li Kaili; Chen Ou; Luan Yun</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">63430-63441</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Baicalin, a flavonoid compound extracted from roots of Scutellaria baicalensis Georgi (huang qin), it has been shown to effectively attenuates pulmonary hypertension (PH), however, the potential mechanism remains unexplored.  In this study, we investigated the potential mechanism of baicalin on monocrotaline (MCT)-induced PH in rats.  The results showed that baicalin attenuated lung damage in PH rat model through inhibiting the pulmonary arterial smooth muscle cell proliferation and induction of cells apoptosis.  Furthermore, we demonstrated that baicalin inhibition the expression of nuclear factor-κB (NF-κB) p65 and bone morphogenetic protein (BMP) antagonists gremlin-1, but increased the expression of inhibitor of NF-κB (I-κBα), BMPR2, BMP-4, BMP-9 and Smad1/5/8.  Additionally, baicalin suppression endothelial-to-mesenchymal transition in PH lung tissue.  Collectively, we confirmed that baicalin via inhibition of NF-κB signaling to further activation of BMP signaling to have a therapeutic effect on PH and providing a promising therapeutic strategy for PH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLSKkSsKMGSHthwrmtH4OBfW6udTcc2ea6mz71d8NAsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FksVSlsQ%253D%253D&md5=cbdf388c963985efd6df07e5a68d1b63</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.18825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.18825%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DO.%26aulast%3DLuan%26aufirst%3DY.%26atitle%3DBaicalin%2520attenuates%2520monocrotaline-induced%2520pulmonary%2520hypertension%2520through%2520bone%2520morphogenetic%2520protein%2520signaling%2520pathway%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D63430%26epage%3D63441%26doi%3D10.18632%2Foncotarget.18825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, W.</span></span> <span> </span><span class="NLM_article-title">Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1177/2045894019878599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F2045894019878599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOntr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1-10&author=G.+Yanauthor=J.+Wangauthor=T.+Yiauthor=J.+Chengauthor=H.+Guoauthor=Y.+Heauthor=X.+Shuiauthor=Z.+Wuauthor=S.+Huangauthor=W.+Lei&title=Baicalin+prevents+pulmonary+arterial+remodeling+in+vivo+via+the+AKT%2FERK%2FNF-%CE%BAB+signaling+pathways&doi=10.1177%2F2045894019878599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways</span></div><div class="casAuthors">Yan, Guosen; Wang, Jinxia; Yi, Tao; Cheng, Junfen; Guo, Haixu; He, Yuan; Shui, Xiaorong; Wu, Zeyong; Huang, Shian; Lei, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">This study investigated the effects and mechanism of baicalin on vascular remodeling in rats with pulmonary arterial hypertension.  A rat pulmonary arterial hypertension model was constructed using i.p. injection of monocrotaline, and different doses of baicalin were used to treat these rats.  The mean pulmonary arterial pressure (mPAP) and right ventricular systolic pressure (RVSP) were measured with a right heart catheter.  Moreover, the hearts were dissected to det. the right ventricular hypertrophy index (RVHI).  The lung tissues were stained with H&E and Masson's staining to est. the pulmonary vascular remodeling and collagen fibrosis, and the expression of proteins in the AKT, ERK, and NF-κB p65 phosphorylation (p-AKT, p-ERK, p-p65) was examd. by Western blot anal.  We found that compared with untreated pulmonary arterial hypertension rats, baicalin ameliorated pulmonary vascular remodeling and cardiorespiratory injury, inhibited p-p65 and p-ERK expression, and promoted p-AKT and p-eNOS expression.  In conclusion, baicalin interfered with pulmonary vascular remodeling and pulmonary arterial hypertension development in rats through the AKT/eNOS, ERK and NF-κB signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOISajJ6mKrVg90H21EOLACvtfcHk0lhPENRfZExNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOntr7O&md5=73d210a96cdff297e1ef39c36db7200e</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1177%2F2045894019878599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045894019878599%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DShui%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DLei%26aufirst%3DW.%26atitle%3DBaicalin%2520prevents%2520pulmonary%2520arterial%2520remodeling%2520in%2520vivo%2520via%2520the%2520AKT%252FERK%252FNF-%25CE%25BAB%2520signaling%2520pathways%26jtitle%3DPulm.%2520Circ.%26date%3D2019%26volume%3D9%26spage%3D1%26epage%3D10%26doi%3D10.1177%2F2045894019878599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span> <span> </span><span class="NLM_article-title">Therapeutic effects of aloperine on the pulmonary arterial hypertension</span>. <i>Farmacia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.31925/farmacia.2019.4.19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.31925%2Ffarmacia.2019.4.19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Chu7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=691-701&author=S.+Liauthor=F.+Zhouauthor=J.+Dongauthor=Q.+Dongauthor=H.+Luanauthor=L.+Liauthor=Y.+Hao&title=Therapeutic+effects+of+aloperine+on+the+pulmonary+arterial+hypertension&doi=10.31925%2Ffarmacia.2019.4.19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic effects of aloperine on the pulmonary arterial hypertension</span></div><div class="casAuthors">Li, Shuang; Zhou, Fubo; Dong, Jianjiang; Dong, Qi; Luan, Hairong; Li, Li; Hao, Yankun</div><div class="citationInfo"><span class="NLM_cas:title">Farmacia (Bucharest, Romania)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">691-701</span>CODEN:
                <span class="NLM_cas:coden">FRMBAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-8237</span>.
    
            (<span class="NLM_cas:orgname">Societatea de Stiinte Farmaceutice din Romania</span>)
        </div><div class="casAbstract">In order to study the therapeutic effect of aloperine (ALO) on the pulmonary arterial hypertension (PAH), 90 male Sprague Dawley (SD) rats were divided into six groups: sham group, PAH group, PAH + 25 mg/kg bw ALO group, PAH + 50 mg/kg bw ALO group, PAH + 100 mg/kg bw ALOgroup, and PAH + 25 mg/kg bw sildenafil group.  The hemodynamic parameters, pulmonary fibrosis, vascular endothelial cell structure, intercellular monocyte chemotactic protein-1 (MCP-1) (adhesion factor-1) and ET-1 (endothelin-1) expression levels, and the expression levels of nuclear factor kappa light chain enhancer of activated B cells (NF-κB), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) pathways were assayed by Western blotting in order to evaluate the influence of ALO on PAH.  It was revealed that after the successful establishment of monocrotaline-induced PAH models in rats, rats showed decreased wall thickness of pulmonary arterioles, vascular stenosis, irregular swelling of vascular endothelial cells, proliferation of pulmonary fibrous tissues, disordered arrangement, increased no. of MCP-1 and ET-1 cells, and increased expression levels of NF-κB, TNF-α, and IL-1β pathways.  Sildenafil is well known to have protective effects on PAH.  According to the achieved results, it can be concluded that ALO also has protective effects on PAH.  ALO could improve the development of PAH through the NF-κB p65 signalling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiQbnvWu4j4bVg90H21EOLACvtfcHk0lhPENRfZExNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Chu7nN&md5=2d127939a2a97d9f5bc1925e737281fb</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.31925%2Ffarmacia.2019.4.19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.31925%252Ffarmacia.2019.4.19%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DQ.%26aulast%3DLuan%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DHao%26aufirst%3DY.%26atitle%3DTherapeutic%2520effects%2520of%2520aloperine%2520on%2520the%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DFarmacia%26date%3D2019%26volume%3D67%26spage%3D691%26epage%3D701%26doi%3D10.31925%2Ffarmacia.2019.4.19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, P.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wann, S.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-C.</span></span> <span> </span><span class="NLM_article-title">Caffeic acid phenethyl ester rescues pulmonary arterial hypertension through the inhibition of AKT/ERK-dependent PDGF/HIF-1α in vitro and in vivo</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1468</span>, <span class="refDoi"> DOI: 10.3390/ijms20061468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fijms20061468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1468&author=C.-C.+Chengauthor=P.-L.+Chiauthor=M.-C.+Shenauthor=C.-W.+Shuauthor=S.-R.+Wannauthor=C.-P.+Liuauthor=C.-J.+Tsengauthor=W.-C.+Huang&title=Caffeic+acid+phenethyl+ester+rescues+pulmonary+arterial+hypertension+through+the+inhibition+of+AKT%2FERK-dependent+PDGF%2FHIF-1%CE%B1+in+vitro+and+in+vivo&doi=10.3390%2Fijms20061468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Caffeic acid phenethyl ester rescues pulmonary arterial hypertension through the inhibition of AKT/ERK-dependent PDGF/HIF-1α in vitro and in vivo</span></div><div class="casAuthors">Cheng, Chin-Chang; Chi, Pei-Ling; Shen, Min-Ci; Shu, Chih-Wen; Wann, Shue-Ren; Liu, Chun-Peng; Tseng, Ching-Jiunn; Huang, Wei-Chun</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is characterized by pulmonary arterial proliferation and remodeling, resulting in a specific increase in right ventricle systolic pressure (RVSP) and, ultimately right ventricular failure.  Recent studies have demonstrated that caffeic acid phenethyl ester (CAPE) exerts a protective role in NF- κB-mediated inflammatory diseases.  However, the effect of CAPE on PAH remains to be elucidated.  In this study, monocrotaline (MCT) was used to establish PAH in rats.  Two weeks after the induction of PAH by MCT, CAPE was administrated by i.p. injection once a day for two weeks.  Pulmonary hemodynamic measurements and pulmonary artery morphol. assessments were examd.  Our results showed that administration of CAPE significantly suppressed MCT-induced vascular remodeling by decreasing the HIF-1α expression and PDGF-BB prodn., and improved in vivo RV systolic performance in rats.  Furthermore, CAPE inhibits hypoxia- and PDGF-BB-induced HIF-1α expression by decreasing the activation of the AKT/ERK pathway, which results in the inhibition of human pulmonary artery smooth muscle cells (hPASMCs) proliferation and prevention of cells resistant to apoptosis.  Overall, our data suggest that HIF-1α is regarded as an alternative target for CAPE in addn. to NF- κB, and may represent a promising therapeutic agent for the treatment of PAH diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCGH9JCmTeD7Vg90H21EOLACvtfcHk0lhLNPxNzKpZyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFWltL8%253D&md5=c9b749591edcd825995439d638b76f40</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.3390%2Fijms20061468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20061468%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.-C.%26aulast%3DChi%26aufirst%3DP.-L.%26aulast%3DShen%26aufirst%3DM.-C.%26aulast%3DShu%26aufirst%3DC.-W.%26aulast%3DWann%26aufirst%3DS.-R.%26aulast%3DLiu%26aufirst%3DC.-P.%26aulast%3DTseng%26aufirst%3DC.-J.%26aulast%3DHuang%26aufirst%3DW.-C.%26atitle%3DCaffeic%2520acid%2520phenethyl%2520ester%2520rescues%2520pulmonary%2520arterial%2520hypertension%2520through%2520the%2520inhibition%2520of%2520AKT%252FERK-dependent%2520PDGF%252FHIF-1%25CE%25B1%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1468%26doi%3D10.3390%2Fijms20061468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-m.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.-r.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.-q.</span></span> <span> </span><span class="NLM_article-title">Betaine attenuates monocrotaline-induced pulmonary arterial hypertension in rats via inhibiting inflammatory response</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1274</span>, <span class="refDoi"> DOI: 10.3390/molecules23061274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.3390%2Fmolecules23061274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=1274&author=J.-m.+Yangauthor=R.+Zhouauthor=M.+Zhangauthor=H.-r.+Tanauthor=J.-q.+Yu&title=Betaine+attenuates+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats+via+inhibiting+inflammatory+response&doi=10.3390%2Fmolecules23061274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Betaine attenuates monocrotaline-induced pulmonary arterial hypertension in rats via inhibiting inflammatory response</span></div><div class="casAuthors">Yang, Jia-mei; Zhou, Ru; Zhang, Min; Tan, Huan-ran; Yu, Jian-qiang</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1274/1-1274/15</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, leading to right ventricular failure and death.  Recent studies have suggested that chronic inflammatory processes are involved in the pathogenesis of PAH.  To test our hypothesis, we aimed to investigate the effects of betaine on monocrotaline-induced PAH in rats and attempted to further clarify the possible mechanisms.  PAH was induced by monocrotaline (50 mg/kg) and oral administration of betaine (100, 200, and 400 mg/kg/day).  The mean pulmonary arterial pressure, right ventricular systolic pressure, and right ventricle hypertrophy index were used to evaluate the development of PAH.  Nuclear factor-kappaB, tumor necrosis factor alpha (TNF-a), and interleukin-1beta were assessed by Western blot.  This study showed that betaine improved the abnormalities in right ventricular systolic pressure, mean pulmonary arterial pressure, right ventricle hypertrophy index, and pulmonary arterial remodeling induced by monocrotaline compared with the PAH group.  The levels of MCP-1 and ET-1 also decreased.  Western blot indicated that the protein expression levels of NF-kappaB, TNF-a, and IL-1beta significantly decreased (p < 0.01).  Our study demonstrated that betaine attenuated PAH through its anti-inflammatory effects.  Hence, the present data may offer novel targets and promising pharmacol. perspectives for treating monocrotaline-induced PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwzIYSjSh7GLVg90H21EOLACvtfcHk0lhLNPxNzKpZyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWksb3P&md5=ba29b457ba33a6abdcfc04f9400314bd</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23061274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23061274%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.-m.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DH.-r.%26aulast%3DYu%26aufirst%3DJ.-q.%26atitle%3DBetaine%2520attenuates%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%2520via%2520inhibiting%2520inflammatory%2520response%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D1274%26doi%3D10.3390%2Fmolecules23061274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the NG, NG-dimethyl-L-arginine metabolism pathways in rats</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>842</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.ejphar.2018.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=30419238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Crur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=842&publication_year=2019&pages=338-344&author=G.+Daiauthor=B.+Liauthor=Y.+Xuauthor=Z.+Zengauthor=H.+Yang&title=Oxymatrine+prevents+the+development+of+monocrotaline-induced+pulmonary+hypertension+via+regulation+of+the+NG%2C+NG-dimethyl-L-arginine+metabolism+pathways+in+rats&doi=10.1016%2Fj.ejphar.2018.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the NG, NG-dimethyl-L-arginine metabolism pathways in rats</span></div><div class="casAuthors">Dai, Guidong; Li, Benpeng; Xu, Yuping; Zeng, Zhuliang; Yang, Hongyun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">842</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">338-344</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the potential effect of oxymatrine in monocrotaline-induced pulmonary hypertension and its possible influence on the NG,NG-dimethyl-L-arginine (ADMA) metab. pathway.  Pulmonary hypertension was induced in rats by a single-dose injection of monocrotaline (60 mg/kg).  Daily oral administration of oxymatrine (25, 50 and 100 mg/kg) was started on the day following the monocrotaline injection for 28 days.  Oxymatrine (50 and 100 mg/kg) significantly attenuated monocrotaline-induced lung and right ventricular hypertrophy, right ventricular systolic pressure elevation, and right ventricular dysfunction.  Meanwhile, oxymatrine normalized the level of pulmonary asym. ADMA and attenuated the upregulated expression of protein arginine methyltransferase 1 (PRMT1).  Oxymatrine had no effect on the expression of protein arginine methyltransferase 2 (PRMT2) and NG,NG-Dimethylarginine dimethylaminohydrolase 1 (DDAH1), which were upregulated in monocrotaline-induced pulmonary arterial hypertensive rats.  However, the expression of the protein NG,NG-Dimethylarginine dimethylaminohydrolase 2 (DDAH2) did not differ among all groups (all P>0.05).  These results suggest that oxymatrine may offer protective effects on the development of pulmonary hypertension by ameliorating pulmonary remodeling and modulating the ADMA metab. pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL-e5boppvb7Vg90H21EOLACvtfcHk0lhLNPxNzKpZyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Crur7I&md5=d572ac3747abba051afbd64582c07118</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DOxymatrine%2520prevents%2520the%2520development%2520of%2520monocrotaline-induced%2520pulmonary%2520hypertension%2520via%2520regulation%2520of%2520the%2520NG%252C%2520NG-dimethyl-L-arginine%2520metabolism%2520pathways%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D842%26spage%3D338%26epage%3D344%26doi%3D10.1016%2Fj.ejphar.2018.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span> <span> </span><span class="NLM_article-title">Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2017.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1016%2Fj.biopha.2017.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=29078260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1yltbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=825-833&author=Q.+Liauthor=J.+Wangauthor=X.+Zhuauthor=Z.+Zengauthor=X.+Wuauthor=Y.+Xuauthor=J.+Xieauthor=J.+Yu&title=Dihydromyricetin+prevents+monocrotaline-induced+pulmonary+arterial+hypertension+in+rats&doi=10.1016%2Fj.biopha.2017.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats</span></div><div class="casAuthors">Li, Qinghai; Wang, Jun; Zhu, Xianying; Zeng, Zhilin; Wu, Xiaomei; Xu, Yongjian; Xie, Jungang; Yu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">825-833</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Pulmonary artery hypertension (PAH) is a chronic and deadly disease, for which effective medical treatments are lacking.  Here, we investigated whether 2R,3R-dihydromyricetin (DHM) could prevent monocrotaline (MCT)-induced PAH in rats.  The MCT-injected rats were treated with normal saline or DHM (100 mg/kg body wt./d) for 4 wk, followed by measurements of right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RVHI), pulmonary arterial remodeling (PAR), and expression levels of IL-6, TNF-α, and IL-10.  In vitro, we assessed the role of DHM on IL-6-induced migration of primary human pulmonary arterial smooth muscle cells (HPASMCs).  We found that DHM treatment attenuated changes in RVSP, RVHI, and PAR in MCT-injected PAH rats.  The obsd. increase of IL-6 levels in PAH rats was inhibited by DHM treatment.  In vitro, DHM pretreatment reduced IL-6-induced HPASMC migration.  Furthermore, MCT- and IL-6-mediated increases in MMP9 and P-STAT3 (tyr705) PY-STAT3 levels were suppressed by DHM treatment in vivo and in vitro.  These results suggest that DHM could prevent MCT-induced rat PAH and IL-6-induced HPASMC migration through a mechanism involving inhibiting of the STAT3/MMP9 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPsUYmgkl9t7Vg90H21EOLACvtfcHk0liUvcVYExipSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1yltbzO&md5=9518191da3a3d2cf9ba8b0987ee04cf5</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2017.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2017.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26atitle%3DDihydromyricetin%2520prevents%2520monocrotaline-induced%2520pulmonary%2520arterial%2520hypertension%2520in%2520rats%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2017%26volume%3D96%26spage%3D825%26epage%3D833%26doi%3D10.1016%2Fj.biopha.2017.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boucherat, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, S.</span></span> <span> </span><span class="NLM_article-title">The cancer theory of pulmonary arterial hypertension</span>. <i>Pulm. Circ.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1177/2045893217701438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1177%2F2045893217701438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=28597757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlCgurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=285-299&author=O.+Boucheratauthor=G.+Vitryauthor=I.+Trinhauthor=R.+Paulinauthor=S.+Provencherauthor=S.+Bonnet&title=The+cancer+theory+of+pulmonary+arterial+hypertension&doi=10.1177%2F2045893217701438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">The cancer theory of pulmonary arterial hypertension</span></div><div class="casAuthors">Boucherat, Olivier; Vitry, Geraldine; Trinh, Isabelle; Paulin, Roxane; Provencher, Steeve; Bonnet, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Circulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">285-299</span>CODEN:
                <span class="NLM_cas:coden">PCUIAX</span>;
        ISSN:<span class="NLM_cas:issn">2045-8940</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">Pulmonary arterial hypertension (PAH) remains a mysterious killer that, like cancer, is characterized by tremendous complexity.  PAH development occurs under sustained and persistent environmental stress, such as inflammation, shear stress, pseudo-hypoxia, and more.  After inducing an initial death of the endothelial cells, these environmental stresses contribute with time to the development of hyper-proliferative and apoptotic resistant clone of cells including pulmonary artery smooth muscle cells, fibroblasts, and even pulmonary artery endothelial cells allowing vascular remodeling and PAH development.  Molecularly, these cells exhibit many features common to cancer cells offering the opportunity to exploit therapeutic strategies used in cancer to treat PAH.  In this review, we outline the signaling pathways and mechanisms described in cancer that drive PAH cells' survival and proliferation and discuss the therapeutic potential of antineoplastic drugs in PAH.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAogNU0qVfVrVg90H21EOLACvtfcHk0liUvcVYExipSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlCgurw%253D&md5=1a0e3aeb31030c1a9465fedf441eda30</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1177%2F2045893217701438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2045893217701438%26sid%3Dliteratum%253Aachs%26aulast%3DBoucherat%26aufirst%3DO.%26aulast%3DVitry%26aufirst%3DG.%26aulast%3DTrinh%26aufirst%3DI.%26aulast%3DPaulin%26aufirst%3DR.%26aulast%3DProvencher%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DS.%26atitle%3DThe%2520cancer%2520theory%2520of%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DPulm.%2520Circ.%26date%3D2017%26volume%3D7%26spage%3D285%26epage%3D299%26doi%3D10.1177%2F2045893217701438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbera, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeper, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peacock, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonneau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vachiery, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudiz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk-Noordegraaf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">834</span>– <span class="NLM_lpage">844</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1056%2FNEJMoa1413687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=26308684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=834-844&author=N.+Galieauthor=J.+A.+Barberaauthor=A.+E.+Frostauthor=H.+A.+Ghofraniauthor=M.+M.+Hoeperauthor=V.+V.+McLaughlinauthor=A.+J.+Peacockauthor=G.+Simonneauauthor=J.+L.+Vachieryauthor=E.+Grunigauthor=R.+J.+Oudizauthor=A.+Vonk-Noordegraafauthor=R.+J.+Whiteauthor=C.+Blairauthor=H.+Gilliesauthor=K.+L.+Millerauthor=J.+H.+N.+Harrisauthor=J.+Langleyauthor=L.+J.+Rubin&title=Initial+use+of+ambrisentan+plus+tadalafil+in+pulmonary+arterial+hypertension&doi=10.1056%2FNEJMoa1413687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension</span></div><div class="casAuthors">Galie, N.; Barbera, J. A.; Frost, A. E.; Ghofrani, H.-A.; Hoeper, M. M.; McLaughlin, V. V.; Peacock, A. J.; Simonneau, G.; Vachiery, J.-L.; Grunig, E.; Oudiz, R. J.; Vonk-Noordegraaf, A.; White, R. J.; Blair, C.; Gillies, H.; Miller, K. L.; Harris, J. H. N.; Langley, J.; Rubin, L. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">834-844</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce.  Methods: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentanmonotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily.  The primary end point in a time-to-event anal. was the first event of clin. failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clin. response.  Results: The primary anal. included 500 participants; 253 were assigned to the combination- therapy group, 126 to the ambrisentan-monotherapy group, and 121 to the tadalafil-monotherapy group.  A primary end-point event occurred in 18%, 34%, and 28% of the participants in these groups, resp., and in 31% of the pooledmonotherapy group (the two monotherapy groups combined).  The hazard ratio for the primary end point in the combination-therapy group vs. the pooled-monotherapy group was 0.50 (95% confidence interval [CI], 0.35 to 0.72; P<0.001).  At week 24, the combination-therapy group had greater redns. from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-monotherapy group (mean change, -67.2% vs. -50.4%; P<0.001), as well as a higher percentage of patients with a satisfactory clin. response (39% vs. 29%; odds ratio, 1.56 [95% CI, 1.05 to 2.32]; P = 0.03) and a greater improvement in the 6-min walk distance (median change from baseline, 48.98 m vs. 23.80 m; P<0.001).  The adverse events that occurred more frequently in the combination-therapy group than in either monotherapy group included peripheral edema, headache, nasal congestion, and anemia.  Conclusions: Among participants with pulmonary arterial hypertension who had not received previous treatment, initial combination therapy with ambrisentan and tadalafil resulted in a significantly lower risk of clin.-failure events than the risk with ambrisentan or tadalafil monotherapy. (Funded by Gilead Sciences and GlaxoSmithKline; AMBITION ClinicalTrials.gov no., NCT01178073).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe4zQLE95kVbVg90H21EOLACvtfcHk0liUvcVYExipSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGisA%253D%253D&md5=018dd6202fa784e3570c7dd6395218e4</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413687%26sid%3Dliteratum%253Aachs%26aulast%3DGalie%26aufirst%3DN.%26aulast%3DBarbera%26aufirst%3DJ.%2BA.%26aulast%3DFrost%26aufirst%3DA.%2BE.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DHoeper%26aufirst%3DM.%2BM.%26aulast%3DMcLaughlin%26aufirst%3DV.%2BV.%26aulast%3DPeacock%26aufirst%3DA.%2BJ.%26aulast%3DSimonneau%26aufirst%3DG.%26aulast%3DVachiery%26aufirst%3DJ.%2BL.%26aulast%3DGrunig%26aufirst%3DE.%26aulast%3DOudiz%26aufirst%3DR.%2BJ.%26aulast%3DVonk-Noordegraaf%26aufirst%3DA.%26aulast%3DWhite%26aufirst%3DR.%2BJ.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DGillies%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DK.%2BL.%26aulast%3DHarris%26aufirst%3DJ.%2BH.%2BN.%26aulast%3DLangley%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DL.%2BJ.%26atitle%3DInitial%2520use%2520of%2520ambrisentan%2520plus%2520tadalafil%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D834%26epage%3D844%26doi%3D10.1056%2FNEJMoa1413687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sitbon, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaine, S.</span></span> <span> </span><span class="NLM_article-title">Beyond a single pathway: combination therapy in pulmonary arterial hypertension</span>. <i>Eur. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">417</span>, <span class="refDoi"> DOI: 10.1183/16000617.0085-2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1183%2F16000617.0085-2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27903663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BC2sjitVOitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=408-417&author=O.+Sitbonauthor=S.+Gaine&title=Beyond+a+single+pathway%3A+combination+therapy+in+pulmonary+arterial+hypertension&doi=10.1183%2F16000617.0085-2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond a single pathway: combination therapy in pulmonary arterial hypertension</span></div><div class="casAuthors">Sitbon Olivier; Sitbon Olivier; Sitbon Olivier; Gaine Sean</div><div class="citationInfo"><span class="NLM_cas:title">European respiratory review : an official journal of the European Respiratory Society</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">142</span>),
    <span class="NLM_cas:pages">408-417</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is a strong rationale for combining therapies to simultaneously target three of the key pathways implicated in the pathogenesis of pulmonary arterial hypertension (PAH).  Evidence to support this strategy is growing, and a number of studies have demonstrated that combination therapy, administered as either a sequential or an initial regimen, can improve long-term outcomes in PAH.  Dual combination therapy with a phosphodiesterase-5 inhibitor and an endothelin receptor antagonist is the most widely utilised combination regimen.  However, some patients fail to achieve their treatment goals on dual therapy and may benefit from the addition of a third drug.  The use of triple therapy in clinical practice was previously reserved for patients with severe disease due to the need for parenteral administration of prostanoids.  Although triple therapy with parenteral prostanoids plays a key role in the management of severe PAH, the approval of oral therapies that target the prostacyclin pathway means that all three pathways can now be targeted with oral drugs at an earlier disease stage.  Furthermore, there is evidence demonstrating that this approach can delay disease progression.  Based on the evidence available, it is becoming increasingly clear that all PAH patients should be offered the benefits of combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnSocOUykyg-qrn-c4Of3KfW6udTcc2ebQ9LLJjiBM6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjitVOitA%253D%253D&md5=8e436a77a02e54bb63f5a76e8144d5e8</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1183%2F16000617.0085-2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F16000617.0085-2016%26sid%3Dliteratum%253Aachs%26aulast%3DSitbon%26aufirst%3DO.%26aulast%3DGaine%26aufirst%3DS.%26atitle%3DBeyond%2520a%2520single%2520pathway%253A%2520combination%2520therapy%2520in%2520pulmonary%2520arterial%2520hypertension%26jtitle%3DEur.%2520Respir.%2520Rev.%26date%3D2016%26volume%3D25%26spage%3D408%26epage%3D417%26doi%3D10.1183%2F16000617.0085-2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cragg, G. M.</span></span> <span> </span><span class="NLM_article-title">Natural products as sources of new drugs from 1981 to 2014</span>. <i>J. Nat. Prod.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1021/acs.jnatprod.5b01055</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jnatprod.5b01055" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1Kqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2016&pages=629-661&author=D.+J.+Newmanauthor=G.+M.+Cragg&title=Natural+products+as+sources+of+new+drugs+from+1981+to+2014&doi=10.1021%2Facs.jnatprod.5b01055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">Natural Products as Sources of New Drugs from 1981 to 2014</span></div><div class="casAuthors">Newman, David J.; Cragg, Gordon M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Natural Products</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">629-661</span>CODEN:
                <span class="NLM_cas:coden">JNPRDF</span>;
        ISSN:<span class="NLM_cas:issn">0163-3864</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society-American Society of Pharmacognosy</span>)
        </div><div class="casAbstract">This contribution is a completely updated and expanded version of the four prior analogous reviews that were published in this journal in 1997, 2003, 2007, and 2012.  In the case of all approved therapeutic agents, the time frame has been extended to cover the 34 years from Jan. 1, 1981, to Dec. 31, 2014, for all diseases worldwide, and from 1950 (earliest so far identified) to Dec. 2014 for all approved antitumor drugs worldwide.  As mentioned in the 2012 review, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions and the designation "natural product botanical", or "NB", to cover those botanical "defined mixts." now recognized as drug entities by the U.S. FDA (and similar organizations).  From the data presented in this review, the utilization of natural products and/or their novel structures, in order to discover and develop the final drug entity, is still alive and well.  For example, in the area of cancer, over the time frame from around the 1940s to the end of 2014, of the 175 small mols. approved, 131, or 75%, are other than "S" (synthetic), with 85, or 49%, actually being either natural products or directly derived therefrom.  In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the anti-infective area being dependent on natural products and their structures.  We wish to draw the attention of readers to the rapidly evolving recognition that a significant no. of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore it is considered that this area of natural product research should be expanded significantly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMgEvq9fVY8bVg90H21EOLACvtfcHk0lgii72JelAkJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1Kqu7k%253D&md5=c9f2a44ab6b66331b7ef6ca64029328a</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1021%2Facs.jnatprod.5b01055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jnatprod.5b01055%26sid%3Dliteratum%253Aachs%26aulast%3DNewman%26aufirst%3DD.%2BJ.%26aulast%3DCragg%26aufirst%3DG.%2BM.%26atitle%3DNatural%2520products%2520as%2520sources%2520of%2520new%2520drugs%2520from%25201981%2520to%25202014%26jtitle%3DJ.%2520Nat.%2520Prod.%26date%3D2016%26volume%3D79%26spage%3D629%26epage%3D661%26doi%3D10.1021%2Facs.jnatprod.5b01055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Nature brings new avenues to the therapy of central nervous system diseases-An overview of possible treatments derived from natural products</span>. <i>Sci. China: Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1332</span>– <span class="NLM_lpage">1367</span>, <span class="refDoi"> DOI: 10.1007/s11427-019-9587-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1007%2Fs11427-019-9587-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=31444682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A280%3ADC%252BB3MrhtFGrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1332-1367&author=J.+Zhangauthor=Y.+Heauthor=X.+Jiangauthor=H.+Jiangauthor=J.+Shen&title=Nature+brings+new+avenues+to+the+therapy+of+central+nervous+system+diseases-An+overview+of+possible+treatments+derived+from+natural+products&doi=10.1007%2Fs11427-019-9587-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">Nature brings new avenues to the therapy of central nervous system diseases-An overview of possible treatments derived from natural products</span></div><div class="casAuthors">Zhang Junchi; He Yang; Jiang Xiangrui; Jiang Hualiang; Shen Jingshan; Zhang Junchi</div><div class="citationInfo"><span class="NLM_cas:title">Science China. Life sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1332-1367</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Natural products (NPs), including traditional Chinese medicine (TCM), have been long and widely used in the prevention and treatment of central nervous system (CNS) diseases by virtue of their abundant sources, diverse structures, and novel activities.  In this review article, we intend to summarize and discuss the situation or status of the clinical employments or trials of the NPs and their derivatives with CNS activities.  NPs that have been extensively studied in preclinical research in recent years are also included.  The compounds presented in this review are classified according to their indications and followed by details such as natural sources, possible biological mechanisms, and development status, while a considerable proportion of them are found in TCM.  In addition, some drug combinations with synergistic effects are also mentioned.  According to their impressive therapeutic effects and novel chemical structures, NPs are not only effective therapeutic remedies in clinic, but also lead compounds for structural modification, which indicate that nature brings new avenues to the therapy of CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzf-JpvpvX-OkdrW1FkXG-fW6udTcc2ebQ9LLJjiBM6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrhtFGrsg%253D%253D&md5=42cc72913f5a721a72d785ec7f626a65</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1007%2Fs11427-019-9587-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11427-019-9587-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DNature%2520brings%2520new%2520avenues%2520to%2520the%2520therapy%2520of%2520central%2520nervous%2520system%2520diseases-An%2520overview%2520of%2520possible%2520treatments%2520derived%2520from%2520natural%2520products%26jtitle%3DSci.%2520China%253A%2520Life%2520Sci.%26date%3D2019%26volume%3D62%26spage%3D1332%26epage%3D1367%26doi%3D10.1007%2Fs11427-019-9587-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Counting on natural products for drug design</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">531</span>– <span class="NLM_lpage">541</span>, <span class="refDoi"> DOI: 10.1038/nchem.2479</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=10.1038%2Fnchem.2479" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=27219696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=531-541&author=T.+Rodriguesauthor=D.+Rekerauthor=P.+Schneiderauthor=G.+Schneider&title=Counting+on+natural+products+for+drug+design&doi=10.1038%2Fnchem.2479"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Counting on natural products for drug design</span></div><div class="casAuthors">Rodrigues, Tiago; Reker, Daniel; Schneider, Petra; Schneider, Gisbert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">531-541</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Natural products and their mol. frameworks have a long tradition as valuable starting points for medicinal chem. and drug discovery.  Recently, there has been a revitalization of interest in the inclusion of these chemotypes in compd. collections for screening and achieving selective target modulation.  Here the authors discuss natural-product-inspired drug discovery with a focus on recent advances in the design of synthetically tractable small mols. that mimic nature's chem.  The authors highlight the potential of innovative computational tools in processing structurally complex natural products to predict their macromol. targets and attempt to forecast the role that natural-product-derived fragments and fragment-like natural products will play in next-generation drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNR16z66-NgLVg90H21EOLACvtfcHk0lgixd11yqTgCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslSrsbk%253D&md5=3f6391192d648de2a54524afafd6203a</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnchem.2479&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchem.2479%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DT.%26aulast%3DReker%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DCounting%2520on%2520natural%2520products%2520for%2520drug%2520design%26jtitle%3DNat.%2520Chem.%26date%3D2016%26volume%3D8%26spage%3D531%26epage%3D541%26doi%3D10.1038%2Fnchem.2479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2h42" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2h42','PDB','2h42'); return false;">PDB: 2h42</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01093&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01093%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01093" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998db29a023c7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
